1	Protease	O
2	activities	O
3	in	O
4	cultures	O
5	of	O
6	the	O
7	streptococcal	O
8	strains	O
9	were	O
10	associated	O
11	with	O
12	species	O
13	of	O
14	different	O
15	molecular	O
16	masses	O
17	ranging	O
18	from	O
19	130	O
20	to	O
21	200	O
22	kDa	O
23	,	O
24	suggesting	O
25	posttranslational	O
26	processing	O
27	possibly	O
28	as	O
29	a	O
30	result	O
31	of	O
32	autoproteolysis	O
33	at	O
34	post	O
35	-	O
36	proline	O
37	peptide	O
38	bonds	O
39	in	O
40	the	O
41	N	O
42	-	O
43	terminal	O
44	parts	O
45	of	O
46	the	O
47	molecules	O
48	.	O

1	Polyhomeotic	O
2	and	O
3	Posterior	O
4	Sex	O
5	Combs	O
6	may	O
7	participate	O
8	in	O
9	a	O
10	more	O
11	general	O
12	transcriptional	O
13	mechanism	O
14	that	O
15	causes	O
16	modulated	O
17	gene	O
18	repression	O
19	,	O
20	whereas	O
21	the	O
22	inclusion	O
23	of	O
24	Polycomb	B
25	protein	I
26	in	O
27	the	O
28	complex	O
29	at	O
30	PREs	O
31	leads	O
32	to	O
33	stable	O
34	silencing	O
35	.	O

1	Parasitological	O
2	and	O
3	pathological	O
4	findings	O
5	in	O
6	capuchin	O
7	monkeys	O
8	infected	O
9	with	O
10	Schistosoma	O
11	japonicum	O
12	or	O
13	Schistosoma	O
14	mansoni	O
15	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bilinear	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	fit	O
11	to	O
12	the	O
13	acuity	O
14	outcome	O
15	data	O
16	.	O

1	Sixteen	O
2	patients	O
3	were	O
4	studied	O
5	within	O
6	24	O
7	hours	O
8	of	O
9	resuscitation	O
10	and	O
11	all	O
12	showed	O
13	depressed	O
14	right	O
15	ventricular	O
16	ejection	O
17	(	O
18	RVEF	O
19	)	O
20	and	O
21	/	O
22	or	O
23	an	O
24	increased	O
25	end	O
26	-	O
27	diastolic	O
28	volume	O
29	(	O
30	RVEDVI	O
31	).	O

1	Studies	O
2	were	O
3	performed	O
4	on	O
5	several	O
6	superficial	O
7	veins	O
8	from	O
9	the	O
10	rabbit	O
11	face	O
12	to	O
13	examine	O
14	the	O
15	relationship	O
16	between	O
17	beta	O
18	adrenoceptor	O
19	subtype	O
20	distribution	O
21	,	O
22	intrinsic	O
23	myogenic	O
24	tone	O
25	and	O
26	sympathetic	O
27	nerve	O
28	innervation	O
29	.	O

1	METHODS	O
2	:	O
3	We	O
4	retrospectively	O
5	reviewed	O
6	242	O
7	adult	O
8	cadaveric	O
9	renal	O
10	transplant	O
11	recipients	O
12	treated	O
13	between	O
14	11	O
15	/	O
16	91	O
17	and	O
18	5	O
19	/	O
20	97	O
21	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	Selenium	O
2	,	O
3	as	O
4	a	O
5	constituent	O
6	of	O
7	glutathione	B
8	peroxidase	I
9	,	O
10	plays	O
11	a	O
12	role	O
13	in	O
14	the	O
15	antioxidant	O
16	defense	O
17	systems	O
18	of	O
19	the	O
20	body	O
21	,	O
22	but	O
23	other	O
24	metabolic	O
25	roles	O
26	for	O
27	selenium	O
28	may	O
29	yet	O
30	be	O
31	discovered	O
32	.	O

1	Using	O
2	an	O
3	oligomer	O
4	duplex	O
5	5	O
6	'-	O
7	A	O
8	(	O
9	GGGTTA	B
10	)(	I
11	5	I
12	)-	I
13	3	I
14	'/	I
15	5	I
16	'-(	I
17	TAACCC	I
18	)(	I
19	5	I
20	)	O
21	T	O
22	-	O
23	3	O
24	'	O
25	as	O
26	a	O
27	template	O
28	-	O
29	primer	O
30	,	O
31	we	O
32	show	O
33	that	O
34	both	O
35	the	O
36	Klenow	O
37	fragment	O
38	of	O
39	Escherichia	B
40	coli	I
41	DNA	I
42	polymerase	I
43	I	I
44	and	I
45	HIV	I
46	reverse	I
47	transcriptase	I
48	could	O
49	expand	O
50	telomere	O
51	DNA	O
52	sequences	O
53	as	O
54	well	O
55	,	O
56	giving	O
57	products	O
58	greater	O
59	than	O
60	the	O
61	size	O
62	of	O
63	the	O
64	template	O
65	DNA	O
66	.	O

1	We	O
2	purified	O
3	a	O
4	Ca2	B
5	+/	I
6	calmodulin	I
7	(	O
8	CaM	B
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O

1	Protein	B
2	tyrosine	I
3	phosphatases	I
4	(	O
5	PTPs	B
6	),	O
7	together	O
8	with	O
9	protein	B
10	tyrosine	I
11	kinases	I
12	(	O
13	PTKs	B
14	),	O
15	are	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	cell	O
22	activation	O
23	,	O
24	growth	O
25	,	O
26	and	O
27	differentiation	O
28	.	O

1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	O
12	factors	O
13	NF	B
14	-	I
15	kappaB	I
16	and	O
17	AP	B
18	-	I
19	1	I
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	I
27	8	I
28	gene	I
29	by	O
30	HTLV	O
31	-	O
32	I	O
33	Tax	B
34	.	O

1	During	O
2	the	O
3	observation	O
4	period	O
5	of	O
6	0	O
7	.	O
8	4	O
9	-	O
10	30	O
11	weeks	O
12	,	O
13	cardiac	O
14	white	O
15	spots	O
16	on	O
17	the	O
18	right	O
19	ventricle	O
20	of	O
21	BALB	O
22	/	O
23	c	O
24	mice	O
25	were	O
26	first	O
27	detected	O
28	at	O
29	three	O
30	weeks	O
31	(	O
32	6	O
33	of	O
34	20	O
35	mice	O
36	;	O
37	30	O
38	%),	O
39	and	O
40	the	O
41	maximal	O
42	incidence	O
43	of	O
44	cardiac	O
45	white	O
46	spots	O
47	was	O
48	obtained	O
49	at	O
50	nine	O
51	weeks	O
52	(	O
53	39	O
54	of	O
55	44	O
56	mice	O
57	;	O
58	88	O
59	%).	O

1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	I
11	p40	I
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	B
25	l	I
26	kappa	I
27	B	I
28	-	I
29	alpha	I
30	(	O
31	p40	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	The	O
2	COL7A1	B
3	gene	I
4	,	O
5	which	O
6	encodes	O
7	type	B
8	VII	I
9	collagen	I
10	,	O
11	has	O
12	been	O
13	implicated	O
14	as	O
15	a	O
16	candidate	O
17	gene	O
18	for	O
19	dominantly	O
20	and	O
21	recessively	O
22	inherited	O
23	forms	O
24	of	O
25	dystrophic	O
26	epidermolysis	O
27	bullosa	O
28	.	O

1	Clinicopathologic	O
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O

1	The	O
2	availability	O
3	of	O
4	sequence	O
5	from	O
6	multiple	O
7	species	O
8	has	O
9	permitted	O
10	us	O
11	to	O
12	determine	O
13	that	O
14	the	O
15	UBE	B
16	site	I
17	has	O
18	close	O
19	similarity	O
20	to	O
21	motifs	O
22	that	O
23	bind	O
24	members	O
25	of	O
26	the	O
27	NF	B
28	-	I
29	1	I
30	family	I
31	of	O
32	transcription	O
33	factors	O
34	.	O

1	Moreover	O
2	,	O
3	the	O
4	ability	O
5	to	O
6	selectivity	O
7	arrest	O
8	elongation	O
9	by	O
10	polIII	O
11	at	O
12	defined	O
13	positions	O
14	within	O
15	the	O
16	tRNA	B
17	gene	I
18	transcription	O
19	unit	O
20	has	O
21	permitted	O
22	the	O
23	identification	O
24	of	O
25	discrete	O
26	functional	O
27	properties	O
28	of	O
29	paused	O
30	mammalian	O
31	polIII	O
32	ternary	O
33	complexes	O
34	.	O

1	The	O
2	nucleotide	O
3	(	O
4	nt	O
5	)	O
6	sequences	O
7	of	O
8	the	O
9	exons	O
10	,	O
11	exon	O
12	/	O
13	intron	O
14	boundaries	O
15	and	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	untranslated	O
22	regions	O
23	were	O
24	determined	O
25	.	O

1	The	O
2	rhaB	B
3	transcription	O
4	start	O
5	site	O
6	was	O
7	mapped	O
8	to	O
9	-	O
10	24	O
11	relative	O
12	to	O
13	the	O
14	start	O
15	of	O
16	translation	O
17	.	O

1	Effects	O
2	of	O
3	dopamine	O
4	and	O
5	of	O
6	a	O
7	dopaminergic	O
8	blocker	O
9	,	O
10	haloperidol	O
11	,	O
12	on	O
13	the	O
14	responses	O
15	of	O
16	carotid	O
17	body	O
18	chemoreceptors	O
19	to	O
20	hypoxia	O
21	and	O
22	hypercapnia	O
23	were	O
24	investigated	O
25	in	O
26	16	O
27	anesthetized	O
28	cats	O
29	.	O

1	Experiments	O
2	on	O
3	23	O
4	white	O
5	rats	O
6	and	O
7	10	O
8	guinea	O
9	pigs	O
10	have	O
11	shown	O
12	that	O
13	preliminarily	O
14	indomethacin	O
15	-	O
16	induced	O
17	inhibition	O
18	of	O
19	prostaglandins	O
20	synthesis	O
21	prevented	O
22	development	O
23	of	O
24	pulmonary	O
25	oedema	O
26	,	O
27	evoked	O
28	by	O
29	heterologous	O
30	serum	O
31	in	O
32	rats	O
33	and	O
34	by	O
35	vagotomy	O
36	in	O
37	guinea	O
38	pigs	O
39	.	O

1	Haplotype	O
2	mapping	O
3	and	O
4	sequence	O
5	analysis	O
6	of	O
7	the	O
8	mouse	O
9	Nramp	O
10	gene	O
11	predict	O
12	susceptibility	O
13	to	O
14	infection	O
15	with	O
16	intracellular	O
17	parasites	O
18	.	O

1	These	O
2	results	O
3	demonstrate	O
4	a	O
5	specific	O
6	association	O
7	of	O
8	SIV	O
9	and	O
10	HIV	B
11	-	I
12	2	I
13	nef	I
14	,	O
15	but	O
16	not	O
17	HIV	B
18	-	I
19	1	I
20	nef	I
21	,	O
22	with	O
23	TCRzeta	B
24	.	O

1	At	O
2	the	O
3	basal	O
4	unstimulated	O
5	condition	O
6	,	O
7	Ren1d	O
8	5	O
9	'	O
10	flanking	O
11	sequence	O
12	in	O
13	the	O
14	sense	O
15	orientation	O
16	inhibited	O
17	basal	O
18	CAT	B
19	expression	O
20	from	O
21	the	O
22	TK	B
23	promoter	I
24	of	O
25	pUTKAT1	B
26	,	O
27	whereas	O
28	the	O
29	same	O
30	sequence	O
31	in	O
32	the	O
33	antisense	O
34	orientation	O
35	did	O
36	not	O
37	.	O

1	Alveolar	O
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	O
6	in	O
7	most	O
8	patients	O
9	with	O
10	AIDS	O
11	(	O
12	mean	O
13	26	O
14	.	O
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	O
34	22	O
35	.	O
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	assess	O
7	the	O
8	role	O
9	of	O
10	additional	O
11	diagnostic	O
12	laparoscopy	O
13	in	O
14	the	O
15	preoperative	O
16	staging	O
17	of	O
18	patients	O
19	with	O
20	adenocarcinoma	O
21	of	O
22	the	O
23	esophagus	O
24	,	O
25	gastric	O
26	cancer	O
27	and	O
28	pancreatic	O
29	cancer	O
30	prior	O
31	to	O
32	intended	O
33	curative	O
34	surgery	O
35	.	O

1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	O
17	1	O
18	.	O
19	8	O
20	kb	O
21	HindIII	B
22	-	I
23	EcoRI	I
24	fragment	I
25	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	O
5	human	O
6	SLF	O
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	O
19	-	O
20	kit	O
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	The	O
2	assay	O
3	exhibits	O
4	a	O
5	dynamic	O
6	range	O
7	of	O
8	0	O
9	.	O
10	1	O
11	-	O
12	100	O
13	micrograms	O
14	l	O
15	-	O
16	1	O
17	using	O
18	a	O
19	monoclonal	O
20	antibody	O
21	or	O
22	alternatively	O
23	10	O
24	micrograms	O
25	l	O
26	-	O
27	1	O
28	to	O
29	10	O
30	mg	O
31	l	O
32	-	O
33	1	O
34	using	O
35	commercially	O
36	available	O
37	antiserum	O
38	.	O

1	Acad	O
2	.	O

1	Moreover	O
2	,	O
3	glucan	B
4	synthase	I
5	activity	O
6	,	O
7	which	O
8	is	O
9	activated	O
10	by	O
11	Rho1p	B
12	,	O
13	was	O
14	significantly	O
15	reduced	O
16	in	O
17	the	O
18	deltabem4	B
19	mutant	I
20	.	O

1	A	O
2	2	O
3	years	O
4	and	O
5	9	O
6	months	O
7	old	O
8	female	O
9	patient	O
10	,	O
11	with	O
12	the	O
13	diagnosis	O
14	of	O
15	Weaver	O
16	syndrome	O
17	is	O
18	reported	O
19	.	O

1	Reporting	O
2	of	O
3	adverse	O
4	events	O
5	occurring	O
6	during	O
7	clinical	O
8	trials	O
9	of	O
10	investigational	O
11	drugs	O
12	is	O
13	a	O
14	complex	O
15	and	O
16	controversial	O
17	issue	O
18	.	O

1	Secretory	O
2	function	O
3	of	O
4	the	O
5	prostate	O
6	gland	O
7	.	O

1	Such	O
2	an	O
3	intervention	O
4	may	O
5	be	O
6	of	O
7	considerable	O
8	use	O
9	for	O
10	the	O
11	treatment	O
12	of	O
13	angiogenesis	O
14	-	O
15	dependent	O
16	diseases	O
17	involving	O
18	FGF	B
19	-	I
20	2	I
21	.	O

1	With	O
2	both	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	the	O
8	mutant	O
9	enzymes	O
10	,	O
11	ATP	O
12	activates	O
13	both	O
14	[	O
15	14C	O
16	]	O
17	Asp	O
18	in	O
19	equilibrium	O
20	N	B
21	-	I
22	carbamyl	I
23	-	I
24	L	I
25	-	I
26	aspartate	I
27	(	I
28	C	I
29	-	I
30	Asp	I
31	)	O
32	and	O
33	the	O
34	[	O
35	32P	O
36	]	O
37	carbamyl	O
38	phosphate	O
39	(	O
40	C	B
41	-	I
42	P	I
43	)	O
44	in	O
45	equilibrium	O
46	Pi	O
47	exchanges	O
48	.	O

1	The	O
2	p55	B
3	mRNA	I
4	is	O
5	undetectable	O
6	in	O
7	non	O
8	-	O
9	EBV	O
10	-	O
11	infected	O
12	B	O
13	-	O
14	and	O
15	T	O
16	-	O
17	cell	O
18	lines	O
19	or	O
20	in	O
21	a	O
22	myelomonocytic	O
23	cell	O
24	line	O
25	(	O
26	U937	O
27	).	O

1	In	O
2	studies	O
3	of	O
4	many	O
5	different	O
6	phenotypically	O
7	distinct	O
8	cells	O
9	,	O
10	the	O
11	CRE	O
12	of	O
13	the	O
14	somatostatin	B
15	gene	I
16	promoter	I
17	is	O
18	a	O
19	prototype	O
20	of	O
21	a	O
22	highly	O
23	cAMP	O
24	-	O
25	responsive	O
26	element	O
27	regulated	O
28	by	O
29	CREB	B
30	.	O

1	CDC31	O
2	is	O
3	required	O
4	for	O
5	SPB	O
6	duplication	O
7	and	O
8	encodes	O
9	a	O
10	calmodulin	B
11	-	I
12	like	I
13	protein	I
14	that	O
15	is	O
16	most	O
17	closely	O
18	related	O
19	to	O
20	caltractin	B
21	/	I
22	centrin	I
23	,	O
24	a	O
25	protein	O
26	associated	O
27	with	O
28	the	O
29	Chlamydomonas	O
30	basal	O
31	body	O
32	.	O

1	CDDP	O
2	is	O
3	active	O
4	as	O
5	a	O
6	single	O
7	agent	O
8	in	O
9	non	O
10	-	O
11	Hodgkin	O
12	'	O
13	s	O
14	lymphoma	O
15	.	O

1	Transcripts	O
2	of	O
3	the	O
4	immunoglobulin	B
5	C	I
6	mu	I
7	gene	I
8	vary	O
9	in	O
10	structure	O
11	and	O
12	splicing	O
13	during	O
14	lymphoid	O
15	development	O
16	.	O

1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	humoral	O
9	immune	O
10	system	O
11	response	O
12	to	O
13	weak	O
14	hapten	O
15	-	O
16	syngeneic	O
17	or	O
18	allogeneic	O
19	protein	O
20	conjugates	O
21	(	O
22	corrosion	O
23	and	O
24	wear	O
25	products	O
26	of	O
27	metallic	O
28	orthopedic	O
29	devices	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	immunosorbent	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	O
47	humoral	O
48	immunity	O
49	)	O
50	to	O
51	metals	O
52	was	O
53	developed	O
54	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	coat	B
6	protein	I
7	promoter	I
8	of	O
9	chloris	O
10	striate	O
11	mosaic	O
12	virus	O
13	is	O
14	enhanced	O
15	by	O
16	its	O
17	own	O
18	and	O
19	C1	B
20	-	I
21	C2	I
22	gene	I
23	products	O
24	.	O

1	A	O
2	portion	O
3	of	O
4	p193	O
5	is	O
6	nuclear	O
7	and	O
8	localizes	O
9	to	O
10	the	O
11	mitotic	O
12	spindle	O
13	.	O

1	The	O
2	results	O
3	strongly	O
4	support	O
5	the	O
6	notion	O
7	that	O
8	the	O
9	OBF1	B
10	-	I
11	binding	I
12	sites	I
13	and	O
14	the	O
15	OBF1	B
16	protein	I
17	are	O
18	important	O
19	for	O
20	normal	O
21	ARS	O
22	function	O
23	as	O
24	an	O
25	origin	O
26	of	O
27	replication	O
28	.	O

1	Whereas	O
2	p82	B
3	expression	O
4	had	O
5	no	O
6	effect	O
7	on	O
8	ERK2	B
9	activation	O
10	by	O
11	p126	O
12	,	O
13	p70	B
14	completely	O
15	abrogated	O
16	this	O
17	activity	O
18	.	O

1	Disruption	O
2	of	O
3	the	O
4	chromosomal	O
5	AAR1	B
6	gene	I
7	in	O
8	alpha	O
9	and	O
10	a	O
11	/	O
12	alpha	O
13	cells	O
14	conferred	O
15	the	O
16	nonmating	O
17	phenotype	O
18	,	O
19	and	O
20	the	O
21	a	O
22	/	O
23	alpha	O
24	diploids	O
25	could	O
26	not	O
27	sporulate	O
28	.	O

1	The	O
2	domain	O
3	structure	O
4	of	O
5	bovine	B
6	LTBP	I
7	-	I
8	2	I
9	is	O
10	very	O
11	similar	O
12	to	O
13	that	O
14	of	O
15	the	O
16	human	B
17	LTBP	I
18	-	I
19	2	I
20	,	O
21	containing	O
22	20	O
23	examples	O
24	of	O
25	6	O
26	-	O
27	cysteine	O
28	epidermal	B
29	growth	I
30	factor	I
31	-	I
32	like	I
33	repeats	I
34	,	O
35	16	O
36	of	O
37	which	O
38	have	O
39	the	O
40	consensus	O
41	sequence	O
42	for	O
43	calcium	O
44	binding	O
45	,	O
46	together	O
47	with	O
48	4	O
49	examples	O
50	of	O
51	8	O
52	-	O
53	cysteine	O
54	motifs	O
55	characteristic	O
56	of	O
57	fibrillins	O
58	and	O
59	LTBP	B
60	-	I
61	1	I
62	.	O

1	RNase	B
2	protection	O
3	assays	O
4	revealed	O
5	a	O
6	correlation	O
7	between	O
8	the	O
9	levels	O
10	of	O
11	dorsal	O
12	and	O
13	ventral	O
14	skin	O
15	expression	O
16	with	O
17	pigmentation	O
18	/	O
19	phaeomelanin	O
20	phenotypes	O
21	.	O

1	All	O
2	three	O
3	genes	O
4	have	O
5	been	O
6	mapped	O
7	precisely	O
8	to	O
9	a	O
10	small	O
11	region	O
12	on	O
13	human	O
14	chromosome	O
15	16p12	O
16	.	O
17	1	O
18	-	O
19	p11	O
20	.	O
21	2	O
22	(	O
23	homologous	O
24	to	O
25	mouse	O
26	chromosome	O
27	7	O
28	),	O
29	using	O
30	somatic	O
31	cell	O
32	hybrids	O
33	and	O
34	cosmid	O
35	clones	O
36	.	O

1	The	O
2	capacity	O
3	to	O
4	repair	O
5	8	O
6	-	O
7	OxoG	O
8	has	O
9	been	O
10	measured	O
11	in	O
12	cell	O
13	-	O
14	free	O
15	extracts	O
16	of	O
17	wild	O
18	-	O
19	type	O
20	and	O
21	ogg1	B
22	strains	O
23	using	O
24	a	O
25	34mer	O
26	DNA	O
27	fragment	O
28	containing	O
29	a	O
30	single	O
31	8	O
32	-	O
33	OxoG	O
34	residue	O
35	paired	O
36	with	O
37	a	O
38	cytosine	O
39	(	O
40	8	O
41	-	O
42	OxoG	O
43	/	O
44	C	O
45	)	O
46	as	O
47	a	O
48	substrate	O
49	.	O

1	SAECG	O
2	,	O
3	echocardiography	O
4	and	O
5	thallium	O
6	-	O
7	201	O
8	imaging	O
9	were	O
10	performed	O
11	before	O
12	and	O
13	1	O
14	month	O
15	after	O
16	attempted	O
17	angioplasty	O
18	.	O

1	Consistent	O
2	with	O
3	this	O
4	,	O
5	we	O
6	show	O
7	that	O
8	peptides	O
9	representing	O
10	docking	O
11	sites	O
12	within	O
13	the	O
14	target	O
15	substrates	O
16	Elk	B
17	-	I
18	1	I
19	and	O
20	p90	B
21	(	O
22	rsk	O
23	)	O
24	inhibit	O
25	ERK	B
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	MKP	B
31	-	I
32	3	I
33	.	O

1	This	O
2	caused	O
3	severe	O
4	cortical	O
5	damage	O
6	and	O
7	neuronal	O
8	loss	O
9	in	O
10	hippocampus	O
11	subfields	O
12	CA1	O
13	,	O
14	CA3	B
15	,	O
16	and	O
17	hilus	O
18	.	O

1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O

1	Two	O
2	evolutionarily	O
3	conserved	O
4	kinases	O
5	,	O
6	the	O
7	cyclin	B
8	B	I
9	(	O
10	Clb	B
11	)/	O
12	cyclin	B
13	-	I
14	dependent	I
15	kinase	I
16	(	O
17	Cdk	B
18	/	O
19	Cdc28p	B
20	)	O
21	and	O
22	Cdc7p	B
23	along	O
24	with	O
25	its	O
26	interacting	O
27	factor	O
28	Dbf4p	B
29	,	O
30	are	O
31	required	O
32	late	O
33	in	O
34	G1	O
35	to	O
36	initiate	O
37	DNA	O
38	replication	O
39	.	O

1	A	O
2	suspected	O
3	hypothalamic	O
4	dysfunction	O
5	and	O
6	a	O
7	slightly	O
8	impaired	O
9	pituitary	O
10	function	O
11	manifested	O
12	as	O
13	GH	B
14	deficiency	O
15	were	O
16	their	O
17	common	O
18	endocrinological	O
19	features	O
20	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	O
32	-	O
33	and	O
34	beta	B
35	-	I
36	adrenoceptors	I
37	.	O

1	Thus	O
2	,	O
3	sgRNA2	B
4	has	O
5	the	O
6	3	O
7	'	O
8	TE	O
9	in	O
10	its	O
11	5	O
12	'	O
13	UTR	O
14	.	O

1	Further	O
2	analysis	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	DNA	O
8	binding	O
9	activities	O
10	in	O
11	7	O
12	-	O
13	to	O
14	14	O
15	-	O
16	day	O
17	culture	O
18	activated	O
19	HSCs	O
20	led	O
21	to	O
22	the	O
23	discovery	O
24	of	O
25	high	B
26	mobility	I
27	AP	I
28	-	I
29	1	I
30	complexes	I
31	(	O
32	HMAP	B
33	-	I
34	1	I
35	).	O

1	A	O
2	catalytic	O
3	domain	O
4	of	O
5	eukaryotic	B
6	DNA	I
7	topoisomerase	I
8	I	I
9	.	O

1	Utilizing	O
2	transient	O
3	transfection	O
4	studies	O
5	in	O
6	HepG2	O
7	cells	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	deletion	O
14	of	O
15	the	O
16	factor	B
17	VIII	I
18	promoter	I
19	sequences	O
20	distal	O
21	to	O
22	nucleotide	O
23	-	O
24	44	O
25	results	O
26	in	O
27	a	O
28	significant	O
29	but	O
30	small	O
31	increase	O
32	in	O
33	promoter	O
34	activity	O
35	.	O

1	Most	O
2	pituitary	B
3	hormone	I
4	-	I
5	coding	I
6	gene	I
7	promoters	I
8	are	O
9	activated	O
10	by	O
11	Ptx1	B
12	.	O

1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O

1	The	O
2	objective	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	examine	O
9	the	O
10	influence	O
11	of	O
12	HHCA	O
13	and	O
14	other	O
15	serological	O
16	factors	O
17	upon	O
18	the	O
19	development	O
20	of	O
21	VGS	O
22	.	O

1	Studying	O
2	intracellular	O
3	signaling	O
4	pathways	O
5	,	O
6	which	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	malignant	O
12	transformation	O
13	of	O
14	Ret	B
15	-	I
16	9bp	I
17	expressing	O
18	NIH3T3	O
19	cells	O
20	,	O
21	we	O
22	could	O
23	demonstrate	O
24	Ret	O
25	-	O
26	9bp	O
27	dependent	O
28	phosphorylation	O
29	of	O
30	insulin	B
31	receptor	I
32	substrate	I
33	-	I
34	2	I
35	(	O
36	IRS	B
37	-	I
38	2	I
39	)	O
40	with	O
41	consecutive	O
42	activation	O
43	of	O
44	phosphatidylinositol	B
45	3	I
46	-	I
47	kinase	I
48	(	O
49	PI	B
50	3	I
51	-	I
52	kinase	I
53	)	O
54	and	O
55	protein	B
56	kinase	I
57	B	I
58	(	O
59	PKB	B
60	/	O
61	AKT	O
62	).	O

1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	The	O
2	humanized	O
3	LL2	O
4	(	O
5	hLL2	O
6	),	O
7	lacking	O
8	light	O
9	chain	O
10	variable	O
11	region	O
12	glycosylation	O
13	,	O
14	exhibited	O
15	immunoreactivities	O
16	that	O
17	were	O
18	comparable	O
19	to	O
20	that	O
21	of	O
22	chimeric	O
23	LL2	O
24	(	O
25	cLL2	O
26	),	O
27	which	O
28	was	O
29	shown	O
30	previously	O
31	to	O
32	have	O
33	antigen	O
34	-	O
35	binding	O
36	properties	O
37	similar	O
38	to	O
39	its	O
40	murine	O
41	counterpart	O
42	,	O
43	suggesting	O
44	that	O
45	the	O
46	VK	O
47	-	O
48	appended	O
49	oligosaccharides	O
50	found	O
51	in	O
52	mLL2	B
53	are	O
54	not	O
55	necessary	O
56	for	O
57	antigen	O
58	binding	O
59	.	O

1	In	O
2	analyses	O
3	with	O
4	control	O
5	for	O
6	multiple	O
7	variables	O
8	,	O
9	relative	O
10	risk	O
11	for	O
12	microalbuminuria	O
13	(	O
14	urinary	O
15	albumin	B
16	excretion	O
17	,	O
18	20	O
19	-	O
20	199	O
21	microg	O
22	/	O
23	min	O
24	)	O
25	in	O
26	men	O
27	and	O
28	women	O
29	was	O
30	2	O
31	.	O
32	51	O
33	and	O
34	1	O
35	.	O
36	62	O
37	,	O
38	respectively	O
39	,	O
40	with	O
41	18	O
42	mm	O
43	Hg	O
44	higher	O
45	(	O
46	1	O
47	SD	O
48	)	O
49	systolic	O
50	blood	O
51	pressure	O
52	;	O
53	2	O
54	.	O
55	25	O
56	and	O
57	2	O
58	.	O
59	10	O
60	,	O
61	respectively	O
62	,	O
63	with	O
64	1	O
65	.	O
66	0	O
67	-	O
68	mmol	O
69	/	O
70	L	O
71	(	O
72	40	O
73	mg	O
74	/	O
75	dL	O
76	)	O
77	higher	O
78	plasma	O
79	cholesterol	O
80	level	O
81	;	O
82	1	O
83	.	O
84	99	O
85	and	O
86	1	O
87	.	O
88	91	O
89	,	O
90	respectively	O
91	,	O
92	for	O
93	smokers	O
94	vs	O
95	nonsmokers	O
96	;	O
97	and	O
98	1	O
99	.	O
100	83	O
101	and	O
102	1	O
103	.	O
104	33	O
105	,	O
106	respectively	O
107	,	O
108	with	O
109	4	O
110	kg	O
111	/	O
112	m2	O
113	higher	O
114	body	O
115	mass	O
116	index	O
117	.	O

1	METHODS	O
2	:	O
3	Ten	O
4	influenza	O
5	A	O
6	(	O
7	H3N2	B
8	)	O
9	viruses	O
10	isolated	O
11	during	O
12	the	O
13	outbreaks	O
14	were	O
15	examined	O
16	for	O
17	resistance	O
18	to	O
19	amantadine	O
20	and	O
21	rimantadine	O
22	by	O
23	means	O
24	of	O
25	an	O
26	enzyme	O
27	immunoassay	O
28	and	O
29	by	O
30	sequencing	O
31	of	O
32	the	O
33	viral	O
34	nucleic	O
35	acid	O
36	that	O
37	encodes	O
38	the	O
39	transmembrane	O
40	domain	O
41	of	O
42	the	O
43	M2	O
44	protein	O
45	.	O

1	It	O
2	may	O
3	be	O
4	time	O
5	to	O
6	reevaluate	O
7	the	O
8	dichotomy	O
9	between	O
10	AD	O
11	and	O
12	VaD	O
13	.	O

1	In	O
2	group	O
3	III	O
4	,	O
5	patients	O
6	also	O
7	received	O
8	their	O
9	own	O
10	mediastinal	O
11	drainage	O
12	blood	O
13	,	O
14	shed	O
15	for	O
16	6	O
17	hours	O
18	after	O
19	operation	O
20	,	O
21	after	O
22	concentration	O
23	and	O
24	washing	O
25	in	O
26	a	O
27	MBRS	O
28	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	neuron	O
11	-	O
12	specific	O
13	SCG10	B
14	gene	I
15	evolved	O
16	by	O
17	duplication	O
18	and	O
19	modification	O
20	of	O
21	the	O
22	more	O
23	broadly	O
24	expressed	O
25	stathmin	B
26	/	O
27	Lap18	B
28	gene	I
29	.	O

1	Variations	O
2	of	O
3	the	O
4	timing	O
5	of	O
6	deflections	O
7	in	O
8	the	O
9	His	O
10	bundle	O
11	recordings	O
12	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	mouse	B
9	HO	I
10	-	I
11	1	I
12	gene	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	of	O
18	p32	B
19	,	O
20	initially	O
21	identified	O
22	as	O
23	a	O
24	stress	O
25	-	O
26	induced	O
27	protein	O
28	in	O
29	mouse	O
30	BALBc	O
31	/	O
32	3T3	O
33	cells	O
34	.	O

1	In	O
2	AcMNPV	O
3	-	O
4	infected	O
5	Sf9	O
6	cells	O
7	,	O
8	late	O
9	transcription	O
10	initiation	O
11	is	O
12	detected	O
13	from	O
14	only	O
15	two	O
16	upstream	O
17	TAAG	O
18	sites	O
19	and	O
20	not	O
21	from	O
22	three	O
23	downstream	O
24	TAAG	O
25	sites	O
26	.	O

1	Human	B
2	GATA	I
3	-	I
4	3	I
5	:	O
6	a	O
7	lineage	O
8	-	O
9	restricted	O
10	transcription	O
11	factor	O
12	that	O
13	regulates	O
14	the	O
15	expression	O
16	of	O
17	the	O
18	T	B
19	cell	I
20	receptor	I
21	alpha	I
22	gene	I
23	.	O

1	This	O
2	differential	O
3	sensitivity	O
4	to	O
5	DB	O
6	,	O
7	as	O
8	measured	O
9	by	O
10	a	O
11	lower	O
12	concentration	O
13	of	O
14	DB	O
15	which	O
16	caused	O
17	loss	O
18	of	O
19	righting	O
20	in	O
21	LS	O
22	,	O
23	was	O
24	accompanied	O
25	by	O
26	an	O
27	equal	O
28	rate	O
29	of	O
30	water	O
31	-	O
32	soluble	O
33	barbiturate	O
34	brain	O
35	distribution	O
36	and	O
37	elimination	O
38	in	O
39	the	O
40	two	O
41	lines	O
42	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O

1	Surprisingly	O
2	,	O
3	a	O
4	C	O
5	to	O
6	G	O
7	transversion	O
8	at	O
9	the	O
10	first	O
11	residue	O
12	of	O
13	the	O
14	CAT	B
15	pentanucleotide	O
16	,	O
17	which	O
18	severely	O
19	impairs	O
20	the	O
21	activity	O
22	of	O
23	both	O
24	promoters	O
25	,	O
26	appears	O
27	to	O
28	increase	O
29	affinity	O
30	of	O
31	the	O
32	CAT	B
33	binding	I
34	protein	I
35	.	O

1	The	O
2	preferential	O
3	serum	O
4	IgA	B
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Risk	O
2	factors	O
3	associated	O
4	with	O
5	a	O
6	high	O
7	seroprevalence	O
8	of	O
9	hepatitis	O
10	C	O
11	virus	O
12	infection	O
13	in	O
14	Egyptian	O
15	blood	O
16	donors	O
17	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	The	O
2	induction	O
3	of	O
4	seizures	O
5	in	O
6	"	O
7	Papio	O
8	papio	O
9	"	O
10	following	O
11	allylglycine	O
12	alone	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	intermittent	O
18	photic	O
19	stimulation	O

1	The	O
2	observed	O
3	sequence	O
4	variation	O
5	disrupts	O
6	the	O
7	first	O
8	ORF	O
9	in	O
10	many	O
11	Y	O
12	'	O
13	s	O
14	while	O
15	most	O
16	of	O
17	the	O
18	second	O
19	ORF	O
20	including	O
21	the	O
22	putative	O
23	helicase	B
24	region	I
25	is	O
26	unaffected	O
27	.	O

1	Some	O
2	users	O
3	will	O
4	willingly	O
5	comply	O
6	with	O
7	management	O
8	measures	O
9	,	O
10	other	O
11	users	O
12	will	O
13	comply	O
14	in	O
15	response	O
16	to	O
17	education	O
18	,	O
19	but	O
20	there	O
21	will	O
22	be	O
23	another	O
24	group	O
25	who	O
26	will	O
27	only	O
28	respond	O
29	to	O
30	enforcement	O
31	activities	O
32	.	O

1	The	O
2	Rlm1	B
3	protein	I
4	,	O
5	a	O
6	member	O
7	of	O
8	the	O
9	MADS	B
10	box	I
11	family	I
12	of	O
13	transcription	O
14	factors	O
15	,	O
16	functions	O
17	downstream	O
18	of	O
19	Mpk1	B
20	in	O
21	the	O
22	pathway	O
23	.	O

1	Collagen	B
2	was	O
3	extracted	O
4	from	O
5	the	O
6	skin	O
7	,	O
8	and	O
9	the	O
10	lack	O
11	of	O
12	type	B
13	III	I
14	collagen	I
15	was	O
16	determined	O
17	by	O
18	means	O
19	of	O
20	sodium	O
21	dodecyl	O
22	sulfate	O
23	-	O
24	polyacrylamide	O
25	gel	O
26	electrophoresis	O
27	(	O
28	SDS	O
29	-	O
30	PAGE	O
31	).	O

1	In	O
2	addition	O
3	,	O
4	narZ	O
5	expression	O
6	was	O
7	induced	O
8	approximately	O
9	20	O
10	-	O
11	fold	O
12	intracellularly	O
13	in	O
14	Madin	O
15	-	O
16	Darby	O
17	canine	O
18	kidney	O
19	epithelial	O
20	cells	O
21	and	O
22	16	O
23	-	O
24	fold	O
25	in	O
26	intracellular	O
27	salts	O
28	medium	O
29	,	O
30	which	O
31	is	O
32	believed	O
33	to	O
34	mimic	O
35	the	O
36	intracellular	O
37	milieu	O
38	.	O

1	False	O
2	positive	O
3	amniotic	O
4	fluid	O
5	alpha	O
6	fetoprotein	O
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	The	O
2	TIMP	O
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	O
8	)	O
9	AP1	B
10	site	I
11	is	O
12	a	O
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	B
18	-	I
19	Fos	I
20	/	O
21	c	B
22	-	I
23	Jun	I
24	AP1	I
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	B
37	AP1	I
38	factors	I
39	to	O
40	the	O
41	consensus	O
42	TRE	O
43	,	O
44	but	O
45	in	O
46	addition	O
47	it	O
48	binds	O
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	O
58	.	O

1	Occupational	O
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O

1	Comparisons	O
2	of	O
3	the	O
4	four	O
5	operon	O
6	control	O
7	regions	O
8	studied	O
9	indicate	O
10	that	O
11	the	O
12	NarL	B
13	heptamers	O
14	are	O
15	arranged	O
16	with	O
17	diverse	O
18	orientations	O
19	and	O
20	spacing	O
21	.	O

1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O

1	Purification	O
2	of	O
3	MvaT	O
4	enriched	O
5	for	O
6	two	O
7	polypeptides	O
8	of	O
9	approximate	O
10	molecular	O
11	mass	O
12	15	O
13	kDa	O
14	and	O
15	16	O
16	kDa	O
17	,	O
18	designated	O
19	P15	B
20	and	O
21	P16	B
22	.	O

1	The	O
2	carcinogen	O
3	bioassay	O
4	therefore	O
5	is	O
6	a	O
7	very	O
8	important	O
9	component	O
10	of	O
11	the	O
12	battery	O
13	of	O
14	toxicological	O
15	tests	O
16	used	O
17	in	O
18	hazard	O
19	evaluation	O
20	.	O

1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	sided	O
8	low	O
9	-	O
10	frequency	O
11	tremor	O
12	and	O
13	hemidystonia	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O

1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	cleaves	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	E960	B
16	-	I
17	A961	I
18	,	O
19	E1071	B
20	-	I
21	S1072	I
22	,	O
23	E1345	B
24	-	I
25	T1346	I
26	,	O
27	and	O
28	E1419	B
29	-	I
30	G1420	I
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O

1	Coenzyme	O
2	Q10	O
3	:	O
4	blood	O
5	levels	O
6	and	O
7	metabolic	O
8	demand	O
9	.	O

1	Iodine	O
2	metabolism	O
3	in	O
4	chronic	O
5	thyroiditis	O
6	.	O

1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	O
6	qualitative	O
7	criteria	O
8	for	O
9	diagnosing	O
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O

1	Isolation	O
2	of	O
3	Proteus	O
4	vulgaris	O
5	MC	O
6	-	O
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	The	O
2	method	O
3	requires	O
4	a	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	and	O
10	a	O
11	paired	O
12	-	O
13	ion	O
14	technique	O
15	to	O
16	separate	O
17	docusate	O
18	sodium	O
19	from	O
20	other	O
21	components	O
22	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	of	O
5	the	O
6	proximal	O
7	promoter	O
8	revealed	O
9	four	O
10	regions	O
11	of	O
12	protection	O
13	.	O

1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O

1	Acoustic	O
2	transmission	O
3	spectra	O
4	in	O
5	the	O
6	Penrose	O
7	lattice	O
8	.	O

1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	B
15	/	O
16	abl	B
17	gene	I
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	B
25	/	O
26	abl	B
27	.	O

1	Immunophenotyping	O
2	in	O
3	four	O
4	cases	O
5	,	O
6	demonstrated	O
7	non	O
8	-	O
9	B	O
10	,	O
11	non	O
12	-	O
13	T	O
14	cell	O
15	origin	O
16	in	O
17	three	O
18	and	O
19	pre	O
20	-	O
21	B	O
22	cell	O
23	origin	O
24	in	O
25	one	O
26	.	O

1	Abstracts	O
2	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	mouse	B
7	growth	I
8	hormone	I
9	receptor	I
10	/	I
11	growth	I
12	hormone	I
13	binding	I
14	protein	I
15	gene	I
16	.	O

1	The	O
2	CVA16	B
3	.	I
4	4	I
5	proteolipid	I
6	transcript	I
7	is	O
8	the	O
9	most	O
10	prevalent	O
11	of	O
12	the	O
13	two	O
14	proteolipid	O
15	messages	O
16	in	O
17	expanding	O
18	ovules	O
19	harvested	O
20	10	O
21	d	O
22	post	O
23	-	O
24	anthesis	O
25	.	O

1	In	O
2	the	O
3	work	O
4	reported	O
5	here	O
6	,	O
7	we	O
8	used	O
9	peptide	O
10	mapping	O
11	,	O
12	mass	O
13	spectrometry	O
14	,	O
15	and	O
16	site	O
17	-	O
18	directed	O
19	mutagenesis	O
20	to	O
21	identify	O
22	two	O
23	sets	O
24	of	O
25	pAP	B
26	phosphorylation	O
27	sites	O
28	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	O
6	genes	O
7	are	O
8	derepressed	O
9	upon	O
10	binding	O
11	of	O
12	Cat8p	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	B
22	(	O
23	Mig1p	B
24	)	O
25	from	O
26	the	O
27	CAT8	B
28	promoter	I
29	.	O

1	Chronic	O
2	endotoxemia	O
3	appears	O
4	to	O
5	be	O
6	associated	O
7	with	O
8	an	O
9	elevated	O
10	pulmonary	O
11	microvascular	O
12	permeability	O
13	and	O
14	a	O
15	tendency	O
16	toward	O
17	a	O
18	hyperdynamic	O
19	circulation	O
20	but	O
21	with	O
22	an	O
23	appreciable	O
24	degree	O
25	of	O
26	refractoriness	O
27	associated	O
28	with	O
29	regional	O
30	hemodynamics	O
31	and	O
32	eicosanoid	O
33	biosynthesis	O
34	.	O

1	These	O
2	similarities	O
3	suggest	O
4	that	O
5	these	O
6	E2	B
7	proteins	I
8	are	O
9	structurally	O
10	and	O
11	evolutionarily	O
12	related	O
13	.	O

1	Cold	O
2	cardioplegia	O
3	was	O
4	administered	O
5	at	O
6	45	O
7	mm	O
8	Hg	O
9	every	O
10	20	O
11	minutes	O
12	for	O
13	2	O
14	hours	O
15	.	O

1	The	O
2	upstream	B
3	delta	I
4	-	I
5	alpha	I
6	breakpoint	I
7	is	O
8	flanked	O
9	by	O
10	the	O
11	direct	O
12	repeats	O
13	of	O
14	the	O
15	acceptor	O
16	splice	O
17	site	O
18	,	O
19	whereas	O
20	the	O
21	down	O
22	-	O
23	stream	O
24	alpha	B
25	-	I
26	delta	I
27	breakpoint	I
28	is	O
29	located	O
30	in	O
31	the	O
32	adjacent	O
33	intron	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	full	O
6	mu	O
7	-	O
8	opioid	O
9	agonists	O
10	fentanyl	O
11	,	O
12	morphine	O
13	,	O
14	I	O
15	-	O
16	methadone	O
17	and	O
18	levorphanol	O
19	produced	O
20	50	O
21	%	O
22	fentanyl	O
23	-	O
24	appropriate	O
25	responding	O
26	at	O
27	doses	O
28	only	O
29	1	O
30	.	O
31	3	O
32	to	O
33	10	O
34	.	O
35	9	O
36	times	O
37	smaller	O
38	than	O
39	those	O
40	required	O
41	to	O
42	decrease	O
43	response	O
44	rates	O
45	by	O
46	50	O
47	%.	O

1	Preceptorship	O
2	of	O
3	CNS	O
4	students	O
5	:	O
6	an	O
7	exploratory	O
8	study	O
9	.	O

1	Characterization	O
2	and	O
3	hormonal	O
4	regulation	O
5	of	O
6	the	O
7	promoter	O
8	of	O
9	the	O
10	rat	B
11	prostaglandin	I
12	endoperoxide	I
13	synthase	I
14	2	I
15	gene	I
16	in	O
17	granulosa	O
18	cells	O
19	.	O

1	Therapeutic	O
2	use	O
3	of	O
4	cannabis	O
5	.	O

1	A	O
2	single	O
3	protease	O
4	-	O
5	resistant	O
6	structure	O
7	formed	O
8	by	O
9	the	O
10	entirety	O
11	of	O
12	both	O
13	PDZ	B
14	repeats	I
15	1	I
16	and	O
17	2	O
18	(	O
19	PDZ1	B
20	-	I
21	2	I
22	)	O
23	contains	O
24	the	O
25	protein	B
26	4	I
27	.	I
28	1	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	Tolerance	O
2	test	O
3	of	O
4	HB	B
5	419	O
6	in	O
7	animal	O
8	experiments	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	B
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	O
13	induced	O
14	differentiation	O
15	may	O
16	be	O
17	bypassed	O
18	during	O
19	retinoid	O
20	induction	O
21	of	O
22	FR	B
23	-	I
24	beta	I
25	expression	O
26	.	O

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	O
24	('	O
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	Using	O
2	immunolocalization	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	ACE3	B
8	,	O
9	a	O
10	440	O
11	-	O
12	bp	O
13	chorion	O
14	element	O
15	that	O
16	contains	O
17	information	O
18	sufficient	O
19	to	O
20	drive	O
21	amplification	O
22	,	O
23	directs	O
24	DmORC	O
25	localization	O
26	in	O
27	follicle	O
28	cells	O
29	.	O

1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O

1	Recent	O
2	target	O
3	BP	O
4	goals	O
5	promulgated	O
6	by	O
7	the	O
8	Sixth	O
9	Report	O
10	from	O
11	the	O
12	Joint	O
13	National	O
14	Committee	O
15	(	O
16	JNC	B
17	VI	I
18	)	O
19	are	O
20	based	O
21	on	O
22	the	O
23	premise	O
24	that	O
25	the	O
26	intensity	O
27	of	O
28	treatment	O
29	directly	O
30	corresponds	O
31	to	O
32	the	O
33	magnitude	O
34	of	O
35	pretreatment	O
36	risk	O
37	.	O

1	The	O
2	effect	O
3	of	O
4	acetazolamide	O
5	(	O
6	ACZ	O
7	)	O
8	on	O
9	HCO3	O
10	-	O
11	and	O
12	Cl	O
13	-	O
14	activities	O
15	in	O
16	inner	O
17	ear	O
18	fluid	O
19	was	O
20	investigated	O
21	by	O
22	ion	O
23	-	O
24	selective	O
25	microelectrode	O
26	methods	O
27	.	O

1	Relaxation	O
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O

1	Platelet	B
2	activating	I
3	factor	I
4	was	O
5	given	O
6	in	O
7	six	O
8	doses	O
9	at	O
10	15	O
11	minute	O
12	intervals	O
13	and	O
14	airway	O
15	response	O
16	measured	O
17	as	O
18	change	O
19	in	O
20	partial	O
21	expiratory	O
22	flow	O
23	at	O
24	30	O
25	%	O
26	of	O
27	vital	O
28	capacity	O
29	(	O
30	Vp30	O
31	).	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	B
5	receptor	I
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	The	O
2	model	O
3	captures	O
4	the	O
5	essence	O
6	of	O
7	predator	O
8	-	O
9	prey	O
10	dynamics	O
11	to	O
12	provide	O
13	reasonable	O
14	predictions	O
15	of	O
16	population	O
17	patterns	O
18	.	O

1	The	O
2	effect	O
3	of	O
4	treatment	O
5	may	O
6	thus	O
7	be	O
8	divided	O
9	into	O
10	two	O
11	main	O
12	phases	O
13	--	O
14	an	O
15	initial	O
16	phase	O
17	with	O
18	a	O
19	reduction	O
20	in	O
21	LV	O
22	mass	O
23	and	O
24	a	O
25	reduction	O
26	in	O
27	cardiac	O
28	output	O
29	and	O
30	no	O
31	change	O
32	in	O
33	total	O
34	peripheral	O
35	resistance	O
36	--	O
37	and	O
38	a	O
39	second	O
40	phase	O
41	with	O
42	a	O
43	constant	O
44	LV	O
45	mass	O
46	but	O
47	an	O
48	increase	O
49	in	O
50	cardiac	O
51	output	O
52	to	O
53	the	O
54	pretreatment	O
55	level	O
56	again	O
57	and	O
58	a	O
59	concomitant	O
60	decrease	O
61	in	O
62	total	O
63	peripheral	O
64	resistance	O
65	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Raf	B
5	-	I
6	1	I
7	kinase	I
8	by	O
9	cyclic	O
10	AMP	O
11	agonists	O
12	causes	O
13	apoptosis	O
14	of	O
15	v	B
16	-	I
17	abl	I
18	-	O
19	transformed	O
20	cells	O
21	.	O

1	Clinical	O
2	nutrition	O
3	of	O
4	adult	O
5	horses	O
6	.	O

1	Nuclear	O
2	localization	O
3	and	O
4	protein	O
5	sequence	O
6	similarities	O
7	suggested	O
8	that	O
9	the	O
10	SPT2	B
11	/	I
12	SIN1	I
13	protein	I
14	may	O
15	be	O
16	related	O
17	to	O
18	the	O
19	nonhistone	O
20	chromosomal	O
21	protein	O
22	HMG1	O
23	.	O

1	Moxidectin	B
2	(	O
3	at	O
4	3	O
5	times	O
6	the	O
7	therapeutic	O
8	dose	O
9	)	O
10	did	O
11	not	O
12	have	O
13	deleterious	O
14	effects	O
15	on	O
16	cow	O
17	reproductive	O
18	performance	O
19	as	O
20	examined	O
21	(	O
22	eg	O
23	,	O
24	at	O
25	folliculogenesis	O
26	,	O
27	ovulation	O
28	,	O
29	and	O
30	the	O
31	early	O
32	embryonic	O
33	phase	O
34	of	O
35	development	O
36	).	O

1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	mother	O
18	without	O
19	pathogens	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O

1	Dissipation	O
2	of	O
3	claudication	O
4	pain	O
5	after	O
6	walking	O
7	:	O
8	implications	O
9	for	O
10	endurance	O
11	training	O
12	.	O

1	In	O
2	the	O
3	final	O
4	model	O
5	,	O
6	grade	O
7	(	O
8	p	O
9	=	O
10	0	O
11	.	O
12	0002	O
13	),	O
14	peritoneal	O
15	cytologic	O
16	results	O
17	(	O
18	p	O
19	=	O
20	0	O
21	.	O
22	0002	O
23	),	O
24	progesterone	B
25	receptor	I
26	status	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	004	O
33	),	O
34	and	O
35	age	O
36	as	O
37	a	O
38	continuous	O
39	variable	O
40	(	O
41	p	O
42	=	O
43	0	O
44	.	O
45	008	O
46	)	O
47	were	O
48	most	O
49	closely	O
50	associated	O
51	with	O
52	disease	O
53	-	O
54	free	O
55	survival	O
56	.	O

1	However	O
2	,	O
3	the	O
4	signaling	O
5	cascade	O
6	utilized	O
7	by	O
8	the	O
9	urokinase	B
10	receptor	I
11	is	O
12	only	O
13	incompletely	O
14	understood	O
15	.	O

1	This	O
2	region	O
3	binds	O
4	two	O
5	ubiquitous	O
6	nuclear	O
7	factors	O
8	,	O
9	USF	B
10	/	I
11	MLTF	I
12	and	O
13	the	O
14	CAAT	B
15	-	I
16	binding	I
17	transcription	I
18	factor	I
19	/	I
20	nuclear	I
21	factor	I
22	1	I
23	(	O
24	CTF	B
25	/	O
26	NF1	B
27	).	O

1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O

1	Stably	O
2	transfected	O
3	human	O
4	kidney	O
5	293	O
6	cells	O
7	expressing	O
8	the	O
9	wild	B
10	type	I
11	rat	I
12	LH	I
13	/	O
14	CG	B
15	receptor	I
16	(	O
17	rLHR	O
18	)	O
19	or	O
20	receptors	O
21	with	O
22	C	O
23	-	O
24	terminal	O
25	tails	O
26	truncated	O
27	at	O
28	residues	O
29	653	O
30	,	O
31	631	O
32	,	O
33	or	O
34	628	O
35	(	O
36	designated	O
37	rLHR	B
38	-	I
39	t653	I
40	,	O
41	rLHR	B
42	-	I
43	t631	I
44	,	O
45	and	O
46	rLHR	B
47	-	I
48	t628	I
49	)	O
50	were	O
51	used	O
52	to	O
53	probe	O
54	the	O
55	importance	O
56	of	O
57	this	O
58	region	O
59	on	O
60	the	O
61	regulation	O
62	of	O
63	hormonal	O
64	responsiveness	O
65	.	O

1	Furthermore	O
2	,	O
3	synergistic	O
4	activation	O
5	of	O
6	ERK2	B
7	occurred	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	changes	O
13	in	O
14	intracellular	O
15	Ca2	O
16	+,	O
17	and	O
18	was	O
19	not	O
20	blocked	O
21	by	O
22	inhibition	O
23	of	O
24	protein	B
25	kinase	I
26	C	I
27	activity	O
28	and	O
29	represents	O
30	a	O
31	separate	O
32	pathway	O
33	by	O
34	which	O
35	CD19	B
36	regulates	O
37	B	O
38	cell	O
39	function	O
40	.	O

1	However	O
2	,	O
3	the	O
4	rtFc	B
5	gamma	I
6	R	I
7	alpha	I
8	cDNA	I
9	clone	I
10	is	O
11	complementary	O
12	to	O
13	at	O
14	least	O
15	two	O
16	different	O
17	-	O
18	sized	O
19	mRNAs	O
20	expressed	O
21	by	O
22	CRNK	O
23	-	O
24	16	O
25	cells	O
26	,	O
27	contrasting	O
28	the	O
29	single	O
30	Fc	B
31	gamma	I
32	R	I
33	-	I
34	related	I
35	mRNA	I
36	species	O
37	expressed	O
38	by	O
39	human	O
40	and	O
41	mouse	O
42	natural	O
43	killer	O
44	cells	O
45	.	O

1	No	O
2	effect	O
3	was	O
4	found	O
5	on	O
6	grooming	O
7	behavior	O
8	.	O

1	It	O
2	consists	O
3	of	O
4	2185	O
5	amino	O
6	acid	O
7	residues	O
8	encoded	O
9	by	O
10	a	O
11	9	O
12	-	O
13	kilobase	O
14	pair	O
15	mRNA	O
16	;	O
17	several	O
18	splice	O
19	variants	O
20	have	O
21	been	O
22	detected	O
23	in	O
24	human	O
25	and	O
26	rat	O
27	cDNA	O
28	libraries	O
29	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	unique	O
7	suppository	O
8	formulation	O
9	of	O
10	CZX	B
11	-	I
12	S	I
13	is	O
14	useful	O
15	in	O
16	the	O
17	treatment	O
18	of	O
19	infections	O
20	in	O
21	children	O
22	with	O
23	heavy	O
24	psychophysiologic	O
25	disorders	O
26	and	O
27	in	O
28	children	O
29	who	O
30	cannot	O
31	take	O
32	oral	O
33	drugs	O
34	because	O
35	of	O
36	severe	O
37	vomiting	O
38	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	Our	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	hexamer	O
7	and	O
8	the	O
9	octamer	O
10	motifs	O
11	may	O
12	play	O
13	important	O
14	role	O
15	(	O
16	s	O
17	)	O
18	in	O
19	regulation	O
20	of	O
21	replication	O
22	-	O
23	dependent	O
24	but	O
25	not	O
26	of	O
27	replication	O
28	-	O
29	independent	O
30	expression	O
31	of	O
32	the	O
33	wheat	O
34	histone	B
35	H3	I
36	gene	I
37	.	O

1	The	O
2	healing	O
3	rate	O
4	in	O
5	HIV	O
6	-	O
7	positive	O
8	patients	O
9	was	O
10	66	O
11	percent	O
12	after	O
13	14	O
14	weeks	O
15	and	O
16	100	O
17	percent	O
18	after	O
19	32	O
20	weeks	O
21	;	O
22	the	O
23	corresponding	O
24	figures	O
25	for	O
26	patients	O
27	with	O
28	acquired	O
29	immunodeficiency	O
30	syndrome	O
31	were	O
32	0	O
33	and	O
34	50	O
35	percent	O
36	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	p65	B
6	binds	O
7	to	O
8	these	O
9	targets	O
10	with	O
11	almost	O
12	equal	O
13	affinity	O
14	and	O
15	that	O
16	different	O
17	residues	O
18	have	O
19	variable	O
20	roles	O
21	in	O
22	binding	O
23	different	O
24	kappaB	B
25	targets	O
26	.	O

1	Velocity	O
2	sedimentation	O
3	,	O
4	cross	O
5	-	O
6	linking	O
7	,	O
8	and	O
9	immunoprecipitation	O
10	analyses	O
11	of	O
12	detergent	O
13	-	O
14	solubilized	O
15	rat	O
16	brain	O
17	revealed	O
18	that	O
19	the	O
20	32	O
21	and	O
22	34	O
23	kDa	O
24	polypeptides	O
25	reside	O
26	within	O
27	heterotetramers	O
28	.	O

1	A	O
2	role	O
3	for	O
4	RalGDS	O
5	and	O
6	a	O
7	novel	O
8	Ras	B
9	effector	O
10	in	O
11	the	O
12	Ras	B
13	-	O
14	mediated	O
15	inhibition	O
16	of	O
17	skeletal	O
18	myogenesis	O
19	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O

1	All	O
2	groups	O
3	were	O
4	tested	O
5	in	O
6	a	O
7	Hebb	O
8	-	O
9	Williams	O
10	maze	O
11	at	O
12	100	O
13	approximately	O
14	10	O
15	days	O
16	of	O
17	age	O
18	.	O

1	Behavior	O
2	of	O
3	aspartate	B
4	aminotransferase	I
5	(	O
6	EC	B
7	2	I
8	.	I
9	6	I
10	.	I
11	1	I
12	.	I
13	1	I
14	)	O
15	and	O
16	alanine	B
17	aminotransferase	I
18	(	O
19	EC	B
20	2	I
21	.	I
22	6	I
23	.	I
24	1	I
25	.	I
26	2	I
27	)	O
28	in	O
29	rat	O
30	serum	O
31	during	O
32	the	O
33	course	O
34	of	O
35	acute	O
36	radiation	O
37	syndrome	O
38	following	O
39	whole	O
40	body	O
41	X	O
42	-	O
43	irradiation	O

1	The	O
2	number	O
3	of	O
4	elements	O
5	and	O
6	their	O
7	sizes	O
8	relative	O
9	to	O
10	the	O
11	configuration	O
12	were	O
13	varied	O
14	in	O
15	a	O
16	series	O
17	of	O
18	five	O
19	experiments	O
20	.	O

1	An	O
2	FP	O
3	mutant	O
4	,	O
5	AcFP875	B
6	-	I
7	2	I
8	,	O
9	had	O
10	a	O
11	1	O
12	.	O
13	6	O
14	-	O
15	kbp	O
16	insertion	O
17	of	O
18	S	O
19	.	O
20	frugiperda	O
21	DNA	O
22	near	O
23	the	O
24	5	O
25	'	O
26	end	O
27	of	O
28	these	O
29	transcripts	O
30	which	O
31	by	O
32	S1	O
33	analysis	O
34	were	O
35	shown	O
36	to	O
37	initiate	O
38	within	O
39	the	O
40	host	O
41	cell	O
42	sequence	O
43	.	O

1	The	O
2	protein	O
3	folds	O
4	correctly	O
5	with	O
6	two	O
7	disulfide	O
8	bonds	O
9	and	O
10	a	O
11	free	O
12	thiol	O
13	group	O
14	at	O
15	Cys25	O
16	.	O

1	Penicillin	O
2	-	O
3	G	O
4	degradation	O
5	products	O
6	inhibit	O
7	in	O
8	vitro	O
9	granulopoiesis	O
10	.	O

1	When	O
2	combined	O
3	with	O
4	serum	O
5	ferritin	B
6	and	O
7	hemoglobin	B
8	determinations	O
9	,	O
10	the	O
11	serum	O
12	transferrin	B
13	receptor	I
14	assay	O
15	is	O
16	a	O
17	valuable	O
18	addition	O
19	in	O
20	epidemiologic	O
21	surveys	O
22	because	O
23	it	O
24	provides	O
25	a	O
26	quantitative	O
27	measure	O
28	of	O
29	functional	O
30	iron	O
31	deficiency	O
32	and	O
33	it	O
34	distinguishes	O
35	true	O
36	IDA	O
37	from	O
38	the	O
39	anemia	O
40	of	O
41	chronic	O
42	disease	O
43	.	O

1	Each	O
2	sample	O
3	was	O
4	analysed	O
5	as	O
6	soon	O
7	as	O
8	possible	O
9	,	O
10	and	O
11	repeated	O
12	15	O
13	,	O
14	30	O
15	,	O
16	60	O
17	and	O
18	120	O
19	min	O
20	after	O
21	sampling	O
22	.	O

1	However	O
2	,	O
3	the	O
4	BCH	O
5	group	O
6	showed	O
7	inferior	O
8	gross	O
9	motor	O
10	performance	O
11	on	O
12	the	O
13	Bruininks	O
14	-	O
15	Oseretsky	O
16	Test	O
17	of	O
18	Motor	O
19	Proficiency	O
20	(	O
21	Bruininks	O
22	1978	O
23	).	O

1	Statement	O
2	of	O
3	the	O
4	American	O
5	Academy	O
6	of	O
7	Implant	O
8	Dentistry	O
9	.	O

1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	B
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	B
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O

1	Grasso	O
2	,	O
3	and	O
4	A	O
5	.	O

1	(	O
2	2	O
3	)	O
4	Diffusion	O
5	limitation	O
6	in	O
7	the	O
8	heterogeneous	O
9	model	O
10	sets	O
11	in	O
12	at	O
13	a	O
14	lower	O
15	O2	O
16	requirement	O
17	value	O
18	,	O
19	and	O
20	increases	O
21	more	O
22	gradually	O
23	with	O
24	increasing	O
25	O2	O
26	requirement	O
27	,	O
28	than	O
29	in	O
30	the	O
31	corresponding	O
32	homogeneous	O
33	models	O
34	with	O
35	the	O
36	same	O
37	average	O
38	cylinder	O
39	diameter	O
40	.	O

1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	Grb2	B
9	-	O
10	mediated	O
11	activation	O
12	of	O
13	Ras	B
14	,	O
15	PLC	B
16	-	I
17	gamma1	I
18	-	O
19	mediated	O
20	DAG	O
21	production	O
22	is	O
23	required	O
24	for	O
25	EGF	B
26	-	O
27	and	O
28	PDGF	B
29	-	O
30	induced	O
31	S	O
32	-	O
33	phase	O
34	entry	O
35	and	O
36	gene	O
37	expression	O
38	,	O
39	possibly	O
40	through	O
41	activation	O
42	of	O
43	PKC	B
44	.	O

1	Fowlpox	O
2	virus	O
3	encodes	O
4	nonessential	O
5	homologs	O
6	of	O
7	cellular	O
8	alpha	O
9	-	O
10	SNAP	B
11	,	O
12	PC	B
13	-	I
14	1	I
15	,	O
16	and	O
17	an	O
18	orphan	O
19	human	O
20	homolog	O
21	of	O
22	a	O
23	secreted	O
24	nematode	O
25	protein	O
26	.	O

1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O

1	The	O
2	physical	O
3	and	O
4	chemical	O
5	stability	O
6	of	O
7	a	O
8	combination	O
9	of	O
10	drugs	O
11	commonly	O
12	administered	O
13	into	O
14	the	O
15	epidural	O
16	or	O
17	intrathecal	O
18	space	O
19	for	O
20	the	O
21	treatment	O
22	of	O
23	chronic	O
24	pain	O
25	was	O
26	investigated	O
27	.	O

1	By	O
2	directly	O
3	interacting	O
4	with	O
5	both	O
6	Arfs	O
7	and	O
8	tyrosine	B
9	kinases	I
10	involved	O
11	in	O
12	regulating	O
13	cell	O
14	growth	O
15	and	O
16	cytoskeletal	O
17	organization	O
18	,	O
19	ASAP1	B
20	could	O
21	coordinate	O
22	membrane	O
23	remodeling	O
24	events	O
25	with	O
26	these	O
27	processes	O
28	.	O

1	PrpB	B
2	showed	O
3	homology	O
4	to	O
5	carboxyphosphonoenolpyruvate	O
6	phosphonomutase	O
7	of	O
8	Streptomyces	O
9	hygroscopicus	O
10	and	O
11	to	O
12	its	O
13	homolog	O
14	in	O
15	the	O
16	carnation	O
17	Dianthus	O
18	caryophyllus	O
19	;	O
20	PrpC	B
21	was	O
22	homologous	O
23	to	O
24	both	O
25	archaeal	O
26	and	O
27	bacterial	O
28	citrate	O
29	synthases	O
30	;	O
31	PrpD	O
32	showed	O
33	homology	O
34	to	O
35	yeast	O
36	and	O
37	Bacillus	O
38	subtilis	O
39	proteins	O
40	of	O
41	unknown	O
42	function	O
43	;	O
44	PrpE	B
45	showed	O
46	homology	O
47	to	O
48	acetyl	B
49	coenzyme	I
50	A	I
51	synthetases	I
52	.	O

1	Of	O
2	the	O
3	drugs	O
4	orally	O
5	administered	O
6	,	O
7	WR	O
8	-	O
9	168643	O
10	was	O
11	the	O
12	best	O
13	protector	O
14	with	O
15	a	O
16	DMF	O
17	of	O
18	1	O
19	.	O
20	51	O
21	.	O

1	However	O
2	,	O
3	the	O
4	a1	B
5	isoform	I
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	B
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	Specific	O
2	clotting	O
3	factor	O
4	assays	O
5	showed	O
6	an	O
7	isolated	O
8	deficiency	O
9	of	O
10	factor	O
11	X	O
12	ranging	O
13	from	O
14	7	O
15	to	O
16	12	O
17	per	O
18	cent	O
19	on	O
20	three	O
21	determinations	O
22	.	O

1	The	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	I
6	peroxidase	I
7	(	O
8	ABC	B
9	-	I
10	P	I
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	O
30	Ziehl	B
31	-	I
32	Neelsen	I
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O

1	All	O
2	members	O
3	are	O
4	also	O
5	capable	O
6	of	O
7	activating	O
8	in	O
9	vivo	O
10	transcription	O
11	from	O
12	promoters	O
13	that	O
14	contain	O
15	a	O
16	C	B
17	/	I
18	EBP	I
19	-	I
20	binding	I
21	site	I
22	.	O

1	Two	O
2	Pax2	B
3	/	I
4	5	I
5	/	I
6	8	I
7	-	I
8	binding	I
9	sites	I
10	in	O
11	Engrailed2	O
12	are	O
13	required	O
14	for	O
15	proper	O
16	initiation	O
17	of	O
18	endogenous	O
19	mid	O
20	-	O
21	hindbrain	O
22	expression	O
23	.	O

1	Fulminant	O
2	hepatitis	O
3	A	O
4	in	O
5	chronic	O
6	HBV	O
7	carrier	O
8	.	O

1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	O
7	a	O
8	Glu	O
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	O
16	tetrapeptide	O
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	O
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	O

1	The	O
2	presence	O
3	of	O
4	unidentified	O
5	macroscopic	O
6	or	O
7	microscopic	O
8	clusters	O
9	of	O
10	neoplastic	O
11	cells	O
12	,	O
13	lying	O
14	around	O
15	,	O
16	more	O
17	or	O
18	less	O
19	close	O
20	to	O
21	,	O
22	the	O
23	line	O
24	of	O
25	insertion	O
26	of	O
27	lesion	O
28	,	O
29	could	O
30	render	O
31	any	O
32	attempt	O
33	to	O
34	gain	O
35	a	O
36	"	O
37	radical	O
38	"	O
39	excision	O
40	useless	O
41	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	B
14	receptor	I
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	I
41	beta	I
42	-	I
43	catenin	I
44	binding	O
45	.	O

1	The	O
2	ORF1	O
3	product	O
4	was	O
5	required	O
6	for	O
7	competence	O
8	,	O
9	while	O
10	ORF2	O
11	,	O
12	which	O
13	was	O
14	cotranscribed	O
15	with	O
16	ORF1	O
17	and	O
18	encoded	O
19	a	O
20	predicted	O
21	protein	O
22	of	O
23	126	O
24	amino	O
25	acids	O
26	,	O
27	was	O
28	not	O
29	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	O
9	Dsg	B
10	protein	I
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	By	O
2	using	O
3	lacZ	B
4	fusions	O
5	,	O
6	it	O
7	was	O
8	possible	O
9	to	O
10	localize	O
11	the	O
12	DNA	O
13	sequences	O
14	required	O
15	to	O
16	mediate	O
17	nitrate	O
18	repression	O
19	to	O
20	the	O
21	pfl	B
22	promoter	I
23	-	I
24	regulatory	I
25	region	I
26	.	O

1	GCD10	B
2	binds	O
3	RNA	O
4	in	O
5	vitro	O
6	and	O
7	we	O
8	present	O
9	strong	O
10	biochemical	O
11	evidence	O
12	that	O
13	it	O
14	is	O
15	identical	O
16	to	O
17	the	O
18	RNA	B
19	-	I
20	binding	I
21	subunit	I
22	of	I
23	yeast	I
24	initiation	I
25	factor	I
26	-	I
27	3	I
28	(	O
29	eIF	B
30	-	I
31	3	I
32	).	I
33	eIF	I
34	-	I
35	3	I
36	is	O
37	a	O
38	multisubunit	O
39	complex	O
40	that	O
41	stimulates	O
42	translation	O
43	initiation	O
44	in	O
45	vitro	O
46	at	O
47	several	O
48	different	O
49	steps	O
50	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	crucial	O
7	role	O
8	of	O
9	the	O
10	mutations	O
11	activating	O
12	v	B
13	-	I
14	erbA	I
15	as	O
16	an	O
17	oncogene	O
18	is	O
19	to	O
20	'	O
21	freeze	O
22	'	O
23	c	O
24	-	O
25	ErbA	B
26	/	O
27	TRalpha	B
28	in	O
29	its	O
30	non	O
31	-	O
32	liganded	O
33	,	O
34	repressive	O
35	conformation	O
36	and	O
37	to	O
38	facilitate	O
39	its	O
40	overexpression	O
41	.	O

1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O

1	Morphogenesis	O
2	of	O
3	the	O
4	trochanter	O
5	produced	O
6	by	O
7	femoral	O
8	regeneration	O
9	in	O
10	the	O
11	phasmid	O
12	Carausius	O
13	morosus	O
14	Br	O

1	The	O
2	two	O
3	cysteine	O
4	residues	O
5	located	O
6	in	O
7	this	O
8	additional	O
9	region	O
10	may	O
11	be	O
12	involved	O
13	in	O
14	the	O
15	formation	O
16	of	O
17	a	O
18	disulfide	O
19	bridge	O
20	associated	O
21	with	O
22	the	O
23	activation	O
24	process	O
25	of	O
26	the	O
27	catalytic	O
28	activity	O
29	.	O

1	Plasma	B
2	secretin	I
3	,	O
4	pancreozymin	O
5	,	O
6	and	O
7	somatostatin	B
8	-	I
9	like	I
10	hormone	I
11	in	O
12	chronic	O
13	renal	O
14	failure	O
15	patients	O
16	.	O

1	As	O
2	PP2A	B
3	exerts	O
4	a	O
5	range	O
6	of	O
7	cellular	O
8	functions	O
9	including	O
10	cell	O
11	cycle	O
12	regulation	O
13	and	O
14	cell	O
15	fate	O
16	determination	O
17	,	O
18	we	O
19	were	O
20	surprised	O
21	to	O
22	find	O
23	that	O
24	these	O
25	embryos	O
26	develop	O
27	normally	O
28	until	O
29	postimplantation	O
30	,	O
31	around	O
32	embryonic	O
33	day	O
34	5	O
35	.	O
36	5	O
37	/	O
38	6	O
39	.	O
40	0	O
41	.	O

1	Two	O
2	XPG	O
3	regions	O
4	with	O
5	putative	O
6	NLS	O
7	[	O
8	amino	O
9	acid	O
10	(	O
11	AA	O
12	)	O
13	coordinates	O
14	:	O
15	NLS	B
16	-	I
17	B	I
18	(	O
19	AA	O
20	1057	O
21	-	O
22	1074	O
23	)	O
24	and	O
25	NLS	B
26	-	I
27	C	I
28	(	O
29	AA	O
30	1171	O
31	-	O
32	1185	O
33	)]	O
34	were	O
35	each	O
36	shown	O
37	to	O
38	independently	O
39	localize	O
40	the	O
41	beta	B
42	-	I
43	gal	I
44	extensively	O
45	(>	O
46	80	O
47	%)	O
48	to	O
49	the	O
50	nucleus	O
51	of	O
52	HeLa	O
53	cells	O
54	.	O

1	Reliability	O
2	of	O
3	cervical	O
4	range	O
5	of	O
6	motion	O
7	using	O
8	the	O
9	OSI	O
10	CA	O
11	6000	O
12	spine	O
13	motion	O
14	analyser	O
15	on	O
16	asymptomatic	O
17	and	O
18	symptomatic	O
19	subjects	O
20	.	O

1	Denaturation	O
2	of	O
3	the	O
4	simian	O
5	virus	O
6	40	O
7	origin	O
8	of	O
9	replication	O
10	mediated	O
11	by	O
12	human	B
13	replication	I
14	protein	I
15	A	I
16	.	O

1	Interestingly	O
2	,	O
3	EGF	B
4	,	O
5	but	O
6	not	O
7	insulin	B
8	,	O
9	stimulated	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	c	B
14	-	I
15	cbl	I
16	and	O
17	its	O
18	association	O
19	with	O
20	Crk	B
21	-	I
22	II	I
23	.	O

1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O

1	The	O
2	RNA	B
3	polymerase	I
4	III	I
5	-	I
6	recruiting	I
7	factor	I
8	TFIIIB	I
9	induces	O
10	a	O
11	DNA	O
12	bend	O
13	between	O
14	the	O
15	TATA	O
16	box	O
17	and	O
18	the	O
19	transcriptional	O
20	start	O
21	site	O
22	.	O

1	Complexes	O
2	containing	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	either	O
8	his175	O
9	or	O
10	his273	B
11	mutant	I
12	p53	I
13	proteins	I
14	are	O
15	completely	O
16	unable	O
17	to	O
18	bind	O
19	to	O
20	the	O
21	RGC	O
22	DNA	O
23	sequence	O
24	.	O

1	Effects	O
2	of	O
3	spatial	O
4	and	O
5	temporal	O
6	smoothing	O
7	on	O
8	stimulated	O
9	brillouin	O
10	scattering	O
11	in	O
12	the	O
13	independent	O
14	-	O
15	hot	O
16	-	O
17	spot	O
18	model	O
19	limit	O
20	The	O
21	influence	O
22	of	O
23	laser	O
24	beam	O
25	smoothing	O
26	on	O
27	stimulated	O
28	Brillouin	O
29	backscattering	O
30	(	O
31	SBBS	O
32	)	O
33	is	O
34	studied	O
35	analytically	O
36	in	O
37	the	O
38	limit	O
39	of	O
40	the	O
41	independent	O
42	hot	O
43	spot	O
44	model	O
45	.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	O

1	Despite	O
2	the	O
3	existence	O
4	of	O
5	30	O
6	cysteine	O
7	residues	O
8	,	O
9	carboxymethylation	O
10	prevented	O
11	the	O
12	formation	O
13	of	O
14	most	O
15	if	O
16	not	O
17	all	O
18	disulfide	O
19	bonds	O
20	that	O
21	otherwise	O
22	occurred	O
23	when	O
24	the	O
25	cells	O
26	were	O
27	sonicated	O
28	.	O

1	As	O
2	hGM	B
3	-	I
4	CSF	I
5	receptor	I
6	(	O
7	hGMR	O
8	)	O
9	does	O
10	not	O
11	contain	O
12	a	O
13	consensus	O
14	sequence	O
15	for	O
16	binding	O
17	of	O
18	PI	B
19	3	I
20	-	I
21	kinase	I
22	,	O
23	hGMR	O
24	must	O
25	use	O
26	a	O
27	distinct	O
28	mechanism	O
29	for	O
30	its	O
31	association	O
32	with	O
33	and	O
34	activation	O
35	of	O
36	PI	B
37	3	I
38	-	I
39	kinase	I
40	.	O

1	Moreover	O
2	,	O
3	this	O
4	enhancement	O
5	of	O
6	transcriptional	O
7	activation	O
8	by	O
9	COUP	B
10	-	I
11	TFI	I
12	requires	O
13	specifically	O
14	the	O
15	AF	O
16	-	O
17	1	O
18	transactivation	O
19	function	O
20	of	O
21	ER	B
22	and	O
23	can	O
24	be	O
25	observed	O
26	in	O
27	the	O
28	presence	O
29	of	O
30	E2	B
31	or	O
32	4	O
33	-	O
34	hydroxytamoxifen	O
35	but	O
36	not	O
37	ICI	O
38	164384	O
39	.	O

1	During	O
2	the	O
3	biosynthesis	O
4	of	O
5	all	O
6	three	O
7	mutant	O
8	polypeptides	O
9	,	O
10	the	O
11	signal	O
12	peptide	O
13	is	O
14	efficiently	O
15	and	O
16	accurately	O
17	cleaved	O
18	from	O
19	the	O
20	nascent	O
21	protein	O
22	,	O
23	even	O
24	though	O
25	in	O
26	mutants	O
27	X2	O
28	and	O
29	X3	O
30	the	O
31	cleavage	O
32	site	O
33	itself	O
34	has	O
35	been	O
36	altered	O
37	.	O

1	We	O
2	have	O
3	developed	O
4	a	O
5	new	O
6	method	O
7	for	O
8	estimation	O
9	of	O
10	regional	O
11	CBF	O
12	(	O
13	rCBF	O
14	)	O
15	and	O
16	cerebrovascular	O
17	reserve	O
18	capacity	O
19	on	O
20	a	O
21	pixel	O
22	-	O
23	by	O
24	-	O
25	pixel	O
26	basis	O
27	by	O
28	means	O
29	of	O
30	dynamic	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	(	O
35	MRI	O
36	).	O

1	Deletion	O
2	of	O
3	the	O
4	apeA	B
5	gene	I
6	,	O
7	either	O
8	with	O
9	or	O
10	without	O
11	deletion	O
12	of	O
13	other	O
14	proteinases	O
15	(	O
16	protease	O
17	IV	O
18	and	O
19	aminopeptidase	B
20	N	I
21	),	O
22	did	O
23	not	O
24	have	O
25	any	O
26	effect	O
27	on	O
28	cell	O
29	growth	O
30	in	O
31	the	O
32	various	O
33	media	O
34	tested	O
35	.	O

1	Generally	O
2	the	O
3	differences	O
4	between	O
5	short	O
6	gut	O
7	and	O
8	sham	O
9	operation	O
10	animals	O
11	disappeared	O
12	when	O
13	the	O
14	data	O
15	were	O
16	normalised	O
17	for	O
18	mucosal	O
19	weight	O
20	.	O

1	The	O
2	effect	O
3	of	O
4	food	O
5	on	O
6	procainamide	O
7	absorption	O
8	.	O

1	In	O
2	agreement	O
3	with	O
4	previous	O
5	in	O
6	vitro	O
7	data	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	UmuD	O
14	and	O
15	UmuD	O
16	'	O
17	are	O
18	able	O
19	to	O
20	form	O
21	both	O
22	homodimers	O
23	(	O
24	UmuD	B
25	-	I
26	UmuD	I
27	and	I
28	UmuD	I
29	'-	I
30	UmuD	I
31	')	I
32	and	O
33	a	O
34	heterodimer	O
35	(	O
36	UmuD	B
37	-	I
38	UmuD	I
39	').	O

1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O

1	Rheumatoid	B
2	factor	I
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O

1	The	O
2	HOI	O
3	induced	O
4	a	O
5	nearly	O
6	fourfold	O
7	increase	O
8	in	O
9	ANF	B
10	in	O
11	the	O
12	elderly	O
13	,	O
14	whereas	O
15	that	O
16	for	O
17	the	O
18	young	O
19	was	O
20	threefold	O
21	.	O

1	CONCLUSION	O
2	:	O
3	Presence	O
4	of	O
5	APOE	B
6	epsilon4	O
7	/*	O
8	seems	O
9	to	O
10	increase	O
11	the	O
12	risk	O
13	for	O
14	dementia	O
15	and	O
16	AD	O
17	independently	O
18	of	O
19	its	O
20	effect	O
21	on	O
22	dyslipidemia	O
23	and	O
24	atherogenesis	O
25	.	O

1	An	O
2	N	O
3	-	O
4	terminal	O
5	arm	O
6	from	O
7	each	O
8	subunit	O
9	wraps	O
10	around	O
11	the	O
12	dinucleotide	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	an	O
18	adjacent	O
19	subunit	O
20	,	O
21	covering	O
22	the	O
23	adenine	O
24	ring	O
25	of	O
26	NADP	O
27	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	acetaminophen	O
7	overdose	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	NAC	B
19	due	O
20	to	O
21	severe	O
22	intoxication	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O

1	Comparison	O
2	with	O
3	the	O
4	bHLH	O
5	/	O
6	PAS	B
7	family	I
8	genes	I
9	revealed	O
10	that	O
11	the	O
12	intron	O
13	/	O
14	exon	O
15	splice	O
16	pattern	O
17	of	O
18	mBMAL1	B
19	most	O
20	closely	O
21	matches	O
22	that	O
23	of	O
24	the	O
25	mAhr	O
26	,	O
27	which	O
28	suggests	O
29	that	O
30	BMAL1	B
31	and	O
32	Ahr	O
33	belong	O
34	to	O
35	the	O
36	same	O
37	subclass	O
38	and	O
39	may	O
40	be	O
41	derived	O
42	from	O
43	a	O
44	common	O
45	primordial	O
46	gene	O
47	.	O

1	Not	O
2	even	O
3	extensive	O
4	pancreatic	O
5	resection	O
6	could	O
7	prevent	O
8	pancreatic	O
9	remnant	O
10	infection	O
11	.	O

1	Furthermore	O
2	,	O
3	the	O
4	negative	O
5	transcriptional	O
6	effect	O
7	of	O
8	COUP	B
9	-	I
10	TFs	I
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	Oct4	O
20	embryonic	O
21	stem	O
22	cell	O
23	-	O
24	specific	O
25	enhancer	O
26	.	O

1	Acad	O
2	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	I
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	O
28	containing	O
29	unit	O
30	in	O
31	rhesus	O
32	macaque	O
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	I
39	repeat	O
40	,	O
41	Alu	B
42	3	I
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	I
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	I
70	repeat	O
71	.	O

1	Exposure	O
2	of	O
3	endothelium	O
4	to	O
5	pulsatile	O
6	shear	O
7	stresses	O
8	that	O
9	followed	O
10	a	O
11	tape	O
12	recording	O
13	of	O
14	physiological	O
15	flow	O
16	waveforms	O
17	(	O
18	electromagnetic	O
19	flowmeter	O
20	)	O
21	did	O
22	not	O
23	cause	O
24	gross	O
25	injury	O
26	or	O
27	denudation	O
28	even	O
29	when	O
30	peak	O
31	shear	O
32	exceeded	O
33	1500	O
34	dyne	O
35	/	O
36	cm2	O
37	.	O

1	High	O
2	ATP	O
3	/	O
4	GTP	O
5	ratios	O
6	promoted	O
7	initiation	O
8	of	O
9	RNA	O
10	primer	O
11	synthesis	O
12	at	O
13	3	O
14	'-	O
15	dCTTT	O
16	sites	O
17	,	O
18	whereas	O
19	low	O
20	ATP	O
21	/	O
22	GTP	O
23	ratios	O
24	promoted	O
25	initiation	O
26	at	O
27	3	O
28	'-	O
29	dCCC	O
30	sites	O
31	.	O

1	A	O
2	comparative	O
3	study	O
4	by	O
5	holographic	O
6	interferometry	O
7	of	O
8	ten	O
9	porcine	O
10	bioprosthetic	O
11	valves	O
12	(	O
13	seven	O
14	Carpentier	O
15	-	O
16	Edwards	O
17	SAV	O
18	,	O
19	two	O
20	BioImplant	O
21	and	O
22	one	O
23	Valcor	O
24	)	O
25	with	O
26	five	O
27	human	O
28	aortic	O
29	valves	O
30	before	O
31	and	O
32	after	O
33	glutaraldehyde	O
34	treatment	O
35	is	O
36	presented	O
37	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	"	O
11	protein	O
12	sensor	O
13	"	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	B
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O

1	They	O
2	self	O
3	-	O
4	completed	O
5	the	O
6	SF	B
7	-	O
8	36	O
9	questionnaire	O
10	and	O
11	their	O
12	QoL	O
13	was	O
14	described	O
15	and	O
16	retrospectively	O
17	compared	O
18	to	O
19	that	O
20	of	O
21	historical	O
22	controls	O
23	.	O

1	The	O
2	pigment	O
3	intensity	O
4	of	O
5	both	O
6	melanized	O
7	colonies	O
8	and	O
9	appressoria	O
10	of	O
11	CAL	O
12	transformants	O
13	was	O
14	weaker	O
15	than	O
16	that	O
17	of	O
18	the	O
19	wild	O
20	type	O
21	.	O

1	The	O
2	number	O
3	of	O
4	lactotropes	O
5	,	O
6	somatotropes	O
7	,	O
8	thyrotropes	O
9	,	O
10	and	O
11	gonadotropes	O
12	was	O
13	not	O
14	altered	O
15	compared	O
16	with	O
17	controls	O
18	,	O
19	indicating	O
20	that	O
21	in	O
22	the	O
23	adult	O
24	pituitary	O
25	,	O
26	POMC	O
27	products	O
28	are	O
29	not	O
30	required	O
31	to	O
32	maintain	O
33	the	O
34	distribution	O
35	of	O
36	cell	O
37	types	O
38	.	O

1	A	O
2	high	O
3	degree	O
4	of	O
5	correlation	O
6	in	O
7	the	O
8	sense	O
9	of	O
10	the	O
11	classic	O
12	conception	O
13	of	O
14	brain	O
15	localization	O
16	of	O
17	neuropsychological	O
18	syndromes	O
19	was	O
20	found	O
21	.	O

1	Only	O
2	the	O
3	3	O
4	.	O
5	0	O
6	-	O
7	kb	O
8	transcript	O
9	was	O
10	detected	O
11	in	O
12	adult	O
13	tissues	O
14	,	O
15	where	O
16	its	O
17	expression	O
18	was	O
19	restricted	O
20	almost	O
21	exclusively	O
22	to	O
23	the	O
24	central	O
25	nervous	O
26	system	O
27	.	O

1	Patients	O
2	with	O
3	acute	O
4	myocardial	O
5	infarction	O
6	had	O
7	higher	O
8	plasma	O
9	concentrations	O
10	of	O
11	neutrophil	B
12	elastase	I
13	and	O
14	the	O
15	non	O
16	-	O
17	peroxide	O
18	diene	O
19	conjugated	O
20	isomer	O
21	of	O
22	linoleic	O
23	acid	O
24	than	O
25	normal	O
26	volunteers	O
27	or	O
28	patients	O
29	with	O
30	stable	O
31	ischaemic	O
32	heart	O
33	disease	O
34	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	indicated	O
6	that	O
7	at	O
8	least	O
9	four	O
10	nuclear	O
11	proteins	O
12	with	O
13	distinct	O
14	biochemical	O
15	and	O
16	binding	O
17	properties	O
18	possess	O
19	the	O
20	ability	O
21	to	O
22	bind	O
23	the	O
24	3	O
25	beta	O
26	I	O
27	-	O
28	A	O
29	element	O
30	to	O
31	produce	O
32	four	O
33	DNA	O
34	-	O
35	protein	O
36	complexes	O
37	(	O
38	R1	O
39	to	O
40	R4	O
41	).	O

1	Heart	O
2	rate	O
3	(	O
4	HR	O
5	),	O
6	rectal	O
7	temperature	O
8	(	O
9	Tre	O
10	),	O
11	blood	O
12	pressure	O
13	,	O
14	temperature	O
15	and	O
16	relative	O
17	humidity	O
18	changes	O
19	inside	O
20	clothing	O
21	were	O
22	measured	O
23	on	O
24	18	O
25	professional	O
26	firemen	O
27	(	O
28	mean	O
29	age	O
30	29	O
31	.	O
32	4	O
33	+/-	O
34	7	O
35	.	O
36	4	O
37	yr	O
38	,	O
39	VO2	O
40	max	O
41	41	O
42	.	O
43	4	O
44	+	O
45	8	O
46	.	O
47	8	O
48	ml	O
49	kg	O
50	-	O
51	1	O
52	min	O
53	-	O
54	1	O
55	)	O
56	wearing	O
57	fire	O
58	fighter	O
59	'	O
60	s	O
61	uniforms	O
62	(	O
63	SU	O
64	)	O
65	or	O
66	aluminized	O
67	,	O
68	fire	O
69	resistant	O
70	,	O
71	impermeable	O
72	clothing	O
73	with	O
74	self	O
75	contained	O
76	breathing	O
77	apparatus	O
78	(	O
79	FE	O
80	).	O

1	A	O
2	Y	O
3	.	O
4	lipolytica	O
5	Kar2p	B
6	mutant	I
7	was	O
8	isolated	O
9	that	O
10	restored	O
11	interaction	O
12	with	O
13	an	O
14	Sls1p	B
15	mutant	I
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	interaction	O
21	with	O
22	Sls1p	B
23	could	O
24	be	O
25	nucleotide	O
26	and	O
27	/	O
28	or	O
29	conformation	O
30	dependent	O
31	.	O

1	Comparison	O
2	of	O
3	genomic	O
4	sequence	O
5	shows	O
6	that	O
7	the	O
8	ph	B
9	locus	I
10	has	O
11	been	O
12	duplicated	O
13	,	O
14	and	O
15	that	O
16	it	O
17	contains	O
18	proximal	O
19	and	O
20	distal	O
21	transcription	O
22	units	O
23	.	O

1	This	O
2	lack	O
3	of	O
4	correlation	O
5	may	O
6	be	O
7	due	O
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	growth	O
10	-	O
11	regulated	O
12	Syrian	B
13	hamster	I
14	CAD	I
15	gene	I
16	.	O

1	There	O
2	are	O
3	two	O
4	immunogenic	O
5	sites	O
6	on	O
7	the	O
8	type	O
9	A	O
10	influenza	O
11	A	O
12	/	O
13	Japan	O
14	/	O
15	57	O
16	(	O
17	H2N2	B
18	)	I
19	hemagglutinin	I
20	(	O
21	HA	B
22	)	O
23	that	O
24	can	O
25	be	O
26	recognized	O
27	by	O
28	class	B
29	I	I
30	major	I
31	histocompatibility	I
32	complex	I
33	(	O
34	MHC	B
35	),	O
36	H	O
37	-	O
38	2Kd	O
39	-	O
40	restricted	O
41	cytolytic	O
42	T	O
43	lymphocytes	O
44	(	O
45	CTLs	O
46	).	O

1	Such	O
2	marked	O
3	differences	O
4	are	O
5	found	O
6	occasionally	O
7	in	O
8	the	O
9	literature	O
10	:	O
11	heterophile	O
12	antibodies	O
13	against	O
14	bovine	B
15	gammaglobulin	I
16	are	O
17	regarded	O
18	as	O
19	responsible	O
20	for	O
21	the	O
22	interference	O
23	in	O
24	the	O
25	Sephadex	O
26	system	O
27	of	O
28	RIST	B
29	.	O

1	The	O
2	extraction	O
3	was	O
4	subsequently	O
5	rated	O
6	as	O
7	'	O
8	easy	O
9	'	O
10	or	O
11	'	O
12	difficult	O
13	'.	O
14	Taking	O
15	Pell	O
16	-	O
17	Gregory	O
18	class	O
19	C	O
20	as	O
21	a	O
22	predictor	O
23	of	O
24	a	O
25	'	O
26	difficult	O
27	'	O
28	extraction	O
29	,	O
30	specificity	O
31	was	O
32	88	O
33	%	O
34	but	O
35	sensitivity	O
36	was	O
37	low	O
38	at	O
39	15	O
40	%.	O

1	A	O
2	total	O
3	of	O
4	57	O
5	patients	O
6	with	O
7	Hodgkin	O
8	'	O
9	s	O
10	disease	O
11	limited	O
12	to	O
13	above	O
14	the	O
15	diaphragm	O
16	(	O
17	Stages	O
18	I	O
19	and	O
20	II	O
21	,	O
22	A	O
23	and	O
24	B	O
25	)	O
26	were	O
27	treated	O
28	with	O
29	radiation	O
30	therapy	O
31	alone	O
32	at	O
33	the	O
34	University	O
35	of	O
36	Florida	O
37	between	O
38	1964	O
39	and	O
40	1974	O
41	.	O

1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O

1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	B
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O

1	SCL	O
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O

1	Transcription	O
2	factor	O
3	binding	O
4	sites	O
5	downstream	O
6	of	O
7	the	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	transcription	O
14	start	O
15	site	O
16	are	O
17	important	O
18	for	O
19	virus	O
20	infectivity	O
21	.	O

1	MICs	O
2	of	O
3	four	O
4	antifungal	O
5	agents	O
6	(	O
7	5	O
8	-	O
9	fluorocytosine	O
10	,	O
11	miconazole	O
12	,	O
13	ketoconazole	O
14	,	O
15	and	O
16	amphotericin	O
17	B	O
18	)	O
19	for	O
20	84	O
21	clinical	O
22	isolates	O
23	of	O
24	various	O
25	Candida	O
26	species	O
27	were	O
28	then	O
29	determined	O
30	with	O
31	both	O
32	media	O
33	in	O
34	agar	O
35	dilution	O
36	and	O
37	microtiter	O
38	broth	O
39	dilution	O
40	systems	O
41	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	region	O
8	encoding	O
9	a	O
10	lipase	B
11	operon	I
12	and	O
13	a	O
14	putative	O
15	,	O
16	previously	O
17	uncharacterized	O
18	metalloprotease	O
19	of	O
20	Vibrio	O
21	cholerae	O
22	O1	O
23	.	O

1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	B
13	-	I
14	1	I
15	mutant	O
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O

1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	B
19	53	I
20	-	I
21	16	I
22	-	I
23	7	I
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	"	O
62	patch	O
63	7D	O
64	").	O

1	Plasma	O
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	B
7	),	O
8	aldosterone	O
9	(	O
10	PAC	O
11	)	O
12	and	O
13	renin	B
14	(	O
15	PRC	O
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	comparison	O
7	to	O
8	reports	O
9	from	O
10	other	O
11	regions	O
12	,	O
13	Scandinavian	O
14	renal	O
15	transplant	O
16	recipients	O
17	are	O
18	at	O
19	high	O
20	risk	O
21	of	O
22	dying	O
23	of	O
24	IHD	O
25	.	O

1	Evaluating	O
2	dietary	O
3	department	O
4	management	O
5	.	O

1	A	O
2	pharmacokinetic	O
3	study	O
4	of	O
5	apalcillin	B
6	was	O
7	performed	O
8	in	O
9	12	O
10	patients	O
11	in	O
12	an	O
13	intensive	O
14	-	O
15	care	O
16	unit	O
17	.	O

1	To	O
2	see	O
3	if	O
4	a	O
5	pulse	O
6	oximeter	O
7	can	O
8	monitor	O
9	the	O
10	fetus	O
11	during	O
12	labour	O
13	we	O
14	recruited	O
15	100	O
16	Caucasian	O
17	women	O
18	in	O
19	normal	O
20	uncomplicated	O
21	labour	O
22	.	O

1	Moreover	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	the	O
7	function	O
8	of	O
9	T3R	B
10	-	O
11	RXR	B
12	heterodimers	O
13	on	O
14	response	O
15	elements	O
16	composed	O
17	of	O
18	two	O
19	half	O
20	-	O
21	sites	O
22	in	O
23	a	O
24	directly	O
25	repeated	O
26	orientation	O
27	spaced	O
28	by	O
29	4	O
30	nucleotides	O
31	is	O
32	determined	O
33	in	O
34	major	O
35	parts	O
36	by	O
37	the	O
38	5	O
39	'-	O
40	flanking	O
41	sequence	O
42	of	O
43	the	O
44	upstream	O
45	half	O
46	-	O
47	site	O
48	.	O

1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	B
7	-	O
8	Akt	B
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	B
20	.	O

1	Cerebral	O
2	vasculitis	O
3	secondary	O
4	to	O
5	Crohn	O
6	'	O
7	s	O
8	disease	O
9	seems	O
10	to	O
11	be	O
12	a	O
13	very	O
14	rare	O
15	phenomenon	O
16	.	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	O
19	C	O
20	-	O
21	terminal	O
22	399	O
23	amino	O
24	acids	O
25	)	O
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O

1	Behind	O
2	the	O
3	ATPase	B
4	cluster	O
5	,	O
6	two	O
7	open	O
8	reading	O
9	frames	O
10	were	O
11	detected	O
12	that	O
13	are	O
14	not	O
15	homologous	O
16	to	O
17	any	O
18	known	O
19	chloroplast	O
20	gene	O
21	.	O

1	Circulating	O
2	platelets	O
3	may	O
4	be	O
5	activated	O
6	by	O
7	exposed	O
8	triple	O
9	-	O
10	helical	O
11	collagen	B
12	in	O
13	atherosclerotic	O
14	lesions	O
15	in	O
16	Mg	O
17	-	O
18	deficient	O
19	ruminants	O
20	.	O

1	Using	O
2	site	O
3	-	O
4	directed	O
5	mutagenesis	O
6	,	O
7	we	O
8	show	O
9	that	O
10	the	O
11	RAREoct	O
12	contributes	O
13	to	O
14	the	O
15	transcriptional	O
16	activation	O
17	of	O
18	Oct	B
19	-	I
20	3	I
21	/	I
22	4	I
23	promoter	I
24	in	O
25	P19	O
26	cells	O
27	and	O
28	,	O
29	most	O
30	interestingly	O
31	,	O
32	mediates	O
33	the	O
34	RA	O
35	-	O
36	induced	O
37	repression	O
38	in	O
39	RA	O
40	-	O
41	differentiated	O
42	EC	O
43	cells	O
44	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	has	O
4	been	O
5	used	O
6	widely	O
7	both	O
8	as	O
9	a	O
10	model	O
11	system	O
12	for	O
13	unraveling	O
14	the	O
15	biochemical	O
16	,	O
17	genetic	O
18	,	O
19	and	O
20	molecular	O
21	details	O
22	of	O
23	gene	O
24	expression	O
25	and	O
26	the	O
27	secretion	O
28	process	O
29	,	O
30	and	O
31	as	O
32	a	O
33	host	O
34	for	O
35	the	O
36	production	O
37	of	O
38	heterologous	O
39	proteins	O
40	of	O
41	biotechnological	O
42	interest	O
43	.	O

1	The	O
2	lengths	O
3	of	O
4	the	O
5	complete	O
6	polypeptide	O
7	chain	O
8	of	O
9	the	O
10	recombinant	O
11	enzyme	O
12	and	O
13	its	O
14	transit	O
15	peptide	O
16	are	O
17	388	O
18	and	O
19	53	O
20	residues	O
21	,	O
22	respectively	O
23	.	O

1	The	O
2	4	O
3	days	O
4	dexamethasone	O
5	suppression	O
6	test	O
7	showed	O
8	more	O
9	than	O
10	80	O
11	%	O
12	suppression	O
13	of	O
14	dehydroepiandrosterone	O
15	-	O
16	sulphate	O
17	and	O
18	a	O
19	variable	O
20	(	O
21	40	O
22	-	O
23	60	O
24	%)	O
25	reduction	O
26	of	O
27	testosterone	O
28	and	O
29	androstenedione	O
30	levels	O
31	.	O

1	To	O
2	determine	O
3	the	O
4	effects	O
5	on	O
6	the	O
7	pulmonary	O
8	barrier	O
9	of	O
10	several	O
11	surface	O
12	active	O
13	agents	O
14	,	O
15	a	O
16	series	O
17	of	O
18	metered	O
19	dose	O
20	inhalers	O
21	(	O
22	MDIs	O
23	)	O
24	was	O
25	prepared	O
26	and	O
27	used	O
28	to	O
29	dose	O
30	aerosolized	O
31	surfactant	O
32	to	O
33	the	O
34	airways	O
35	of	O
36	isolated	O
37	perfused	O
38	rat	O
39	lungs	O
40	.	O

1	271	O
2	:	O
3	31290	O
4	-	O
5	31295	O
6	,	O
7	1996	O
8	).	O

1	ALT	B
2	levels	O
3	in	O
4	responders	O
5	were	O
6	lowered	O
7	by	O
8	46	O
9	%	O
10	and	O
11	AST	O
12	levels	O
13	were	O
14	lowered	O
15	by	O
16	35	O
17	%	O
18	after	O
19	12	O
20	weeks	O
21	of	O
22	vitamin	O
23	E	O
24	treatment	O
25	.	O

1	Finally	O
2	,	O
3	over	O
4	a	O
5	similar	O
6	range	O
7	of	O
8	QO2	O
9	,	O
10	oxygen	O
11	extraction	O
12	was	O
13	greater	O
14	in	O
15	patients	O
16	with	O
17	ARDS	O
18	compared	O
19	to	O
20	patients	O
21	with	O
22	non	O
23	-	O
24	ARDS	O
25	respiratory	O
26	failure	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	67	O
34	and	O
35	slope	O
36	=	O
37	-	O
38	0	O
39	.	O
40	62	O
41	vs	O
42	r	O
43	=	O
44	-	O
45	0	O
46	.	O
47	45	O
48	and	O
49	slope	O
50	=	O
51	-	O
52	0	O
53	.	O
54	35	O
55	;	O
56	p	O
57	less	O
58	than	O
59	0	O
60	.	O
61	05	O
62	).	O

1	The	O
2	mortality	O
3	rate	O
4	and	O
5	histopathological	O
6	features	O
7	of	O
8	Nocardia	O
9	asteroides	O
10	and	O
11	Nocardia	O
12	brasiliensis	O
13	infections	O
14	in	O
15	congenitally	O
16	athymic	O
17	(	O
18	nude	O
19	)	O
20	mice	O
21	of	O
22	ICR	O
23	and	O
24	C3H	O
25	/	O
26	eB	O
27	origins	O
28	were	O
29	quite	O
30	different	O
31	from	O
32	what	O
33	we	O
34	found	O
35	for	O
36	Swiss	O
37	white	O
38	mice	O
39	and	O
40	other	O
41	inbred	O
42	mouse	O
43	strains	O
44	(	O
45	namely	O
46	,	O
47	C57	B
48	/	O
49	BL	B
50	/	O
51	6J	O
52	,	O
53	New	O
54	Zealand	O
55	Black	O
56	,	O
57	BALB	O
58	/	O
59	c	B
60	,	O
61	CBA	B
62	/	O
63	LAC	B
64	,	O
65	and	O
66	C3H	O
67	/	O
68	eB	O
69	).	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	BAP2	B
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	BAP3	B
17	gene	I
18	in	O
19	S	O
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	branched	O
29	-	O
30	chain	O
31	amino	O
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O

1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	cCrgl	O
10	or	O
11	BALB	O
12	/	O
13	cfC3HCrgl	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	O
24	-	O
25	estradiol	O
26	or	O
27	sesame	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	ovariectomized	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	vaginal	O
49	concretions	O
50	(	O
51	Experiments	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	silica	O
58	(	O
59	Experiment	O
60	II	O
61	)	O
62	were	O
63	implanted	O
64	intravaginally	O
65	.	O

1	In	O
2	addition	O
3	,	O
4	an	O
5	mck1	B
6	mds1	I
7	mrk1	I
8	triple	O
9	disruptant	O
10	was	O
11	viable	O
12	.	O

1	The	O
2	Functional	O
3	Independence	O
4	Measure	O
5	:	O
6	a	O
7	comparative	O
8	study	O
9	of	O
10	clinician	O
11	and	O
12	self	O
13	ratings	O
14	.	O

1	Aggregation	O
2	of	O
3	vHnf1	B
4	-	O
5	deficient	O
6	embryonic	O
7	stem	O
8	cells	O
9	with	O
10	wild	O
11	-	O
12	type	O
13	tetraploid	O
14	embryos	O
15	,	O
16	which	O
17	contribute	O
18	exclusively	O
19	to	O
20	extraembryonic	O
21	tissues	O
22	,	O
23	rescues	O
24	periimplantation	O
25	lethality	O
26	and	O
27	allows	O
28	development	O
29	to	O
30	progress	O
31	to	O
32	early	O
33	organogenesis	O
34	.	O

1	A	B
2	4	I
3	.	I
4	8	I
5	-	I
6	kilobase	I
7	BamHI	I
8	-	I
9	HindIII	I
10	fragment	I
11	encoding	O
12	the	O
13	entire	O
14	Neurospora	B
15	crassa	I
16	CuZn	I
17	superoxide	I
18	dismutase	I
19	gene	I
20	(	O
21	herein	O
22	designated	O
23	sod	B
24	-	I
25	1	I
26	)	O
27	was	O
28	isolated	O
29	from	O
30	a	O
31	genomic	O
32	library	O
33	using	O
34	two	O
35	60	O
36	-	O
37	base	O
38	deoxyoligonucleotide	O
39	probes	O
40	corresponding	O
41	to	O
42	the	O
43	published	O
44	N	O
45	.	O
46	crassa	O
47	amino	O
48	acid	O
49	sequence	O
50	.	O

1	The	O
2	etiology	O
3	,	O
4	pathology	O
5	,	O
6	brain	O
7	CT	O
8	scan	O
9	features	O
10	,	O
11	clinical	O
12	manifestations	O
13	and	O
14	treatment	O
15	of	O
16	these	O
17	accidents	O
18	were	O
19	discussed	O
20	.	O

1	LH	B
2	/	O
3	CG	B
4	receptor	I
5	activation	O
6	of	O
7	ARNO	B
8	is	O
9	not	O
10	mediated	O
11	by	O
12	activation	O
13	of	O
14	phosphatidylinositol	B
15	3	I
16	-	I
17	kinase	I
18	(	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	)	O
24	or	O
25	by	O
26	G	B
27	protein	I
28	beta	I
29	gamma	I
30	subunits	I
31	.	O

1	Identical	O
2	c	O
3	-	O
4	erbB3	B
5	transcripts	I
6	are	O
7	expressed	O
8	in	O
9	normal	O
10	human	O
11	placental	O
12	tissues	O
13	.	O

1	We	O
2	found	O
3	the	O
4	following	O
5	:	O
6	Specific	O
7	mutations	O
8	affected	O
9	the	O
10	precise	O
11	carbohydrate	O
12	structure	O
13	and	O
14	folding	O
15	of	O
16	the	O
17	HA	O
18	trimer	O
19	.	O

1	This	O
2	sequence	O
3	,	O
4	Thr	O
5	-	O
6	Gly	O
7	-	O
8	X	O
9	-	O
10	X	O
11	-	O
12	Gly	O
13	-	O
14	Asp	O
15	-	O
16	Gly	O
17	-	O
18	Lys	O
19	-	O
20	Ile	O
21	-	O
22	Phe	O
23	,	O
24	forms	O
25	part	O
26	of	O
27	the	O
28	B	O
29	-	O
30	loop	O
31	and	O
32	is	O
33	conserved	O
34	in	O
35	a	O
36	wide	O
37	variety	O
38	of	O
39	organisms	O
40	that	O
41	include	O
42	bacteria	O
43	,	O
44	algae	O
45	and	O
46	archeabacteria	O
47	.	O

1	This	O
2	report	O
3	presents	O
4	state	O
5	-	O
6	specific	O
7	MMRs	O
8	for	O
9	1987	O
10	-	O
11	1996	O
12	,	O
13	focusing	O
14	on	O
15	persistent	O
16	disparities	O
17	in	O
18	maternal	O
19	mortality	O
20	between	O
21	black	O
22	and	O
23	white	O
24	women	O
25	.	O

1	The	O
2	mean	O
3	body	O
4	mass	O
5	index	O
6	(	O
7	BMI	O
8	)	O
9	was	O
10	31	O
11	.	O
12	8	O
13	+/-	O
14	6	O
15	.	O
16	3	O
17	kg	O
18	/	O
19	m2	O
20	and	O
21	28	O
22	.	O
23	5	O
24	+/-	O
25	6	O
26	.	O
27	3	O
28	kg	O
29	/	O
30	m2	O
31	in	O
32	women	O
33	and	O
34	men	O
35	,	O
36	respectively	O
37	.	O

1	The	O
2	lacS	B
3	gene	I
4	was	O
5	cloned	O
6	in	O
7	an	O
8	E	O
9	.	O
10	coli	O
11	-	O
12	Streptococcus	O
13	shuttle	O
14	vector	O
15	and	O
16	was	O
17	expressed	O
18	both	O
19	in	O
20	a	O
21	lacS	O
22	deletion	O
23	derivative	O
24	of	O
25	S	O
26	.	O
27	thermophilus	O
28	and	O
29	in	O
30	a	O
31	pNZ63	O
32	-	O
33	cured	O
34	strain	O
35	,	O
36	L	O
37	.	O
38	lactis	O
39	NZ6091	O
40	.	O

1	PowerBLAST	O
2	analysis	O
3	identified	O
4	six	O
5	clusters	O
6	of	O
7	expressed	O
8	sequence	O
9	tags	O
10	(	O
11	ESTs	O
12	),	O
13	two	O
14	known	O
15	genes	O
16	(	O
17	BIR	B
18	,	O
19	SUR1	B
20	)	O
21	mapped	O
22	previously	O
23	to	O
24	this	O
25	region	O
26	,	O
27	and	O
28	a	O
29	previously	O
30	characterized	O
31	but	O
32	unmapped	O
33	gene	O
34	NEFA	O
35	(	O
36	DNA	O
37	binding	O
38	/	O
39	EF	O
40	hand	O
41	/	O
42	acidic	O
43	amino	O
44	-	O
45	acid	O
46	-	O
47	rich	O
48	).	O

1	Eucaryotic	O
2	transcription	O
3	factors	O
4	that	O
5	stimulate	B
6	RNA	I
7	polymerase	I
8	II	I
9	by	O
10	increasing	O
11	the	O
12	efficiency	O
13	of	O
14	elongation	O
15	of	O
16	specifically	O
17	or	O
18	randomly	O
19	initiated	O
20	RNA	O
21	chains	O
22	have	O
23	been	O
24	isolated	O
25	and	O
26	characterized	O
27	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	with	O
6	each	O
7	of	O
8	these	O
9	sequences	O
10	demonstrated	O
11	complexes	O
12	with	O
13	mobilities	O
14	identical	O
15	to	O
16	those	O
17	of	O
18	the	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	site	I
24	from	O
25	the	O
26	kappa	B
27	light	I
28	-	I
29	chain	I
30	gene	I
31	.	O

1	Mycotoxins	O
2	in	O
3	feeds	O
4	and	O
5	foods	O
6	.	O

1	Estrogen	O
2	replacement	O
3	therapy	O
4	and	O
5	risk	O
6	of	O
7	breast	O
8	cancer	O
9	:	O
10	results	O
11	of	O
12	two	O
13	meta	O
14	-	O
15	analyses	O
16	.	O

1	A	O
2	review	O
3	of	O
4	studies	O
5	published	O
6	between	O
7	1983	O
8	and	O
9	1995	O
10	shows	O
11	that	O
12	there	O
13	are	O
14	some	O
15	common	O
16	factors	O
17	as	O
18	regards	O
19	the	O
20	psychological	O
21	distress	O
22	and	O
23	social	O
24	and	O
25	functional	O
26	limitations	O
27	this	O
28	group	O
29	of	O
30	patients	O
31	has	O
32	to	O
33	deal	O
34	with	O
35	.	O

1	A	O
2	lambda	O
3	gt10	O
4	cDNA	O
5	library	O
6	was	O
7	constructed	O
8	from	O
9	poly	O
10	(	O
11	A	O
12	)+	O
13	RNA	O
14	of	O
15	young	O
16	green	O
17	leaves	O
18	of	O
19	spinach	O
20	.	O

1	L3	B
2	-	I
3	L4	I
4	compressive	O
5	load	O
6	was	O
7	calculated	O
8	using	O
9	a	O
10	model	O
11	of	O
12	the	O
13	anatomy	O
14	of	O
15	the	O
16	trunk	O
17	musculoskeletal	O
18	system	O
19	.	O

1	Biological	O
2	action	O
3	and	O
4	kinetics	O
5	of	O
6	the	O
7	elimination	O
8	of	O
9	tritium	O
10	oxide	O
11	in	O
12	dogs	O

1	0	O
2	.	O
3	61	O
4	+/-	O
5	0	O
6	.	O
7	04	O
8	).	O

1	Serotonin	O
2	concentration	O
3	in	O
4	the	O
5	blood	O
6	of	O
7	patients	O
8	with	O
9	hemorrhagic	O
10	fever	O
11	with	O
12	renal	O
13	syndrome	O

1	The	O
2	sacT	O
3	gene	O
4	regulating	O
5	the	O
6	sacPA	B
7	operon	I
8	in	I
9	Bacillus	I
10	subtilis	I
11	shares	O
12	strong	O
13	homology	O
14	with	O
15	transcriptional	O
16	antiterminators	O
17	.	O

1	We	O
2	observed	O
3	that	O
4	dephosphorylation	O
5	severely	O
6	inhibits	O
7	the	O
8	DNA	O
9	-	O
10	binding	O
11	ability	O
12	of	O
13	C	B
14	/	I
15	EBP	I
16	-	I
17	delta	I
18	and	O
19	its	O
20	transactivating	O
21	potential	O
22	increases	O
23	in	O
24	the	O
25	presence	O
26	of	O
27	cellular	B
28	phosphatase	I
29	inhibitors	O
30	,	O
31	such	O
32	as	O
33	okadaic	O
34	acid	O
35	and	O
36	sodium	O
37	orthovanadate	O
38	.	O

1	The	O
2	most	O
3	common	O
4	risk	O
5	factor	O
6	reported	O
7	for	O
8	both	O
9	recent	O
10	and	O
11	all	O
12	other	O
13	hepatitis	O
14	C	O
15	cases	O
16	was	O
17	a	O
18	history	O
19	of	O
20	injecting	O
21	drug	O
22	use	O
23	,	O
24	although	O
25	the	O
26	proportion	O
27	of	O
28	cases	O
29	with	O
30	that	O
31	history	O
32	was	O
33	different	O
34	in	O
35	NT	O
36	from	O
37	ACT	O
38	and	O
39	Queensland	O
40	.	O

1	The	O
2	IPL1	B
3	gene	I
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	fidelity	O
10	chromosome	O
11	segregation	O
12	in	O
13	the	O
14	budding	O
15	yeast	O
16	Saccharomyces	O
17	cerevisiae	O
18	.	O

1	MSSP	B
2	proteins	I
3	have	O
4	been	O
5	identified	O
6	by	O
7	their	O
8	binding	O
9	to	O
10	an	O
11	upstream	O
12	element	O
13	of	O
14	c	B
15	-	I
16	myc	I
17	.	O

1	After	O
2	one	O
3	accommodation	O
4	night	O
5	,	O
6	sleep	O
7	EEG	O
8	recordings	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	nights	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	inpatients	O
21	presenting	O
22	generalized	O
23	anxiety	O
24	disorder	O
25	(	O
26	GAD	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	GAD	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	depressive	O
53	disorder	O
54	(	O
55	MDD	O
56	)	O
57	patients	O
58	.	O

1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	B
19	mutant	I
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	B
26	and	O
27	VP23	B
28	null	I
29	mutants	I
30	.	O

1	Calcitriol	O
2	therapy	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	decrease	O
8	in	O
9	serum	O
10	iPTH	B
11	levels	O
12	(	O
13	701	O
14	+/-	O
15	103	O
16	.	O
17	9	O
18	vs	O
19	.	O

1	Furthermore	O
2	,	O
3	unlike	O
4	the	O
5	case	O
6	for	O
7	HIS3	B
8	where	O
9	only	O
10	a	O
11	limited	O
12	subset	O
13	of	O
14	TATA	O
15	-	O
16	like	O
17	sequences	O
18	can	O
19	activate	O
20	transcription	O
21	in	O
22	conjunction	O
23	with	O
24	GCN4p	B
25	,	O
26	many	O
27	divergent	O
28	TATA	O
29	-	O
30	like	O
31	sequences	O
32	allowed	O
33	GCN4p	B
34	activation	O
35	of	O
36	TRP3	O
37	.	O

1	The	O
2	level	O
3	of	O
4	carboxyl	O
5	-	O
6	terminal	O
7	parathyroid	O
8	hormone	O
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O

1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O

1	Salivary	O
2	estradiol	O
3	17	O
4	beta	O
5	(	O
6	E2	B
7	-	I
8	17	I
9	beta	I
10	)	O
11	and	O
12	progesterone	O
13	(	O
14	P	O
15	)	O
16	were	O
17	determined	O
18	by	O
19	using	O
20	radioimmunoassay	O
21	techniques	O
22	in	O
23	30	O
24	pregnant	O
25	females	O
26	in	O
27	the	O
28	first	O
29	,	O
30	second	O
31	and	O
32	third	O
33	trimesters	O
34	as	O
35	well	O
36	as	O
37	in	O
38	10	O
39	non	O
40	-	O
41	pregnant	O
42	controls	O
43	during	O
44	the	O
45	luteal	O
46	phase	O
47	of	O
48	the	O
49	menstrual	O
50	cycle	O
51	.	O

1	Closure	O
2	of	O
3	an	O
4	open	O
5	high	O
6	below	O
7	-	O
8	knee	O
9	guillotine	O
10	amputation	O
11	wound	O
12	using	O
13	a	O
14	skin	O
15	-	O
16	stretching	O
17	device	O
18	.	O

1	Lysine	B
2	-	I
3	ketoglutarate	I
4	reductase	I
5	and	I
6	saccharopine	I
7	dehydrogenase	I
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O

1	TEMTU	O
2	and	O
3	DPTU	O
4	were	O
5	the	O
6	most	O
7	potent	O
8	teratogens	O
9	.	O

1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	O
8	individual	O
9	elements	O
10	of	O
11	secondary	O
12	structure	O
13	derived	O
14	from	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	B
23	protein	I
24	L9	I
25	have	O
26	been	O
27	synthesized	O
28	.	O

1	In	O
2	11	O
3	eyes	O
4	that	O
5	had	O
6	been	O
7	selected	O
8	at	O
9	random	O
10	10	O
11	micrograms	O
12	of	O
13	recombinant	B
14	tissue	I
15	plasminogen	I
16	activator	I
17	were	O
18	injected	O
19	midvitreally	O
20	24	O
21	hrs	O
22	later	O
23	.	O

1	The	O
2	signalling	O
3	molecules	O
4	Wnt1	B
5	and	O
6	Sonic	O
7	hedgehog	O
8	,	O
9	implicated	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	Myf5	O
15	in	O
16	myogenic	O
17	progenitor	O
18	cells	O
19	in	O
20	the	O
21	somite	O
22	,	O
23	are	O
24	also	O
25	produced	O
26	in	O
27	the	O
28	viscinity	O
29	of	O
30	the	O
31	Myf5	O
32	expression	O
33	domain	O
34	in	O
35	the	O
36	mesencephalon	O
37	.	O

1	A	O
2	chromosome	O
3	transmission	O
4	fidelity	O
5	(	O
6	ctf	O
7	)	O
8	mutant	O
9	,	O
10	s138	B
11	,	O
12	of	O
13	Saccharomyces	O
14	cerevisiae	O
15	was	O
16	identified	O
17	by	O
18	its	O
19	centromere	O
20	(	O
21	CEN	O
22	)	O
23	transcriptional	O
24	readthrough	O
25	phenotype	O
26	,	O
27	suggesting	O
28	perturbed	O
29	kinetochore	O
30	integrity	O
31	in	O
32	vivo	O
33	.	O

1	The	O
2	introduction	O
3	of	O
4	hARF4	O
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	Sec7p	O
18	pools	O
19	.	O

1	RESULTS	O
2	:	O
3	We	O
4	isolated	O
5	a	O
6	C	O
7	.	O
8	elegans	O
9	cDNA	O
10	that	O
11	encoded	O
12	a	O
13	protein	O
14	which	O
15	was	O
16	similar	O
17	to	O
18	,	O
19	but	O
20	not	O
21	exactly	O
22	homologous	O
23	with	O
24	mammalian	O
25	p120	O
26	Ras	B
27	-	O
28	GAP	B
29	.	O

1	The	O
2	bZP2	B
3	cDNA	I
4	(	O
5	115	O
6	-	O
7	1914	O
8	nt	O
9	,	O
10	1	O
11	.	O
12	8	O
13	kb	O
14	),	O
15	excluding	O
16	sequences	O
17	coding	O
18	for	O
19	N	O
20	-	O
21	terminal	O
22	signal	O
23	sequence	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	transmembranelike	O
29	domain	O
30	,	O
31	was	O
32	PCR	O
33	amplified	O
34	and	O
35	Sac1	B
36	-	I
37	Sal1	I
38	restricted	O
39	fragment	O
40	cloned	O
41	in	O
42	frame	O
43	downstream	O
44	of	O
45	the	O
46	T5	B
47	promoter	I
48	under	O
49	the	O
50	lac	B
51	operator	I
52	control	I
53	in	O
54	a	O
55	pQE	O
56	-	O
57	30	O
58	vector	O
59	.	O

1	As	O
2	for	O
3	31	O
4	stage	O
5	I	O
6	-	O
7	II	O
8	lung	O
9	cancer	O
10	patients	O
11	,	O
12	CR	O
13	has	O
14	been	O
15	observed	O
16	in	O
17	82	O
18	.	O
19	8	O
20	%	O
21	of	O
22	them	O
23	and	O
24	PR	B
25	in	O
26	13	O
27	.	O
28	8	O
29	%;	O
30	the	O
31	response	O
32	was	O
33	always	O
34	assessed	O
35	with	O
36	chest	O
37	radiography	O
38	,	O
39	CT	O
40	,	O
41	FBS	O
42	,	O
43	cytology	O
44	and	O
45	/	O
46	or	O
47	histology	O
48	.	O

1	D5	B
2	/	O
3	D1	B
4	(	O
5	CT	O
6	)	O
7	or	O
8	D5	B
9	/	O
10	D1D	O
11	(	O
12	CT	O
13	)	O
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	O
29	-	O
30	type	O
31	(	O
32	wt	O
33	)	O
34	D1	B
35	receptors	I
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	B
56	D1	I
57	receptors	I
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O

1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	O
18	-	O
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O

1	[	O
2	Pulmonary	O
3	vascular	O
4	resistance	O
5	(	O
6	PVR	O
7	)	O
8	during	O
9	10	O
10	%	O
11	O2	O
12	-	O
13	PVR	O
14	during	O
15	21	O
16	%	O
17	O2	O
18	/	O
19	PVR	O
20	during	O
21	21	O
22	%	O
23	O2	O
24	]	O
25	x	O
26	100	O
27	was	O
28	termed	O
29	as	O
30	hypoxic	O
31	pulmonary	O
32	vasoconstriction	O
33	(	O
34	HPV	O
35	).	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	B
8	protein	I
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	B
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	contribute	O
6	to	O
7	the	O
8	transcript	O
9	map	O
10	of	O
11	human	O
12	chromosome	O
13	21	O
14	and	O
15	the	O
16	understanding	O
17	of	O
18	the	O
19	pathophysiology	O
20	of	O
21	trisomy	O
22	21	O
23	,	O
24	we	O
25	have	O
26	used	O
27	exon	O
28	trapping	O
29	to	O
30	identify	O
31	fragments	O
32	of	O
33	chromosome	O
34	21	O
35	genes	O
36	.	O

1	Biological	O
2	evaluation	O
3	of	O
4	mibolerone	O
5	in	O
6	the	O
7	female	O
8	Beagle	O
9	.	O

1	Differences	O
2	in	O
3	profiles	O
4	of	O
5	viscosity	O
6	variables	O
7	between	O
8	subgroups	O
9	of	O
10	EAD	O
11	in	O
12	RA	O
13	patients	O
14	were	O
15	observed	O
16	.	O

1	Three	O
2	new	O
3	aromatase	B
4	inhibitors	O
5	have	O
6	recently	O
7	completed	O
8	phase	O
9	III	O
10	evaluation	O
11	as	O
12	treatment	O
13	of	O
14	metastatic	O
15	breast	O
16	cancer	O
17	in	O
18	post	O
19	-	O
20	menopausal	O
21	women	O
22	whose	O
23	disease	O
24	has	O
25	progressed	O
26	despite	O
27	tamoxifen	O
28	therapy	O
29	:	O
30	anastrozole	O
31	(	O
32	ARIMIDEX	O
33	,	O
34	Zeneca	O
35	),	O
36	letrozole	O
37	(	O
38	FEMARA	O
39	,	O
40	Novartis	O
41	)	O
42	and	O
43	vorozole	O
44	(	O
45	RIVIZOR	O
46	,	O
47	Janssen	O
48	).	O

1	These	O
2	regions	O
3	contain	O
4	inverted	O
5	E	O
6	-	O
7	box	O
8	palindromic	O
9	or	O
10	direct	O
11	repeat	O
12	motifs	O
13	and	O
14	bind	O
15	SREBP	B
16	-	I
17	1	I
18	with	O
19	different	O
20	affinities	O
21	.	O

1	The	O
2	structure	O
3	of	O
4	these	O
5	genes	O
6	suggests	O
7	a	O
8	common	O
9	ancestor	O
10	for	O
11	all	O
12	viperid	O
13	PLA2	B
14	genes	I
15	.	O

1	According	O
2	to	O
3	the	O
4	investigation	O
5	,	O
6	the	O
7	recent	O
8	burst	O
9	of	O
10	pseudoterranovosis	O
11	in	O
12	this	O
13	area	O
14	can	O
15	be	O
16	attributed	O
17	to	O
18	the	O
19	increased	O
20	presence	O
21	of	O
22	sea	O
23	lions	O
24	,	O
25	which	O
26	proliferate	O
27	in	O
28	the	O
29	Arctic	O
30	region	O
31	,	O
32	then	O
33	migrate	O
34	to	O
35	the	O
36	northern	O
37	Japan	O
38	Sea	O
39	and	O
40	eat	O
41	the	O
42	intermediate	O
43	host	O
44	fish	O
45	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	O
5	MB	O
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	O
16	-	O
17	CPK	B
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	Menstrual	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	personality	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O

1	The	O
2	investigation	O
3	was	O
4	thereafter	O
5	continued	O
6	in	O
7	an	O
8	open	O
9	fashion	O
10	by	O
11	administering	O
12	a	O
13	single	O
14	10	O
15	mg	O
16	dose	O
17	of	O
18	the	O
19	MAO	B
20	-	I
21	B	I
22	inhibitor	O
23	deprenyl	O
24	to	O
25	the	O
26	same	O
27	subjects	O
28	.	O

1	As	O
2	demonstrated	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	analysis	O
8	and	O
9	supershift	O
10	experiments	O
11	,	O
12	FIRE1	B
13	,	O
14	located	O
15	between	O
16	-	O
17	516	O
18	and	O
19	-	O
20	498	O
21	,	O
22	is	O
23	responsible	O
24	for	O
25	binding	O
26	NF	B
27	-	I
28	Y	I
29	.	O

1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O

1	The	O
2	level	O
3	of	O
4	contamination	O
5	in	O
6	the	O
7	wound	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	the	O
13	rapid	O
14	biopsy	O
15	fixation	O
16	technique	O
17	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	O
6	protein	O
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	MKK3	O
2	autophosphorylation	O
3	and	O
4	activation	O
5	of	O
6	p38	B
7	was	O
8	also	O
9	observed	O
10	following	O
11	coexpression	O
12	of	O
13	MKK3	O
14	with	O
15	MEKK3	B
16	,	O
17	but	O
18	not	O
19	with	O
20	MEKK2	B
21	.	O

1	Following	O
2	iv	O
3	injection	O
4	of	O
5	0	O
6	.	O
7	5	O
8	g	O
9	galactose	O
10	per	O
11	kg	O
12	body	O
13	weight	O
14	,	O
15	together	O
16	with	O
17	2	B
18	mu	I
19	Ci	I
20	generally	O
21	14C	O
22	-	O
23	labelled	O
24	galactose	O
25	,	O
26	14CO2	O
27	is	O
28	collected	O
29	in	O
30	regular	O
31	intervals	O
32	during	O
33	one	O
34	hour	O
35	.	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	B
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	O
18	factor	O
19	binding	O
20	sites	O
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	O
26	-	O
27	responsive	O
28	element	O
29	)	O
30	were	O
31	found	O
32	.	O

1	In	O
2	E	O
3	.	O
4	coli	O
5	,	O
6	CheW	O
7	mediates	O
8	the	O
9	physical	O
10	coupling	O
11	of	O
12	the	O
13	receptors	O
14	to	O
15	the	O
16	kinase	O
17	CheA	B
18	.	O

1	Anesthesia	O
2	was	O
3	maintained	O
4	with	O
5	isoflurane	O
6	(	O
7	ISO	O
8	)/	O
9	N2O	B
10	/	O
11	O2	O
12	inhalation	O
13	.	O

1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	other	O
6	pathways	O
7	involve	O
8	alternate	O
9	signal	O
10	transduction	O
11	events	O
12	(	O
13	e	O
14	.	O
15	g	O
16	.,	O
17	calcium	O
18	mobilization	O
19	)	O
20	and	O
21	promoter	O
22	response	O
23	elements	O
24	(	O
25	e	O
26	.	O
27	g	O
28	.,	O
29	SRE	O
30	).	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	3574	O
8	-	O
9	bp	O
10	Bacillus	O
11	subtilis	O
12	(	O
13	Bs	O
14	)	O
15	DNA	O
16	fragment	O
17	located	O
18	between	O
19	the	O
20	nrdA	O
21	and	O
22	citB	B
23	genes	I
24	at	O
25	about	O
26	169	O
27	degrees	O
28	on	O
29	the	O
30	chromosome	O
31	.	O

1	Although	O
2	linker	O
3	regions	O
4	in	O
5	transcription	O
6	factors	O
7	are	O
8	known	O
9	to	O
10	modulate	O
11	DNA	O
12	binding	O
13	specificity	O
14	,	O
15	our	O
16	studies	O
17	suggest	O
18	that	O
19	the	O
20	human	B
21	HSF1	I
22	linker	I
23	plays	O
24	no	O
25	role	O
26	in	O
27	determining	O
28	HSF1	B
29	binding	O
30	preferences	O
31	in	O
32	vivo	O
33	but	O
34	is	O
35	a	O
36	critical	O
37	determinant	O
38	in	O
39	regulating	O
40	the	O
41	HSF1	B
42	monomer	O
43	-	O
44	trimer	O
45	equilibrium	O
46	.	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	A	O
2	330	O
3	-	O
4	kb	O
5	YAC	O
6	,	O
7	A148A7	O
8	,	O
9	spanned	O
10	from	O
11	the	O
12	HLA	B
13	-	I
14	DQA1	I
15	locus	I
16	through	O
17	the	O
18	Y3	B
19	/	O
20	Ring	O
21	4	O
22	locus	O
23	and	O
24	extended	O
25	at	O
26	least	O
27	130	O
28	kb	O
29	centromeric	O
30	of	O
31	YAC	O
32	B1D12	O
33	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	phosphorylation	O
6	of	O
7	M	B
8	protein	I
9	at	O
10	the	O
11	major	O
12	in	O
13	vivo	O
14	sites	O
15	is	O
16	not	O
17	essential	O
18	for	O
19	virus	O
20	assembly	O
21	.	O

1	We	O
2	show	O
3	that	O
4	Rlm1	B
5	and	O
6	Smp1	B
7	have	O
8	MEF2	B
9	-	O
10	related	O
11	DNA	O
12	-	O
13	binding	O
14	specificities	O
15	:	O
16	Rlm1	B
17	binds	O
18	with	O
19	the	O
20	same	O
21	specificity	O
22	as	O
23	MEF2	B
24	,	O
25	CTA	O
26	(	O
27	T	O
28	/	O
29	A	O
30	)	O
31	4TAG	O
32	,	O
33	while	O
34	SMP1	B
35	binds	O
36	a	O
37	more	O
38	extended	O
39	consensus	O
40	sequence	O
41	,	O
42	ACTACTA	O
43	(	O
44	T	O
45	/	O
46	A	O
47	)	O
48	4TAG	O
49	.	O

1	On	O
2	the	O
3	trail	O
4	of	O
5	Dr	O
6	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	[	O
6	Hisanaga	O
7	,	O
8	S	O
9	.,	O
10	Kusubata	O
11	,	O
12	M	O
13	.,	O
14	Okumura	O
15	,	O
16	E	O
17	.	O
18	&	O
19	Kishimoto	O
20	,	O
21	T	O
22	.	O

1	It	O
2	can	O
3	also	O
4	be	O
5	used	O
6	to	O
7	examine	O
8	various	O
9	laryngeal	O
10	parameters	O
11	obtained	O
12	from	O
13	videotaped	O
14	endoscopic	O
15	and	O
16	stroboscopic	O
17	examinations	O
18	.	O

1	In	O
2	the	O
3	current	O
4	study	O
5	,	O
6	the	O
7	roles	O
8	of	O
9	two	O
10	putative	O
11	cis	O
12	-	O
13	acting	O
14	elements	O
15	within	O
16	the	O
17	-	O
18	73	O
19	to	O
20	+	O
21	44	O
22	region	O
23	in	O
24	basal	O
25	exon	O
26	2	O
27	promoter	O
28	activity	O
29	were	O
30	evaluated	O
31	using	O
32	mutagenesis	O
33	and	O
34	nuclear	O
35	protein	O
36	-	O
37	DNA	O
38	binding	O
39	assays	O
40	.	O

1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	MdPin1	B
9	,	O
10	a	O
11	Pin1	B
12	homologue	O
13	from	O
14	the	O
15	plant	O
16	species	O
17	apple	O
18	(	O
19	Malus	O
20	domestica	O
21	)	O
22	and	O
23	show	O
24	that	O
25	it	O
26	has	O
27	the	O
28	same	O
29	phosphorylation	O
30	-	O
31	specific	O
32	substrate	O
33	specificity	O
34	and	O
35	can	O
36	be	O
37	inhibited	O
38	by	O
39	juglone	O
40	in	O
41	vitro	O
42	,	O
43	as	O
44	is	O
45	the	O
46	case	O
47	for	O
48	Pin1	B
49	.	O

1	To	O
2	explore	O
3	the	O
4	function	O
5	of	O
6	human	B
7	SINA	I
8	-	I
9	homologous	I
10	(	I
11	Siah	I
12	)	I
13	proteins	I
14	,	O
15	expression	O
16	plasmids	O
17	encoding	O
18	Siah	B
19	-	I
20	1A	I
21	were	O
22	transiently	O
23	transfected	O
24	into	O
25	293	O
26	epithelial	O
27	cells	O
28	and	O
29	GM701	O
30	fibroblast	O
31	cells	O
32	,	O
33	resulting	O
34	in	O
35	growth	O
36	arrest	O
37	without	O
38	induction	O
39	of	O
40	apoptosis	O
41	.	O

1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	B
8	protein	I
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O

1	Relations	O
2	between	O
3	cellular	O
4	electrical	O
5	activity	O
6	and	O
7	cardiac	O
8	mechanical	O
9	activity	O
10	in	O
11	man	O
12	,	O
13	the	O
14	dog	O
15	and	O
16	the	O
17	rabbit	O

1	In	O
2	a	O
3	series	O
4	of	O
5	16	O
6	full	O
7	-	O
8	scale	O
9	fire	O
10	tests	O
11	,	O
12	investigators	O
13	at	O
14	the	O
15	IIT	O
16	Research	O
17	Institute	O
18	have	O
19	concluded	O
20	that	O
21	automatic	O
22	door	O
23	control	O
24	in	O
25	the	O
26	room	O
27	of	O
28	fire	O
29	origin	O
30	can	O
31	significantly	O
32	reduce	O
33	the	O
34	spread	O
35	of	O
36	toxic	O
37	smoke	O
38	and	O
39	gases	O
40	.	O

1	There	O
2	was	O
3	a	O
4	close	O
5	correlation	O
6	between	O
7	plasma	O
8	clearance	O
9	of	O
10	NT	O
11	by	O
12	10	O
13	-	O
14	hydroxylation	O
15	and	O
16	the	O
17	D	O
18	metabolic	O
19	ratio	O
20	(	O
21	D	O
22	/	O
23	4	O
24	-	O
25	OH	O
26	-	O
27	D	O
28	in	O
29	urine	O
30	)	O
31	in	O
32	the	O
33	Ghanaians	O
34	(	O
35	rs	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	01	O
48	)	O
49	and	O
50	Swedes	O
51	(	O
52	rs	O
53	=	O
54	-	O
55	0	O
56	.	O
57	84	O
58	;	O
59	P	O
60	less	O
61	than	O
62	0	O
63	.	O
64	01	O
65	).	O

1	Immunohistochemical	O
2	staining	O
3	was	O
4	positive	O
5	for	O
6	S	O
7	-	O
8	100	O
9	in	O
10	all	O
11	9	O
12	cases	O
13	stained	O
14	,	O
15	positive	O
16	for	O
17	HMB	O
18	-	O
19	45	O
20	in	O
21	9	O
22	(	O
23	90	O
24	%)	O
25	of	O
26	10	O
27	,	O
28	and	O
29	negative	O
30	for	O
31	cytokeratin	B
32	in	O
33	all	O
34	9	O
35	cases	O
36	in	O
37	which	O
38	myxoid	O
39	melanoma	O
40	remained	O
41	in	O
42	the	O
43	block	O
44	after	O
45	previous	O
46	sections	O
47	.	O

1	The	O
2	number	O
3	of	O
4	crystalline	O
5	deposits	O
6	is	O
7	less	O
8	in	O
9	the	O
10	advanced	O
11	atrophic	O
12	areas	O
13	of	O
14	the	O
15	RPE	O
16	-	O
17	choriocapillaris	O
18	complex	O
19	.	O

1	Interestingly	O
2	,	O
3	however	O
4	,	O
5	it	O
6	is	O
7	homologous	O
8	to	O
9	several	O
10	expressed	O
11	sequence	O
12	tags	O
13	(	O
14	EST	O
15	)	O
16	of	O
17	unknown	O
18	function	O
19	from	O
20	Caenorhabditis	O
21	elegans	O
22	,	O
23	Oryza	O
24	sativa	O
25	and	O
26	Homo	O
27	sapiens	O
28	.	O

1	In	O
2	the	O
3	PMR	O
4	target	O
5	area	O
6	but	O
7	not	O
8	in	O
9	the	O
10	nontreated	O
11	area	O
12	an	O
13	improvement	O
14	in	O
15	regional	O
16	myocardial	O
17	flow	O
18	reserve	O
19	occurs	O
20	in	O
21	wall	O
22	segments	O
23	with	O
24	initially	O
25	severely	O
26	or	O
27	moderately	O
28	reduced	O
29	stress	O
30	perfusion	O
31	.	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	O
16	T4	O
17	/	O
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	O
26	%	O
27	respectively	O
28	were	O
29	studied	O
30	.	O

1	Oligonucleotides	O
2	,	O
3	designed	O
4	on	O
5	the	O
6	basis	O
7	of	O
8	conserved	O
9	flanking	O
10	amino	O
11	acid	O
12	sequence	O
13	segments	O
14	within	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	eukaryotic	B
20	protein	I
21	kinase	I
22	C	I
23	(	I
24	PKC	I
25	)	I
26	proteins	I
27	,	O
28	were	O
29	used	O
30	as	O
31	primers	O
32	for	O
33	polymerase	O
34	chain	O
35	reactions	O
36	to	O
37	amplify	O
38	a	O
39	427	O
40	-	O
41	bp	O
42	chromosomal	O
43	DNA	O
44	fragment	O
45	from	O
46	the	O
47	filamentous	O
48	fungus	O
49	Trichoderma	O
50	reesei	O
51	.	O

1	In	O
2	patients	O
3	with	O
4	complete	O
5	or	O
6	partial	O
7	remission	O
8	of	O
9	the	O
10	tumor	O
11	,	O
12	the	O
13	neopterine	O
14	excretion	O
15	dropped	O
16	to	O
17	normal	O
18	values	O
19	.	O

1	The	O
2	patient	O
3	was	O
4	homozygous	O
5	for	O
6	the	O
7	underlying	O
8	mutation	O
9	,	O
10	which	O
11	was	O
12	found	O
13	to	O
14	be	O
15	a	O
16	G	O
17	-->	O
18	T	O
19	transversion	O
20	within	O
21	the	O
22	acceptor	O
23	splice	O
24	site	O
25	between	O
26	intron	O
27	e	O
28	and	O
29	exon	O
30	6	O
31	,	O
32	abolishing	O
33	normal	O
34	RNA	O
35	splicing	O
36	.	O

1	Vitamin	O
2	D3	O
3	plus	O
4	nicotine	O
5	treatment	O
6	produced	O
7	parallel	O
8	increases	O
9	in	O
10	cardiac	O
11	mass	O
12	and	O
13	elastic	O
14	modulus	O
15	,	O
16	with	O
17	a	O
18	significant	O
19	correlation	O
20	between	O
21	the	O
22	two	O
23	.	O

1	When	O
2	the	O
3	first	O
4	twitch	O
5	of	O
6	TOF	O
7	spontaneously	O
8	recovered	O
9	to	O
10	10	O
11	%	O
12	of	O
13	control	O
14	value	O
15	,	O
16	neostigmine	O
17	was	O
18	injected	O
19	(	O
20	40	O
21	micrograms	O
22	/	O
23	kg	O
24	in	O
25	adults	O
26	,	O
27	30	O
28	micrograms	O
29	/	O
30	kg	O
31	in	O
32	infants	O
33	and	O
34	children	O
35	).	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Whereas	O
2	a	O
3	PR55	B
4	beta	I
5	transcript	I
6	of	O
7	about	O
8	2	O
9	.	O
10	3	O
11	kb	O
12	was	O
13	detected	O
14	at	O
15	high	O
16	levels	O
17	in	O
18	the	O
19	neuroblastoma	O
20	derived	O
21	cell	O
22	line	O
23	LA	O
24	-	O
25	N	O
26	-	O
27	1	O
28	,	O
29	the	O
30	level	O
31	of	O
32	the	O
33	mRNA	O
34	was	O
35	very	O
36	low	O
37	in	O
38	the	O
39	other	O
40	human	O
41	cell	O
42	lines	O
43	analyzed	O
44	.	O

1	FAK	B
2	localizes	O
3	to	O
4	sites	O
5	of	O
6	transmembrane	B
7	integrin	I
8	receptor	I
9	clustering	O
10	and	O
11	facilitates	O
12	intracellular	O
13	signaling	O
14	events	O
15	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	14DM	I
5	gene	I
6	,	I
7	encoding	I
8	cytochrome	I
9	P450	I
10	lanosterol	I
11	14	I
12	alpha	I
13	-	I
14	demethylase	I
15	(	O
16	14DM	O
17	),	O
18	was	O
19	overexpressed	O
20	in	O
21	various	O
22	S	O
23	.	O
24	cerevisiae	O
25	strains	O
26	under	O
27	the	O
28	control	O
29	of	O
30	three	O
31	strong	O
32	heterologous	O
33	yeast	O
34	transcription	O
35	promoters	O
36	(	O
37	pADC1	B
38	,	O
39	pGPD	O
40	,	O
41	pPHO5	O
42	)	O
43	and	O
44	under	O
45	the	O
46	control	O
47	of	O
48	its	O
49	own	O
50	promoter	O
51	.	O

1	Me	B
2	(	O
3	2	O
4	)	O
5	SO	O
6	-	O
7	induced	O
8	neuronal	O
9	differentiation	O
10	of	O
11	N1E	O
12	-	O
13	115	O
14	neuroblastoma	O
15	cells	O
16	increased	O
17	both	O
18	the	O
19	expression	O
20	of	O
21	the	O
22	endogenous	O
23	Ntr	B
24	-	I
25	1	I
26	gene	I
27	and	O
28	reporter	O
29	genes	O
30	driven	O
31	by	O
32	NTR	B
33	-	I
34	1	I
35	promoter	I
36	sequences	I
37	by	O
38	3	O
39	-	O
40	4	O
41	-	O
42	fold	O
43	.	O

1	Limits	O
2	of	O
3	energy	O
4	turnover	O
5	in	O
6	relation	O
7	to	O
8	physical	O
9	performance	O
10	were	O
11	addressed	O
12	in	O
13	terms	O
14	of	O
15	upper	O
16	and	O
17	lower	O
18	limit	O
19	,	O
20	changes	O
21	during	O
22	a	O
23	training	O
24	programme	O
25	and	O
26	how	O
27	to	O
28	regulate	O
29	energy	O
30	balance	O
31	at	O
32	a	O
33	changing	O
34	energy	O
35	turnover	O
36	.	O

1	The	O
2	MCA	O
3	and	O
4	UA	O
5	PI	O
6	values	O
7	showed	O
8	the	O
9	greatest	O
10	deviation	O
11	for	O
12	any	O
13	single	O
14	-	O
15	vessel	O
16	parameter	O
17	.	O

1	Similar	O
2	waves	O
3	were	O
4	seen	O
5	on	O
6	cross	O
7	-	O
8	correlating	O
9	a	O
10	motor	O
11	unit	O
12	with	O
13	an	O
14	electronic	O
15	oscillator	O
16	,	O
17	confirming	O
18	that	O
19	their	O
20	occurrence	O
21	does	O
22	not	O
23	necessarily	O
24	demonstrate	O
25	the	O
26	existence	O
27	of	O
28	active	O
29	neural	O
30	interactions	O
31	.	O

1	The	O
2	loss	O
3	of	O
4	SKO1	B
5	completely	O
6	restored	O
7	ENA1	B
8	expression	O
9	in	O
10	a	O
11	hog1	B
12	mutant	I
13	and	O
14	partially	O
15	suppressed	O
16	the	O
17	osmotic	O
18	stress	O
19	sensitivity	O
20	,	O
21	qualifying	O
22	Sko1p	B
23	as	O
24	a	O
25	downstream	O
26	effector	O
27	of	O
28	the	O
29	HOG	B
30	pathway	O
31	.	O

1	Orthop	O
2	.	O

1	Cell	O
2	49	O
3	,	O
4	753	O
5	-	O
6	761	O
7	].	O

1	Angiographic	O
2	work	O
3	-	O
4	up	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	late	O
10	vaginal	O
11	metastasis	O
12	from	O
13	a	O
14	renal	O
15	carcinoma	O
16	.	O

1	Technique	O
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	amino	O
7	acid	O
8	sequences	O
9	of	O
10	the	O
11	two	O
12	human	B
13	PKC	I
14	-	I
15	delta	I
16	clones	O
17	with	O
18	the	O
19	rat	O
20	and	O
21	mouse	B
22	homologues	I
23	indicated	O
24	a	O
25	greater	O
26	degree	O
27	of	O
28	sequence	O
29	divergence	O
30	(	O
31	89	O
32	-	O
33	90	O
34	%	O
35	homology	O
36	)	O
37	compared	O
38	to	O
39	the	O
40	high	O
41	degree	O
42	of	O
43	sequence	O
44	conservation	O
45	observed	O
46	with	O
47	other	O
48	human	B
49	PKC	I
50	family	I
51	members	I
52	and	O
53	their	O
54	mammalian	O
55	counterparts	O
56	.	O

1	Downregulation	O
2	of	O
3	FUS	B
4	expression	O
5	in	O
6	BCR	B
7	/	O
8	ABL	B
9	-	O
10	expressing	O
11	32Dcl3	O
12	cells	O
13	was	O
14	associated	O
15	with	O
16	suppression	O
17	of	O
18	growth	O
19	factor	O
20	-	O
21	independent	O
22	colony	O
23	formation	O
24	,	O
25	restoration	O
26	of	O
27	G	B
28	-	I
29	CSF	I
30	-	O
31	induced	O
32	granulocytic	O
33	differentiation	O
34	and	O
35	reduced	O
36	tumorigenic	O
37	potential	O
38	in	O
39	vivo	O
40	.	O

1	We	O
2	infer	O
3	that	O
4	the	O
5	dominant	O
6	negative	O
7	inhibition	O
8	results	O
9	from	O
10	both	O
11	direct	O
12	proteolysis	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	galactosidase	I
18	tetramer	O
19	by	O
20	the	O
21	fusion	O
22	subunit	O
23	and	O
24	detour	O
25	of	O
26	the	O
27	tetramer	O
28	to	O
29	the	O
30	lysosome	O
31	.	O

1	Hrs	O
2	has	O
3	a	O
4	FYVE	O
5	double	O
6	zinc	O
7	finger	O
8	domain	O
9	,	O
10	which	O
11	specifically	O
12	binds	O
13	phosphatidylinositol	O
14	(	O
15	3	O
16	)-	O
17	phosphate	O
18	and	O
19	is	O
20	conserved	O
21	in	O
22	several	O
23	proteins	O
24	involved	O
25	in	O
26	vesicular	O
27	traffic	O
28	.	O

1	CCAAT	O
2	displacement	O
3	protein	O
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	B
10	papillomavirus	I
11	type	I
12	6	I
13	E6	I
14	,	O
15	E7	B
16	,	O
17	and	O
18	E1	B
19	promoters	I
20	.	O

1	The	O
2	effects	O
3	of	O
4	antithrombotic	O
5	drugs	O
6	in	O
7	patients	O
8	with	O
9	left	O
10	ventricular	O
11	thrombi	O
12	:	O
13	assessment	O
14	with	O
15	indium	O
16	-	O
17	111	O
18	platelet	O
19	imaging	O
20	and	O
21	two	O
22	-	O
23	dimensional	O
24	echocardiography	O
25	.	O

1	Piperacillin	B
2	-	O
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O

1	The	O
2	relative	O
3	abundance	O
4	of	O
5	each	O
6	alternatively	O
7	spliced	O
8	mRNA	O
9	was	O
10	determined	O
11	by	O
12	reverse	O
13	transcription	O
14	-	O
15	polymerase	O
16	chain	O
17	reaction	O
18	in	O
19	various	O
20	human	O
21	tissues	O
22	and	O
23	cell	O
24	lines	O
25	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	indicate	O
7	that	O
8	the	O
9	VirD2	B
10	omega	I
11	domain	I
12	is	O
13	important	O
14	for	O
15	efficient	O
16	T	O
17	-	O
18	DNA	O
19	integration	O
20	.	O

1	The	O
2	identified	O
3	isolates	O
4	of	O
5	CSF	B
6	(	O
7	20	O
8	of	O
9	29	O
10	)	O
11	were	O
12	:	O
13	ECHO	O
14	30	O
15	(	O
16	9	O
17	),	O
18	ECHO	O
19	11	O
20	(	O
21	7	O
22	),	O
23	ECHO	O
24	9	O
25	(	O
26	3	O
27	)	O
28	and	O
29	ECHO	O
30	7	O
31	(	O
32	1	O
33	).	O

1	Partial	O
2	N	O
3	-	O
4	terminal	O
5	amino	O
6	acid	O
7	sequence	O
8	analysis	O
9	showed	O
10	that	O
11	the	O
12	43K	B
13	and	O
14	42K	B
15	T	I
16	antigens	I
17	contain	O
18	methionine	O
19	at	O
20	residues	O
21	1	O
22	and	O
23	5	O
24	,	O
25	as	O
26	predicted	O
27	from	O
28	the	O
29	DNA	O
30	sequence	O
31	,	O
32	whereas	O
33	no	O
34	methionine	O
35	was	O
36	released	O
37	from	O
38	the	O
39	39K	B
40	T	I
41	antigen	I
42	during	O
43	the	O
44	first	O
45	six	O
46	cycles	O
47	of	O
48	Edman	O
49	degradation	O
50	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	vacuolar	B
6	H	I
7	(+)-	I
8	ATPase	I
9	B2	I
10	subunit	I
11	gene	I
12	in	O
13	differentiating	O
14	THP	O
15	-	O
16	1	O
17	cells	O
18	.	O

1	Cervicovaginal	O
2	foetal	O
3	fibronectin	B
4	in	O
5	the	O
6	prediction	O
7	of	O
8	preterm	O
9	labour	O
10	in	O
11	a	O
12	low	O
13	-	O
14	risk	O
15	population	O
16	.	O

1	Disturbance	O
2	of	O
3	regeneration	O
4	in	O
5	the	O
6	above	O
7	pathological	O
8	condition	O
9	results	O
10	from	O
11	the	O
12	damage	O
13	to	O
14	tunica	O
15	propria	O
16	and	O
17	loss	O
18	of	O
19	its	O
20	function	O
21	for	O
22	the	O
23	support	O
24	of	O
25	structural	O
26	homeostasis	O
27	.	O

1	An	O
2	additional	O
3	advantage	O
4	is	O
5	that	O
6	the	O
7	resin	O
8	can	O
9	be	O
10	removed	O
11	and	O
12	the	O
13	immunoperoxidase	B
14	technique	O
15	carried	O
16	out	O
17	on	O
18	thin	O
19	sections	O
20	.	O

1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	protein	I
18	(	O
19	THZif	B
20	-	I
21	1	I
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	O
62	-	O
63	hypersensitive	O
64	element	O
65	(	O
66	NHE	O
67	)	O
68	of	O
69	the	O
70	human	B
71	c	I
72	-	I
73	myc	I
74	gene	I
75	.	O

1	Neurons	O
2	were	O
3	held	O
4	at	O
5	-	O
6	67	O
7	mV	O
8	to	O
9	equate	O
10	voltage	O
11	-	O
12	dependent	O
13	effects	O
14	.	O

1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	address	O
8	antimicrobial	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	O
18	a	O
19	survival	O
20	benefit	O
21	.	O

1	Clinical	O
2	findings	O
3	were	O
4	:	O
5	height	O
6	183	O
7	cm	O
8	,	O
9	weight	O
10	62	O
11	kg	O
12	,	O
13	increased	O
14	length	O
15	of	O
16	lower	O
17	limbs	O
18	,	O
19	P2	B
20	-	I
21	A2	I
22	pilosity	O
23	and	O
24	micropenis	O
25	.	O

1	We	O
2	evaluated	O
3	the	O
4	likelihood	O
5	of	O
6	tissues	O
7	to	O
8	be	O
9	positive	O
10	for	O
11	carcinoembryonic	B
12	antigen	I
13	and	O
14	the	O
15	intensity	O
16	of	O
17	carcinoembryonic	B
18	antigen	I
19	staining	O
20	in	O
21	specimens	O
22	of	O
23	villous	O
24	adenomas	O
25	,	O
26	mixed	O
27	polypoid	O
28	villous	O
29	adenomas	O
30	,	O
31	polypoid	O
32	adenomas	O
33	,	O
34	and	O
35	diverticulitis	O
36	using	O
37	the	O
38	peroxidase	B
39	-	I
40	antiperoxidase	I
41	technique	O
42	.	O

1	1	O
2	.	O

1	Chordoma	O
2	of	O
3	the	O
4	spinal	O
5	cord	O
6	in	O
7	a	O
8	F344	O
9	rat	O
10	.	O

1	Based	O
2	on	O
3	16S	B
4	rRNA	I
5	gene	I
6	sequence	I
7	analysis	O
8	,	O
9	the	O
10	11	O
11	species	O
12	having	O
13	two	O
14	tuf	B
15	genes	I
16	all	O
17	have	O
18	a	O
19	common	O
20	ancestor	O
21	,	O
22	while	O
23	the	O
24	six	O
25	species	O
26	having	O
27	only	O
28	one	O
29	copy	O
30	diverged	O
31	from	O
32	the	O
33	enterococcal	O
34	lineage	O
35	before	O
36	that	O
37	common	O
38	ancestor	O
39	.	O

1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	B
14	protein	I
15	genes	I
16	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	expression	O
6	vectors	O
7	for	O
8	CCAAT	B
9	/	I
10	enhancer	I
11	binding	I
12	protein	I
13	(	O
14	C	B
15	/	I
16	EBP	I
17	)	I
18	alpha	I
19	and	O
20	C	B
21	/	I
22	EBP	I
23	beta	I
24	trans	O
25	-	O
26	activated	O
27	the	O
28	rat	B
29	uncoupling	I
30	protein	I
31	gene	I
32	promoter	I
33	due	O
34	to	O
35	sequences	O
36	in	O
37	the	O
38	5	O
39	'	O
40	proximal	O
41	region	O
42	.	O

1	The	O
2	low	O
3	number	O
4	of	O
5	false	O
6	positives	O
7	indicates	O
8	that	O
9	our	O
10	scheme	O
11	would	O
12	not	O
13	confuse	O
14	the	O
15	radiologist	O
16	by	O
17	suggesting	O
18	normal	O
19	regions	O
20	as	O
21	suspicious	O
22	.	O

1	The	O
2	molecular	O
3	weight	O
4	of	O
5	in	O
6	vivo	O
7	-	O
8	labeled	O
9	proteins	O
10	was	O
11	increased	O
12	relative	O
13	to	O
14	that	O
15	of	O
16	in	O
17	vitro	O
18	-	O
19	translated	O
20	proteins	O
21	,	O
22	indicating	O
23	that	O
24	a	O
25	posttranslational	O
26	modification	O
27	had	O
28	occurred	O
29	.	O

1	With	O
2	respect	O
3	to	O
4	the	O
5	distribution	O
6	of	O
7	active	O
8	MREs	O
9	over	O
10	the	O
11	promoter	O
12	region	O
13	,	O
14	the	O
15	hMT	B
16	-	I
17	IIA	I
18	gene	I
19	is	O
20	largely	O
21	different	O
22	from	O
23	the	O
24	mouse	B
25	metallothionein	I
26	-	I
27	I	I
28	gene	I
29	,	O
30	suggesting	O
31	that	O
32	MRE	O
33	arrangement	O
34	is	O
35	not	O
36	an	O
37	important	O
38	factor	O
39	for	O
40	metal	O
41	regulation	O
42	.	O

1	Indeed	O
2	,	O
3	ERM	O
4	and	O
5	c	B
6	-	I
7	Jun	I
8	synergistically	O
9	activated	O
10	the	O
11	EBS	O
12	-	O
13	CRE	O
14	without	O
15	making	O
16	an	O
17	apparent	O
18	ternary	O
19	complex	O
20	.	O

1	In	O
2	line	O
3	with	O
4	the	O
5	small	O
6	values	O
7	for	O
8	QS	O
9	/	O
10	QC	O
11	,	O
12	our	O
13	results	O
14	further	O
15	indicate	O
16	that	O
17	even	O
18	large	O
19	,	O
20	well	O
21	-	O
22	perfused	O
23	,	O
24	occluded	O
25	air	O
26	spaces	O
27	in	O
28	the	O
29	lung	O
30	will	O
31	hardly	O
32	affect	O
33	the	O
34	recovered	O
35	ventilation	O
36	/	O
37	perfusion	O
38	distribution	O
39	obtained	O
40	from	O
41	inert	O
42	gas	O
43	data	O
44	when	O
45	CDCSF6	O
46	exceeds	O
47	0	O
48	.	O
49	1	O
50	ml	O
51	.	O
52	min	O
53	-	O
54	1	O
55	.	O
56	mmHg	O
57	-	O
58	1	O
59	.	O

1	RNase	B
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	O
8	-	O
9	kDa	O
10	CaM	B
11	PDE	I
12	mRNA	I
13	or	O
14	structurally	O
15	related	O
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	B
20	PDE	I
21	isoforms	I
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O

1	Grimelius	O
2	stain	O
3	was	O
4	positive	O
5	,	O
6	Masson	O
7	Fontana	O
8	stain	O
9	negative	O
10	.	O

1	In	O
2	sorted	O
3	bone	O
4	marrow	O
5	cells	O
6	expression	O
7	of	O
8	both	O
9	VpreB	B
10	genes	I
11	was	O
12	detected	O
13	in	O
14	pro	O
15	-	O
16	B	O
17	/	O
18	pre	O
19	-	O
20	BI	O
21	and	O
22	large	O
23	pre	O
24	-	O
25	BII	O
26	cells	O
27	,	O
28	while	O
29	the	O
30	RNA	O
31	steady	O
32	state	O
33	levels	O
34	were	O
35	at	O
36	least	O
37	100	O
38	-	O
39	fold	O
40	lower	O
41	in	O
42	small	O
43	pre	O
44	-	O
45	BII	O
46	and	O
47	immature	O
48	/	O
49	mature	O
50	B	O
51	cells	O
52	.	O

1	The	O
2	complement	O
3	C3a	B
4	anaphylatoxin	I
5	receptor	I
6	(	O
7	C3aR	B
8	)	O
9	is	O
10	a	O
11	seven	O
12	-	O
13	transmembrane	O
14	G	B
15	-	I
16	protein	I
17	coupled	I
18	chemoattractant	I
19	receptor	I
20	that	O
21	on	O
22	binding	O
23	the	O
24	C3a	O
25	peptide	O
26	ligand	O
27	mediates	O
28	numerous	O
29	cellular	O
30	responses	O
31	,	O
32	including	O
33	histamine	O
34	release	O
35	from	O
36	mast	O
37	cells	O
38	.	O
39	smooth	O
40	muscle	O
41	contraction	O
42	,	O
43	and	O
44	the	O
45	directed	O
46	migration	O
47	of	O
48	eosinophils	O
49	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	O
21	EFP	O
22	.	O

1	Specifically	O
2	,	O
3	the	O
4	deduced	O
5	FR	B
6	-	I
7	19	I
8	amino	I
9	acid	I
10	sequence	I
11	has	O
12	approximately89	O
13	,	O
14	77	O
15	,	O
16	and	O
17	68	O
18	%	O
19	overall	O
20	identity	O
21	to	O
22	chicken	O
23	TEF	B
24	-	I
25	1A	I
26	,	O
27	mouse	B
28	TEF	I
29	-	I
30	1	I
31	,	O
32	and	O
33	mouse	O
34	embryonic	O
35	TEA	O
36	domain	O
37	-	O
38	containing	O
39	factor	O
40	,	O
41	respectively	O
42	.	O

1	The	O
2	study	O
3	included	O
4	139	O
5	eyes	O
6	with	O
7	presumed	O
8	ocular	O
9	histoplasmosis	O
10	syndrome	O
11	(	O
12	POHS	O
13	)	O
14	and	O
15	age	O
16	-	O
17	related	O
18	macular	O
19	degeneration	O
20	(	O
21	AMD	O
22	).	O

1	We	O
2	find	O
3	that	O
4	3T1	B
5	-	I
6	3T2	I
7	mixing	O
8	has	O
9	a	O
10	pronounced	O
11	effect	O
12	on	O
13	the	O
14	line	O
15	shape	O
16	and	O
17	radiative	O
18	decay	O
19	rate	O
20	of	O
21	emission	O
22	from	O
23	the	O
24	3T2	O
25	state	O
26	and	O
27	that	O
28	the	O
29	extent	O
30	of	O
31	mixing	O
32	depends	O
33	critically	O
34	on	O
35	the	O
36	magnitude	O
37	of	O
38	nontetrahedral	O
39	distortions	O
40	.	O

1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O

1	Two	O
2	new	O
3	flavone	O
4	glucosides	O
5	,	O
6	nevadensin	B
7	5	I
8	-	I
9	O	I
10	-	I
11	beta	I
12	-	I
13	D	I
14	-	I
15	glucoside	I
16	and	I
17	nevadensin	I
18	5	I
19	-	I
20	O	I
21	-	I
22	beta	I
23	-	I
24	D	I
25	-	I
26	glucosyl	I
27	(	I
28	1	I
29	-->	I
30	6	I
31	)	I
32	beta	I
33	-	I
34	D	I
35	-	I
36	glucoside	I
37	,	O
38	have	O
39	been	O
40	isolated	O
41	from	O
42	the	O
43	aerial	O
44	parts	O
45	of	O
46	Lysionotus	O
47	pauciflorus	O
48	.	O

1	Age	O
2	>/=	O
3	50	O
4	years	O
5	(	O
6	odds	O
7	ratio	O
8	[	O
9	OR	O
10	],	O
11	14	O
12	.	O
13	1	O
14	),	O
15	BMI	O
16	>/=	O
17	28	O
18	kg	O
19	/	O
20	m	O
21	(	O
22	2	O
23	)	O
24	(	O
25	OR	O
26	,	O
27	5	O
28	.	O
29	7	O
30	),	O
31	triglycerides	O
32	>/=	O
33	1	O
34	.	O
35	7	O
36	mmol	O
37	/	O
38	L	O
39	(	O
40	OR	O
41	,	O
42	5	O
43	),	O
44	and	O
45	alanine	B
46	aminotransferase	I
47	(	O
48	ALT	B
49	)	O
50	>/=	O
51	2N	O
52	(	O
53	OR	O
54	,	O
55	4	O
56	.	O
57	6	O
58	)	O
59	were	O
60	independently	O
61	associated	O
62	with	O
63	septal	O
64	fibrosis	O
65	.	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	Members	O
2	of	O
3	the	O
4	titin	B
5	/	O
6	myosin	B
7	light	I
8	chain	I
9	kinase	I
10	family	I
11	play	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	the	O
17	organization	O
18	of	O
19	the	O
20	actin	B
21	/	O
22	myosin	B
23	cytoskeleton	I
24	,	O
25	especially	O
26	in	O
27	sarcomere	O
28	assembly	O
29	and	O
30	function	O
31	.	O

1	Moreover	O
2	,	O
3	it	O
4	is	O
5	the	O
6	assumptions	O
7	behind	O
8	steady	O
9	-	O
10	state	O
11	O2	O
12	uptake	O
13	that	O
14	do	O
15	not	O
16	permit	O
17	proper	O
18	interpretation	O
19	of	O
20	energy	O
21	expenditure	O
22	during	O
23	EPOC	O
24	;	O
25	1	O
26	l	O
27	O2	O
28	not	O
29	=	O
30	20	O
31	.	O
32	9	O
33	kJ	O
34	.	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	the	O
7	study	O
8	was	O
9	to	O
10	analyze	O
11	the	O
12	clinical	O
13	characteristics	O
14	,	O
15	treatment	O
16	and	O
17	outcome	O
18	of	O
19	310	O
20	patients	O
21	with	O
22	hydatidiform	O
23	mole	O
24	.	O

1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O

1	T	O
2	.,	O
3	Mahasneh	O
4	,	O
5	A	O
6	.,	O
7	and	O
8	Cote	O
9	,	O
10	G	O
11	.	O

1	Erythromycin	O
2	and	O
3	clindamycin	O
4	resistance	O
5	in	O
6	Corynebacterium	O
7	diphtheriae	O
8	from	O
9	skin	O
10	lesions	O
11	.	O

1	A	O
2	recent	O
3	index	O
4	(	O
5	Fluorosis	O
6	Risk	O
7	Index	O
8	)	O
9	developed	O
10	by	O
11	Pendrys	O
12	(	O
13	1990	O
14	)	O
15	is	O
16	also	O
17	included	O
18	in	O
19	this	O
20	review	O
21	.	O

1	Antithrombin	B
2	III	I
3	in	O
4	hip	O
5	surgery	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	O
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	O
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	O
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	Finally	O
2	,	O
3	Cas	B
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	B
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O

1	Terminal	O
2	deoxynucleotidyl	O
3	transferase	O
4	-	O
5	mediated	O
6	nick	O
7	end	O
8	labeling	O
9	assays	O
10	revealed	O
11	that	O
12	hormonal	O
13	activation	O
14	of	O
15	the	O
16	PAX3	O
17	repressors	O
18	induced	O
19	extensive	O
20	apoptosis	O
21	that	O
22	correlated	O
23	with	O
24	down	O
25	-	O
26	regulation	O
27	of	O
28	BCL	B
29	-	I
30	X	I
31	(	O
32	L	O
33	)	O
34	expression	O
35	.	O

1	Moritta	O
2	)	O
3	and	O
4	contains	O
5	Bis	O
6	-	O
7	GMA	O
8	.	O

1	A	O
2	long	O
3	follow	O
4	-	O
5	up	O
6	study	O
7	revealed	O
8	that	O
9	convalescent	O
10	stage	O
11	children	O
12	still	O
13	have	O
14	the	O
15	potency	O
16	to	O
17	have	O
18	an	O
19	immediate	O
20	type	O
21	hypersensitivity	O
22	reaction	O
23	on	O
24	exposure	O
25	to	O
26	mite	O
27	antigen	O
28	,	O
29	with	O
30	a	O
31	high	O
32	titer	O
33	of	O
34	mite	O
35	specific	O
36	IgE	B
37	in	O
38	their	O
39	sera	O
40	,	O
41	but	O
42	they	O
43	are	O
44	free	O
45	from	O
46	asthmatic	O
47	attacks	O
48	because	O
49	of	O
50	the	O
51	reduction	O
52	in	O
53	the	O
54	amount	O
55	of	O
56	mite	O
57	antigen	O
58	in	O
59	the	O
60	body	O
61	,	O
62	as	O
63	shown	O
64	by	O
65	the	O
66	reduction	O
67	in	O
68	the	O
69	amount	O
70	of	O
71	mite	O
72	specific	O
73	IgG	B
74	.	O

1	Aortic	O
2	diameters	O
3	in	O
4	infants	O
5	and	O
6	young	O
7	children	O
8	:	O
9	normative	O
10	angiographic	O
11	data	O
12	.	O

1	The	O
2	human	B
3	SHBG	I
4	proximal	I
5	promoter	I
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	I
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	B
23	-	I
24	FP6	I
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O

1	Only	O
2	fully	O
3	processed	O
4	Pra	B
5	(	O
6	N0	O
7	and	O
8	Nb	O
9	)	O
10	and	O
11	ICP35	B
12	(	O
13	ICP35	O
14	e	O
15	,	O
16	f	O
17	)	O
18	are	O
19	present	O
20	in	O
21	B	O
22	capsids	O
23	,	O
24	which	O
25	are	O
26	believed	O
27	to	O
28	be	O
29	precursors	O
30	of	O
31	mature	O
32	virions	O
33	.	O

1	In	O
2	addition	O
3	,	O
4	both	O
5	the	O
6	exon	O
7	1	O
8	-	O
9	and	O
10	exon	O
11	2	O
12	-	O
13	initiated	O
14	forms	O
15	of	O
16	the	O
17	c	B
18	-	I
19	Myc	I
20	protein	I
21	stimulated	O
22	transcription	O
23	of	O
24	a	O
25	Myc	B
26	/	O
27	Max	B
28	-	O
29	responsive	O
30	reporter	O
31	construct	O
32	to	O
33	a	O
34	similar	O
35	level	O
36	.	O

1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	O
15	-	O
16	terminally	O
17	truncated	O
18	MIP	B
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O

1	A	O
2	novel	O
3	phosphotyrosine	O
4	-	O
5	binding	O
6	domain	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	transforming	O
13	region	O
14	of	O
15	Cbl	B
16	interacts	O
17	directly	O
18	and	O
19	selectively	O
20	with	O
21	ZAP	B
22	-	I
23	70	I
24	in	O
25	T	O
26	cells	O
27	.	O

1	One	O
2	missense	O
3	allele	O
4	(	O
5	P236S	O
6	)	O
7	with	O
8	complete	O
9	loss	O
10	of	O
11	function	O
12	at	O
13	30	O
14	degreesC	O
15	and	O
16	four	O
17	missense	O
18	alleles	O
19	(	O
20	L173F	O
21	,	O
22	E225K	O
23	,	O
24	S269L	O
25	and	O
26	E274K	O
27	)	O
28	that	O
29	conferred	O
30	a	O
31	temperature	O
32	sensitive	O
33	phenotype	O
34	were	O
35	identified	O
36	.	O

1	Serum	O
2	magnesium	O
3	in	O
4	79	O
5	patients	O
6	of	O
7	gynecologic	O
8	neoplasms	O
9	treated	O
10	with	O
11	cisplatin	O
12	and	O
13	their	O
14	controls	O
15	was	O
16	measured	O
17	.	O

1	3	O
2	Significant	O
3	reductions	O
4	in	O
5	lying	O
6	mean	O
7	arterial	O
8	blood	O
9	pressure	O
10	were	O
11	observed	O
12	with	O
13	daily	O
14	doses	O
15	of	O
16	200	O
17	mg	O
18	(-	O
19	9	O
20	%),	O
21	400	O
22	mg	O
23	(-	O
24	10	O
25	%)	O
26	and	O
27	800	O
28	mg	O
29	(-	O
30	14	O
31	%),	O
32	and	O
33	were	O
34	associated	O
35	with	O
36	significant	O
37	decreases	O
38	in	O
39	heart	O
40	rate	O
41	and	O
42	plasma	B
43	renin	I
44	activity	O
45	.	O

1	Scintigraphic	O
2	visualisation	O
3	of	O
4	Walker	O
5	carcinoma	O
6	-	O
7	256	O
8	in	O
9	Sprague	O
10	-	O
11	Dawley	O
12	rats	O
13	by	O
14	means	O
15	of	O
16	99mTc	O
17	-	O
18	labelled	O
19	monocytes	O
20	.	O

1	Rather	O
2	,	O
3	usp	O
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O

1	BACKGROUND	O
2	:	O
3	It	O
4	is	O
5	generally	O
6	accepted	O
7	that	O
8	smoking	O
9	increases	O
10	blood	O
11	pressure	O
12	and	O
13	inhibits	O
14	muscle	O
15	sympathetic	O
16	nerve	O
17	activity	O
18	(	O
19	SNA	O
20	).	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	protein	O
7	product	O
8	of	O
9	the	O
10	ref	B
11	-	I
12	1	I
13	gene	I
14	stimulates	O
15	the	O
16	DNA	O
17	binding	O
18	activity	O
19	of	O
20	Fos	B
21	-	I
22	Jun	I
23	heterodimers	O
24	,	O
25	Jun	B
26	-	I
27	Jun	I
28	homodimers	I
29	and	O
30	Hela	O
31	cell	O
32	AP	B
33	-	I
34	1	I
35	proteins	I
36	as	O
37	well	O
38	as	O
39	that	O
40	of	O
41	several	O
42	other	O
43	transcription	O
44	factors	O
45	including	O
46	NF	B
47	-	I
48	kappa	I
49	B	I
50	,	O
51	Myb	B
52	and	O
53	members	O
54	of	O
55	the	O
56	ATF	B
57	/	O
58	CREB	B
59	family	I
60	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	Identification	O
2	of	O
3	Ste4	O
4	as	O
5	a	O
6	potential	O
7	regulator	O
8	of	O
9	Byr2	O
10	in	O
11	the	O
12	sexual	O
13	response	O
14	pathway	O
15	of	O
16	Schizosaccharomyces	O
17	pombe	O
18	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	total	O
6	cellular	O
7	RNA	O
8	indicated	O
9	that	O
10	xylP	B
11	encodes	O
12	a	O
13	1	O
14	.	O
15	3	O
16	-	O
17	kb	O
18	transcript	O
19	which	O
20	is	O
21	induced	O
22	by	O
23	xylan	O
24	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	dopaminergic	O
6	regulation	O
7	of	O
8	adrenal	O
9	zona	O
10	glomerulosa	O
11	corticosteroid	O
12	and	O
13	renal	B
14	renin	I
15	secretion	O
16	is	O
17	absent	O
18	in	O
19	patients	O
20	with	O
21	high	O
22	spinal	O
23	cord	O
24	transections	O
25	,	O
26	suggesting	O
27	that	O
28	intact	O
29	neural	O
30	pathways	O
31	from	O
32	the	O
33	central	O
34	nervous	O
35	system	O
36	are	O
37	necessary	O
38	for	O
39	metoclopramide	O
40	stimulation	O
41	of	O
42	aldosterone	O
43	and	O
44	renin	B
45	secretion	O
46	in	O
47	men	O
48	.	O

1	Trinipatch	O
2	is	O
3	a	O
4	small	O
5	,	O
6	transparent	O
7	,	O
8	matricial	O
9	,	O
10	monolayer	O
11	patch	O
12	with	O
13	an	O
14	absorption	O
15	promoter	O
16	,	O
17	marketed	O
18	in	O
19	two	O
20	dose	O
21	-	O
22	strengths	O
23	(	O
24	5	O
25	mg	O
26	/	O
27	24	O
28	h	O
29	and	O
30	10	O
31	mg	O
32	/	O
33	24	O
34	h	O
35	)	O
36	by	O
37	Laboratoires	O
38	Synthelabo	O
39	.	O

1	Gonadotropin	B
2	levels	O
3	in	O
4	mothers	O
5	who	O
6	have	O
7	had	O
8	two	O
9	sets	O
10	of	O
11	DZ	B
12	twins	I
13	.	O

1	Monkeys	O
2	were	O
3	evaluated	O
4	before	O
5	and	O
6	after	O
7	unilateral	O
8	and	O
9	serial	O
10	bilateral	O
11	removal	O
12	of	O
13	superior	O
14	temporal	O
15	cortex	O
16	.	O

1	Cytohesin	B
2	-	I
3	1	I
4	,	O
5	a	O
6	protein	O
7	abundant	O
8	in	O
9	cells	O
10	of	O
11	the	O
12	immune	O
13	system	O
14	,	O
15	has	O
16	been	O
17	proposed	O
18	to	O
19	be	O
20	a	O
21	human	O
22	homolog	O
23	of	O
24	the	O
25	Saccharomyces	B
26	cerevisiae	I
27	Sec7	I
28	gene	I
29	product	I
30	,	O
31	which	O
32	is	O
33	crucial	O
34	in	O
35	protein	O
36	transport	O
37	.	O

1	Our	O
2	laboratory	O
3	and	O
4	others	O
5	have	O
6	shown	O
7	alternative	O
8	splicing	O
9	of	O
10	up	O
11	to	O
12	ten	O
13	exons	O
14	at	O
15	a	O
16	discrete	O
17	extracellular	O
18	site	O
19	to	O
20	be	O
21	primarily	O
22	responsible	O
23	for	O
24	the	O
25	generation	O
26	of	O
27	CD44	B
28	variant	I
29	(	O
30	CD44v	B
31	)	O
32	isoforms	O
33	.	O

1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	O
16	operons	O
17	.	O

1	We	O
2	demonstrate	O
3	that	O
4	a	O
5	VT	O
6	+	O
7	peptide	O
8	was	O
9	specifically	O
10	phosphorylated	O
11	by	O
12	protein	B
13	kinase	I
14	C	I
15	(	I
16	PKC	I
17	)	O
18	in	O
19	vitro	O
20	,	O
21	but	O
22	not	O
23	by	O
24	protein	B
25	kinase	I
26	A	I
27	(	O
28	PKA	B
29	).	O

1	Single	O
2	-	O
3	alanine	O
4	-	O
5	substitution	O
6	mutations	O
7	had	O
8	minimal	O
9	,	O
10	if	O
11	any	O
12	,	O
13	effects	O
14	on	O
15	S	O
16	-	O
17	induced	O
18	cell	O
19	-	O
20	to	O
21	-	O
22	cell	O
23	fusion	O
24	.	O

1	In	O
2	a	O
3	country	O
4	where	O
5	general	O
6	HIV	O
7	prevalence	O
8	is	O
9	low	O
10	,	O
11	the	O
12	strategy	O
13	is	O
14	cost	O
15	-	O
16	effective	O
17	for	O
18	location	O
19	and	O
20	counselling	O
21	of	O
22	unknowingly	O
23	seropositive	O
24	individuals	O
25	.	O

1	San	O
2	Martin	O
3	'	O
4	s	O
5	psychological	O
6	traits	O
7	coupled	O
8	to	O
9	his	O
10	work	O
11	with	O
12	masonic	O
13	lodges	O
14	that	O
15	allowed	O
16	him	O
17	to	O
18	display	O
19	his	O
20	abilities	O
21	as	O
22	strategist	O
23	and	O
24	political	O
25	ruler	O
26	.	O

1	Consistent	O
2	with	O
3	ErbB	B
4	-	I
5	2	I
6	being	O
7	a	O
8	shared	O
9	receptor	O
10	subunit	O
11	,	O
12	its	O
13	tyrosine	O
14	phosphorylation	O
15	was	O
16	increased	O
17	by	O
18	both	O
19	heterologous	O
20	ligands	O
21	and	O
22	it	O
23	mediated	O
24	a	O
25	trans	O
26	-	O
27	inhibitory	O
28	effect	O
29	of	O
30	NDF	O
31	on	O
32	EGF	B
33	binding	O
34	.	O

1	Failure	O
2	of	O
3	stapedius	O
4	reflexometry	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	myasthenia	O
10	gravis	O
11	.	O

1	These	O
2	losses	O
3	account	O
4	for	O
5	the	O
6	resistance	O
7	of	O
8	EDS	B
9	-	I
10	IV	I
11	collagen	I
12	to	O
13	cyanogen	O
14	bromide	O
15	and	O
16	mammalian	B
17	collagenase	I
18	digestion	O
19	.	O

1	Significance	O
2	of	O
3	the	O
4	biopsy	O
5	site	O
6	of	O
7	the	O
8	latissimus	O
9	dorsi	O
10	muscle	O
11	for	O
12	fiber	O
13	typing	O
14	.	O

1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	I
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	I	O
2	.	O

1	Recently	O
2	,	O
3	cell	O
4	-	O
5	surface	O
6	TRAIL	O
7	has	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	expressed	O
13	by	O
14	activated	O
15	human	O
16	and	O
17	mouse	O
18	T	O
19	lymphocytes	O
20	,	O
21	raising	O
22	the	O
23	possibility	O
24	that	O
25	TRAIL	B
26	might	O
27	be	O
28	involved	O
29	in	O
30	T	O
31	cell	O
32	-	O
33	mediated	O
34	cytotoxicity	O
35	and	O
36	/	O
37	or	O
38	immune	O
39	regulation	O
40	.	O

1	RESULTS	O
2	:	O
3	Average	O
4	age	O
5	at	O
6	symptom	O
7	onset	O
8	was	O
9	41	O
10	.	O
11	2	O
12	years	O
13	.	O

1	Our	O
2	results	O
3	establish	O
4	GKLF	O
5	as	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcription	O
11	factor	O
12	likely	O
13	involved	O
14	in	O
15	regulation	O
16	of	O
17	expression	O
18	of	O
19	endogenous	O
20	genes	O
21	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	The	O
2	in	O
3	vitro	O
4	activity	O
5	of	O
6	mecillinam	O
7	and	O
8	amoxicillin	O
9	/	O
10	clavulanic	O
11	acid	O
12	against	O
13	Escherichia	O
14	coli	O
15	strains	O
16	producing	O
17	beta	O
18	-	O
19	lactamases	O
20	of	O
21	the	O
22	TEM	B
23	-	I
24	1	I
25	,	O
26	Oxa	B
27	-	I
28	1	I
29	and	O
30	chromosomal	O
31	type	O
32	were	O
33	studied	O
34	using	O
35	the	O
36	broth	O
37	and	O
38	agar	O
39	dilution	O
40	technique	O
41	.	O

1	Dermatology	O
2	is	O
3	no	O
4	exception	O
5	.	O

1	Although	O
2	there	O
3	is	O
4	little	O
5	evidence	O
6	that	O
7	diet	O
8	composition	O
9	plays	O
10	a	O
11	clinically	O
12	important	O
13	role	O
14	in	O
15	the	O
16	absorption	O
17	or	O
18	expenditure	O
19	of	O
20	energy	O
21	,	O
22	it	O
23	does	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	food	O
31	intake	O
32	.	O

1	The	O
2	preferences	O
3	were	O
4	for	O
5	intact	O
6	vis	O
7	-	O
8	a	O
9	-	O
10	vis	O
11	castrated	O
12	males	O
13	,	O
14	though	O
15	injections	O
16	of	O
17	TP	O
18	restored	O
19	the	O
20	castrates	O
21	'	O
22	attractiveness	O
23	to	O
24	the	O
25	females	O
26	.	O

1	Army	O
2	veterans	O
3	given	O
4	yellow	O
5	fever	O
6	vaccine	O
7	contaminated	O
8	with	O
9	hepatitis	O
10	B	O
11	virus	O
12	in	O
13	1942	O
14	and	O
15	controls	O
16	and	O
17	(	O
18	b	O
19	)	O
20	a	O
21	case	O
22	-	O
23	control	O
24	study	O
25	comparing	O
26	veterans	O
27	with	O
28	hepatocellular	O
29	carcinoma	O
30	in	O
31	Veterans	O
32	Affairs	O
33	hospitals	O
34	with	O
35	matched	O
36	controls	O
37	with	O
38	respect	O
39	to	O
40	receipt	O
41	of	O
42	contaminated	O
43	vaccine	O
44	in	O
45	1942	O
46	.	O

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	B
15	-	I
16	PAR	I
17	gene	I
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	60A	B
8	gene	I
9	which	O
10	encodes	O
11	another	O
12	TGF	B
13	-	I
14	beta	I
15	-	I
16	related	I
17	factor	I
18	in	O
19	Drosophila	O
20	.	O

1	The	O
2	murine	O
3	chromosomal	O
4	locations	O
5	of	O
6	the	O
7	five	O
8	NMDA	B
9	receptor	I
10	channel	I
11	subunits	I
12	,	O
13	the	O
14	epsilon	O
15	1	O
16	(	O
17	Grin2a	B
18	),	I
19	epsilon	I
20	2	I
21	(	O
22	Grin2b	O
23	),	O
24	epsilon	O
25	3	O
26	(	O
27	Grin2c	O
28	),	O
29	epsilon	O
30	4	O
31	(	O
32	Grin2d	O
33	)	O
34	and	O
35	zeta	B
36	1	I
37	(	O
38	Grinl	O
39	)	O
40	subunits	O
41	,	O
42	were	O
43	determined	O
44	using	O
45	an	O
46	interspecific	O
47	backcross	O
48	mapping	O
49	panel	O
50	derived	O
51	from	O
52	crosses	O
53	of	O
54	[(	O
55	C57BL	O
56	/	O
57	6JxM	O
58	.	O
59	spretus	O
60	)	O
61	F1xC57BL	O
62	/	O
63	6J	O
64	]	O
65	mice	O
66	.	O

1	PTP	B
2	-	O
3	S3	O
4	differs	O
5	from	O
6	PTP	B
7	-	I
8	S4	I
9	in	O
10	having	O
11	a	O
12	deletion	O
13	of	O
14	19	O
15	amino	O
16	acids	O
17	corresponding	O
18	to	O
19	exon	O
20	E1	O
21	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	This	O
2	tendency	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	biased	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	asparagus	O
14	genome	O
15	,	O
16	rather	O
17	than	O
18	to	O
19	the	O
20	translational	O
21	selection	O
22	for	O
23	specific	O
24	codons	O
25	.	O

1	Mouse	O
2	Impact	O
3	is	O
4	a	O
5	paternally	O
6	expressed	O
7	gene	O
8	encoding	O
9	an	O
10	evolutionarily	O
11	conserved	O
12	protein	O
13	of	O
14	unknown	O
15	function	O
16	.	O

1	In	O
2	similar	O
3	transient	O
4	transfection	O
5	experiments	O
6	in	O
7	HeLa	O
8	cells	O
9	,	O
10	overexpression	O
11	of	O
12	the	O
13	wt	B
14	human	I
15	retinoblastoma	I
16	susceptibility	I
17	gene	I
18	product	I
19	,	O
20	RB	B
21	,	O
22	was	O
23	found	O
24	to	O
25	repress	O
26	the	O
27	serum	O
28	-	O
29	induced	O
30	IL	B
31	-	I
32	6	I
33	(-	O
34	225	O
35	to	O
36	+	O
37	13	O
38	),	O
39	c	B
40	-	I
41	fos	I
42	(-	O
43	711	O
44	to	O
45	+	O
46	42	O
47	),	O
48	and	O
49	beta	B
50	-	I
51	actin	I
52	(-	O
53	3400	O
54	to	O
55	+	O
56	912	O
57	)	O
58	promoters	O
59	but	O
60	not	O
61	the	O
62	PRV	O
63	-	O
64	induced	O
65	IL	B
66	-	I
67	6	I
68	(-	O
69	110	O
70	to	O
71	+	O
72	13	O
73	)	O
74	or	O
75	the	O
76	serum	O
77	-	O
78	induced	O
79	MHC	O
80	(-	O
81	528	O
82	to	O
83	-	O
84	38	O
85	)	O
86	promoters	O
87	.	O

1	This	O
2	review	O
3	seeks	O
4	to	O
5	summarize	O
6	the	O
7	disease	O
8	,	O
9	to	O
10	propose	O
11	pathways	O
12	of	O
13	carcinogenesis	O
14	and	O
15	to	O
16	suggest	O
17	ways	O
18	in	O
19	which	O
20	the	O
21	"	O
22	traditional	O
23	"	O
24	risk	O
25	factors	O
26	may	O
27	be	O
28	interpreted	O
29	on	O
30	the	O
31	basis	O
32	of	O
33	evolving	O
34	knowledge	O
35	.	O

1	In	O
2	broken	O
3	L	O
4	-	O
5	cell	O
6	membranes	O
7	expressing	O
8	wild	O
9	type	O
10	or	O
11	mutant	O
12	M6P	O
13	/	O
14	IGF	B
15	II	I
16	receptors	I
17	,	O
18	30	O
19	nM	B
20	IGF	I
21	II	I
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	B
28	toxin	I
29	substrate	O
30	activity	O
31	.	O

1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O

1	Nursing	O
2	education	O
3	--	O
4	the	O
5	computer	O
6	obligation	O
7	.	O

1	PAO	O
2	blocks	O
3	turnover	O
4	of	O
5	the	O
6	phosphoryl	O
7	group	O
8	of	O
9	pp15	O
10	,	O
11	causing	O
12	its	O
13	accumulation	O
14	,	O
15	and	O
16	thereby	O
17	appears	O
18	to	O
19	interrupt	O
20	signal	O
21	transmission	O
22	from	O
23	the	O
24	receptor	O
25	to	O
26	the	O
27	glucose	O
28	-	O
29	transport	O
30	system	O
31	.	O

1	In	O
2	visible	O
3	tumours	O
4	the	O
5	best	O
6	results	O
7	were	O
8	obtained	O
9	with	O
10	FB	O
11	(	O
12	85	O
13	%)	O
14	while	O
15	TBN	O
16	was	O
17	positive	O
18	in	O
19	65	O
20	%.	O

1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	B
6	product	I
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	B
17	proteins	I
18	.	O

1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	eight	O
6	patients	O
7	who	O
8	underwent	O
9	a	O
10	curative	O
11	hepatic	O
12	resection	O
13	for	O
14	HCC	O
15	and	O
16	whose	O
17	preoperative	O
18	AFP	O
19	levels	O
20	were	O
21	>	O
22	100	O
23	ng	O
24	/	O
25	ml	O
26	,	O
27	were	O
28	selected	O
29	for	O
30	this	O
31	study	O
32	.	O

1	Ongoing	O
2	and	O
3	future	O
4	investigations	O
5	may	O
6	better	O
7	define	O
8	the	O
9	optimal	O
10	approach	O
11	for	O
12	local	O
13	control	O
14	,	O
15	the	O
16	optimal	O
17	duration	O
18	of	O
19	maintenance	O
20	chemotherapy	O
21	,	O
22	and	O
23	the	O
24	possible	O
25	role	O
26	of	O
27	biologic	O
28	response	O
29	modifiers	O
30	and	O
31	growth	O
32	factors	O
33	in	O
34	further	O
35	improving	O
36	the	O
37	outcome	O
38	for	O
39	patients	O
40	with	O
41	this	O
42	disease	O
43	.	O

1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	O
10	mutants	O
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	O
20	plate	O
21	inducer	O
22	shh	O
23	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O

1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	greatest	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	green	O
16	alga	O
17	Scenedemus	O
18	obliquus	O
19	plastocyanin	O
20	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	B
28	mRNA	I
29	levels	O
30	.	O

1	Moreover	O
2	,	O
3	the	O
4	observation	O
5	of	O
6	enhanced	O
7	luteal	O
8	HSP	O
9	-	O
10	27	O
11	phosphorylation	O
12	in	O
13	vivo	O
14	,	O
15	in	O
16	late	O
17	pregnancy	O
18	,	O
19	when	O
20	PKC	B
21	-	I
22	delta	I
23	is	O
24	abundant	O
25	and	O
26	active	O
27	,	O
28	suggests	O
29	that	O
30	select	O
31	PKC	B
32	family	O
33	members	O
34	contribute	O
35	to	O
36	sHSP	O
37	phosphorylation	O
38	events	O
39	in	O
40	vivo	O
41	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	O
28	protein	O
29	(	O
30	TP	O
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	B
11	-	I
12	1	I
13	allergen	I
14	of	O
15	Ascaris	O
16	,	O
17	the	O
18	gp15	B
19	/	O
20	400	O
21	'	O
22	ladder	O
23	'	O
24	protein	O
25	of	O
26	Brugia	O
27	malayi	O
28	,	O
29	Brugia	O
30	pahangi	O
31	and	O
32	Wuchereria	O
33	bancrofti	O
34	,	O
35	and	O
36	a	O
37	15	B
38	-	I
39	kDa	I
40	antigen	I
41	of	O
42	Dirofilaria	O
43	immitis	O
44	.	O

1	Although	O
2	methods	O
3	to	O
4	align	O
5	the	O
6	control	O
7	and	O
8	activation	O
9	fMR	O
10	images	O
11	may	O
12	correct	O
13	for	O
14	some	O
15	of	O
16	this	O
17	motional	O
18	error	O
19	,	O
20	they	O
21	will	O
22	be	O
23	incomplete	O
24	in	O
25	correcting	O
26	for	O
27	those	O
28	that	O
29	depend	O
30	on	O
31	spatial	O
32	orientation	O
33	.	O

1	Selenium	O
2	(.	O
3	1	O
4	ppm	O
5	)	O
6	and	O
7	E	O
8	(	O
9	50	O
10	IU	O
11	/	O
12	kg	O
13	)	O
14	supplementation	O
15	of	O
16	the	O
17	diet	O
18	of	O
19	the	O
20	sow	O
21	increased	O
22	plasma	O
23	tocopherol	O
24	and	O
25	Se	O
26	concentrations	O
27	,	O
28	but	O
29	did	O
30	not	O
31	increase	O
32	plasma	B
33	glutathione	I
34	peroxidase	I
35	(	O
36	GSH	B
37	-	I
38	Px	I
39	)	O
40	activity	O
41	.	O

1	This	O
2	indicates	O
3	that	O
4	under	O
5	certain	O
6	experimental	O
7	conditions	O
8	cdc2	B
9	/	O
10	p58	B
11	and	O
12	cdc2	B
13	/	O
14	p62	B
15	may	O
16	express	O
17	some	O
18	differences	O
19	in	O
20	their	O
21	catalytic	O
22	activity	O
23	.	O

1	Both	O
2	mutations	O
3	completely	O
4	abolished	O
5	binding	O
6	of	O
7	the	O
8	Abl	B
9	SH3	I
10	domain	I
11	to	O
12	proline	O
13	-	O
14	rich	O
15	target	O
16	proteins	O
17	in	O
18	a	O
19	filter	O
20	-	O
21	binding	O
22	assay	O
23	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	B
12	and	O
13	hepatic	O
14	leukemia	O
15	factor	O
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	I
28	DBP	I
29	fusion	I
30	proteins	I
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	Biol	O
2	.	O

1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	They	O
2	were	O
3	found	O
4	to	O
5	stimulate	O
6	at	O
7	nanomolar	O
8	concentrations	O
9	the	O
10	turnover	O
11	of	O
12	biosynthetically	O
13	labeled	O
14	ceramide	O
15	,	O
16	glucosylceramide	O
17	,	O
18	and	O
19	lactosylceramide	O
20	.	O

1	The	O
2	DNA	O
3	sequencing	O
4	of	O
5	the	O
6	recombinant	O
7	clones	O
8	revealed	O
9	the	O
10	expression	O
11	of	O
12	RXR	B
13	alpha	I
14	and	O
15	RXR	B
16	beta	I
17	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	Apo	B
5	-	I
6	3	I
7	in	O
8	HEK293	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O

1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	O
14	serum	B
15	alanine	I
16	aminotransferase	I
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O

1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	O
5	fusions	O
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O

1	Proteolysis	O
2	of	O
3	Mbp1	B
4	and	O
5	Swi4	B
6	DNA	I
7	-	I
8	protein	I
9	complexes	I
10	has	O
11	revealed	O
12	the	O
13	extent	O
14	of	O
15	these	O
16	sequences	O
17	,	O
18	and	O
19	C	O
20	-	O
21	terminally	O
22	extended	O
23	molecules	O
24	with	O
25	substantially	O
26	enhanced	O
27	DNA	O
28	binding	O
29	activity	O
30	compared	O
31	to	O
32	the	O
33	core	O
34	domains	O
35	alone	O
36	have	O
37	been	O
38	produced	O
39	.	O

1	Mutations	O
2	at	O
3	the	O
4	suf12	B
5	locus	I
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O

1	To	O
2	explore	O
3	the	O
4	mechanism	O
5	of	O
6	RSK	B
7	activation	O
8	,	O
9	a	O
10	cloned	O
11	human	B
12	RSK	I
13	cDNA	I
14	(	O
15	RSK3	B
16	)	O
17	was	O
18	used	O
19	to	O
20	generate	O
21	and	O
22	characterize	O
23	several	O
24	site	O
25	-	O
26	directed	O
27	RSK	B
28	mutants	I
29	;	O
30	K91A	B
31	(	O
32	N	O
33	-	O
34	Lys	O
35	,	O
36	NH2	O
37	-	O
38	terminal	O
39	ATP	O
40	-	O
41	binding	O
42	mutant	O
43	),	O
44	K444A	B
45	(	O
46	C	O
47	-	O
48	Lys	O
49	,	O
50	COOH	O
51	-	O
52	terminal	O
53	ATP	O
54	-	O
55	binding	O
56	mutant	O
57	),	O
58	N	O
59	/	O
60	C	O
61	-	O
62	Lys	O
63	(	O
64	double	O
65	ATP	O
66	-	O
67	binding	O
68	mutant	O
69	)	O
70	T570A	O
71	(	O
72	C	O
73	-	O
74	Thr	O
75	,	O
76	mutant	O
77	of	O
78	the	O
79	putative	O
80	MAPK	B
81	phosphorylation	O
82	site	O
83	in	O
84	subdomain	B
85	VIII	I
86	of	O
87	the	O
88	C	O
89	-	O
90	domain	O
91	),	O
92	S218A	O
93	(	O
94	N	O
95	-	O
96	Ser	O
97	,	O
98	mutant	O
99	of	O
100	the	O
101	corresponding	O
102	NH2	O
103	-	O
104	terminal	O
105	residue	O
106	).	O

1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O

1	Gap	O
2	b3	O
3	consists	O
4	of	O
5	two	O
6	polypeptide	O
7	chains	O
8	(	O
9	Mr	O
10	=	O
11	110	O
12	,	O
13	000	O
14	and	O
15	30	O
16	,	O
17	000	O
18	),	O
19	which	O
20	seem	O
21	to	O
22	be	O
23	proteolytic	O
24	cleavage	O
25	products	O
26	connected	O
27	by	O
28	disulfide	O
29	bonds	O
30	from	O
31	a	O
32	precursor	O
33	protein	O
34	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	(	O
7	EMSA	O
8	),	O
9	this	O
10	GLUT4	B
11	repressor	I
12	element	I
13	(	O
14	G4RE	O
15	)	O
16	generated	O
17	specific	O
18	bands	O
19	with	O
20	nuclear	O
21	extracts	O
22	from	O
23	preadipocytes	O
24	,	O
25	but	O
26	not	O
27	from	O
28	adipocytes	O
29	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	The	O
2	gene	O
3	is	O
4	1	O
5	,	O
6	139	O
7	base	O
8	pairs	O
9	(	O
10	bp	O
11	)	O
12	long	O
13	,	O
14	and	O
15	,	O
16	like	O
17	other	O
18	members	O
19	of	O
20	the	O
21	SIG	B
22	family	I
23	,	O
24	the	O
25	beta	B
26	TG	I
27	gene	I
28	is	O
29	divided	O
30	into	O
31	3	O
32	exons	O
33	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	GH3	O
7	cells	O
8	transfected	O
9	with	O
10	the	O
11	rat	B
12	GnRH	I
13	receptor	I
14	cDNA	I
15	(	O
16	GGH3	O
17	-	O
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	cotransfected	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	797	O
33	base	O
34	pairs	O
35	of	O
36	rat	B
37	LHbeta	I
38	gene	I
39	5	I
40	'-	I
41	flanking	I
42	sequence	I
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	O
58	luciferase	B
59	reporter	O
60	(-	O
61	797	O
62	/+	O
63	5LHbetaLUC	O
64	)	O
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	B
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O

1	Only	O
2	transcripts	O
3	specific	O
4	for	O
5	TSGF	B
6	-	I
7	2	I
8	are	O
9	detected	O
10	in	O
11	ovary	O
12	and	O
13	testes	O
14	tissues	O
15	of	O
16	adults	O
17	as	O
18	well	O
19	as	O
20	in	O
21	puparia	O
22	,	O
23	while	O
24	neither	O
25	gene	O
26	is	O
27	expressed	O
28	during	O
29	the	O
30	larval	O
31	developmental	O
32	stages	O
33	.	O

1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O

1	In	O
2	humans	O
3	,	O
4	four	B
5	AMP	I
6	deaminase	I
7	variants	I
8	,	O
9	termed	O
10	M	O
11	(	O
12	muscle	O
13	),	O
14	L	O
15	(	O
16	liver	O
17	),	O
18	E1	B
19	,	O
20	and	O
21	E2	B
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	Modern	O
2	cancer	O
3	therapy	O
4	has	O
5	included	O
6	surgery	O
7	,	O
8	radiotherapy	O
9	,	O
10	chemotherapy	O
11	,	O
12	and	O
13	most	O
14	recently	O
15	,	O
16	immunotherapy	O
17	and	O
18	hyperthermia	O
19	.	O

1	These	O
2	cells	O
3	averaged	O
4	17	O
5	microns	O
6	in	O
7	diameter	O
8	and	O
9	reproduced	O
10	by	O
11	fission	O
12	,	O
13	forming	O
14	clusters	O
15	of	O
16	two	O
17	or	O
18	four	O
19	daughter	O
20	cells	O
21	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	a	O
6	range	O
7	of	O
8	microenvironmental	O
9	conditions	O
10	exist	O
11	within	O
12	purified	O
13	water	O
14	systems	O
15	,	O
16	leading	O
17	to	O
18	variable	O
19	populations	O
20	of	O
21	bacteria	O
22	.	O

1	Constipation	O
2	is	O
3	not	O
4	a	O
5	risk	O
6	factor	O
7	for	O
8	hemorrhoids	O
9	:	O
10	a	O
11	case	O
12	-	O
13	control	O
14	study	O
15	of	O
16	potential	O
17	etiological	O
18	agents	O
19	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	The	O
2	downstream	O
3	,	O
4	TATA	O
5	-	O
6	less	O
7	promoter	O
8	has	O
9	high	O
10	G	O
11	+	O
12	C	O
13	content	O
14	,	O
15	and	O
16	exon	O
17	1b	O
18	predominates	O
19	among	O
20	abundantly	O
21	expressed	O
22	mRNA	O
23	species	O
24	.	O

1	The	O
2	proteasome	O
3	is	O
4	a	O
5	large	O
6	complex	O
7	consisting	O
8	of	O
9	two	O
10	multisubunit	O
11	structures	O
12	,	O
13	the	O
14	20S	B
15	and	O
16	19S	O
17	(	O
18	PA700	O
19	)	O
20	or	O
21	P28	B
22	complexes	I
23	,	O
24	that	O
25	combine	O
26	to	O
27	form	O
28	the	O
29	26S	O
30	particles	O
31	.	O

1	In	O
2	summary	O
3	,	O
4	Ca	O
5	(	O
6	2	O
7	+)-	O
8	dependent	O
9	activation	O
10	of	O
11	NO	O
12	production	O
13	mediates	O
14	apoptosis	O
15	after	O
16	TG	O
17	exposure	O
18	in	O
19	JT	O
20	/	O
21	Neo	O
22	cells	O
23	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	I
5	MB	I
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	Regulation	O
2	of	O
3	myosin	B
4	phosphatase	I
5	activity	O
6	involves	O
7	changes	O
8	in	O
9	subunit	O
10	interactions	O
11	,	O
12	although	O
13	molecular	O
14	mechanisms	O
15	are	O
16	not	O
17	defined	O
18	.	O

1	Constructs	O
2	were	O
3	made	O
4	in	O
5	which	O
6	an	O
7	AATAAA	O
8	and	O
9	the	O
10	GT	O
11	-	O
12	rich	O
13	region	O
14	were	O
15	separated	O
16	by	O
17	various	O
18	distances	O
19	ranging	O
20	from	O
21	7	O
22	to	O
23	43	O
24	bp	O
25	.	O

1	Glycogen	O
2	utilization	O
3	was	O
4	increased	O
5	,	O
6	but	O
7	tissue	O
8	levels	O
9	of	O
10	creatine	O
11	phosphate	O
12	,	O
13	ATP	O
14	,	O
15	and	O
16	lactate	O
17	were	O
18	similar	O
19	to	O
20	those	O
21	in	O
22	hearts	O
23	receiving	O
24	normal	O
25	flow	O
26	.	O

1	State	O
2	of	O
3	the	O
4	body	O
5	in	O
6	disorders	O
7	of	O
8	diurnal	O
9	physiological	O
10	rhythms	O
11	and	O
12	long	O
13	-	O
14	term	O
15	hypokinesia	O

1	The	O
2	LMW	B
3	FGF	I
4	-	I
5	2	I
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	I
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	O
24	isoform	O
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	I
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O

1	All	O
2	groups	O
3	were	O
4	challenged	O
5	subsequently	O
6	with	O
7	naloxone	O
8	(	O
9	0	O
10	.	O
11	4	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	in	O
17	the	O
18	distinctive	O
19	environment	O
20	and	O
21	then	O
22	observed	O
23	for	O
24	signs	O
25	of	O
26	opiate	O
27	withdrawal	O
28	.	O

1	The	O
2	effects	O
3	of	O
4	social	O
5	isolation	O
6	on	O
7	morphine	O
8	-	O
9	induced	O
10	locomotor	O
11	activity	O
12	were	O
13	compared	O
14	in	O
15	:	O
16	(	O
17	i	O
18	)	O
19	animals	O
20	with	O
21	an	O
22	intact	O
23	hypothalamo	O
24	-	O
25	pituitary	O
26	-	O
27	adrenal	O
28	(	O
29	HPA	O
30	)	O
31	axis	O
32	;	O
33	(	O
34	ii	O
35	)	O
36	animals	O
37	in	O
38	which	O
39	stress	O
40	-	O
41	induced	O
42	corticosterone	O
43	secretion	O
44	was	O
45	blocked	O
46	by	O
47	adrenalectomy	O
48	.	O

1	Antivitamin	O
2	K	O
3	agents	O

1	Influence	O
2	of	O
3	oil	O
4	emulsions	O
5	and	O
6	diphenyl	O
7	on	O
8	post	O
9	-	O
10	harvest	O
11	physiconutritional	O
12	changes	O
13	in	O
14	Kagzi	O
15	limes	O
16	(	O
17	Citrus	O
18	aurantifolia	O
19	)	O
20	was	O
21	studied	O
22	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	identification	O
6	and	O
7	characterization	O
8	of	O
9	several	O
10	Sp100	B
11	splice	I
12	variant	I
13	proteins	I
14	and	O
15	support	O
16	their	O
17	existence	O
18	by	O
19	elucidation	O
20	of	O
21	the	O
22	3	O
23	'-	O
24	end	O
25	of	O
26	the	O
27	Sp100	B
28	gene	I
29	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	O
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	I
20	fos	I
21	gene	I
22	family	I
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	Alanine	O
2	substitution	O
3	mutations	O
4	in	O
5	the	O
6	Zta	B
7	activation	I
8	domain	I
9	which	O
10	eliminate	O
11	the	O
12	ability	O
13	of	O
14	Zta	B
15	to	O
16	stimulate	O
17	the	O
18	D	O
19	-	O
20	A	O
21	complex	O
22	were	O
23	examined	O
24	.	O

1	Mean	O
2	rCBF	O
3	increased	O
4	in	O
5	some	O
6	patients	O
7	4	O
8	-	O
9	8	O
10	weeks	O
11	after	O
12	surgery	O
13	on	O
14	the	O
15	ipsilateral	O
16	side	O
17	.	O

1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O

1	The	O
2	sequences	O
3	showed	O
4	extensive	O
5	homologies	O
6	with	O
7	squalene	B
8	synthase	I
9	genes	I
10	and	O
11	enzymes	O
12	from	O
13	a	O
14	number	O
15	of	O
16	other	O
17	organisms	O
18	and	O
19	extreme	O
20	amino	O
21	acid	O
22	conservation	O
23	within	O
24	the	O
25	binding	O
26	and	O
27	catalytic	O
28	domains	O
29	.	O

1	The	O
2	5	O
3	'	O
4	ends	O
5	of	O
6	F3R	O
7	late	O
8	transcripts	O
9	were	O
10	located	O
11	to	O
12	an	O
13	A	O
14	within	O
15	the	O
16	sequence	O
17	5	O
18	'-	O
19	TAAAG	O
20	,	O
21	41	O
22	nt	O
23	downstream	O
24	from	O
25	the	O
26	early	O
27	promoter	O
28	and	O
29	17	O
30	nt	O
31	upstream	O
32	from	O
33	the	O
34	initiation	O
35	codon	O
36	.	O

1	Peripheral	O
2	visual	O
3	stimuli	O
4	and	O
5	monoaural	O
6	auditory	O
7	stimuli	O
8	were	O
9	used	O
10	as	O
11	targets	O
12	.	O

1	The	O
2	cleavage	O
3	dipeptides	O
4	of	O
5	C1YVV	B
6	NIa	I
7	protease	I
8	are	I
9	Q	I
10	(	I
11	E	I
12	)/	O
13	S	O
14	(	O
15	A	O
16	,	O
17	G	O
18	).	O

1	Infants	O
2	who	O
3	died	O
4	in	O
5	the	O
6	first	O
7	12	O
8	hours	O
9	from	O
10	'	O
11	IVH	O
12	only	O
13	'	O
14	had	O
15	suffered	O
16	severe	O
17	birth	O
18	asphyxia	O
19	but	O
20	in	O
21	those	O
22	who	O
23	died	O
24	later	O
25	the	O
26	main	O
27	symptom	O
28	was	O
29	recurrent	O
30	apnoea	O
31	.	O

1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O

1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O

1	GW	O
2	Gamma	O
3	approximation	O
4	for	O
5	electron	O
6	self	O
7	-	O
8	energies	O
9	in	O
10	semiconductors	O
11	and	O
12	insulators	O
13	.	O

1	Furthermore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	43	O
8	-	O
9	bp	O
10	region	O
11	of	O
12	the	O
13	24p3	B
14	promoter	I
15	required	O
16	for	O
17	the	O
18	Dex	O
19	responsiveness	O
20	.	O

1	A	O
2	patient	O
3	with	O
4	an	O
5	infected	O
6	wound	O
7	or	O
8	one	O
9	on	O
10	a	O
11	primary	O
12	area	O
13	(	O
14	hands	O
15	,	O
16	feet	O
17	,	O
18	face	O
19	,	O
20	or	O
21	perineum	O
22	)	O
23	may	O
24	have	O
25	to	O
26	be	O
27	hospitalized	O
28	to	O
29	ensure	O
30	proper	O
31	care	O
32	.	O

1	Mg2	O
2	+	O
3	and	O
4	Mn2	O
5	+	O
6	compete	O
7	for	O
8	binding	O
9	sites	O
10	,	O
11	with	O
12	the	O
13	former	O
14	having	O
15	lower	O
16	affinity	O
17	.	O

1	We	O
2	concluded	O
3	that	O
4	Ga	O
5	-	O
6	fbg	O
7	scintigraphy	O
8	is	O
9	a	O
10	very	O
11	simple	O
12	method	O
13	and	O
14	sufficiently	O
15	useful	O
16	for	O
17	detecting	O
18	active	O
19	left	O
20	ventricular	O
21	thrombi	O
22	and	O
23	for	O
24	monitoring	O
25	the	O
26	effect	O
27	of	O
28	anticoagulant	O
29	therapy	O
30	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	alpha2	B
5	-	I
6	adrenergic	I
7	antagonist	O
8	idazoxan	O
9	increases	O
10	glucose	O
11	-	O
12	induced	O
13	sympathetic	O
14	activity	O
15	but	O
16	not	O
17	energy	O
18	expenditure	O
19	in	O
20	obese	O
21	subjects	O
22	.	O

1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	correspond	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	p55	B
16	protein	I
17	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	O
6	desmin	O
7	in	O
8	SW13	O
9	(	O
10	vim	O
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	O
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O

1	Intraoperative	O
2	measurement	O
3	of	O
4	activated	O
5	partial	O
6	thromboplastin	B
7	time	O
8	and	O
9	prothrombin	B
10	time	O
11	with	O
12	a	O
13	new	O
14	compact	O
15	monitor	O
16	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	O
24	neuraminidases	O
25	.	O

1	Deletion	O
2	analysis	O
3	indicates	O
4	that	O
5	TBP	B
6	and	O
7	hTAFII18	B
8	bind	O
9	to	O
10	distinct	O
11	domains	O
12	of	O
13	hTAFII28	B
14	.	O
15	hTAFII18	O
16	also	O
17	interacts	O
18	with	O
19	TBP	B
20	,	O
21	but	O
22	it	O
23	interacts	O
24	more	O
25	strongly	O
26	with	O
27	hTAFII28	B
28	and	O
29	hTAFII30	B
30	.	O

1	The	O
2	films	O
3	were	O
4	analyzed	O
5	using	O
6	a	O
7	scanning	O
8	helium	O
9	-	O
10	neon	O
11	laser	O
12	densitometer	O
13	with	O
14	a	O
15	small	O
16	aperture	O
17	of	O
18	5	O
19	-	O
20	10	O
21	microns	O
22	.	O

1	In	O
2	contrast	O
3	,	O
4	similar	O
5	rates	O
6	of	O
7	B	O
8	.	O
9	sphaericus	O
10	products	O
11	,	O
12	ABG	O
13	-	O
14	6184	O
15	technical	O
16	powder	O
17	and	O
18	BSP	B
19	-	I
20	2	I
21	flowable	O
22	concentrate	O
23	,	O
24	produced	O
25	no	O
26	significant	O
27	reduction	O
28	.	O

1	IX	O
2	.	O

1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	mouse	O
6	cDNA	O
7	library	O
8	of	O
9	an	O
10	MIN6	O
11	cell	O
12	line	O
13	,	O
14	derived	O
15	from	O
16	pancreatic	O
17	beta	O
18	cells	O
19	,	O
20	for	O
21	its	O
22	novel	O
23	isoform	O
24	and	O
25	have	O
26	identified	O
27	a	O
28	cDNA	O
29	encoding	O
30	a	O
31	593	O
32	-	O
33	amino	O
34	acid	O
35	protein	O
36	having	O
37	63	O
38	,	O
39	53	O
40	,	O
41	and	O
42	30	O
43	%	O
44	identity	O
45	with	O
46	munc	O
47	-	O
48	18	O
49	/	O
50	n	O
51	-	O
52	Sec1	B
53	/	O
54	rbSec1	B
55	,	O
56	Caenorhabditis	O
57	elegans	O
58	unc18	O
59	,	O
60	and	O
61	Saccharomyces	B
62	cerevisiae	I
63	Sec1p	I
64	,	O
65	respectively	O
66	.	O

1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	The	O
2	third	O
3	ORF	O
4	generates	O
5	a	O
6	transcript	O
7	of	O
8	1	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	382	O
18	residues	O
19	including	O
20	a	O
21	perfect	O
22	match	O
23	to	O
24	the	O
25	consensus	O
26	sequence	O
27	of	O
28	a	O
29	C2H2	B
30	zinc	I
31	finger	I
32	domain	I
33	;	O
34	it	O
35	shares	O
36	a	O
37	strong	O
38	homology	O
39	with	O
40	yeast	O
41	Mig1p	B
42	and	O
43	Cre	O
44	-	O
45	A	O
46	from	O
47	Aspergillus	O
48	,	O
49	Emericella	O
50	and	O
51	E	O
52	.	O
53	coli	O
54	.	O

1	In	O
2	patients	O
3	who	O
4	had	O
5	received	O
6	no	O
7	previous	O
8	drug	O
9	treatment	O
10	,	O
11	log	O
12	baseline	O
13	plasma	O
14	renin	B
15	activity	O
16	and	O
17	change	O
18	in	O
19	mean	O
20	blood	O
21	pressure	O
22	after	O
23	SQ	O
24	20881	O
25	correlated	O
26	significantly	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	651	O
33	,	O
34	P	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	).	O

1	The	O
2	significance	O
3	of	O
4	the	O
5	phenolphthalein	B
6	sulphatase	I
7	test	O
8	for	O
9	the	O
10	differentiation	O
11	and	O
12	identification	O
13	of	O
14	Nocardia	O
15	species	O
16	.	O

1	These	O
2	are	O
3	two	O
4	regions	O
5	of	O
6	known	O
7	conserved	O
8	synteny	O
9	,	O
10	providing	O
11	further	O
12	evidence	O
13	that	O
14	the	O
15	human	B
16	STEP	I
17	is	O
18	a	O
19	true	O
20	homolog	O
21	of	O
22	the	O
23	murine	B
24	STEP	I
25	gene	I
26	.	O

1	An	O
2	AP	B
3	-	I
4	1	I
5	binding	I
6	sequence	I
7	is	O
8	essential	O
9	for	O
10	regulation	O
11	of	O
12	the	O
13	human	B
14	alpha2	I
15	(	I
16	I	I
17	)	I
18	collagen	I
19	(	O
20	COL1A2	B
21	)	O
22	promoter	O
23	activity	O
24	by	O
25	transforming	B
26	growth	I
27	factor	I
28	-	I
29	beta	I
30	.	O

1	Factors	O
2	associated	O
3	with	O
4	intrafamilial	O
5	transmission	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	infection	O
11	in	O
12	Korea	O
13	.	O

1	Van	O
2	der	O
3	Ende	O
4	,	O
5	R	O
6	.	O

1	The	O
2	maps	O
3	of	O
4	Case	O
5	2	O
6	showed	O
7	that	O
8	a	O
9	maximum	O
10	first	O
11	appeared	O
12	on	O
13	the	O
14	upper	O
15	right	O
16	back	O
17	and	O
18	then	O
19	moved	O
20	down	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	posterior	O
27	thorax	O
28	.	O

1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	values	O
6	obtained	O
7	by	O
8	the	O
9	two	O
10	methods	O
11	were	O
12	in	O
13	agreement	O
14	for	O
15	each	O
16	species	O
17	of	O
18	epidermal	B
19	growth	I
20	factor	I
21	and	O
22	followed	O
23	the	O
24	order	O
25	:	O
26	wild	O
27	type	O
28	greater	O
29	than	O
30	Glu24	O
31	----	O
32	Gly	O
33	greater	O
34	than	O
35	Asp27	O
36	----	O
37	Gly	O
38	much	O
39	greater	O
40	than	O
41	Pro7	O
42	----	O
43	Thr	O
44	greater	O
45	than	O
46	Tyr29	O
47	----	O
48	Gly	O
49	greater	O
50	than	O
51	Leu47	O
52	----	O
53	His	O
54	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	O
6	these	O
7	expression	O
8	patterns	O
9	are	O
10	established	O
11	,	O
12	we	O
13	fused	O
14	promoter	O
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	B
22	glucanase	I
23	gene	I
24	to	O
25	the	O
26	beta	B
27	-	I
28	glucuronidase	I
29	(	O
30	GUS	B
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	O
37	of	O
38	these	O
39	constructs	O
40	in	O
41	transgenic	O
42	tobacco	O
43	plants	O
44	.	O

1	GnRH	B
2	treatment	O
3	was	O
4	found	O
5	to	O
6	increase	O
7	the	O
8	phosphorylation	O
9	of	O
10	tyrosine	O
11	residues	O
12	of	O
13	MAPK	B
14	and	O
15	to	O
16	increase	O
17	MAPK	B
18	activity	O
19	,	O
20	as	O
21	determined	O
22	by	O
23	an	O
24	immune	O
25	complex	O
26	kinase	O
27	assay	O
28	.	O

1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O

1	Our	O
2	data	O
3	therefore	O
4	indicate	O
5	that	O
6	it	O
7	is	O
8	possible	O
9	to	O
10	engineer	O
11	the	O
12	HA	B
13	envelope	I
14	glycoprotein	I
15	by	O
16	fusing	O
17	ligands	O
18	to	O
19	its	O
20	amino	O
21	-	O
22	terminal	O
23	end	O
24	without	O
25	affecting	O
26	its	O
27	fusion	O
28	activity	O
29	.	O

1	Serum	B
2	IgM	I
3	and	O
4	IgE	B
5	concentrations	O
6	,	O
7	allergen	O
8	-	O
9	specific	O
10	IgE	B
11	scores	O
12	,	O
13	and	O
14	the	O
15	tumor	O
16	E2R	O
17	status	O
18	were	O
19	combined	O
20	to	O
21	construct	O
22	a	O
23	three	O
24	-	O
25	level	O
26	risk	O
27	classification	O
28	that	O
29	was	O
30	more	O
31	prognostic	O
32	than	O
33	any	O
34	of	O
35	the	O
36	individual	O
37	components	O
38	.	O

1	Analysis	O
2	of	O
3	intragenic	O
4	revertants	O
5	shows	O
6	that	O
7	this	O
8	function	O
9	depends	O
10	on	O
11	the	O
12	amino	O
13	acid	O
14	preceding	O
15	the	O
16	first	O
17	cysteine	O
18	residue	O
19	of	O
20	the	O
21	DNA	O
22	-	O
23	binding	O
24	domain	O
25	of	O
26	Hap1p	B
27	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	the	O
8	PERE	O
9	formed	O
10	three	O
11	major	O
12	complexes	O
13	(	O
14	P1	O
15	,	O
16	P2	O
17	and	O
18	P3	O
19	)	O
20	with	O
21	proteins	O
22	in	O
23	nuclear	O
24	extracts	O
25	from	O
26	HeLa	O
27	or	O
28	293	O
29	cells	O
30	.	O

1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	B
6	-	I
7	1	I
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	enhancer	O
6	sequences	O
7	,	O
8	the	O
9	adenovirus	B
10	E1A	I
11	gene	I
12	can	O
13	not	O
14	stimulate	O
15	CATase	O
16	synthesis	O
17	.	O

1	PET	O
2	activation	O
3	studies	O
4	are	O
5	performed	O
6	widely	O
7	to	O
8	study	O
9	human	O
10	brain	O
11	function	O
12	.	O

1	Over	O
2	-	O
3	expression	O
4	of	O
5	the	O
6	cofactor	O
7	p300	B
8	,	O
9	which	O
10	functions	O
11	as	O
12	a	O
13	coactivator	O
14	of	O
15	myoD	B
16	-	O
17	mediated	O
18	transcription	O
19	,	O
20	alleviated	O
21	repression	O
22	by	O
23	COUP	B
24	-	I
25	TF	I
26	II	I
27	.	O

1	No	O
2	significant	O
3	correlations	O
4	of	O
5	peak	O
6	VO2	O
7	were	O
8	observed	O
9	between	O
10	the	O
11	3	O
12	tests	O
13	.	O

1	COGLAB	O
2	includes	O
3	measures	O
4	of	O
5	preattentional	O
6	,	O
7	attentional	O
8	,	O
9	conceptual	O
10	,	O
11	and	O
12	psychomotor	O
13	performance	O
14	.	O

1	In	O
2	conclusion	O
3	,	O
4	marmoset	O
5	monkey	O
6	LHR	O
7	seems	O
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	O
18	LHR	B
19	gene	I
20	in	O
21	other	O
22	mammalian	O
23	species	O
24	.	O

1	Impaction	O
2	of	O
3	gastrostomy	O
4	tube	O
5	in	O
6	the	O
7	abdominal	O
8	wall	O
9	.	O

1	A	O
2	randomized	O
3	clinical	O
4	trial	O
5	in	O
6	sixty	O
7	-	O
8	two	O
9	adult	O
10	patients	O
11	suffering	O
12	from	O
13	typhoid	O
14	fever	O
15	,	O
16	proved	O
17	by	O
18	blood	O
19	and	O
20	marrow	O
21	culture	O
22	,	O
23	showed	O
24	that	O
25	amoxycillin	B
26	in	O
27	a	O
28	dosage	O
29	schedule	O
30	of	O
31	1	O
32	g	O
33	8	O
34	-	O
35	hourly	O
36	orally	O
37	for	O
38	fourteen	O
39	days	O
40	was	O
41	better	O
42	than	O
43	chloramphenicol	O
44	with	O
45	regard	O
46	to	O
47	clinical	O
48	and	O
49	temperature	O
50	response	O
51	and	O
52	in	O
53	respect	O
54	of	O
55	carriers	O
56	and	O
57	relapse	O
58	rates	O
59	.	O

1	For	O
2	E2	B
3	,	O
4	each	O
5	cat	O
6	was	O
7	given	O
8	either	O
9	5	O
10	(	O
11	group	O
12	[	O
13	G	O
14	]	O
15	1	O
16	)	O
17	or	O
18	10	O
19	(	O
20	G2	O
21	)	O
22	mg	O
23	of	O
24	itraconazole	O
25	/	O
26	kg	O
27	(	O
28	capsules	O
29	)	O
30	twice	O
31	daily	O
32	for	O
33	6	O
34	weeks	O
35	.	O

1	When	O
2	tethered	O
3	to	O
4	a	O
5	heterologous	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	,	O
11	PSU1	B
12	can	O
13	activate	O
14	transcription	O
15	on	O
16	its	O
17	own	O
18	.	O

1	As	O
2	the	O
3	components	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	at	O
9	least	O
10	five	O
11	TRBPs	B
12	(	O
13	p30	B
14	,	O
15	p37	B
16	,	O
17	p46	B
18	,	O
19	p50	B
20	,	O
21	and	O
22	p56	B
23	)	O
24	showing	O
25	specific	O
26	binding	O
27	to	O
28	the	O
29	TAR	O
30	RNA	O
31	were	O
32	detected	O
33	in	O
34	the	O
35	uv	O
36	cross	O
37	-	O
38	linking	O
39	assay	O
40	.	O

1	DNase	B
2	I	I
3	footprint	O
4	analysis	O
5	identified	O
6	a	O
7	protected	O
8	region	O
9	from	O
10	-	O
11	37	O
12	to	O
13	-	O
14	53	O
15	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	Vpr	O
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	O
39	virus	O
40	(	O
41	MLV	O
42	)	O
43	SL3	B
44	-	I
45	3	I
46	LTR	I
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	HA	B
7	gene	I
8	in	O
9	these	O
10	two	O
11	mutants	O
12	confirmed	O
13	the	O
14	HA	B
15	-	I
16	phenotype	I
17	.	O

1	The	O
2	routine	O
3	administration	O
4	of	O
5	fat	O
6	-	O
7	soluble	O
8	vitamins	O
9	appears	O
10	unnecessary	O
11	but	O
12	it	O
13	is	O
14	prudent	O
15	to	O
16	measure	O
17	prothrombin	B
18	time	O
19	and	O
20	serum	O
21	vitamins	O
22	A	O
23	and	O
24	E	O
25	at	O
26	intervals	O
27	.	O

1	Using	O
2	a	O
3	polymerase	O
4	chain	O
5	reaction	O
6	-	O
7	based	O
8	approach	O
9	,	O
10	we	O
11	cloned	O
12	a	O
13	150	O
14	-	O
15	base	O
16	pair	O
17	fragment	O
18	of	O
19	a	O
20	new	O
21	sialymotif	O
22	from	O
23	human	B
24	placenta	I
25	mRNA	I
26	,	O
27	which	O
28	was	O
29	then	O
30	used	O
31	as	O
32	a	O
33	probe	O
34	to	O
35	clone	O
36	the	O
37	complete	O
38	coding	O
39	sequence	O
40	of	O
41	the	O
42	corresponding	O
43	gene	O
44	from	O
45	a	O
46	cDNA	O
47	library	O
48	.	O

1	IgG	B
2	levels	O
3	of	O
4	1	O
5	/	O
6	100	O
7	were	O
8	present	O
9	in	O
10	only	O
11	four	O
12	out	O
13	of	O
14	ten	O
15	samples	O
16	obtained	O
17	150	O
18	days	O
19	after	O
20	the	O
21	clinical	O
22	onset	O
23	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	O
17	resistance	O
18	gene	O
19	region	O
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	The	O
2	plant	O
3	hormone	O
4	auxin	O
5	transcriptionally	O
6	activates	O
7	early	O
8	genes	O
9	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	its	O
7	expression	O
8	,	O
9	the	O
10	human	B
11	aldehyde	I
12	reductase	I
13	gene	I
14	and	O
15	promoter	O
16	were	O
17	cloned	O
18	and	O
19	characterized	O
20	.	O

1	On	O
2	-	O
3	line	O
4	angioscopic	O
5	images	O
6	of	O
7	tissue	O
8	flaps	O
9	floating	O
10	in	O
11	the	O
12	lumen	O
13	,	O
14	recent	O
15	or	O
16	structured	O
17	thrombi	O
18	,	O
19	artery	O
20	wall	O
21	dissections	O
22	,	O
23	plaque	O
24	ruptures	O
25	,	O
26	deep	O
27	fissurations	O
28	and	O
29	sub	O
30	-	O
31	intimal	O
32	haemorrhages	O
33	demonstrate	O
34	,	O
35	in	O
36	live	O
37	colour	O
38	,	O
39	the	O
40	pathophysiological	O
41	mechanisms	O
42	of	O
43	coronary	O
44	artery	O
45	stenosis	O
46	.	O

1	Sip1	B
2	was	O
3	initially	O
4	identified	O
5	by	O
6	virtue	O
7	of	O
8	its	O
9	interaction	O
10	with	O
11	SC35	O
12	,	O
13	a	O
14	splicing	O
15	factor	O
16	of	O
17	the	O
18	SR	B
19	family	I
20	.	O

1	Fluorescence	O
2	in	O
3	situ	O
4	hybridization	O
5	of	O
6	metaphase	B
7	spreads	O
8	of	O
9	chromosome	O
10	8	O
11	,	O
12	containing	O
13	hybrid	O
14	cell	O
15	line	O
16	706	O
17	-	O
18	B6	O
19	clone	O
20	17	O
21	(	O
22	CL	O
23	-	O
24	17	O
25	)	O
26	with	O
27	cosmid	O
28	c101F1	B
29	,	O
30	placed	O
31	the	O
32	9804	O
33	gene	O
34	close	O
35	to	O
36	the	O
37	telomere	O
38	at	O
39	8q24	O
40	.	O
41	3	O
42	.	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	analysis	O
6	demonstrated	O
7	expression	O
8	of	O
9	human	B
10	PI	I
11	3	I
12	-	I
13	kinase	I
14	in	O
15	all	O
16	tissues	O
17	and	O
18	cell	O
19	lines	O
20	tested	O
21	.	O

1	Urine	O
2	antibodies	O
3	could	O
4	not	O
5	be	O
6	demonstrated	O
7	in	O
8	any	O
9	other	O
10	cases	O
11	.	O

1	Identification	O
2	of	O
3	the	O
4	region	O
5	in	O
6	actin	B
7	-	I
8	binding	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	the	O
14	cytoplasmic	O
15	domain	O
16	of	O
17	glycoprotein	O
18	IBalpha	B
19	.	O

1	Chem	O
2	.	O

1	Tolerance	O
2	to	O
3	fenfluramine	O
4	anorexia	O
5	:	O
6	fact	O
7	or	O
8	fiction	O
9	?	O
10	Recent	O
11	findings	O
12	in	O
13	this	O
14	laboratory	O
15	with	O
16	regard	O
17	to	O
18	tolerance	O
19	to	O
20	fenfluramine	O
21	anorexia	O
22	are	O
23	reviewed	O
24	with	O
25	respect	O
26	to	O
27	generality	O
28	of	O
29	the	O
30	behavioural	O
31	phenomenon	O
32	.	O

1	The	O
2	12	O
3	,	O
4	000	O
5	MW	O
6	(	O
7	12K	O
8	)	O
9	IE	O
10	polypeptide	O
11	encoded	O
12	by	O
13	IEmRNA	B
14	-	I
15	5	I
16	is	O
17	translated	O
18	from	O
19	an	O
20	88	O
21	codon	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	leaving	O
27	a	O
28	1200	O
29	base	O
30	3	O
31	'	O
32	non	O
33	-	O
34	translated	O
35	region	O
36	.	O

1	Results	O
2	indicate	O
3	that	O
4	KNM	B
5	-	I
6	LU	I
7	335	I
8	differs	O
9	from	O
10	both	O
11	human	O
12	and	O
13	chimpanzee	O
14	M1s	O
15	in	O
16	relative	O
17	distances	O
18	(	O
19	measured	O
20	in	O
21	three	O
22	dimensions	O
23	)	O
24	between	O
25	crown	O
26	fissure	O
27	termini	O
28	.	O

1	In	O
2	untreated	O
3	mice	O
4	,	O
5	bactericidal	O
6	activity	O
7	of	O
8	peritoneal	O
9	macrophages	O
10	decreased	O
11	from	O
12	one	O
13	day	O
14	to	O
15	3	O
16	days	O
17	after	O
18	ip	O
19	injection	O
20	of	O
21	killed	O
22	L	O
23	.	O
24	monocytogenes	O
25	.	O

1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	O
6	alkaline	B
7	phosphatase	I
8	in	O
9	children	O

1	However	O
2	,	O
3	we	O
4	did	O
5	not	O
6	observe	O
7	a	O
8	correlation	O
9	between	O
10	serum	O
11	and	O
12	seminal	O
13	plasma	O
14	PSA	B
15	levels	O
16	.	O

1	Radiative	O
2	corrections	O
3	to	O
4	beta	O
5	decay	O
6	and	O
7	the	O
8	possibility	O
9	of	O
10	a	O
11	fourth	O
12	generation	O
13	.	O

1	The	O
2	subunit	O
3	-	O
4	a	O
5	gene	O
6	is	O
7	preceded	O
8	by	O
9	a	O
10	gene	O
11	coding	O
12	for	O
13	a	O
14	small	O
15	hydrophobic	O
16	protein	O
17	,	O
18	as	O
19	has	O
20	been	O
21	observed	O
22	previously	O
23	in	O
24	the	O
25	atp	B
26	operons	I
27	in	O
28	E	O
29	.	O
30	coli	O
31	,	O
32	bacterium	O
33	PS3	O
34	and	O
35	cyanobacteria	O
36	.	O

1	Tonometry	O
2	of	O
3	blood	O
4	samples	O
5	from	O
6	patients	O
7	may	O
8	also	O
9	be	O
10	used	O
11	in	O
12	the	O
13	determination	O
14	of	O
15	acid	O
16	-	O
17	base	O
18	quantities	O
19	and	O
20	hemoglobin	B
21	-	O
22	oxygen	O
23	affinity	O
24	e	O
25	.	O
26	g	O
27	.	O
28	p50	O
29	.	O

1	We	O
2	report	O
3	an	O
4	example	O
5	of	O
6	an	O
7	MDV	O
8	-	O
9	transformed	O
10	T	O
11	-	O
12	lymphoblastoid	O
13	cell	O
14	line	O
15	(	O
16	T9	O
17	)	O
18	expressing	O
19	high	O
20	levels	O
21	of	O
22	a	O
23	truncated	B
24	C	I
25	-	I
26	MYB	I
27	protein	I
28	as	O
29	a	O
30	result	O
31	of	O
32	RAV	O
33	integration	O
34	within	O
35	one	O
36	c	B
37	-	I
38	myb	I
39	allele	I
40	.	O

1	After	O
2	nitric	O
3	oxide	O
4	inhalation	O
5	,	O
6	the	O
7	results	O
8	showed	O
9	moderate	O
10	increases	O
11	in	O
12	PaO2	O
13	and	O
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	O
37	01	O
38	).	O

1	The	O
2	potential	O
3	impact	O
4	of	O
5	using	O
6	a	O
7	rapid	O
8	diagnostic	O
9	test	O
10	(	O
11	Strep	O
12	A	O
13	OIA	O
14	)	O
15	on	O
16	detection	O
17	and	O
18	treatment	O
19	of	O
20	group	O
21	A	O
22	beta	O
23	-	O
24	hemolytic	O
25	streptococcal	O
26	(	O
27	GABHS	O
28	)	O
29	pharyngitis	O
30	in	O
31	a	O
32	large	O
33	-	O
34	volume	O
35	pediatric	O
36	and	O
37	adolescent	O
38	clinic	O
39	was	O
40	examined	O
41	.	O

1	A	O
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	B
13	mRNA	I
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O

1	The	O
2	human	B
3	p100	I
4	protein	I
5	was	O
6	recently	O
7	identified	O
8	as	O
9	a	O
10	coactivator	O
11	of	O
12	the	O
13	Epstein	B
14	-	I
15	Barr	I
16	virus	I
17	nuclear	I
18	antigen	I
19	2	I
20	.	O

1	Utero	O
2	-	O
3	placental	O
4	blood	O
5	flow	O
6	and	O
7	the	O
8	effect	O
9	of	O
10	beta	B
11	2	I
12	-	I
13	adrenoceptor	I
14	stimulating	O
15	drugs	O
16	.	O

1	74	O
2	,	O
3	193	O
4	-	O
5	197	O
6	).	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	both	O
8	the	O
9	N	O
10	-	O
11	and	O
12	C	O
13	-	O
14	terminal	O
15	regions	O
16	of	O
17	talin	B
18	bind	O
19	actin	B
20	,	O
21	the	O
22	properties	O
23	of	O
24	these	O
25	two	O
26	regions	O
27	of	O
28	the	O
29	protein	O
30	are	O
31	distinct	O
32	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	O
12	suppressor	O
13	ING1	O
14	with	O
15	the	O
16	mSin3	B
17	/	O
18	HDAC1	B
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	In	O
2	macrophages	O
3	,	O
4	LPS	B
5	-	I
6	inducible	I
7	HIV	I
8	-	I
9	1	I
10	gene	I
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	to	O
24	identical	O
25	tandem	O
26	binding	O
27	sites	O
28	located	O
29	within	O
30	the	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	LTR	O
36	).	O

1	Sequencing	O
2	revealed	O
3	one	O
4	large	O
5	open	O
6	reading	O
7	frame	O
8	encoding	O
9	a	O
10	39	O
11	-	O
12	kDa	O
13	protein	O
14	.	O

1	Specialized	O
2	actin	B
3	tails	O
4	that	O
5	propel	O
6	IEV	O
7	particles	O
8	to	O
9	the	O
10	periphery	O
11	and	O
12	virus	O
13	-	O
14	tipped	O
15	microvilli	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	vA33delta	O
34	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	plasma	O
7	prolactin	B
8	response	O
9	to	O
10	12	O
11	.	O
12	5	O
13	micrograms	O
14	i	O
15	.	O
16	v	O
17	.	O

1	LON	O
2	-	O
3	72	O
4	(	O
5	34	O
6	isolates	O
7	),	O
8	LON	B
9	-	I
10	73	I
11	(	O
12	1	O
13	),	O
14	LON	O
15	-	O
16	71	O
17	(	O
18	2	O
19	)	O
20	and	O
21	LON	B
22	-	I
23	10	I
24	(	O
25	2	O
26	)	O
27	were	O
28	found	O
29	at	O
30	altitudes	O
31	around	O
32	2000	O
33	m	O
34	,	O
35	3	O
36	of	O
37	them	O
38	in	O
39	a	O
40	single	O
41	village	O
42	.	O

1	Analysis	O
2	of	O
3	the	O
4	inferred	O
5	1	O
6	,	O
7	859	O
8	-	O
9	residue	O
10	ama	O
11	-	O
12	1	O
13	product	O
14	showed	O
15	considerable	O
16	identity	O
17	with	O
18	the	O
19	largest	O
20	subunit	O
21	of	O
22	RNAP	B
23	II	I
24	from	O
25	other	O
26	organisms	O
27	,	O
28	including	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	zinc	O
34	finger	O
35	motif	O
36	near	O
37	the	O
38	amino	O
39	terminus	O
40	,	O
41	and	O
42	a	O
43	carboxyl	O
44	-	O
45	terminal	O
46	domain	O
47	of	O
48	42	O
49	tandemly	O
50	reiterated	O
51	heptamers	O
52	with	O
53	the	O
54	consensus	O
55	Tyr	O
56	Ser	O
57	Pro	O
58	Thr	O
59	Ser	O
60	Pro	O
61	Ser	O
62	.	O

1	U73	B
2	contains	O
3	C	O
4	,	O
5	D	O
6	and	O
7	D	O
8	'	O
9	boxes	O
10	and	O
11	a	O
12	12	O
13	-	O
14	nucleotide	O
15	antisense	O
16	complementarity	O
17	to	O
18	the	O
19	28S	B
20	ribosomal	I
21	RNA	I
22	.	O

1	Deglutition	O
2	is	O
3	considered	O
4	to	O
5	be	O
6	immature	O
7	in	O
8	infants	O
9	and	O
10	to	O
11	mature	O
12	postnatally	O
13	.	O

1	Significant	O
2	correlations	O
3	between	O
4	mental	O
5	status	O
6	as	O
7	measured	O
8	by	O
9	the	O
10	Mini	O
11	-	O
12	Mental	O
13	State	O
14	Examination	O
15	and	O
16	NA	O
17	/	O
18	mI	O
19	,	O
20	mI	O
21	/	O
22	Cr	O
23	and	O
24	NA	O
25	were	O
26	found	O
27	.	O

1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	"	O
14	sperm	O
15	fall	O
16	"	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	kinetics	O
7	of	O
8	erythropoietin	B
9	(	O
10	EPO	B
11	)	O
12	production	O
13	and	O
14	address	O
15	the	O
16	pathogenesis	O
17	of	O
18	anemia	O
19	of	O
20	prematurity	O
21	,	O
22	we	O
23	measured	O
24	EPO	B
25	levels	O
26	in	O
27	infants	O
28	during	O
29	the	O
30	first	O
31	year	O
32	of	O
33	life	O
34	.	O

1	The	O
2	E1	B
3	replication	I
4	protein	I
5	of	O
6	bovine	O
7	papillomavirus	O
8	type	O
9	1	O
10	contains	O
11	an	O
12	extended	O
13	nuclear	O
14	localization	O
15	signal	O
16	that	O
17	includes	O
18	a	O
19	p34cdc2	B
20	phosphorylation	O
21	site	O
22	.	O

1	MpB	O
2	GroEL	O
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	O
12	coli	O
13	GroEL	O
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O

1	Following	O
2	the	O
3	injection	O
4	of	O
5	PGF2	O
6	alpha	O
7	,	O
8	heifers	O
9	were	O
10	observed	O
11	visually	O
12	for	O
13	signs	O
14	of	O
15	estrus	O
16	at	O
17	0730	O
18	and	O
19	1630	O
20	(	O
21	45	O
22	min	O
23	each	O
24	).	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	Cdk2	B
7	-	O
8	phosphorylated	O
9	MARCKS	B
10	was	O
11	digested	O
12	with	O
13	lysyl	B
14	endoprotease	I
15	and	O
16	analysed	O
17	by	O
18	electrospray	O
19	MS	O
20	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	I
11	activated	I
12	protein	I
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	O
45	133	O
46	phosphoacceptor	O
47	motif	O
48	.	O

1	Areas	O
2	with	O
3	significantly	O
4	greater	O
5	rCBF	O
6	for	O
7	targeting	O
8	were	O
9	the	O
10	left	O
11	motor	O
12	cortex	O
13	,	O
14	left	O
15	intraparietal	O
16	sulcus	O
17	,	O
18	and	O
19	left	O
20	caudate	O
21	.	O

1	We	O
2	have	O
3	recently	O
4	shown	O
5	that	O
6	the	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	of	O
12	the	O
13	RAR	B
14	beta	I
15	2	I
16	gene	I
17	in	O
18	mouse	O
19	embryos	O
20	is	O
21	regulated	O
22	at	O
23	the	O
24	translational	O
25	level	O
26	by	O
27	short	O
28	upstream	O
29	open	O
30	reading	O
31	frames	O
32	(	O
33	uORFs	O
34	)	O
35	In	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	Zimmer	O
43	,	O
44	A	O
45	.,	O
46	A	O
47	.	O
48	M	O
49	.	O

1	Results	O
2	of	O
3	the	O
4	official	O
5	inspection	O
6	of	O
7	the	O
8	commercial	O
9	anti	O
10	-	O
11	inflammatory	O
12	enzyme	O
13	preparations	O
14	containing	O
15	chymotrypsin	B
16	and	O
17	trypsin	B
18	by	O
19	means	O
20	of	O
21	modified	O
22	NF	B
23	13	I
24	methods	O

1	Magnetotherapy	O
2	of	O
3	hepatitis	O
4	A	O
5	and	O
6	B	O
7	in	O
8	children	O

1	Chem	O
2	.,	O
3	270	O
4	:	O
5	7117	O
6	-	O
7	7124	O
8	,	O
9	1995	O
10	;	O
11	and	O
12	MT	B
13	Hartsough	O
14	et	O
15	al	O
16	.,	O
17	J	O
18	.	O

1	We	O
2	discuss	O
3	the	O
4	results	O
5	in	O
6	relation	O
7	to	O
8	previous	O
9	systems	O
10	for	O
11	parcellating	O
12	the	O
13	posterior	O
14	ectosylvian	O
15	gyrus	O
16	of	O
17	the	O
18	cat	O
19	and	O
20	consider	O
21	the	O
22	possibility	O
23	that	O
24	divisions	O
25	of	O
26	the	O
27	feline	O
28	posterior	O
29	ectosylvian	O
30	gyrus	O
31	correspond	O
32	directly	O
33	to	O
34	areas	O
35	making	O
36	up	O
37	the	O
38	superior	O
39	temporal	O
40	gyrus	O
41	in	O
42	primates	O
43	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mature	O
6	region	O
7	is	O
8	highly	O
9	conserved	O
10	in	O
11	other	O
12	serine	O
13	carboxypeptidases	O
14	.	O

1	Therefore	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	p27	B
7	represents	O
8	a	O
9	crucial	O
10	molecule	O
11	in	O
12	HMBA	B
13	signaling	O
14	that	O
15	cannot	O
16	be	O
17	replaced	O
18	by	O
19	p21	B
20	.	O

1	All	O
2	radiologists	O
3	using	O
4	the	O
5	machine	O
6	found	O
7	that	O
8	the	O
9	reporting	O
10	terminal	O
11	was	O
12	simple	O
13	to	O
14	operate	O
15	,	O
16	but	O
17	found	O
18	that	O
19	reporting	O
20	abnormalities	O
21	caused	O
22	an	O
23	increased	O
24	effort	O
25	and	O
26	took	O
27	a	O
28	longer	O
29	time	O
30	.	O

1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	O
27	-	O
28	3	O
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O

1	The	O
2	ensembles	O
3	are	O
4	considered	O
5	to	O
6	be	O
7	one	O
8	of	O
9	the	O
10	forms	O
11	of	O
12	activity	O
13	of	O
14	the	O
15	structured	O
16	morphofunctional	O
17	cortical	O
18	units	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	columns	O
26	.	O

1	Inspection	O
2	of	O
3	enhancer	O
4	mutants	O
5	suggests	O
6	that	O
7	trans	O
8	-	O
9	activation	O
10	by	O
11	hLEF	B
12	/	O
13	GAL4	B
14	is	O
15	especially	O
16	dependent	O
17	on	O
18	TCF	B
19	-	I
20	2	I
21	,	O
22	a	O
23	distinct	O
24	T	O
25	-	O
26	cell	O
27	-	O
28	enriched	O
29	protein	O
30	that	O
31	binds	O
32	to	O
33	sequences	O
34	flanking	O
35	the	O
36	hLEF	B
37	-	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	enhancer	O
43	.	O

1	RNP1	B
2	,	O
3	a	O
4	new	O
5	ribonucleoprotein	O
6	gene	O
7	of	O
8	the	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	.	O

1	Thirty	O
2	Class	O
3	I	O
4	and	O
5	Class	O
6	II	O
7	recessions	O
8	in	O
9	30	O
10	patients	O
11	were	O
12	treated	O
13	with	O
14	a	O
15	modified	O
16	subepithelial	O
17	connective	O
18	tissue	O
19	graft	O
20	procedure	O
21	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	induced	O
8	tenascin	O
9	-	O
10	C	O
11	expression	O
12	in	O
13	primary	O
14	REF	O
15	and	O
16	in	O
17	FR3T3	O
18	,	O
19	an	O
20	established	O
21	fibroblast	O
22	cell	O
23	line	O
24	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	O
14	'	O
15	mdr1b	O
16	sequences	O
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O

1	Cramps	O
2	in	O
3	extrapyramidal	O
4	disorders	O
5	.	O

1	In	O
2	both	O
3	settings	O
4	,	O
5	it	O
6	can	O
7	be	O
8	phosphorylated	O
9	by	O
10	cyclin	B
11	D	I
12	-	I
13	dependent	I
14	kinases	I
15	,	O
16	suggesting	O
17	that	O
18	its	O
19	transcriptional	O
20	activity	O
21	may	O
22	normally	O
23	be	O
24	regulated	O
25	through	O
26	such	O
27	mechanisms	O
28	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	The	O
7	two	O
8	groups	O
9	were	O
10	similar	O
11	on	O
12	entry	O
13	into	O
14	the	O
15	study	O
16	,	O
17	including	O
18	mean	O
19	FEV1	O
20	measurements	O
21	(	O
22	0	O
23	.	O
24	70	O
25	L	O
26	atropine	O
27	/	O
28	0	O
29	.	O
30	60	O
31	L	O
32	metaproterenol	O
33	,	O
34	P	O
35	greater	O
36	than	O
37	.	O
38	05	O
39	).	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	O
9	-	O
10	Pto	O
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	O
16	/	O
17	AB	B
18	genes	I
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	When	O
2	two	O
3	-	O
4	dimensional	O
5	polyacrylamide	O
6	gel	O
7	electrophoretic	O
8	patterns	O
9	of	O
10	[	O
11	35S	O
12	]	O
13	methionine	O
14	-	O
15	labeled	O
16	proteins	O
17	secreted	O
18	from	O
19	cells	O
20	infected	O
21	with	O
22	parental	O
23	and	O
24	recombinant	O
25	viruses	O
26	were	O
27	compared	O
28	,	O
29	a	O
30	spot	O
31	missing	O
32	from	O
33	the	O
34	latter	O
35	corresponded	O
36	in	O
37	molecular	O
38	weigh	O
39	and	O
40	isoelectric	O
41	point	O
42	with	O
43	that	O
44	predicted	O
45	from	O
46	the	O
47	N1L	B
48	ORF	I
49	.	O

1	TCR	B
2	alpha	I
3	and	I
4	beta	I
5	gene	I
6	expression	O
7	may	O
8	be	O
9	regulated	O
10	by	O
11	a	O
12	common	O
13	set	O
14	of	O
15	T	O
16	-	O
17	cell	O
18	nuclear	O
19	proteins	O
20	in	O
21	that	O
22	the	O
23	T	B
24	beta	I
25	2	I
26	element	I
27	binding	O
28	a	O
29	set	O
30	of	O
31	cyclic	B
32	AMP	I
33	response	I
34	element	I
35	-	I
36	binding	I
37	proteins	I
38	that	O
39	are	O
40	also	O
41	bound	O
42	by	O
43	the	O
44	T	B
45	alpha	I
46	1	I
47	element	I
48	of	O
49	the	O
50	human	B
51	TCR	I
52	alpha	I
53	enhancer	I
54	and	O
55	the	O
56	decamer	O
57	element	O
58	present	O
59	in	O
60	a	O
61	large	O
62	number	O
63	of	O
64	human	O
65	and	O
66	murine	B
67	TCR	I
68	beta	I
69	promoters	I
70	.	O

1	After	O
2	two	O
3	successive	O
4	rounds	O
5	of	O
6	selection	O
7	by	O
8	focus	O
9	formation	O
10	assay	O
11	,	O
12	a	O
13	transforming	O
14	ribozyme	O
15	(	O
16	Rz007	B
17	)	O
18	was	O
19	identified	O
20	.	O

1	The	O
2	general	O
3	recombination	O
4	at	O
5	a	O
6	polarizing	O
7	voltage	O
8	of	O
9	300	O
10	V	O
11	is	O
12	less	O
13	than	O
14	2	O
15	%	O
16	for	O
17	dose	O
18	-	O
19	rates	O
20	up	O
21	to	O
22	about	O
23	100	O
24	mGy	O
25	min	O
26	-	O
27	1	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	thromboxane	O
6	A2	O
7	(	O
8	TXA2	B
9	)/	O
10	prostaglandin	B
11	endoperoxide	I
12	receptor	I
13	antagonist	O
14	,	O
15	SQ	O
16	29	O
17	,	O
18	548	O
19	on	O
20	pacing	O
21	-	O
22	induced	O
23	ischemia	O
24	was	O
25	determined	O
26	in	O
27	anesthetized	O
28	open	O
29	-	O
30	chest	O
31	dogs	O
32	.	O

1	The	O
2	measurement	O
3	of	O
4	the	O
5	areas	O
6	of	O
7	fibrin	B
8	,	O
9	of	O
10	tissue	O
11	and	O
12	fibrinolysis	O
13	,	O
14	at	O
15	the	O
16	above	O
17	mentioned	O
18	times	O
19	,	O
20	has	O
21	been	O
22	effected	O
23	at	O
24	standard	O
25	magnification	O
26	(	O
27	15	O
28	X	O
29	)	O
30	by	O
31	an	O
32	image	O
33	analyser	O
34	(	O
35	Videoplan	O
36	)	O
37	scale	O
38	1	O
39	:	O
40	8	O
41	.	O

1	However	O
2	,	O
3	changing	O
4	the	O
5	half	O
6	-	O
7	site	O
8	to	O
9	the	O
10	consensus	O
11	sequence	O
12	AGGTCA	O
13	(	O
14	IRper	O
15	-	O
16	1	O
17	)	O
18	increased	O
19	binding	O
20	of	O
21	AaEcR	B
22	.	O
23	AaUSP	O
24	10	O
25	-	O
26	fold	O
27	over	O
28	IRhsp	O
29	-	O
30	1	O
31	and	O
32	,	O
33	at	O
34	the	O
35	same	O
36	time	O
37	,	O
38	reduced	O
39	the	O
40	stringency	O
41	of	O
42	the	O
43	spacer	O
44	length	O
45	requirement	O
46	,	O
47	with	O
48	IRper	O
49	-	O
50	0	O
51	to	O
52	IRper	O
53	-	O
54	5	O
55	showing	O
56	detectable	O
57	binding	O
58	.	O

1	With	O
2	the	O
3	human	B
4	Rhotekin	I
5	cDNA	I
6	as	O
7	a	O
8	probe	O
9	,	O
10	Northern	O
11	hybridization	O
12	revealed	O
13	that	O
14	a	O
15	4	O
16	.	O
17	0	O
18	-	O
19	kb	O
20	transcript	O
21	was	O
22	expressed	O
23	at	O
24	a	O
25	high	O
26	level	O
27	in	O
28	prostate	O
29	and	O
30	at	O
31	a	O
32	middle	O
33	level	O
34	in	O
35	13	O
36	of	O
37	16	O
38	tissues	O
39	examined	O
40	,	O
41	but	O
42	it	O
43	cannot	O
44	be	O
45	detected	O
46	in	O
47	liver	O
48	and	O
49	lung	O
50	tissues	O
51	.	O

1	At	O
2	Cabras	O
3	(	O
4	Oristano	O
5	),	O
6	a	O
7	town	O
8	characterized	O
9	by	O
10	a	O
11	high	O
12	incidence	O
13	of	O
14	thalassaemia	O
15	and	O
16	G6PD	O
17	deficiency	O
18	less	O
19	than	O
20	half	O
21	the	O
22	people	O
23	between	O
24	18	O
25	and	O
26	35	O
27	have	O
28	a	O
29	fair	O
30	knowledge	O
31	of	O
32	genetic	O
33	diseases	O
34	and	O
35	of	O
36	their	O
37	prevention	O
38	.	O

1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	B
37	enhancer	I
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O

1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O

1	Presidential	O
2	address	O
3	1990	O
4	--	O
5	coming	O
6	in	O
7	from	O
8	the	O
9	cold	O
10	.	O

1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O

1	Adenyl	B
2	cyclase	I
3	activity	O
4	of	O
5	gastric	O
6	mucosa	O
7	in	O
8	patients	O
9	with	O
10	duodenal	O
11	ulcer	O
12	before	O
13	and	O
14	after	O
15	treatment	O

1	Full	O
2	-	O
3	length	O
4	FLAP	B
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O

1	The	O
2	major	O
3	PKC	B
4	beta	I
5	transcription	I
6	initiation	I
7	site	I
8	was	O
9	identified	O
10	by	O
11	primer	O
12	extension	O
13	and	O
14	S1	B
15	nuclease	I
16	protection	O
17	.	O

1	Members	O
2	of	O
3	the	O
4	JAK	B
5	/	O
6	Tyk	B
7	family	I
8	of	O
9	tyrosine	B
10	kinases	I
11	mediate	O
12	phosphorylation	O
13	of	O
14	STAT3	B
15	at	O
16	Tyr705	O
17	during	O
18	CNTF	B
19	signaling	O
20	;	O
21	however	O
22	,	O
23	the	O
24	kinase	O
25	responsible	O
26	for	O
27	phosphorylation	O
28	at	O
29	STAT3	B
30	Tyr727	I
31	appears	O
32	to	O
33	depend	O
34	on	O
35	both	O
36	the	O
37	extracellular	O
38	stimulus	O
39	and	O
40	the	O
41	cellular	O
42	context	O
43	.	O

1	The	O
2	optimal	O
3	sequence	O
4	for	O
5	interaction	O
6	with	O
7	mu	B
8	2	I
9	and	O
10	with	O
11	AP	B
12	-	I
13	2	I
14	has	O
15	tyrosine	O
16	as	O
17	an	O
18	anchor	O
19	and	O
20	prefers	O
21	arginine	O
22	at	O
23	position	O
24	Y	O
25	+	O
26	2	O
27	and	O
28	leucine	O
29	at	O
30	position	O
31	Y	O
32	+	O
33	3	O
34	.	O

1	Assay	O
2	of	O
3	serum	O
4	immunoreactive	O
5	trypsin	B
6	in	O
7	dried	O
8	blood	O
9	spots	O
10	and	O
11	the	O
12	early	O
13	detection	O
14	of	O
15	cystic	O
16	fibrosis	O
17	.	O

1	The	O
2	influence	O
3	of	O
4	a	O
5	high	O
6	ionic	O
7	strength	O
8	on	O
9	the	O
10	resolution	O
11	was	O
12	clearly	O
13	shown	O
14	.	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	B
6	alpha	I
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	Oscilloscope	O
2	triggering	O
3	circuit	O
4	for	O
5	recording	O
6	long	O
7	transients	O
8	at	O
9	fast	O
10	sweep	O
11	speeds	O
12	.	O

1	To	O
2	determine	O
3	whether	O
4	P35	B
5	could	O
6	activate	O
7	the	O
8	39k	B
9	promoter	I
10	in	O
11	the	O
12	absence	O
13	of	O
14	IE1	B
15	,	O
16	the	O
17	p35	B
18	open	O
19	reading	O
20	frame	O
21	was	O
22	cloned	O
23	under	O
24	the	O
25	control	O
26	of	O
27	the	O
28	ie1	B
29	promoter	I
30	.	O

1	Each	O
2	immunoprecipitate	O
3	contained	O
4	a	O
5	complex	O
6	of	O
7	N1	O
8	(	O
9	deltaEC	O
10	)	O
11	and	O
12	CBF1	B
13	.	O

1	The	O
2	aim	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	level	O
11	of	O
12	oxidative	O
13	stress	O
14	in	O
15	healthy	O
16	controls	O
17	(	O
18	CTL	O
19	)	O
20	compared	O
21	with	O
22	CRF	B
23	and	O
24	HD	O
25	patients	O
26	before	O
27	(	O
28	pre	O
29	-	O
30	HD	O
31	)	O
32	and	O
33	after	O
34	(	O
35	post	O
36	-	O
37	HD	O
38	)	O
39	the	O
40	dialysis	O
41	session	O
42	,	O
43	carried	O
44	out	O
45	on	O
46	a	O
47	high	O
48	biocompatible	O
49	polyacrylonitrile	O
50	membrane	O
51	AN69	O
52	.	O

1	Furthermore	O
2	,	O
3	the	O
4	over	O
5	-	O
6	replication	O
7	phenotype	O
8	produced	O
9	by	O
10	this	O
11	mutant	O
12	p65cdc18	O
13	is	O
14	resistant	O
15	to	O
16	increased	O
17	mitotic	O
18	cyclin	B
19	/	O
20	CDK	B
21	activity	O
22	,	O
23	a	O
24	known	O
25	inhibitor	O
26	of	O
27	over	O
28	-	O
29	replication	O
30	.	O

1	A	O
2	synthetic	O
3	oligonucleotide	O
4	containing	O
5	the	O
6	SRE	O
7	sequence	O
8	from	O
9	the	O
10	mouse	B
11	c	I
12	-	I
13	fos	I
14	gene	I
15	promoter	I
16	(-	O
17	299	O
18	to	O
19	-	O
20	322	O
21	)	O
22	was	O
23	radioactively	O
24	labeled	O
25	,	O
26	used	O
27	as	O
28	a	O
29	probe	O
30	for	O
31	the	O
32	mobility	O
33	shift	O
34	assay	O
35	and	O
36	Southwestern	O
37	(	O
38	DNA	O
39	-	O
40	protein	O
41	)	O
42	blotting	O
43	,	O
44	and	O
45	also	O
46	used	O
47	for	O
48	sequence	O
49	-	O
50	specific	O
51	affinity	O
52	chromatography	O
53	.	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	B
15	-	I
16	specific	I
17	regulatory	I
18	factor	I
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	RESULTS	O
2	:	O
3	The	O
4	age	O
5	distribution	O
6	was	O
7	28	O
8	to	O
9	83	O
10	years	O
11	old	O
12	(	O
13	mean	O
14	was	O
15	54	O
16	.	O
17	1	O
18	years	O
19	).	O

1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	B
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O

1	Lacrimal	O
2	secretion	O
3	in	O
4	hyperthyroidism	O

1	K	O
2	.	O

1	In	O
2	49	O
3	patients	O
4	in	O
5	whom	O
6	gated	O
7	equilibrium	O
8	ventriculography	O
9	and	O
10	cardiac	O
11	catheterization	O
12	were	O
13	performed	O
14	within	O
15	a	O
16	6	O
17	day	O
18	interval	O
19	,	O
20	total	O
21	and	O
22	fractional	O
23	portions	O
24	of	O
25	global	O
26	and	O
27	regional	O
28	right	O
29	ventricular	O
30	ejection	O
31	fraction	O
32	(	O
33	RVEF	O
34	)	O
35	were	O
36	correlated	O
37	with	O
38	pulmonary	O
39	arterial	O
40	systolic	O
41	pressure	O
42	.	O

1	A	O
2	cDNA	O
3	,	O
4	cak1At	O
5	,	O
6	was	O
7	isolated	O
8	that	O
9	suppressed	O
10	the	O
11	CAK	B
12	mutation	I
13	in	I
14	budding	I
15	yeast	I
16	,	O
17	and	O
18	it	O
19	also	O
20	complemented	O
21	a	O
22	fission	O
23	yeast	O
24	CAK	B
25	mutant	I
26	.	I
27	cak1At	I
28	encodes	O
29	a	O
30	protein	O
31	related	O
32	to	O
33	animal	O
34	CAKs	B
35	.	O

1	Changes	O
2	induced	O
3	in	O
4	the	O
5	gills	O
6	of	O
7	milkfish	O
8	(	O
9	Chanos	O
10	chanos	O
11	Forsskal	O
12	)	O
13	fingerlings	O
14	after	O
15	acute	O
16	exposure	O
17	to	O
18	nifurpirinol	O
19	(	O
20	Furanace	O
21	;	O
22	P	O
23	-	O
24	7138	O
25	).	O

1	Altogether	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	Ypt51p	B
8	,	O
9	Ypt52p	B
10	,	O
11	and	O
12	Ypt53p	B
13	are	O
14	required	O
15	for	O
16	transport	O
17	in	O
18	the	O
19	endocytic	O
20	pathway	O
21	and	O
22	for	O
23	correct	O
24	sorting	O
25	of	O
26	vacuolar	B
27	hydrolases	I
28	suggesting	O
29	a	O
30	possible	O
31	intersection	O
32	of	O
33	the	O
34	endocytic	O
35	with	O
36	the	O
37	vacuolar	O
38	sorting	O
39	pathway	O
40	.	O

1	One	O
2	cDNA	O
3	clone	O
4	designated	O
5	NCoA	B
6	-	I
7	62	I
8	,	O
9	encoded	O
10	a	O
11	62	O
12	,	O
13	000	O
14	-	O
15	Da	O
16	protein	O
17	that	O
18	is	O
19	highly	O
20	related	O
21	to	O
22	BX42	B
23	,	O
24	a	O
25	Drosophila	B
26	melanogaster	I
27	nuclear	I
28	protein	I
29	involved	O
30	in	O
31	ecdysone	O
32	-	O
33	stimulated	O
34	gene	O
35	expression	O
36	.	O

1	From	O
2	day	O
3	30	O
4	after	O
5	turnout	O
6	,	O
7	the	O
8	PFB	O
9	-	O
10	group	O
11	had	O
12	significantly	O
13	lower	O
14	serum	O
15	pepsinogen	O
16	levels	O
17	,	O
18	which	O
19	reflects	O
20	the	O
21	low	O
22	degree	O
23	of	O
24	abomasal	O
25	damage	O
26	in	O
27	these	O
28	animals	O
29	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	This	O
2	repression	O
3	does	O
4	not	O
5	require	O
6	the	O
7	PU	B
8	.	I
9	1	I
10	transactivation	O
11	or	O
12	PEST	O
13	domains	O
14	and	O
15	cannot	O
16	be	O
17	reversed	O
18	by	O
19	p300	B
20	expression	O
21	.	O

1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O

1	Men	O
2	were	O
3	more	O
4	positive	O
5	about	O
6	their	O
7	physical	O
8	fitness	O
9	than	O
10	women	O
11	.	O

1	Manganese	O
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	B
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O

1	Cyclin	B
2	D1	I
3	could	O
4	not	O
5	be	O
6	displaced	O
7	from	O
8	cdk4	B
9	in	O
10	the	O
11	resistant	O
12	184A1L5R	O
13	cell	O
14	lysates	O
15	.	O

1	Ang	B
2	II	I
3	-	O
4	induced	O
5	fibronectin	B
6	mRNA	I
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	O
28	negative	O
29	EGF	B
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	B
35	AG1478	I
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O

1	The	O
2	uteroglobin	B
3	promoter	I
4	contains	O
5	a	O
6	noncanonical	O
7	estrogen	O
8	responsive	O
9	element	O
10	.	O

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	B
17	-	I
18	R	I
19	gene	I
20	.	O

1	Lauciello	O
2	describes	O
3	a	O
4	technique	O
5	for	O
6	the	O
7	placement	O
8	of	O
9	functionally	O
10	generated	O
11	amalgam	O
12	stops	O
13	as	O
14	restorations	O
15	within	O
16	mandibular	O
17	acrylic	O
18	teeth	O
19	.	O

1	20	O
2	%	O
3	of	O
4	total	O
5	HSL	B
6	transcripts	I
7	in	O
8	human	O
9	subcutaneous	O
10	adipocytes	O
11	.	O

1	Effects	O
2	of	O
3	repeated	O
4	exposures	O
5	of	O
6	hydrogen	O
7	sulphide	O
8	on	O
9	rat	O
10	hippocampal	O
11	EEG	O
12	.	O

1	The	O
2	Sarns	O
3	51F	O
4	cavoatrial	O
5	cannula	O
6	decompressed	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	caval	O
16	cannulas	O
17	.	O

1	French	O
2	,	O
3	M	O
4	.	O

1	E2	O
2	treatments	O
3	elevated	O
4	hen	O
5	plasma	O
6	TG	O
7	7	O
8	.	O
9	2X	O
10	,	O
11	PL	O
12	5	O
13	.	O
14	1X	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	2X	O
21	;	O
22	and	O
23	pullet	O
24	plasma	O
25	TG	B
26	6	I
27	.	O
28	8X	O
29	,	O
30	PL	B
31	3	I
32	.	O
33	7X	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	5X	O
40	.	O

1	100	O
2	and	O
3	14	O
4	p	O
5	.	O

1	The	O
2	majority	O
3	of	O
4	MRF	O
5	units	O
6	were	O
7	behaviorally	O
8	incongruent	O
9	;	O
10	in	O
11	the	O
12	most	O
13	frequently	O
14	observed	O
15	case	O
16	,	O
17	their	O
18	activity	O
19	failed	O
20	to	O
21	change	O
22	reliably	O
23	when	O
24	behavior	O
25	habituated	O
26	.	O

1	The	O
2	following	O
3	evidence	O
4	indicates	O
5	that	O
6	the	O
7	69	O
8	-	O
9	kD	O
10	protein	O
11	is	O
12	a	O
13	common	O
14	,	O
15	rather	O
16	than	O
17	a	O
18	U1	B
19	-	O
20	specific	O
21	,	O
22	protein	O
23	,	O
24	possibly	O
25	associating	O
26	with	O
27	the	O
28	snRNP	O
29	core	O
30	particles	O
31	by	O
32	protein	O
33	-	O
34	protein	O
35	interaction	O
36	.	O

1	The	O
2	coordinated	O
3	expression	O
4	of	O
5	CD4	B
6	and	O
7	CD8	B
8	during	O
9	T	O
10	-	O
11	cell	O
12	development	O
13	is	O
14	tightly	O
15	coupled	O
16	with	O
17	the	O
18	maturation	O
19	state	O
20	of	O
21	the	O
22	T	O
23	cell	O
24	.	O

1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O

1	The	O
2	TEA1	B
3	(	O
4	Ty	B
5	enhancer	I
6	activator	I
7	)	I
8	gene	I
9	sequence	I
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	B
32	-	I
33	type	I
34	family	I
35	of	O
36	DNA	O
37	-	O
38	binding	O
39	proteins	O
40	.	O

1	Anti	B
2	-	I
3	CRK	I
4	antibodies	I
5	detect	O
6	a	O
7	53kDa	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	fasciculata	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O

1	The	O
2	promoter	O
3	mutation	O
4	is	O
5	complemented	O
6	in	O
7	trans	O
8	by	O
9	E1A	B
10	products	O
11	of	O
12	the	O
13	heterologous	O
14	helper	O
15	adenovirus	O
16	type	O
17	5	O
18	(	O
19	Ad5	O
20	).	O

1	The	O
2	introns	O
3	are	O
4	1	O
5	.	O
6	6	O
7	-	O
8	1	O
9	.	O
10	9	O
11	kbp	O
12	long	O
13	.	O

1	Overexpression	O
2	of	O
3	CDP	B
4	/	O
5	cut	B
6	in	O
7	ROS	O
8	17	O
9	/	O
10	2	O
11	.	O
12	8	O
13	osteosarcoma	O
14	cells	O
15	results	O
16	in	O
17	repression	O
18	of	O
19	OC	B
20	promoter	I
21	activity	O
22	;	O
23	this	O
24	repression	O
25	is	O
26	abrogated	O
27	by	O
28	mutating	O
29	OC	B
30	box	I
31	I	I
32	.	O

1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	O
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	enhancer	O
6	was	O
7	also	O
8	probed	O
9	by	O
10	inserting	O
11	a	O
12	pair	O
13	of	O
14	complementary	O
15	synthetic	O
16	oligodeoxynucleotides	O
17	which	O
18	represented	O
19	the	O
20	region	O
21	between	O
22	nt	O
23	positions	O
24	-	O
25	235	O
26	and	O
27	-	O
28	215	O
29	into	O
30	a	O
31	truncated	O
32	template	O
33	which	O
34	lacked	O
35	the	O
36	enhancer	O
37	.	O

1	Regulation	O
2	of	O
3	mitochondrial	B
4	single	I
5	-	I
6	stranded	I
7	DNA	I
8	-	I
9	binding	I
10	protein	I
11	gene	I
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O

1	Overexpression	O
2	of	O
3	H411	B
4	cDNA	I
5	in	O
6	the	O
7	RAW	O
8	264	O
9	.	O
10	7	O
11	macrophage	O
12	cell	O
13	line	O
14	promoted	O
15	an	O
16	increased	O
17	growth	O
18	rate	O
19	,	O
20	suggesting	O
21	that	O
22	expression	O
23	of	O
24	H411	B
25	is	O
26	part	O
27	of	O
28	the	O
29	proliferative	O
30	cell	O
31	response	O
32	to	O
33	LPS	O
34	.	O

1	The	O
2	radiation	O
3	burden	O
4	associated	O
5	with	O
6	the	O
7	majority	O
8	of	O
9	examinations	O
10	in	O
11	nuclear	O
12	medicine	O
13	expressed	O
14	as	O
15	the	O
16	effective	O
17	dose	O
18	is	O
19	comparable	O
20	with	O
21	the	O
22	radiation	O
23	burden	O
24	of	O
25	radiodiagnostic	O
26	examinations	O
27	,	O
28	only	O
29	after	O
30	administration	O
31	of	O
32	preparations	O
33	with	O
34	131I	O
35	,	O
36	201Tl	O
37	,	O
38	67Ga	O
39	and	O
40	111In	O
41	it	O
42	is	O
43	markedly	O
44	higher	O
45	.	O

1	To	O
2	estimate	O
3	the	O
4	locations	O
5	of	O
6	sources	O
7	with	O
8	the	O
9	TF	B
10	-	O
11	MUSIC	O
12	algorithm	O
13	,	O
14	we	O
15	first	O
16	set	O
17	the	O
18	target	O
19	region	O
20	on	O
21	the	O
22	spectrogram	O
23	of	O
24	the	O
25	somatosensory	O
26	responses	O
27	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	'	O
6	morning	O
7	dip	O
8	'	O
9	observed	O
10	in	O
11	asthmatic	O
12	patients	O
13	cannot	O
14	simply	O
15	be	O
16	explained	O
17	by	O
18	changes	O
19	in	O
20	cell	O
21	receptor	O
22	number	O
23	or	O
24	affinity	O
25	,	O
26	as	O
27	our	O
28	results	O
29	suggest	O
30	that	O
31	both	O
32	groups	O
33	have	O
34	intact	O
35	beta	B
36	-	I
37	adrenoceptor	I
38	function	O
39	.	O

1	In	O
2	10	O
3	control	O
4	sheep	O
5	mean	O
6	plasma	O
7	TXB2	O
8	concentration	O
9	increased	O
10	from	O
11	0	O
12	.	O
13	39	O
14	ng	O
15	/	O
16	ml	O
17	prebypass	O
18	to	O
19	about	O
20	1	O
21	.	O
22	1	O
23	ng	O
24	/	O
25	ml	O
26	at	O
27	8	O
28	and	O
29	16	O
30	min	O
31	of	O
32	bypass	O
33	.	O

1	In	O
2	light	O
3	of	O
4	the	O
5	importance	O
6	of	O
7	GnRHR	O
8	,	O
9	the	O
10	molecular	O
11	mechanisms	O
12	underlying	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	the	O
18	human	B
19	GnRHR	I
20	(	O
21	hGnRHR	O
22	)	O
23	gene	O
24	become	O
25	a	O
26	key	O
27	issue	O
28	in	O
29	understanding	O
30	human	O
31	reproduction	O
32	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	O
20	-	O
21	kDa	O
22	component	O
23	of	O
24	cleavage	O
25	stimulation	O
26	factor	O
27	(	O
28	CstF	O
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	O
53	.	O

1	Secondly	O
2	,	O
3	an	O
4	ethanol	O
5	repression	O
6	autoregulation	O
7	(	O
8	ERA	O
9	)/	O
10	twelve	O
11	-	O
12	fold	O
13	TA	O
14	repeat	O
15	(	O
16	TAB	O
17	)	O
18	repressor	O
19	element	O
20	was	O
21	identified	O
22	within	O
23	the	O
24	promoter	O
25	region	O
26	of	O
27	the	O
28	GLK1	B
29	gene	I
30	.	O

1	A	O
2	causal	O
3	analysis	O
4	of	O
5	secondary	O
6	variables	O
7	showed	O
8	that	O
9	the	O
10	formation	O
11	of	O
12	FB	O
13	memories	O
14	was	O
15	primarily	O
16	associated	O
17	with	O
18	the	O
19	level	O
20	of	O
21	importance	O
22	attached	O
23	to	O
24	the	O
25	event	O
26	and	O
27	level	O
28	of	O
29	affective	O
30	response	O
31	to	O
32	the	O
33	news	O
34	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	carbon	O
7	-	O
8	perfused	O
9	areas	O
10	and	O
11	MBF	O
12	in	O
13	the	O
14	liver	O
15	,	O
16	renal	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	and	O
22	small	O
23	intestinal	O
24	serosa	O
25	(	O
26	only	O
27	MBF	O
28	)	O
29	increased	O
30	significantly	O
31	5	O
32	h	O
33	after	O
34	CLP	O
35	.	O

1	This	O
2	suggested	O
3	that	O
4	delta	O
5	6	O
6	and	O
7	delta	O
8	5	O
9	desaturation	O
10	activities	O
11	are	O
12	normal	O
13	in	O
14	these	O
15	conditions	O
16	with	O
17	this	O
18	C18	O
19	:	O
20	2w6	O
21	supply	O
22	.	O

1	In	O
2	the	O
3	studies	O
4	reported	O
5	here	O
6	,	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	the	O
14	human	B
15	gp130	I
16	gene	I
17	was	O
18	isolated	O
19	and	O
20	the	O
21	transcription	O
22	initiation	O
23	sites	O
24	were	O
25	mapped	O
26	.	O

1	Significance	O
2	of	O
3	delta	O
4	-	O
5	aminolevulinic	O
6	acid	O
7	analysis	O
8	in	O
9	clinical	O
10	tests	O

1	The	O
2	effectiveness	O
3	of	O
4	alpha	O
5	-	O
6	mercapto	O
7	-	O
8	beta	O
9	-(	O
10	2	O
11	-	O
12	furyl	O
13	)	O
14	acrylic	O
15	acid	O
16	(	O
17	MFA	O
18	)	O
19	and	O
20	N	O
21	-	O
22	benzyl	O
23	-	O
24	N	O
25	-	O
26	dithiocarboxy	O
27	-	O
28	D	O
29	-	O
30	glucamine	O
31	(	O
32	NaB	B
33	),	O
34	used	O
35	in	O
36	combination	O
37	,	O
38	in	O
39	the	O
40	mobilization	O
41	and	O
42	excretion	O
43	of	O
44	lead	O
45	was	O
46	investigated	O
47	in	O
48	rats	O
49	.	O

1	In	O
2	a	O
3	Hoosier	O
4	Oncology	O
5	Group	O
6	randomized	O
7	study	O
8	involving	O
9	extensive	O
10	-	O
11	disease	O
12	SCLC	O
13	patients	O
14	,	O
15	VIP	B
16	was	O
17	superior	O
18	to	O
19	etoposide	O
20	/	O
21	cisplatin	O
22	with	O
23	regard	O
24	to	O
25	median	O
26	time	O
27	to	O
28	progression	O
29	(	O
30	6	O
31	.	O
32	6	O
33	v	O
34	5	O
35	.	O
36	8	O
37	months	O
38	),	O
39	median	O
40	survival	O
41	times	O
42	(	O
43	9	O
44	.	O
45	1	O
46	v	O
47	7	O
48	.	O
49	3	O
50	months	O
51	),	O
52	and	O
53	2	O
54	-	O
55	and	O
56	3	O
57	-	O
58	year	O
59	survival	O
60	rates	O
61	(	O
62	13	O
63	%	O
64	v	O
65	5	O
66	%	O
67	and	O
68	5	O
69	%	O
70	v	O
71	0	O
72	%,	O
73	respectively	O
74	).	O

1	Activation	O
2	mediated	O
3	by	O
4	Cat8p	B
5	was	O
6	no	O
7	longer	O
8	detectable	O
9	in	O
10	a	O
11	cat1	B
12	mutant	I
13	.	O

1	Ab	B
2	-	I
3	MLV	I
4	strains	O
5	expressing	O
6	P70	B
7	/	O
8	S2	O
9	failed	O
10	to	O
11	transform	O
12	NIH	O
13	3T3	O
14	cells	O
15	and	O
16	demonstrated	O
17	a	O
18	greatly	O
19	reduced	O
20	capacity	O
21	to	O
22	mediate	O
23	signaling	O
24	events	O
25	associated	O
26	with	O
27	the	O
28	Ras	B
29	-	I
30	dependent	I
31	mitogen	I
32	-	I
33	activated	I
34	protein	I
35	(	I
36	MAP	I
37	)	I
38	kinase	I
39	pathway	O
40	.	O

1	The	O
2	kallistatin	B
3	gene	I
4	was	O
5	localized	O
6	by	O
7	in	O
8	situ	O
9	hybridization	O
10	to	O
11	human	O
12	chromosome	O
13	14q31	O
14	-	O
15	q32	O
16	.	O
17	1	O
18	,	O
19	close	O
20	to	O
21	the	O
22	serpin	B
23	genes	I
24	encoding	I
25	alpha	I
26	1	I
27	-	I
28	antichymotrypsin	I
29	,	I
30	protein	I
31	C	I
32	inhibitor	I
33	,	I
34	alpha	I
35	1	I
36	-	I
37	antitrypsin	I
38	,	O
39	and	O
40	corticosteroid	B
41	-	I
42	binding	I
43	globulin	I
44	.	O

1	TRAF2	B
2	is	O
3	known	O
4	to	O
5	associate	O
6	with	O
7	TRADD	B
8	,	O
9	and	O
10	expression	O
11	of	O
12	a	O
13	dominant	O
14	-	O
15	negative	O
16	N	O
17	-	O
18	terminal	O
19	deletion	O
20	TRAF2	B
21	mutant	I
22	was	O
23	found	O
24	to	O
25	partially	O
26	inhibit	O
27	LMP1	B
28	-	O
29	induced	O
30	JNK	B
31	activation	O
32	in	O
33	293	O
34	cells	O
35	.	O

1	Identification	O
2	of	O
3	an	O
4	enhancer	O
5	and	O
6	an	O
7	alternative	O
8	promoter	O
9	in	O
10	the	O
11	first	O
12	intron	O
13	of	O
14	the	O
15	alpha	B
16	-	I
17	fetoprotein	I
18	gene	I
19	.	O

1	Following	O
2	extended	O
3	recovery	O
4	hippocampal	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	CA3	O
15	and	O
16	CA4	O
17	.	O

1	Autotransplantation	O
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	O

1	We	O
2	suggest	O
3	that	O
4	apart	O
5	from	O
6	the	O
7	World	O
8	Summit	O
9	for	O
10	Children	O
11	'	O
12	s	O
13	under	O
14	-	O
15	five	O
16	mortality	O
17	target	O
18	for	O
19	the	O
20	year	O
21	2000	O
22	,	O
23	intraregional	O
24	targets	O
25	to	O
26	reduce	O
27	geographical	O
28	inequalities	O
29	in	O
30	under	O
31	-	O
32	five	O
33	mortality	O
34	should	O
35	be	O
36	specified	O
37	.	O

1	The	O
2	standard	O
3	principles	O
4	of	O
5	surgical	O
6	management	O
7	must	O
8	be	O
9	adhered	O
10	to	O
11	when	O
12	using	O
13	Sandostatin	B
14	to	O
15	treat	O
16	patients	O
17	with	O
18	these	O
19	disorders	O
20	.	O

1	High	O
2	ADR1	B
3	gene	I
4	dosage	O
5	increased	O
6	the	O
7	transcription	O
8	of	O
9	genes	O
10	encoding	O
11	peroxisomal	O
12	proteins	O
13	as	O
14	compared	O
15	to	O
16	one	O
17	copy	O
18	of	O
19	the	O
20	ADR1	B
21	gene	I
22	.	O

1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O

1	The	O
2	content	O
3	of	O
4	glucosamine	O
5	and	O
6	galactosamine	O
7	in	O
8	tartar	O

1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	B
8	-	I
9	I	I
10	promoter	I
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O

1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	tolerant	O
10	to	O
11	gp100	B
12	Ag	I
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	CD8	O
19	+	O
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	O
25	HLA	B
26	-	I
27	A	I
28	*	O
29	0201	O
30	-	O
31	restricted	O
32	,	O
33	gp100	O
34	-	O
35	derived	O
36	epitopes	O
37	.	O

1	Pao2	O
2	increased	O
3	from	O
4	15	O
5	.	O
6	5	O
7	+/-	O
8	5	O
9	.	O
10	6	O
11	kPa	O
12	(	O
13	116	O
14	+/-	O
15	42	O
16	mm	O
17	Hg	O
18	)	O
19	to	O
20	17	O
21	.	O
22	3	O
23	+/-	O
24	6	O
25	.	O
26	3	O
27	kPa	O
28	(	O
29	130	O
30	+/-	O
31	47	O
32	mm	O
33	Hg	O
34	)	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	05	O
41	).	O

1	Calmodulin	B
2	-	I
3	binding	I
4	peptide	I
5	(	O
6	CBP	B
7	),	O
8	a	O
9	peptide	O
10	of	O
11	26	O
12	amino	O
13	acids	O
14	derived	O
15	from	O
16	muscle	O
17	myosin	B
18	light	I
19	chain	I
20	kinase	I
21	(	O
22	MLCK	B
23	),	O
24	binds	O
25	to	O
26	calmodulin	B
27	with	O
28	nanomolar	O
29	affinity	O
30	.	O

1	HBB	O
2	concentration	O
3	in	O
4	the	O
5	fetuses	O
6	indicated	O
7	little	O
8	,	O
9	if	O
10	any	O
11	accumulation	O
12	.	O

1	Luteinizing	B
2	hormone	I
3	-	I
4	releasing	I
5	hormone	I
6	analog	O
7	therapy	O
8	of	O
9	uterine	O
10	fibroid	O
11	:	O
12	analysis	O
13	of	O
14	results	O
15	obtained	O
16	with	O
17	buserelin	O
18	administered	O
19	intranasally	O
20	and	O
21	goserelin	B
22	administered	O
23	subcutaneously	O
24	as	O
25	a	O
26	monthly	O
27	depot	O
28	.	O

1	CONCLUSION	O
2	:	O
3	We	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	features	O
9	of	O
10	disease	O
11	likely	O
12	to	O
13	be	O
14	associated	O
15	with	O
16	a	O
17	clinically	O
18	useful	O
19	response	O
20	to	O
21	inhaled	O
22	NO	O
23	therapy	O
24	using	O
25	the	O
26	parameters	O
27	studied	O
28	.	O

1	The	O
2	patient	O
3	was	O
4	treated	O
5	with	O
6	benzathine	O
7	penicillin	O
8	,	O
9	2	O
10	,	O
11	400	O
12	,	O
13	000	O
14	U	O
15	weekly	O
16	for	O
17	three	O
18	weeks	O
19	.	O

1	Monitoring	O
2	changes	O
3	in	O
4	the	O
5	heart	O
6	rate	O
7	of	O
8	the	O
9	premature	O
10	fetus	O
11	during	O
12	tocolysis	O
13	with	O
14	the	O
15	beta	O
16	-	O
17	adrenomimetics	O
18	partusisten	O
19	and	O
20	Pre	O
21	-	O
22	par	O

1	Serum	O
2	antibodies	O
3	were	O
4	detected	O
5	in	O
6	at	O
7	least	O
8	95	O
9	%	O
10	of	O
11	the	O
12	infected	O
13	guinea	O
14	pigs	O
15	between	O
16	4	O
17	-	O
18	30	O
19	WPI	O
20	and	O
21	rats	O
22	between	O
23	3	O
24	-	O
25	16	O
26	WPI	O
27	.	O

1	IGF	B
2	I	I
3	and	O
4	insulin	B
5	receptors	I
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O

1	Merlie	O
2	,	O
3	Cold	O
4	Spring	O
5	Harbor	O
6	Symp	O
7	.	O

1	We	O
2	characterized	O
3	the	O
4	structure	O
5	of	O
6	this	O
7	leader	O
8	mRNA	O
9	by	O
10	using	O
11	the	O
12	program	O
13	Mfold	O
14	and	O
15	a	O
16	combination	O
17	of	O
18	nested	O
19	and	O
20	internal	O
21	deletions	O
22	transcriptionally	O
23	fused	O
24	to	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	.	O

1	A	O
2	needs	O
3	assessment	O
4	of	O
5	these	O
6	families	O
7	was	O
8	also	O
9	done	O
10	.	O

1	Using	O
2	5	O
3	'	O
4	RACE	O
5	and	O
6	reverse	O
7	transcription	O
8	-	O
9	PCR	O
10	(	O
11	RT	O
12	-	O
13	PCR	O
14	)	O
15	methodologies	O
16	,	O
17	we	O
18	cloned	O
19	these	O
20	sequences	O
21	from	O
22	brain	O
23	and	O
24	placenta	O
25	and	O
26	found	O
27	this	O
28	material	O
29	to	O
30	be	O
31	composed	O
32	of	O
33	alternatively	O
34	spliced	O
35	exons	O
36	using	O
37	a	O
38	previously	O
39	reported	O
40	noncoding	O
41	exon	O
42	(	O
43	1A	B
44	)	O
45	and	O
46	a	O
47	novel	O
48	97	O
49	-	O
50	bp	O
51	noncoding	O
52	exon	O
53	(	O
54	1B	O
55	).	O

1	One	O
2	unit	O
3	encodes	O
4	traA	O
5	,	O
6	traF	B
7	,	O
8	and	O
9	traB	B
10	,	O
11	while	O
12	the	O
13	second	O
14	encodes	O
15	traC	O
16	,	O
17	traD	O
18	,	O
19	and	O
20	traG	B
21	.	O

1	The	O
2	full	O
3	length	O
4	cDNA	O
5	sequence	O
6	of	O
7	a	O
8	Type	B
9	I	I
10	transforming	I
11	growth	I
12	factor	I
13	-	I
14	beta	I
15	(	O
16	TGF	B
17	-	I
18	beta	I
19	)	I
20	receptor	I
21	has	O
22	been	O
23	isolated	O
24	from	O
25	the	O
26	filarial	O
27	parasitic	O
28	nematode	O
29	Brugia	O
30	pahangi	O
31	.	O

1	Using	O
2	backcross	O
3	analysis	O
4	,	O
5	both	O
6	exons	O
7	1	O
8	and	O
9	4	O
10	mapped	O
11	to	O
12	a	O
13	proximal	O
14	region	O
15	of	O
16	murine	O
17	Chromosome	O
18	4	O
19	indistinguishable	O
20	from	O
21	the	O
22	vacillans	O
23	gene	O
24	.	O

1	Doppler	O
2	echo	O
3	in	O
4	evaluating	O
5	arteriovenous	O
6	fistulae	O
7	for	O
8	dialysis	O

1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	B
9	-	I
10	phosphoglycerate	I
11	kinase	I
12	gene	I
13	of	O
14	Pyrococcus	O
15	woesei	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O

1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	B
22	/	O
23	HAP3	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	B
34	consensus	I
35	recognition	I
36	sequence	I
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O

1	The	O
2	pulmonary	O
3	effects	O
4	observed	O
5	,	O
6	became	O
7	more	O
8	pronounced	O
9	with	O
10	increasing	O
11	NO2	O
12	concentrations	O
13	(	O
14	0	O
15	,	O
16	25	O
17	,	O
18	75	O
19	,	O
20	125	O
21	,	O
22	175	O
23	or	O
24	200	O
25	ppm	O
26	,	O
27	1	O
28	ppm	O
29	NO2	O
30	=	O
31	1	O
32	.	O
33	88	O
34	mg	O
35	m	O
36	-	O
37	3	O
38	NO2	O
39	)	O
40	and	O
41	exposure	O
42	times	O
43	(	O
44	5	O
45	,	O
46	10	O
47	,	O
48	20	O
49	or	O
50	30	O
51	min	O
52	).	O

1	In	O
2	contrast	O
3	,	O
4	H	O
5	-	O
6	NS	O
7	negative	O
8	regulation	O
9	operated	O
10	only	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	Fur	B
16	.	O

1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O

1	It	O
2	is	O
3	impossible	O
4	to	O
5	define	O
6	only	O
7	one	O
8	clinical	O
9	outline	O
10	because	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	infected	O
16	NB	O
17	may	O
18	be	O
19	found	O
20	with	O
21	gestational	O
22	age	O
23	at	O
24	term	O
25	and	O
26	pre	O
27	-	O
28	term	O
29	and	O
30	when	O
31	born	O
32	with	O
33	a	O
34	weight	O
35	above	O
36	or	O
37	below	O
38	2000	O
39	g	O
40	.	O

1	Krox	B
2	-	I
3	24	I
4	is	O
5	therefore	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcriptional	O
11	activator	O
12	.	O

1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O

1	Re	O
2	-	O
3	examining	O
4	methylbenzene	O
5	(	O
6	toluene	O
7	)	O
8	as	O
9	a	O
10	treatment	O
11	for	O
12	Ancylostomum	O
13	caninum	O
14	.	O

1	Lack	O
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	vibration	O
7	measurements	O
8	and	O
9	employment	O
10	durations	O
11	add	O
12	to	O
13	the	O
14	uncertainty	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	tool	O
21	conditions	O
22	(	O
23	grinder	O
24	wheels	O
25	,	O
26	etc	O
27	)	O
28	and	O
29	inherent	O
30	difficulties	O
31	in	O
32	measurement	O
33	.	O

1	Current	O
2	status	O
3	of	O
4	zinc	O
5	deficiency	O
6	in	O
7	the	O
8	pathogenesis	O
9	of	O
10	neurological	O
11	,	O
12	dermatological	O
13	and	O
14	musculoskeletal	O
15	disorders	O
16	.	O

1	Stress	B
2	-	I
3	activated	I
4	protein	I
5	kinase	I
6	1	I
7	(	O
8	SAPK1	B
9	),	O
10	also	O
11	called	O
12	c	B
13	-	I
14	Jun	I
15	N	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O

1	A	O
2	coiled	O
3	-	O
4	coil	O
5	related	O
6	protein	O
7	specific	O
8	for	O
9	synapsed	O
10	regions	O
11	of	O
12	meiotic	O
13	prophase	O
14	chromosomes	O
15	.	O

1	Unaided	O
2	attempts	O
3	to	O
4	quit	O
5	smoking	O
6	are	O
7	generally	O
8	unsuccessful	O
9	.	O

1	To	O
2	do	O
3	this	O
4	,	O
5	segments	O
6	of	O
7	DNA	O
8	from	O
9	the	O
10	5	O
11	'	O
12	flank	O
13	of	O
14	the	O
15	initiation	O
16	sites	O
17	for	O
18	germline	O
19	epsilon	O
20	RNA	O
21	were	O
22	ligated	O
23	to	O
24	a	O
25	luciferase	B
26	reporter	I
27	gene	I
28	and	O
29	transfected	O
30	into	O
31	two	O
32	mouse	O
33	B	O
34	cell	O
35	lines	O
36	,	O
37	one	O
38	of	O
39	which	O
40	can	O
41	be	O
42	induced	O
43	to	O
44	switch	O
45	to	O
46	IgE	B
47	.	O

1	Furthermore	O
2	,	O
3	direct	O
4	association	O
5	with	O
6	D3	O
7	phosphatidylinositides	O
8	seems	O
9	to	O
10	be	O
11	essential	O
12	for	O
13	activation	O
14	of	O
15	PKB	B
16	/	O
17	Akt	B
18	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	the	O
7	protein	O
8	in	O
9	the	O
10	region	O
11	of	O
12	the	O
13	specificity	O
14	pocket	O
15	is	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	S	O
21	.	O
22	griseus	O
23	proteases	O
24	A	O
25	,	O
26	B	O
27	,	O
28	and	O
29	C	O
30	.	O

1	These	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	E2F	B
8	or	O
9	an	O
10	E2F	B
11	-	I
12	related	I
13	transcription	I
14	factor	I
15	is	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	nonmuscle	O
22	myosin	B
23	expression	O
24	.	O

1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O

1	Furthermore	O
2	,	O
3	formation	O
4	of	O
5	foci	O
6	of	O
7	transformed	O
8	RECs	O
9	by	O
10	the	O
11	c	B
12	-	I
13	jun	I
14	/	O
15	ras	B
16	combination	O
17	was	O
18	augmented	O
19	3	O
20	-	O
21	fold	O
22	by	O
23	the	O
24	tumor	O
25	promoter	O
26	phorbol	O
27	12	O
28	-	O
29	tetradecanoate	O
30	13	O
31	-	O
32	acetate	O
33	.	O

1	However	O
2	,	O
3	ICK1	B
4	was	O
5	induced	O
6	by	O
7	ABA	O
8	,	O
9	and	O
10	along	O
11	with	O
12	ICK1	B
13	induction	O
14	there	O
15	was	O
16	a	O
17	decrease	O
18	in	O
19	Cdc2	B
20	-	I
21	like	I
22	histone	I
23	H1	I
24	kinase	I
25	activity	O
26	.	O

1	The	O
2	protein	O
3	kinase	O
4	domains	O
5	of	O
6	LIMK1	B
7	and	O
8	LIMK2	B
9	are	O
10	unique	O
11	in	O
12	that	O
13	they	O
14	contain	O
15	an	O
16	unusual	O
17	sequence	O
18	motif	O
19	Asp	O
20	-	O
21	Leu	O
22	-	O
23	Asn	O
24	-	O
25	Ser	O
26	-	O
27	His	O
28	-	O
29	Asn	O
30	in	O
31	subdomain	O
32	VIB	O
33	and	O
34	a	O
35	highly	O
36	basic	O
37	insert	O
38	between	O
39	subdomains	B
40	VII	I
41	and	I
42	VIII	I
43	.	O

1	High	O
2	levels	O
3	of	O
4	C	O
5	subunits	O
6	are	O
7	observed	O
8	in	O
9	several	O
10	subsequent	O
11	larval	O
12	and	O
13	adult	O
14	stages	O
15	of	O
16	development	O
17	.	O

1	When	O
2	expressed	O
3	in	O
4	COS	O
5	-	O
6	7	O
7	cells	O
8	,	O
9	MKP	B
10	-	I
11	4	I
12	blocks	O
13	activation	O
14	of	O
15	MAP	B
16	kinases	I
17	with	O
18	the	O
19	selectivity	O
20	ERK	B
21	>	O
22	p38	B
23	=	O
24	JNK	B
25	/	O
26	SAPK	B
27	.	O

1	Problems	O
2	in	O
3	the	O
4	determination	O
5	of	O
6	the	O
7	antigenic	O
8	content	O
9	of	O
10	influenza	O
11	vaccines	O
12	.	O

1	The	O
2	presence	O
3	in	O
4	such	O
5	patients	O
6	of	O
7	antibodies	O
8	to	O
9	adrenaline	O
10	and	O
11	noradrenaline	O
12	is	O
13	indicative	O
14	of	O
15	considerable	O
16	disruption	O
17	of	O
18	catecholamine	O
19	biotransformation	O
20	.	O

1	Albumin	B
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	B
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	)	I
29	alpha	I
30	and	O
31	C	B
32	/	I
33	EBPbeta	I
34	.	O

1	A	O
2	total	O
3	of	O
4	7	O
5	(	O
6	4	O
7	males	O
8	and	O
9	3	O
10	females	O
11	)	O
12	patients	O
13	were	O
14	included	O
15	in	O
16	this	O
17	retrospective	O
18	study	O
19	to	O
20	determine	O
21	the	O
22	sensitivity	O
23	of	O
24	radioimmunoscintigraphy	O
25	with	O
26	I	O
27	-	O
28	131	O
29	labeled	O
30	anti	O
31	CEA	B
32	/	O
33	CA	B
34	19	I
35	-	I
36	9	I
37	monoclonal	I
38	antibodies	I
39	.	O

1	Twenty	O
2	-	O
3	eight	O
4	were	O
5	excluded	O
6	as	O
7	gallstones	O
8	were	O
9	not	O
10	proved	O
11	:	O
12	of	O
13	the	O
14	remainder	O
15	,	O
16	21	O
17	patients	O
18	received	O
19	glucagon	O
20	and	O
21	22	O
22	placebo	O
23	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	are	O
5	being	O
6	used	O
7	to	O
8	accelerate	O
9	the	O
10	recovery	O
11	of	O
12	myelopoiesis	O
13	following	O
14	high	O
15	-	O
16	dose	O
17	chemotherapy	O
18	in	O
19	cancer	O
20	patients	O
21	.	O

1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	B
13	L	I
14	-	I
15	CAM	I
16	gene	I
17	.	O

1	During	O
2	the	O
3	dose	O
4	-	O
5	finding	O
6	,	O
7	two	O
8	patients	O
9	were	O
10	temporarily	O
11	withdrawn	O
12	from	O
13	medication	O
14	and	O
15	one	O
16	patient	O
17	was	O
18	excluded	O
19	because	O
20	of	O
21	elevated	O
22	levels	O
23	of	O
24	liver	O
25	enzymes	O
26	.	O

1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O

1	Forskolin	O
2	significantly	O
3	enhanced	O
4	heregulin	B
5	-	O
6	stimulated	O
7	expression	O
8	of	O
9	cyclin	B
10	D	I
11	and	O
12	phosphorylation	O
13	of	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	.	O

1	The	O
2	observation	O
3	of	O
4	late	O
5	effects	O
6	after	O
7	irradiations	O
8	or	O
9	after	O
10	space	O
11	flights	O
12	show	O
13	the	O
14	difficulties	O
15	encountered	O
16	in	O
17	assessing	O
18	radiative	O
19	risks	O
20	during	O
21	long	O
22	duration	O
23	space	O
24	flights	O
25	.	O

1	Twenty	O
2	-	O
3	nine	O
4	days	O
5	after	O
6	injection	O
7	of	O
8	5	O
9	.	O
10	8	O
11	mCi	O
12	of	O
13	Tc	O
14	-	O
15	99m	O
16	,	O
17	which	O
18	gives	O
19	28	O
20	rads	O
21	to	O
22	the	O
23	testis	O
24	,	O
25	the	O
26	number	O
27	of	O
28	sperm	O
29	hads	O
30	decreased	O
31	to	O
32	70	O
33	%	O
34	of	O
35	control	O
36	.	O

1	Plasma	O
2	lactoferrin	O
3	and	O
4	the	O
5	blood	O
6	count	O
7	of	O
8	polynuclear	O
9	neutrophils	O

1	In	O
2	MCCP	O
3	functions	O
4	of	O
5	the	O
6	source	O
7	emission	O
8	,	O
9	surface	O
10	reflection	O
11	,	O
12	photoacceptor	O
13	sensitivity	O
14	are	O
15	approximated	O
16	by	O
17	the	O
18	normal	O
19	distribution	O
20	curves	O
21	.	O

1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O

1	The	O
2	basal	O
3	promoter	O
4	strength	O
5	of	O
6	constructs	O
7	that	O
8	contained	O
9	deletions	O
10	in	O
11	the	O
12	U5	B
13	region	I
14	of	O
15	the	O
16	LTR	O
17	was	O
18	analyzed	O
19	by	O
20	chloramphenicol	B
21	acetyltransferase	I
22	(	O
23	CAT	B
24	)	O
25	assays	O
26	following	O
27	transfection	O
28	of	O
29	HeLa	O
30	cells	O
31	or	O
32	Jurkat	O
33	T	O
34	-	O
35	cells	O
36	in	O
37	the	O
38	presence	O
39	or	O
40	absence	O
41	of	O
42	viral	B
43	transactivator	I
44	tax	I
45	protein	I
46	.	O

1	When	O
2	cells	O
3	were	O
4	microinjected	O
5	with	O
6	TFOs	O
7	designed	O
8	to	O
9	bind	O
10	to	O
11	a	O
12	30	O
13	-	O
14	bp	O
15	polypurine	O
16	site	O
17	situated	O
18	between	O
19	the	O
20	two	O
21	TK	B
22	genes	I
23	,	O
24	recombination	O
25	was	O
26	observed	O
27	at	O
28	frequencies	O
29	in	O
30	the	O
31	range	O
32	of	O
33	1	O
34	%,	O
35	2	O
36	,	O
37	500	O
38	-	O
39	fold	O
40	above	O
41	the	O
42	background	O
43	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	gene	O
9	has	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	interferon	B
15	regulatory	I
16	factors	I
17	(	O
18	IRFs	O
19	).	O

1	There	O
2	was	O
3	no	O
4	further	O
5	increase	O
6	in	O
7	oxygen	O
8	consumption	O
9	when	O
10	these	O
11	subjects	O
12	breathed	O
13	with	O
14	inspiratory	O
15	pressures	O
16	above	O
17	SIP	O
18	.	O

1	Retinoblastoma	O
2	:	O
3	a	O
4	study	O
5	of	O
6	natural	O
7	history	O
8	and	O
9	prognosis	O
10	of	O
11	268	O
12	cases	O
13	.	O

1	Thyroid	O
2	function	O
3	tests	O
4	were	O
5	performed	O
6	on	O
7	300	O
8	admissions	O
9	,	O
10	leaving	O
11	707	O
12	untested	O
13	.	O

1	During	O
2	the	O
3	conditioning	O
4	procedure	O
5	,	O
6	the	O
7	C	O
8	-	O
9	fiber	O
10	reflex	O
11	was	O
12	facilitated	O
13	(	O
14	wind	O
15	-	O
16	up	O
17	)	O
18	in	O
19	a	O
20	stimulus	O
21	-	O
22	dependent	O
23	fashion	O
24	in	O
25	intact	O
26	,	O
27	anesthetized	O
28	animals	O
29	during	O
30	the	O
31	application	O
32	of	O
33	the	O
34	first	O
35	seven	O
36	conditioning	O
37	stimuli	O
38	;	O
39	thereafter	O
40	,	O
41	the	O
42	magnitude	O
43	of	O
44	the	O
45	responses	O
46	reached	O
47	a	O
48	plateau	O
49	and	O
50	then	O
51	decreased	O
52	.	O

1	Diclofenac	O
2	sodium	O
3	-	O
4	chlormezanone	O
5	poisoning	O
6	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	O

1	Among	O
2	them	O
3	,	O
4	26	O
5	cases	O
6	were	O
7	benign	O
8	and	O
9	34	O
10	malignant	O
11	.	O

1	The	O
2	sequence	O
3	upstream	O
4	of	O
5	the	O
6	rhlA	B
7	promoter	I
8	contains	O
9	two	O
10	inverted	O
11	repeats	O
12	which	O
13	define	O
14	putative	O
15	binding	O
16	sites	O
17	for	O
18	the	O
19	RhlR	O
20	regulator	O
21	.	O

1	The	O
2	number	O
3	of	O
4	fecal	O
5	pellets	O
6	ingested	O
7	peaked	O
8	at	O
9	5	O
10	to	O
11	6	O
12	weeks	O
13	old	O
14	(	O
15	13	O
16	pellets	O
17	/	O
18	day	O
19	)	O
20	and	O
21	gradually	O
22	decreased	O
23	,	O
24	thereafter	O
25	(	O
26	2	O
27	.	O
28	1	O
29	pellets	O
30	at	O
31	78	O
32	weeks	O
33	old	O
34	,	O
35	1	O
36	.	O
37	5	O
38	pellets	O
39	at	O
40	104	O
41	weeks	O
42	old	O
43	).	O

1	The	O
2	effect	O
3	of	O
4	emotional	O
5	-	O
6	painful	O
7	stress	O
8	(	O
9	EPS	O
10	)	O
11	on	O
12	myocardial	O
13	extensibility	O
14	and	O
15	contractility	O
16	was	O
17	studied	O
18	on	O
19	an	O
20	isolated	O
21	rat	O
22	atrium	O
23	.	O

1	It	O
2	has	O
3	been	O
4	demonstrated	O
5	previously	O
6	that	O
7	Pax	B
8	-	I
9	6	I
10	,	O
11	a	O
12	paired	B
13	domain	I
14	(	O
15	PD	O
16	)/	O
17	homeodomain	B
18	(	O
19	HD	O
20	)	O
21	transcription	O
22	factor	O
23	critical	O
24	for	O
25	eye	O
26	development	O
27	,	O
28	contributes	O
29	to	O
30	the	O
31	activation	O
32	of	O
33	the	O
34	alphaB	B
35	-,	O
36	alphaA	B
37	-,	O
38	delta1	B
39	-,	O
40	and	O
41	zeta	B
42	-	I
43	crystallin	I
44	genes	I
45	in	O
46	the	O
47	lens	O
48	.	O

1	The	O
2	data	O
3	indicate	O
4	a	O
5	three	O
6	-	O
7	phase	O
8	reaction	O
9	after	O
10	B1	O
11	injection	O
12	:	O
13	Phase	O
14	1	O
15	--	O
16	shortly	O
17	after	O
18	injection	O
19	there	O
20	is	O
21	a	O
22	drop	O
23	of	O
24	all	O
25	parameters	O
26	lasting	O
27	for	O
28	30	O
29	sec	O
30	.	O

1	This	O
2	spindle	O
3	defect	O
4	of	O
5	pds1	B
6	mutants	I
7	results	O
8	from	O
9	a	O
10	temperature	O
11	-	O
12	sensitive	O
13	step	O
14	that	O
15	occurs	O
16	around	O
17	the	O
18	G1	O
19	/	O
20	S	O
21	boundary	O
22	about	O
23	the	O
24	time	O
25	of	O
26	spindle	O
27	assembly	O
28	.	O

1	U24	O
2	has	O
3	two	O
4	separate	O
5	12	O
6	nt	O
7	long	O
8	complementarities	O
9	to	O
10	a	O
11	highly	O
12	conserved	O
13	tract	O
14	of	O
15	28S	B
16	rRNA	I
17	.	O

1	Results	O
2	for	O
3	men	O
4	who	O
5	drank	O
6	up	O
7	to	O
8	two	O
9	drinks	O
10	per	O
11	day	O
12	suggest	O
13	that	O
14	if	O
15	the	O
16	dependence	O
17	criteria	O
18	were	O
19	invalid	O
20	,	O
21	reductions	O
22	in	O
23	the	O
24	prevalence	O
25	of	O
26	specific	O
27	indicators	O
28	of	O
29	alcohol	O
30	dependence	O
31	would	O
32	range	O
33	from	O
34	0	O
35	.	O
36	3	O
37	%	O
38	to	O
39	5	O
40	.	O
41	2	O
42	%.	O

1	Commun	O
2	.	O

1	ORFA	O
2	and	O
3	ccdA	O
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	B
8	AM	I
9	gene	I
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	O
21	gene	O
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	,	O
7	from	O
8	nucleotide	O
9	-	O
10	837	O
11	to	O
12	-	O
13	336	O
14	,	O
15	contains	O
16	TATA	O
17	and	O
18	inverted	O
19	CAAT	O
20	boxes	O
21	as	O
22	well	O
23	as	O
24	GATA	B
25	-	I
26	1	I
27	/	O
28	SP1	B
29	erythroid	O
30	-	O
31	specific	O
32	cis	O
33	-	O
34	acting	O
35	regulatory	O
36	elements	O
37	.	O

1	The	O
2	full	O
3	protocol	O
4	was	O
5	completed	O
6	by	O
7	33	O
8	patients	O
9	(	O
10	45	O
11	%	O
12	of	O
13	original	O
14	cohort	O
15	).	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	relationship	O
7	between	O
8	comprehension	O
9	and	O
10	production	O
11	is	O
12	different	O
13	at	O
14	different	O
15	stages	O
16	in	O
17	development	O
18	.	O

1	In	O
2	experiments	O
3	with	O
4	the	O
5	D1	B
6	antagonist	O
7	SCH	O
8	23390	O
9	,	O
10	buprenorphine	O
11	-	O
12	induced	O
13	depression	O
14	was	O
15	consistently	O
16	blocked	O
17	,	O
18	but	O
19	facilitation	O
20	was	O
21	unaffected	O
22	.	O

1	Reviewing	O
2	manuscripts	O
3	:	O
4	developing	O
5	an	O
6	efficient	O
7	system	O
8	.	O

1	Ras	B
2	is	O
3	not	O
4	associated	O
5	with	O
6	the	O
7	tegument	O
8	.	O

1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	B
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	O
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O

1	Herpes	O
2	virus	O
3	infection	O
4	was	O
5	characterized	O
6	by	O
7	inversion	O
8	of	O
9	the	O
10	T4	O
11	/	O
12	T8	O
13	ratio	O
14	below	O
15	1	O
16	.	O
17	0	O
18	(	O
19	sensitivity	O
20	90	O
21	%,	O
22	specificity	O
23	88	O
24	%),	O
25	caused	O
26	by	O
27	proliferation	O
28	of	O
29	the	O
30	T8	O
31	subpopulation	O
32	,	O
33	which	O
34	--	O
35	compared	O
36	with	O
37	the	O
38	findings	O
39	in	O
40	patients	O
41	with	O
42	rejection	O
43	crises	O
44	--	O
45	was	O
46	significantly	O
47	raised	O
48	(	O
49	P	O
50	less	O
51	than	O
52	0	O
53	.	O
54	001	O
55	).	O

1	Control	O
2	Tmuscle	O
3	was	O
4	35	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	7	O
11	degrees	O
12	C	O
13	,	O
14	with	O
15	control	O
16	Wi	O
17	,	O
18	max	O
19	being	O
20	51	O
21	.	O
22	6	O
23	(	O
24	SD	O
25	8	O
26	.	O
27	7	O
28	)	O
29	W	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	.	O

1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	complexes	O
7	similar	O
8	to	O
9	the	O
10	C25	O
11	,	O
12	C30	B
13	and	O
14	C35	B
15	complexes	I
16	are	O
17	formed	O
18	by	O
19	rat	O
20	cortex	O
21	nuclear	O
22	extracts	O
23	and	O
24	the	O
25	SAA	O
26	element	O
27	in	O
28	EMSA	O
29	experiments	O
30	,	O
31	suggesting	O
32	the	O
33	relevance	O
34	of	O
35	our	O
36	in	O
37	vitro	O
38	observations	O
39	to	O
40	the	O
41	in	O
42	vivo	O
43	functioning	O
44	of	O
45	the	O
46	rat	B
47	APP	I
48	promoter	I
49	.	O

1	Effects	O
2	of	O
3	long	O
4	-	O
5	term	O
6	parenteral	O
7	nutrition	O
8	on	O
9	gastrin	B
10	release	O
11	in	O
12	dogs	O
13	.	O

1	The	O
2	cDNA	O
3	clone	O
4	was	O
5	used	O
6	as	O
7	a	O
8	homologous	O
9	probe	O
10	to	O
11	isolate	O
12	a	O
13	truncated	O
14	genomic	O
15	clone	O
16	encoding	O
17	H2A1	B
18	.	O

1	In	O
2	vivo	O
3	,	O
4	MyoD	B
5	requires	O
6	this	O
7	tryptophan	O
8	motif	O
9	to	O
10	evoke	O
11	chromatin	O
12	remodeling	O
13	in	O
14	the	O
15	Myogenin	B
16	promoter	I
17	and	O
18	to	O
19	activate	O
20	Myogenin	B
21	transcription	O
22	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	O
7	cyclin	B
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O

1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	I
8	D	I
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	jun	B
22	-	I
23	B	I
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	B
34	growth	I
35	factors	I
36	.	O

1	Functional	O
2	disorders	O
3	of	O
4	the	O
5	ureter	O
6	following	O
7	gynecologic	O
8	surgery	O

1	Hospital	O
2	hit	O
3	for	O
4	hiring	O
5	AHERF	O
6	physicians	O
7	.	O

1	Sp1	B
2	and	O
3	two	O
4	Sp3	B
5	isoforms	I
6	were	O
7	detected	O
8	as	O
9	the	O
10	primary	O
11	cellular	O
12	constituents	O
13	of	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	formed	O
19	with	O
20	the	O
21	NF	B
22	-	I
23	kappaB	I
24	-	I
25	proximal	I
26	site	I
27	.	O

1	Articles	O
2	addressing	O
3	valvular	O
4	heart	O
5	disease	O
6	or	O
7	heart	O
8	failure	O
9	secondary	O
10	to	O
11	acute	O
12	myocardial	O
13	infarction	O
14	or	O
15	Chagas	O
16	'	O
17	disease	O
18	were	O
19	excluded	O
20	.	O

1	The	O
2	CNXA	O
3	domain	O
4	is	O
5	similar	O
6	at	O
7	the	O
8	amino	O
9	acid	O
10	level	O
11	to	O
12	the	O
13	Escherichia	B
14	coli	I
15	moaA	I
16	gene	I
17	product	I
18	,	O
19	while	O
20	CNXC	O
21	is	O
22	similar	O
23	to	O
24	the	O
25	E	O
26	.	O
27	coli	O
28	moaC	O
29	product	O
30	,	O
31	with	O
32	both	O
33	E	O
34	.	O
35	coli	O
36	products	O
37	encoded	O
38	by	O
39	different	O
40	cistrons	O
41	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	yeast	O
8	and	O
9	mammalian	O
10	mitochondrial	O
11	targeting	O
12	sequences	O
13	are	O
14	similar	O
15	but	O
16	less	O
17	related	O
18	than	O
19	the	O
20	mature	O
21	polypeptides	O
22	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	O
13	expression	O
14	.	O

1	Biol	O
2	.	O

1	The	O
2	cloned	O
3	HindIII	B
4	fragment	I
5	,	O
6	which	O
7	was	O
8	shown	O
9	by	O
10	DNA	O
11	sequence	O
12	analysis	O
13	to	O
14	encode	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	half	O
20	of	O
21	the	O
22	B	O
23	.	O
24	subtilis	O
25	IF2	B
26	protein	I
27	and	O
28	0	O
29	.	O
30	2	O
31	kb	O
32	of	O
33	upstream	O
34	flanking	O
35	sequence	O
36	,	O
37	was	O
38	utilized	O
39	as	O
40	a	O
41	homologous	O
42	probe	O
43	to	O
44	clone	O
45	an	O
46	overlapping	O
47	2	O
48	.	O
49	76	O
50	-	O
51	kb	O
52	ClaI	B
53	chromosomal	O
54	fragment	O
55	containing	O
56	the	O
57	entire	O
58	IF2	B
59	structural	I
60	gene	I
61	.	O

1	Immunochemotherapy	O
2	with	O
3	schizophyllan	O
4	(	O
5	SPG	O
6	)	O
7	combined	O
8	with	O
9	chemotherapeutic	O
10	agents	O
11	was	O
12	evaluated	O
13	in	O
14	two	O
15	syngeneic	O
16	tumor	O
17	-	O
18	C3H	O
19	/	O
20	He	O
21	mouse	O
22	systems	O
23	.	O

1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O

1	Substantial	O
2	amounts	O
3	of	O
4	liposomal	O
5	ampicillin	O
6	were	O
7	recovered	O
8	from	O
9	isolated	O
10	Kupffer	O
11	cells	O
12	,	O
13	the	O
14	target	O
15	cells	O
16	of	O
17	L	O
18	.	O
19	monocytogenes	O
20	after	O
21	intravenous	O
22	inoculation	O
23	.	O

1	HIV	O
2	infectiousness	O
3	and	O
4	the	O
5	AIDS	O
6	epidemic	O
7	.	O

1	The	O
2	median	O
3	survival	O
4	is	O
5	not	O
6	reached	O
7	with	O
8	a	O
9	median	O
10	follow	O
11	-	O
12	up	O
13	time	O
14	of	O
15	9	O
16	.	O
17	6	O
18	years	O
19	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	constant	O
6	magnetic	O
7	field	O
8	on	O
9	the	O
10	phagocytic	O
11	activity	O
12	of	O
13	Paramecia	O

1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	O
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	aggregates	O
28	(	O
29	Ackerman	O
30	,	O
31	S	O
32	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O

1	These	O
2	mutants	O
3	were	O
4	tested	O
5	for	O
6	ability	O
7	to	O
8	bind	O
9	each	O
10	of	O
11	the	O
12	Site	O
13	II	O
14	cognate	O
15	proteins	O
16	,	O
17	and	O
18	subsequently	O
19	evaluated	O
20	for	O
21	ability	O
22	to	O
23	confer	O
24	H4	B
25	transcriptional	O
26	activity	O
27	using	O
28	chimeric	O
29	H4	B
30	promoter	I
31	/	O
32	CAT	B
33	fusion	O
34	constructs	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	Sequential	O
2	cleavage	O
3	by	O
4	metallopeptidases	O
5	and	O
6	proteasomes	O
7	is	O
8	involved	O
9	in	O
10	processing	O
11	HIV	O
12	-	O
13	1	O
14	ENV	O
15	epitope	O
16	for	O
17	endogenous	O
18	MHC	B
19	class	I
20	I	I
21	antigen	I
22	presentation	O
23	.	O

1	The	O
2	present	O
3	data	O
4	also	O
5	suggest	O
6	that	O
7	when	O
8	compared	O
9	to	O
10	the	O
11	systemic	O
12	vascular	O
13	bed	O
14	,	O
15	the	O
16	pulmonary	O
17	vascular	O
18	bed	O
19	is	O
20	less	O
21	responsive	O
22	to	O
23	bolus	O
24	administration	O
25	of	O
26	ET	B
27	-	I
28	1	I
29	.	O

1	Notice	O
2	of	O
3	retraction	O
4	.	O

1	Furthermore	O
2	,	O
3	Zelen	O
4	'	O
5	s	O
6	method	O
7	is	O
8	used	O
9	to	O
10	balance	O
11	the	O
12	number	O
13	of	O
14	patients	O
15	allocated	O
16	to	O
17	the	O
18	two	O
19	groups	O
20	within	O
21	each	O
22	institution	O
23	(	O
24	M	O
25	.	O

1	Thus	O
2	,	O
3	included	O
4	in	O
5	the	O
6	KG1a	B
7	EST	O
8	dataset	O
9	are	O
10	candidates	O
11	for	O
12	new	O
13	human	O
14	genes	O
15	that	O
16	may	O
17	play	O
18	roles	O
19	in	O
20	hematopoietic	O
21	differentiative	O
22	progression	O
23	and	O
24	lineage	O
25	commitment	O
26	.	O

1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	O
13	9	O
14	x	O
15	10	O
16	(-	O
17	6	O
18	)	O
19	M	O
20	and	O
21	3	O
22	.	O
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O

1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	O
15	lipoxygenase	B
16	activity	O
17	.	O

1	A	O
2	high	O
3	reactor	O
4	pH	O
5	(+/-	O
6	8	O
7	),	O
8	a	O
9	short	O
10	solid	O
11	retention	O
12	time	O
13	(<	O
14	150	O
15	days	O
16	),	O
17	and	O
18	the	O
19	presence	O
20	of	O
21	a	O
22	substantial	O
23	SRB	O
24	population	O
25	in	O
26	the	O
27	inoculum	O
28	may	O
29	considerably	O
30	reduce	O
31	the	O
32	time	O
33	required	O
34	for	O
35	acetate	O
36	-	O
37	utilising	O
38	SRB	O
39	to	O
40	outcompete	O
41	MB	O
42	.	O

1	Members	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	family	I
8	of	O
9	basic	B
10	-	I
11	leucine	I
12	zipper	I
13	(	I
14	bZip	I
15	)	I
16	transcription	I
17	factors	I
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O

1	A	O
2	short	O
3	history	O
4	of	O
5	dermatology	O
6	in	O
7	Lagos	O
8	,	O
9	Nigeria	O
10	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	O
16	IV	O
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	O
27	P	B
28	-	I
29	450e	I
30	gene	I
31	.	O

1	Ste18p	O
2	was	O
3	targeted	O
4	to	O
5	the	O
6	plasma	O
7	membrane	O
8	even	O
9	in	O
10	the	O
11	absence	O
12	of	O
13	prenylation	O
14	or	O
15	thioacylation	O
16	.	O

1	Several	O
2	authors	O
3	have	O
4	recently	O
5	reported	O
6	interference	O
7	in	O
8	theophylline	O
9	analysis	O
10	by	O
11	paraxanthine	O
12	(	O
13	1	O
14	,	O
15	7	O
16	-	O
17	dimethylxanthine	O
18	),	O
19	an	O
20	important	O
21	metabolite	O
22	of	O
23	caffeine	O
24	.	O

1	Radiotherapy	O
2	and	O
3	early	O
4	orchiectomy	O
5	in	O
6	stage	O
7	D1	O
8	prostatic	O
9	carcinoma	O

1	The	O
2	same	O
3	response	O
4	occurs	O
5	whether	O
6	acrylamide	O
7	is	O
8	given	O
9	immediately	O
10	after	O
11	nerve	O
12	ligation	O
13	or	O
14	1	O
15	week	O
16	later	O
17	.	O

1	The	O
2	chloramphenicol	B
3	-	I
4	resistance	I
5	transposon	I
6	Tn4451	I
7	undergoes	O
8	precise	O
9	conjugative	O
10	deletion	O
11	from	O
12	its	O
13	parent	O
14	plasmid	O
15	plP401	O
16	in	O
17	Clostridium	O
18	perfringens	O
19	and	O
20	precise	O
21	spontaneous	O
22	excision	O
23	from	O
24	multicopy	O
25	plasmids	O
26	in	O
27	Escherichia	O
28	coli	O
29	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O

1	The	O
2	high	B
3	density	I
4	lipoprotein	I
5	(	O
6	HDL	B
7	)	I
8	receptor	I
9	mediates	O
10	the	O
11	uptake	O
12	of	O
13	cholesterol	O
14	and	O
15	cholesteryl	O
16	esters	O
17	,	O
18	substrates	O
19	for	O
20	steroidogenesis	O
21	,	O
22	from	O
23	an	O
24	HDL	B
25	particle	I
26	in	O
27	the	O
28	adrenal	O
29	gland	O
30	and	O
31	gonads	O
32	.	O

1	Protein	B
2	kinase	I
3	C	I
4	(	O
5	PKC	B
6	),	O
7	a	O
8	widely	O
9	-	O
10	distributed	O
11	enzyme	O
12	implicated	O
13	in	O
14	the	O
15	regulation	O
16	of	O
17	many	O
18	physiological	O
19	processes	O
20	,	O
21	consists	O
22	of	O
23	a	O
24	family	O
25	of	O
26	at	O
27	least	O
28	twelve	O
29	isoenzymes	O
30	which	O
31	differ	O
32	in	O
33	tissue	O
34	distribution	O
35	,	O
36	subcellular	O
37	localization	O
38	,	O
39	regulatory	O
40	properties	O
41	,	O
42	etc	O
43	.	O

1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	O
39	tsp	O
40	).	O

1	Drug	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	medications	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	narrow	O
22	therapeutic	O
23	window	O
24	.	O

1	The	O
2	imino	O
3	proton	O
4	of	O
5	T3	O
6	in	O
7	the	O
8	O6meG	O
9	.	O
10	T	O
11	12	O
12	-	O
13	mer	O
14	and	O
15	G3	O
16	in	O
17	the	O
18	O6meG	O
19	.	O
20	N	O
21	12	O
22	-	O
23	mer	O
24	helix	O
25	,	O
26	which	O
27	are	O
28	associated	O
29	with	O
30	the	O
31	modification	O
32	site	O
33	,	O
34	resonate	O
35	at	O
36	unusually	O
37	high	O
38	field	O
39	(	O
40	8	O
41	.	O
42	5	O
43	to	O
44	9	O
45	.	O
46	0	O
47	ppm	O
48	)	O
49	compared	O
50	to	O
51	imino	O
52	protons	O
53	in	O
54	Watson	O
55	-	O
56	Crick	O
57	base	O
58	pairs	O
59	(	O
60	12	O
61	.	O
62	5	O
63	to	O
64	14	O
65	.	O
66	5	O
67	ppm	O
68	).	O

1	We	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	cDNAs	O
7	against	O
8	genomic	O
9	RNA	O
10	and	O
11	mRNA	O
12	for	O
13	phosphoprotein	O
14	(	O
15	P	O
16	)	O
17	of	O
18	human	O
19	parainfluenza	O
20	type	O
21	2	O
22	virus	O
23	(	O
24	PIV	O
25	-	O
26	2	O
27	).	O
28	cDNA	O
29	clone	O
30	from	O
31	genomic	O
32	RNA	O
33	was	O
34	1439	O
35	nucleotides	O
36	in	O
37	length	O
38	excluding	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	and	O
44	was	O
45	found	O
46	to	O
47	have	O
48	two	O
49	small	O
50	open	O
51	reading	O
52	frames	O
53	encoding	O
54	proteins	O
55	of	O
56	233	O
57	and	O
58	249	O
59	amino	O
60	acids	O
61	.	O

1	2	O
2	.	O

1	Electrocardiograms	O
2	of	O
3	the	O
4	month	O
5	.	O

1	Epithelial	O
2	damage	O
3	was	O
4	not	O
5	observed	O
6	in	O
7	any	O
8	controls	O
9	but	O
10	was	O
11	in	O
12	all	O
13	tissues	O
14	exposed	O
15	to	O
16	SO2	O
17	.	O

1	Both	O
2	inhaled	O
3	and	O
4	superfused	O
5	isoflurane	O
6	dilated	O
7	the	O
8	baseline	O
9	vein	O
10	diameter	O
11	before	O
12	stimulation	O
13	.	O

1	One	O
2	enigmatic	O
3	aspect	O
4	of	O
5	GATA	B
6	factor	I
7	expression	O
8	is	O
9	that	O
10	several	O
11	GATA	B
12	proteins	I
13	,	O
14	which	O
15	ostensibly	O
16	share	O
17	the	O
18	same	O
19	DNA	O
20	-	O
21	binding	O
22	site	O
23	specificity	O
24	,	O
25	are	O
26	coexpressed	O
27	in	O
28	erythroid	O
29	cells	O
30	.	O

1	Three	O
2	patients	O
3	had	O
4	well	O
5	-,	O
6	6	O
7	patients	O
8	had	O
9	moderately	O
10	-,	O
11	and	O
12	5	O
13	patients	O
14	had	O
15	poorly	O
16	-	O
17	differentiated	O
18	adenocarcinoma	O
19	of	O
20	the	O
21	prostate	O
22	.	O

1	Most	O
2	importantly	O
3	,	O
4	the	O
5	addition	O
6	of	O
7	purified	O
8	17S	B
9	U2	I
10	snRNPs	I
11	,	O
12	but	O
13	not	O
14	of	O
15	12S	B
16	U2	I
17	snRNPs	I
18	,	O
19	to	O
20	HeLa	O
21	splicing	O
22	extracts	O
23	in	O
24	which	O
25	the	O
26	endogeneous	O
27	U2	B
28	snRNPs	I
29	have	O
30	been	O
31	functionally	O
32	neutralized	O
33	with	O
34	anti	B
35	-	I
36	PRP9	I
37	antibodies	I
38	fully	O
39	restores	O
40	the	O
41	mRNA	O
42	-	O
43	splicing	O
44	activity	O
45	of	O
46	the	O
47	extracts	O
48	.	O

1	As	O
2	a	O
3	part	O
4	of	O
5	a	O
6	large	O
7	examination	O
8	,	O
9	total	O
10	and	O
11	free	O
12	serum	O
13	cholesterol	O
14	,	O
15	total	O
16	lipid	O
17	and	O
18	triglyceride	O
19	levels	O
20	were	O
21	determined	O
22	.	O

1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	I
13	myc	I
14	protein	I
15	,	O
16	p64	B
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O

1	Which	O
2	cineangiographically	O
3	assessed	O
4	anatomic	O
5	variable	O
6	correlates	O
7	best	O
8	with	O
9	functional	O
10	measurements	O
11	of	O
12	stenosis	O
13	severity	O
14	?	O
15	A	O
16	comparison	O
17	of	O
18	quantitative	O
19	analysis	O
20	of	O
21	the	O
22	coronary	O
23	cineangiogram	O
24	with	O
25	measured	O
26	coronary	O
27	flow	O
28	reserve	O
29	and	O
30	exercise	O
31	/	O
32	redistribution	O
33	thallium	O
34	-	O
35	201	O
36	scintigraphy	O
37	.	O

1	Echinococcus	O
2	granulosus	O
3	was	O
4	diagnosed	O
5	by	O
6	fine	O
7	-	O
8	needle	O
9	aspiration	O
10	cytology	O
11	of	O
12	a	O
13	lung	O
14	cyst	O
15	in	O
16	a	O
17	6	O
18	-	O
19	yr	O
20	-	O
21	old	O
22	white	O
23	female	O
24	in	O
25	central	O
26	Missouri	O
27	.	O

1	The	O
2	other	O
3	element	O
4	bound	O
5	RBP	B
6	-	I
7	J	I
8	kappa	I
9	with	O
10	low	O
11	affinity	O
12	.	O

1	The	O
2	gene	O
3	amplification	O
4	model	O
5	of	O
6	Coquelle	O
7	et	O
8	al	O
9	.	O

1	Anastrozole	O
2	is	O
3	the	O
4	first	O
5	aromatase	B
6	inhibitor	O
7	to	O
8	show	O
9	a	O
10	significant	O
11	survival	O
12	advantage	O
13	over	O
14	megestrol	O
15	acetate	O
16	in	O
17	post	O
18	-	O
19	menopausal	O
20	women	O
21	with	O
22	advanced	O
23	breast	O
24	cancer	O
25	.	O

1	Study	O
2	on	O
3	re	O
4	-	O
5	establishment	O
6	of	O
7	ovulation	O
8	after	O
9	termination	O
10	of	O
11	sex	O
12	-	O
13	steroidal	O
14	treatment	O
15	--	O
16	compared	O
17	with	O
18	re	O
19	-	O
20	appearance	O
21	of	O
22	ovulation	O
23	after	O
24	abortion	O
25	and	O
26	premature	O
27	delivery	O
28	.	O

1	Thin	O
2	-	O
3	layer	O
4	chromatographic	O
5	methods	O
6	were	O
7	up	O
8	-	O
9	dated	O
10	for	O
11	pharmacokinetic	O
12	studies	O
13	of	O
14	imipramine	O
15	in	O
16	plasma	O
17	and	O
18	urine	O
19	.	O

1	GAL4	B
2	-	I
3	VP16	I
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	Furthermore	O
2	,	O
3	binding	O
4	of	O
5	recombinant	B
6	Myb	I
7	and	O
8	Ets	B
9	-	I
10	2	I
11	protein	I
12	to	O
13	these	O
14	fragments	O
15	could	O
16	be	O
17	competed	O
18	with	O
19	an	O
20	excess	O
21	of	O
22	double	O
23	stranded	O
24	oligodeoxynucleotides	O
25	containing	O
26	canonical	O
27	,	O
28	but	O
29	not	O
30	mutated	O
31	,	O
32	Myb	B
33	-	O
34	or	O
35	Ets	B
36	-	I
37	binding	I
38	sites	I
39	.	O

1	Cloning	O
2	,	O
3	expression	O
4	,	O
5	and	O
6	nucleotide	O
7	sequence	O
8	of	O
9	rat	B
10	liver	I
11	sterol	I
12	carrier	I
13	protein	I
14	2	I
15	cDNAs	I
16	.	O

1	Spatial	O
2	zones	O
3	for	O
4	muscle	O
5	coactivation	O
6	and	O
7	the	O
8	control	O
9	of	O
10	postural	O
11	stability	O
12	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	O
30	mutants	O
31	.	O

1	On	O
2	cessation	O
3	of	O
4	steroid	O
5	therapy	O
6	the	O
7	patient	O
8	was	O
9	noted	O
10	to	O
11	have	O
12	radiologic	O
13	manifestations	O
14	of	O
15	hypertrophic	O
16	osteoarthropathy	O
17	(	O
18	HOA	O
19	)	O
20	as	O
21	well	O
22	as	O
23	clinical	O
24	and	O
25	laboratory	O
26	features	O
27	of	O
28	rheumatoid	O
29	arthritis	O
30	(	O
31	RA	O
32	).	O

1	The	O
2	murine	B
3	MHC	I
4	class	I
5	I	I
6	genes	I
7	,	O
8	H	O
9	-	O
10	2Dq	O
11	and	O
12	H	O
13	-	O
14	2Lq	O
15	,	O
16	are	O
17	strikingly	O
18	homologous	O
19	to	O
20	each	O
21	other	O
22	,	O
23	H	O
24	-	O
25	2Ld	O
26	,	O
27	and	O
28	two	O
29	genes	O
30	reported	O
31	to	O
32	encode	O
33	tumor	O
34	-	O
35	specific	O
36	antigens	O
37	.	O

1	The	O
2	risk	O
3	for	O
4	these	O
5	complications	O
6	is	O
7	increased	O
8	by	O
9	the	O
10	following	O
11	factors	O
12	:	O
13	multiple	O
14	gestation	O
15	,	O
16	the	O
17	combination	O
18	of	O
19	magnesium	O
20	sulfate	O
21	and	O
22	beta	O
23	-	O
24	adrenergic	O
25	agonist	O
26	,	O
27	and	O
28	the	O
29	use	O
30	of	O
31	adrenocortico	O
32	-	O
33	steroids	O
34	to	O
35	hasten	O
36	fetal	O
37	pulmonary	O
38	maturity	O
39	.	O

1	We	O
2	show	O
3	that	O
4	cytR	B
5	expression	O
6	is	O
7	negatively	O
8	controlled	O
9	by	O
10	the	O
11	CytR	B
12	protein	I
13	and	O
14	positively	O
15	affected	O
16	by	O
17	the	O
18	cAMP	O
19	/	O
20	CAP	B
21	complex	O
22	.	O

1	METHODS	O
2	:	O
3	Millipore	O
4	ultrafiltration	O
5	membranes	O
6	of	O
7	three	O
8	different	O
9	pore	O
10	sizes	O
11	were	O
12	used	O
13	as	O
14	model	O
15	lenticule	O
16	materials	O
17	.	O
18	The	O
19	nominal	O
20	membrane	O
21	pore	O
22	sizes	O
23	were	O
24	0	O
25	.	O
26	1	O
27	microm	O
28	,	O
29	0	O
30	.	O
31	45	O
32	microm	O
33	,	O
34	and	O
35	3	O
36	microm	O
37	;	O
38	the	O
39	surface	O
40	roughness	O
41	increased	O
42	in	O
43	the	O
44	same	O
45	order	O
46	The	O
47	membranes	O
48	were	O
49	coated	O
50	with	O
51	a	O
52	thin	O
53	layer	O
54	of	O
55	collagen	B
56	I	I
57	and	O
58	implanted	O
59	in	O
60	a	O
61	circular	O
62	pocket	O
63	of	O
64	the	O
65	anterior	O
66	cornea	O
67	of	O
68	adult	O
69	cats	O
70	,	O
71	and	O
72	were	O
73	clinically	O
74	evaluated	O
75	for	O
76	the	O
77	extent	O
78	of	O
79	epithelialization	O
80	and	O
81	the	O
82	persistence	O
83	of	O
84	epithelial	O
85	attachment	O
86	.	O

1	The	O
2	Siglecs	O
3	are	O
4	a	O
5	subfamily	O
6	of	O
7	I	B
8	-	I
9	type	I
10	lectins	I
11	(	I
12	immunoglobulin	I
13	superfamily	I
14	proteins	I
15	that	O
16	bind	O
17	sugars	O
18	)	O
19	that	O
20	specifically	O
21	recognize	O
22	sialic	O
23	acids	O
24	.	O

1	However	O
2	,	O
3	reoperation	O
4	for	O
5	bulky	O
6	cervical	O
7	disease	O
8	(	O
9	group	O
10	3	O
11	)	O
12	rarely	O
13	results	O
14	in	O
15	normal	O
16	calcitonin	B
17	levels	O
18	and	O
19	is	O
20	associated	O
21	with	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	permanent	O
27	hypoparathyroidism	O
28	.	O

1	A	O
2	transgenic	O
3	complementation	O
4	assay	O
5	was	O
6	used	O
7	to	O
8	test	O
9	whether	O
10	NIa	O
11	supplied	O
12	in	O
13	trans	O
14	could	O
15	rescue	O
16	amplification	O
17	-	O
18	defective	O
19	viral	O
20	genomes	O
21	encoding	O
22	altered	O
23	NIa	B
24	proteins	I
25	.	O

1	Recombinant	O
2	Ffh	O
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	Its	O
2	clinical	O
3	and	O
4	histopathologic	O
5	characteristics	O
6	.	O

1	In	O
2	mammals	O
3	,	O
4	the	O
5	Rb	B
6	protein	I
7	interacts	O
8	specifically	O
9	with	O
10	D	B
11	-	I
12	type	I
13	cyclins	I
14	and	O
15	regulates	O
16	cell	O
17	proliferation	O
18	by	O
19	binding	O
20	and	O
21	inhibiting	O
22	E2F	B
23	transcription	I
24	factors	I
25	.	O

1	In	O
2	addition	O
3	,	O
4	lexical	O
5	priming	O
6	was	O
7	examined	O
8	by	O
9	presenting	O
10	an	O
11	identity	O
12	prime	O
13	earlier	O
14	in	O
15	the	O
16	text	O
17	.	O

1	Northern	O
2	and	O
3	RT	O
4	-	O
5	PCR	O
6	analysis	O
7	of	O
8	Ube3a	B
9	expression	O
10	in	O
11	mouse	O
12	tissues	O
13	from	O
14	animals	O
15	with	O
16	segmental	O
17	,	O
18	paternal	O
19	uniparental	O
20	disomy	O
21	failed	O
22	to	O
23	detect	O
24	substantially	O
25	reduced	O
26	or	O
27	absent	O
28	expression	O
29	compared	O
30	to	O
31	control	O
32	animals	O
33	,	O
34	failing	O
35	to	O
36	provide	O
37	any	O
38	evidence	O
39	for	O
40	maternal	O
41	-	O
42	specific	O
43	expression	O
44	from	O
45	this	O
46	locus	O
47	.	O

1	A	O
2	study	O
3	of	O
4	chromosomes	O
5	of	O
6	lymphocytes	O
7	from	O
8	patients	O
9	treated	O
10	with	O
11	hycanthone	O
12	.	O

1	Human	O
2	Duo	O
3	contains	O
4	a	O
5	guanine	B
6	nucleotide	I
7	exchange	I
8	factor	I
9	(	I
10	GEF	I
11	)	O
12	domain	O
13	that	O
14	is	O
15	likely	O
16	to	O
17	be	O
18	rac1	B
19	-	O
20	specific	O
21	,	O
22	a	O
23	pleckstrin	B
24	homology	I
25	(	O
26	PH	B
27	)	O
28	domain	O
29	and	O
30	spectrin	O
31	-	O
32	like	O
33	repeat	O
34	units	O
35	.	O

1	After	O
2	age	O
3	30	O
4	,	O
5	mean	O
6	hemoglobin	B
7	levels	O
8	for	O
9	men	O
10	gradually	O
11	declined	O
12	,	O
13	while	O
14	those	O
15	in	O
16	women	O
17	rose	O
18	,	O
19	so	O
20	that	O
21	the	O
22	sex	O
23	difference	O
24	diminished	O
25	after	O
26	60	O
27	years	O
28	of	O
29	age	O
30	.	O

1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	O
20	cyclin	B
21	B1	I
22	mRNA	I
23	reside	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O

1	ERK	B
2	MAP	I
3	kinase	I
4	links	O
5	cytokine	O
6	signals	O
7	to	O
8	activation	O
9	of	O
10	latent	O
11	HIV	O
12	-	O
13	1	O
14	infection	O
15	by	O
16	stimulating	O
17	a	O
18	cooperative	O
19	interaction	O
20	of	O
21	AP	B
22	-	I
23	1	I
24	and	O
25	NF	B
26	-	I
27	kappaB	I
28	.	O

1	The	O
2	use	O
3	of	O
4	CRF	B
5	-	O
6	41	O
7	in	O
8	the	O
9	differential	O
10	diagnosis	O
11	of	O
12	Cushing	O
13	'	O
14	s	O
15	syndrome	O
16	and	O
17	obesity	O
18	.	O

1	Though	O
2	hepatomegaly	O
3	and	O
4	mild	O
5	elevation	O
6	of	O
7	enzymes	O
8	can	O
9	be	O
10	observed	O
11	in	O
12	a	O
13	significant	O
14	proportion	O
15	of	O
16	patients	O
17	,	O
18	involvement	O
19	of	O
20	liver	O
21	leading	O
22	to	O
23	acute	O
24	hepatitis	O
25	or	O
26	liver	O
27	cell	O
28	necrosis	O
29	is	O
30	a	O
31	relatively	O
32	uncommon	O
33	complication	O
34	in	O
35	P	O
36	.	O
37	falciparum	O
38	malaria	O
39	.	O

1	A	O
2	third	O
3	series	O
4	of	O
5	mice	O
6	were	O
7	given	O
8	a	O
9	single	O
10	injection	O
11	of	O
12	5	O
13	-	O
14	OH	O
15	-	O
16	DA	O
17	,	O
18	sacrificed	O
19	,	O
20	and	O
21	prepared	O
22	for	O
23	ultrastructural	O
24	study	O
25	.	O

1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	hexamethylmelamine	O
9	,	O
10	adriamycin	O
11	and	O
12	cisplatin	O
13	(	O
14	CHAP	B
15	-	I
16	5	I
17	),	O
18	6	O
19	had	O
20	measurable	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O

1	The	O
2	impact	O
3	of	O
4	social	O
5	support	O
6	on	O
7	the	O
8	relationships	O
9	of	O
10	gay	O
11	male	O
12	couples	O
13	is	O
14	examined	O
15	.	O

1	Modulation	O
2	of	O
3	AUUUA	O
4	response	O
5	element	O
6	binding	O
7	by	O
8	heterogeneous	B
9	nuclear	I
10	ribonucleoprotein	I
11	A1	I
12	in	O
13	human	O
14	T	O
15	lymphocytes	O
16	.	O

1	Deletion	O
2	or	O
3	inactivation	O
4	of	O
5	CRY1	O
6	leads	O
7	to	O
8	5	O
9	-	O
10	to	O
11	10	O
12	-	O
13	fold	O
14	-	O
15	increased	O
16	levels	O
17	of	O
18	CRY2	B
19	mRNA	I
20	.	O

1	Early	O
2	heparin	O
3	therapy	O
4	in	O
5	60	O
6	children	O
7	with	O
8	acute	O
9	meningococcemia	O
10	.	O

1	Both	O
2	carbachol	O
3	(	O
4	100	O
5	microM	O
6	)	O
7	and	O
8	EGF	B
9	(	O
10	10	O
11	nM	O
12	)	O
13	induced	O
14	Ras	B
15	activation	O
16	.	O

1	The	O
2	pyramidal	O
3	tract	O
4	and	O
5	Mesencephalic	O
6	Reticular	O
7	Formation	O
8	(	O
9	MRF	O
10	)	O
11	were	O
12	stimulated	O
13	before	O
14	and	O
15	after	O
16	the	O
17	transection	O
18	.	O

1	The	O
2	interpretation	O
3	of	O
4	antibiotic	O
5	disc	O
6	sensitivities	O
7	.	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	Our	O
2	findings	O
3	also	O
4	provide	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	development	O
10	of	O
11	assays	O
12	to	O
13	screen	O
14	for	O
15	the	O
16	ligands	O
17	to	O
18	testis	B
19	receptor	I
20	2	I
21	and	O
22	hERR1	B
23	.	O

1	One	O
2	phage	O
3	clone	O
4	contains	O
5	a	O
6	junction	O
7	between	O
8	alpha	O
9	satellite	O
10	DNA	O
11	and	O
12	a	O
13	novel	O
14	low	O
15	-	O
16	copy	O
17	repeated	O
18	sequence	O
19	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	B
10	anemia	I
11	group	I
12	C	I
13	protein	I
14	(	O
15	FANCC	O
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	Thus	O
2	,	O
3	this	O
4	study	O
5	provides	O
6	evidence	O
7	that	O
8	a	O
9	novel	O
10	,	O
11	ubiquitous	O
12	factor	O
13	(	O
14	HF	B
15	-	I
16	1a	I
17	)	O
18	and	O
19	a	O
20	muscle	O
21	factor	O
22	(	O
23	HF	B
24	-	I
25	1b	I
26	/	O
27	MEF	B
28	-	I
29	2	I
30	)	O
31	can	O
32	form	O
33	a	O
34	novel	O
35	,	O
36	E	O
37	-	O
38	box	O
39	-	O
40	independent	O
41	pathway	O
42	for	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	in	O
48	ventricular	O
49	cardiac	O
50	muscle	O
51	cells	O
52	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	region	O
9	revealed	O
10	several	O
11	GC	O
12	boxes	O
13	but	O
14	no	O
15	identifiable	O
16	TATA	O
17	box	O
18	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	MTD	O
5	for	O
6	CPT	O
7	-	O
8	11	O
9	administered	O
10	in	O
11	a	O
12	3	O
13	consecutive	O
14	-	O
15	days	O
16	-	O
17	every	O
18	-	O
19	3	O
20	weeks	O
21	schedule	O
22	in	O
23	this	O
24	patient	O
25	population	O
26	is	O
27	115	O
28	mg	O
29	/	O
30	m2	O
31	/	O
32	day	O
33	.	O

1	IRF	B
2	-	I
3	1	I
4	acts	O
5	as	O
6	a	O
7	transcriptional	O
8	activator	O
9	,	O
10	while	O
11	IRF	B
12	-	I
13	2	I
14	acts	O
15	as	O
16	a	O
17	repressor	O
18	.	O

1	Isolation	O
2	and	O
3	identification	O
4	of	O
5	genes	O
6	activating	O
7	UAS2	O
8	-	O
9	dependent	O
10	ADH2	B
11	expression	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	HRT	O
7	on	O
8	those	O
9	factors	O
10	in	O
11	end	O
12	-	O
13	stage	O
14	renal	O
15	disease	O
16	(	O
17	ESRD	O
18	)	O
19	patients	O
20	,	O
21	we	O
22	evaluated	O
23	the	O
24	changes	O
25	of	O
26	lipid	O
27	profile	O
28	,	O
29	coagulation	O
30	and	O
31	fibrinolysis	O
32	markers	O
33	,	O
34	and	O
35	plasma	O
36	homocysteine	O
37	levels	O
38	after	O
39	treatment	O
40	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	of	O
5	the	O
6	reverse	B
7	transcriptase	I
8	domain	O
9	confirms	O
10	our	O
11	differential	O
12	genetic	O
13	assessment	O
14	that	O
15	Cyclops	B
16	from	O
17	pea	O
18	is	O
19	a	O
20	novel	O
21	element	O
22	with	O
23	no	O
24	specific	O
25	relationship	O
26	to	O
27	the	O
28	previously	O
29	described	O
30	Gypsy	O
31	-	O
32	like	O
33	elements	O
34	from	O
35	plants	O
36	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Subjects	O
2	were	O
3	16	O
4	male	O
5	chronic	O
6	schizophrenics	O
7	consisting	O
8	of	O
9	8	O
10	DST	O
11	suppressors	O
12	and	O
13	8	O
14	nonsuppressors	O
15	.	O

1	The	O
2	major	O
3	urinary	O
4	metabolites	O
5	were	O
6	3	O
7	-(	O
8	3	O
9	-	O
10	carboxyphenyl	O
11	)-	O
12	5	O
13	-	O
14	hydroxymethyl	O
15	-	O
16	2	O
17	-	O
18	oxazolidinone	O
19	and	O
20	a	O
21	glucuronide	O
22	of	O
23	toloxatone	O
24	.	O

1	Hyaluronan	O
2	treatment	O
3	stimulated	O
4	collagen	B
5	remodeling	O
6	in	O
7	the	O
8	peripheral	O
9	region	O
10	and	O
11	inhibited	O
12	swelling	O
13	of	O
14	the	O
15	meniscus	O
16	repaired	O
17	in	O
18	the	O
19	inner	O
20	region	O
21	.	O

1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	O
7	as	O
8	newborns	O
9	;	O
10	heterozygous	O
11	protein	O
12	C	O
13	-	O
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	O
20	for	O
21	venous	O
22	thrombosis	O
23	and	O
24	pulmonary	O
25	embolism	O
26	.	O

1	Pilot	O
2	study	O
3	of	O
4	blood	O
5	coagulation	O
6	in	O
7	gout	O
8	patients	O
9	.	O

1	Can	O
2	thyroglobulin	O
3	assay	O
4	really	O
5	supplant	O
6	radioiodine	O
7	scans	O
8	in	O
9	patients	O
10	with	O
11	differentiated	O
12	thyroid	O
13	cancer	O
14	?	O

1	Symptoms	O
2	,	O
3	however	O
4	,	O
5	appear	O
6	to	O
7	correlate	O
8	poorly	O
9	with	O
10	oesophagitis	O
11	;	O
12	hence	O
13	,	O
14	severe	O
15	symptoms	O
16	do	O
17	not	O
18	indicate	O
19	there	O
20	is	O
21	greater	O
22	oesophageal	O
23	damage	O
24	.	O

1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	coding	O
8	region	O
9	was	O
10	located	O
11	precisely	O
12	by	O
13	comparing	O
14	the	O
15	deduced	O
16	amino	O
17	acid	O
18	sequence	O
19	to	O
20	the	O
21	actual	O
22	N	O
23	-	O
24	terminal	O
25	amino	O
26	acid	O
27	sequence	O
28	of	O
29	IHF	B
30	.	O

1	Effect	O
2	of	O
3	proteolytic	O
4	enzymes	O
5	and	O
6	polypeptides	O
7	on	O
8	the	O
9	antacid	O
10	activity	O
11	of	O
12	almagate	O
13	and	O
14	other	O
15	antacids	O
16	.	O

1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	O
21	'-	O
22	rearranged	O
23	myb	B
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	121	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	I
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	B
52	myb	I
53	oncogene	I
54	.	O

1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	O
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	I
21	ERRalpha1	I
22	fusion	O
23	protein	O
24	.	O

1	Changes	O
2	in	O
3	stimulation	O
4	levels	O
5	over	O
6	time	O
7	in	O
8	nucleus	O
9	22	O
10	cochlear	O
11	implant	O
12	users	O
13	.	O

1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O

1	Both	O
2	mu	O
3	and	O
4	gamma	B
5	2b	I
6	heavy	I
7	chain	I
8	genes	I
9	cause	O
10	this	O
11	feedback	O
12	inhibition	O
13	of	O
14	heavy	O
15	chain	O
16	gene	O
17	rearrangement	O
18	.	O

1	Initial	O
2	screening	O
3	of	O
4	a	O
5	rat	O
6	liver	O
7	cDNA	O
8	library	O
9	with	O
10	an	O
11	oligonucleotide	O
12	probe	O
13	derived	O
14	from	O
15	the	O
16	rat	B
17	SCP2	I
18	protein	I
19	sequence	I
20	revealed	O
21	an	O
22	825	O
23	-	O
24	base	O
25	pair	O
26	cDNA	O
27	clone	O
28	coding	O
29	for	O
30	the	O
31	complete	O
32	SCP2	B
33	protein	I
34	sequence	I
35	.	O

1	OND	O
2	8	O
3	mg	O
4	tid	O
5	days	O
6	2	O
7	-	O
8	3	O
9	,	O
10	and	O
11	8	O
12	mg	O
13	tid	O
14	prn	O
15	days	O
16	4	O
17	-	O
18	5	O
19	and	O
20	prednisolone	O
21	75	O
22	-	O
23	100	O
24	mg	O
25	qds	O
26	days	O
27	2	O
28	-	O
29	5	O
30	and	O
31	2	O
32	)	O
33	MCP	O
34	30	O
35	mg	O
36	/	O
37	metylprednisolone	O
38	80	O
39	mg	O
40	i	O
41	.	O
42	v	O
43	.	O
44	before	O
45	CT	O
46	and	O
47	MCP	B
48	20	O
49	mg	O
50	p	O
51	.	O
52	r	O
53	.	O
54	after	O
55	4	O
56	and	O
57	8	O
58	h	O
59	respectively	O
60	.	O

1	The	O
2	PSD2	B
3	gene	I
4	was	O
5	heterologously	O
6	expressed	O
7	by	O
8	infection	O
9	of	O
10	Sf	O
11	-	O
12	9	O
13	insect	O
14	cells	O
15	with	O
16	recombinant	O
17	baculovirus	O
18	,	O
19	resulting	O
20	in	O
21	a	O
22	10	O
23	-	O
24	fold	O
25	increase	O
26	in	O
27	PSD	O
28	activity	O
29	.	O

1	Decreased	O
2	cardiac	O
3	glycogen	O
4	following	O
5	phenformin	O
6	injection	O
7	in	O
8	hyperglycemic	O
9	,	O
10	hyperinsulinemic	O
11	anaesthetized	O
12	rats	O
13	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	This	O
2	finding	O
3	is	O
4	the	O
5	first	O
6	example	O
7	of	O
8	utilization	O
9	of	O
10	noncomplementary	O
11	dinucleotide	O
12	primer	O
13	by	O
14	an	O
15	RNA	B
16	polymerase	I
17	.	O

1	Possible	O
2	factors	O
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O

1	Cystatin	B
2	A	I
3	,	O
4	a	O
5	cysteine	B
6	proteinase	I
7	inhibitor	O
8	,	O
9	is	O
10	one	O
11	of	O
12	the	O
13	precursor	O
14	proteins	O
15	of	O
16	cornified	O
17	cell	O
18	envelope	O
19	of	O
20	keratinocytes	O
21	and	O
22	is	O
23	expressed	O
24	during	O
25	the	O
26	late	O
27	stage	O
28	of	O
29	keratinocyte	O
30	differentiation	O
31	.	O

1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	hypnotic	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O

1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O

1	Naturally	O
2	acquired	O
3	antibodies	O
4	were	O
5	demonstrated	O
6	in	O
7	some	O
8	rabbits	O
9	kept	O
10	on	O
11	commercial	O
12	farms	O
13	.	O

1	Dentalplaque	O
2	was	O
3	controlled	O
4	by	O
5	the	O
6	oral	O
7	higienic	O
8	index	O
9	of	O
10	the	O
11	whole	O
12	dentition	O
13	daily	O
14	,	O
15	after	O
16	staining	O
17	with	O
18	1	O
19	per	O
20	cent	O
21	alkaline	B
22	fuxin	I
23	.	O

1	Increased	O
2	plasma	O
3	IgE	B
4	was	O
5	also	O
6	confirmed	O
7	in	O
8	the	O
9	NC	O
10	mice	O
11	,	O
12	and	O
13	treatment	O
14	with	O
15	FK506	O
16	ointment	O
17	reduced	O
18	the	O
19	plasma	B
20	IgE	I
21	level	O
22	.	O

1	Overexpression	O
2	of	O
3	CARP	B
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	O
8	troponin	B
9	C	I
10	and	O
11	atrial	B
12	natriuretic	I
13	factor	I
14	transcription	O
15	.	O

1	To	O
2	study	O
3	the	O
4	structure	O
5	-	O
6	function	O
7	of	O
8	the	O
9	gene	O
10	5	O
11	product	O
12	,	O
13	wild	O
14	-	O
15	type	O
16	and	O
17	mutant	O
18	forms	O
19	of	O
20	NS53	B
21	were	O
22	produced	O
23	by	O
24	using	O
25	a	O
26	recombinant	O
27	baculovirus	O
28	expression	O
29	system	O
30	and	O
31	a	O
32	recombinant	O
33	vaccinia	O
34	virus	O
35	/	O
36	T7	O
37	(	O
38	vTF7	B
39	-	I
40	3	I
41	)	O
42	expression	O
43	system	O
44	.	O

1	Stromelysin	B
2	-	I
3	1	I
4	,	I
5	matrix	I
6	metalloproteinase	I
7	-	I
8	3	I
9	(	O
10	MMP	O
11	-	O
12	3	O
13	),	O
14	is	O
15	an	O
16	important	O
17	endopeptidase	O
18	selectively	O
19	expressed	O
20	by	O
21	somatic	O
22	cells	O
23	in	O
24	organ	O
25	tissues	O
26	.	O

1	The	O
2	median	O
3	levels	O
4	of	O
5	particles	O
6	with	O
7	50	O
8	%	O
9	cut	O
10	-	O
11	off	O
12	aerodynamic	O
13	diameters	O
14	of	O
15	10	O
16	(	O
17	PM10	B
18	)	O
19	and	O
20	2	O
21	.	O
22	5	O
23	microm	O
24	(	O
25	PM2	O
26	.	O
27	5	O
28	)	O
29	were	O
30	170	O
31	(	O
32	range	O
33	103	O
34	-	O
35	613	O
36	)	O
37	and	O
38	95	O
39	(	O
40	range	O
41	61	O
42	-	O
43	218	O
44	)	O
45	micro	O
46	x	O
47	m	B
48	-	I
49	3	I
50	,	O
51	respectively	O
52	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	the	O
6	same	O
7	males	O
8	,	O
9	breeding	O
10	in	O
11	different	O
12	years	O
13	on	O
14	the	O
15	same	O
16	territories	O
17	,	O
18	had	O
19	significantly	O
20	larger	O
21	harems	O
22	in	O
23	the	O
24	years	O
25	they	O
26	had	O
27	familiar	O
28	neighbors	O
29	.	O

1	This	O
2	region	O
3	of	O
4	60	O
5	amino	O
6	acids	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	coiled	O
12	-	O
13	coil	O
14	interactions	O
15	similar	O
16	to	O
17	those	O
18	that	O
19	facilitate	O
20	the	O
21	filament	O
22	formation	O
23	in	O
24	the	O
25	rod	O
26	region	O
27	.	O

1	Similarity	O
2	is	O
3	most	O
4	striking	O
5	in	O
6	the	O
7	zinc	O
8	knuckle	O
9	region	O
10	,	O
11	a	O
12	region	O
13	characteristic	O
14	of	O
15	gag	B
16	genes	I
17	of	O
18	most	O
19	replication	O
20	-	O
21	competent	O
22	retroelements	O
23	.	O

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	Whipple	O
8	-	O
9	specific	O
10	DNA	O
11	fragments	O
12	of	O
13	284	O
14	base	O
15	pairs	O
16	from	O
17	the	O
18	genome	O
19	of	O
20	the	O
21	Whipple	O
22	bacterium	O
23	(	O
24	Tropheryma	O
25	whippelii	O
26	)	O
27	were	O
28	demonstrated	O
29	.	O

1	Neither	O
2	Ha	B
3	-	I
4	Ras	I
5	(	O
6	G12V	O
7	,	O
8	T35S	B
9	)	O
10	(	O
11	Ha	B
12	-	I
13	RasV12S35	I
14	),	O
15	which	O
16	activates	O
17	the	O
18	Rafl	B
19	signaling	O
20	pathway	O
21	,	O
22	nor	O
23	Ha	B
24	-	I
25	Ras	I
26	(	O
27	G12V	O
28	,	O
29	E37G	O
30	)	O
31	(	O
32	Ha	O
33	-	O
34	RasV12G37	O
35	),	O
36	which	O
37	stimulates	O
38	the	O
39	RalGDS	O
40	pathway	O
41	,	O
42	did	O
43	not	O
44	have	O
45	significant	O
46	effects	O
47	on	O
48	factor	O
49	-	O
50	withdrawal	O
51	apoptosis	O
52	of	O
53	myeloid	O
54	cells	O
55	.	O

1	Normal	O
2	values	O
3	for	O
4	the	O
5	peripheral	O
6	blood	O
7	and	O
8	bone	O
9	marrow	O
10	of	O
11	the	O
12	grey	O
13	(	O
14	Armenian	O
15	)	O
16	hamster	O

1	The	O
2	differentiation	O
3	and	O
4	maintenance	O
5	of	O
6	a	O
7	neurotransmitter	O
8	phenotype	O
9	is	O
10	guided	O
11	by	O
12	the	O
13	interaction	O
14	of	O
15	exogenous	O
16	cues	O
17	with	O
18	intrinsic	O
19	genetic	O
20	machinery	O
21	.	O

1	In	O
2	addition	O
3	serum	O
4	IgE	B
5	concentrations	O
6	were	O
7	not	O
8	statistically	O
9	different	O
10	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	segments	O
6	of	O
7	C3	B
8	represented	O
9	by	O
10	amino	O
11	acid	O
12	residues	O
13	1082	O
14	-	O
15	1118	O
16	,	O
17	1117	O
18	-	O
19	1155	O
20	,	O
21	1234	O
22	-	O
23	1294	O
24	and	O
25	1312	O
26	-	O
27	1404	O
28	accommodate	O
29	C3	O
30	(	O
31	D	O
32	)	O
33	epitopes	O
34	that	O
35	are	O
36	expressed	O
37	by	O
38	erythrocyte	O
39	-	O
40	bound	O
41	C3	B
42	fragments	I
43	,	O
44	but	O
45	not	O
46	by	O
47	the	O
48	corresponding	O
49	fluid	O
50	-	O
51	phase	O
52	fragment	O
53	,	O
54	whereas	O
55	the	O
56	segments	O
57	spanning	O
58	residues	O
59	973	O
60	-	O
61	1026	O
62	and	O
63	1477	O
64	-	O
65	1510	O
66	contain	O
67	C3	B
68	(	O
69	D	O
70	)	O
71	epitopes	O
72	that	O
73	are	O
74	exposed	O
75	exclusively	O
76	in	O
77	denatured	O
78	C3	B
79	and	O
80	therefore	O
81	hidden	O
82	in	O
83	physiological	O
84	fragments	O
85	of	O
86	the	O
87	protein	O
88	.	O

1	Chaperones	O
2	/	O
3	HSPs	B
4	thus	O
5	play	O
6	important	O
7	roles	O
8	within	O
9	cell	O
10	cycle	O
11	processes	O
12	.	O

1	Sci	O
2	.	O

1	X2	O
2	test	O
3	,	O
4	with	O
5	Yates	O
6	correction	O
7	if	O
8	need	O
9	,	O
10	was	O
11	used	O
12	as	O
13	statistical	O
14	.	O
15	method	O
16	.	O

1	Fgd3	B
2	and	O
3	FGD1	B
4	share	O
5	a	O
6	high	O
7	degree	O
8	of	O
9	sequence	O
10	identity	O
11	that	O
12	spans	O
13	>	O
14	560	O
15	contiguous	O
16	amino	O
17	acid	O
18	residues	O
19	.	O

1	Iron	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O

1	Acad	O
2	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	B
12	-	I
13	Myb	I
14	activity	O
15	by	O
16	cyclin	B
17	-	I
18	Cdks	I
19	.	O

1	The	O
2	C4BP	B
3	alpha	I
4	gene	I
5	is	O
6	organized	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	codes	O
14	for	O
15	the	O
16	first	O
17	198	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	O
24	.	O

1	GATA	B
2	-	I
3	1	I
4	mRNA	I
5	was	O
6	present	O
7	in	O
8	equivalent	O
9	levels	O
10	in	O
11	both	O
12	erythroid	O
13	cell	O
14	lines	O
15	,	O
16	but	O
17	at	O
18	a	O
19	low	O
20	level	O
21	in	O
22	FDC	O
23	-	O
24	P1	O
25	cells	O
26	.	O

1	There	O
2	was	O
3	no	O
4	competition	O
5	between	O
6	activin	B
7	A	O
8	and	O
9	OP	B
10	-	I
11	1	I
12	for	O
13	availability	O
14	of	O
15	Smad4	B
16	,	O
17	indicating	O
18	that	O
19	the	O
20	concentration	O
21	of	O
22	this	O
23	common	O
24	signal	O
25	transducer	O
26	is	O
27	not	O
28	limiting	O
29	for	O
30	generating	O
31	the	O
32	observed	O
33	biological	O
34	responses	O
35	.	O

1	During	O
2	the	O
3	past	O
4	4	O
5	years	O
6	,	O
7	a	O
8	purposeful	O
9	search	O
10	was	O
11	made	O
12	for	O
13	electrocardiograms	O
14	with	O
15	documented	O
16	reversible	O
17	QRS	O
18	changes	O
19	associated	O
20	with	O
21	all	O
22	acute	O
23	injury	O
24	pattern	O
25	.	O

1	MBI	O
2	and	O
3	MMBI	O
4	showed	O
5	similar	O
6	Cmax	O
7	values	O
8	,	O
9	but	O
10	the	O
11	former	O
12	disappeared	O
13	slower	O
14	in	O
15	the	O
16	serum	O
17	than	O
18	the	O
19	latter	O
20	and	O
21	resulted	O
22	in	O
23	its	O
24	larger	O
25	AUC	O
26	values	O
27	.	O

1	An	O
2	essential	O
3	role	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	and	O
9	c	B
10	-	I
11	Fos	I
12	in	O
13	basal	O
14	and	O
15	PMA	O
16	-	O
17	stimulated	O
18	transcription	O
19	of	O
20	the	O
21	PAI	B
22	-	I
23	1	I
24	gene	I
25	is	O
26	demonstrated	O
27	by	O
28	our	O
29	finding	O
30	that	O
31	antisense	O
32	c	B
33	-	I
34	jun	I
35	and	O
36	c	B
37	-	I
38	fos	I
39	oligodeoxynucleotides	O
40	both	O
41	strongly	O
42	reduced	O
43	basal	O
44	and	O
45	PMA	O
46	-	O
47	stimulated	O
48	PAI	B
49	-	I
50	1	I
51	synthesis	O
52	.	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	describe	O
6	properties	O
7	of	O
8	the	O
9	cdc10	B
10	-	I
11	C4	I
12	mutant	I
13	of	O
14	the	O
15	fission	O
16	yeast	O
17	Schizosaccharomyces	O
18	pombe	O
19	.	O

1	These	O
2	HPV16	B
3	E6	I
4	/	I
5	E7	I
6	cDNAs	I
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	B
12	enhancer	I
13	/	I
14	promoter	I
15	and	O
16	the	O
17	MMTV	B
18	LTR	I
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	O
26	collaborative	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	B
42	gene	I
43	product	I
44	.	O

1	Gel	O
2	-	O
3	mobility	O
4	shift	O
5	analysis	O
6	was	O
7	also	O
8	performed	O
9	for	O
10	the	O
11	CCAAT	O
12	motif	O
13	at	O
14	-	O
15	67	O
16	.	O

1	The	O
2	human	O
3	immunodeficiency	O
4	virus	O
5	type	O
6	-	O
7	1	O
8	(	O
9	HIV	O
10	-	O
11	1	O
12	)	O
13	Tat	B
14	protein	I
15	regulates	O
16	transcription	O
17	by	O
18	stimulating	O
19	RNA	B
20	polymerase	I
21	processivity	O
22	.	O

1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O

1	Reverse	B
2	transcriptase	I
3	-	O
4	polymerase	O
5	chain	O
6	reaction	O
7	(	O
8	RT	O
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	There	O
2	were	O
3	15	O
4	deaths	O
5	,	O
6	seven	O
7	of	O
8	which	O
9	were	O
10	felt	O
11	to	O
12	be	O
13	avoidable	O
14	.	O

1	In	O
2	the	O
3	DNAs	O
4	of	O
5	all	O
6	Ph1	B
7	-	O
8	positive	O
9	chronic	O
10	myelocytic	O
11	leukemia	O
12	patients	O
13	studied	O
14	to	O
15	date	O
16	,	O
17	a	O
18	breakpoint	O
19	on	O
20	chromosome	O
21	22	O
22	(	O
23	the	O
24	Ph1	B
25	chromosome	I
26	)	O
27	can	O
28	be	O
29	demonstrated	O
30	with	O
31	a	O
32	probe	O
33	from	O
34	the	O
35	bcr	B
36	(	O
37	breakpoint	O
38	cluster	O
39	region	O
40	).	O

1	Transfection	O
2	experiments	O
3	using	O
4	preformed	O
5	triplexes	O
6	with	O
7	a	O
8	reporter	O
9	plasmid	O
10	containing	O
11	the	O
12	collagen	B
13	promoter	I
14	sequence	I
15	showed	O
16	significant	O
17	inhibition	O
18	of	O
19	transcription	O
20	when	O
21	compared	O
22	with	O
23	a	O
24	control	O
25	phosphorothioate	O
26	ODN	O
27	.	O

1	The	O
2	monoexponential	O
3	rate	O
4	of	O
5	clearance	O
6	of	O
7	tracer	O
8	--	O
9	obtained	O
10	from	O
11	the	O
12	portion	O
13	of	O
14	the	O
15	residue	O
16	-	O
17	detection	O
18	curve	O
19	reflecting	O
20	metabolism	O
21	of	O
22	fatty	O
23	acid	O
24	incorporated	O
25	into	O
26	neutral	O
27	lipids	O
28	--	O
29	correlated	O
30	directly	O
31	with	O
32	induced	O
33	changes	O
34	in	O
35	tension	O
36	-	O
37	time	O
38	index	O
39	after	O
40	injections	O
41	into	O
42	the	O
43	left	O
44	atrium	O
45	(	O
46	r	O
47	=	O
48	0	O
49	.	O
50	96	O
51	,	O
52	n	O
53	=	O
54	12	O
55	),	O
56	right	O
57	atrium	O
58	(	O
59	r	O
60	=	O
61	0	O
62	.	O
63	86	O
64	,	O
65	n	O
66	=	O
67	14	O
68	),	O
69	and	O
70	ear	O
71	vein	O
72	(	O
73	r	O
74	=	O
75	0	O
76	.	O
77	93	O
78	,	O
79	n	O
80	=	O
81	14	O
82	).	O

1	Regulation	O
2	of	O
3	Gax	B
4	homeobox	I
5	gene	I
6	transcription	O
7	by	O
8	a	O
9	combination	O
10	of	O
11	positive	O
12	factors	O
13	including	O
14	myocyte	B
15	-	I
16	specific	I
17	enhancer	I
18	factor	I
19	2	I
20	.	O

1	In	O
2	support	O
3	of	O
4	a	O
5	role	O
6	at	O
7	the	O
8	spindle	O
9	,	O
10	two	O
11	-	O
12	hybrid	O
13	library	O
14	screening	O
15	with	O
16	HEF1	B
17	identifies	O
18	the	O
19	human	O
20	homolog	O
21	of	O
22	the	O
23	G2	B
24	/	I
25	M	I
26	spindle	I
27	-	I
28	regulatory	I
29	protein	I
30	Dim1p	I
31	as	O
32	a	O
33	specific	O
34	interactor	O
35	with	O
36	a	O
37	region	O
38	of	O
39	HEF1	B
40	encompassed	O
41	in	O
42	p55	B
43	(	O
44	HEF1	B
45	).	O

1	Neutron	O
2	scattering	O
3	measurements	O
4	of	O
5	critical	O
6	exponents	O
7	in	O
8	CsMnBr3	O
9	:	O
10	A	O
11	Z2	O
12	&	O
13	gt	O
14	;=	O
15	1	O
16	antiferromagnet	O
17	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	MYC	B
6	-	I
7	related	I
8	DNA	I
9	binding	I
10	protein	I
11	was	O
12	isolated	O
13	by	O
14	DNA	O
15	-	O
16	ligand	O
17	binding	O
18	screening	O
19	,	O
20	using	O
21	the	O
22	67	O
23	-	O
24	bp	O
25	region	O
26	as	O
27	a	O
28	probe	O
29	,	O
30	and	O
31	designated	O
32	rd22BP1	B
33	.	O

1	The	O
2	B	B
3	cell	I
4	antigen	I
5	receptor	I
6	activates	O
7	the	O
8	Akt	B
9	(	I
10	protein	I
11	kinase	I
12	B	I
13	)/	O
14	glycogen	B
15	synthase	I
16	kinase	I
17	-	I
18	3	I
19	signaling	O
20	pathway	O
21	via	O
22	phosphatidylinositol	B
23	3	I
24	-	I
25	kinase	I
26	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	kinase	O
6	,	O
7	Nlk	O
8	,	O
9	that	O
10	is	O
11	a	O
12	murine	O
13	homolog	O
14	of	O
15	the	O
16	Drosophila	O
17	nemo	O
18	(	O
19	nmo	O
20	)	O
21	gene	O
22	.	O

1	The	O
2	roll	O
3	-	O
4	over	O
5	test	O
6	to	O
7	predict	O
8	toxemia	O
9	in	O
10	pregnancy	O
11	.	O

1	3600	O
2	-	O
3	fold	O
4	to	O
5	apparent	O
6	homogeneity	O
7	with	O
8	a	O
9	41	O
10	%	O
11	yield	O
12	by	O
13	affinity	O
14	chromatography	O
15	utilizing	O
16	DNA	O
17	-	O
18	cellulose	O
19	;	O
20	the	O
21	purity	O
22	of	O
23	the	O
24	final	O
25	preparation	O
26	was	O
27	assessed	O
28	by	O
29	SDS	O
30	/	O
31	PAGE	O
32	,	O
33	lack	O
34	of	O
35	contamination	O
36	by	O
37	other	O
38	nucleases	O
39	and	O
40	production	O
41	of	O
42	a	O
43	monospecific	O
44	antibody	O
45	against	O
46	the	O
47	enzyme	O
48	.	O

1	DAF16	B
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	B
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	The	O
2	mouse	B
3	beta	I
4	2	I
5	-	I
6	syntrophin	I
7	gene	I
8	(	O
9	>	O
10	33	O
11	kilobases	O
12	)	O
13	contains	O
14	seven	O
15	exons	O
16	,	O
17	all	O
18	of	O
19	which	O
20	have	O
21	homologues	O
22	at	O
23	the	O
24	corresponding	O
25	position	O
26	in	O
27	the	O
28	alpha	B
29	1	I
30	-	I
31	syntrophin	I
32	gene	I
33	.	O

1	The	O
2	Fas	B
3	receptor	I
4	mediates	O
5	a	O
6	signalling	O
7	cascade	O
8	resulting	O
9	in	O
10	programmed	O
11	cell	O
12	death	O
13	(	O
14	apoptosis	O
15	)	O
16	within	O
17	hours	O
18	of	O
19	receptor	O
20	cross	O
21	-	O
22	linking	O
23	.	O

1	Theories	O
2	proffered	O
3	to	O
4	account	O
5	for	O
6	the	O
7	modality	O
8	shift	O
9	effect	O
10	are	O
11	critically	O
12	evaluated	O
13	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	O
8	IVS2C	B
9	beta	I
10	1	I
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O

1	Low	O
2	-	O
3	grade	O
4	glioma	O
5	.	O

1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O

1	Mutation	O
2	of	O
3	the	O
4	P450BM	O
5	-	O
6	3	O
7	Barbie	O
8	box	O
9	significantly	O
10	increased	O
11	the	O
12	expression	O
13	of	O
14	both	O
15	P450BM	B
16	-	I
17	3	I
18	and	O
19	Bm3P1	B
20	(	O
21	another	O
22	small	O
23	gene	O
24	located	O
25	upstream	O
26	of	O
27	the	O
28	P450BM	B
29	-	I
30	3	I
31	gene	I
32	that	O
33	encodes	O
34	a	O
35	second	O
36	putative	O
37	regulatory	O
38	protein	O
39	)	O
40	in	O
41	response	O
42	to	O
43	pentobarbital	O
44	induction	O
45	but	O
46	left	O
47	the	O
48	basal	O
49	levels	O
50	unaffected	O
51	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	B
8	splicing	I
9	suppressor	I
10	1	I
11	(	O
12	ESS1	B
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	O
6	T	O
7	antigens	O
8	expressed	O
9	by	O
10	recombinant	O
11	baculoviruses	O
12	in	O
13	Sf9	O
14	cells	O
15	,	O
16	we	O
17	find	O
18	that	O
19	the	O
20	origin	O
21	unwinding	O
22	activities	O
23	of	O
24	both	O
25	TS677	O
26	-->	O
27	A	O
28	and	O
29	TS677	O
30	,	O
31	679	O
32	-->	O
33	A	O
34	are	O
35	inhibited	O
36	by	O
37	the	O
38	T	B
39	-	I
40	antigen	I
41	kinase	I
42	,	O
43	as	O
44	is	O
45	wild	B
46	-	I
47	type	I
48	T	I
49	antigen	I
50	.	O

1	At	O
2	the	O
3	carboxyl	O
4	terminus	O
5	,	O
6	deletion	O
7	as	O
8	far	O
9	as	O
10	residue	O
11	388	O
12	did	O
13	not	O
14	affect	O
15	in	O
16	vitro	O
17	TRF	O
18	.	O
19	C	O
20	assembly	O
21	,	O
22	although	O
23	trans	O
24	-	O
25	activating	O
26	activity	O
27	was	O
28	abolished	O
29	.	O

1	On	O
2	histologic	O
3	examination	O
4	the	O
5	cuboidal	O
6	epithelium	O
7	of	O
8	the	O
9	mucous	O
10	membrane	O
11	was	O
12	found	O
13	to	O
14	be	O
15	changed	O
16	into	O
17	columnar	O
18	epithelium	O
19	,	O
20	with	O
21	uneven	O
22	distribution	O
23	of	O
24	enlarged	O
25	nuclei	O
26	in	O
27	the	O
28	vacuolized	O
29	cytoplasm	O
30	.	O

1	J	O
2	.	O

1	The	O
2	PCr	O
3	resynthesis	O
4	rate	O
5	(	O
6	P	O
7	<	O
8	0	O
9	.	O
10	01	O
11	)	O
12	and	O
13	the	O
14	effective	O
15	maximal	O
16	rate	O
17	of	O
18	mitochondrial	O
19	ATP	O
20	synthesis	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	)	O
28	also	O
29	improved	O
30	.	O

1	Urease	B
2	activity	O
3	of	O
4	97	O
5	%	O
6	of	O
7	these	O
8	organisms	O
9	became	O
10	evident	O
11	within	O
12	30	O
13	min	O
14	.	O

1	Forty	O
2	-	O
3	five	O
4	patients	O
5	with	O
6	pleural	O
7	lesions	O
8	identified	O
9	on	O
10	CT	O
11	scans	O
12	were	O
13	subsequently	O
14	examined	O
15	by	O
16	MR	O
17	imaging	O
18	at	O
19	0	O
20	.	O
21	5	O
22	T	O
23	.	O

1	Cloning	O
2	of	O
3	higher	O
4	plant	O
5	omega	B
6	-	I
7	3	I
8	fatty	I
9	acid	I
10	desaturases	I
11	.	O

1	Morphological	O
2	and	O
3	functional	O
4	alterations	O
5	noted	O
6	after	O
7	baboon	O
8	renal	O
9	allotransplantation	O
10	.	O

1	Although	O
2	most	O
3	SH2	B
4	-	O
5	pTyr	O
6	interactions	O
7	occur	O
8	between	O
9	two	O
10	different	O
11	types	O
12	of	O
13	molecules	O
14	,	O
15	some	O
16	appear	O
17	to	O
18	involve	O
19	only	O
20	a	O
21	single	O
22	molecular	O
23	type	O
24	.	O

1	Human	B
2	LAF	I
3	-	I
4	4	I
5	readily	O
6	hybridized	O
7	with	O
8	genes	O
9	in	O
10	mouse	O
11	and	O
12	chicken	O
13	,	O
14	thus	O
15	showing	O
16	that	O
17	this	O
18	gene	O
19	family	O
20	has	O
21	been	O
22	highly	O
23	conserved	O
24	during	O
25	vertebrate	O
26	evolution	O
27	.	O

1	Treatment	O
2	of	O
3	meat	O
4	muscle	O
5	800	O
6	V	O
7	for	O
8	45	O
9	s	O
10	reduced	O
11	weeping	O
12	but	O
13	increased	O
14	slightly	O
15	the	O
16	rate	O
17	of	O
18	autoxidation	O
19	of	O
20	lipids	O
21	.	O

1	Aryl	B
2	hydrocarbon	I
3	receptor	I
4	nuclear	I
5	translocator	I
6	(	O
7	ARNT	O
8	)	O
9	is	O
10	a	O
11	component	O
12	of	O
13	the	O
14	transcription	O
15	factors	O
16	,	O
17	aryl	B
18	hydrocarbon	I
19	receptor	I
20	(	O
21	AhR	B
22	)	O
23	and	O
24	hypoxia	B
25	-	I
26	inducible	I
27	factor	I
28	1	I
29	,	O
30	which	O
31	transactivate	O
32	their	O
33	target	O
34	genes	O
35	,	O
36	such	O
37	as	O
38	CYP1A1	B
39	and	O
40	erythropoietin	B
41	,	O
42	in	O
43	response	O
44	to	O
45	xenobiotic	O
46	aromatic	O
47	hydrocarbons	O
48	and	O
49	to	O
50	low	O
51	O2	O
52	concentration	O
53	,	O
54	respectively	O
55	.	O

1	However	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	SF	B
9	levels	O
10	of	O
11	IL	B
12	-	I
13	8	I
14	with	O
15	those	O
16	of	O
17	lactate	O
18	,	O
19	LDH	B
20	,	O
21	beta	B
22	2	I
23	-	I
24	microglobulin	I
25	and	O
26	glucose	O
27	.	O

1	Pharmacologic	O
2	properties	O
3	of	O
4	serotonergic	O
5	agents	O
6	and	O
7	antidepressant	O
8	drugs	O
9	.	O

1	Alternatively	O
2	processed	O
3	isoforms	O
4	of	O
5	cellular	O
6	nucleic	O
7	acid	O
8	-	O
9	binding	O
10	protein	O
11	interact	O
12	with	O
13	a	O
14	suppressor	O
15	region	O
16	of	O
17	the	O
18	human	B
19	beta	I
20	-	I
21	myosin	I
22	heavy	I
23	chain	I
24	gene	I
25	.	O

1	The	O
2	U17	B
3	/	O
4	U16	B
5	and	O
6	the	O
7	U16	B
8	+	I
9	gene	I
10	products	O
11	transactivated	O
12	the	O
13	HIV	B
14	LTR	I
15	.	O

1	Sample	O
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O

1	Statins	O
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O

1	This	O
2	dominant	O
3	-	O
4	negative	O
5	effect	O
6	of	O
7	FRNK	B
8	was	O
9	reversed	O
10	by	O
11	a	O
12	point	O
13	mutation	O
14	(	O
15	Leu	O
16	-	O
17	1034	O
18	to	O
19	Ser	O
20	)	O
21	which	O
22	prevented	O
23	FRNK	O
24	localization	O
25	to	O
26	focal	O
27	contact	O
28	sites	O
29	.	O

1	An	O
2	anatomical	O
3	and	O
4	histochemical	O
5	study	O
6	has	O
7	been	O
8	undertaken	O
9	and	O
10	as	O
11	a	O
12	result	O
13	emphasis	O
14	is	O
15	given	O
16	to	O
17	recent	O
18	hypotheses	O
19	that	O
20	suggest	O
21	there	O
22	are	O
23	similarities	O
24	with	O
25	Type	O
26	IV	O
27	glycogen	O
28	storage	O
29	disease	O
30	(	O
31	Andersen	O
32	'	O
33	s	O
34	disease	O
35	)	O
36	which	O
37	,	O
38	although	O
39	clinically	O
40	distinct	O
41	,	O
42	has	O
43	the	O
44	same	O
45	enzyme	O
46	defect	O
47	.	O

1	Slp1	B
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	O
22	stripes	O
23	in	O
24	interstripe	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O

1	New	O
2	beta	O
3	-	O
4	blocking	O
5	drugs	O
6	have	O
7	been	O
8	introduced	O
9	which	O
10	may	O
11	prove	O
12	beneficial	O
13	in	O
14	certain	O
15	clinical	O
16	situations	O
17	since	O
18	they	O
19	exert	O
20	more	O
21	selective	O
22	blockade	O
23	of	O
24	the	O
25	cardiac	B
26	receptors	I
27	(	O
28	beta1	B
29	)	O
30	as	O
31	opposed	O
32	to	O
33	smooth	B
34	muscle	I
35	receptors	I
36	(	O
37	beta2	O
38	).	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	[	O
2	14C	O
3	]-	O
4	beta	O
5	-	O
6	phenethylamine	O
7	,	O
8	its	O
9	distribution	O
10	after	O
11	administration	O
12	by	O
13	various	O
14	routes	O
15	to	O
16	cats	O
17	,	O
18	and	O
19	the	O
20	effects	O
21	of	O
22	monoamine	B
23	oxidase	I
24	inhibitors	O
25	.	O

1	The	O
2	ORF3	B
3	mutant	I
4	produced	O
5	reduced	O
6	levels	O
7	of	O
8	tabtoxin	O
9	,	O
10	indicating	O
11	that	O
12	ORF3	B
13	may	O
14	have	O
15	a	O
16	role	O
17	in	O
18	T	O
19	beta	O
20	L	O
21	biosynthesis	O
22	.	O

1	Tryptic	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	O
23	A	O
24	-	O
25	T	B
26	-	I
27	rich	I
28	binding	I
29	protein	I
30	1	I
31	(	O
32	SATB1	B
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	scaffold	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	MARs	B
49	/	O
50	SARs	B
51	).	O

1	This	O
2	article	O
3	reviews	O
4	recent	O
5	information	O
6	on	O
7	the	O
8	frequency	O
9	,	O
10	characteristics	O
11	,	O
12	and	O
13	possible	O
14	pathogenic	O
15	mechanisms	O
16	of	O
17	the	O
18	vasculitides	O
19	occurring	O
20	in	O
21	patients	O
22	with	O
23	the	O
24	main	O
25	connective	O
26	tissue	O
27	diseases	O
28	.	O

1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	O
7	sites	O
8	for	O
9	the	O
10	repressor	O
11	proteins	O
12	BP1	B
13	and	O
14	BP2	B
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	B
22	globin	I
23	gene	I
24	flanking	I
25	region	I
26	led	O
27	to	O
28	a	O
29	4	O
30	-	O
31	6	O
32	fold	O
33	increase	O
34	in	O
35	promoter	O
36	activity	O
37	.	O

1	A	O
2	new	O
3	vector	O
4	,	O
5	pHBK280	O
6	,	O
7	was	O
8	designed	O
9	to	O
10	facilitate	O
11	this	O
12	analysis	O
13	.	O

1	Val	O
2	-->	O
3	Ala	O
4	mutations	O
5	selectively	O
6	alter	O
7	helix	O
8	-	O
9	helix	O
10	packing	O
11	in	O
12	the	O
13	transmembrane	O
14	segment	O
15	of	O
16	phage	O
17	M13	B
18	coat	I
19	protein	I
20	.	O

1	The	O
2	major	O
3	RNase	B
4	E	I
5	cleavage	I
6	product	I
7	(	O
8	denoted	O
9	pSok	B
10	-	I
11	6	I
12	)	O
13	is	O
14	rapidly	O
15	degraded	O
16	by	O
17	polynucleotide	B
18	phosphorylase	I
19	(	I
20	PNPase	I
21	).	O

1	Chloroplast	O
2	mutator	O
3	(	O
4	chm	O
5	)	O
6	of	O
7	Arabidopsis	O
8	is	O
9	a	O
10	recessive	O
11	nuclear	O
12	mutation	O
13	that	O
14	causes	O
15	green	O
16	and	O
17	white	O
18	variegation	O
19	in	O
20	leaves	O
21	and	O
22	is	O
23	inherited	O
24	in	O
25	a	O
26	non	O
27	-	O
28	Mendelian	O
29	fashion	O
30	.	O

1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	B
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	B
18	BALB	I
19	/	I
20	c	I
21	-	I
22	specific	I
23	variants	I
24	of	O
25	p16	B
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	O
39	CDK4	B
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	B
72	(	O
73	INK4a	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O

1	For	O
2	HeLa	O
3	,	O
4	293	O
5	,	O
6	U937	O
7	,	O
8	and	O
9	A549	O
10	cells	O
11	,	O
12	participation	O
13	of	O
14	E2F	B
15	-	I
16	1	I
17	,	O
18	DP	B
19	-	I
20	1	I
21	,	O
22	cyclin	B
23	A	I
24	,	O
25	and	O
26	RB	B
27	was	O
28	involved	O
29	in	O
30	formation	O
31	of	O
32	some	O
33	complexes	O
34	only	O
35	,	O
36	assuming	O
37	participation	O
38	of	O
39	factors	O
40	different	O
41	from	O
42	E2F	B
43	-	I
44	1	I
45	or	O
46	DP	B
47	-	I
48	1	I
49	in	O
50	others	O
51	.	O

1	To	O
2	assess	O
3	the	O
4	health	O
5	significance	O
6	of	O
7	the	O
8	early	O
9	renal	O
10	changes	O
11	after	O
12	chronic	O
13	exposure	O
14	to	O
15	cadmium	O
16	,	O
17	23	O
18	workers	O
19	removed	O
20	from	O
21	exposure	O
22	because	O
23	of	O
24	the	O
25	discovery	O
26	of	O
27	an	O
28	increased	O
29	urinary	O
30	excretion	O
31	of	O
32	beta	B
33	2	I
34	-	I
35	microglobulin	I
36	or	O
37	retinol	O
38	binding	O
39	protein	O
40	,	O
41	or	O
42	both	O
43	,	O
44	have	O
45	been	O
46	examined	O
47	once	O
48	a	O
49	year	O
50	for	O
51	five	O
52	years	O
53	.	O

1	Hu	B
2	-	I
3	Met	I
4	-	I
5	1	I
6	mRNA	I
7	expression	O
8	in	O
9	a	O
10	small	O
11	number	O
12	of	O
13	human	O
14	T	O
15	cell	O
16	tumor	O
17	lines	O
18	did	O
19	not	O
20	correlate	O
21	with	O
22	any	O
23	particular	O
24	phenotype	O
25	or	O
26	stage	O
27	of	O
28	development	O
29	.	O

1	The	O
2	purpose	O
3	of	O
4	the	O
5	study	O
6	reported	O
7	here	O
8	was	O
9	to	O
10	investigate	O
11	whether	O
12	differences	O
13	in	O
14	T1	O
15	and	O
16	T2	O
17	between	O
18	tumors	O
19	are	O
20	mainly	O
21	a	O
22	consequence	O
23	of	O
24	differences	O
25	in	O
26	the	O
27	fractional	O
28	volume	O
29	of	O
30	the	O
31	extracellular	O
32	compartment	O
33	.	O

1	The	O
2	asymmetric	O
3	methylation	O
4	was	O
5	associated	O
6	with	O
7	tissue	O
8	-	O
9	specific	O
10	disruption	O
11	of	O
12	H19	B
13	genomic	O
14	imprinting	O
15	in	O
16	fetal	O
17	brain	O
18	.	O

1	Remarkably	O
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	O
10	970	O
11	,	O
12	which	O
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	O
18	and	O
19	the	O
20	AD1	B
21	region	I
22	of	O
23	SRC1	B
24	,	O
25	retained	O
26	strong	O
27	coactivator	O
28	activity	O
29	in	O
30	our	O
31	assays	O
32	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	O
31	(	O
32	Suvar3	O
33	-	O
34	9	O
35	,	O
36	Enhancer	O
37	-	O
38	of	O
39	-	O
40	zeste	O
41	,	O
42	Trithorax	O
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	O
51	.	O

1	An	O
2	ELISA	O
3	procedure	O
4	was	O
5	developed	O
6	for	O
7	monitoring	O
8	the	O
9	specific	O
10	IgE	B
11	response	O
12	in	O
13	dogs	O
14	to	O
15	Dirofilaria	O
16	immitis	O
17	infection	O
18	.	O

1	Evaluation	O
2	of	O
3	automatic	O
4	blood	O
5	cell	O
6	counters	O
7	.	O

1	2	O
2	.	O

1	A	O
2	new	O
3	UASH	B
4	consensus	I
5	sequence	I
6	derived	O
7	from	O
8	this	O
9	mutational	O
10	analysis	O
11	closely	O
12	matches	O
13	a	O
14	consensus	O
15	Abf1	B
16	binding	I
17	site	I
18	.	O

1	The	O
2	MMA	O
3	,	O
4	DMA	O
5	,	O
6	and	O
7	TMA	O
8	methyltransferases	O
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	O
26	and	O
27	TMA	O
28	methyltransferases	O
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	A	O
2	5	O
3	.	O
4	0	O
5	-	O
6	kb	O
7	transcript	O
8	detected	O
9	by	O
10	the	O
11	differential	O
12	display	O
13	amplicon	O
14	3G1	O
15	was	O
16	found	O
17	to	O
18	correlate	O
19	strongly	O
20	with	O
21	RAG1	B
22	mRNA	I
23	expression	O
24	in	O
25	various	O
26	human	O
27	cell	O
28	lines	O
29	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Limited	O
5	Joint	O
6	Mobility	O
7	(	O
8	LJM	O
9	)	O
10	in	O
11	diabetes	O
12	is	O
13	unknown	O
14	,	O
15	but	O
16	the	O
17	abnormality	O
18	is	O
19	said	O
20	to	O
21	be	O
22	associated	O
23	with	O
24	an	O
25	increased	O
26	incidence	O
27	of	O
28	microangiopathy	O
29	.	O

1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O

1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	O
8	-	O
9	type	O
10	Salmonella	O
11	typhimurium	O
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	B
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	B
28	-	I
29	dependent	I
30	nuclease	I
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	B
42	-	I
43	modified	I
44	RecBCD	I
45	nuclease	I
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O

1	Analysis	O
2	of	O
3	Msy2	B
4	mRNA	I
5	expression	O
6	in	O
7	prepubertal	O
8	and	O
9	adult	O
10	mouse	O
11	testes	O
12	,	O
13	and	O
14	in	O
15	isolated	O
16	populations	O
17	of	O
18	germ	O
19	cells	O
20	,	O
21	reveals	O
22	maximal	O
23	expression	O
24	in	O
25	postmeiotic	O
26	round	O
27	spermatids	O
28	,	O
29	a	O
30	cell	O
31	type	O
32	with	O
33	abundant	O
34	amounts	O
35	of	O
36	stored	O
37	messenger	O
38	ribonucleoproteins	O
39	.	O

1	The	O
2	Laser	O
3	Scanning	O
4	Ophthalmoscope	O
5	enables	O
6	a	O
7	fundus	O
8	-	O
9	based	O
10	examination	O
11	and	O
12	therefore	O
13	allows	O
14	exact	O
15	comparison	O
16	between	O
17	morphologic	O
18	appearance	O
19	and	O
20	corresponding	O
21	function	O
22	.	O

1	Intravenous	O
2	injections	O
3	of	O
4	SG	B
5	-	I
6	75	I
7	(	O
8	0	O
9	.	O
10	03	O
11	-	O
12	1	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	decreased	O
18	systemic	O
19	blood	O
20	pressure	O
21	(	O
22	SBP	B
23	)	O
24	and	O
25	increased	O
26	peripheral	O
27	(	O
28	coronary	O
29	,	O
30	renal	O
31	,	O
32	mesenteric	O
33	and	O
34	femoral	O
35	)	O
36	blood	O
37	flow	O
38	(	O
39	PBF	O
40	)	O
41	dose	O
42	-	O
43	dependently	O
44	.	O

1	Two	O
2	patients	O
3	had	O
4	immediate	O
5	adverse	O
6	effects	O
7	from	O
8	NMF	O
9	;	O
10	one	O
11	had	O
12	a	O
13	grand	O
14	mal	O
15	seizure	O
16	and	O
17	the	O
18	other	O
19	developed	O
20	severe	O
21	abdominal	O
22	pain	O
23	.	O

1	Facts	O
2	on	O
3	the	O
4	Economic	O
5	Recovery	O
6	Tax	B
7	Act	O
8	of	O
9	1981	O
10	for	O
11	speech	O
12	-	O
13	language	O
14	pathologists	O
15	and	O
16	audiologists	O
17	.	O

1	5	O
2	)	O
3	Before	O
4	and	O
5	ten	O
6	days	O
7	after	O
8	DOTC	O
9	infusion	O
10	,	O
11	laboratory	O
12	tests	O
13	for	O
14	liver	O
15	and	O
16	renal	O
17	functions	O
18	and	O
19	blood	O
20	were	O
21	performed	O
22	.	O

1	2	O
2	.	O

1	Therefore	O
2	,	O
3	high	O
4	set	O
5	-	O
6	up	O
7	accuracy	O
8	and	O
9	reproducibility	O
10	are	O
11	mandatory	O
12	.	O

1	Studies	O
2	on	O
3	the	O
4	intracutaneous	O
5	infection	O
6	of	O
7	rabbits	O
8	by	O
9	Staphylococcus	O
10	aureus	O
11	.	O

1	METHODS	O
2	:	O
3	Fibrotic	O
4	changes	O
5	involving	O
6	bone	O
7	marrow	O
8	were	O
9	evaluated	O
10	histologically	O
11	semiquantitatively	O
12	using	O
13	reticulin	O
14	fiber	O
15	impregnation	O
16	(	O
17	method	O
18	of	O
19	Gomori	O
20	).	O

1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	O
7	regulatory	O
8	protein	O
9	,	O
10	CYS3	B
11	,	O
12	of	O
13	Neurospora	O
14	crassa	O
15	turns	O
16	on	O
17	the	O
18	expression	O
19	of	O
20	a	O
21	family	O
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O

1	Homologous	O
2	recombination	O
3	between	O
4	the	O
5	Autographa	O
6	californica	O
7	nuclear	O
8	polyhedrosis	O
9	virus	O
10	(	O
11	AcNPV	O
12	)	O
13	genome	O
14	and	O
15	a	O
16	0	O
17	.	O
18	6	O
19	-	O
20	kbp	B
21	-	I
22	long	I
23	DNA	I
24	fragment	I
25	derived	O
26	from	O
27	the	O
28	putative	O
29	DNA	B
30	helicase	I
31	gene	I
32	of	O
33	Bombyx	O
34	mori	O
35	nuclear	O
36	polyhedrosis	O
37	virus	O
38	generates	O
39	eh2	O
40	-	O
41	AcNPV	O
42	,	O
43	an	O
44	expanded	O
45	-	O
46	host	O
47	-	O
48	range	O
49	AcNPV	O
50	mutant	O
51	(	O
52	S	O
53	.	O

1	The	O
2	abluminal	O
3	surface	O
4	is	O
5	often	O
6	almost	O
7	entirely	O
8	encircled	O
9	by	O
10	a	O
11	thick	O
12	layer	O
13	of	O
14	fibrillary	O
15	connective	O
16	tissue	O
17	.	O

1	Therefore	O
2	,	O
3	the	O
4	rbcL	B
5	-	I
6	rbcS	I
7	locus	I
8	seems	O
9	to	O
10	be	O
11	barely	O
12	expressed	O
13	under	O
14	a	O
15	standard	O
16	condition	O
17	for	O
18	photoautotrophic	O
19	growth	O
20	.	O

1	Gene	O
2	1	O
3	has	O
4	been	O
5	completely	O
6	sequenced	O
7	.	O

1	We	O
2	have	O
3	also	O
4	found	O
5	that	O
6	the	O
7	in	O
8	vitro	O
9	interaction	O
10	between	O
11	the	O
12	SV40	O
13	octamer	O
14	motif	O
15	and	O
16	the	O
17	lymphoid	B
18	cell	I
19	-	I
20	specific	I
21	protein	I
22	oct	I
23	-	I
24	B2	I
25	was	O
26	negatively	O
27	modulated	O
28	by	O
29	a	O
30	component	O
31	present	O
32	in	O
33	the	O
34	nuclear	O
35	extracts	O
36	from	O
37	several	O
38	lymphoid	O
39	cell	O
40	lines	O
41	.	O

1	We	O
2	reviewed	O
3	the	O
4	records	O
5	of	O
6	151	O
7	patients	O
8	with	O
9	optic	O
10	neuritis	O
11	examined	O
12	over	O
13	an	O
14	eight	O
15	-	O
16	year	O
17	period	O
18	.	O

1	Hemolytic	O
2	jaundice	O
3	due	O
4	to	O
5	G6PD	O
6	deficiency	O
7	causing	O
8	kernicterus	O
9	in	O
10	a	O
11	female	O
12	newborn	O
13	.	O

1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O

1	The	O
2	clinical	O
3	application	O
4	of	O
5	the	O
6	antibody	O
7	-	O
8	targeted	O
9	Phthalocyanine	O
10	was	O
11	performed	O
12	in	O
13	3	O
14	patients	O
15	suffering	O
16	from	O
17	an	O
18	advanced	O
19	ovarian	O
20	carcinoma	O
21	(	O
22	FIGO	O
23	III	O
24	).	O

1	The	O
2	'	O
3	Newcastle	O
4	'	O
5	model	O
6	,	O
7	which	O
8	is	O
9	based	O
10	on	O
11	Hotelling	O
12	'	O
13	s	O
14	T2	O
15	statistic	O
16	,	O
17	proved	O
18	to	O
19	be	O
20	more	O
21	sensitive	O
22	and	O
23	diagnosed	O
24	a	O
25	systematic	O
26	displacement	O
27	for	O
28	three	O
29	prostate	O
30	patients	O
31	.	O

1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	B
7	sites	I
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O

1	The	O
2	c	B
3	-	I
4	Ets	I
5	-	I
6	1	I
7	oncoprotein	I
8	is	O
9	a	O
10	transcription	O
11	activator	O
12	that	O
13	specifically	O
14	binds	O
15	to	O
16	DNA	O
17	.	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	correlation	O
6	between	O
7	tubular	O
8	diameter	O
9	and	O
10	spg	O
11	(	O
12	r	O
13	=	O
14	0	O
15	.	O
16	68	O
17	,	O
18	P	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	)	O
25	suggesting	O
26	that	O
27	tubular	O
28	diameter	O
29	measurements	O
30	in	O
31	histological	O
32	sections	O
33	could	O
34	be	O
35	used	O
36	to	O
37	predict	O
38	sperm	O
39	production	O
40	.	O

1	Forty	O
2	-	O
3	five	O
4	cases	O
5	were	O
6	surgically	O
7	by	O
8	direct	O
9	approach	O
10	to	O
11	the	O
12	tumour	O
13	,	O
14	while	O
15	two	O
16	cases	O
17	were	O
18	treated	O
19	only	O
20	with	O
21	a	O
22	shunt	O
23	.	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	B
15	carboxyhemoglobin	I
16	(	O
17	COHb	O
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	Because	O
2	GH	B
3	-	O
4	induced	O
5	Akt	B
6	activation	O
7	was	O
8	completely	O
9	inhibited	O
10	in	O
11	both	O
12	cells	O
13	by	O
14	the	O
15	same	O
16	concentration	O
17	of	O
18	LY294002	O
19	,	O
20	these	O
21	findings	O
22	indicate	O
23	that	O
24	the	O
25	wortmannin	O
26	sensitivity	O
27	of	O
28	both	O
29	the	O
30	IRS	B
31	-	I
32	1	I
33	-	O
34	independent	O
35	and	O
36	-	O
37	dependent	O
38	GH	B
39	-	O
40	induced	O
41	MAP	B
42	kinase	I
43	activation	O
44	may	O
45	reflect	O
46	the	O
47	activity	O
48	of	O
49	another	O
50	wortmannin	O
51	-	O
52	sensitive	O
53	target	O
54	(	O
55	s	O
56	)	O
57	in	O
58	addition	O
59	to	O
60	PI3K	B
61	in	O
62	mediation	O
63	of	O
64	GH	B
65	-	O
66	induced	O
67	MAP	B
68	kinase	I
69	activation	O
70	in	O
71	these	O
72	cells	O
73	.	O

1	Circulatory	O
2	arrest	O
3	in	O
4	the	O
5	operating	O
6	room	O
7	.	O

1	The	O
2	Escherichia	O
3	coli	O
4	tet	O
5	-	O
6	repressor	O
7	(	O
8	TetR	O
9	)	O
10	operator	O
11	system	O
12	was	O
13	used	O
14	to	O
15	develop	O
16	a	O
17	variation	O
18	of	O
19	the	O
20	yeast	O
21	two	O
22	-	O
23	hybrid	O
24	assay	O
25	in	O
26	which	O
27	disruptions	O
28	of	O
29	protein	O
30	-	O
31	protein	O
32	interactions	O
33	can	O
34	be	O
35	identified	O
36	by	O
37	a	O
38	positive	O
39	selection	O
40	.	O

1	Differences	O
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	These	O
2	latter	O
3	results	O
4	showed	O
5	that	O
6	the	O
7	ABFI	B
8	protein	I
9	,	O
10	like	O
11	the	O
12	RAP1	B
13	protein	I
14	,	O
15	bound	O
16	sequences	O
17	required	O
18	for	O
19	positive	O
20	as	O
21	well	O
22	as	O
23	negative	O
24	regulation	O
25	of	O
26	gene	O
27	expression	O
28	.	O

1	Altogether	O
2	our	O
3	data	O
4	indicate	O
5	that	O
6	PEDF	B
7	belongs	O
8	to	O
9	the	O
10	subgroup	O
11	of	O
12	noninhibitory	O
13	serpins	O
14	and	O
15	that	O
16	its	O
17	N	O
18	-	O
19	terminal	O
20	region	O
21	confers	O
22	a	O
23	neurite	O
24	-	O
25	promoting	O
26	activity	O
27	to	O
28	the	O
29	protein	O
30	.	O

1	Losartan	O
2	Intervention	O
3	For	O
4	Endpoint	O
5	.	O

1	However	O
2	,	O
3	as	O
4	determined	O
5	by	O
6	PCR	O
7	with	O
8	primers	O
9	specific	O
10	for	O
11	the	O
12	26	O
13	-	O
14	kDa	O
15	product	O
16	,	O
17	the	O
18	majority	O
19	of	O
20	cats	O
21	at	O
22	2	O
23	and	O
24	4	O
25	weeks	O
26	p	O
27	.	O
28	t	O
29	.	O
30	had	O
31	gastric	O
32	fluid	O
33	samples	O
34	which	O
35	were	O
36	positive	O
37	for	O
38	H	O
39	.	O
40	pylori	O
41	and	O
42	three	O
43	of	O
44	three	O
45	cats	O
46	at	O
47	2	O
48	weeks	O
49	p	O
50	.	O
51	t	O
52	.	O
53	had	O
54	dental	O
55	plaque	O
56	which	O
57	was	O
58	positive	O
59	for	O
60	H	O
61	.	O
62	pylori	O
63	.	O

1	Toluene	O
2	is	O
3	the	O
4	chemical	O
5	most	O
6	frequently	O
7	present	O
8	in	O
9	cases	O
10	involving	O
11	volatile	O
12	solvents	O
13	.	O

1	Isolation	O
2	of	O
3	tha	O
4	avian	O
5	reticuloendothelial	O
6	virus	O
7	(	O
8	strain	O
9	T	O
10	).	O

1	CONCLUSION	O
2	:	O
3	Some	O
4	Gulf	O
5	War	O
6	veterans	O
7	may	O
8	have	O
9	delayed	O
10	,	O
11	chronic	O
12	neurotoxic	O
13	syndromes	O
14	from	O
15	wartime	O
16	exposure	O
17	to	O
18	combinations	O
19	of	O
20	chemicals	O
21	that	O
22	inhibit	O
23	butyrylcholinesterase	B
24	and	O
25	neuropathy	O
26	target	O
27	esterase	B
28	.	O

1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O

1	Serum	O
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	O
24	transcriptosomal	O
25	component	O
26	scaffold	O
27	attachment	O
28	factor	O
29	B	O
30	,	O
31	and	O
32	the	O
33	68	B
34	-	I
35	kDa	I
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O

1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O

1	Oncogenic	O
2	capacity	O
3	of	O
4	the	O
5	E2F1	B
6	gene	I
7	.	O

1	These	O
2	two	O
3	repeat	O
4	motifs	O
5	are	O
6	organized	O
7	in	O
8	an	O
9	extremely	O
10	well	O
11	-	O
12	ordered	O
13	pattern	O
14	in	O
15	each	O
16	domain	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	SbHRGP3	B
22	belongs	O
23	to	O
24	a	O
25	new	O
26	group	O
27	of	O
28	proteins	O
29	having	O
30	the	O
31	repeat	O
32	motifs	O
33	of	O
34	two	O
35	distinct	O
36	groups	O
37	of	O
38	dicot	B
39	extensins	I
40	.	O

1	The	O
2	ratio	O
3	of	O
4	radioactivity	O
5	in	O
6	tumour	O
7	compared	O
8	with	O
9	normal	O
10	tissue	O
11	(	O
12	T	O
13	:	O
14	N	O
15	ratio	O
16	)	O
17	was	O
18	determined	O
19	after	O
20	simultaneously	O
21	injecting	O
22	microspheres	O
23	into	O
24	the	O
25	portal	O
26	and	O
27	arterial	O
28	circulation	O
29	of	O
30	each	O
31	animal	O
32	.	O

1	Their	O
2	mean	O
3	IOP	O
4	was	O
5	15	O
6	.	O
7	3	O
8	(	O
9	SD	O
10	3	O
11	.	O
12	7	O
13	)	O
14	mmHg	O
15	prior	O
16	to	O
17	induction	O
18	of	O
19	anesthesia	O
20	,	O
21	13	O
22	.	O
23	5	O
24	(	O
25	SD	O
26	3	O
27	.	O
28	5	O
29	)	O
30	mmHg	O
31	after	O
32	loss	O
33	of	O
34	eyelash	O
35	reflex	O
36	following	O
37	injection	O
38	of	O
39	methohexitone	O
40	,	O
41	16	O
42	.	O
43	1	O
44	(	O
45	SD	O
46	2	O
47	.	O
48	4	O
49	)	O
50	mmHg	O
51	after	O
52	cessation	O
53	of	O
54	muscle	O
55	fasciculations	O
56	induced	O
57	by	O
58	suxamethonium	O
59	,	O
60	19	O
61	.	O
62	2	O
63	(	O
64	SD	O
65	5	O
66	.	O
67	6	O
68	)	O
69	mmHg	O
70	after	O
71	cessation	O
72	of	O
73	convulsion	O
74	and	O
75	15	O
76	.	O
77	5	O
78	(	O
79	SD	O
80	4	O
81	.	O
82	4	O
83	)	O
84	mmHg	O
85	following	O
86	resumption	O
87	of	O
88	regular	O
89	spontaneous	O
90	respiration	O
91	.	O

1	Paradoxically	O
2	,	O
3	coexpression	O
4	of	O
5	the	O
6	transcriptionally	O
7	inactive	O
8	,	O
9	amino	O
10	-	O
11	terminally	O
12	deleted	O
13	IDX	B
14	-	I
15	1	I
16	mutant	I
17	proteins	I
18	,	O
19	either	O
20	with	O
21	the	O
22	wild	B
23	-	I
24	type	I
25	IDX	I
26	-	I
27	1	I
28	or	O
29	with	O
30	themselves	O
31	,	O
32	results	O
33	in	O
34	a	O
35	marked	O
36	enhancement	O
37	of	O
38	transactivation	O
39	of	O
40	the	O
41	transcriptional	O
42	TAAT	O
43	-	O
44	1	O
45	element	O
46	reporter	O
47	.	O

1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O

1	These	O
2	results	O
3	show	O
4	that	O
5	Ski	B
6	is	O
7	a	O
8	component	O
9	of	O
10	the	O
11	HDAC	O
12	complex	O
13	and	O
14	that	O
15	Ski	B
16	is	O
17	required	O
18	for	O
19	the	O
20	transcriptional	O
21	repression	O
22	mediated	O
23	by	O
24	this	O
25	complex	O
26	.	O

1	Reduction	O
2	in	O
3	dosage	O
4	restored	O
5	normal	O
6	taste	O
7	sense	O
8	in	O
9	all	O
10	three	O
11	,	O
12	but	O
13	in	O
14	two	O
15	the	O
16	drug	O
17	had	O
18	to	O
19	be	O
20	discontinued	O
21	because	O
22	of	O
23	persisting	O
24	high	O
25	transaminase	B
26	levels	O
27	.	O

1	Thus	O
2	,	O
3	the	O
4	nematode	O
5	genes	O
6	could	O
7	be	O
8	the	O
9	homologs	O
10	of	O
11	Hh	B
12	molecules	I
13	in	O
14	other	O
15	phyla	O
16	.	O

1	Disruption	O
2	of	O
3	ARF2	B
4	causes	O
5	no	O
6	detectable	O
7	phenotype	O
8	.	O

1	Similar	O
2	memory	O
3	impairments	O
4	found	O
5	in	O
6	medial	O
7	septal	O
8	-	O
9	vertical	O
10	diagonal	O
11	band	O
12	of	O
13	Broca	O
14	and	O
15	nucleus	O
16	basalis	O
17	lesioned	O
18	rats	O
19	:	O
20	are	O
21	memory	O
22	defects	O
23	induced	O
24	by	O
25	nucleus	O
26	basalis	O
27	lesions	O
28	related	O
29	to	O
30	the	O
31	degree	O
32	of	O
33	non	O
34	-	O
35	specific	O
36	subcortical	O
37	cell	O
38	loss	O
39	?	O
40	The	O
41	function	O
42	of	O
43	nucleus	O
44	basalis	O
45	(	O
46	NB	O
47	)	O
48	and	O
49	medial	O
50	septal	O
51	-	O
52	vertical	O
53	diagonal	O
54	band	O
55	of	O
56	Broca	O
57	(	O
58	MS	O
59	-	O
60	VDBB	O
61	)	O
62	in	O
63	a	O
64	place	O
65	navigation	O
66	task	O
67	requiring	O
68	reference	O
69	memory	O
70	was	O
71	investigated	O
72	.	O

1	Although	O
2	there	O
3	are	O
4	no	O
5	octamer	O
6	elements	O
7	in	O
8	the	O
9	adenovirus	O
10	genome	O
11	that	O
12	are	O
13	known	O
14	to	O
15	be	O
16	important	O
17	for	O
18	transcription	O
19	,	O
20	there	O
21	are	O
22	octamer	O
23	elements	O
24	in	O
25	the	O
26	viral	O
27	terminal	O
28	repeat	O
29	sequences	O
30	.	O

1	Holliday	O
2	junction	O
3	resolvase	O
4	in	O
5	Schizosaccharomyces	O
6	pombe	O
7	has	O
8	identical	O
9	endonuclease	O
10	activity	O
11	to	O
12	the	O
13	CCE1	B
14	homologue	I
15	YDC2	I
16	.	O

1	This	O
2	report	O
3	describes	O
4	a	O
5	patient	O
6	with	O
7	a	O
8	previous	O
9	inferior	O
10	acute	O
11	myocardial	O
12	infarction	O
13	who	O
14	developed	O
15	right	O
16	ventricular	O
17	infarction	O
18	with	O
19	significant	O
20	anterior	O
21	lead	O
22	ST	O
23	segment	O
24	elevation	O
25	(	O
26	V1	O
27	-	O
28	V4	O
29	)	O
30	caused	O
31	by	O
32	the	O
33	loss	O
34	of	O
35	two	O
36	large	O
37	right	O
38	ventricular	O
39	branches	O
40	during	O
41	a	O
42	coronary	O
43	angioplasty	O
44	of	O
45	the	O
46	right	O
47	coronary	O
48	artery	O
49	.	O

1	Auto	O
2	-	O
3	and	O
4	isotopy	O
5	of	O
6	the	O
7	conjunctiva	O

1	Purified	O
2	Hsk1	B
3	phosphorylates	O
4	the	O
5	Cdc19	O
6	(	O
7	Mcm2	O
8	)	O
9	subunit	O
10	of	O
11	the	O
12	six	O
13	-	O
14	member	O
15	minichromosome	O
16	maintenance	O
17	protein	O
18	complex	O
19	purified	O
20	from	O
21	fission	O
22	yeast	O
23	.	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	effect	O
6	of	O
7	proteolytic	O
8	processing	O
9	in	O
10	the	O
11	MVE	O
12	nonstructural	O
13	polyprotein	O
14	segment	O
15	mediated	O
16	by	O
17	the	O
18	viral	B
19	proteinase	I
20	NS3	I
21	on	I
22	antigen	I
23	processing	O
24	and	O
25	presentation	O
26	of	O
27	the	O
28	MVE	O
29	H	O
30	-	O
31	2Kk	O
32	-	O
33	restricted	O
34	T	O
35	cell	O
36	determinant	O
37	.	O

1	Sequencing	O
2	of	O
3	the	O
4	TP53	B
5	transcripts	I
6	from	O
7	exons	O
8	2	O
9	to	O
10	10	O
11	,	O
12	however	O
13	,	O
14	did	O
15	not	O
16	reveal	O
17	mutations	O
18	of	O
19	the	O
20	remaining	O
21	allele	O
22	in	O
23	any	O
24	of	O
25	these	O
26	tumors	O
27	.	O

1	Transcription	O
2	from	O
3	adenovirus	O
4	E2	B
5	-	I
6	early	I
7	promoter	I
8	is	O
9	controlled	O
10	by	O
11	a	O
12	unique	O
13	array	O
14	of	O
15	four	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	which	O
21	include	O
22	an	O
23	atypical	O
24	TBP	B
25	site	I
26	,	O
27	two	O
28	E2F	B
29	sites	I
30	present	O
31	in	O
32	an	O
33	inverted	O
34	orientation	O
35	relative	O
36	to	O
37	each	O
38	other	O
39	,	O
40	and	O
41	an	O
42	ATF	B
43	site	I
44	.	O

1	Copper	O
2	treatments	O
3	were	O
4	assigned	O
5	to	O
6	simulate	O
7	the	O
8	different	O
9	levels	O
10	of	O
11	copper	O
12	intake	O
13	that	O
14	might	O
15	result	O
16	from	O
17	differences	O
18	in	O
19	daily	O
20	feed	O
21	intake	O
22	similar	O
23	to	O
24	the	O
25	practice	O
26	followed	O
27	with	O
28	commercial	O
29	industry	O
30	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	Moreover	O
2	,	O
3	we	O
4	found	O
5	that	O
6	cyclin	B
7	E	I
8	,	O
9	in	O
10	contrast	O
11	to	O
12	cyclin	B
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	O
24	in	O
25	cells	O
26	lacking	O
27	retinoblastoma	B
28	protein	I
29	function	O
30	.	O

1	The	O
2	pet56	B
3	and	O
4	his3	B
5	genes	I
6	are	O
7	transcribed	O
8	divergently	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	192	O
18	bp	O
19	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	Cdk2	B
6	truncations	O
7	,	O
8	however	O
9	,	O
10	were	O
11	non	O
12	-	O
13	functional	O
14	in	O
15	these	O
16	strains	O
17	and	O
18	thus	O
19	dependent	O
20	for	O
21	activity	O
22	on	O
23	the	O
24	pho85	B
25	coding	O
26	region	O
27	which	O
28	remained	O
29	in	O
30	the	O
31	mutant	O
32	pho85	O
33	::	O
34	HIS3	B
35	chromosomal	I
36	locus	I
37	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	O
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	O
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	Although	O
2	the	O
3	Src	B
4	tyrosine	I
5	kinase	I
6	induces	O
7	constitutive	O
8	Stat3	B
9	phosphorylation	O
10	on	O
11	tyrosine	O
12	,	O
13	activation	O
14	of	O
15	Stat3	B
16	-	O
17	mediated	O
18	gene	O
19	regulation	O
20	requires	O
21	both	O
22	tyrosine	O
23	and	O
24	serine	O
25	phosphorylation	O
26	of	O
27	Stat3	B
28	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	We	O
2	have	O
3	identified	O
4	SWI5	B
5	'	O
6	s	O
7	nuclear	O
8	localization	O
9	signal	O
10	(	O
11	NLS	O
12	)	O
13	and	O
14	show	O
15	that	O
16	it	O
17	can	O
18	confer	O
19	cell	O
20	cycle	O
21	-	O
22	dependent	O
23	nuclear	O
24	entry	O
25	to	O
26	a	O
27	heterologous	O
28	protein	O
29	.	O

1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	O
8	anaesthesia	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O

1	Static	O
2	lung	O
3	function	O
4	in	O
5	puppies	O
6	after	O
7	pneumonectomy	O
8	.	O

1	At	O
2	cuticular	O
3	positions	O
4	exhibiting	O
5	the	O
6	Brd	O
7	bristle	O
8	loss	O
9	phenotype	O
10	,	O
11	we	O
12	have	O
13	found	O
14	that	O
15	the	O
16	progeny	O
17	of	O
18	the	O
19	multiplied	O
20	SOPs	O
21	develop	O
22	aberrantly	O
23	,	O
24	in	O
25	that	O
26	neurons	O
27	and	O
28	thecogen	O
29	(	O
30	sheath	O
31	)	O
32	cells	O
33	appear	O
34	but	O
35	not	O
36	trichogen	O
37	(	O
38	shaft	O
39	)	O
40	and	O
41	tormogen	O
42	(	O
43	socket	O
44	)	O
45	cells	O
46	.	O

1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	O
25	.	O
26	5S	B
27	RNA	I
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O

1	A	O
2	site	O
3	-	O
4	directed	O
5	R618K	O
6	mutation	O
7	in	O
8	the	O
9	Stat5	B
10	SH2	I
11	domain	I
12	abolished	O
13	the	O
14	phosphorylation	O
15	by	O
16	Jak2	B
17	,	O
18	while	O
19	deletion	O
20	of	O
21	the	O
22	C	O
23	terminus	O
24	led	O
25	to	O
26	Stat5	B
27	hyperphosphorylation	O
28	.	O

1	Acute	O
2	appearance	O
3	of	O
4	hemiparesis	O
5	or	O
6	hemiplegia	O
7	with	O
8	initial	O
9	marked	O
10	spasticity	O
11	was	O
12	observed	O
13	in	O
14	8	O
15	stroke	O
16	patients	O
17	.	O

1	These	O
2	rearrangements	O
3	result	O
4	in	O
5	the	O
6	formation	O
7	of	O
8	chimeric	O
9	genes	O
10	showing	O
11	the	O
12	tyrosine	B
13	kinase	I
14	domain	I
15	of	O
16	ret	O
17	fused	O
18	with	O
19	the	O
20	5	O
21	'	O
22	end	O
23	sequences	O
24	of	O
25	different	O
26	genes	O
27	.	O

1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O

1	Endogenous	O
2	RMP	O
3	was	O
4	immunologically	O
5	detected	O
6	interacting	O
7	with	O
8	assembled	O
9	RPB5	O
10	in	O
11	RNA	B
12	polymerase	I
13	in	O
14	mammalian	O
15	cells	O
16	.	O

1	Videonystagmoscopy	O
2	has	O
3	been	O
4	used	O
5	to	O
6	subjectively	O
7	observe	O
8	the	O
9	responses	O
10	of	O
11	the	O
12	vestibular	O
13	system	O
14	in	O
15	a	O
16	population	O
17	of	O
18	patients	O
19	with	O
20	vestibular	O
21	deficits	O
22	.	O

1	We	O
2	discuss	O
3	the	O
4	need	O
5	to	O
6	use	O
7	animals	O
8	older	O
9	than	O
10	3	O
11	months	O
12	for	O
13	the	O
14	study	O
15	of	O
16	'	O
17	adult	O
18	'	O
19	regeneration	O
20	phenomena	O
21	since	O
22	3	O
23	-	O
24	month	O
25	-	O
26	old	O
27	rats	O
28	may	O
29	be	O
30	somewhat	O
31	immature	O
32	.	O

1	Although	O
2	YopH	O
3	is	O
4	a	O
5	highly	O
6	active	O
7	PTP	B
8	,	O
9	it	O
10	preferentially	O
11	targets	O
12	a	O
13	subset	O
14	of	O
15	tyrosine	O
16	-	O
17	phosphorylated	O
18	proteins	O
19	in	O
20	host	O
21	cells	O
22	,	O
23	including	O
24	p130Cas	O
25	.	O

1	The	O
2	mean	O
3	(+/-	O
4	sd	O
5	)	O
6	intra	O
7	-	O
8	vesicular	O
9	pressure	O
10	(	O
11	IVP	O
12	)	O
13	and	O
14	maximal	O
15	urethral	O
16	closure	O
17	pressures	O
18	(	O
19	MUCP	O
20	)	O
21	were	O
22	10	O
23	.	O
24	3	O
25	(+/-	O
26	1	O
27	.	O
28	7	O
29	)	O
30	and	O
31	129	O
32	.	O
33	8	O
34	(+/-	O
35	19	O
36	.	O
37	6	O
38	)	O
39	cmH2O	O
40	,	O
41	respectively	O
42	,	O
43	and	O
44	the	O
45	ratio	O
46	between	O
47	MUCP	O
48	and	O
49	IVP	O
50	was	O
51	13	O
52	.	O
53	2	O
54	(+/-	O
55	2	O
56	.	O
57	5	O
58	).	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	B
10	-	I
11	AP	I
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	B
23	-	I
24	4	I
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	Bazett	O
5	-	O
6	corrected	O
7	QT	O
8	(	O
9	QTc	O
10	)	O
11	interval	O
12	during	O
13	exercise	O
14	has	O
15	been	O
16	used	O
17	as	O
18	a	O
19	marker	O
20	for	O
21	ischemic	O
22	disease	O
23	,	O
24	arrhythmogenic	O
25	substrate	O
26	and	O
27	the	O
28	long	O
29	QT	O
30	syndrome	O
31	.	O

1	(	O
2	2	O
3	)	O
4	Erythroid	O
5	32D	O
6	Epo1	O
7	cells	O
8	showed	O
9	a	O
10	lower	O
11	level	O
12	of	O
13	bulk	B
14	PKC	I
15	catalytic	O
16	activity	O
17	,	O
18	lacked	O
19	the	O
20	expression	O
21	of	O
22	epsilon	O
23	and	O
24	eta	B
25	PKC	I
26	isoforms	I
27	,	O
28	and	O
29	showed	O
30	a	O
31	weak	O
32	or	O
33	absent	O
34	upregulation	O
35	of	O
36	the	O
37	remaining	O
38	isoforms	O
39	,	O
40	except	O
41	betaI	O
42	,	O
43	upon	O
44	readdition	O
45	of	O
46	Epo	B
47	to	O
48	growth	O
49	factor	O
50	-	O
51	starved	O
52	cells	O
53	.	O

1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	B
17	tyrosinase	I
18	gene	I
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	ICP10	B
6	constitutively	O
7	increases	O
8	ras	B
9	activity	O
10	,	O
11	and	O
12	its	O
13	TM	O
14	segment	O
15	plays	O
16	a	O
17	critical	O
18	role	O
19	in	O
20	transformation	O
21	-	O
22	related	O
23	signaling	O
24	pathways	O
25	.	O

1	Phosphorylation	O
2	of	O
3	myosin	B
4	-	I
5	binding	I
6	subunit	I
7	(	O
8	MBS	B
9	)	O
10	of	O
11	myosin	B
12	phosphatase	I
13	by	O
14	Rho	B
15	-	I
16	kinase	I
17	in	O
18	vivo	O
19	.	O

1	Clinical	O
2	and	O
3	angiographic	O
4	examinations	O
5	in	O
6	occlusion	O
7	disease	O
8	of	O
9	the	O
10	great	O
11	intestinal	O
12	arteries	O

1	Regulation	O
2	of	O
3	ASN1	B
4	and	O
5	ASN2	B
6	expression	O
7	was	O
8	studied	O
9	using	O
10	lacZ	B
11	fusions	O
12	and	O
13	both	O
14	genes	O
15	were	O
16	found	O
17	to	O
18	be	O
19	several	O
20	times	O
21	less	O
22	expressed	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	the	O
28	transcription	O
29	activator	O
30	Gcn4p	B
31	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O

1	Therefore	O
2	,	O
3	magnetic	O
4	resonance	O
5	imaging	O
6	was	O
7	used	O
8	to	O
9	determine	O
10	liver	O
11	volume	O
12	in	O
13	pediatric	O
14	and	O
15	adolescent	O
16	patients	O
17	,	O
18	in	O
19	whom	O
20	systemic	O
21	clearance	O
22	of	O
23	three	O
24	model	O
25	substrates	O
26	[	O
27	lorazepam	O
28	(	O
29	0	O
30	.	O
31	03	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	antipyrine	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	and	O
44	indocyanine	O
45	green	O
46	(	O
47	ICG	O
48	;	O
49	0	O
50	.	O
51	5	O
52	mg	O
53	/	O
54	kg	O
55	)]	O
56	was	O
57	also	O
58	determined	O
59	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	B
6	of	O
7	a	O
8	double	O
9	-	O
10	stranded	O
11	-	O
12	RNA	O
13	-	O
14	specific	O
15	adenosine	B
16	deaminase	I
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	B
28	.	O

1	Combined	O
2	intravenous	O
3	and	O
4	intra	B
5	-	I
6	arterial	I
7	recombinant	I
8	tissue	I
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O

1	This	O
2	study	O
3	is	O
4	a	O
5	further	O
6	and	O
7	more	O
8	extensive	O
9	validation	O
10	of	O
11	the	O
12	clinician	O
13	rated	O
14	NIMH	O
15	-	O
16	LCM	O
17	-	O
18	p	O
19	.	O

1	Simple	O
2	models	O
3	of	O
4	bimolecular	O
5	interaction	O
6	did	O
7	not	O
8	fully	O
9	account	O
10	for	O
11	the	O
12	kinetic	O
13	profiles	O
14	obtained	O
15	with	O
16	the	O
17	parental	O
18	antibodies	O
19	and	O
20	the	O
21	hybrids	O
22	,	O
23	and	O
24	this	O
25	complexity	O
26	suggested	O
27	the	O
28	existence	O
29	of	O
30	a	O
31	conformational	O
32	heterogeneity	O
33	in	O
34	these	O
35	molecules	O
36	.	O

1	In	O
2	another	O
3	study	O
4	,	O
5	intravenous	O
6	administration	O
7	of	O
8	devazepide	O
9	,	O
10	a	O
11	specific	O
12	cholecystokinin	B
13	-	I
14	A	I
15	receptor	I
16	antagonist	O
17	,	O
18	at	O
19	a	O
20	dose	O
21	of	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	/	O
27	kg	O
28	/	O
29	hr	O
30	was	O
31	begun	O
32	15	O
33	min	O
34	before	O
35	postprandial	O
36	saline	O
37	intake	O
38	and	O
39	continued	O
40	for	O
41	1	O
42	hr	O
43	.	O

1	A	O
2	comparative	O
3	study	O
4	was	O
5	undertaken	O
6	between	O
7	an	O
8	enzymatic	O
9	immunohistochemical	O
10	technique	O
11	(	O
12	EIT	O
13	)	O
14	developed	O
15	for	O
16	the	O
17	diagnosis	O
18	of	O
19	human	O
20	trichinellosis	O
21	and	O
22	the	O
23	indirect	O
24	immunofluorescence	O
25	test	O
26	(	O
27	IIF	B
28	),	O
29	analysing	O
30	sera	O
31	from	O
32	outbreaks	O
33	of	O
34	human	O
35	trichinellosis	O
36	in	O
37	Argentina	O
38	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mammalian	B
5	translation	I
6	initiation	I
7	factor	I
8	5	I
9	(	O
10	eIF5	B
11	):	O
12	role	O
13	of	O
14	interaction	O
15	between	O
16	the	O
17	beta	O
18	subunit	O
19	of	O
20	eIF2	B
21	and	O
22	eIF5	B
23	in	O
24	eIF5	B
25	function	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	.	O

1	Serum	O
2	antibody	O
3	titre	O
4	was	O
5	not	O
6	significantly	O
7	associated	O
8	with	O
9	the	O
10	recurrence	O
11	rate	O
12	or	O
13	the	O
14	duration	O
15	of	O
16	infection	O
17	.	O

1	The	O
2	gene	O
3	is	O
4	separated	O
5	into	O
6	four	O
7	exons	O
8	by	O
9	three	O
10	short	O
11	introns	O
12	,	O
13	and	O
14	the	O
15	open	O
16	reading	O
17	frame	O
18	consists	O
19	of	O
20	6660	O
21	base	O
22	pairs	O
23	(	O
24	bp	O
25	)	O
26	capable	O
27	of	O
28	encoding	O
29	a	O
30	polypeptide	O
31	of	O
32	2220	O
33	amino	O
34	acid	O
35	residues	O
36	.	O

1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O

1	Primary	O
2	and	O
3	secondary	O
4	structural	O
5	elements	O
6	required	O
7	for	O
8	synthesis	O
9	of	O
10	barley	O
11	yellow	O
12	dwarf	O
13	virus	O
14	subgenomic	O
15	RNA1	B
16	.	O

1	CONCLUSIONS	O
2	:	O
3	We	O
4	obtained	O
5	normal	O
6	EPO	B
7	levels	O
8	for	O
9	mothers	O
10	and	O
11	newborns	O
12	for	O
13	our	O
14	area	O
15	,	O
16	similarly	O
17	to	O
18	the	O
19	previously	O
20	described	O
21	ones	O
22	.	O

1	The	O
2	p130	B
3	and	O
4	p62	B
5	tyrosine	I
6	-	I
7	phosphorylated	I
8	proteins	I
9	that	O
10	complexed	O
11	v	B
12	-	I
13	Src	I
14	SH2	I
15	in	O
16	vitro	O
17	also	O
18	associated	O
19	with	O
20	v	B
21	-	I
22	Src	I
23	in	O
24	v	B
25	-	I
26	src	I
27	-	O
28	transformed	O
29	Rat	O
30	-	O
31	2	O
32	cells	O
33	;	O
34	this	O
35	in	O
36	vivo	O
37	binding	O
38	was	O
39	dependent	O
40	on	O
41	the	O
42	v	B
43	-	I
44	Src	I
45	SH2	I
46	domain	I
47	.	O

1	These	O
2	studies	O
3	identify	O
4	several	O
5	of	O
6	the	O
7	signal	O
8	-	O
9	transduction	O
10	events	O
11	involved	O
12	in	O
13	the	O
14	apoptosis	O
15	of	O
16	malignant	O
17	B	O
18	cells	O
19	that	O
20	transpire	O
21	following	O
22	ligation	O
23	of	O
24	CD20	B
25	by	O
26	anti	B
27	-	I
28	CD20	I
29	antibodies	I
30	in	O
31	the	O
32	presence	O
33	of	O
34	Fc	B
35	-	I
36	receptor	I
37	-	O
38	expressing	O
39	cells	O
40	or	O
41	secondary	O
42	goat	O
43	anti	O
44	-(	O
45	mouse	B
46	Ig	I
47	)	I
48	antibodies	I
49	and	O
50	which	O
51	may	O
52	contribute	O
53	to	O
54	the	O
55	tumor	O
56	regressions	O
57	observed	O
58	in	O
59	mouse	O
60	models	O
61	and	O
62	clinical	O
63	trials	O
64	.	O

1	METHODS	O
2	:	O
3	Total	O
4	muscle	O
5	paralysis	O
6	was	O
7	induced	O
8	under	O
9	general	O
10	anesthesia	O
11	in	O
12	a	O
13	group	O
14	of	O
15	obese	O
16	persons	O
17	(	O
18	n	O
19	=	O
20	9	O
21	;	O
22	body	O
23	mass	O
24	index	O
25	,	O
26	32	O
27	+/-	O
28	3	O
29	kg	O
30	[-	O
31	2	O
32	])	O
33	and	O
34	in	O
35	a	O
36	group	O
37	of	O
38	nonobese	O
39	persons	O
40	(	O
41	n	O
42	=	O
43	9	O
44	;	O
45	body	O
46	mas	O
47	index	O
48	,	O
49	21	O
50	+/-	O
51	2	O
52	kg	O
53	[-	O
54	2	O
55	]).	O

1	Deletion	O
2	of	O
3	the	O
4	NF	B
5	-	I
6	IL6	I
7	beta	I
8	leucine	I
9	zipper	I
10	domain	I
11	also	O
12	greatly	O
13	diminished	O
14	the	O
15	interaction	O
16	between	O
17	these	O
18	two	O
19	proteins	O
20	.	O

1	Effect	O
2	of	O
3	Azadirachta	O
4	indica	O
5	hydroalcoholic	O
6	leaf	O
7	extract	O
8	on	O
9	the	O
10	cardiovascular	O
11	system	O
12	.	O

1	In	O
2	view	O
3	of	O
4	the	O
5	short	O
6	t1	O
7	/	O
8	2	O
9	,	O
10	we	O
11	used	O
12	three	O
13	doses	O
14	/	O
15	day	O
16	.	O

1	The	O
2	maximum	O
3	induction	O
4	of	O
5	ACC	B
6	-	I
7	oxidase	I
8	transcripts	I
9	occurred	O
10	at	O
11	about	O
12	6	O
13	h	O
14	after	O
15	excision	O
16	,	O
17	while	O
18	the	O
19	maximum	O
20	enzyme	O
21	activity	O
22	was	O
23	observed	O
24	at	O
25	24	O
26	h	O
27	.	O

1	Sterols	O
2	in	O
3	pollen	O
4	.	O

1	These	O
2	alternative	O
3	splice	O
4	variants	O
5	were	O
6	detected	O
7	in	O
8	RNA	O
9	isolated	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	primary	O
16	leptomeningeal	O
17	tissue	O
18	and	O
19	an	O
20	established	O
21	line	O
22	of	O
23	leptomeningeal	O
24	cells	O
25	(	O
26	LMC	O
27	).	O

1	Localization	O
2	of	O
3	the	O
4	insertion	O
5	locus	O
6	in	O
7	the	O
8	yeast	O
9	genome	O
10	and	O
11	complementation	O
12	studies	O
13	with	O
14	the	O
15	temperature	O
16	-	O
17	sensitive	O
18	mutant	O
19	indicate	O
20	that	O
21	the	O
22	two	O
23	mutations	O
24	are	O
25	allelic	O
26	.	O

1	As	O
2	normal	O
3	B	O
4	cells	O
5	also	O
6	present	O
7	this	O
8	variant	O
9	,	O
10	the	O
11	mechanism	O
12	of	O
13	CD79b	B
14	posttranscriptional	O
15	regulation	O
16	might	O
17	reflect	O
18	the	O
19	activation	O
20	stage	O
21	of	O
22	the	O
23	normal	O
24	B	O
25	cell	O
26	from	O
27	which	O
28	B	O
29	-	O
30	CLL	O
31	derives	O
32	.	O

1	Non	O
2	-	O
3	complement	O
4	-	O
5	dependent	O
6	sperm	O
7	-	O
8	immobilizing	O
9	activity	O
10	was	O
11	also	O
12	detected	O
13	in	O
14	the	O
15	cervical	O
16	mucus	O
17	of	O
18	several	O
19	patients	O
20	.	O

1	Unified	O
2	theory	O
3	of	O
4	segregated	O
5	-	O
6	stack	O
7	organic	O
8	charge	O
9	-	O
10	transfer	O
11	solids	O
12	:	O
13	Magnetic	O
14	properties	O
15	.	O

1	In	O
2	Experiment	O
3	2	O
4	scopolamine	O
5	hydrobromide	O
6	,	O
7	0	O
8	.	O
9	5	O
10	and	O
11	1	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	i	O
18	.	O
19	p	O
20	.,	O
21	was	O
22	administered	O
23	1	O
24	h	O
25	before	O
26	each	O
27	electrical	O
28	stimulation	O
29	until	O
30	each	O
31	rat	O
32	showed	O
33	the	O
34	stage	O
35	-	O
36	3	O
37	seizure	O
38	.	O

1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	B
18	5	I
19	'-	I
20	triphosphatase	I
21	(	O
22	Cet1p	B
23	),	O
24	RNA	B
25	guanylyltransferase	I
26	(	O
27	Ceg1p	B
28	),	O
29	and	O
30	Abd1p	B
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	B
48	-	I
49	guanylyltransferase	I
50	Mce1p	I
51	and	O
52	the	O
53	methyltransferase	B
54	Hcm1	I
55	(	O
56	121	O
57	-	O
58	476	O
59	)	O
60	p	O
61	.	O

1	Volume	O
2	of	O
3	distribution	O
4	of	O
5	total	O
6	DMDZ	O
7	(	O
8	range	O
9	,	O
10	1	O
11	.	O
12	33	O
13	to	O
14	6	O
15	.	O
16	30	O
17	l	O
18	/	O
19	kg	O
20	)	O
21	and	O
22	of	O
23	unbound	O
24	DMDZ	O
25	after	O
26	correction	O
27	for	O
28	protein	O
29	binding	O
30	(	O
31	range	O
32	,	O
33	43	O
34	to	O
35	243	O
36	l	O
37	/	O
38	kg	O
39	)	O
40	was	O
41	larger	O
42	in	O
43	women	O
44	than	O
45	in	O
46	men	O
47	of	O
48	all	O
49	ages	O
50	,	O
51	and	O
52	in	O
53	the	O
54	elderly	O
55	as	O
56	opposed	O
57	to	O
58	the	O
59	young	O
60	.	O

1	Goodpasture	O
2	'	O
3	s	O
4	-	O
5	like	O
6	syndrome	O
7	and	O
8	effect	O
9	of	O
10	extracorporeal	O
11	membrane	O
12	oxygenator	O
13	support	O
14	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	two	O
7	genes	O
8	encoding	O
9	gp138	B
10	,	O
11	a	O
12	cell	O
13	surface	O
14	glycoprotein	O
15	involved	O
16	in	O
17	the	O
18	sexual	O
19	cell	O
20	fusion	O
21	of	O
22	Dictyostelium	O
23	discoideum	O
24	.	O

1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O

1	A	O
2	mouse	B
3	brain	I
4	beta	I
5	-	I
6	spectrin	I
7	of	I
8	cDNA	I
9	was	O
10	identified	O
11	within	O
12	a	O
13	lambda	O
14	Gt11	O
15	expression	O
16	library	O
17	using	O
18	an	O
19	antibody	O
20	which	O
21	specifically	O
22	binds	O
23	with	O
24	the	O
25	235	B
26	kDa	I
27	spectrin	I
28	beta	I
29	-	I
30	subunit	I
31	.	O

1	During	O
2	skeletal	O
3	muscle	O
4	development	O
5	,	O
6	different	O
7	types	O
8	of	O
9	muscle	O
10	fibers	O
11	are	O
12	generated	O
13	,	O
14	which	O
15	express	O
16	different	O
17	combinations	O
18	of	O
19	muscle	O
20	-	O
21	specific	O
22	gene	O
23	products	O
24	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	It	O
2	acts	O
3	on	O
4	Cdks	B
5	in	O
6	the	O
7	G1	O
8	and	O
9	S	O
10	phases	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	,	O
16	and	O
17	also	O
18	binds	O
19	to	O
20	proliferating	O
21	cell	O
22	nuclear	O
23	antigen	O
24	(	O
25	PCNA	B
26	),	O
27	blocking	O
28	DNA	O
29	replication	O
30	in	O
31	vitro	O
32	.	O

1	The	O
2	structural	O
3	study	O
4	of	O
5	peptides	O
6	belonging	O
7	to	O
8	the	O
9	terminal	O
10	domains	O
11	of	O
12	histone	B
13	H1	I
14	can	O
15	be	O
16	considered	O
17	as	O
18	a	O
19	step	O
20	toward	O
21	the	O
22	understanding	O
23	of	O
24	the	O
25	function	O
26	of	O
27	H1	B
28	in	O
29	chromatin	O
30	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	B
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	B
24	/	O
25	U6	B
26	helix	O
27	.	O

1	Two	O
2	of	O
3	these	O
4	motifs	O
5	are	O
6	part	O
7	of	O
8	a	O
9	highly	O
10	conserved	O
11	and	O
12	inducible	O
13	dyad	O
14	symmetry	O
15	element	O
16	shown	O
17	previously	O
18	to	O
19	control	O
20	a	O
21	remote	O
22	IL	B
23	-	I
24	2	I
25	enhancer	I
26	and	O
27	the	O
28	CD18	B
29	promoter	I
30	.	O

1	Escherichia	O
2	coli	O
3	BL21	O
4	(	O
5	DE3	O
6	)	O
7	plysS	O
8	,	O
9	harbouring	O
10	a	O
11	recombinant	O
12	plasmid	O
13	containing	O
14	the	O
15	catalase	B
16	-	I
17	peroxidase	I
18	gene	I
19	,	O
20	produced	O
21	a	O
22	large	O
23	amount	O
24	of	O
25	proteins	O
26	that	O
27	co	O
28	-	O
29	migrated	O
30	on	O
31	SDS	O
32	/	O
33	PAGE	O
34	with	O
35	the	O
36	native	O
37	enzyme	O
38	.	O

1	To	O
2	further	O
3	characterize	O
4	the	O
5	structure	O
6	and	O
7	evolutionary	O
8	synthesis	O
9	of	O
10	the	O
11	CMT1A	B
12	-	I
13	REP	I
14	repeat	O
15	,	O
16	fluorescent	O
17	in	O
18	situ	O
19	hybridization	O
20	(	O
21	FISH	O
22	)	O
23	analysis	O
24	and	O
25	heterologous	O
26	PCR	O
27	-	O
28	based	O
29	assays	O
30	were	O
31	carried	O
32	out	O
33	for	O
34	a	O
35	series	O
36	of	O
37	primates	O
38	.	O

1	The	O
2	effects	O
3	of	O
4	anabolic	O
5	implants	O
6	on	O
7	rate	O
8	,	O
9	composition	O
10	and	O
11	energetic	O
12	efficiency	O
13	of	O
14	growth	O
15	were	O
16	determined	O
17	in	O
18	steers	O
19	fed	O
20	diets	O
21	varying	O
22	in	O
23	forage	O
24	and	O
25	grain	O
26	content	O
27	.	O

1	UGA	O
2	codon	O
3	position	O
4	affects	O
5	the	O
6	efficiency	O
7	of	O
8	selenocysteine	O
9	incorporation	O
10	into	O
11	glutathione	B
12	peroxidase	I
13	-	I
14	1	I
15	.	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	The	O
2	microcirculatory	O
3	dynamics	O
4	of	O
5	prostaglandin	O
6	E1	O
7	and	O
8	/	O
9	or	O
10	nicardipine	O
11	and	O
12	their	O
13	different	O
14	reactions	O
15	in	O
16	the	O
17	hyper	O
18	-	O
19	and	O
20	hypodynamic	O
21	state	O
22	of	O
23	septic	O
24	shock	O
25	in	O
26	a	O
27	rat	O
28	model	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	the	O
7	simultaneous	O
8	determination	O
9	of	O
10	1	O
11	,	O
12	alpha	O
13	-	O
14	acetylmethadol	O
15	(	O
16	LAAM	O
17	)	O
18	and	O
19	five	O
20	active	O
21	metabolites	O
22	--	O
23	noracetylmethadol	O
24	,	O
25	dinoracetylmethadol	O
26	,	O
27	methadol	O
28	,	O
29	normethadol	O
30	,	O
31	and	O
32	dinormethadol	O
33	--	O
34	in	O
35	biofluids	O
36	by	O
37	high	O
38	-	O
39	performance	O
40	liquid	O
41	chromatography	O
42	using	O
43	a	O
44	normal	O
45	-	O
46	phase	O
47	column	O
48	and	O
49	a	O
50	UV	O
51	detector	O
52	at	O
53	218	O
54	nm	O
55	.	O

1	First	O
2	,	O
3	a	O
4	pet54	B
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	B
19	introns	I
20	aI5	I
21	alpha	I
22	and	O
23	aI5	B
24	beta	I
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	B
30	gene	I
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	B
36	mRNA	I
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O

1	Neither	O
2	CES1	B
3	nor	O
4	CES4	B
5	is	O
6	essential	O
7	for	O
8	cell	O
9	growth	O
10	,	O
11	and	O
12	a	O
13	double	O
14	deletion	O
15	mutant	O
16	is	O
17	viable	O
18	.	O

1	Furthermore	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	both	O
8	p46	O
9	and	O
10	p54	B
11	subunits	I
12	markedly	O
13	altered	O
14	the	O
15	subcellular	O
16	distribution	O
17	of	O
18	p46	O
19	;	O
20	co	O
21	-	O
22	expressed	O
23	p46	B
24	was	O
25	transported	O
26	into	O
27	the	O
28	nucleus	O
29	as	O
30	efficiently	O
31	as	O
32	p54	B
33	.	O

1	However	O
2	,	O
3	at	O
4	lower	O
5	temperature	O
6	the	O
7	positive	O
8	staircase	O
9	was	O
10	not	O
11	clear	O
12	and	O
13	rather	O
14	negative	O
15	staircase	O
16	appeared	O
17	(	O
18	1	O
19	--	O
20	3	O
21	Hz	O
22	).	O

1	Biometric	O
2	analysis	O
3	of	O
4	intraocular	O
5	lens	O
6	power	O
7	required	O
8	to	O
9	produce	O
10	emmetropia	O
11	:	O
12	results	O
13	of	O
14	450	O
15	implants	O
16	.	O

1	DNA	O
2	blot	O
3	hybridization	O
4	suggests	O
5	that	O
6	the	O
7	rat	O
8	genome	O
9	may	O
10	contain	O
11	more	O
12	than	O
13	one	O
14	gene	O
15	encoding	O
16	PtdIns	B
17	transfer	I
18	protein	I
19	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	that	O
7	cell	O
8	-	O
9	specific	O
10	suppression	O
11	of	O
12	RA	O
13	-	O
14	stimulated	O
15	zif268	B
16	gene	I
17	expression	O
18	can	O
19	be	O
20	attributed	O
21	to	O
22	a	O
23	29	O
24	base	O
25	pair	O
26	nucleotide	O
27	sequence	O
28	,	O
29	located	O
30	downstream	O
31	of	O
32	the	O
33	RA	O
34	-	O
35	responsive	O
36	region	O
37	in	O
38	the	O
39	zif268	B
40	gene	I
41	.	O

1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O

1	EEG	O
2	theta	O
3	waves	O
4	and	O
5	psychological	O
6	phenomena	O
7	:	O
8	a	O
9	review	O
10	and	O
11	analysis	O
12	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	We	O
2	conclude	O
3	that	O
4	Hansel	O
5	'	O
6	s	O
7	stain	O
8	substantially	O
9	improves	O
10	the	O
11	recognition	O
12	of	O
13	eosinophiluria	O
14	as	O
15	compared	O
16	with	O
17	Wright	O
18	'	O
19	s	O
20	stain	O
21	.	O

1	3	O
2	)	O
3	and	O
4	one	O
5	distal	O
6	(-	O
7	11	O
8	.	O
9	8	O
10	/-	O
11	10	O
12	.	O
13	9	O
14	),	O
15	presented	O
16	an	O
17	enhancer	O
18	activity	O
19	in	O
20	pituitary	O
21	cells	O
22	when	O
23	placed	O
24	upstream	O
25	of	O
26	the	O
27	SV40	B
28	promoter	I
29	.	O

1	Twenty	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	these	O
7	patients	O
8	had	O
9	neurologic	O
10	disease	O
11	that	O
12	appeared	O
13	to	O
14	be	O
15	responsible	O
16	for	O
17	the	O
18	tinnitus	O
19	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	I	O
9	-	O
10	POU	B
11	/	O
12	tI	B
13	-	I
14	POU	I
15	message	I
16	is	O
17	maximal	O
18	late	O
19	in	O
20	the	O
21	embryonic	O
22	phase	O
23	of	O
24	Drosophila	O
25	development	O
26	,	O
27	and	O
28	I	B
29	-	I
30	POU	I
31	is	O
32	the	O
33	preferred	O
34	splice	O
35	variant	O
36	.	O

1	The	O
2	method	O
3	is	O
4	accurate	O
5	,	O
6	with	O
7	good	O
8	precision	O
9	and	O
10	adequate	O
11	sensitivity	O
12	.	O

1	Closure	O
2	of	O
3	the	O
4	patent	O
5	ductus	O
6	arteriosus	O
7	with	O
8	a	O
9	Ligaclip	O
10	through	O
11	a	O
12	minithoracotomy	O
13	.	O

1	In	O
2	rats	O
3	anaesthetized	O
4	with	O
5	+-	O
6	chloralose	O
7	the	O
8	changes	O
9	in	O
10	extracellular	O
11	pH	O
12	and	O
13	K	O
14	+	O
15	in	O
16	spinal	O
17	cord	O
18	dorsal	O
19	horn	O
20	were	O
21	studied	O
22	using	O
23	pH	O
24	and	O
25	K	O
26	+	O
27	ion	O
28	-	O
29	selective	O
30	electrodes	O
31	.	O

1	In	O
2	the	O
3	unclipped	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	diuresis	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O

1	Interestingly	O
2	,	O
3	an	O
4	antibody	O
5	against	O
6	N	B
7	-	I
8	SMase	I
9	can	O
10	abrogate	O
11	Ox	O
12	-	O
13	LDL	B
14	-	O
15	and	O
16	TNF	B
17	-	I
18	alpha	I
19	-	O
20	induced	O
21	apoptosis	O
22	and	O
23	therefore	O
24	may	O
25	be	O
26	useful	O
27	for	O
28	in	O
29	vivo	O
30	studies	O
31	of	O
32	apoptosis	O
33	in	O
34	experimental	O
35	animals	O
36	.	O

1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	Isolated	O
2	proteinuria	O
3	(	O
4	i	O
5	.	O
6	e	O
7	.	O
8	without	O
9	hematuria	O
10	and	O
11	/	O
12	or	O
13	pyuria	O
14	)	O
15	is	O
16	a	O
17	frequent	O
18	finding	O
19	.	O

1	Vascular	B
2	endothelial	I
3	growth	I
4	factor	I
5	(	O
6	VEGF	B
7	),	O
8	a	O
9	potent	O
10	agonist	O
11	secreted	O
12	by	O
13	virtually	O
14	all	O
15	cells	O
16	,	O
17	controls	O
18	migration	O
19	and	O
20	division	O
21	of	O
22	vascular	O
23	endothelial	O
24	cells	O
25	.	O

1	It	O
2	bound	O
3	to	O
4	vitamin	B
5	D	I
6	receptor	I
7	(	O
8	VDR	B
9	)	O
10	but	O
11	not	O
12	retinoic	B
13	acid	I
14	Xalpha	I
15	receptor	I
16	(	O
17	RXRalpha	B
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O

1	Epidemiology	O
2	and	O
3	prevention	O
4	of	O
5	hospital	O
6	infections	O
7	in	O
8	the	O
9	Local	O
10	Health	O
11	Unit	O
12	of	O
13	Sassari	O
14	:	O
15	profile	O
16	of	O
17	bacterial	O
18	resistance	O
19	and	O
20	antimicrobial	O
21	agents	O
22	of	O
23	large	O
24	usage	O
25	.	O

1	Stable	O
2	expression	O
3	of	O
4	the	O
5	chimeric	B
6	alpha	I
7	i	I
8	(	I
9	54	I
10	)/	I
11	s	I
12	polypeptide	I
13	in	O
14	Chinese	O
15	hamster	O
16	ovary	O
17	(	O
18	CHO	O
19	)	O
20	cells	O
21	constitutively	O
22	increased	O
23	both	O
24	cAMP	O
25	synthesis	O
26	and	O
27	cAMP	B
28	-	I
29	dependent	I
30	protein	I
31	kinase	I
32	activity	O
33	.	O

1	The	O
2	conserved	O
3	ninth	O
4	C	O
5	-	O
6	terminal	O
7	heptad	O
8	in	O
9	thyroid	O
10	hormone	O
11	and	O
12	retinoic	B
13	acid	I
14	receptors	I
15	mediates	O
16	diverse	O
17	responses	O
18	by	O
19	affecting	O
20	heterodimer	O
21	but	O
22	not	O
23	homodimer	O
24	formation	O
25	.	O

1	Performance	O
2	on	O
3	two	O
4	verbal	O
5	measures	O
6	-	O
7	the	O
8	National	O
9	Adult	O
10	Reading	O
11	Test	O
12	-	O
13	Revised	O
14	(	O
15	NART	B
16	-	I
17	R	I
18	)	O
19	and	O
20	the	O
21	Vocabulary	O
22	subtest	O
23	from	O
24	the	O
25	Wechsler	O
26	Adult	O
27	Intelligence	O
28	Scale	O
29	-	O
30	Revised	O
31	(	O
32	WAIS	O
33	-	O
34	R	O
35	)-	O
36	showed	O
37	strong	O
38	correlations	O
39	with	O
40	level	O
41	of	O
42	education	O
43	.	O

1	4	O
2	.	O
3	26	O
4	+/-	O
5	1	O
6	.	O
7	54	O
8	mmol	O
9	/	O
10	l	O
11	,	O
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	),	O
18	and	O
19	systolic	O
20	BP	O
21	responses	O
22	to	O
23	intravenous	O
24	norepinephrine	O
25	and	O
26	angiotensin	B
27	II	I
28	were	O
29	significantly	O
30	higher	O
31	on	O
32	glibenclamide	O
33	than	O
34	on	O
35	metformin	O
36	(	O
37	P	O
38	<	O
39	0	O
40	.	O
41	02	O
42	and	O
43	P	O
44	<	O
45	0	O
46	.	O
47	05	O
48	,	O
49	respectively	O
50	).	O

1	This	O
2	sequence	O
3	possessed	O
4	homology	O
5	with	O
6	a	O
7	methylation	O
8	-	O
9	sensitive	O
10	promoter	O
11	element	O
12	,	O
13	Enh2	O
14	,	O
15	present	O
16	in	O
17	the	O
18	LTR	O
19	of	O
20	mouse	O
21	intractisternal	O
22	A	O
23	-	O
24	particles	O
25	.	O

1	The	O
2	p73pct1	B
3	/	O
4	p85cdc10	B
5	complex	I
6	binds	O
7	both	O
8	in	O
9	vitro	O
10	and	O
11	in	O
12	vivo	O
13	to	O
14	MCB	O
15	but	O
16	not	O
17	SCB	O
18	or	O
19	E2F	B
20	sites	I
21	.	O

1	Strikingly	O
2	,	O
3	these	O
4	cells	O
5	contain	O
6	a	O
7	missense	O
8	mutation	O
9	of	O
10	the	O
11	p53	B
12	gene	I
13	at	O
14	codon	O
15	242	O
16	(	O
17	p53	B
18	(	O
19	242	O
20	)),	O
21	which	O
22	substitutes	O
23	alanine	O
24	for	O
25	glycine	O
26	.	O

1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	B
18	-	I
19	finger	I
20	transcription	I
21	factor	I
22	NGFI	I
23	-	I
24	C	I
25	.	O

1	The	O
2	effects	O
3	of	O
4	coenzyme	O
5	Q10	O
6	(	O
7	CoQ	O
8	)	O
9	and	O
10	captopril	O
11	on	O
12	functional	O
13	capacity	O
14	,	O
15	hemodynamics	O
16	and	O
17	survival	O
18	were	O
19	studied	O
20	in	O
21	154	O
22	rats	O
23	that	O
24	recovered	O
25	after	O
26	experimental	O
27	myocardial	O
28	infarction	O
29	.	O

1	The	O
2	subunit	O
3	protein	O
4	of	O
5	curli	O
6	was	O
7	highly	O
8	homologous	O
9	at	O
10	its	O
11	amino	O
12	terminus	O
13	to	O
14	SEF	B
15	-	I
16	17	I
17	,	O
18	the	O
19	subunit	O
20	protein	O
21	of	O
22	thin	O
23	,	O
24	aggregative	O
25	fimbriae	O
26	of	O
27	Salmonella	O
28	enteritidis	O
29	27655	O
30	strain	O
31	3b	O
32	,	O
33	suggesting	O
34	that	O
35	these	O
36	fibres	O
37	form	O
38	a	O
39	novel	O
40	class	O
41	of	O
42	surface	O
43	organelles	O
44	on	O
45	enterobacteria	O
46	.	O

1	The	O
2	location	O
3	of	O
4	multiple	O
5	GRK2	B
6	and	O
7	GRK5	B
8	phosphoacceptor	I
9	sites	I
10	at	O
11	the	O
12	extreme	O
13	carboxyl	O
14	terminus	O
15	of	O
16	the	O
17	beta2AR	B
18	is	O
19	highly	O
20	reminiscent	O
21	of	O
22	GRK1	B
23	-	O
24	mediated	O
25	phosphorylation	O
26	of	O
27	rhodopsin	B
28	.	O

1	We	O
2	conclude	O
3	that	O
4	cAMP	O
5	,	O
6	acting	O
7	through	O
8	PKA	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	regulator	O
14	of	O
15	basal	O
16	CFTR	B
17	gene	I
18	expression	O
19	and	O
20	may	O
21	mediate	O
22	an	O
23	induction	O
24	of	O
25	CFTR	B
26	in	O
27	responsive	O
28	cell	O
29	types	O
30	.	O

1	Sputum	B
2	IL	I
3	-	I
4	8	I
5	and	O
6	MPO	B
7	were	O
8	significantly	O
9	increased	O
10	after	O
11	BPT	O
12	in	O
13	both	O
14	TDI	O
15	-	O
16	and	O
17	grain	O
18	dust	O
19	-	O
20	asthma	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	The	O
2	C	O
3	-	O
4	LIP	O
5	also	O
6	was	O
7	compared	O
8	with	O
9	transcather	O
10	arterial	O
11	embolization	O
12	(	O
13	TAE	O
14	;	O
15	C	O
16	-	O
17	LIP	O
18	followed	O
19	by	O
20	gelatin	B
21	sponge	O
22	)	O
23	and	O
24	percutaneous	O
25	ethanol	O
26	injection	O
27	therapy	O
28	(	O
29	PEIT	O
30	).	O

1	Laboratory	O
2	evaluation	O
3	was	O
4	normal	O
5	,	O
6	and	O
7	neuroimaging	O
8	failed	O
9	to	O
10	confirm	O
11	obstruction	O
12	of	O
13	venous	O
14	or	O
15	lymphatic	O
16	drainage	O
17	.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	pecT	O
5	regulatory	O
6	region	O
7	revealed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	sites	O
13	in	O
14	which	O
15	insertions	O
16	reproduced	O
17	the	O
18	pec	B
19	-	I
20	1	I
21	phenotype	O
22	.	O

1	RESULTS	O
2	:	O
3	At	O
4	the	O
5	beginning	O
6	of	O
7	the	O
8	QA	B
9	/	O
10	QI	O
11	process	O
12	,	O
13	monitoring	O
14	of	O
15	blood	O
16	administration	O
17	practices	O
18	revealed	O
19	that	O
20	a	O
21	variance	O
22	from	O
23	institutional	O
24	blood	O
25	administration	O
26	policy	O
27	occurred	O
28	during	O
29	50	O
30	percent	O
31	of	O
32	blood	O
33	and	O
34	component	O
35	transfusions	O
36	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	previously	O
6	identified	O
7	and	O
8	characterized	O
9	attenuator	O
10	1	O
11	situated	O
12	93	O
13	nucleotides	O
14	downstream	O
15	from	O
16	the	O
17	major	O
18	late	O
19	transcription	O
20	start	O
21	site	O
22	,	O
23	a	O
24	second	O
25	attenuator	O
26	,	O
27	attenuator	O
28	2	O
29	,	O
30	situated	O
31	55	O
32	nucleotides	O
33	downstream	O
34	from	O
35	it	O
36	,	O
37	has	O
38	been	O
39	identified	O
40	.	O

1	DMCM	O
2	also	O
3	permits	O
4	extension	O
5	of	O
6	the	O
7	possibilities	O
8	of	O
9	obtaining	O
10	and	O
11	transplanting	O
12	donor	O
13	organs	O
14	.	O

1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	O
8	provides	O
9	an	O
10	easy	O
11	and	O
12	accurate	O
13	P0	O
14	.	O
15	1	O
16	measurement	O
17	using	O
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O

1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	alpha	I
5	,	O
6	the	O
7	cytokine	O
8	that	O
9	participates	O
10	in	O
11	the	O
12	autocrine	O
13	growth	O
14	control	O
15	of	O
16	hairy	O
17	cell	O
18	leukemia	O
19	has	O
20	strong	O
21	bone	O
22	resorptive	O
23	properties	O
24	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	megabase	B
6	region	I
7	surrounding	O
8	the	O
9	dagA	B
10	locus	I
11	was	O
12	mapped	O
13	.	O

1	Sixty	O
2	-	O
3	nine	O
4	(	O
5	44	O
6	%)	O
7	patients	O
8	were	O
9	administered	O
10	250	O
11	MBq	O
12	(	O
13	7	O
14	mCi	O
15	)	O
16	99Tcm	B
17	-	I
18	tetrofosmin	I
19	at	O
20	rest	O
21	followed	O
22	4	O
23	h	O
24	later	O
25	by	O
26	750	O
27	MBq	O
28	(	O
29	21	O
30	mCi	O
31	)	O
32	during	O
33	stress	O
34	(	O
35	the	O
36	1	O
37	day	O
38	protocol	O
39	),	O
40	whereas	O
41	88	O
42	(	O
43	56	O
44	%)	O
45	patients	O
46	had	O
47	rest	O
48	and	O
49	stress	O
50	imaging	O
51	studies	O
52	on	O
53	two	O
54	separate	O
55	days	O
56	,	O
57	receiving	O
58	a	O
59	500	O
60	MBq	O
61	(	O
62	14	O
63	mCi	O
64	)	O
65	dose	O
66	of	O
67	99Tcm	B
68	-	I
69	tetrofosmin	I
70	on	O
71	each	O
72	occasion	O
73	(	O
74	the	O
75	2	O
76	day	O
77	protocol	O
78	).	O

1	Muscle	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	For	O
2	85Sr	O
3	,	O
4	larger	O
5	-	O
6	than	O
7	-	O
8	expected	O
9	distribution	O
10	coefficients	O
11	were	O
12	obtained	O
13	in	O
14	the	O
15	desorption	O
16	experiments	O
17	,	O
18	an	O
19	indication	O
20	of	O
21	the	O
22	irreversible	O
23	formation	O
24	of	O
25	metal	O
26	-	O
27	oxyhydroxides	O
28	during	O
29	a	O
30	slow	O
31	reaction	O
32	.	O

1	In	O
2	the	O
3	latter	O
4	category	O
5	particular	O
6	emphasis	O
7	is	O
8	being	O
9	placed	O
10	on	O
11	new	O
12	anthracycline	O
13	analogues	O
14	of	O
15	doxorubicin	O
16	and	O
17	analogues	O
18	of	O
19	cisplatinum	O
20	diammine	O
21	dichloride	O
22	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	O
6	-	O
7	PA	O
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	O
14	cyclooxygenase	O
15	product	O
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	B
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O

1	Pet	O
2	-	O
3	1	O
4	can	O
5	bind	O
6	specifically	O
7	to	O
8	a	O
9	PEA3	B
10	ETS	I
11	DNA	I
12	-	I
13	binding	I
14	motif	I
15	and	O
16	can	O
17	modulate	O
18	transcription	O
19	of	O
20	synthetic	O
21	promoter	O
22	constructs	O
23	in	O
24	a	O
25	sequence	O
26	-	O
27	specific	O
28	manner	O
29	.	O

1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O

1	Sustained	O
2	activation	O
3	of	O
4	p21	B
5	expression	O
6	is	O
7	proposed	O
8	to	O
9	be	O
10	a	O
11	distinguishing	O
12	feature	O
13	of	O
14	the	O
15	activity	O
16	of	O
17	NGF	B
18	that	O
19	contributes	O
20	to	O
21	PC12	O
22	growth	O
23	arrest	O
24	during	O
25	differentiation	O

1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	O
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O

1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O

1	We	O
2	have	O
3	earlier	O
4	evolved	O
5	an	O
6	experimental	O
7	model	O
8	by	O
9	means	O
10	of	O
11	which	O
12	changes	O
13	identical	O
14	to	O
15	the	O
16	microembolism	O
17	syndrome	O
18	can	O
19	be	O
20	induced	O
21	from	O
22	a	O
23	reproducible	O
24	musculo	O
25	-	O
26	skeletal	O
27	trauma	O
28	in	O
29	pigs	O
30	observed	O
31	under	O
32	long	O
33	-	O
34	term	O
35	anesthesia	O
36	under	O
37	standardized	O
38	conditions	O
39	.	O

1	Regulation	O
2	of	O
3	embryonic	O
4	growth	O
5	and	O
6	lysosomal	O
7	targeting	O
8	by	O
9	the	O
10	imprinted	O
11	Igf2	B
12	/	O
13	Mpr	B
14	gene	I
15	.	O

1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O

1	Conservation	O
2	of	O
3	function	O
4	of	O
5	Drosophila	O
6	melanogaster	O
7	abl	B
8	and	I
9	murine	I
10	v	I
11	-	I
12	abl	I
13	proteins	I
14	in	O
15	transformation	O
16	of	O
17	mammalian	O
18	cells	O
19	.	O

1	The	O
2	1	O
3	.	O
4	7	O
5	kb	O
6	cloned	O
7	fragment	O
8	was	O
9	sequenced	O
10	and	O
11	shown	O
12	to	O
13	contain	O
14	the	O
15	entire	O
16	fliA	B
17	gene	I
18	.	O

1	The	O
2	cwg2	B
3	-	I
4	1	I
5	mutation	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	604	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	originating	O
23	the	O
24	change	O
25	A202T	O
26	in	O
27	the	O
28	cwg2p	B
29	.	O

1	Using	O
2	mutagenesis	O
3	,	O
4	we	O
5	have	O
6	identified	O
7	two	O
8	mutations	O
9	of	O
10	the	O
11	second	O
12	actin	B
13	-	O
14	binding	O
15	domain	O
16	that	O
17	can	O
18	also	O
19	suppress	O
20	the	O
21	act1	B
22	mutations	O
23	of	O
24	interest	O
25	.	O

1	Gap1	B
2	(	O
3	IP4BP	B
4	),	O
5	one	O
6	of	O
7	a	O
8	member	O
9	of	O
10	Ras	B
11	GTPase	I
12	-	I
13	activating	I
14	proteins	I
15	,	O
16	has	O
17	been	O
18	identified	O
19	as	O
20	a	O
21	specific	O
22	inositol	O
23	1	O
24	,	O
25	3	O
26	,	O
27	4	O
28	,	O
29	5	O
30	-	O
31	tetrakisphosphate	O
32	(	O
33	IP4	B
34	)-	I
35	binding	I
36	protein	I
37	(	O
38	Cullen	O
39	,	O
40	P	O
41	.	O

1	Sensory	O
2	kindling	O
3	:	O
4	implications	O
5	for	O
6	development	O
7	of	O
8	sensory	O
9	prostheses	O
10	.	O

1	Intraperitoneal	O
2	administration	O
3	of	O
4	L	B
5	-	I
6	5	I
7	-	I
8	hydroxytryptophan	I
9	(	I
10	L	I
11	-	I
12	5	I
13	-	I
14	HTP	I
15	)	O
16	at	O
17	doses	O
18	of	O
19	25	O
20	to	O
21	100	O
22	mg	O
23	/	O
24	kg	O
25	dramatically	O
26	increase	O
27	defecation	O
28	in	O
29	mice	O
30	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	If	O
2	this	O
3	is	O
4	unavailable	O
5	,	O
6	then	O
7	Supramid	O
8	has	O
9	a	O
10	proven	O
11	record	O
12	for	O
13	good	O
14	tissue	O
15	compatibility	O
16	and	O
17	resistance	O
18	to	O
19	infection	O
20	.	O

1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	O
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	O
30	16	O
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	isolated	O
6	from	O
7	a	O
8	chicken	O
9	embryo	O
10	cDNA	O
11	library	O
12	employing	O
13	a	O
14	PCR	O
15	-	O
16	generated	O
17	radiolabeled	O
18	probe	O
19	specific	O
20	for	O
21	the	O
22	U3	O
23	region	O
24	of	O
25	the	O
26	Rous	B
27	sarcoma	I
28	virus	I
29	LTR	I
30	.	O

1	Transcription	O
2	readthrough	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O

1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	TRH	B
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	permitted	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	thyrotropin	O
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	discriminating	O
42	.	O

1	Mature	O
2	mRNA	O
3	for	O
4	cytosolic	O
5	phosphoenolpyruvate	B
6	carboxykinase	I
7	of	O
8	the	O
9	chicken	O
10	is	O
11	2	O
12	.	O
13	8	O
14	kilobases	O
15	in	O
16	length	O
17	,	O
18	similar	O
19	to	O
20	that	O
21	previously	O
22	noted	O
23	for	O
24	mRNA	O
25	coding	O
26	for	O
27	the	O
28	same	O
29	enzyme	O
30	in	O
31	the	O
32	rat	O
33	.	O

1	Concordance	O
2	of	O
3	IBDQ	O
4	scores	O
5	was	O
6	tested	O
7	in	O
8	280	O
9	stable	O
10	subjects	O
11	.	O

1	Three	O
2	high	O
3	mobility	O
4	group	O
5	-	O
6	like	O
7	sequences	O
8	within	O
9	a	O
10	48	O
11	-	O
12	base	O
13	pair	O
14	enhancer	O
15	of	O
16	the	O
17	Col2a1	B
18	gene	I
19	are	O
20	required	O
21	for	O
22	cartilage	O
23	-	O
24	specific	O
25	expression	O
26	in	O
27	vivo	O
28	.	O

1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	437	O
12	amino	O
13	acids	O
14	of	O
15	IE1	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O

1	Thirty	O
2	of	O
3	the	O
4	clones	O
5	contained	O
6	a	O
7	complete	O
8	340	O
9	base	O
10	-	O
11	pair	O
12	dimer	O
13	unit	O
14	of	O
15	the	O
16	repeat	O
17	.	O

1	One	O
2	linker	O
3	-	O
4	peptide	O
5	insertion	O
6	in	O
7	the	O
8	RsaA	B
9	C	I
10	terminus	I
11	(	O
12	amino	O
13	acid	O
14	784	O
15	)	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	S	O
21	-	O
22	layer	O
23	biogenesis	O
24	,	O
25	while	O
26	another	O
27	(	O
28	amino	O
29	acid	O
30	907	O
31	)	O
32	disrupted	O
33	secretion	O
34	of	O
35	the	O
36	protein	O
37	,	O
38	suggesting	O
39	that	O
40	RsaA	B
41	possesses	O
42	a	O
43	secretion	O
44	signal	O
45	lying	O
46	C	O
47	terminal	O
48	to	O
49	amino	O
50	acid	O
51	784	O
52	,	O
53	near	O
54	or	O
55	including	O
56	amino	O
57	acid	O
58	907	O
59	.	O

1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	I
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O

1	Penicillin	B
2	acylase	I
3	(	I
4	PA	I
5	)	I
6	from	I
7	Escherichia	I
8	coli	I
9	ATCC11105	I
10	is	O
11	a	O
12	periplasmic	O
13	heterodimer	O
14	consisting	O
15	of	O
16	a	O
17	24	O
18	kDa	O
19	small	O
20	subunit	O
21	and	O
22	a	O
23	65	O
24	kDa	O
25	large	O
26	subunit	O
27	.	O

1	N	O
2	.	O
3	van	O
4	Hoek	O
5	,	O
6	and	O
7	M	O
8	.	O

1	This	O
2	region	O
3	includes	O
4	verA	O
5	,	O
6	a	O
7	structural	O
8	gene	O
9	previously	O
10	shown	O
11	to	O
12	be	O
13	required	O
14	for	O
15	ST	O
16	biosynthesis	O
17	,	O
18	and	O
19	24	O
20	additional	O
21	closely	O
22	spaced	O
23	transcripts	O
24	ranging	O
25	in	O
26	size	O
27	from	O
28	0	O
29	.	O
30	6	O
31	to	O
32	7	O
33	.	O
34	2	O
35	kb	O
36	that	O
37	are	O
38	coordinately	O
39	induced	O
40	only	O
41	under	O
42	ST	O
43	-	O
44	producing	O
45	conditions	O
46	.	O

1	Feed	O
2	intake	O
3	and	O
4	BW	O
5	gains	O
6	were	O
7	decreased	O
8	(	O
9	P	O
10	<	O
11	0	O
12	.	O
13	05	O
14	)	O
15	by	O
16	dietary	O
17	treatments	O
18	containing	O
19	M	O
20	.	O

1	Carbon	O
2	catabolite	O
3	repression	O
4	of	O
5	the	O
6	gnt	B
7	operon	I
8	of	I
9	Bacillus	I
10	subtilis	I
11	is	O
12	mediated	O
13	by	O
14	the	O
15	catabolite	B
16	control	I
17	protein	I
18	CcpA	I
19	and	O
20	by	O
21	HPr	B
22	,	O
23	a	O
24	phosphocarrier	O
25	protein	O
26	of	O
27	the	O
28	phosphotransferase	O
29	system	O
30	.	O

1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	I
6	digestion	O
7	of	O
8	finP305	B
9	RNA	I
10	differed	O
11	from	O
12	FinP	O
13	,	O
14	and	O
15	GST	B
16	-	O
17	FinO	O
18	did	O
19	not	O
20	protect	O
21	finP305	O
22	RNA	O
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O

1	Genomic	O
2	and	O
3	cDNA	O
4	clones	O
5	homologous	O
6	to	O
7	the	O
8	yeast	O
9	GCN2	B
10	eIF	I
11	-	I
12	2alpha	I
13	kinase	I
14	(	O
15	yGCN2	B
16	)	O
17	were	O
18	isolated	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	.	O

1	Functional	O
2	postnatal	O
3	development	O
4	of	O
5	the	O
6	rat	O
7	primary	O
8	visual	O
9	cortex	O
10	and	O
11	the	O
12	role	O
13	of	O
14	visual	O
15	experience	O
16	:	O
17	dark	O
18	rearing	O
19	and	O
20	monocular	O
21	deprivation	O
22	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	B
17	domain	I
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	B
27	genes	I
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O

1	This	O
2	study	O
3	demonstrated	O
4	that	O
5	the	O
6	PFA	O
7	-	O
8	100	O
9	analyzer	O
10	can	O
11	accurately	O
12	assess	O
13	vWF	B
14	-	O
15	dependent	O
16	platelet	O
17	function	O
18	and	O
19	detect	O
20	other	O
21	platelet	O
22	defects	O
23	under	O
24	high	O
25	shear	O
26	stress	O
27	in	O
28	complex	O
29	patient	O
30	populations	O
31	.	O

1	In	O
2	1990	O
3	,	O
4	an	O
5	International	O
6	Commission	O
7	for	O
8	the	O
9	Certification	O
10	of	O
11	Eradication	O
12	of	O
13	Poliomyelitis	O
14	Eradication	O
15	(	O
16	ICCPE	O
17	)	O
18	was	O
19	established	O
20	by	O
21	the	O
22	Pan	O
23	American	O
24	Health	O
25	Organization	O
26	to	O
27	eventually	O
28	determine	O
29	if	O
30	transmission	O
31	was	O
32	interrupted	O
33	.	O

1	Electroglottography	O
2	is	O
3	a	O
4	useful	O
5	,	O
6	non	O
7	-	O
8	invasive	O
9	technique	O
10	that	O
11	can	O
12	assist	O
13	in	O
14	the	O
15	assessment	O
16	of	O
17	vocal	O
18	fold	O
19	dysfunction	O
20	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	possibility	O
6	by	O
7	constructing	O
8	a	O
9	consecutive	O
10	series	O
11	of	O
12	cysteine	O
13	substitutions	O
14	in	O
15	the	O
16	Neu	B
17	juxtamembrane	I
18	domain	I
19	in	O
20	order	O
21	to	O
22	force	O
23	dimerization	O
24	along	O
25	a	O
26	series	O
27	of	O
28	interreceptor	O
29	faces	O
30	.	O

1	Forty	O
2	-	O
3	eight	O
4	10	O
5	-	O
6	12	O
7	-	O
8	week	O
9	-	O
10	old	O
11	male	O
12	Sprague	O
13	-	O
14	Dawley	O
15	rats	O
16	were	O
17	randomized	O
18	to	O
19	receive	O
20	,	O
21	daily	O
22	for	O
23	28	O
24	days	O
25	:	O
26	(	O
27	1	O
28	)	O
29	CsA	O
30	vehicle	O
31	p	O
32	.	O
33	o	O
34	.	O
35	plus	O
36	FB	O
37	vehicle	O
38	sc	O
39	;	O
40	(	O
41	2	O
42	)	O
43	CsA	O
44	(	O
45	15	O
46	mg	O
47	/	O
48	kg	O
49	)	O
50	p	O
51	.	O
52	o	O
53	.	O
54	plus	O
55	FB	O
56	vehicle	O
57	sc	O
58	,	O
59	(	O
60	3	O
61	)	O
62	CsA	O
63	vehicle	O
64	p	O
65	.	O
66	o	O
67	.	O
68	plus	O
69	FB	O
70	(	O
71	1	O
72	.	O
73	5	O
74	mg	O
75	/	O
76	kg	O
77	)	O
78	sc	O
79	;	O
80	and	O
81	(	O
82	4	O
83	)	O
84	CsA	O
85	(	O
86	15	O
87	mg	O
88	/	O
89	kg	O
90	)	O
91	p	O
92	.	O
93	o	O
94	.	O
95	plus	O
96	FB	O
97	(	O
98	1	O
99	.	O
100	5	O
101	mg	O
102	/	O
103	kg	O
104	)	O
105	sc	O
106	.	O

1	We	O
2	detected	O
3	no	O
4	effect	O
5	of	O
6	deleting	O
7	YCL024W	O
8	,	O
9	either	O
10	alone	O
11	or	O
12	in	O
13	combination	O
14	with	O
15	deletion	O
16	of	O
17	GIN4	B
18	.	O

1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O

1	Femoral	O
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	O
14	porous	O
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	Potential	O
2	translational	O
3	start	O
4	signals	O
5	are	O
6	upstream	O
7	of	O
8	ORF1	O
9	and	O
10	ORF2	O
11	.	O

1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	O
16	/	O
17	B	B
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O

1	Epidemiological	O
2	data	O
3	are	O
4	quite	O
5	controversial	O
6	but	O
7	sudden	O
8	death	O
9	occurring	O
10	during	O
11	sporting	O
12	activity	O
13	is	O
14	probably	O
15	not	O
16	a	O
17	rare	O
18	occurrence	O
19	.	O

1	Substrate	O
2	specificity	O
3	of	O
4	the	O
5	RNase	B
6	activity	O
7	of	O
8	yeast	B
9	RNA	I
10	polymerase	I
11	III	I
12	.	O

1	One	O
2	patients	O
3	had	O
4	plasma	O
5	C	O
6	-	O
7	peptide	O
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O

1	During	O
2	chronic	O
3	treatment	O
4	,	O
5	when	O
6	plasma	O
7	concentrations	O
8	fluctuated	O
9	between	O
10	23	O
11	.	O
12	5	O
13	ng	O
14	.	O
15	ml	O
16	-	O
17	1	O
18	at	O
19	8	O
20	h	O
21	and	O
22	14	O
23	ng	O
24	.	O
25	ml	O
26	-	O
27	1	O
28	at	O
29	24	O
30	h	O
31	post	O
32	-	O
33	dosing	O
34	,	O
35	ST	O
36	segment	O
37	depression	O
38	at	O
39	an	O
40	individually	O
41	comparable	O
42	workload	O
43	was	O
44	significantly	O
45	decreased	O
46	by	O
47	28	O
48	%	O
49	compared	O
50	with	O
51	placebo	O
52	(	O
53	P	O
54	<	O
55	0	O
56	.	O
57	005	O
58	)	O
59	at	O
60	both	O
61	points	O
62	in	O
63	time	O
64	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	The	O
2	available	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	NF	B
8	kappa	I
9	B2	I
10	nucleoprotein	I
11	complex	I
12	may	O
13	cooperate	O
14	with	O
15	DNA	O
16	-	O
17	bound	O
18	STAT6	B
19	to	O
20	achieve	O
21	IL	B
22	-	I
23	4	I
24	-	O
25	dependent	O
26	activation	O
27	of	O
28	the	O
29	human	B
30	IgE	I
31	germline	I
32	gene	I
33	.	O

1	These	O
2	indications	O
3	of	O
4	deregulated	O
5	signalling	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	tyrosine	O
11	118	O
12	were	O
13	substantiated	O
14	by	O
15	sustained	O
16	activation	O
17	of	O
18	STAT3	B
19	.	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O

1	However	O
2	,	O
3	mean	O
4	food	O
5	intake	O
6	in	O
7	the	O
8	40	O
9	%	O
10	group	O
11	was	O
12	half	O
13	that	O
14	of	O
15	the	O
16	ACT	O
17	group	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	001	O
24	)	O
25	and	O
26	significantly	O
27	less	O
28	(	O
29	p	O
30	<	O
31	0	O
32	.	O
33	01	O
34	)	O
35	than	O
36	the	O
37	SEP	O
38	group	O
39	,	O
40	which	O
41	consumed	O
42	amounts	O
43	equivalent	O
44	to	O
45	65	O
46	%	O
47	of	O
48	daily	O
49	requirement	O
50	.	O

1	Formation	O
2	of	O
3	hyphae	O
4	and	O
5	chlamydospores	O
6	by	O
7	Cryptococcus	O
8	laurentii	O
9	.	O

1	SSG1	B
2	,	O
3	a	O
4	gene	O
5	encoding	O
6	a	O
7	sporulation	O
8	-	O
9	specific	O
10	1	O
11	,	O
12	3	B
13	-	I
14	beta	I
15	-	I
16	glucanase	I
17	in	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	Nonvascular	O
2	ophthalmic	O
3	and	O
4	neurologic	O
5	disorders	O
6	that	O
7	can	O
8	be	O
9	confused	O
10	with	O
11	amaurosis	O
12	fugax	O
13	are	O
14	listed	O
15	,	O
16	and	O
17	an	O
18	algorithm	O
19	for	O
20	evaluation	O
21	(	O
22	which	O
23	includes	O
24	ophthalmic	O
25	examination	O
26	,	O
27	laboratory	O
28	studies	O
29	,	O
30	and	O
31	noninvasive	O
32	carotid	O
33	artery	O
34	studies	O
35	)	O
36	is	O
37	given	O
38	.	O

1	Altogether	O
2	these	O
3	results	O
4	indicate	O
5	that	O
6	the	O
7	Syn	B
8	5	I
9	locus	I
10	segregates	O
11	from	O
12	the	O
13	gene	O
14	specifying	O
15	gH	B
16	,	O
17	to	O
18	a	O
19	region	O
20	encompassing	O
21	portions	O
22	of	O
23	the	O
24	TK	B
25	and	O
26	UL	O
27	24	O
28	genes	O
29	,	O
30	and	O
31	that	O
32	the	O
33	syn	B
34	mutation	I
35	does	O
36	not	O
37	affect	O
38	the	O
39	expression	O
40	or	O
41	activity	O
42	of	O
43	TK	B
44	.	O

1	We	O
2	conducted	O
3	a	O
4	prospective	O
5	,	O
6	randomized	O
7	controlled	O
8	trial	O
9	of	O
10	metoprolol	O
11	,	O
12	a	O
13	selective	O
14	beta	O
15	-	O
16	blocker	O
17	for	O
18	prevention	O
19	of	O
20	gastrointestinal	O
21	bleeding	O
22	from	O
23	portal	O
24	hypertension	O
25	in	O
26	29	O
27	non	O
28	-	O
29	selected	O
30	patients	O
31	with	O
32	liver	O
33	disease	O
34	and	O
35	previous	O
36	gastrointestinal	O
37	bleeding	O
38	.	O

1	A	O
2	one	O
3	-	O
4	week	O
5	ulcer	O
6	therapy	O
7	with	O
8	atropine	O
9	and	O
10	Vikalin	B
11	(	O
12	Roter	O
13	)	O
14	led	O
15	to	O
16	a	O
17	significant	O
18	(	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	01	O
25	)	O
26	reduction	O
27	of	O
28	the	O
29	nocturnal	O
30	proteolytic	O
31	activity	O
32	.	O

1	Drosophila	B
2	UbcD1	I
3	encodes	O
4	a	O
5	highly	O
6	conserved	O
7	ubiquitin	B
8	-	I
9	conjugating	I
10	enzyme	I
11	involved	O
12	in	O
13	selective	O
14	protein	O
15	degradation	O
16	.	O

1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	"	O
9	off	O
10	"	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	"	O
21	on	O
22	"	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O

1	The	O
2	results	O
3	suggested	O
4	that	O
5	,	O
6	depending	O
7	upon	O
8	the	O
9	cell	O
10	type	O
11	,	O
12	gene	O
13	cotransfer	O
14	using	O
15	aminoglycoside	O
16	resistance	O
17	as	O
18	a	O
19	selectable	O
20	marker	O
21	may	O
22	seriously	O
23	perturb	O
24	important	O
25	cellular	O
26	control	O
27	mechanisms	O
28	such	O
29	as	O
30	the	O
31	PKC	B
32	pathway	O
33	leading	O
34	to	O
35	activation	O
36	of	O
37	gene	O
38	expression	O
39	.	O

1	Another	O
2	segment	O
3	of	O
4	CRL3	O
5	(-	O
6	296	O
7	to	O
8	-	O
9	184	O
10	),	O
11	also	O
12	displaying	O
13	enhancer	O
14	function	O
15	,	O
16	contained	O
17	tandem	O
18	repeated	O
19	sequences	O
20	(	O
21	DR	B
22	-	I
23	A1	I
24	and	I
25	DR	I
26	-	I
27	A2	I
28	).	O

1	High	O
2	-	O
3	level	O
4	expression	O
5	in	O
6	Escherichia	O
7	coli	O
8	of	O
9	selenocysteine	O
10	-	O
11	containing	O
12	rat	B
13	thioredoxin	I
14	reductase	I
15	utilizing	I
16	gene	I
17	fusions	O
18	with	O
19	engineered	O
20	bacterial	O
21	-	O
22	type	O
23	SECIS	O
24	elements	O
25	and	O
26	co	O
27	-	O
28	expression	O
29	with	O
30	the	O
31	selA	B
32	,	O
33	selB	B
34	and	O
35	selC	B
36	genes	I
37	.	O

1	Therapeutic	O
2	action	O
3	of	O
4	a	O
5	new	O
6	antibiotic	O
7	-	O
8	corticoid	O
9	association	O
10	used	O
11	for	O
12	instillations	O
13	in	O
14	otology	O

1	Patients	O
2	with	O
3	low	O
4	probability	O
5	of	O
6	having	O
7	aluminum	O
8	overload	O
9	(	O
10	serum	O
11	iron	O
12	levels	O
13	<	O
14	40	O
15	micrograms	O
16	/	O
17	L	O
18	and	O
19	DAI	O
20	<	O
21	150	O
22	micrograms	O
23	/	O
24	L	O
25	)	O
26	had	O
27	significantly	O
28	higher	O
29	values	O
30	of	O
31	serum	O
32	iron	O
33	,	O
34	iron	O
35	transferrin	B
36	saturation	O
37	,	O
38	and	O
39	serum	O
40	ferritin	B
41	levels	O
42	compared	O
43	with	O
44	those	O
45	patients	O
46	with	O
47	a	O
48	high	O
49	probability	O
50	of	O
51	having	O
52	aluminum	O
53	overload	O
54	(	O
55	serum	O
56	aluminum	O
57	levels	O
58	>	O
59	40	O
60	micrograms	O
61	/	O
62	L	O
63	and	O
64	DAI	B
65	>	O
66	150	O
67	micrograms	O
68	/	O
69	L	O
70	).	O

1	CD3	B
2	cross	O
3	-	O
4	linking	O
5	induced	O
6	tyrosine	O
7	phosphorylation	O
8	of	O
9	Sam68	B
10	in	O
11	uninfected	O
12	T	O
13	cells	O
14	.	O

1	About	O
2	20	O
3	%	O
4	of	O
5	single	O
6	-	O
7	stranded	O
8	DNA	O
9	binding	O
10	was	O
11	observed	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	MgdTDP	O
17	,	O
18	but	O
19	none	O
20	was	O
21	detectable	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	nucleotides	O
27	.	O

1	All	O
2	patients	O
3	had	O
4	elevated	O
5	levels	O
6	of	O
7	serum	B
8	IgE	I
9	antibodies	I
10	to	O
11	the	O
12	crude	O
13	soybean	O
14	extract	O
15	;	O
16	binding	O
17	values	O
18	ranged	O
19	from	O
20	2	O
21	.	O
22	3	O
23	to	O
24	28	O
25	.	O
26	1	O
27	times	O
28	that	O
29	of	O
30	a	O
31	negative	O
32	control	O
33	serum	O
34	.	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	although	O
6	PI2	O
7	and	O
8	PI3	O
9	viruses	O
10	belong	O
11	to	O
12	the	O
13	same	O
14	parainfluenza	O
15	virus	O
16	genus	O
17	,	O
18	these	O
19	viruses	O
20	show	O
21	marked	O
22	differences	O
23	with	O
24	respect	O
25	to	O
26	functional	O
27	requirements	O
28	for	O
29	the	O
30	cytoplasmic	O
31	tail	O
32	of	O
33	the	O
34	F	O
35	glycoprotein	O
36	.	O

1	Intensive	O
2	synthesis	O
3	of	O
4	PNA	O
5	in	O
6	the	O
7	cells	O
8	of	O
9	microvascular	O
10	wall	O
11	evidenced	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	.--	O
35	for	O
36	growth	O
37	.	O

1	Intravesical	O
2	chemotherapy	O
3	.	O

1	Mo	O
2	+	O
3	SV	O
4	M	O
5	-	O
6	MuLV	O
7	-	O
8	inoculated	O
9	animals	O
10	became	O
11	moribund	O
12	at	O
13	3	O
14	to	O
15	13	O
16	months	O
17	postinoculation	O
18	,	O
19	whereas	O
20	delta	O
21	Mo	O
22	+	O
23	SV	O
24	M	O
25	-	O
26	MuLV	O
27	-	O
28	inoculated	O
29	animals	O
30	became	O
31	moribund	O
32	at	O
33	6	O
34	to	O
35	24	O
36	months	O
37	postinoculation	O
38	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	to	O
8	occur	O
9	66	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	initiating	O
15	Met	O
16	.	O

1	Temperature	O
2	-	O
3	shift	O
4	experiments	O
5	using	O
6	synchronously	O
7	grown	O
8	cells	O
9	of	O
10	a	O
11	delta	O
12	top1	O
13	top2	O
14	temperature	O
15	-	O
16	sensitive	O
17	(	O
18	ts	O
19	)	O
20	double	O
21	mutant	O
22	and	O
23	its	O
24	isogenic	O
25	top2	B
26	ts	I
27	strain	I
28	show	O
29	that	O
30	,	O
31	whereas	O
32	mitotic	O
33	blocks	O
34	can	O
35	prevent	O
36	killing	O
37	of	O
38	the	O
39	top2	B
40	ts	I
41	mutant	I
42	at	O
43	a	O
44	nonpermissive	O
45	temperature	O
46	,	O
47	the	O
48	same	O
49	treatments	O
50	are	O
51	ineffective	O
52	in	O
53	preventing	O
54	cell	O
55	death	O
56	of	O
57	the	O
58	delta	B
59	top1	I
60	top2	I
61	ts	I
62	double	I
63	mutant	I
64	.	O

1	The	O
2	glomerular	O
3	filtration	O
4	rate	O
5	and	O
6	effective	O
7	renal	O
8	plasma	O
9	flow	O
10	were	O
11	determined	O
12	by	O
13	a	O
14	standard	O
15	clearance	O
16	method	O
17	,	O
18	employing	O
19	continuous	O
20	infusion	O
21	of	O
22	inulin	B
23	and	O
24	para	O
25	-	O
26	aminohippuric	O
27	acid	O
28	.	O

1	The	O
2	minimum	O
3	and	O
4	essential	O
5	subunits	O
6	for	O
7	RNA	O
8	synthesis	O
9	have	O
10	not	O
11	yet	O
12	been	O
13	identified	O
14	.	O

1	Mastocytosis	O
2	.	O

1	Among	O
2	the	O
3	total	O
4	CDSs	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	match	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O

1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	B
17	sows	I
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O

1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	B
8	growth	I
9	factor	I
10	-	I
11	beta	I
12	member	O
13	activin	B
14	induces	O
15	the	O
16	gene	O
17	Mix	O
18	.	O
19	2	O
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	B
30	-	I
31	responsive	I
32	factor	I
33	(	O
34	ARF	B
35	).	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	the	O
8	150	O
9	-	O
10	kDa	O
11	protein	O
12	contains	O
13	an	O
14	NTP	B
15	-	I
16	binding	I
17	helicase	I
18	motif	I
19	and	O
20	the	O
21	readthrough	O
22	region	O
23	,	O
24	an	O
25	RNA	B
26	polymerase	I
27	motif	I
28	,	O
29	indicating	O
30	that	O
31	these	O
32	two	O
33	overlapping	O
34	proteins	O
35	may	O
36	form	O
37	an	O
38	RNA	O
39	replication	O
40	complex	O
41	similar	O
42	to	O
43	those	O
44	of	O
45	tobamo	O
46	-	O
47	and	O
48	tobraviruses	O
49	.	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	B
12	heavy	I
13	chain	I
14	gene	I
15	which	O
16	relies	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	selectable	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O

1	Subsets	O
2	of	O
3	patients	O
4	were	O
5	performed	O
6	according	O
7	to	O
8	the	O
9	severity	O
10	of	O
11	trauma	O
12	(	O
13	ISS	O
14	<	O
15	9	O
16	;	O
17	9	O
18	-	O
19	17	O
20	;	O
21	18	O
22	-	O
23	31	O
24	;	O
25	>	O
26	32	O
27	),	O
28	based	O
29	on	O
30	the	O
31	different	O
32	injury	O
33	pattern	O
34	,	O
35	and	O
36	survivors	O
37	versus	O
38	nonsurvivors	O
39	as	O
40	well	O
41	.	O

1	This	O
2	paper	O
3	describes	O
4	the	O
5	advantages	O
6	and	O
7	limitations	O
8	of	O
9	the	O
10	main	O
11	study	O
12	approaches	O
13	used	O
14	.	O

1	Recombinant	O
2	unr	O
3	acts	O
4	synergistically	O
5	with	O
6	recombinant	O
7	PTB	O
8	to	O
9	stimulate	O
10	translation	O
11	dependent	O
12	on	O
13	the	O
14	rhinovirus	O
15	IRES	O
16	.	O

1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	PKA	B
2	phosphorylated	O
3	WT1	B
4	at	O
5	Ser	O
6	-	O
7	365	O
8	and	O
9	Ser	O
10	-	O
11	393	O
12	in	O
13	vitro	O
14	,	O
15	as	O
16	well	O
17	as	O
18	at	O
19	additional	O
20	sites	O
21	,	O
22	and	O
23	this	O
24	phosphorylation	O
25	abolished	O
26	the	O
27	DNA	O
28	-	O
29	binding	O
30	activity	O
31	of	O
32	WT1	B
33	in	O
34	vitro	O
35	.	O

1	The	O
2	tryptase	B
3	locus	I
4	also	O
5	contains	O
6	at	O
7	least	O
8	four	O
9	tryptase	B
10	-	I
11	like	I
12	pseudogenes	I
13	,	O
14	including	O
15	mastin	B
16	,	O
17	a	O
18	gene	O
19	expressed	O
20	in	O
21	dogs	O
22	but	O
23	not	O
24	in	O
25	humans	O
26	.	O

1	The	O
2	debate	O
3	over	O
4	electives	O
5	--	O
6	1899	O
7	.	O

1	Effect	O
2	of	O
3	bromazepam	O
4	on	O
5	growth	B
6	hormone	I
7	and	O
8	prolactin	B
9	secretion	O
10	in	O
11	normal	O
12	subjects	O
13	.	O

1	Sequencing	O
2	of	O
3	the	O
4	three	O
5	pag	B
6	-	I
7	3	I
8	alleles	I
9	showed	O
10	that	O
11	two	O
12	apparent	O
13	null	O
14	alleles	O
15	encode	O
16	a	O
17	nonsense	O
18	mutation	O
19	before	O
20	the	O
21	zinc	O
22	fingers	O
23	and	O
24	a	O
25	missense	O
26	mutation	O
27	in	O
28	the	O
29	fourth	O
30	zinc	O
31	finger	O
32	that	O
33	changes	O
34	a	O
35	coordinating	O
36	histidine	O
37	to	O
38	a	O
39	tyrosine	O
40	.	O

1	Five	O
2	of	O
3	the	O
4	patients	O
5	with	O
6	increased	O
7	L	O
8	-	O
9	L	O
10	size	O
11	had	O
12	a	O
13	normal	O
14	A	O
15	-	O
16	P	O
17	diameter	O
18	.	O

1	Novel	O
2	multigene	O
3	families	O
4	encoding	O
5	highly	O
6	repetitive	O
7	peptide	O
8	sequences	O
9	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	with	O
6	autonomic	O
7	nervous	O
8	system	O
9	activity	O
10	intact	O
11	,	O
12	carotid	O
13	chemoreceptor	O
14	reflex	O
15	activation	O
16	can	O
17	elicit	O
18	an	O
19	absolute	O
20	reflexly	O
21	mediated	O
22	reduction	O
23	in	O
24	coronary	O
25	blood	O
26	flow	O
27	in	O
28	the	O
29	normal	O
30	,	O
31	conscious	O
32	dog	O
33	,	O
34	despite	O
35	an	O
36	increase	O
37	in	O
38	arterial	O
39	pressure	O
40	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	experiments	O
6	indicate	O
7	that	O
8	at	O
9	least	O
10	two	O
11	upstream	O
12	activator	O
13	sequences	O
14	(	O
15	UAS	O
16	)	O
17	mediate	O
18	maximum	O
19	induction	O
20	by	O
21	galactose	O
22	.	O

1	To	O
2	achieve	O
3	complete	O
4	dissection	O
5	of	O
6	the	O
7	anterior	O
8	vitreous	O
9	,	O
10	we	O
11	remove	O
12	even	O
13	a	O
14	clear	O
15	lens	O
16	during	O
17	the	O
18	first	O
19	surgical	O
20	intervention	O
21	in	O
22	selected	O
23	cases	O
24	.	O

1	This	O
2	study	O
3	was	O
4	aimed	O
5	at	O
6	assessing	O
7	whether	O
8	c	O
9	-	O
10	DDP	O
11	administration	O
12	immediately	O
13	before	O
14	radiotherapy	O
15	could	O
16	increase	O
17	frequency	O
18	and	O
19	duration	O
20	of	O
21	objective	O
22	responses	O
23	,	O
24	as	O
25	well	O
26	as	O
27	survival	O
28	,	O
29	in	O
30	patients	O
31	affected	O
32	with	O
33	locally	O
34	advanced	O
35	stages	O
36	of	O
37	squamous	O
38	carcinomas	O
39	of	O
40	the	O
41	head	O
42	and	O
43	neck	O
44	.	O

1	When	O
2	cysteine	O
3	is	O
4	scanned	O
5	through	O
6	the	O
7	helices	O
8	,	O
9	characteristic	O
10	repeating	O
11	patterns	O
12	of	O
13	solvent	O
14	exposure	O
15	and	O
16	burial	O
17	are	O
18	observed	O
19	.	O

1	A	O
2	mutant	O
3	areA	O
4	product	O
5	truncated	O
6	immediately	O
7	after	O
8	the	O
9	last	O
10	residue	O
11	of	O
12	the	O
13	highly	O
14	conserved	O
15	GATA	O
16	(	O
17	DNA	O
18	-	O
19	binding	O
20	)	O
21	domain	O
22	retains	O
23	partial	O
24	function	O
25	.	O

1	Data	O
2	supported	O
3	the	O
4	brevity	O
5	of	O
6	the	O
7	WISC	B
8	-	I
9	III	I
10	short	O
11	form	O
12	and	O
13	the	O
14	criterion	O
15	-	O
16	related	O
17	validity	O
18	of	O
19	both	O
20	the	O
21	K	O
22	-	O
23	FAST	O
24	and	O
25	and	O
26	Kaufman	O
27	Short	O
28	Neuropsychological	O
29	Assessment	O
30	Procedure	O
31	(	O
32	K	O
33	-	O
34	SNAP	O
35	).	O

1	Here	O
2	we	O
3	have	O
4	determined	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	3	O
10	.	O
11	5	O
12	kb	O
13	from	O
14	the	O
15	3	O
16	'	O
17	end	O
18	of	O
19	delta	B
20	gag	I
21	to	O
22	the	O
23	3	O
24	'	O
25	end	O
26	of	O
27	molecularly	O
28	cloned	O
29	proviral	O
30	MH2	O
31	DNA	O
32	,	O
33	in	O
34	order	O
35	to	O
36	elucidate	O
37	the	O
38	genetic	O
39	structure	O
40	of	O
41	the	O
42	virus	O
43	and	O
44	to	O
45	compare	O
46	it	O
47	with	O
48	other	O
49	mht	O
50	-	O
51	and	O
52	myc	B
53	-	O
54	containing	O
55	oncogenic	O
56	viruses	O
57	as	O
58	well	O
59	as	O
60	with	O
61	the	O
62	chicken	B
63	proto	I
64	-	I
65	myc	I
66	gene	I
67	.	O

1	Transcription	O
2	of	O
3	the	O
4	gene	O
5	for	O
6	ivanolysin	B
7	O	I
8	and	O
9	expression	O
10	of	O
11	other	O
12	genes	O
13	of	O
14	the	O
15	virulence	O
16	gene	O
17	cluster	O
18	in	O
19	L	O
20	.	O
21	ivanovii	O
22	were	O
23	dependent	O
24	on	O
25	PrfA	B
26	.	O

1	STP1	B
2	is	O
3	an	O
4	unessential	O
5	yeast	O
6	gene	O
7	involved	O
8	in	O
9	the	O
10	removal	O
11	of	O
12	intervening	O
13	sequences	O
14	from	O
15	some	O
16	,	O
17	but	O
18	not	O
19	all	O
20	,	O
21	families	O
22	of	O
23	intervening	O
24	sequence	O
25	-	O
26	containing	O
27	pre	O
28	-	O
29	tRNAs	O
30	.	O

1	Thalamotomy	O
2	aiming	O
3	at	O
4	the	O
5	CM	O
6	-	O
7	Pf	O
8	complex	O
9	and	O
10	using	O
11	stereotactic	O
12	gamma	O
13	irradiation	O
14	has	O
15	been	O
16	performed	O
17	in	O
18	a	O
19	series	O
20	of	O
21	52	O
22	patients	O
23	with	O
24	severe	O
25	pain	O
26	due	O
27	to	O
28	malignancy	O
29	.	O

1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	B
8	might	O
9	target	O
10	Glc7	B
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	B
18	kinase	O
19	complex	O
20	.	O

1	Here	O
2	we	O
3	investigate	O
4	the	O
5	role	O
6	of	O
7	c	B
8	-	I
9	Cbl	I
10	in	O
11	development	O
12	and	O
13	homeostasis	O
14	in	O
15	mice	O
16	by	O
17	targeted	O
18	disruption	O
19	of	O
20	the	O
21	c	B
22	-	I
23	Cbl	I
24	locus	I
25	.	I
26	c	I
27	-	I
28	Cbl	I
29	-	O
30	deficient	O
31	mice	O
32	were	O
33	viable	O
34	,	O
35	fertile	O
36	,	O
37	and	O
38	outwardly	O
39	normal	O
40	in	O
41	appearance	O
42	.	O

1	Calcitonin	B
2	simultaneously	O
3	regulates	O
4	both	O
5	periosteal	O
6	hyperostosis	O
7	and	O
8	trabecular	O
9	osteopenia	O
10	in	O
11	the	O
12	spinal	O
13	hyperostotic	O
14	mouse	O
15	(	O
16	twy	O
17	/	O
18	twy	O
19	)	O
20	in	O
21	vivo	O
22	.	O

1	Primer	O
2	extension	O
3	and	O
4	cDNA	O
5	cloning	O
6	were	O
7	used	O
8	to	O
9	isolate	O
10	the	O
11	complete	O
12	5	O
13	'	O
14	end	O
15	of	O
16	the	O
17	Nramp1	B
18	mRNA	I
19	.	O

1	The	O
2	equivalent	O
3	of	O
4	the	O
5	third	O
6	ligand	O
7	,	O
8	H	O
9	-	O
10	87	O
11	,	O
12	is	O
13	T	O
14	-	O
15	47	O
16	in	O
17	the	O
18	PSTAIRE	O
19	sequence	O
20	motif	O
21	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	ORF113	O
6	contains	O
7	a	O
8	transmembrane	O
9	domain	O
10	.	O

1	Deletion	O
2	of	O
3	the	O
4	POR2	B
5	gene	I
6	alone	O
7	had	O
8	no	O
9	detectable	O
10	phenotype	O
11	,	O
12	while	O
13	yeasts	O
14	with	O
15	deletions	O
16	of	O
17	both	O
18	the	O
19	POR1	B
20	and	O
21	POR2	B
22	genes	I
23	were	O
24	viable	O
25	and	O
26	able	O
27	to	O
28	grow	O
29	on	O
30	glycerol	O
31	at	O
32	30	O
33	degrees	O
34	C	O
35	,	O
36	albeit	O
37	more	O
38	slowly	O
39	than	O
40	delta	O
41	por1	O
42	single	O
43	mutants	O
44	.	O

1	The	O
2	TAF	B
3	factor	I
4	appears	O
5	to	O
6	be	O
7	particularly	O
8	significant	O
9	in	O
10	OCD	O
11	.	O

1	Lck	B
2	has	O
3	been	O
4	postulated	O
5	to	O
6	dimerize	O
7	through	O
8	the	O
9	SH2	B
10	and	O
11	SH3	B
12	domains	I
13	.	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	O
7	,	O
8	attB	B
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	O
15	and	O
16	attR	B
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	B
38	gene	I
39	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	B
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	B
12	trimeric	O
13	and	O
14	dimeric	O
15	complexes	O
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	B
22	function	O
23	.	O

1	The	O
2	small	O
3	size	O
4	and	O
5	placement	O
6	of	O
7	the	O
8	mutagenesis	O
9	marker	O
10	(	O
11	the	O
12	supF	B
13	suppressor	I
14	tRNA	I
15	gene	I
16	from	I
17	Escherichia	I
18	coli	I
19	)	O
20	within	O
21	the	O
22	vector	O
23	substantially	O
24	reduced	O
25	the	O
26	frequency	O
27	of	O
28	spontaneous	O
29	mutations	O
30	normally	O
31	observed	O
32	after	O
33	transfection	O
34	of	O
35	mammalian	O
36	cells	O
37	with	O
38	plasmid	O
39	DNA	O
40	;	O
41	hence	O
42	,	O
43	UV	O
44	-	O
45	induced	O
46	mutations	O
47	were	O
48	easily	O
49	identified	O
50	above	O
51	the	O
52	spontaneous	O
53	background	O
54	.	O

1	Utilization	O
2	of	O
3	alternative	O
4	polyadenylation	O
5	signals	O
6	was	O
7	previously	O
8	shown	O
9	to	O
10	generate	O
11	two	O
12	sialophorin	B
13	mRNAs	I
14	of	O
15	1	O
16	.	O
17	9	O
18	and	O
19	4	O
20	.	O
21	3	O
22	kb	O
23	,	O
24	which	O
25	differ	O
26	in	O
27	the	O
28	length	O
29	of	O
30	their	O
31	3	O
32	'	O
33	untranslated	O
34	regions	O
35	.	O

1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	O
25	bodies	O
26	to	O
27	A60	B
28	antigen	I
29	.	O

1	The	O
2	harpin	B
3	-	I
4	encoding	I
5	hrpZ	I
6	gene	I
7	is	O
8	located	O
9	in	O
10	an	O
11	operon	O
12	that	O
13	also	O
14	encodes	O
15	Hrp	B
16	secretion	O
17	pathway	O
18	components	O
19	and	O
20	is	O
21	part	O
22	of	O
23	the	O
24	functional	O
25	cluster	O
26	of	O
27	hrp	B
28	genes	I
29	carried	O
30	on	O
31	cosmid	O
32	pHIR11	O
33	that	O
34	enables	O
35	saprophytic	O
36	bacteria	O
37	like	O
38	Escherichia	O
39	coli	O
40	and	O
41	Pseudomonas	O
42	fluorescens	O
43	to	O
44	elicit	O
45	the	O
46	HR	O
47	in	O
48	tobacco	O
49	leaves	O
50	.	O

1	The	O
2	pattern	O
3	and	O
4	timing	O
5	of	O
6	CARP	B
7	mRNA	I
8	expression	O
9	,	O
10	including	O
11	transient	O
12	expression	O
13	in	O
14	the	O
15	tongue	O
16	at	O
17	14	O
18	.	O
19	5	O
20	days	O
21	p	O
22	.	O
23	c	O
24	.,	O
25	coincides	O
26	with	O
27	that	O
28	of	O
29	Nkx2	B
30	.	I
31	5	I
32	/	I
33	Csx	I
34	(	O
35	a	O
36	putative	O
37	homolog	O
38	of	O
39	tinman	O
40	,	O
41	the	O
42	Drosophila	B
43	melanogaster	I
44	gene	I
45	responsible	O
46	for	O
47	cardiac	O
48	development	O
49	).	O

1	The	O
2	SSB	B
3	-	I
4	poly	I
5	(	O
6	dT	O
7	)	O
8	affinity	O
9	is	O
10	too	O
11	high	O
12	to	O
13	measure	O
14	in	O
15	buffers	O
16	containing	O
17	even	O
18	5	O
19	M	O
20	NaCl	O
21	;	O
22	however	O
23	,	O
24	in	O
25	1	O
26	.	O
27	8	O
28	-	O
29	2	O
30	.	O
31	5	O
32	M	O
33	NaBr	O
34	,	O
35	we	O
36	measure	O
37	alpha	O
38	log	O
39	Kobsd	O
40	/	O
41	alpha	O
42	log	O
43	[	O
44	NaBr	O
45	]	O
46	=	O
47	-	O
48	5	O
49	.	O
50	7	O
51	+/-	O
52	0	O
53	.	O
54	7	O
55	,	O
56	with	O
57	a	O
58	lower	O
59	value	O
60	of	O
61	omega	O
62	T	O
63	/	O
64	O	O
65	=	O
66	130	O
67	+/-	O
68	70	O
69	.	O

1	The	O
2	yeast	O
3	retrotransposon	O
4	Ty5	O
5	preferentially	O
6	integrates	O
7	into	O
8	regions	O
9	of	O
10	silent	O
11	chromatin	O
12	.	O

1	Mutational	O
2	analysis	O
3	supports	O
4	a	O
5	role	O
6	for	O
7	multiple	O
8	structural	O
9	features	O
10	in	O
11	the	O
12	C	B
13	-	I
14	terminal	I
15	secretion	I
16	signal	I
17	of	I
18	Escherichia	I
19	coli	I
20	haemolysin	I
21	.	O

1	In	O
2	the	O
3	present	O
4	experiments	O
5	,	O
6	we	O
7	investigate	O
8	the	O
9	role	O
10	played	O
11	by	O
12	the	O
13	temporal	O
14	pattern	O
15	of	O
16	neural	O
17	activity	O
18	during	O
19	the	O
20	ontogeny	O
21	of	O
22	frequency	O
23	tuning	O
24	in	O
25	the	O
26	mouse	O
27	central	O
28	auditory	O
29	system	O
30	.	O

1	We	O
2	compared	O
3	the	O
4	inhibitory	O
5	effect	O
6	of	O
7	naturally	O
8	occurring	O
9	mutant	B
10	hTR	I
11	beta	I
12	1	I
13	,	O
14	artificially	O
15	created	O
16	hTR	B
17	alpha	I
18	1	I
19	mutants	I
20	,	O
21	c	B
22	-	I
23	erbA	I
24	alpha	I
25	2	I
26	and	O
27	the	O
28	human	B
29	peroxisome	I
30	proliferator	I
31	-	I
32	activated	I
33	receptor	I
34	(	O
35	hPPAR	B
36	)	O
37	on	O
38	three	O
39	prototypic	O
40	T3	O
41	-	O
42	response	O
43	elements	O
44	(	O
45	TREs	O
46	),	O
47	TRE	B
48	-	I
49	PAL	I
50	,	I
51	DR	I
52	+	I
53	4	I
54	and	O
55	TRE	O
56	-	O
57	LAP	B
58	.	O

1	Two	O
2	techniques	O
3	based	O
4	on	O
5	assay	O
6	coefficients	O
7	of	O
8	variation	O
9	were	O
10	employed	O
11	to	O
12	characterize	O
13	a	O
14	normal	O
15	circadian	O
16	pattern	O
17	of	O
18	cortisol	O
19	.	O

1	SEA	B
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	This	O
2	proposed	O
3	method	O
4	is	O
5	similar	O
6	in	O
7	principle	O
8	to	O
9	the	O
10	sets	O
11	technique	O
12	but	O
13	is	O
14	shown	O
15	to	O
16	have	O
17	much	O
18	better	O
19	expected	O
20	time	O
21	to	O
22	alarm	O
23	properties	O
24	.	O

1	Long	O
2	-	O
3	latency	O
4	:	O
5	locked	O
6	units	O
7	responded	O
8	to	O
9	shocks	O
10	with	O
11	little	O
12	jitter	O
13	and	O
14	long	O
15	latency	O
16	(	O
17	4	O
18	-	O
19	11	O
20	ms	O
21	).	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	ELL	O
12	functional	O
13	domains	O
14	that	O
15	govern	O
16	its	O
17	interaction	O
18	with	O
19	RNA	B
20	polymerase	I
21	II	I
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O

1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O

1	(	O
2	1988	O
3	)	O
4	J	O
5	.	O

1	A	O
2	73	O
3	bp	O
4	fragment	O
5	(	O
6	X1	B
7	region	I
8	)	O
9	of	O
10	the	O
11	PRB	B
12	-	I
13	1b	I
14	promoter	I
15	,	O
16	located	O
17	between	O
18	positions	O
19	-	O
20	213	O
21	and	O
22	-	O
23	141	O
24	,	O
25	was	O
26	sufficient	O
27	to	O
28	confer	O
29	ethylene	O
30	responsiveness	O
31	to	O
32	the	O
33	reporter	O
34	gene	O
35	.	O

1	Ig	B
2	-	I
3	alpha	I
4	and	O
5	Ig	B
6	-	I
7	beta	I
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	effectors	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O

1	The	O
2	authors	O
3	conclude	O
4	that	O
5	nonspecificity	O
6	of	O
7	low	B
8	platelet	I
9	MAO	I
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	bipolar	O
16	affective	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	schizophrenia	O
23	,	O
24	increases	O
25	the	O
26	burden	O
27	of	O
28	proof	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	B
34	platelet	I
35	MAO	I
36	can	O
37	be	O
38	accepted	O
39	as	O
40	primary	O
41	.	O

1	II	O
2	.	O

1	Transcriptional	O
2	control	O
3	signals	O
4	of	O
5	a	O
6	herpes	O
7	simplex	O
8	virus	O
9	type	O
10	1	O
11	late	O
12	(	O
13	gamma	B
14	2	I
15	)	O
16	gene	O
17	lie	O
18	within	O
19	bases	O
20	-	O
21	34	O
22	to	O
23	+	O
24	124	O
25	relative	O
26	to	O
27	the	O
28	5	O
29	'	O
30	terminus	O
31	of	O
32	the	O
33	mRNA	O
34	.	O

1	The	O
2	ESEG	O
3	'	O
4	s	O
5	are	O
6	a	O
7	direct	O
8	result	O
9	of	O
10	the	O
11	NEXT	O
12	study	O
13	.	O

1	By	O
2	contrast	O
3	,	O
4	their	O
5	basal	O
6	adrenal	O
7	androgen	O
8	levels	O
9	were	O
10	significantly	O
11	decreased	O
12	compared	O
13	to	O
14	those	O
15	in	O
16	normal	O
17	subjects	O
18	on	O
19	both	O
20	the	O
21	day	O
22	on	O
23	and	O
24	the	O
25	day	O
26	off	O
27	prednisone	O
28	(	O
29	P	O
30	less	O
31	than	O
32	0	O
33	.	O
34	05	O
35	).	O

1	The	O
2	location	O
3	of	O
4	the	O
5	IBS	O
6	within	O
7	the	O
8	catB	B
9	structural	I
10	gene	I
11	,	O
12	the	O
13	cooperativity	O
14	observed	O
15	in	O
16	footprinting	O
17	studies	O
18	and	O
19	phasing	O
20	studies	O
21	suggest	O
22	that	O
23	the	O
24	IBS	O
25	participates	O
26	in	O
27	the	O
28	interaction	O
29	of	O
30	CatR	O
31	with	O
32	the	O
33	upstream	O
34	binding	O
35	sites	O
36	by	O
37	looping	O
38	out	O
39	the	O
40	intervening	O
41	DNA	O
42	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	B
9	-	I
10	Myb	I
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	B
18	A	I
19	/	O
20	Cdk2	B
21	.	O

1	Arachnoid	O
2	cyst	O
3	.	O

1	When	O
2	the	O
3	coding	O
4	segments	O
5	,	O
6	including	O
7	both	O
8	framework	O
9	and	O
10	complementarity	O
11	-	O
12	determining	O
13	regions	O
14	,	O
15	of	O
16	these	O
17	genes	O
18	and	O
19	the	O
20	murine	O
21	probe	O
22	sequences	O
23	are	O
24	compared	O
25	by	O
26	metric	O
27	analysis	O
28	,	O
29	it	O
30	is	O
31	apparent	O
32	that	O
33	the	O
34	caiman	O
35	genes	O
36	are	O
37	only	O
38	slightly	O
39	more	O
40	related	O
41	to	O
42	each	O
43	other	O
44	than	O
45	to	O
46	the	O
47	mammalian	O
48	sequence	O
49	,	O
50	consistent	O
51	with	O
52	significant	O
53	preservation	O
54	of	O
55	nucleotide	O
56	sequence	O
57	over	O
58	an	O
59	extended	O
60	period	O
61	of	O
62	phylogenetic	O
63	time	O
64	.	O

1	Morphine	O
2	-	O
3	dependent	O
4	and	O
5	control	O
6	rats	O
7	in	O
8	an	O
9	oral	O
10	free	O
11	-	O
12	choice	O
13	protocol	O
14	were	O
15	treated	O
16	with	O
17	gamma	O
18	-	O
19	vinyl	O
20	GABA	O
21	(	O
22	GVG	O
23	),	O
24	60	O
25	,	O
26	120	O
27	and	O
28	240	O
29	mg	O
30	/	O
31	kg	O
32	IP	O
33	,	O
34	for	O
35	3	O
36	days	O
37	over	O
38	three	O
39	successive	O
40	periods	O
41	.	O

1	Hyperactivation	O
2	of	O
3	Cdc2	B
4	in	I
5	fission	I
6	yeast	I
7	causes	O
8	cells	O
9	to	O
10	undergo	O
11	a	O
12	lethal	O
13	premature	O
14	mitosis	O
15	called	O
16	mitotic	O
17	catastrophe	O
18	.	O

1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	I
6	GAL4	I
7	and	O
8	LexA	B
9	-	I
10	Bicoid	I
11	fusion	I
12	proteins	I
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	B
18	,	O
19	SNF5	B
20	,	O
21	and	O
22	SNF6	B
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	B
33	operators	I
34	.	O

1	From	O
2	the	O
3	National	O
4	Institutes	O
5	of	O
6	Health	O
7	.	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	of	O
16	477	O
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	O
40	human	B
41	U1	I
42	-	I
43	C	I
44	protein	I
45	.	O

1	The	O
2	outer	O
3	diameter	O
4	and	O
5	the	O
6	thickness	O
7	of	O
8	the	O
9	rotor	O
10	are	O
11	60	O
12	mm	O
13	and	O
14	8	O
15	mm	O
16	,	O
17	respectively	O
18	.	O

1	Lesions	O
2	were	O
3	made	O
4	by	O
5	pressure	O
6	injection	O
7	of	O
8	kainic	O
9	acid	O
10	into	O
11	the	O
12	SOC	O
13	through	O
14	a	O
15	stereotaxically	O
16	positioned	O
17	glass	O
18	micropipette	O
19	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	The	O
2	mEmBP	B
3	-	I
4	1	I
5	protein	I
6	can	O
7	activate	O
8	transcription	O
9	from	O
10	a	O
11	truncated	O
12	promoter	O
13	containing	O
14	a	O
15	pentamer	O
16	of	O
17	the	O
18	O2	O
19	site	O
20	in	O
21	yeast	O
22	cells	O
23	;	O
24	however	O
25	,	O
26	it	O
27	inhibited	O
28	regulated	O
29	transcription	O
30	of	O
31	a	O
32	22	O
33	kDa	O
34	zein	O
35	promoter	O
36	in	O
37	a	O
38	transient	O
39	expression	O
40	assay	O
41	using	O
42	cultured	O
43	maize	O
44	endosperm	O
45	cells	O
46	.	O

1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Derepression	O
2	of	O
3	gene	O
4	expression	O
5	mediated	O
6	by	O
7	the	O
8	5	O
9	'	O
10	upstream	O
11	region	O
12	of	O
13	the	O
14	isocitrate	B
15	lyase	I
16	gene	I
17	of	O
18	Candida	O
19	tropicalis	O
20	is	O
21	controlled	O
22	by	O
23	two	O
24	distinct	O
25	regulatory	O
26	pathways	O
27	in	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	For	O
2	the	O
3	first	O
4	time	O
5	we	O
6	describe	O
7	deletion	O
8	and	O
9	point	O
10	mutations	O
11	within	O
12	the	O
13	plasma	O
14	membrane	O
15	family	O
16	of	O
17	guanylyl	B
18	cyclase	I
19	receptors	I
20	that	O
21	result	O
22	in	O
23	the	O
24	formation	O
25	of	O
26	effective	O
27	dominant	O
28	negative	O
29	proteins	O
30	.	O

1	Thin	O
2	melanomas	O
3	can	O
4	metastasize	O
5	and	O
6	be	O
7	lethal	O
8	.	O

1	Control	O
2	examination	O
3	was	O
4	performed	O
5	at	O
6	the	O
7	end	O
8	of	O
9	each	O
10	period	O
11	.	O

1	Induction	O
2	of	O
3	correctly	O
4	spliced	O
5	germline	O
6	transcripts	O
7	is	O
8	necessary	O
9	to	O
10	target	O
11	a	O
12	switch	O
13	region	O
14	for	O
15	recombination	O
16	and	O
17	switching	O
18	.	O

1	In	O
2	ferrets	O
3	naturally	O
4	infected	O
5	with	O
6	H	O
7	.	O
8	mustelae	O
9	,	O
10	a	O
11	single	O
12	dose	O
13	(	O
14	50	O
15	mg	O
16	/	O
17	kg	O
18	,	O
19	per	O
20	os	O
21	)	O
22	of	O
23	fluorofamide	O
24	completely	O
25	inhibited	O
26	bacterial	B
27	urease	I
28	.	O

1	We	O
2	studied	O
3	the	O
4	functional	O
5	interaction	O
6	between	O
7	human	B
8	embryonic	I
9	zeta	I
10	2	I
11	globin	I
12	promoter	I
13	and	O
14	the	O
15	alpha	B
16	globin	I
17	regulatory	I
18	element	I
19	(	O
20	HS	B
21	-	I
22	40	I
23	)	I
24	located	I
25	40	I
26	kb	I
27	upstream	I
28	of	I
29	the	I
30	zeta	I
31	2	I
32	globin	I
33	gene	I
34	.	O

1	A	O
2	series	O
3	of	O
4	5	O
5	'-	O
6	deletions	O
7	revealed	O
8	that	O
9	the	O
10	fragment	O
11	-	O
12	218	O
13	to	O
14	+	O
15	4	O
16	from	O
17	the	O
18	TSS	O
19	had	O
20	the	O
21	highest	O
22	promoter	O
23	activity	O
24	,	O
25	nearly	O
26	1000	O
27	-	O
28	fold	O
29	greater	O
30	than	O
31	the	O
32	promoterless	O
33	chloramphenicol	B
34	acetyltransferase	I
35	construct	I
36	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	B
9	Ig	I
10	engagement	O
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	B
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	B
27	-	I
28	like	I
29	protein	I
30	tyrosine	I
31	kinases	I
32	lyn	I
33	,	O
34	fyn	B
35	,	O
36	and	O
37	btk	B
38	,	O
39	or	O
40	of	O
41	vav	B
42	-	O
43	and	O
44	ras	B
45	-	I
46	GTPase	I
47	-	I
48	activating	I
49	protein	I
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O

1	Competition	O
2	needs	O
3	to	O
4	be	O
5	better	O
6	studied	O
7	,	O
8	since	O
9	in	O
10	Central	O
11	America	O
12	and	O
13	Caribean	O
14	islands	O
15	this	O
16	kind	O
17	of	O
18	study	O
19	has	O
20	favored	O
21	the	O
22	biological	O
23	control	O
24	of	O
25	planorbid	O
26	species	O
27	.	O

1	HBx	O
2	strongly	O
3	elevates	O
4	levels	O
5	of	O
6	GTP	O
7	-	O
8	bound	O
9	Ras	B
10	,	O
11	activated	O
12	and	O
13	phosphorylated	O
14	Raf	B
15	,	O
16	and	O
17	tyrosine	O
18	-	O
19	phosphorylated	O
20	and	O
21	activated	O
22	MAP	B
23	kinase	I
24	.	O

1	Haycocknema	O
2	perplexum	O
3	n	O
4	.	O
5	g	O
6	.,	O
7	n	O
8	.	O
9	sp	O
10	.	O

1	Breast	O
2	-	O
3	fed	O
4	newborn	O
5	infants	O
6	synthesize	O
7	n	O
8	-	O
9	6	O
10	long	O
11	-	O
12	chain	O
13	polyunsaturated	O
14	fatty	O
15	acids	O
16	already	O
17	during	O
18	the	O
19	first	O
20	week	O
21	of	O
22	life	O
23	,	O
24	but	O
25	the	O
26	contribution	O
27	of	O
28	endogenous	O
29	synthesis	O
30	to	O
31	the	O
32	total	O
33	plasma	O
34	long	O
35	-	O
36	chain	O
37	polyunsaturated	O
38	pool	O
39	is	O
40	small	O
41	.	O

1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O

1	This	O
2	agent	O
3	,	O
4	isolated	O
5	from	O
6	the	O
7	fungus	O
8	Streptomyces	O
9	tsukubaensis	O
10	,	O
11	has	O
12	a	O
13	mechanism	O
14	of	O
15	action	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	cyclosporine	O
21	.	O

1	The	O
2	feed	O
3	consumed	O
4	which	O
5	was	O
6	lowered	O
7	by	O
8	25	O
9	%	O
10	initially	O
11	,	O
12	did	O
13	not	O
14	alter	O
15	later	O
16	.	O

1	(	O
2	3	O
3	).	O

1	The	O
2	serine	B
3	-	I
4	threonine	I
5	kinase	I
6	gene	I
7	is	O
8	likely	O
9	functional	O
10	,	O
11	whereas	O
12	the	O
13	zinc	O
14	finger	O
15	motif	O
16	is	O
17	likely	O
18	nonfunctional	O
19	.	O

1	Autopsy	O
2	demonstrated	O
3	good	O
4	survival	O
5	of	O
6	the	O
7	transplanted	O
8	cells	O
9	with	O
10	good	O
11	integration	O
12	with	O
13	the	O
14	brain	O
15	of	O
16	the	O
17	recipient	O
18	and	O
19	traces	O
20	of	O
21	positive	O
22	immunocytochemical	O
23	reaction	O
24	for	O
25	tyrosine	B
26	hydroxylase	I
27	.	O

1	METHODS	O
2	:	O
3	We	O
4	obtained	O
5	maximal	O
6	inspiratory	O
7	and	O
8	expiratory	O
9	flow	O
10	-	O
11	volume	O
12	curves	O
13	in	O
14	41	O
15	unselected	O
16	patients	O
17	with	O
18	essential	O
19	tremor	O
20	(	O
21	14	O
22	males	O
23	,	O
24	27	O
25	females	O
26	,	O
27	age	O
28	61	O
29	.	O
30	7	O
31	+/-	O
32	2	O
33	.	O
34	14	O
35	years	O
36	).	O

1	We	O
2	now	O
3	report	O
4	the	O
5	isolation	O
6	and	O
7	expression	O
8	of	O
9	cDNAs	O
10	encoding	O
11	PTF	B
12	gamma	I
13	and	O
14	PTF	B
15	delta	I
16	,	O
17	as	O
18	well	O
19	as	O
20	functional	O
21	studies	O
22	with	O
23	cognate	O
24	antibodies	O
25	that	O
26	recognize	O
27	the	O
28	native	O
29	PTF	B
30	complex	O
31	in	O
32	HeLa	O
33	extracts	O
34	.	O

1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	O
17	tasks	O
18	at	O
19	T1	O
20	,	O
21	in	O
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	O
35	differences	O
36	were	O
37	detected	O
38	at	O
39	T4	O
40	.	O

1	We	O
2	describe	O
3	here	O
4	17	O
5	dominant	O
6	GCN2	B
7	mutations	O
8	that	O
9	lead	O
10	to	O
11	derepression	O
12	of	O
13	GCN4	B
14	expression	O
15	in	O
16	the	O
17	absence	O
18	of	O
19	amino	O
20	acid	O
21	starvation	O
22	.	O

1	RESULTS	O
2	:	O
3	The	O
4	medians	O
5	of	O
6	average	O
7	daily	O
8	CD34	O
9	+	O
10	cell	O
11	yields	O
12	for	O
13	patients	O
14	who	O
15	received	O
16	paclitaxel	O
17	plus	O
18	CY	O
19	,	O
20	CE	B
21	,	O
22	and	O
23	CEP	O
24	with	O
25	G	B
26	-	I
27	CSF	I
28	were	O
29	12	O
30	.	O
31	9	O
32	,	O
33	11	O
34	.	O
35	03	O
36	,	O
37	and	O
38	5	O
39	.	O
40	37	O
41	x	O
42	10	O
43	(	O
44	6	O
45	)/	O
46	kg	O
47	,	O
48	respectively	O
49	,	O
50	compared	O
51	with	O
52	2	O
53	.	O
54	02	O
55	x	O
56	10	O
57	(	O
58	6	O
59	)/	O
60	kg	O
61	in	O
62	the	O
63	reference	O
64	group	O
65	that	O
66	received	O
67	CY	O
68	with	O
69	G	B
70	-	I
71	CSF	I
72	(	O
73	P	O
74	=	O
75	<	O
76	.	O
77	0001	O
78	,	O
79	.	O
80	002	O
81	,	O
82	and	O
83	.	O
84	09	O
85	,	O
86	respectively	O
87	).	O

1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	Asn	O
18	-	O
19	285	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	220	O
25	and	O
26	Gln	O
27	-	O
28	220	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	Asn	O
36	-	O
37	285	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	tetracycline	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O

1	The	O
2	initial	O
3	phase	O
4	of	O
5	increased	O
6	vascular	O
7	permeability	O
8	in	O
9	the	O
10	peritoneal	O
11	cavity	O
12	and	O
13	LTB4	B
14	production	O
15	was	O
16	dose	O
17	dependently	O
18	inhibited	O
19	by	O
20	the	O
21	5	O
22	-	O
23	LO	O
24	inhibitors	O
25	phenidone	O
26	,	O
27	BW	O
28	A4C	O
29	,	O
30	A63162	B
31	,	O
32	and	O
33	ICI	O
34	207	O
35	968	O
36	but	O
37	not	O
38	by	O
39	dexamethasone	O
40	or	O
41	colchicine	O
42	.	O

1	Evolutionary	O
2	relationships	O
3	among	O
4	putative	O
5	RNA	O
6	-	O
7	dependent	O
8	RNA	O
9	polymerases	O
10	encoded	O
11	by	O
12	a	O
13	mitochondrial	O
14	virus	O
15	-	O
16	like	O
17	RNA	O
18	in	O
19	the	O
20	Dutch	O
21	elm	B
22	disease	I
23	fungus	I
24	,	I
25	Ophiostoma	I
26	novo	I
27	-	I
28	ulmi	I
29	,	O
30	by	O
31	other	O
32	viruses	O
33	and	O
34	virus	O
35	-	O
36	like	O
37	RNAs	O
38	and	O
39	by	O
40	the	O
41	Arabidopsis	O
42	mitochondrial	O
43	genome	O
44	.	O

1	Five	O
2	concensus	O
3	poly	O
4	A	O
5	addition	O
6	sites	O
7	are	O
8	located	O
9	in	O
10	the	O
11	350	O
12	base	O
13	pairs	O
14	immediately	O
15	following	O
16	the	O
17	protein	B
18	IX	I
19	coding	I
20	region	I
21	.	O

1	Stimulation	O
2	of	O
3	[	O
4	3H	O
5	]	O
6	PA	O
7	production	O
8	upon	O
9	CD3	B
10	cross	O
11	-	O
12	linking	O
13	was	O
14	77	O
15	%	O
16	lower	O
17	in	O
18	permeabilized	O
19	CD45	O
20	-	O
21	cells	O
22	than	O
23	in	O
24	CD45	O
25	+	O
26	cells	O
27	,	O
28	consistent	O
29	with	O
30	the	O
31	reduced	O
32	activity	O
33	of	O
34	p59fyn	B
35	in	O
36	CD45	O
37	-	O
38	cells	O
39	.	O

1	Furthermore	O
2	,	O
3	a	O
4	minor	O
5	start	O
6	site	O
7	was	O
8	localized	O
9	179	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	major	O
15	site	O
16	using	O
17	reverse	B
18	transcriptase	I
19	-	O
20	polymerase	O
21	chain	O
22	reaction	O
23	with	O
24	various	O
25	P1	O
26	primers	O
27	(	O
28	primer	O
29	walking	O
30	),	O
31	primer	O
32	extension	O
33	,	O
34	and	O
35	cDNA	O
36	cloning	O
37	.	O

1	Phosphoamino	O
2	acid	O
3	analysis	O
4	of	O
5	radiolabeled	O
6	ASGPR	O
7	subunits	O
8	identified	O
9	Ser	O
10	(	O
11	P	O
12	)	O
13	as	O
14	the	O
15	predominant	O
16	(	O
17	approximately	O
18	95	O
19	%)	O
20	and	O
21	Thr	O
22	(	O
23	P	O
24	)	O
25	as	O
26	a	O
27	minor	O
28	(	O
29	approximately	O
30	5	O
31	%)	O
32	phosphoamino	O
33	acid	O
34	in	O
35	each	O
36	polypeptide	O
37	and	O
38	confirmed	O
39	the	O
40	presence	O
41	of	O
42	Tyr	O
43	(	O
44	P	O
45	)	O
46	(	O
47	approximately	O
48	1	O
49	%)	O
50	in	O
51	RHL1	B
52	.	O

1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	New	O
2	-	O
3	onset	O
4	angina	O
5	preceding	O
6	acute	O
7	myocardial	O
8	infarction	O
9	is	O
10	associated	O
11	with	O
12	improved	O
13	contractile	O
14	recovery	O
15	after	O
16	thrombolysis	O
17	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	B
7	lymphocyte	I
8	antigen	I
9	receptor	I
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	Increased	O
2	p53	B
3	activity	O
4	induced	O
5	by	O
6	OP	O
7	is	O
8	not	O
9	due	O
10	to	O
11	elevated	O
12	p53	B
13	mRNA	I
14	nor	O
15	to	O
16	protein	O
17	levels	O
18	.	O

1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	these	O
5	genes	O
6	and	O
7	their	O
8	surrounding	O
9	sequences	O
10	are	O
11	presented	O
12	and	O
13	compared	O
14	with	O
15	other	O
16	known	O
17	tRNA	B
18	genes	I
19	from	O
20	plant	O
21	mitochondria	O
22	.	O

1	Elevated	O
2	expression	O
3	of	O
4	a	O
5	previously	O
6	uncharacterized	O
7	gene	O
8	,	O
9	SPP381	O
10	,	O
11	efficiently	O
12	suppresses	O
13	the	O
14	growth	O
15	and	O
16	splicing	O
17	defects	O
18	of	O
19	a	O
20	temperature	O
21	-	O
22	sensitive	O
23	(	O
24	Ts	B
25	)	I
26	mutant	I
27	prp38	I
28	-	I
29	1	I
30	.	O

1	Gene	O
2	constructs	O
3	possessing	O
4	the	O
5	complete	O
6	tat	B
7	,	O
8	rev	B
9	(	O
10	tat	B
11	+	I
12	rev	I
13	+)	O
14	and	O
15	env	B
16	genes	I
17	were	O
18	transiently	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	1	O
24	cells	O
25	as	O
26	precursor	O
27	SU	B
28	-	I
29	TM	I
30	(	O
31	gp160	B
32	),	O
33	SU	B
34	.	I
35	TM	I
36	(	O
37	gp120	B
38	x	O
39	41	O
40	),	O
41	and	O
42	nucleolar	O
43	rev	B
44	protein	I
45	.	O

1	The	O
2	expression	O
3	pattern	O
4	of	O
5	GL2	B
6	,	O
7	as	O
8	demonstrated	O
9	by	O
10	in	O
11	situ	O
12	hybridization	O
13	,	O
14	indicated	O
15	that	O
16	the	O
17	gene	O
18	is	O
19	expressed	O
20	in	O
21	trichome	O
22	progenitor	O
23	cells	O
24	and	O
25	at	O
26	stages	O
27	associated	O
28	with	O
29	trichome	O
30	development	O
31	.	O

1	The	O
2	BAL	O
3	concentrations	O
4	of	O
5	the	O
6	nine	O
7	cytokines	O
8	evaluated	O
9	for	O
10	the	O
11	more	O
12	and	O
13	less	O
14	affected	O
15	lungs	O
16	were	O
17	compared	O
18	:	O
19	interleukin	B
20	-	I
21	6	I
22	(	O
23	IL	B
24	-	I
25	6	I
26	),	O
27	IL	B
28	-	I
29	8	I
30	,	O
31	IL	B
32	-	I
33	12	I
34	,	O
35	tumor	B
36	necrosis	I
37	factor	I
38	-	I
39	alpha	I
40	(	O
41	TNF	B
42	-	I
43	alpha	I
44	),	O
45	and	O
46	interferon	B
47	gamma	I
48	(	O
49	IFN	B
50	-	I
51	gamma	I
52	)	O
53	showed	O
54	significant	O
55	differences	O
56	(	O
57	p	O
58	ranged	O
59	between	O
60	0	O
61	.	O

1	Subjects	O
2	with	O
3	a	O
4	short	O
5	postexposure	O
6	time	O
7	and	O
8	a	O
9	dioxin	O
10	burden	O
11	>	O
12	0	O
13	.	O
14	6	O
15	pg	O
16	/	O
17	m3	O
18	had	O
19	a	O
20	significantly	O
21	higher	O
22	risk	O
23	of	O
24	hypoergy	O
25	than	O
26	unexposed	O
27	subjects	O
28	(	O
29	hypoergy	O
30	I	O
31	:	O
32	OR	O
33	=	O
34	9	O
35	.	O
36	51	O
37	,	O
38	95	O
39	%	O
40	CI	O
41	=	O
42	1	O
43	.	O
44	96	O
45	-	O
46	42	O
47	.	O
48	02	O
49	;	O
50	hypoergy	O
51	II	O
52	:	O
53	OR	O
54	=	O
55	2	O
56	.	O
57	92	O
58	,	O
59	95	O
60	%	O
61	CI	O
62	=	O
63	1	O
64	.	O
65	14	O
66	-	O
67	7	O
68	.	O
69	5	O
70	).	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	The	O
2	remaining	O
3	80	O
4	patients	O
5	underwent	O
6	recordings	O
7	of	O
8	ECG	O
9	,	O
10	beat	O
11	-	O
12	to	O
13	-	O
14	beat	O
15	arterial	O
16	oxygen	O
17	saturation	O
18	(	O
19	SaO2	O
20	),	O
21	and	O
22	respiration	O
23	during	O
24	both	O
25	spontaneous	O
26	and	O
27	controlled	O
28	breathing	O
29	.	O

1	A	O
2	major	O
3	pool	O
4	of	O
5	Dsg	B
6	-	I
7	plakoglobin	I
8	complexes	O
9	sedimented	O
10	at	O
11	8S	O
12	and	O
13	exhibited	O
14	a	O
15	1	O
16	:	O
17	1	O
18	stoichiometry	O
19	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	The	O
2	mean	O
3	marginal	O
4	discrepancy	O
5	of	O
6	provisional	O
7	restorations	O
8	was	O
9	compared	O
10	for	O
11	restorations	O
12	fabricated	O
13	from	O
14	stone	O
15	,	O
16	low	O
17	-	O
18	viscosity	O
19	poly	O
20	(	O
21	vinyl	O
22	siloxane	O
23	),	O
24	and	O
25	medium	O
26	-	O
27	viscosity	O
28	poly	O
29	(	O
30	vinyl	O
31	siloxane	O
32	).	O

1	With	O
2	the	O
3	help	O
4	of	O
5	a	O
6	nomogram	O
7	one	O
8	can	O
9	read	O
10	off	O
11	the	O
12	refraction	O
13	,	O
14	when	O
15	axis	O
16	length	O
17	and	O
18	corneal	O
19	curvature	O
20	are	O
21	known	O
22	.	O

1	On	O
2	the	O
3	other	O
4	side	O
5	,	O
6	when	O
7	the	O
8	aortic	O
9	ring	O
10	was	O
11	perfused	O
12	with	O
13	L	O
14	-	O
15	NNA	O
16	(	O
17	NO	O
18	-	O
19	synthesis	O
20	inhibitor	O
21	)	O
22	or	O
23	methylene	O
24	blue	O
25	(	O
26	soluble	B
27	cGMPase	I
28	inhibitor	O
29	),	O
30	the	O
31	changes	O
32	could	O
33	be	O
34	attenuated	O
35	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	the	O
5	cytoplasmic	O
6	tail	O
7	appears	O
8	to	O
9	generate	O
10	multiple	O
11	PECAM	B
12	-	I
13	1	I
14	isoforms	I
15	that	O
16	may	O
17	regulate	O
18	phosphorylation	O
19	,	O
20	cytoskeletal	O
21	association	O
22	,	O
23	and	O
24	affinity	O
25	modulation	O
26	of	O
27	the	O
28	mature	O
29	protein	O
30	.	O

1	A	O
2	recombinant	O
3	derivative	O
4	harboring	O
5	the	O
6	pMJ101	O
7	replication	O
8	region	O
9	proved	O
10	to	O
11	be	O
12	compatible	O
13	with	O
14	pJM1	B
15	,	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	iron	O
21	acquisition	O
22	system	O
23	required	O
24	for	O
25	the	O
26	virulence	O
27	of	O
28	V	O
29	.	O
30	anguillarum	O
31	775	O
32	,	O
33	another	O
34	important	O
35	pathogen	O
36	that	O
37	causes	O
38	vibriosis	O
39	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	efficacies	O
6	of	O
7	adjuvant	O
8	carboplatin	O
9	and	O
10	of	O
11	abdominal	O
12	radiotherapy	O
13	seem	O
14	to	O
15	be	O
16	identical	O
17	.	O

1	Two	O
2	Lab	O
3	8	O
4	computer	O
5	programmes	O
6	for	O
7	use	O
8	in	O
9	the	O
10	study	O
11	of	O
12	the	O
13	isometric	O
14	and	O
15	isotonic	O
16	contractile	O
17	characteristics	O
18	of	O
19	skeletal	O
20	muscle	O
21	.	O

1	A	O
2	transparent	O
3	overlay	O
4	for	O
5	assessing	O
6	amplitude	O
7	of	O
8	ECG	O
9	wave	O
10	forms	O
11	.	O

1	Null	O
2	mutations	O
3	in	O
4	daf	B
5	-	I
6	3	I
7	suppress	O
8	mutations	O
9	in	O
10	genes	O
11	encoding	O
12	this	O
13	TGF	B
14	-	I
15	beta	I
16	signal	I
17	,	O
18	its	O
19	receptors	O
20	,	O
21	and	O
22	associated	O
23	Smad	B
24	signal	I
25	transduction	I
26	proteins	I
27	.	O
28	daf	B
29	-	I
30	3	I
31	encodes	O
32	a	O
33	Smad	B
34	protein	I
35	that	O
36	is	O
37	most	O
38	closely	O
39	related	O
40	to	O
41	mammalian	O
42	DPC4	O
43	,	O
44	and	O
45	is	O
46	expressed	O
47	throughout	O
48	development	O
49	in	O
50	many	O
51	of	O
52	the	O
53	tissues	O
54	that	O
55	are	O
56	remodeled	O
57	during	O
58	dauer	O
59	development	O
60	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	assess	O
9	the	O
10	reproducibility	O
11	of	O
12	a	O
13	number	O
14	of	O
15	simplified	O
16	clearance	O
17	methods	O
18	using	O
19	chromium	O
20	-	O
21	51	O
22	ethylenediamine	O
23	tetraacetic	O
24	acid	O
25	(	O
26	51Cr	O
27	-	O
28	EDTA	O
29	)	O
30	and	O
31	to	O
32	compare	O
33	these	O
34	with	O
35	the	O
36	multiple	O
37	blood	O
38	sample	O
39	technique	O
40	.	O

1	II	O
2	.	O

1	A	O
2	secondary	O
3	spread	O
4	of	O
5	an	O
6	imported	O
7	methicillin	O
8	-	O
9	resistant	O
10	Staphylococcus	O
11	aureus	O
12	strain	O
13	(	O
14	MRSA	O
15	)	O
16	to	O
17	two	O
18	other	O
19	patients	O
20	occurred	O
21	within	O
22	a	O
23	Danish	O
24	surgical	O
25	ward	O
26	in	O
27	spite	O
28	of	O
29	isolation	O
30	of	O
31	a	O
32	multitraumatized	O
33	index	O
34	-	O
35	patient	O
36	immediately	O
37	after	O
38	arrival	O
39	from	O
40	a	O
41	hospital	O
42	in	O
43	the	O
44	Mediterranean	O
45	area	O
46	.	O

1	SCID	B
2	V	I
3	(	I
4	D	I
5	)	O
6	J	O
7	recombination	O
8	can	O
9	be	O
10	partly	O
11	rescued	O
12	in	O
13	T	O
14	-	O
15	lymphocytes	O
16	by	O
17	either	O
18	DNA	O
19	-	O
20	damaging	O
21	agents	O
22	(	O
23	gamma	O
24	-	O
25	irradiation	O
26	and	O
27	bieomycin	O
28	)	O
29	or	O
30	a	O
31	null	O
32	mutation	O
33	of	O
34	the	O
35	p53	B
36	gene	I
37	,	O
38	possibly	O
39	because	O
40	of	O
41	transiently	O
42	elevated	O
43	DNA	O
44	repair	O
45	activity	O
46	in	O
47	response	O
48	to	O
49	DNA	O
50	damage	O
51	or	O
52	to	O
53	delayed	O
54	apoptosis	O
55	in	O
56	the	O
57	absence	O
58	of	O
59	p53	B
60	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O

1	ATF1	B
2	transcription	O
3	is	O
4	negatively	O
5	regulated	O
6	by	O
7	unsaturated	O
8	fatty	O
9	acids	O
10	and	O
11	oxygen	O
12	.	O

1	It	O
2	is	O
3	present	O
4	in	O
5	the	O
6	nucleus	O
7	of	O
8	the	O
9	cells	O
10	in	O
11	which	O
12	it	O
13	is	O
14	expressed	O
15	and	O
16	can	O
17	phosphorylate	O
18	and	O
19	activate	O
20	the	O
21	cyclic	B
22	AMP	I
23	response	I
24	element	I
25	binding	I
26	proteins	I
27	CREB	I
28	and	O
29	CREM	O
30	tau	O
31	in	O
32	a	O
33	manner	O
34	analogous	O
35	to	O
36	protein	B
37	kinase	I
38	A	I
39	.	O

1	Collectively	O
2	,	O
3	our	O
4	findings	O
5	demonstrate	O
6	that	O
7	SF	B
8	-	I
9	1	I
10	plays	O
11	a	O
12	key	O
13	role	O
14	in	O
15	controlling	O
16	the	O
17	basal	O
18	and	O
19	cAMP	O
20	-	O
21	stimulated	O
22	expression	O
23	of	O
24	the	O
25	StAR	B
26	gene	I
27	.	O

1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O

1	A	O
2	series	O
3	of	O
4	amino	O
5	terminal	O
6	deletion	O
7	mutants	O
8	(	O
9	d10	B
10	,	O
11	d20	B
12	,	O
13	d27	B
14	,	O
15	d31	O
16	,	O
17	d40	B
18	,	O
19	d44	O
20	,	O
21	and	O
22	d73	B
23	)	O
24	were	O
25	compared	O
26	for	O
27	processing	O
28	,	O
29	cell	O
30	surface	O
31	expression	O
32	,	O
33	and	O
34	maintenance	O
35	of	O
36	their	O
37	biological	O
38	attributes	O
39	by	O
40	recombinant	O
41	expression	O
42	of	O
43	mutant	O
44	genes	O
45	using	O
46	a	O
47	plasmid	O
48	vector	O
49	(	O
50	pcDL	B
51	-	I
52	SR	I
53	alpha	I
54	-	I
55	296	I
56	)	O
57	in	O
58	CV	O
59	-	O
60	1	O
61	and	O
62	HeLa	O
63	cells	O
64	.	O

1	Furthermore	O
2	,	O
3	using	O
4	transgenic	O
5	mouse	O
6	technology	O
7	we	O
8	localized	O
9	independent	O
10	cis	O
11	-	O
12	regulatory	O
13	elements	O
14	controlling	O
15	the	O
16	tissue	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	Pax6	O
22	.	O

1	Moloney	O
2	murine	O
3	leukemia	O
4	virus	O
5	(	O
6	MMLV	O
7	)-	O
8	derived	O
9	pUCMoTiN	O
10	-	O
11	based	O
12	retroviral	O
13	vectors	O
14	were	O
15	engineered	O
16	to	O
17	allow	O
18	constitutive	O
19	and	O
20	Tat	B
21	(	O
22	trans	O
23	-	O
24	activator	O
25	of	O
26	transcription	O
27	)-	O
28	inducible	O
29	expression	O
30	of	O
31	five	O
32	hammerhead	O
33	ribozymes	O
34	targeted	O
35	against	O
36	highly	O
37	conserved	O
38	sequences	O
39	within	O
40	the	O
41	group	O
42	antigen	O
43	(	O
44	Gag	B
45	),	O
46	protease	O
47	(	O
48	Pro	O
49	),	O
50	reverse	B
51	transcriptase	I
52	(	O
53	RT	O
54	),	O
55	tat	B
56	,	O
57	and	O
58	envelope	O
59	(	O
60	Env	B
61	)	O
62	coding	O
63	regions	O
64	of	O
65	human	O
66	immunodeficiency	O
67	virus	O
68	type	O
69	-	O
70	1	O
71	(	O
72	HIV	O
73	-	O
74	1	O
75	)	O
76	RNA	O
77	.	O

1	INF	B
2	-	I
3	alpha	I
4	therapy	O
5	has	O
6	been	O
7	a	O
8	major	O
9	development	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	CML	O
15	.	O

1	Discrepant	O
2	results	O
3	with	O
4	a	O
5	latex	O
6	agglutination	O
7	test	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	cytomegalovirus	O
13	antibody	O
14	status	O
15	of	O
16	cardiac	O
17	transplant	O
18	donors	O
19	.	O

1	One	O
2	hundred	O
3	replicate	O
4	data	O
5	sets	O
6	of	O
7	100	O
8	subjects	O
9	each	O
10	were	O
11	simulated	O
12	for	O
13	each	O
14	missing	O
15	data	O
16	scenario	O
17	.	O

1	Thus	O
2	our	O
3	observations	O
4	establish	O
5	a	O
6	functional	O
7	link	O
8	between	O
9	the	O
10	PKC	B
11	and	O
12	retinoid	O
13	pathways	O
14	,	O
15	which	O
16	are	O
17	generally	O
18	considered	O
19	to	O
20	have	O
21	antagonistic	O
22	activities	O
23	on	O
24	differentiation	O
25	processes	O
26	.	O

1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O

1	Analysis	O
2	by	O
3	cell	O
4	surface	O
5	immunofluorescence	O
6	showed	O
7	that	O
8	the	O
9	UL28	B
10	gene	I
11	is	O
12	not	O
13	required	O
14	for	O
15	expression	O
16	of	O
17	viral	O
18	glycoproteins	O
19	on	O
20	the	O
21	surface	O
22	of	O
23	infected	O
24	cells	O
25	.	O

1	The	O
2	corn	O
3	and	O
4	mineral	O
5	oil	O
6	emulsions	O
7	were	O
8	almost	O
9	as	O
10	effective	O
11	as	O
12	milk	O
13	but	O
14	less	O
15	effective	O
16	than	O
17	sucrose	O
18	(	O
19	0	O
20	.	O
21	3M	O
22	)	O
23	in	O
24	stimulating	O
25	ingestion	O
26	.	O

1	Assessment	O
2	of	O
3	the	O
4	carcinogenicity	O
5	of	O
6	non	O
7	-	O
8	nutritive	O
9	sweetners	O
10	II	O
11	:	O
12	Cyclamates	O
13	and	O
14	cyclohexylamine	O
15	.	O

1	T	B
2	-	I
3	cell	I
4	receptor	I
5	beta	I
6	(	O
7	TCR	B
8	beta	I
9	)	I
10	gene	I
11	rearrangements	O
12	occur	O
13	in	O
14	a	O
15	third	O
16	of	O
17	early	O
18	B	O
19	-	O
20	cell	O
21	acute	O
22	lymphoblastic	O
23	leukemias	O
24	(	O
25	ALLs	O
26	).	O

1	DNA	O
2	sequencing	O
3	of	O
4	a	O
5	17	O
6	-	O
7	kb	O
8	segment	O
9	encompassing	O
10	a	O
11	gammaherpesvirus	O
12	divergent	O
13	locus	O
14	(	O
15	DL	B
16	-	I
17	B	I
18	)	O
19	between	O
20	ORF11	B
21	and	O
22	ORF17	B
23	revealed	O
24	the	O
25	presence	O
26	of	O
27	nine	O
28	viral	O
29	ORFs	O
30	with	O
31	predicted	O
32	gene	O
33	products	O
34	related	O
35	to	O
36	cellular	O
37	proteins	O
38	.	O

1	Computer	O
2	assisted	O
3	mapping	O
4	in	O
5	quantitative	O
6	analysis	O
7	of	O
8	cerebral	O
9	positron	O
10	emission	O
11	tomograms	O
12	.	O

1	Additionally	O
2	,	O
3	the	O
4	enzyme	O
5	shows	O
6	activity	O
7	towards	O
8	triglycerides	O
9	such	O
10	as	O
11	olive	O
12	oil	O
13	and	O
14	tributyrin	B
15	and	O
16	towards	O
17	egg	O
18	-	O
19	yolk	O
20	emulsions	O
21	.	O

1	The	O
2	yeast	O
3	silent	O
4	information	O
5	regulator	O
6	Sir4p	B
7	anchors	I
8	and	O
9	partitions	O
10	plasmids	O
11	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	while	O
6	many	O
7	muscle	O
8	gene	O
9	E	O
10	-	O
11	boxes	O
12	are	O
13	capable	O
14	of	O
15	binding	O
16	the	O
17	previously	O
18	characterized	O
19	spectrum	O
20	of	O
21	MDF	B
22	/	O
23	bH	B
24	-	I
25	L	I
26	-	I
27	H	I
28	heterodimers	I
29	in	O
30	vitro	O
31	,	O
32	MCK	B
33	-	I
34	L	I
35	type	I
36	E	I
37	-	I
38	boxes	I
39	probably	O
40	bind	O
41	qualitatively	O
42	different	O
43	factors	O
44	in	O
45	vivo	O
46	.	O

1	GTPase	B
2	activating	O
3	specificity	O
4	of	O
5	RGS12	B
6	and	O
7	binding	O
8	specificity	O
9	of	O
10	an	O
11	alternatively	O
12	spliced	O
13	PDZ	O
14	(	O
15	PSD	O
16	-	O
17	95	O
18	/	O
19	Dlg	B
20	/	O
21	ZO	B
22	-	I
23	1	I
24	)	O
25	domain	O
26	.	O

1	Detailed	O
2	molecular	O
3	organization	O
4	of	O
5	the	O
6	coding	O
7	and	O
8	upstream	O
9	regulatory	O
10	regions	O
11	of	O
12	the	O
13	murine	B
14	homeodomain	I
15	-	I
16	containing	I
17	gene	I
18	,	O
19	Msx	B
20	-	I
21	1	I
22	,	O
23	is	O
24	reported	O
25	.	O

1	BACKGROUND	O
2	:	O
3	We	O
4	conducted	O
5	a	O
6	phase	O
7	I	O
8	study	O
9	with	O
10	MDL	B
11	73	I
12	,	O
13	147EF	B
14	,	O
15	a	O
16	new	O
17	5	O
18	hydroxytryptamine	O
19	3	O
20	(	O
21	5	B
22	-	I
23	HT3	I
24	)	I
25	receptor	I
26	antagonist	O
27	,	O
28	in	O
29	25	O
30	patients	O
31	requiring	O
32	emetogenic	O
33	chemotherapy	O
34	.	O

1	Imaging	O
2	of	O
3	D2	B
4	dopamine	I
5	receptor	I

1	CONCLUSION	O
2	:	O
3	Rheumatic	O
4	fever	O
5	in	O
6	the	O
7	Nazareth	O
8	area	O
9	is	O
10	still	O
11	manifest	O
12	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	O
19	head	O
20	DNA	O
21	binding	O
22	domain	O
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O

1	In	O
2	control	O
3	patients	O
4	,	O
5	baseline	O
6	images	O
7	presented	O
8	Type	O
9	I	O
10	in	O
11	25	O
12	,	O
13	Type	O
14	II	O
15	in	O
16	7	O
17	,	O
18	and	O
19	the	O
20	Type	O
21	III	O
22	&	O
23	IV	O
24	in	O
25	0	O
26	,	O
27	and	O
28	the	O
29	Type	O
30	after	O
31	loading	O
32	was	O
33	the	O
34	same	O
35	as	O
36	the	O
37	Type	O
38	at	O
39	baseline	O
40	.	O

1	An	O
2	intact	O
3	5	O
4	.	O
5	7	O
6	-	O
7	kb	O
8	provirus	O
9	of	O
10	the	O
11	avian	O
12	erythroblastosis	O
13	virus	O
14	E26	O
15	has	O
16	been	O
17	molecularly	O
18	cloned	O
19	for	O
20	comparisons	O
21	with	O
22	avian	O
23	myeloblastosis	O
24	virus	O
25	(	O
26	AMV	O
27	)	O
28	and	O
29	other	O
30	avian	O
31	tumor	O
32	viruses	O
33	.	O

1	By	O
2	deletion	O
3	analysis	O
4	of	O
5	the	O
6	MLS1	B
7	control	I
8	region	I
9	,	O
10	we	O
11	identified	O
12	two	O
13	sites	O
14	,	O
15	UAS1	O
16	and	O
17	UAS2	O
18	,	O
19	as	O
20	important	O
21	for	O
22	efficient	O
23	derepression	O
24	of	O
25	the	O
26	gene	O
27	.	O

1	Dose	O
2	of	O
3	20	O
4	ig	O
5	were	O
6	administered	O
7	within	O
8	a	O
9	scheme	O
10	from	O
11	0	O
12	.	O
13	1	O
14	to	O
15	6	O
16	months	O
17	in	O
18	order	O
19	to	O
20	study	O
21	its	O
22	immunogenicity	O
23	,	O
24	which	O
25	was	O
26	evaluated	O
27	at	O
28	2	O
29	,	O
30	7	O
31	,	O
32	and	O
33	12	O
34	months	O
35	after	O
36	the	O
37	first	O
38	dose	O
39	.	O

1	Overall	O
2	,	O
3	our	O
4	results	O
5	suggest	O
6	that	O
7	resistant	O
8	genotypes	O
9	exist	O
10	among	O
11	the	O
12	WAD	O
13	goat	O
14	population	O
15	.	O

1	Mutation	O
2	of	O
3	either	O
4	the	O
5	AP	B
6	-	I
7	1	I
8	or	O
9	the	O
10	ets	B
11	component	O
12	of	O
13	this	O
14	site	O
15	also	O
16	prevented	O
17	promoter	O
18	activity	O
19	in	O
20	SMCs	O
21	.	O

1	The	O
2	interferon	B
3	-	O
4	induced	O
5	RNA	B
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	(	O
11	PKR	B
12	)	O
13	is	O
14	considered	O
15	to	O
16	play	O
17	an	O
18	important	O
19	role	O
20	in	O
21	the	O
22	cellular	O
23	defense	O
24	against	O
25	viral	O
26	infection	O
27	and	O
28	,	O
29	in	O
30	addition	O
31	,	O
32	has	O
33	been	O
34	suggested	O
35	to	O
36	be	O
37	a	O
38	tumor	O
39	suppressor	O
40	gene	O
41	because	O
42	of	O
43	its	O
44	growth	O
45	-	O
46	suppressive	O
47	properties	O
48	.	O

1	Convulsive	O
2	seizure	O
3	during	O
4	a	O
5	treatment	O
6	with	O
7	interferon	B
8	alpha	I
9	for	O
10	chronic	O
11	viral	O
12	hepatitis	O
13	C	O

1	Dr	O
2	.	O

1	Derivatives	O
2	of	O
3	fluorene	O
4	.	O

1	All	O
2	these	O
3	processes	O
4	were	O
5	fully	O
6	developed	O
7	during	O
8	the	O
9	last	O
10	month	O
11	of	O
12	pregnancy	O
13	,	O
14	offering	O
15	the	O
16	same	O
17	picture	O
18	as	O
19	the	O
20	controls	O
21	.	O

1	The	O
2	response	O
3	properties	O
4	of	O
5	cat	O
6	horizontal	O
7	canal	O
8	afferents	O
9	(	O
10	N	O
11	=	O
12	81	O
13	)	O
14	were	O
15	characterized	O
16	by	O
17	three	O
18	parameters	O
19	:	O
20	their	O
21	long	O
22	time	O
23	constants	O
24	(	O
25	tau	O
26	),	O
27	low	O
28	frequency	O
29	gain	O
30	constants	O
31	(	O
32	G1	O
33	),	O
34	and	O
35	middle	O
36	frequency	O
37	gain	O
38	constants	O
39	(	O
40	Gm	O
41	).	O

1	We	O
2	are	O
3	reporting	O
4	an	O
5	autopsy	O
6	case	O
7	of	O
8	so	O
9	-	O
10	called	O
11	"	O
12	acute	O
13	multiple	O
14	sclerosis	O
15	"	O
16	that	O
17	was	O
18	difficult	O
19	to	O
20	differentiate	O
21	from	O
22	a	O
23	brain	O
24	tumor	O
25	on	O
26	MRI	O
27	findings	O
28	.	O

1	No	O
2	reflow	O
3	occurred	O
4	in	O
5	approximately	O
6	30	O
7	percent	O
8	of	O
9	the	O
10	muscle	O
11	microvasculature	O
12	upon	O
13	reperfusion	O
14	.	O

1	Interference	O
2	with	O
3	rheumatoid	B
4	factor	I
5	was	O
6	only	O
7	observed	O
8	in	O
9	the	O
10	ELISA	O
11	enzygnost	O
12	if	O
13	sera	O
14	were	O
15	not	O
16	pretreated	O
17	with	O
18	latex	O
19	adsorbents	O
20	.	O

1	It	O
2	was	O
3	argued	O
4	that	O
5	this	O
6	arose	O
7	from	O
8	the	O
9	possibility	O
10	that	O
11	the	O
12	nature	O
13	of	O
14	blue	O
15	collar	O
16	jobs	O
17	was	O
18	physical	O
19	,	O
20	and	O
21	that	O
22	loss	O
23	of	O
24	myocardial	O
25	tissue	O
26	might	O
27	be	O
28	expected	O
29	to	O
30	more	O
31	markedly	O
32	interfere	O
33	with	O
34	their	O
35	work	O
36	efficiency	O
37	(	O
38	on	O
39	returning	O
40	to	O
41	work	O
42	)	O
43	than	O
44	it	O
45	would	O
46	the	O
47	efficiency	O
48	of	O
49	the	O
50	more	O
51	sedentary	O
52	jobs	O
53	of	O
54	white	O
55	collar	O
56	workers	O
57	.	O

1	The	O
2	genome	O
3	of	O
4	the	O
5	human	O
6	herpesvirus	O
7	8	O
8	(	O
9	HHV	O
10	-	O
11	8	O
12	)	O
13	contains	O
14	a	O
15	cluster	O
16	of	O
17	open	O
18	reading	O
19	frames	O
20	(	O
21	ORFs	O
22	)	O
23	encoding	O
24	proteins	O
25	with	O
26	homology	O
27	to	O
28	the	O
29	cellular	O
30	transcription	O
31	factors	O
32	of	O
33	the	O
34	interferon	B
35	regulatory	I
36	factor	I
37	(	O
38	IRF	B
39	)	O
40	family	O
41	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	Gag	B
2	protein	I
3	sequence	I
4	motifs	I
5	of	O
6	the	O
7	NC	B
8	domain	I
9	of	O
10	primate	O
11	foamy	O
12	viruses	O
13	assumed	O
14	to	O
15	be	O
16	involved	O
17	in	O
18	genome	O
19	encapsidation	O
20	are	O
21	not	O
22	conserved	O
23	in	O
24	FeFV	O
25	.	O

1	PBSX	O
2	is	O
3	induced	O
4	by	O
5	agents	O
6	which	O
7	elicit	O
8	the	O
9	SOS	O
10	response	O
11	.	O

1	Clipping	O
2	resulted	O
3	in	O
4	a	O
5	serious	O
6	mislocalization	O
7	of	O
8	the	O
9	position	O
10	of	O
11	the	O
12	peak	O
13	of	O
14	the	O
15	epicortical	O
16	potential	O
17	field	O
18	.	O

1	Thus	O
2	in	O
3	this	O
4	region	O
5	of	O
6	the	O
7	vessel	O
8	pyridinoline	O
9	represents	O
10	the	O
11	major	O
12	stabilising	O
13	crosslink	O
14	of	O
15	collagen	B
16	.	O

1	High	O
2	-	O
3	frequency	O
4	electrical	O
5	stimulation	O
6	in	O
7	the	O
8	hippocampus	O
9	leads	O
10	to	O
11	an	O
12	increase	O
13	in	O
14	synaptic	O
15	efficacy	O
16	that	O
17	lasts	O
18	for	O
19	many	O
20	hours	O
21	.	O

1	Analysis	O
2	with	O
3	additional	O
4	anti	B
5	-	I
6	peptide	I
7	antibodies	I
8	specific	O
9	for	O
10	alpha	O
11	,	O
12	beta	O
13	,	O
14	or	O
15	gamma	B
16	PKC	I
17	indicated	O
18	that	O
19	all	O
20	three	O
21	types	O
22	of	O
23	PKC	B
24	are	O
25	expressed	O
26	in	O
27	JK	O
28	cells	O
29	;	O
30	however	O
31	,	O
32	JKPE	O
33	cells	O
34	lost	O
35	a	O
36	major	O
37	approximately	O
38	82	O
39	kDa	O
40	immunoreactive	O
41	cytosolic	O
42	protein	O
43	detectable	O
44	with	O
45	anti	B
46	-	I
47	PKC	I
48	alpha	I
49	antibody	I
50	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	a	O
5	6	O
6	.	O
7	3	O
8	-	O
9	kbp	B
10	genomic	I
11	EcoRI	I
12	-	I
13	fragment	I
14	of	O
15	Alcaligenes	O
16	eutrophus	O
17	,	O
18	which	O
19	was	O
20	recently	O
21	identified	O
22	by	O
23	using	O
24	a	O
25	dihydrolipoamide	B
26	dehydrogenase	I
27	-	O
28	specific	O
29	DNA	O
30	probe	O
31	(	O
32	A	O
33	.	O

1	When	O
2	two	O
3	determinations	O
4	were	O
5	performed	O
6	on	O
7	12	O
8	samples	O
9	of	O
10	plasma	O
11	taken	O
12	from	O
13	normal	O
14	adults	O
15	in	O
16	October	O
17	,	O
18	the	O
19	values	O
20	were	O
21	22	O
22	.	O
23	6	O
24	+/-	O
25	4	O
26	.	O
27	8	O
28	and	O
29	21	O
30	.	O
31	0	O
32	+/-	O
33	3	O
34	.	O
35	6	O
36	(	O
37	mean	O
38	+/-	O
39	SD	O
40	)	O
41	ng	O
42	/	O
43	ml	O
44	,	O
45	respectively	O
46	.	O

1	Regulation	O
2	of	O
3	yeast	B
4	LEU2	I
5	.	O

1	In	O
2	one	O
3	acromegalic	O
4	patient	O
5	visual	O
6	improvement	O
7	was	O
8	obtained	O
9	while	O
10	the	O
11	abnormal	O
12	GH	B
13	secretion	O
14	remained	O
15	unaltered	O
16	.	O

1	Absence	O
2	of	O
3	action	O
4	potentials	O
5	in	O
6	frog	O
7	slow	O
8	muscle	O
9	fibres	O
10	paralysed	O
11	by	O
12	botulinum	B
13	toxin	I
14	.	O

1	The	O
2	negative	O
3	predictive	O
4	value	O
5	is	O
6	92	O
7	%,	O
8	vs	O
9	80	O
10	%	O
11	for	O
12	the	O
13	NCEP	B
14	I	I
15	.	O

1	Movement	O
2	programming	O
3	depends	O
4	on	O
5	understanding	O
6	of	O
7	behavioral	O
8	requirements	O
9	.	O

1	Expression	O
2	of	O
3	various	O
4	FAK	B
5	mutants	I
6	in	O
7	the	O
8	FAK	B
9	-	O
10	cells	O
11	showed	O
12	that	O
13	FAK	B
14	kinase	I
15	activity	O
16	,	O
17	the	O
18	Tyr	O
19	-	O
20	397	O
21	/	O
22	SH2	B
23	domain	I
24	binding	I
25	site	I
26	,	O
27	and	O
28	the	O
29	first	O
30	proline	O
31	-	O
32	rich	O
33	SH3	B
34	binding	I
35	region	I
36	in	O
37	the	O
38	FAK	B
39	C	I
40	-	I
41	terminal	I
42	domain	I
43	were	O
44	individually	O
45	needed	O
46	to	O
47	promote	O
48	full	O
49	FAK	B
50	-	O
51	mediated	O
52	FAK	B
53	-	O
54	cell	O
55	migration	O
56	to	O
57	FN	B
58	whereas	O
59	direct	O
60	paxillin	B
61	binding	O
62	to	O
63	FAK	B
64	was	O
65	not	O
66	required	O
67	.	O

1	QBMDs	O
2	for	O
3	a	O
4	5	O
5	%	O
6	change	O
7	in	O
8	response	O
9	(	O
10	QBMD05	O
11	)	O
12	were	O
13	6	O
14	-	O
15	fold	O
16	lower	O
17	,	O
18	on	O
19	average	O
20	,	O
21	than	O
22	the	O
23	corresponding	O
24	NOAEL	O
25	.	O

1	X	O
2	-	O
3	ray	O
4	crystallographic	O
5	data	O
6	show	O
7	that	O
8	the	O
9	PLZF	B
10	BTB	I
11	/	O
12	POZ	O
13	domain	O
14	forms	O
15	an	O
16	obligate	O
17	homodimer	O
18	via	O
19	an	O
20	extensive	O
21	interface	O
22	.	O

1	To	O
2	compare	O
3	the	O
4	PAX3	B
5	and	O
6	putative	O
7	PAX3	B
8	-	I
9	FKHR	I
10	transactivation	O
11	domains	O
12	,	O
13	we	O
14	fused	O
15	C	O
16	-	O
17	terminal	O
18	test	O
19	fragments	O
20	to	O
21	the	O
22	heterologous	O
23	GAL4	B
24	DNA	O
25	-	O
26	binding	O
27	domain	O
28	and	O
29	tested	O
30	activation	O
31	of	O
32	a	O
33	reporter	O
34	gene	O
35	co	O
36	-	O
37	transfected	O
38	into	O
39	four	O
40	cell	O
41	types	O
42	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RXRalphaF318A	O
5	constitutive	O
6	activity	O
7	generated	O
8	within	O
9	heterodimers	O
10	in	O
11	the	O
12	presence	O
13	of	O
14	BMS614	B
15	requires	O
16	the	O
17	integrity	O
18	of	O
19	both	O
20	RXR	B
21	and	O
22	RAR	B
23	AF	I
24	-	I
25	2	I
26	domains	I
27	.	O

1	The	O
2	Dax	B
3	-	I
4	1	I
5	gene	I
6	encodes	O
7	a	O
8	protein	O
9	that	O
10	is	O
11	structurally	O
12	related	O
13	to	O
14	members	O
15	of	O
16	the	O
17	orphan	B
18	nuclear	I
19	receptor	I
20	superfamily	I
21	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	O
6	-	O
7	2	O
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	O
20	aspirin	O
21	is	O
22	mandatory	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	B
15	-	I
16	alpha	I
17	-	I
18	acetyldigoxin	I
19	.	O

1	No	B
2	UOxase	I
3	mRNA	I
4	was	O
5	detected	O
6	in	O
7	11	O
8	nonhepatic	O
9	tissues	O
10	of	O
11	rat	O
12	,	O
13	suggesting	O
14	tissue	O
15	specificity	O
16	of	O
17	expression	O
18	of	O
19	this	O
20	UOxase	B
21	gene	I
22	.	O

1	These	O
2	REPs	O
3	,	O
4	or	O
5	clusters	O
6	of	O
7	paralogous	O
8	loci	O
9	,	O
10	are	O
11	15	O
12	-	O
13	100	O
14	kb	O
15	and	O
16	harbor	O
17	at	O
18	least	O
19	four	O
20	ESTs	O
21	and	O
22	an	O
23	expressed	O
24	SH3GL	B
25	pseudogene	I
26	.	O

1	Strain	O
2	CFN037	O
3	is	O
4	an	O
5	R	O
6	.	O
7	etli	O
8	mutant	O
9	induced	O
10	by	O
11	a	O
12	single	O
13	Tn5mob	O
14	insertion	O
15	in	O
16	the	O
17	promoter	O
18	region	O
19	of	O
20	the	O
21	thiCOGE	B
22	gene	I
23	cluster	I
24	.	O

1	After	O
2	selection	O
3	and	O
4	conversion	O
5	to	O
6	adipocytes	O
7	,	O
8	the	O
9	level	O
10	of	O
11	EGFR	B
12	expression	O
13	was	O
14	retained	O
15	in	O
16	infectant	O
17	adipocytes	O
18	(	O
19	150	O
20	,	O
21	000	O
22	and	O
23	250	O
24	,	O
25	000	O
26	/	O
27	cell	O
28	,	O
29	respectively	O
30	),	O
31	but	O
32	not	O
33	in	O
34	the	O
35	parental	O
36	3T3	O
37	-	O
38	L1	O
39	adipocytes	O
40	(<	O
41	5000	O
42	/	O
43	cell	O
44	).	O

1	NuA4	O
2	has	O
3	an	O
4	apparent	O
5	molecular	O
6	mass	O
7	of	O
8	1	O
9	.	O
10	3	O
11	MDa	O
12	.	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	PHO85	B
6	encodes	O
7	a	O
8	cyclin	B
9	-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	Cdk	B
15	)	O
16	catalytic	O
17	subunit	O
18	with	O
19	multiple	O
20	regulatory	O
21	roles	O
22	thought	O
23	to	O
24	be	O
25	specified	O
26	by	O
27	association	O
28	with	O
29	different	O
30	cyclin	B
31	partners	I
32	(	O
33	Pcls	O
34	).	O

1	NiCl	O
2	(	O
3	2	O
4	)-	O
5	induced	O
6	MCP	B
7	-	I
8	1	I
9	synthesis	O
10	required	O
11	activation	O
12	of	O
13	NF	B
14	-	I
15	kappaB	I
16	since	O
17	mutation	O
18	of	O
19	NF	B
20	-	I
21	kappaB	I
22	-	I
23	binding	I
24	sites	I
25	in	O
26	the	O
27	promoter	O
28	resulted	O
29	in	O
30	complete	O
31	loss	O
32	of	O
33	inducible	O
34	promoter	O
35	activity	O
36	.	O

1	An	O
2	ASIC	O
3	-	O
4	chip	O
5	for	O
6	stereoscopic	O
7	depth	O
8	analysis	O
9	in	O
10	video	O
11	-	O
12	real	O
13	-	O
14	time	O
15	based	O
16	on	O
17	visual	O
18	cortical	O
19	cell	O
20	behavior	O
21	.	O

1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	O
8	repair	O
9	enzyme	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O

1	Wild	O
2	type	O
3	HA	O
4	-	O
5	p190	O
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparison	O
5	revealed	O
6	significant	O
7	homology	O
8	between	O
9	the	O
10	yeast	O
11	and	O
12	Escherichia	B
13	coli	I
14	gamma	I
15	-	I
16	glutamyl	I
17	kinases	I
18	throughout	O
19	their	O
20	lengths	O
21	.	O

1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O

1	The	O
2	3ASubE	O
3	cells	O
4	expressing	O
5	CXCR2	O
6	with	O
7	mutation	O
8	of	O
9	Ser	O
10	-	O
11	346	O
12	,	O
13	-	O
14	347	O
15	,	O
16	and	O
17	-	O
18	348	O
19	to	O
20	alanine	O
21	,	O
22	or	O
23	with	O
24	mutation	O
25	of	O
26	only	O
27	one	O
28	serine	O
29	in	O
30	this	O
31	domain	O
32	,	O
33	continue	O
34	to	O
35	be	O
36	phosphorylated	O
37	in	O
38	response	O
39	to	O
40	ligand	O
41	and	O
42	are	O
43	60	O
44	-	O
45	70	O
46	%	O
47	desensitized	O
48	following	O
49	the	O
50	initial	O
51	ligand	O
52	challenge	O
53	.	O

1	This	O
2	L	B
3	-	I
4	myc	I
5	sequence	I
6	is	O
7	amplified	O
8	10	O
9	-	O
10	20	O
11	-	O
12	fold	O
13	in	O
14	four	O
15	SCLC	O
16	cell	O
17	line	O
18	DNAs	O
19	and	O
20	in	O
21	one	O
22	SCLC	O
23	tumour	O
24	specimen	O
25	taken	O
26	directly	O
27	from	O
28	a	O
29	patient	O
30	.	O

1	This	O
2	result	O
3	supports	O
4	the	O
5	argument	O
6	that	O
7	the	O
8	beta	O
9	'	O
10	subunit	O
11	plays	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	determining	O
17	the	O
18	progress	O
19	of	O
20	transcription	O
21	elongation	O
22	.	O

1	[	O
2	18F	O
3	](+)-	O
4	4	O
5	-	O
6	fluorobenzyltrozamicol	O
7	(	O
8	FBT	O
9	),	O
10	which	O
11	selectively	O
12	binds	O
13	to	O
14	the	O
15	vesicular	O
16	acetylcholine	O
17	transporter	O
18	in	O
19	the	O
20	presynaptic	O
21	cholinergic	O
22	neuron	O
23	,	O
24	has	O
25	previously	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	a	O
31	useful	O
32	ligand	O
33	for	O
34	the	O
35	study	O
36	of	O
37	cholinergic	O
38	terminal	O
39	density	O
40	in	O
41	the	O
42	basal	O
43	ganglia	O
44	with	O
45	PET	O
46	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	RNU2	B
6	fragility	O
7	can	O
8	be	O
9	induced	O
10	by	O
11	transfection	O
12	with	O
13	an	O
14	expression	O
15	vector	O
16	encoding	O
17	Ad12	B
18	E1B	I
19	55	I
20	kDa	I
21	alone	O
22	but	O
23	not	O
24	by	O
25	an	O
26	E1	O
27	vector	O
28	encoding	O
29	all	O
30	E1	B
31	products	I
32	(	I
33	3	I
34	E1A	I
35	proteins	I
36	,	O
37	as	O
38	well	O
39	as	O
40	the	O
41	E1B	B
42	19	I
43	kDa	I
44	and	I
45	55	I
46	kDa	I
47	proteins	I
48	).	O

1	It	O
2	contains	O
3	a	O
4	5	O
5	'-	O
6	noncoding	O
7	region	O
8	(	O
9	NCR	O
10	)	O
11	of	O
12	73	O
13	nucleotides	O
14	,	O
15	five	O
16	open	O
17	reading	O
18	frames	O
19	(	O
20	ORFs	O
21	1	O
22	to	O
23	5	O
24	)	O
25	which	O
26	encode	O
27	proteins	O
28	with	O
29	M	O
30	(	O
31	r	B
32	)	I
33	160	I
34	kDa	I
35	RNA	I
36	-	I
37	dependent	I
38	RNA	I
39	polymerase	I
40	(	O
41	ORF1	O
42	),	O
43	26	O
44	kDa	O
45	movement	O
46	protein	O
47	1	O
48	(	O
49	ORF2	O
50	),	O
51	13	O
52	kDa	O
53	movement	O
54	protein	O
55	2	O
56	(	O
57	ORF3	O
58	),	O
59	10	O
60	kDa	O
61	movement	O
62	protein	O
63	3	O
64	(	O
65	ORF4	O
66	),	O
67	24	O
68	kDa	O
69	coat	B
70	protein	I
71	(	O
72	OFR5	O
73	),	O
74	and	O
75	a	O
76	3	O
77	'	O
78	NCR	O
79	of	O
80	76	O
81	nucleotides	O
82	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	acetyltransferase	B
6	activity	O
7	of	O
8	p300	B
9	was	O
10	observed	O
11	to	O
12	be	O
13	distinct	O
14	from	O
15	the	O
16	broadly	O
17	essential	O
18	activation	O
19	function	O
20	of	O
21	the	O
22	CH3	B
23	domain	I
24	/	O
25	E1A	B
26	-	I
27	binding	I
28	region	I
29	.	O

1	Therefore	O
2	,	O
3	use	O
4	of	O
5	presaturation	O
6	is	O
7	recommended	O
8	for	O
9	myocardial	O
10	motion	O
11	studies	O
12	using	O
13	cine	O
14	PC	O
15	velocity	O
16	data	O
17	.	O

1	Sp1	B
2	can	O
3	activate	O
4	transcription	O
5	through	O
6	immunoglobulin	B
7	kappa	I
8	-	I
9	chain	I
10	enhancer	I
11	or	O
12	P	B
13	-	I
14	selectin	I
15	promoter	I
16	NF	I
17	-	I
18	kappaB	I
19	sites	I
20	.	I
21	p50	I
22	homodimers	I
23	replace	I
24	Sp1	I
25	from	O
26	the	O
27	P	B
28	-	I
29	selectin	I
30	promoter	I
31	by	O
32	binding	O
33	site	O
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	O
40	Sp1	B
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	O
49	Bcl	B
50	-	I
51	3	I
52	,	O
53	stimulate	O
54	expression	O
55	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	binding	I
8	protein	I
9	-	I
10	2	I
11	(	O
12	IGF	B
13	-	I
14	BP	I
15	-	I
16	2	I
17	)	O
18	transcription	O
19	in	O
20	rat	O
21	liver	O
22	varies	O
23	with	O
24	developmental	O
25	age	O
26	and	O
27	fasting	O
28	.	O

1	Selected	O
2	topics	O
3	in	O
4	pediatric	O
5	ultrasonography	O
6	--	O
7	1992	O
8	.	O

1	Concordantly	O
2	,	O
3	it	O
4	was	O
5	shown	O
6	that	O
7	the	O
8	dnHLH	B
9	protein	I
10	Id1	I
11	inhibits	O
12	differentiation	O
13	of	O
14	muscle	O
15	and	O
16	myeloid	O
17	cells	O
18	in	O
19	vitro	O
20	.	O

1	Nevertheless	O
2	,	O
3	in	O
4	view	O
5	of	O
6	the	O
7	potential	O
8	transmission	O
9	rates	O
10	of	O
11	HGV	O
12	and	O
13	the	O
14	lack	O
15	of	O
16	effective	O
17	immunization	O
18	,	O
19	HGV	O
20	should	O
21	be	O
22	regarded	O
23	as	O
24	a	O
25	potential	O
26	occupational	O
27	hazard	O
28	for	O
29	medical	O
30	and	O
31	dental	O
32	staff	O
33	.	O

1	Thus	O
2	,	O
3	the	O
4	PCE	B
5	binds	O
6	a	O
7	Pbx	O
8	dimer	O
9	partner	O
10	that	O
11	behaves	O
12	unlike	O
13	Class	B
14	I	I
15	Hox	I
16	proteins	I
17	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	fibroblast	B
5	growth	I
6	factor	I
7	receptor	I
8	2	I
9	(	O
10	FGF	B
11	-	I
12	R2	I
13	)	O
14	is	O
15	an	O
16	example	O
17	of	O
18	highly	O
19	regulated	O
20	alternative	O
21	splicing	O
22	in	O
23	which	O
24	exons	O
25	IIIb	O
26	and	O
27	IIIc	O
28	are	O
29	utilized	O
30	in	O
31	a	O
32	mutually	O
33	exclusive	O
34	manner	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	Two	O
2	-	O
3	dimensional	O
4	phosphotryptic	O
5	analyses	O
6	indicate	O
7	that	O
8	phosphorylation	O
9	on	O
10	Ser	O
11	-	O
12	12	O
13	and	O
14	Ser	O
15	-	O
16	48	O
17	in	O
18	unstimulated	O
19	cells	O
20	is	O
21	associated	O
22	with	O
23	the	O
24	ability	O
25	of	O
26	overexpressed	O
27	pp60c	B
28	-	I
29	src	I
30	to	O
31	potentiate	O
32	beta	O
33	-	O
34	adrenergic	O
35	signalling	O
36	.	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	thioredoxin	I
6	reductases	I
7	.	O

1	Bacterial	O
2	meningitis	O
3	secondary	O
4	to	O
5	abscess	O
6	of	O
7	the	O
8	nasal	O
9	septum	O
10	.	O

1	Our	O
2	findings	O
3	suggest	O
4	that	O
5	striatal	O
6	FDG	O
7	and	O
8	particularly	O
9	RACLO	O
10	are	O
11	sensitive	O
12	and	O
13	effective	O
14	measures	O
15	of	O
16	striatal	O
17	function	O
18	and	O
19	may	O
20	help	O
21	characterizing	O
22	patients	O
23	with	O
24	multiple	O
25	system	O
26	atrophy	O
27	.	O

1	The	O
2	science	O
3	of	O
4	tissue	O
5	engineering	O
6	.	O

1	However	O
2	,	O
3	although	O
4	deletion	O
5	of	O
6	Fp1	B
7	in	O
8	the	O
9	hCRBP1	B
10	gene	I
11	yielded	O
12	increased	O
13	CAT	B
14	activity	O
15	,	O
16	pointing	O
17	toward	O
18	a	O
19	negative	O
20	regulatory	O
21	function	O
22	exerted	O
23	by	O
24	this	O
25	element	O
26	,	O
27	its	O
28	insertion	O
29	upstream	O
30	of	O
31	the	O
32	p12	B
33	basal	I
34	promoter	I
35	results	O
36	in	O
37	an	O
38	impressive	O
39	positive	O
40	stimulation	O
41	of	O
42	CAT	B
43	gene	I
44	expression	O
45	.	O

1	All	O
2	samples	O
3	exhibited	O
4	a	O
5	decline	O
6	in	O
7	ethanol	O
8	concentration	O
9	,	O
10	with	O
11	most	O
12	losses	O
13	falling	O
14	within	O
15	the	O
16	expected	O
17	20	O
18	to	O
19	40	O
20	mg	O
21	%	O
22	range	O
23	.	O

1	Western	O
2	blot	O
3	analysis	O
4	showed	O
5	a	O
6	rapid	O
7	corresponding	O
8	increase	O
9	in	O
10	p21WAF1	B
11	/	O
12	CIP1	B
13	protein	O
14	,	O
15	whereas	O
16	protein	O
17	levels	O
18	of	O
19	another	O
20	member	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	I
28	family	I
29	,	O
30	p27kip1	B
31	,	O
32	were	O
33	unchanged	O
34	.	O

1	Among	O
2	genes	O
3	induced	O
4	by	O
5	added	O
6	pMesogenin1	O
7	is	O
8	Xwnt	O
9	-	O
10	8	O
11	,	O
12	a	O
13	signaling	O
14	factor	O
15	that	O
16	induces	O
17	a	O
18	similar	O
19	repertoire	O
20	of	O
21	marker	O
22	genes	O
23	and	O
24	a	O
25	similar	O
26	cellular	O
27	phenotype	O
28	.	O

1	A	O
2	rapid	O
3	fluorimetric	O
4	procedure	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	the	O
10	fungicide	O
11	5	O
12	-	O
13	fluorocytosine	O
14	in	O
15	serum	O
16	is	O
17	described	O
18	.	O

1	The	O
2	percentages	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	monthly	O
11	estimated	O
12	and	O
13	analyzed	O
14	rhythmometrically	O
15	by	O
16	cosinor	O
17	for	O
18	5	O
19	clonal	O
20	cultures	O
21	of	O
22	Scripsiella	O
23	trochoidea	O
24	Stein	O
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	rended	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	lighting	O
53	(	O
54	25	O
55	microEin	O
56	m	B
57	-	I
58	2	I
59	s	I
60	-	I
61	1	I
62	),	O
63	and	O
64	artificial	O
65	seawater	O
66	.	O

1	The	O
2	results	O
3	of	O
4	induced	O
5	coexpression	O
6	were	O
7	also	O
8	supported	O
9	by	O
10	rapid	O
11	generation	O
12	of	O
13	FeLV	O
14	recombinants	O
15	when	O
16	FeLV	O
17	-	O
18	C	O
19	was	O
20	used	O
21	to	O
22	infect	O
23	the	O
24	feline	B
25	3201B	I
26	cell	O
27	line	O
28	that	O
29	constitutively	O
30	expresses	O
31	high	O
32	levels	O
33	of	O
34	endogenous	O
35	FeLV	O
36	-	O
37	specific	O
38	mRNAs	O
39	.	O

1	NF	B
2	-	I
3	kappaB	I
4	plays	O
5	a	O
6	critical	O
7	role	O
8	in	O
9	activation	O
10	of	O
11	HIV	B
12	-	I
13	1	I
14	gene	I
15	expression	O
16	by	O
17	cytokines	O
18	and	O
19	other	O
20	stimuli	O
21	,	O
22	but	O
23	the	O
24	signal	O
25	transduction	O
26	pathways	O
27	that	O
28	regulate	O
29	the	O
30	switch	O
31	from	O
32	latent	O
33	to	O
34	productive	O
35	infection	O
36	have	O
37	not	O
38	been	O
39	defined	O
40	.	O

1	Hybridization	O
2	data	O
3	indicate	O
4	that	O
5	6F6	B
6	.	O
7	2	O
8	corresponds	O
9	to	O
10	the	O
11	previously	O
12	characterized	O
13	m6F6	B
14	cDNA	I
15	clone	I
16	and	O
17	that	O
18	6F6	B
19	.	I
20	1	I
21	and	O
22	6F6	B
23	.	O
24	3	O
25	,	O
26	but	O
27	not	O
28	6F6	B
29	.	I
30	2	I
31	,	O
32	are	O
33	adjacent	O
34	to	O
35	alpha	B
36	-	I
37	type	I
38	genes	I
39	.	O

1	JCAHO	O
2	revised	O
3	interpretation	O

1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	assays	O
9	indicate	O
10	that	O
11	PBP	B
12	binds	O
13	to	O
14	the	O
15	half	O
16	-	O
17	site	O
18	of	O
19	each	O
20	palindrome	O
21	with	O
22	the	O
23	core	O
24	recognition	O
25	sequence	O
26	TGGGAG	O
27	.	O

1	DAF	B
2	is	O
3	a	O
4	70	O
5	kD	O
6	glycoprotein	O
7	containing	O
8	complement	O
9	regulatory	O
10	short	O
11	consensus	O
12	repeats	O
13	(	O
14	SCRs	O
15	);	O
16	its	O
17	gene	O
18	is	O
19	located	O
20	in	O
21	the	O
22	regulation	O
23	of	O
24	complement	O
25	activation	O
26	(	O
27	RCA	O
28	)	O
29	gene	O
30	cluster	O
31	on	O
32	chromosome	O
33	1	O
34	and	O
35	is	O
36	about	O
37	40	O
38	kb	O
39	in	O
40	size	O
41	.	O

1	Copyright	O
2	1998	O
3	Elsevier	O
4	Science	O
5	B	O
6	.	O
7	V	O
8	.	O

1	The	O
2	centromeric	O
3	YAC	O
4	contig	O
5	,	O
6	which	O
7	consists	O
8	of	O
9	23	O
10	overlapping	O
11	YACs	O
12	and	O
13	orders	O
14	19	O
15	sequence	O
16	-	O
17	tagged	O
18	sites	O
19	(	O
20	STSs	O
21	),	O
22	covers	O
23	a	O
24	minimum	O
25	of	O
26	2	O
27	.	O
28	2	O
29	Mb	O
30	and	O
31	spans	O
32	the	O
33	Ewing	O
34	sarcoma	O
35	breakpoint	O
36	.	O
37	c	B
38	-	I
39	ets	I
40	1	I
41	and	O
42	Fli	B
43	-	I
44	1	I
45	,	O
46	two	O
47	members	O
48	of	O
49	the	O
50	ets	B
51	family	I
52	,	O
53	have	O
54	been	O
55	linked	O
56	within	O
57	400	O
58	kb	O
59	of	O
60	intervening	O
61	DNA	O
62	within	O
63	this	O
64	contig	O
65	,	O
66	which	O
67	also	O
68	comprises	O
69	a	O
70	polymorphic	O
71	microsatellite	O
72	,	O
73	D11S912	B
74	(	O
75	CA	O
76	)	O
77	n	O
78	,	O
79	which	O
80	we	O
81	have	O
82	localized	O
83	within	O
84	the	O
85	Fli	B
86	-	I
87	1	I
88	gene	I
89	.	O

1	Encapsidation	O
2	of	O
3	poliovirus	O
4	replicons	O
5	encoding	O
6	the	O
7	complete	O
8	human	B
9	immunodeficiency	I
10	virus	I
11	type	I
12	1	I
13	gag	I
14	gene	I
15	by	O
16	using	O
17	a	O
18	complementation	O
19	system	O
20	which	O
21	provides	O
22	the	O
23	P1	B
24	capsid	I
25	protein	I
26	in	O
27	trans	O
28	.	O

1	Naphthalene	O
2	and	O
3	paradichlorobenzene	O
4	in	O
5	clinical	O
6	toxicology	O

1	The	O
2	Spo0F	O
3	residues	O
4	making	O
5	up	O
6	the	O
7	hydrophobic	O
8	patch	O
9	are	O
10	very	O
11	similar	O
12	in	O
13	all	O
14	response	O
15	regulators	O
16	suggesting	O
17	that	O
18	the	O
19	binding	O
20	is	O
21	initiated	O
22	through	O
23	the	O
24	same	O
25	residues	O
26	in	O
27	all	O
28	interacting	O
29	response	O
30	regulator	O
31	-	O
32	kinase	O
33	pairs	O
34	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	sites	O
6	of	O
7	recombinational	O
8	resolution	O
9	is	O
10	inversely	O
11	correlated	O
12	with	O
13	that	O
14	of	O
15	the	O
16	gradient	O
17	of	O
18	sequence	O
19	divergence	O
20	,	O
21	with	O
22	only	O
23	approximately	O
24	7	O
25	%	O
26	of	O
27	the	O
28	X	O
29	recombinants	O
30	resolved	O
31	within	O
32	the	O
33	3	O
34	'	O
35	third	O
36	of	O
37	the	O
38	X	O
39	blocks	O
40	where	O
41	two	O
42	diverged	O
43	Alu	B
44	family	I
45	repeats	O
46	reside	O
47	.	O

1	Comparison	O
2	of	O
3	the	O
4	plant	O
5	nuclear	O
6	tRNA	O
7	3	O
8	'	O
9	processing	O
10	enzyme	O
11	with	O
12	the	O
13	plant	O
14	mitochondrial	O
15	one	O
16	suggests	O
17	that	O
18	both	O
19	activities	O
20	are	O
21	different	O
22	enzymes	O
23	.	O

1	Leukemia	B
2	-	I
3	inhibitory	I
4	factor	I
5	(	O
6	LIF	O
7	)	O
8	is	O
9	a	O
10	neuropoietin	O
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	B
11	multidrug	I
12	resistance	I
13	protein	I
14	2	I
15	(	O
16	MRP2	B
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	O
26	resistance	O
27	protein	O
28	3	O
29	(	O
30	MRP3	O
31	)	O
32	gene	O
33	.	O

1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O

1	The	O
2	sequencing	O
3	of	O
4	the	O
5	conditional	O
6	lethal	O
7	mutation	B
8	ts	I
9	-	I
10	A13	I
11	,	O
12	localized	O
13	in	O
14	the	O
15	nrdE	O
16	cistron	O
17	,	O
18	and	O
19	the	O
20	lethality	O
21	of	O
22	insertional	O
23	mutations	O
24	targeted	O
25	in	O
26	the	O
27	internal	O
28	region	O
29	of	O
30	nrdE	O
31	and	O
32	nrdF	O
33	,	O
34	demonstrated	O
35	the	O
36	essential	O
37	role	O
38	of	O
39	this	O
40	locus	O
41	.	O

1	In	O
2	literature	O
3	,	O
4	the	O
5	HBE	O
6	has	O
7	been	O
8	displayed	O
9	by	O
10	application	O
11	of	O
12	the	O
13	averaging	O
14	method	O
15	.	O

1	The	O
2	comparison	O
3	of	O
4	the	O
5	expression	O
6	patterns	O
7	of	O
8	the	O
9	known	O
10	Kv4	B
11	family	I
12	members	I
13	shows	O
14	subtype	O
15	specificity	O
16	with	O
17	significant	O
18	overlaps	O
19	.	O

1	2	O
2	.	O

1	CONCLUSION	O
2	:	O
3	This	O
4	study	O
5	documents	O
6	that	O
7	regression	O
8	of	O
9	choroidal	O
10	neovascularization	O
11	that	O
12	occurred	O
13	with	O
14	alpha	B
15	interferon	I
16	treatment	O
17	was	O
18	minimal	O
19	.	O

1	A	O
2	cAMP	O
3	-	O
4	responsive	O
5	element	O
6	-	O
7	like	O
8	(	O
9	CRE	O
10	-	O
11	like	O
12	,	O
13	TGACGTGA	O
14	)	O
15	promoter	O
16	sequence	O
17	and	O
18	a	O
19	protein	B
20	kinase	I
21	A	I
22	signaling	O
23	pathway	O
24	are	O
25	involved	O
26	in	O
27	this	O
28	induction	O
29	,	O
30	and	O
31	activation	O
32	of	O
33	both	O
34	CRE	B
35	binding	I
36	protein	I
37	(	O
38	CREB	B
39	)	O
40	and	O
41	activating	B
42	transcription	I
43	factor	I
44	-	I
45	2	I
46	(	O
47	ATF	B
48	-	I
49	2	I
50	)	O
51	is	O
52	required	O
53	in	O
54	the	O
55	above	O
56	process	O
57	.	O

1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	actual	O
12	egg	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O

1	Underlying	O
2	the	O
3	clustering	O
4	of	O
5	these	O
6	risk	O
7	variables	O
8	were	O
9	three	O
10	factors	O
11	.	O

1	The	O
2	modalities	O
3	for	O
4	using	O
5	reference	O
6	values	O
7	for	O
8	individual	O
9	subjects	O
10	as	O
11	well	O
12	as	O
13	for	O
14	groups	O
15	are	O
16	then	O
17	discussed	O
18	and	O
19	the	O
20	main	O
21	points	O
22	of	O
23	research	O
24	which	O
25	must	O
26	be	O
27	faced	O
28	in	O
29	the	O
30	near	O
31	future	O
32	regarding	O
33	reference	O
34	values	O
35	are	O
36	highlighted	O
37	.	O

1	These	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	those	O
7	obtained	O
8	in	O
9	-	O
10	D	O
11	mothers	O
12	and	O
13	pups	O
14	,	O
15	after	O
16	giving	O
17	the	O
18	mothers	O
19	an	O
20	oral	O
21	supplement	O
22	(	O
23	10	O
24	i	O
25	.	O
26	u	O
27	.	O
28	vitamin	O
29	D3	O
30	/	O
31	day	O
32	)	O
33	during	O
34	the	O
35	period	O
36	of	O
37	lactation	O
38	(	O
39	20	O
40	days	O
41	).	O

1	Pulmonary	O
2	vascular	O
3	resistance	O
4	was	O
5	not	O
6	altered	O
7	,	O
8	ejection	O
9	fraction	O
10	remained	O
11	unchanged	O
12	and	O
13	isovolumic	O
14	relaxation	O
15	period	O
16	was	O
17	lengthened	O
18	(	O
19	119	O
20	+/-	O
21	20	O
22	.	O
23	1	O
24	to	O
25	147	O
26	.	O
27	39	O
28	+/-	O
29	21	O
30	.	O
31	15	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	To	O
2	better	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	Ets	B
8	proteins	I
9	in	O
10	Ras	B
11	transformation	O
12	,	O
13	we	O
14	have	O
15	now	O
16	analyzed	O
17	the	O
18	effects	O
19	of	O
20	stably	O
21	expressing	O
22	a	O
23	variety	O
24	of	O
25	Ets2	B
26	constructs	I
27	in	O
28	Ras	B
29	-	O
30	transformed	O
31	NIH3T3	O
32	(	O
33	DT	O
34	)	O
35	cells	O
36	.	O

1	IgG	B
2	and	O
3	IgM	B
4	antibody	I
5	activity	O
6	was	O
7	determined	O
8	by	O
9	adding	O
10	a	O
11	1	O
12	:	O
13	100	O
14	dilution	O
15	of	O
16	serum	O
17	to	O
18	plates	O
19	coated	O
20	with	O
21	A60	B
22	antigen	I
23	.	O

1	Ventilatory	O
2	management	O
3	casebook	O
4	.	O

1	Althoug	O
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O

1	Also	O
2	,	O
3	the	O
4	deduced	O
5	amino	O
6	acids	O
7	of	O
8	the	O
9	antigenic	O
10	regions	O
11	A	O
12	,	O
13	B	O
14	and	O
15	C	O
16	of	O
17	VP7	O
18	were	O
19	nearly	O
20	conserved	O
21	within	O
22	the	O
23	phylogenetic	O
24	lineages	O
25	.	O

1	Platelet	O
2	aggregation	O
3	in	O
4	response	O
5	to	O
6	10	O
7	micrograms	O
8	collagen	B
9	/	O
10	ml	O
11	was	O
12	decreased	O
13	in	O
14	parallel	O
15	after	O
16	treatment	O
17	with	O
18	ASA	O
19	.	O

1	A	O
2	chicken	O
3	paxillin	B
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	O
21	paxil	O
22	-	O
23	lin	O
24	.	O

1	Protein	O
2	phosphorylation	O
3	appears	O
4	to	O
5	play	O
6	a	O
7	critical	O
8	role	O
9	in	O
10	uPA	B
11	gene	I
12	expression	O
13	in	O
14	these	O
15	cells	O
16	;	O
17	protein	O
18	kinase	O
19	C	O
20	-	O
21	activating	O
22	phorbol	O
23	esters	O
24	cooperate	O
25	with	O
26	pp60v	B
27	-	I
28	src	I
29	to	O
30	synergistically	O
31	increase	O
32	uPA	B
33	mRNA	I
34	,	O
35	whereas	O
36	cyclic	O
37	AMP	O
38	(	O
39	cAMP	O
40	)-	O
41	dependent	O
42	protein	O
43	kinase	O
44	-	O
45	activating	O
46	agents	O
47	(	O
48	e	O
49	.	O
50	g	O
51	.,	O
52	8	O
53	-	O
54	bromo	O
55	cAMP	O
56	)	O
57	repress	O
58	uPA	B
59	mRNA	I
60	levels	O
61	.	O

1	R	O
2	-	O
3	wave	O
4	voltage	O
5	in	O
6	the	O
7	right	O
8	precordial	O
9	leads	O
10	in	O
11	anthracycline	O
12	cardiomyopathy	O
13	:	O
14	a	O
15	clinical	O
16	study	O
17	.	O

1	Interestingly	O
2	,	O
3	dTFIIA	B
4	-	I
5	L	I
6	/	I
7	S	I
8	is	O
9	also	O
10	able	O
11	to	O
12	significantly	O
13	enhance	O
14	transcriptional	O
15	activation	O
16	by	O
17	upstream	O
18	transcription	O
19	factors	O
20	including	O
21	Sp1	B
22	,	O
23	VP16	B
24	,	O
25	and	O
26	NTF	B
27	-	I
28	1	I
29	.	O

1	It	O
2	has	O
3	been	O
4	calculated	O
5	that	O
6	600	O
7	,	O
8	000	O
9	new	O
10	cases	O
11	of	O
12	lung	O
13	cancer	O
14	occur	O
15	worldwide	O
16	every	O
17	year	O
18	,	O
19	most	O
20	of	O
21	them	O
22	due	O
23	to	O
24	smoking	O
25	.	O

1	The	O
2	full	B
3	-	I
4	length	I
5	N	I
6	gene	I
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	B
24	-	I
25	8	I
26	.	O

1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	B
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	B
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	B
31	-	I
32	early	I
33	39K	I
34	promoter	I
35	.	O

1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	O
11	magnitude	O
12	of	O
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O

1	A	O
2	survey	O
3	is	O
4	given	O
5	of	O
6	the	O
7	pharmacological	O
8	backgrounds	O
9	that	O
10	are	O
11	relevant	O
12	for	O
13	the	O
14	drug	O
15	treatment	O
16	of	O
17	essential	O
18	hypertension	O
19	in	O
20	the	O
21	elderly	O
22	.	O

1	Determined	O
2	as	O
3	migration	O
4	differentials	O
5	,	O
6	chemotactic	O
7	and	O
8	chemokinetic	O
9	responsiveness	O
10	tended	O
11	to	O
12	be	O
13	higher	O
14	in	O
15	the	O
16	neutropenic	O
17	group	O
18	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	Similarly	O
2	,	O
3	expression	O
4	of	O
5	a	O
6	transiently	O
7	transfected	O
8	wild	B
9	-	I
10	type	I
11	prothymosin	I
12	alpha	I
13	gene	I
14	as	O
15	the	O
16	reporter	O
17	was	O
18	not	O
19	affected	O
20	by	O
21	a	O
22	repertoire	O
23	of	O
24	myc	B
25	-	I
26	derived	I
27	genes	I
28	,	O
29	including	O
30	myc	B
31	itself	O
32	and	O
33	dominant	O
34	or	O
35	recessive	O
36	negative	O
37	myc	B
38	mutants	I
39	.	O

1	Radiation	O
2	decreased	O
3	the	O
4	levels	O
5	of	O
6	T4	O
7	and	O
8	T3	O
9	6	O
10	h	O
11	and	O
12	72	O
13	h	O
14	in	O
15	group	O
16	C	O
17	,	O
18	in	O
19	group	O
20	A	O
21	at	O
22	72	O
23	h	O
24	,	O
25	in	O
26	group	O
27	B	O
28	at	O
29	24	O
30	h	O
31	postexposure	O
32	.	O

1	The	O
2	hybridizing	O
3	clone	O
4	of	O
5	V	O
6	.	O
7	vulnificus	O
8	chromosomal	O
9	DNA	O
10	complemented	O
11	a	O
12	V	O
13	.	O
14	cholerae	O
15	fur	O
16	mutant	O
17	.	O

1	Haemodynamic	O
2	responses	O
3	to	O
4	antagonism	O
5	of	O
6	bocurarine	O
7	block	O
8	with	O
9	atropine	O
10	-	O
11	neostigmine	O
12	mixture	O
13	in	O
14	children	O
15	.	O

1	After	O
2	clofelin	O
3	administration	O
4	the	O
5	autoregulation	O
6	borders	O
7	shifted	O
8	to	O
9	the	O
10	right	O
11	i	O
12	.	O
13	e	O
14	.	O
15	towards	O
16	higher	O
17	AP	O
18	levels	O
19	.	O

1	Enzyme	O
2	histochemical	O
3	findings	O
4	in	O
5	the	O
6	ultimobranchial	O
7	body	O
8	of	O
9	the	O
10	horse	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	both	O
6	in	O
7	the	O
8	early	O
9	stages	O
10	(	O
11	0T	O
12	,	O
13	0N	O
14	)	O
15	and	O
16	in	O
17	more	O
18	severe	O
19	stages	O
20	of	O
21	VWF	B
22	(	O
23	stages	O
24	1	O
25	-	O
26	2	O
27	)	O
28	cold	O
29	induced	O
30	hyperreactivity	O
31	in	O
32	the	O
33	digital	O
34	vessels	O
35	and	O
36	Raynaud	O
37	'	O
38	s	O
39	syndrome	O
40	are	O
41	vascular	O
42	disorders	O
43	of	O
44	functional	O
45	origin	O
46	occurring	O
47	without	O
48	any	O
49	prethrombotic	O
50	alterations	O
51	.	O

1	Motile	O
2	nocardoid	O
3	Actinomycetales	O
4	.	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	O
27	lit	O
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	Grade	O
2	3	O
3	-	O
4	4	O
5	mucositis	O
6	was	O
7	present	O
8	in	O
9	13	O
10	%	O
11	of	O
12	the	O
13	cycles	O
14	.	O

1	Another	O
2	tentative	O
3	hotspot	O
4	mutation	O
5	in	O
6	the	O
7	third	O
8	patient	O
9	,	O
10	a	O
11	frame	O
12	shift	O
13	caused	O
14	by	O
15	a	O
16	G	O
17	nucleotide	O
18	insertion	O
19	in	O
20	a	O
21	monotonous	O
22	repeat	O
23	of	O
24	six	O
25	Gs	B
26	in	O
27	HPRT	O
28	exon	O
29	3	O
30	,	O
31	has	O
32	been	O
33	reported	O
34	previously	O
35	in	O
36	three	O
37	other	O
38	LN	O
39	patients	O
40	.	O

1	In	O
2	agreement	O
3	with	O
4	these	O
5	data	O
6	,	O
7	western	O
8	blot	O
9	experiments	O
10	using	O
11	an	O
12	antibody	O
13	directed	O
14	against	O
15	the	O
16	carboxy	O
17	-	O
18	terminal	O
19	portion	O
20	of	O
21	the	O
22	mouse	B
23	c	I
24	-	I
25	kit	I
26	protein	I
27	showed	O
28	that	O
29	a	O
30	polypeptide	O
31	,	O
32	of	O
33	the	O
34	size	O
35	predicted	O
36	by	O
37	the	O
38	open	O
39	reading	O
40	frame	O
41	of	O
42	the	O
43	spermatid	O
44	-	O
45	specific	O
46	c	B
47	-	I
48	kit	I
49	cDNA	I
50	,	O
51	accumulates	O
52	in	O
53	the	O
54	latest	O
55	stages	O
56	of	O
57	spermatogenesis	O
58	and	O
59	in	O
60	epididymal	O
61	spermatozoa	O
62	.	O

1	The	O
2	polyubiquitin	B
3	gene	I
4	was	O
5	transcribed	O
6	throughout	O
7	the	O
8	Volvox	O
9	life	O
10	cycle	O
11	with	O
12	peaks	O
13	in	O
14	the	O
15	1	O
16	.	O
17	6	O
18	-	O
19	kb	O
20	mRNA	O
21	levels	O
22	during	O
23	pre	O
24	-	O
25	cleavage	O
26	,	O
27	cleavage	O
28	,	O
29	and	O
30	post	O
31	-	O
32	inversion	O
33	.	O

1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O

1	Promoter	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	dependently	O
7	inhibited	O
8	by	O
9	cotransfection	O
10	with	O
11	either	O
12	ras	B
13	or	O
14	mos	B
15	oncogenes	I
16	,	O
17	but	O
18	oncogene	O
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	O
25	activity	O
26	increased	O
27	when	O
28	cells	O
29	were	O
30	treated	O
31	with	O
32	the	O
33	MAP	B
34	kinase	I
35	kinase	I
36	(	O
37	MKK	B
38	)	O
39	inhibitor	O
40	PD98059	O
41	.	O

1	W	O
2	.	O

1	A	O
2	data	O
3	base	O
4	homology	O
5	search	O
6	revealed	O
7	that	O
8	the	O
9	predicted	O
10	ER1	B
11	amino	I
12	acid	I
13	sequence	I
14	contains	O
15	three	O
16	regions	O
17	of	O
18	similarity	O
19	to	O
20	the	O
21	rat	O
22	and	O
23	human	O
24	proteins	O
25	encoded	O
26	by	O
27	the	O
28	metastasis	O
29	-	O
30	associated	O
31	gene	O
32	,	O
33	mta1	B
34	,	O
35	and	O
36	two	O
37	regions	O
38	of	O
39	similarity	O
40	to	O
41	the	O
42	Caenorhabditis	O
43	elegans	O
44	sequence	O
45	that	O
46	is	O
47	similar	O
48	to	O
49	mta1	B
50	.	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	other	O
6	Ras	B
7	effectors	O
8	can	O
9	collaborate	O
10	with	O
11	PI	B
12	3	I
13	-	I
14	kinase	I
15	and	O
16	with	O
17	each	O
18	other	O
19	to	O
20	activate	O
21	Pak	O
22	.	O

1	The	O
2	construction	O
3	of	O
4	a	O
5	small	O
6	library	O
7	of	O
8	mouse	O
9	repetitive	O
10	DNA	O
11	has	O
12	been	O
13	previously	O
14	reported	O
15	(	O
16	Pietras	O
17	et	O
18	al	O
19	.,	O
20	Nucleic	O
21	Acids	O
22	Res	O
23	.	O

1	The	O
2	extended	O
3	rat	O
4	SP	O
5	-	O
6	A	O
7	isoforms	O
8	were	O
9	enriched	O
10	in	O
11	the	O
12	more	O
13	fully	O
14	glycosylated	O
15	and	O
16	multimeric	O
17	SP	O
18	-	O
19	A	O
20	species	O
21	separated	O
22	on	O
23	SDS	O
24	-	O
25	PAGE	O
26	gels	O
27	.	O

1	The	O
2	neural	O
3	mechanism	O
4	of	O
5	parkinsonian	O
6	motor	O
7	symptoms	O
8	,	O
9	i	O
10	.	O
11	e	O
12	.,	O
13	rigidity	O
14	,	O
15	tremor	O
16	and	O
17	akinesia	O
18	,	O
19	which	O
20	are	O
21	the	O
22	result	O
23	of	O
24	nigrostriatal	O
25	dopamine	O
26	deficiency	O
27	,	O
28	is	O
29	interpreted	O
30	from	O
31	long	O
32	-	O
33	term	O
34	observations	O
35	on	O
36	the	O
37	effect	O
38	of	O
39	surgical	O
40	and	O
41	pharmacological	O
42	treatment	O
43	of	O
44	the	O
45	disease	O
46	in	O
47	relation	O
48	to	O
49	the	O
50	neuropathological	O
51	findings	O
52	within	O
53	the	O
54	substantia	O
55	nigra	O
56	zona	O
57	compacta	O
58	(	O
59	SNc	O
60	).	O

1	The	O
2	retinoid	B
3	Z	I
4	receptor	I
5	beta	I
6	(	O
7	RZR	B
8	beta	I
9	),	O
10	an	O
11	orphan	B
12	receptor	I
13	,	O
14	is	O
15	a	O
16	member	O
17	of	O
18	the	O
19	retinoic	B
20	acid	I
21	receptor	I
22	(	O
23	RAR	B
24	)/	I
25	thyroid	I
26	hormone	I
27	receptor	I
28	(	O
29	TR	B
30	)	O
31	subfamily	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O

1	Problems	O
2	common	O
3	to	O
4	pediatrics	O
5	and	O
6	anesthesiology	O

1	The	O
2	second	O
3	transcriptional	O
4	unit	O
5	,	O
6	designated	O
7	UL26	B
8	.	I
9	5	I
10	,	O
11	predicted	O
12	to	O
13	specify	O
14	a	O
15	protein	O
16	of	O
17	329	O
18	amino	O
19	acids	O
20	,	O
21	encodes	O
22	the	O
23	family	O
24	35	O
25	proteins	O
26	;	O
27	it	O
28	is	O
29	transcribed	O
30	by	O
31	an	O
32	mRNA	O
33	which	O
34	initiates	O
35	at	O
36	approximately	O
37	nucleotide	O
38	+	O
39	1000	O
40	of	O
41	the	O
42	UL26	B
43	transcription	I
44	initiation	I
45	site	I
46	and	O
47	is	O
48	translated	O
49	from	O
50	the	O
51	methionine	O
52	initiation	O
53	codon	O
54	located	O
55	at	O
56	position	O
57	+	O
58	1099	O
59	of	O
60	the	O
61	UL26	B
62	transcriptional	I
63	unit	I
64	.	O

1	A	O
2	comparison	O
3	of	O
4	physical	O
5	and	O
6	cytogenetic	O
7	estimates	O
8	of	O
9	radiation	O
10	dose	O
11	in	O
12	patients	O
13	treated	O
14	with	O
15	iodine	O
16	-	O
17	131	O
18	for	O
19	thyroid	O
20	carcinoma	O
21	.	O

1	Metal	O
2	coordination	O
3	compounds	O
4	of	O
5	thiabendazole	O
6	.	O

1	A	O
2	leucine	O
3	zipper	O
4	domain	O
5	of	O
6	the	O
7	suppressor	O
8	of	O
9	Hairy	O
10	-	O
11	wing	O
12	protein	O
13	mediates	O
14	its	O
15	repressive	O
16	effect	O
17	on	O
18	enhancer	O
19	function	O
20	.	O

1	The	O
2	end	O
3	-	O
4	stage	O
5	or	O
6	involutional	O
7	phase	O
8	of	O
9	proliferative	O
10	diabetic	O
11	retinopathy	O
12	may	O
13	result	O
14	in	O
15	stabilization	O
16	of	O
17	vision	O
18	for	O
19	long	O
20	periods	O
21	of	O
22	time	O
23	.	O

1	Functional	O
2	flow	O
3	was	O
4	evaluated	O
5	using	O
6	laser	O
7	Doppler	O
8	flowmetry	O
9	(	O
10	LDF	O
11	),	O
12	for	O
13	which	O
14	the	O
15	output	O
16	signal	O
17	,	O
18	blood	O
19	cell	O
20	flux	O
21	(	O
22	BCF	O
23	),	O
24	is	O
25	expressed	O
26	in	O
27	terms	O
28	of	O
29	volts	O
30	.	O

1	The	O
2	genome	O
3	of	O
4	all	O
5	retroviruses	O
6	consists	O
7	of	O
8	two	O
9	identical	O
10	RNAs	O
11	noncovalently	O
12	linked	O
13	near	O
14	their	O
15	5	O
16	'	O
17	end	O
18	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	BACKGROUND	O
2	/	O
3	PURPOSE	O
4	:	O
5	Anomalous	O
6	arrangement	O
7	of	O
8	the	O
9	pancreaticobiliary	O
10	duct	O
11	(	O
12	AAPBD	O
13	)	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	congenital	O
19	biliary	O
20	dilatation	O
21	and	O
22	frequently	O
23	associated	O
24	with	O
25	biliary	O
26	tract	O
27	malignancy	O
28	.	O

1	Levels	O
2	of	O
3	both	O
4	PGF	O
5	and	O
6	PGFM	O
7	were	O
8	significantly	O
9	higher	O
10	during	O
11	early	O
12	spontaneous	O
13	labour	O
14	,	O
15	at	O
16	a	O
17	cervical	O
18	dilatation	O
19	of	O
20	less	O
21	than	O
22	4	O
23	cm	O
24	,	O
25	than	O
26	before	O
27	the	O
28	onset	O
29	of	O
30	labour	O
31	.	O

1	Differential	O
2	expression	O
3	of	O
4	AP	B
5	-	I
6	2alpha	I
7	and	O
8	AP	B
9	-	I
10	2beta	I
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	B
20	-	I
21	FABP	I
22	promoter	I
23	activity	O
24	by	O
25	AP	B
26	-	I
27	2	I
28	.	O

1	Conjugated	O
2	estrogens	O
3	shorten	O
4	bleeding	O
5	time	O
6	in	O
7	uraemia	O
8	:	O
9	a	O
10	possible	O
11	role	O
12	of	O
13	serotonin	O
14	?	O

1	Intron	O
2	-	O
3	exon	O
4	structure	O
5	of	O
6	the	O
7	porcine	O
8	I	B
9	kappa	I
10	B	I
11	alpha	I
12	-	I
13	encoding	I
14	gene	I
15	.	O

1	Cells	O
2	differentiate	O
3	in	O
4	response	O
5	to	O
6	various	O
7	extracellular	O
8	stimuli	O
9	.	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	O
21	-	O
22	protein	O
23	interactions	O
24	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	Analysis	O
2	of	O
3	the	O
4	entire	O
5	16	O
6	.	O
7	7	O
8	-	O
9	kb	O
10	mt	O
11	genome	O
12	determined	O
13	that	O
14	a	O
15	MDP1	B
16	mediates	O
17	cleavage	O
18	of	O
19	chick	O
20	mtDNA	O
21	in	O
22	vitro	O
23	at	O
24	three	O
25	H	O
26	-	O
27	and	O
28	two	O
29	L	O
30	-	O
31	strand	O
32	sequence	O
33	-	O
34	specific	O
35	target	O
36	sites	O
37	located	O
38	within	O
39	a	O
40	90	O
41	-	O
42	bp	O
43	A	O
44	+	O
45	T	O
46	-	O
47	rich	O
48	genomic	O
49	tract	O
50	,	O
51	theoretically	O
52	capable	O
53	of	O
54	forming	O
55	stable	O
56	secondary	O
57	structures	O
58	,	O
59	approximately	O
60	200	O
61	bases	O
62	upstream	O
63	from	O
64	the	O
65	H	O
66	-	O
67	strand	O
68	origin	O
69	(	O
70	OH	O
71	)	O
72	of	O
73	replication	O
74	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O

1	Furthermore	O
2	,	O
3	beta	B
4	2	I
5	-	I
6	adrenoceptor	I
7	sensitivity	O
8	appears	O
9	to	O
10	be	O
11	unaltered	O
12	in	O
13	BHT	O
14	.	O

1	Antibodies	O
2	to	O
3	the	O
4	human	O
5	PTS1R	O
6	recognize	O
7	this	O
8	protein	O
9	in	O
10	human	O
11	,	O
12	monkey	O
13	,	O
14	rat	O
15	,	O
16	and	O
17	hamster	O
18	cells	O
19	.	O

1	It	O
2	also	O
3	suggests	O
4	that	O
5	there	O
6	is	O
7	another	O
8	pathway	O
9	which	O
10	can	O
11	activate	O
12	SWI4	B
13	transcription	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	SWI6	B
19	.	O

1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	moderate	O
7	cooling	O
8	increases	O
9	the	O
10	responsiveness	O
11	of	O
12	vascular	O
13	alpha2	B
14	-	I
15	adrenoceptors	I
16	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	B
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	A	O
2	strong	O
3	correlation	O
4	exists	O
5	between	O
6	the	O
7	numbers	O
8	of	O
9	CFU	O
10	-	O
11	GM	O
12	transfused	O
13	and	O
14	the	O
15	rate	O
16	of	O
17	granulocytes	O
18	and	O
19	platelets	O
20	recovery	O
21	.	O

1	Unrecognized	O
2	amnionitis	O
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	Stable	O
2	patients	O
3	have	O
4	mucous	O
5	hypersecretion	O
6	and	O
7	little	O
8	evidence	O
9	of	O
10	acute	O
11	inflammation	O
12	.	O

1	Imaging	O
2	features	O
3	of	O
4	splenic	O
5	epidermoid	O
6	cyst	O
7	with	O
8	pathologic	O
9	correlation	O
10	.	O

1	4	O
2	.	O

1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	B
59	/	O
60	m	B
61	-	I
62	2	I
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	Spinal	O
2	cord	O
3	representation	O
4	of	O
5	the	O
6	micturition	O
7	reflex	O
8	.	O

1	In	O
2	the	O
3	past	O
4	,	O
5	immunology	O
6	in	O
7	Singapore	O
8	was	O
9	mainly	O
10	confined	O
11	to	O
12	serology	O
13	for	O
14	the	O
15	diagnosis	O
16	of	O
17	certain	O
18	infectious	O
19	diseases	O
20	.	O

1	The	O
2	predicted	O
3	receptor	O
4	structure	O
5	includes	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	extracellular	O
11	domain	O
12	,	O
13	a	O
14	single	O
15	hydrophobic	O
16	transmembrane	O
17	domain	O
18	,	O
19	and	O
20	a	O
21	predicted	O
22	cytoplasmic	B
23	serine	I
24	/	I
25	threonine	I
26	kinase	I
27	domain	I
28	.	O

1	Improved	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	breeding	O
10	the	O
11	neotropical	O
12	short	O
13	-	O
14	tailed	O
15	fruit	O
16	bat	O
17	,	O
18	Carollia	O
19	perspicillata	O
20	,	O
21	in	O
22	an	O
23	easily	O
24	-	O
25	reproduced	O
26	,	O
27	laboratory	O
28	setting	O
29	.	O

1	The	O
2	atp	B
3	1	I
4	and	O
5	atp	O
6	2	O
7	types	O
8	of	O
9	cDNA	O
10	sequences	O
11	were	O
12	the	O
13	most	O
14	redundant	O
15	among	O
16	the	O
17	28	O
18	different	O
19	isoperoxidases	O
20	identified	O
21	among	O
22	about	O
23	200	O
24	peroxidase	O
25	encoding	O
26	ESTs	O
27	.	O

1	Mouse	B
2	mast	I
3	cell	I
4	protease	I
5	9	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	chromosome	O
13	14	O
14	family	O
15	of	O
16	serine	O
17	proteases	O
18	that	O
19	is	O
20	selectively	O
21	expressed	O
22	in	O
23	uterine	O
24	mast	O
25	cells	O
26	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	the	O
9	antagonistic	O
10	effects	O
11	of	O
12	CRP	B
13	and	O
14	KdgR	B
15	on	O
16	the	O
17	expression	O
18	of	O
19	the	O
20	pectinolysis	O
21	genes	O
22	occur	O
23	by	O
24	different	O
25	mechanisms	O
26	,	O
27	including	O
28	direct	O
29	competition	O
30	between	O
31	the	O
32	two	O
33	regulators	O
34	or	O
35	between	O
36	the	O
37	repressor	O
38	and	O
39	RNA	B
40	polymerase	I
41	for	O
42	the	O
43	occupation	O
44	of	O
45	a	O
46	common	O
47	DNA	O
48	region	O
49	on	O
50	the	O
51	target	O
52	genes	O
53	.	O

1	Seventy	O
2	-	O
3	two	O
4	of	O
5	73	O
6	negative	O
7	controls	O
8	and	O
9	all	O
10	positive	O
11	blocks	O
12	as	O
13	seen	O
14	on	O
15	soft	O
16	tissue	O
17	radiographs	O
18	(	O
19	STRs	O
20	)	O
21	were	O
22	correctly	O
23	coded	O
24	(	O
25	specificity	O
26	98	O
27	.	O
28	6	O
29	%,	O
30	sensitivity	O
31	100	O
32	%).	O

1	Site	B
2	S	I
3	-	I
4	II	I
5	also	O
6	spans	O
7	a	O
8	23	O
9	bp	O
10	sequence	O
11	containing	O
12	two	O
13	tandem	O
14	consensus	O
15	binding	O
16	sites	O
17	with	O
18	three	O
19	base	O
20	pair	O
21	mismatches	O
22	in	O
23	each	O
24	and	O
25	a	O
26	one	O
27	base	O
28	pair	O
29	deletion	O
30	.	O

1	Amino	O
2	acid	O
3	residues	O
4	of	O
5	beta	B
6	1	I
7	',	I
8	alpha	I
9	A	I
10	',	I
11	alpha	I
12	B	I
13	',	I
14	and	O
15	the	O
16	loop	O
17	containing	O
18	His539	O
19	of	O
20	the	O
21	RNase	B
22	H	I
23	domain	I
24	interact	O
25	with	O
26	the	O
27	primer	O
28	strand	O
29	of	O
30	the	O
31	dsDNA	O
32	.	O

1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O

1	In	O
2	one	O
3	glioblastoma	O
4	cell	O
5	line	O
6	,	O
7	a	O
8	Shc	B
9	-	I
10	associated	I
11	p190	I
12	was	O
13	identified	O
14	as	O
15	the	O
16	activated	O
17	PDGFR	B
18	.	O

1	Data	O
2	are	O
3	presented	O
4	hinting	O
5	that	O
6	the	O
7	15	O
8	beta	O
9	-	O
10	hydroxy	O
11	-,	O
12	metabolite	O
13	of	O
14	CPA	B
15	may	O
16	actually	O
17	be	O
18	the	O
19	biologically	O
20	active	O
21	agent	O
22	.	O

1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	B
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	O
43	gene	O
44	using	O
45	a	O
46	prokaryotic	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	pGEX	B
52	-	I
53	4T	I
54	-	I
55	2	I
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	B
72	-	I
73	thrombin	I
74	.	O

1	Nine	O
2	DNA	O
3	fragments	O
4	that	O
5	were	O
6	specifically	O
7	recognized	O
8	and	O
9	bound	O
10	by	O
11	histidine	O
12	-	O
13	tagged	O
14	AdpA	B
15	were	O
16	isolated	O
17	by	O
18	cycles	O
19	of	O
20	a	O
21	gel	O
22	mobility	O
23	shift	O
24	-	O
25	PCR	O
26	method	O
27	.	O

1	A	O
2	new	O
3	generation	O
4	of	O
5	information	O
6	retrieval	O
7	tools	O
8	for	O
9	biologists	O
10	:	O
11	the	O
12	example	O
13	of	O
14	the	O
15	ExPASy	O
16	WWW	O
17	server	O
18	.	O

1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	I
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	O
11	-	O
12	1	O
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	I
24	AP1	I
25	(	I
26	activator	I
27	protein	I
28	1	I
29	)	O
30	element	O
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	O
46	ras	B
47	and	O
48	protein	B
49	kinase	I
50	C	I
51	pathways	O
52	.	O

1	Restoration	O
2	of	O
3	impaired	O
4	immune	O
5	functions	O
6	in	O
7	aging	O
8	animals	O
9	.	O

1	RESULTS	O
2	:	O
3	Using	O
4	information	O
5	in	O
6	the	O
7	dbEST	O
8	database	O
9	of	O
10	expressed	O
11	sequence	O
12	tags	O
13	,	O
14	we	O
15	isolated	O
16	an	O
17	Arabidopsis	O
18	thaliana	O
19	gene	O
20	(	O
21	GCR1	B
22	)	O
23	that	O
24	encodes	O
25	a	O
26	protein	O
27	with	O
28	seven	O
29	predicted	O
30	membrane	O
31	-	O
32	spanning	O
33	domains	O
34	and	O
35	other	O
36	features	O
37	characteristic	O
38	of	O
39	7TM	B
40	receptors	I
41	.	O

1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

1	Nitrogen	O
2	-	O
3	hydrogen	O
4	tautomerism	O
5	in	O
6	porphyrins	O
7	and	O
8	chlorins	O
9	.	O

1	Erythrocyte	O
2	AA	O
3	in	O
4	FO	O
5	+	O
6	EPO	B
7	-	O
8	supplemented	O
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	formula	O
19	-	O
20	fed	O
21	levels	O
22	.	O

1	The	O
2	transport	O
3	of	O
4	a	O
5	genetically	O
6	engineered	O
7	chimeric	O
8	transmembrane	O
9	protein	O
10	connected	O
11	to	O
12	this	O
13	ER	O
14	leader	O
15	sequence	O
16	was	O
17	as	O
18	efficient	O
19	as	O
20	that	O
21	of	O
22	the	O
23	original	O
24	protein	O
25	from	O
26	which	O
27	the	O
28	ER	B
29	sequence	I
30	has	O
31	been	O
32	derived	O
33	.	O

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	monotherapy	O
13	.	O

1	The	O
2	latter	O
3	method	O
4	adds	O
5	clamping	O
6	of	O
7	the	O
8	inferior	O
9	vena	O
10	cava	O
11	,	O
12	which	O
13	results	O
14	in	O
15	hypotension	O
16	,	O
17	requiring	O
18	invasive	O
19	anesthetic	O
20	management	O
21	.	O

1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	B
6	gene	I
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	B
12	(+)	I
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O

1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O

1	Transient	O
2	transfection	O
3	experiments	O
4	revealed	O
5	that	O
6	Pax	B
7	-	I
8	8	I
9	isoforms	O
10	a	O
11	and	O
12	b	O
13	,	O
14	but	O
15	not	O
16	c	O
17	and	O
18	d	O
19	,	O
20	strongly	O
21	stimulate	O
22	transcription	O
23	from	O
24	a	O
25	promoter	O
26	containing	O
27	six	O
28	copies	O
29	of	O
30	a	O
31	paired	O
32	-	O
33	domain	O
34	recognition	O
35	sequence	O
36	.	O

1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	O
17	RBCC	B
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O

1	In	O
2	18	O
3	%	O
4	lymphography	O
5	was	O
6	clearly	O
7	positive	O
8	and	O
9	CT	O
10	negative	O
11	.	O

1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	we	O
8	analyzed	O
9	the	O
10	U6	B
11	RNA	I
12	genes	I
13	of	O
14	52	O
15	organisms	O
16	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	O
32	membrane	O
33	-	O
34	bound	O
35	receptors	O
36	.	O

1	One	O
2	of	O
3	the	O
4	sequelae	O
5	of	O
6	the	O
7	antiphospholipid	B
8	-	I
9	antibodies	I
10	is	O
11	an	O
12	impaired	O
13	uteroplacental	O
14	circulation	O
15	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	at	O
5	the	O
6	5	O
7	'	O
8	and	O
9	3	O
10	'	O
11	ends	O
12	of	O
13	these	O
14	introns	O
15	are	O
16	characteristic	O
17	of	O
18	spliced	O
19	transcripts	O
20	from	O
21	eukaryotic	O
22	protein	O
23	-	O
24	encoding	O
25	genes	O
26	,	O
27	with	O
28	one	O
29	significant	O
30	difference	O
31	;	O
32	i	O
33	.	O
34	e	O
35	.,	O
36	the	O
37	5	O
38	'	O
39	end	O
40	of	O
41	the	O
42	LAT	B
43	intron	I
44	is	O
45	GC	O
46	instead	O
47	of	O
48	the	O
49	consensus	O
50	sequence	O
51	GT	O
52	.	O

1	Although	O
2	noninhibitory	O
3	fluid	O
4	had	O
5	higher	O
6	mean	O
7	concentrations	O
8	of	O
9	phosphorus	O
10	and	O
11	zinc	O
12	,	O
13	these	O
14	differences	O
15	did	O
16	not	O
17	hold	O
18	after	O
19	meconium	O
20	-	O
21	stained	O
22	samples	O
23	were	O
24	excluded	O
25	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	O
12	glutamic	B
13	acid	I
14	decarboxylase	I
15	gene	I
16	.	O

1	SL1	B
2	trans	O
3	-	O
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	B
20	elegans	I
21	pre	I
22	-	I
23	mRNA	I
24	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	Here	O
2	we	O
3	have	O
4	examined	O
5	the	O
6	ability	O
7	of	O
8	the	O
9	cellular	O
10	protein	O
11	YB	B
12	-	I
13	1	I
14	to	O
15	modulate	O
16	transcription	O
17	of	O
18	the	O
19	HIV	B
20	-	I
21	1	I
22	promoter	I
23	in	O
24	a	O
25	human	O
26	astrocytic	O
27	cell	O
28	line	O
29	(	O
30	U	O
31	-	O
32	87MG	O
33	),	O
34	a	O
35	neuronal	O
36	cell	O
37	line	O
38	(	O
39	SK	O
40	-	O
41	N	O
42	-	O
43	MC	O
44	)	O
45	and	O
46	lymphoid	O
47	cells	O
48	(	O
49	Jurkat	O
50	)	O
51	by	O
52	transfection	O
53	assay	O
54	.	O

1	The	O
2	levels	O
3	of	O
4	NSE	B
5	and	O
6	MBP	B
7	in	O
8	the	O
9	IJVB	O
10	were	O
11	compared	O
12	to	O
13	those	O
14	in	O
15	the	O
16	PVB	O
17	.	O

1	Buflomedil	O
2	(	O
3	i	O
4	.	O
5	v	O
6	.)	O
7	induced	O
8	a	O
9	dose	O
10	-	O
11	dependent	O
12	increase	O
13	of	O
14	cardiac	O
15	output	O
16	at	O
17	0	O
18	.	O
19	16	O
20	-	O
21	0	O
22	.	O
23	64	O
24	mg	O
25	/	O
26	kg	O
27	,	O
28	biphasic	O
29	changes	O
30	at	O
31	1	O
32	.	O
33	28	O
34	and	O
35	2	O
36	.	O
37	56	O
38	mg	O
39	/	O
40	kg	O
41	and	O
42	a	O
43	marked	O
44	decrease	O
45	and	O
46	subsequent	O
47	slight	O
48	increase	O
49	at	O
50	a	O
51	large	O
52	dose	O
53	of	O
54	5	O
55	.	O
56	12	O
57	mg	O
58	/	O
59	kg	O
60	.	O

1	Several	O
2	particular	O
3	features	O
4	of	O
5	this	O
6	polypeptide	O
7	fragment	O
8	from	O
9	the	O
10	hamster	B
11	lysyl	I
12	-	I
13	tRNA	I
14	synthetase	I
15	suggest	O
16	that	O
17	it	O
18	is	O
19	implicated	O
20	in	O
21	the	O
22	assembly	O
23	of	O
24	that	O
25	enzyme	O
26	within	O
27	the	O
28	multisynthetase	B
29	complex	I
30	.	O

1	NERVTRACK	B
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O

1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O

1	The	O
2	cytosolic	O
3	glutathione	B
4	S	I
5	-	I
6	transferases	I
7	(	O
8	GSTs	O
9	,	O
10	EC	B
11	2	I
12	.	I
13	5	I
14	.	I
15	1	I
16	.	I
17	18	I
18	)	O
19	are	O
20	a	O
21	superfamily	O
22	of	O
23	dimeric	O
24	isoenzymes	O
25	which	O
26	catalyze	O
27	the	O
28	conjugation	O
29	of	O
30	electrophilic	O
31	substrates	O
32	with	O
33	glutathione	O
34	.	O

1	The	O
2	transverse	O
3	relaxation	O
4	time	O
5	(	O
6	T2	O
7	)	O
8	and	O
9	apparent	O
10	diffusion	O
11	coefficient	O
12	of	O
13	water	O
14	were	O
15	determined	O
16	.	O

1	The	O
2	P131	B
3	ORF	I
4	is	O
5	followed	O
6	in	O
7	-	O
8	frame	O
9	by	O
10	a	O
11	second	O
12	ORF	O
13	which	O
14	is	O
15	probably	O
16	expressed	O
17	by	O
18	partial	O
19	readthrough	O
20	of	O
21	the	O
22	UGA	O
23	termination	O
24	codon	O
25	of	O
26	the	O
27	P131	B
28	ORF	I
29	to	O
30	produce	O
31	a	O
32	polypeptide	O
33	of	O
34	M	O
35	(	O
36	r	O
37	)	O
38	191044	O
39	(	O
40	P191	O
41	).	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	neuron	B
10	-	I
11	specific	I
12	protein	I
13	kinase	I
14	C	I
15	substrate	I
16	neurogranin	I
17	(	I
18	RC3	I
19	protein	I
20	).	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	SRF	B
6	accessory	O
7	proteins	O
8	.	O

1	Expression	O
2	,	O
3	nucleotide	O
4	sequence	O
5	and	O
6	mutational	O
7	analysis	O
8	of	O
9	two	O
10	open	O
11	reading	O
12	frames	O
13	in	O
14	the	O
15	nif	B
16	gene	I
17	region	I
18	of	O
19	Anabaena	O
20	sp	O
21	.	O
22	strain	O
23	PCC7120	O
24	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	Constitutive	O
2	function	O
3	of	O
4	a	O
5	positively	O
6	regulated	O
7	promoter	O
8	reveals	O
9	new	O
10	sequences	O
11	essential	O
12	for	O
13	activity	O
14	.	O

1	When	O
2	expressed	O
3	in	O
4	and	O
5	purified	O
6	from	O
7	Escherichia	O
8	coli	O
9	,	O
10	both	O
11	full	O
12	-	O
13	length	O
14	Fpr3	O
15	and	O
16	its	O
17	isolated	O
18	COOH	O
19	-	O
20	terminal	O
21	domain	O
22	exhibit	O
23	readily	O
24	detectable	O
25	PPIase	O
26	activity	O
27	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	O
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	O
42	loci	O
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O

1	Syndecan	O
2	-	O
3	4	O
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	localize	O
16	PKC	B
17	and	O
18	amplify	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	adhesions	O
26	.	O

1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	I
19	'	I
20	UTR	I
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	O
33	)	O
34	binding	O
35	proteins	O
36	of	O
37	the	O
38	alpha	O
39	-	O
40	complex	O
41	.	O

1	Cross	O
2	-	O
3	talking	O
4	among	O
5	Drosophila	B
6	nuclear	I
7	receptors	I
8	at	O
9	the	O
10	promiscuous	O
11	response	O
12	element	O
13	of	O
14	the	O
15	ng	B
16	-	I
17	1	I
18	and	O
19	ng	O
20	-	O
21	2	O
22	intermolt	O
23	genes	O
24	.	O

1	The	O
2	hepatitis	B
3	A	I
4	virus	I
5	antibody	I
6	(	O
7	anti	B
8	-	I
9	HAV	I
10	)	O
11	in	O
12	chronic	O
13	diffuse	O
14	liver	O
15	diseases	O

1	From	O
2	our	O
3	ultrastructural	O
4	and	O
5	biochemical	O
6	studies	O
7	,	O
8	it	O
9	is	O
10	evident	O
11	that	O
12	Type	O
13	II	O
14	pneumocytes	O
15	are	O
16	an	O
17	early	O
18	target	O
19	of	O
20	radiation	O
21	and	O
22	the	O
23	release	O
24	of	O
25	surfactant	O
26	into	O
27	the	O
28	alveolus	O
29	shortly	O
30	after	O
31	exposure	O
32	persists	O
33	for	O
34	days	O
35	and	O
36	weeks	O
37	.	O

1	The	O
2	effect	O
3	of	O
4	osmotic	O
5	flow	O
6	on	O
7	the	O
8	distribution	O
9	of	O
10	horseradish	B
11	peroxidase	I
12	within	O
13	the	O
14	intercellular	O
15	spaces	O
16	of	O
17	toad	O
18	bladder	O
19	epithelium	O
20	.	O

1	These	O
2	results	O
3	support	O
4	a	O
5	model	O
6	in	O
7	which	O
8	p53	B
9	protein	I
10	contributes	O
11	to	O
12	the	O
13	maintenance	O
14	of	O
15	genomic	O
16	integrity	O
17	through	O
18	recombinational	O
19	repair	O
20	.	O

1	The	O
2	average	O
3	backscatter	O
4	coefficient	O
5	was	O
6	six	O
7	time	O
8	larger	O
9	in	O
10	regions	O
11	of	O
12	infarct	O
13	studied	O
14	8	O
15	--	O
16	10	O
17	weeks	O
18	after	O
19	occlusion	O
20	than	O
21	that	O
22	in	O
23	regions	O
24	of	O
25	infarct	O
26	studied	O
27	5	O
28	--	O
29	6	O
30	weeks	O
31	after	O
32	occlusion	O
33	.	O

1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	O
16	them	O
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O

1	These	O
2	residues	O
3	,	O
4	Ile244	O
5	at	O
6	the	O
7	extracellular	O
8	end	O
9	of	O
10	transmembrane	B
11	helix	I
12	3	I
13	,	O
14	and	O
15	Tyr318	O
16	at	O
17	the	O
18	COOH	O
19	-	O
20	terminal	O
21	portion	O
22	of	O
23	extracellular	O
24	loop	O
25	2	O
26	,	O
27	are	O
28	replaced	O
29	by	O
30	Leu	O
31	and	O
32	Ile	O
33	in	O
34	the	O
35	PTH	B
36	-	I
37	1	I
38	receptor	I
39	,	O
40	respectively	O
41	.	O

1	In	O
2	Malmo	O
3	,	O
4	Sweden	O
5	,	O
6	17	O
7	,	O
8	181	O
9	school	O
10	children	O
11	born	O
12	in	O
13	the	O
14	years	O
15	1961	O
16	-	O
17	1965	O
18	were	O
19	screened	O
20	for	O
21	scoliosis	O
22	once	O
23	a	O
24	year	O
25	between	O
26	the	O
27	ages	O
28	of	O
29	7	O
30	and	O
31	16	O
32	years	O
33	,	O
34	during	O
35	1971	O
36	-	O
37	1980	O
38	.	O

1	Also	O
2	,	O
3	HR21ap	O
4	as	O
5	well	O
6	as	O
7	HR21Xap	O
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	B
15	binding	O
16	.	O

1	It	O
2	is	O
3	reported	O
4	that	O
5	,	O
6	at	O
7	present	O
8	,	O
9	most	O
10	of	O
11	the	O
12	MRSAs	O
13	spreading	O
14	in	O
15	Japan	O
16	are	O
17	acceleratedly	O
18	acquiring	O
19	resistance	O
20	to	O
21	many	O
22	drugs	O
23	,	O
24	and	O
25	especially	O
26	,	O
27	they	O
28	are	O
29	developing	O
30	high	O
31	resistance	O
32	against	O
33	beta	O
34	-	O
35	lactams	O
36	.	O

1	METHODS	O
2	:	O
3	We	O
4	studied	O
5	20	O
6	symptomatic	O
7	patients	O
8	with	O
9	HOCM	O
10	(	O
11	12	O
12	men	O
13	),	O
14	mean	O
15	age	O
16	52	O
17	+/-	O
18	17	O
19	years	O
20	,	O
21	before	O
22	and	O
23	after	O
24	septal	O
25	reduction	O
26	using	O
27	echocardiography	O
28	and	O
29	electrocardiogram	O
30	(	O
31	ECG	O
32	).	O

1	However	O
2	,	O
3	when	O
4	combined	O
5	with	O
6	mitomycin	O
7	C	O
8	given	O
9	with	O
10	1	O
11	to	O
12	5	O
13	-	O
14	days	O
15	interval	O
16	,	O
17	the	O
18	concurrent	O
19	administration	O
20	of	O
21	SPG	O
22	prolonged	O
23	significantly	O
24	the	O
25	life	O
26	-	O
27	span	O
28	of	O
29	the	O
30	tumor	O
31	-	O
32	bearing	O
33	mice	O
34	.	O

1	The	O
2	temporal	O
3	and	O
4	static	O
5	plasma	O
6	concentration	O
7	-	O
8	effect	O
9	relationships	O
10	were	O
11	evaluated	O
12	by	O
13	pharmacodynamic	O
14	modeling	O
15	and	O
16	linear	O
17	regression	O
18	.	O

1	Medicare	O
2	SNF	B
3	benefits	O
4	revised	O
5	--	O
6	again	O
7	.	O

1	Homograft	O
2	response	O
3	and	O
4	hemagglutinin	B
5	production	O
6	by	O
7	sensitized	O
8	thymectomized	O
9	irradiated	O
10	adult	O
11	mice	O
12	.	O

1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	concurrently	O
12	with	O
13	SSc	O
14	that	O
15	subsequently	O
16	progressed	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	just	O
25	1	O
26	month	O
27	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	PEA2	B
6	is	O
7	also	O
8	required	O
9	for	O
10	the	O
11	bipolar	O
12	budding	O
13	pattern	O
14	and	O
15	that	O
16	it	O
17	encodes	O
18	a	O
19	novel	O
20	protein	O
21	with	O
22	a	O
23	predicted	O
24	coiled	O
25	-	O
26	coil	O
27	domain	O
28	.	O

1	Sensitive	O
2	fluorometric	O
3	method	O
4	of	O
5	determining	O
6	SH	O
7	-	O
8	and	O
9	S	O
10	-	O
11	S	O
12	-	O
13	groups	O
14	when	O
15	jointly	O
16	present	O

1	Translational	O
2	fusions	O
3	of	O
4	the	O
5	aroF	O
6	regulatory	O
7	regions	O
8	to	O
9	lacZ	B
10	were	O
11	constructed	O
12	and	O
13	then	O
14	introduced	O
15	in	O
16	single	O
17	copy	O
18	into	O
19	the	O
20	E	O
21	.	O
22	coli	O
23	chromosome	O
24	.	O
25	beta	B
26	-	I
27	Galactosidase	I
28	assays	O
29	for	O
30	tyrR	B
31	-	O
32	mediated	O
33	regulation	O
34	of	O
35	aroF	O
36	-	O
37	lacZ	B
38	expression	O
39	revealed	O
40	that	O
41	the	O
42	E	O
43	.	O
44	coli	O
45	TyrR	O
46	repressor	O
47	apparently	O
48	recognizes	O
49	the	O
50	operators	O
51	of	O
52	both	O
53	organisms	O
54	with	O
55	about	O
56	equal	O
57	efficiency	O
58	.	O

1	Breitbart	O
2	,	O
3	L	O
4	.	O

1	Type	O
2	I	O
3	position	O
4	-	O
5	vestibular	O
6	-	O
7	pause	O
8	(	O
9	PVP	B
10	I	I
11	)	O
12	and	O
13	vestibular	O
14	-	O
15	only	O
16	(	O
17	V	B
18	I	I
19	)	O
20	neurons	O
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	smaller	O
27	number	O
28	of	O
29	other	O
30	type	O
31	I	O
32	and	O
33	type	O
34	II	O
35	eye	O
36	-	O
37	plus	O
38	-	O
39	vestibular	O
40	neurons	O
41	were	O
42	studied	O
43	.	O

1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	O
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	Intron	O
2	8	O
3	harbored	O
4	a	O
5	strong	O
6	erythroid	O
7	-	O
8	specific	O
9	enhancer	O
10	activity	O
11	which	O
12	was	O
13	orientation	O
14	-	O
15	dependent	O
16	.	O

1	Effect	O
2	of	O
3	tracheal	O
4	insufflation	O
5	of	O
6	deferoxamine	O
7	on	O
8	acute	O
9	ozone	O
10	toxicity	O
11	in	O
12	rats	O
13	.	O

1	Genetic	O
2	and	O
3	phenotypic	O
4	analysis	O
5	indicates	O
6	that	O
7	NHP6A	O
8	and	O
9	NHP6B	O
10	function	O
11	downstream	O
12	of	O
13	SLT2	B
14	.	O

1	A	O
2	case	O
3	of	O
4	manifest	O
5	latent	O
6	nystagmus	O
7	of	O
8	late	O
9	onset	O
10	in	O
11	a	O
12	13	O
13	-	O
14	year	O
15	-	O
16	old	O
17	girl	O
18	is	O
19	reported	O
20	.	O

1	We	O
2	have	O
3	generated	O
4	various	O
5	base	O
6	substitutions	O
7	and	O
8	internal	O
9	deletions	O
10	in	O
11	and	O
12	around	O
13	DRE	O
14	(	O
15	nucleotide	O
16	positions	O
17	-	O
18	93	O
19	to	O
20	-	O
21	100	O
22	with	O
23	respect	O
24	to	O
25	the	O
26	transcription	O
27	initiation	O
28	site	O
29	)	O
30	of	O
31	the	O
32	PCNA	B
33	gene	I
34	in	O
35	vitro	O
36	and	O
37	subsequently	O
38	examined	O
39	their	O
40	effects	O
41	on	O
42	the	O
43	binding	O
44	to	O
45	DREF	B
46	(	O
47	DRE	B
48	-	I
49	binding	I
50	factor	I
51	)	O
52	and	O
53	PCNA	B
54	gene	I
55	promote	O
56	activity	O
57	in	O
58	cultured	O
59	Drosophila	O
60	Kc	O
61	cells	O
62	as	O
63	well	O
64	as	O
65	in	O
66	living	O
67	flies	O
68	.	O

1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O

1	The	O
2	gene	O
3	encoding	O
4	the	O
5	receptor	O
6	for	O
7	macrophage	B
8	colony	I
9	-	I
10	stimulating	I
11	factor	I
12	1	I
13	(	O
14	CSF	B
15	-	I
16	1	I
17	),	O
18	the	O
19	c	B
20	-	I
21	fms	I
22	protooncogene	I
23	,	O
24	is	O
25	selectively	O
26	expressed	O
27	in	O
28	immature	O
29	and	O
30	mature	O
31	mononuclear	O
32	phagocytes	O
33	and	O
34	trophoblasts	O
35	.	O

1	E1A	B
2	represses	O
3	apolipoprotein	B
4	AI	I
5	enhancer	I
6	activity	O
7	in	O
8	liver	O
9	cells	O
10	through	O
11	a	O
12	pRb	B
13	-	O
14	and	O
15	CBP	B
16	-	O
17	independent	O
18	pathway	O
19	.	O

1	In	O
2	the	O
3	first	O
4	part	O
5	of	O
6	our	O
7	study	O
8	,	O
9	the	O
10	highest	O
11	mutagenicity	O
12	was	O
13	revealed	O
14	by	O
15	TA98	O
16	strain	O
17	without	O
18	enzymatic	O
19	activation	O
20	,	O
21	suggesting	O
22	a	O
23	direct	O
24	-	O
25	acting	O
26	mutagenicity	O
27	prevalence	O
28	in	O
29	diesel	O
30	particulate	O
31	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	B
7	-	O
8	C3	O
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	SCOB	O
2	testing	O
3	of	O
4	food	O
5	-	O
6	restricted	O
7	animals	O
8	,	O
9	using	O
10	a	O
11	multiple	O
12	fixed	O
13	ratio	O
14	(	O
15	FR	O
16	)/	O
17	fixed	O
18	interval	O
19	(	O
20	FI	B
21	)	O
22	schedule	O
23	(	O
24	FR20	O
25	:	O
26	FI120	O
27	),	O
28	was	O
29	conducted	O
30	prior	O
31	to	O
32	each	O
33	exposure	O
34	to	O
35	maintain	O
36	the	O
37	operant	O
38	behavior	O
39	;	O
40	the	O
41	data	O
42	from	O
43	Weeks	O
44	-	O
45	1	O
46	,	O
47	4	O
48	,	O
49	8	O
50	,	O
51	and	O
52	13	O
53	were	O
54	evaluated	O
55	for	O
56	evidence	O
57	of	O
58	neurotoxicity	O
59	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bovine	O
5	cDNA	O
6	insert	O
7	sequence	O
8	was	O
9	273	O
10	nucleotides	O
11	in	O
12	length	O
13	for	O
14	the	O
15	entire	O
16	mRNA	O
17	coding	O
18	region	O
19	,	O
20	212	O
21	nucleotides	O
22	in	O
23	the	O
24	5	O
25	'	O
26	untranslated	O
27	region	O
28	,	O
29	83	O
30	nucleotides	O
31	in	O
32	the	O
33	3	O
34	'	O
35	untranslated	O
36	region	O
37	and	O
38	a	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	tail	O
44	.	O

1	The	O
2	therapeutic	O
3	protocole	O
4	used	O
5	at	O
6	the	O
7	Gustave	O
8	Roussy	O
9	Institute	O
10	for	O
11	invasive	O
12	epithelioma	O
13	of	O
14	the	O
15	uterine	O
16	cervix	O
17	rests	O
18	,	O
19	for	O
20	limited	O
21	forms	O
22	(	O
23	T1B	B
24	-	I
25	T2	I
26	proximal	I
27	),	O
28	on	O
29	combined	O
30	radiology	O
31	and	O
32	surgery	O
33	.	O

1	The	O
2	data	O
3	further	O
4	indicate	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	7R	I
10	alpha	I
11	chains	I
12	are	O
13	directly	O
14	involved	O
15	in	O
16	the	O
17	activation	O
18	of	O
19	JAKs	B
20	and	O
21	STATs	B
22	and	O
23	have	O
24	a	O
25	major	O
26	role	O
27	in	O
28	proliferative	O
29	signaling	O
30	in	O
31	precursor	O
32	B	O
33	cells	O
34	.	O

1	Of	O
2	the	O
3	21	O
4	quadrants	O
5	positive	O
6	in	O
7	the	O
8	controls	O
9	,	O
10	17	O
11	were	O
12	correlated	O
13	with	O
14	previously	O
15	detected	O
16	jaw	O
17	pathoses	O
18	.	O

1	Mechanism	O
2	of	O
3	immunogenesis	O
4	in	O
5	vaccination	O
6	with	O
7	streptomycin	O
8	-	O
9	dependent	O
10	mutants	O
11	of	O
12	salmonellae	O
13	and	O
14	shigellae	O
15	.	O

1	Each	O
2	expressed	O
3	domain	O
4	,	O
5	as	O
6	well	O
7	as	O
8	FKBP	B
9	-	I
10	33	I
11	itself	I
12	,	I
13	possesses	I
14	peptidyl	I
15	-	I
16	prolyl	I
17	cis	I
18	-	I
19	trans	I
20	isomerase	I
21	activity	O
22	,	O
23	though	O
24	with	O
25	much	O
26	lower	O
27	specific	O
28	activities	O
29	than	O
30	FKBP	B
31	-	I
32	12	I
33	.	O

1	Thus	O
2	,	O
3	in	O
4	normal	O
5	intestinal	O
6	epithelial	O
7	goblet	O
8	cells	O
9	,	O
10	TbetaRI	B
11	and	O
12	TbetaRII	B
13	can	O
14	respond	O
15	to	O
16	autocrine	O
17	but	O
18	not	O
19	exogenous	O
20	TGF	B
21	-	I
22	beta	I
23	without	O
24	the	O
25	participation	O
26	of	O
27	TbetaRIII	B
28	.	O

1	The	O
2	hypothesis	O
3	of	O
4	Geisler	O
5	(	O
6	Brain	O
7	Res	O
8	.	O

1	Despite	O
2	this	O
3	there	O
4	was	O
5	no	O
6	difference	O
7	in	O
8	the	O
9	intubating	O
10	conditions	O
11	at	O
12	one	O
13	minute	O
14	with	O
15	25	O
16	excellent	O
17	/	O
18	5	O
19	good	O
20	in	O
21	the	O
22	suxamethonium	O
23	group	O
24	and	O
25	27	O
26	excellent	O
27	/	O
28	3	O
29	good	O
30	in	O
31	the	O
32	rocuronium	O
33	group	O
34	.	O

1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	O
16	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	portion	O
10	common	O
11	to	O
12	various	O
13	chimeric	O
14	MLL	O
15	products	O
16	,	O
17	as	O
18	well	O
19	as	O
20	to	O
21	MLL	B
22	-	I
23	LTG9	I
24	and	O
25	MLL	B
26	-	I
27	LTG19	I
28	,	O
29	localizes	O
30	in	O
31	the	O
32	nuclei	O
33	,	O
34	and	O
35	therefore	O
36	suggested	O
37	that	O
38	it	O
39	might	O
40	play	O
41	an	O
42	important	O
43	role	O
44	in	O
45	leukemogenesis	O
46	.	O

1	The	O
2	elevations	O
3	achieved	O
4	by	O
5	LDEE	O
6	given	O
7	s	O
8	.	O
9	c	O
10	.	O
11	were	O
12	higher	O
13	than	O
14	those	O
15	achieved	O
16	after	O
17	i	O
18	.	O
19	p	O
20	.	O
21	administration	O
22	and	O
23	lasted	O
24	for	O
25	longer	O
26	periods	O
27	.	O

1	Fenfluramine	O
2	(	O
3	in	O
4	doses	O
5	ranging	O
6	from	O
7	0	O
8	.	O
9	0625	O
10	-	O
11	4	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	infusion	O
19	)	O
20	did	O
21	not	O
22	maintain	O
23	self	O
24	-	O
25	administration	O
26	behavior	O
27	at	O
28	or	O
29	above	O
30	the	O
31	minimum	O
32	requirement	O
33	(	O
34	FR	O
35	30	O
36	).	O

1	Also	O
2	,	O
3	except	O
4	in	O
5	one	O
6	patient	O
7	who	O
8	developed	O
9	gallstones	O
10	following	O
11	institution	O
12	of	O
13	colestipol	O
14	,	O
15	saturation	O
16	of	O
17	gallbladder	O
18	bile	O
19	with	O
20	cholesterol	O
21	was	O
22	not	O
23	markedly	O
24	increased	O
25	by	O
26	this	O
27	drug	O
28	alone	O
29	.	O

1	A	O
2	P22	O
3	R17	O
4	derivative	O
5	with	O
6	an	O
7	OcRNA	O
8	site	O
9	(	O
10	P22	B
11	R17	I
12	[	O
13	A	O
14	(-	O
15	10	O
16	)	O
17	U	O
18	])	O
19	develops	O
20	lytically	O
21	following	O
22	infection	O
23	of	O
24	these	O
25	strains	O
26	.	O

1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O

1	It	O
2	then	O
3	merged	O
4	with	O
5	right	O
6	ventricular	O
7	wavefronts	O
8	ending	O
9	along	O
10	the	O
11	right	O
12	ventricular	O
13	anterior	O
14	atrioventricular	O
15	groove	O
16	and	O
17	outflow	O
18	tract	O
19	.	O

1	However	O
2	,	O
3	in	O
4	those	O
5	studies	O
6	due	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	thiol	O
12	agents	O
13	in	O
14	the	O
15	PKC	B
16	preparations	O
17	,	O
18	the	O
19	sensitive	O
20	reaction	O
21	of	O
22	BPO	B
23	with	O
24	redox	O
25	-	O
26	active	O
27	cysteine	O
28	residues	O
29	in	O
30	PKC	B
31	was	O
32	not	O
33	observed	O
34	.	O

1	While	O
2	these	O
3	findings	O
4	may	O
5	reflect	O
6	the	O
7	sensitivity	O
8	of	O
9	a	O
10	thick	O
11	myocardial	O
12	wall	O
13	to	O
14	ischaemia	O
15	during	O
16	surgery	O
17	,	O
18	the	O
19	postoperative	O
20	recovery	O
21	was	O
22	not	O
23	related	O
24	to	O
25	the	O
26	serum	O
27	CK	B
28	-	I
29	MB	I
30	level	O
31	.	O

1	MSSP	B
2	-	I
3	1	I
4	produced	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	as	O
10	a	O
11	fusion	O
12	protein	O
13	with	O
14	GST	B
15	specifically	O
16	interacted	O
17	with	O
18	single	O
19	-	O
20	stranded	O
21	TCTTAT	O
22	(	O
23	plus	O
24	myc	B
25	(	O
26	H	O
27	-	O
28	P	O
29	)	O
30	21	O
31	)	O
32	and	O
33	ACT	O
34	-	O
35	ATT	O
36	(	O
37	in	O
38	minus	B
39	myc	I
40	(	O
41	H	O
42	-	O
43	P	O
44	)	O
45	21	O
46	),	O
47	the	O
48	consensus	O
49	of	O
50	which	O
51	can	O
52	be	O
53	referred	O
54	to	O
55	as	O
56	A	O
57	/	O
58	TCTA	O
59	/	O
60	TA	O
61	/	O
62	TT	O
63	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	B
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	B
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	under	O
6	the	O
7	selected	O
8	conditions	O
9	a	O
10	linear	O
11	dependence	O
12	exists	O
13	between	O
14	the	O
15	betaI	O
16	%	O
17	value	O
18	and	O
19	lgC	O
20	within	O
21	the	O
22	range	O
23	of	O
24	0	O
25	.	O
26	5	O
27	--	O
28	10	O
29	mug	O
30	ruscogenin	O
31	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	sequences	O
5	revealed	O
6	that	O
7	the	O
8	two	O
9	mRNA	O
10	species	O
11	arise	O
12	as	O
13	a	O
14	result	O
15	of	O
16	alternate	O
17	use	O
18	of	O
19	poly	O
20	(	O
21	A	O
22	)-	O
23	addition	O
24	sites	O
25	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	show	O
7	that	O
8	TEP	O
9	has	O
10	an	O
11	apparent	O
12	molecular	O
13	mass	O
14	of	O
15	approximately	O
16	65	O
17	kDa	O
18	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	the	O
5	steady	O
6	state	O
7	kinetics	O
8	of	O
9	MEK	B
10	inhibition	O
11	by	O
12	these	O
13	compounds	O
14	reveals	O
15	that	O
16	U0126	B
17	has	O
18	approximately	O
19	100	O
20	-	O
21	fold	O
22	higher	O
23	affinity	O
24	for	O
25	deltaN3	B
26	-	I
27	S218E	I
28	/	I
29	S222D	I
30	MEK	I
31	than	O
32	does	O
33	PD098059	O
34	.	O

1	RESULTS	O
2	:	O
3	Glaucoma	O
4	suspects	O
5	were	O
6	divided	O
7	into	O
8	two	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	SWAP	O
14	results	O
15	:	O
16	high	O
17	risk	O
18	(	O
19	with	O
20	SWAP	O
21	abnormalities	O
22	)	O
23	and	O
24	low	O
25	risk	O
26	(	O
27	with	O
28	normal	O
29	SWAP	O
30	result	O
31	).	O

1	Pseudocontact	O
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O

1	Three	O
2	cases	O
3	of	O
4	primary	O
5	signet	O
6	-	O
7	ring	O
8	cell	O
9	carcinoma	O
10	of	O
11	the	O
12	rectum	O
13	are	O
14	described	O
15	.	O

1	Antimicrobial	O
2	substance	O
3	isolated	O
4	from	O
5	an	O
6	acorn	O
7	extract	O
8	.	O

1	Differential	O
2	signaling	O
3	and	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	activation	O
9	by	O
10	four	O
11	splice	O
12	variants	O
13	of	O
14	the	O
15	human	B
16	pituitary	I
17	adenylate	I
18	cyclase	I
19	-	I
20	activating	I
21	polypeptide	I
22	receptor	I
23	(	O
24	hPACAP	B
25	-	I
26	R	I
27	).	O

1	Animals	O
2	may	O
3	be	O
4	immunized	O
5	by	O
6	oral	O
7	vaccination	O
8	,	O
9	but	O
10	natural	O
11	mechanisms	O
12	that	O
13	also	O
14	can	O
15	terminate	O
16	outbreaks	O
17	are	O
18	discussed	O
19	.	O

1	Of	O
2	the	O
3	remaining	O
4	seven	O
5	,	O
6	five	O
7	reacted	O
8	either	O
9	with	O
10	immediate	O
11	and	O
12	strong	O
13	symptoms	O
14	or	O
15	had	O
16	spontaneously	O
17	reduced	O
18	gluten	O
19	intake	O
20	,	O
21	or	O
22	had	O
23	an	O
24	acquired	O
25	IgA	B
26	deficiency	O
27	.	O

1	nos	B
2	-	I
3	1	I
4	and	O
5	nos	B
6	-	I
7	2	I
8	,	O
9	two	O
10	genes	O
11	related	O
12	to	O
13	Drosophila	O
14	nanos	O
15	,	O
16	regulate	O
17	primordial	O
18	germ	O
19	cell	O
20	development	O
21	and	O
22	survival	O
23	in	O
24	Caenorhabditis	O
25	elegans	O
26	.	O

1	Epitopes	O
2	of	O
3	adhesion	B
4	-	I
5	perturbing	I
6	monoclonal	I
7	antibodies	I
8	map	O
9	within	O
10	a	O
11	predicted	O
12	alpha	O
13	-	O
14	helical	O
15	domain	O
16	of	O
17	the	O
18	integrin	B
19	beta	I
20	1	I
21	subunit	I
22	.	O

1	The	O
2	Mauriceville	O
3	and	O
4	Varkud	O
5	mitochondrial	O
6	plasmids	O
7	are	O
8	closely	O
9	related	O
10	,	O
11	closed	O
12	-	O
13	circular	O
14	DNAs	O
15	(	O
16	3	O
17	.	O
18	6	O
19	and	O
20	3	O
21	.	O
22	7	O
23	kb	O
24	,	O
25	respectively	O
26	)	O
27	that	O
28	have	O
29	characteristics	O
30	of	O
31	mtDNA	O
32	introns	O
33	and	O
34	retroid	O
35	elements	O
36	.	O

1	Study	O
2	of	O
3	the	O
4	alterations	O
5	of	O
6	intestinal	O
7	absorption	O
8	,	O
9	by	O
10	means	O
11	of	O
12	I	O
13	-	O
14	131	O
15	-	O
16	triolein	O
17	,	O
18	in	O
19	the	O
20	whole	O
21	body	O
22	irradiated	O
23	rat	O

1	Thyroid	O
2	lymphoma	O
3	and	O
4	its	O
5	management	O
6	.	O

1	A	O
2	further	O
3	study	O
4	on	O
5	plasminogen	B
6	activator	I
7	release	O
8	by	O
9	vasoactive	O
10	agents	O
11	in	O
12	the	O
13	isolated	O
14	perfused	O
15	dog	O
16	leg	O
17	.	O

1	A	O
2	second	O
3	even	O
4	more	O
5	significant	O
6	match	O
7	to	O
8	this	O
9	E	O
10	.	O
11	coli	O
12	region	O
13	was	O
14	found	O
15	in	O
16	the	O
17	retroviral	O
18	ribonuclease	O
19	H	O
20	(	O
21	RNase	B
22	H	I
23	)	O
24	domain	O
25	,	O
26	and	O
27	corresponds	O
28	precisely	O
29	to	O
30	a	O
31	region	O
32	that	O
33	has	O
34	been	O
35	aligned	O
36	by	O
37	previous	O
38	investigators	O
39	with	O
40	the	O
41	E	B
42	.	I
43	coli	I
44	RNase	I
45	H	I
46	,	O
47	suggesting	O
48	that	O
49	Pol	B
50	I	I
51	helices	I
52	O	I
53	and	O
54	P	O
55	are	O
56	homologous	O
57	to	O
58	helices	O
59	A	O
60	and	O
61	D	O
62	of	O
63	the	O
64	RNase	B
65	H	I
66	crystal	I
67	structure	I
68	,	O
69	respectively	O
70	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	B
17	loci	I
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	None	O
2	of	O
3	these	O
4	organic	O
5	manifestations	O
6	was	O
7	discovered	O
8	by	O
9	scintigraphic	O
10	means	O
11	.	O

1	Chronotherapeutics	O
2	in	O
3	cardiovascular	O
4	disease	O
5	.	O

1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	O
28	receptors	O
29	GAL	B
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	B
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	O
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	O
58	responsive	O
59	CAT	B
60	reporter	I
61	gene	I
62	.	O

1	There	O
2	was	O
3	no	O
4	clear	O
5	correlation	O
6	between	O
7	the	O
8	MFA	O
9	and	O
10	the	O
11	severity	O
12	of	O
13	the	O
14	UTS	O
15	phenotype	O
16	.	O

1	Since	O
2	the	O
3	ETS	B
4	domain	I
5	,	O
6	which	O
7	is	O
8	localized	O
9	in	O
10	the	O
11	carboxy	O
12	terminal	O
13	region	O
14	of	O
15	the	O
16	encoded	O
17	protein	O
18	,	O
19	is	O
20	95	O
21	%	O
22	and	O
23	96	O
24	%	O
25	identical	O
26	to	O
27	that	O
28	of	O
29	PEA3	B
30	and	O
31	ER81	O
32	,	O
33	respectively	O
34	,	O
35	we	O
36	named	O
37	this	O
38	new	O
39	member	O
40	'	B
41	Ets	I
42	Related	I
43	Molecule	I
44	PEA3	I
45	-	I
46	like	I
47	'	I
48	(	O
49	ERM	O
50	).	O

1	IMPLICATIONS	O
2	:	O
3	Given	O
4	the	O
5	small	O
6	size	O
7	of	O
8	this	O
9	study	O
10	and	O
11	the	O
12	inconsistency	O
13	of	O
14	results	O
15	among	O
16	the	O
17	few	O
18	prospective	O
19	studies	O
20	of	O
21	ovarian	O
22	cancer	O
23	conducted	O
24	to	O
25	test	O
26	these	O
27	associations	O
28	,	O
29	replications	O
30	of	O
31	these	O
32	findings	O
33	are	O
34	highly	O
35	desirable	O
36	.	O

1	Positive	O
2	correlations	O
3	were	O
4	seen	O
5	between	O
6	the	O
7	measurements	O
8	for	O
9	protein	O
10	intake	O
11	(	O
12	r	O
13	=.	O
14	58	O
15	,	O
16	P	O
17	=.	O
18	0026	O
19	)	O
20	energy	O
21	intake	O
22	(	O
23	r	O
24	=.	O
25	78	O
26	,	O
27	P	O
28	<.	O
29	00001	O
30	),	O
31	with	O
32	mean	O
33	differences	O
34	of	O
35	.	O
36	066	O
37	g	O
38	/	O
39	kg	O
40	/	O
41	d	O
42	(	O
43	SD	O
44	.	O
45	38	O
46	)	O
47	2	O
48	.	O
49	04	O
50	kcal	O
51	/	O
52	kg	O
53	/	O
54	day	O
55	(	O
56	SD	O
57	6	O
58	.	O
59	67	O
60	),	O
61	respectively	O
62	.	O

1	The	O
2	protein	O
3	expressed	O
4	by	O
5	F2771	B
6	cDNA	I
7	in	O
8	transfected	O
9	COS	O
10	cells	O
11	is	O
12	localized	O
13	in	O
14	the	O
15	cytoplasm	O
16	.	O

1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	B
21	)/	I
22	tretinoin	I
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O

1	RESULTS	O
2	:	O
3	Total	O
4	IgE	B
5	levels	O
6	showed	O
7	a	O
8	tendency	O
9	to	O
10	diminish	O
11	.	O

1	EsaR	B
2	can	O
3	repress	O
4	its	O
5	own	O
6	expression	O
7	but	O
8	seems	O
9	not	O
10	to	O
11	regulate	O
12	the	O
13	expression	O
14	of	O
15	esaI	B
16	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	The	O
2	relative	O
3	toxicity	O
4	of	O
5	nickel	O
6	oxide	O
7	(	O
8	NiO	O
9	),	O
10	nickel	O
11	sulfate	O
12	hexahydrate	O
13	(	O
14	NiSO4	O
15	.	O
16	6H2O	O
17	),	O
18	and	O
19	nickel	O
20	subsulfide	O
21	(	O
22	Ni3S2	O
23	)	O
24	was	O
25	studied	O
26	in	O
27	F344	B
28	/	O
29	N	O
30	rats	O
31	and	O
32	B6C3F1	O
33	mice	O
34	after	O
35	inhalation	O
36	exposure	O
37	for	O
38	6	O
39	hr	O
40	/	O
41	day	O
42	,	O
43	5	O
44	days	O
45	/	O
46	week	O
47	,	O
48	for	O
49	13	O
50	weeks	O
51	.	O

1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	O
8	a	O
9	third	O
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	48K5	O
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	Marynen	O
22	,	O
23	P	O
24	.,	O
25	Zhang	O
26	,	O
27	J	O
28	.,	O
29	Cassiman	O
30	,	O
31	J	O
32	.,	O
33	Vanden	O
34	Berghe	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	David	O
40	,	O
41	C	O
42	.	O

1	Cutaneous	O
2	necrosis	O
3	associated	O
4	with	O
5	protein	B
6	S	I
7	deficiency	O
8	.	O

1	Newcastle	O
2	disease	O
3	virus	O
4	surveillance	O
5	in	O
6	Hong	O
7	Kong	O
8	on	O
9	local	O
10	and	O
11	imported	O
12	poultry	O
13	.	O

1	Different	O
2	sequence	O
3	elements	O
4	of	O
5	both	O
6	the	O
7	retroviral	O
8	vectors	O
9	and	O
10	the	O
11	c	B
12	-	I
13	myc	I
14	gene	I
15	recombined	O
16	during	O
17	genesis	O
18	of	O
19	highly	O
20	oncogenic	O
21	retroviruses	O
22	CMII	O
23	,	O
24	MC29	O
25	,	O
26	or	O
27	MH2	O
28	.	O

1	Marine	O
2	oils	O
3	and	O
4	cardiovascular	O
5	reactivity	O
6	.	O

1	Spores	O
2	from	O
3	Rhizopus	O
4	stolonifer	O
5	were	O
6	suspended	O
7	in	O
8	distilled	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	spores	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	starter	O
25	.	O

1	Although	O
2	inactive	O
3	in	O
4	cells	O
5	under	O
6	normal	O
7	conditions	O
8	,	O
9	the	O
10	CHOP	B
11	gene	I
12	is	O
13	markedly	O
14	induced	O
15	by	O
16	a	O
17	variety	O
18	of	O
19	cellular	O
20	stresses	O
21	,	O
22	including	O
23	nutrient	O
24	deprivation	O
25	and	O
26	metabolic	O
27	perturbations	O
28	.	O

1	A	O
2	rat	O
3	cDNA	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	has	O
10	been	O
11	isolated	O
12	and	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	to	O
18	yield	O
19	a	O
20	catalytically	O
21	active	O
22	eIF	B
23	-	I
24	5	I
25	protein	I
26	.	O

1	To	O
2	elucidate	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	Fyn	B
8	in	O
9	the	O
10	expression	O
11	of	O
12	viral	O
13	promoters	O
14	,	O
15	we	O
16	transfected	O
17	a	O
18	Fyn	B
19	-	O
20	expression	O
21	vector	O
22	together	O
23	with	O
24	a	O
25	reporter	O
26	plasmid	O
27	containing	O
28	the	O
29	chloramphenicol	B
30	acetyltransferase	I
31	gene	I
32	driven	O
33	by	O
34	HIV	B
35	LTR	I
36	into	O
37	a	O
38	human	O
39	T	O
40	cell	O
41	line	O
42	,	O
43	Jurkat	O
44	.	O

1	Although	O
2	no	O
3	Rh	B
4	-	I
5	antibodies	I
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O

1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	B
30	aromatase	I
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O

1	Results	O
2	were	O
3	supported	O
4	by	O
5	the	O
6	agar	O
7	diffusion	O
8	method	O
9	for	O
10	Y	O
11	.	O
12	enterocolitica	O
13	,	O
14	whereas	O
15	inhibition	O
16	activity	O
17	was	O
18	not	O
19	found	O
20	for	O
21	A	O
22	.	O
23	hydrophila	O
24	.	O

1	73	O
2	:	O
3	658	O
4	-	O
5	666	O
6	,	O
7	1999	O
8	).	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	However	O
2	,	O
3	if	O
4	EMPD	O
5	involves	O
6	the	O
7	glans	O
8	penis	O
9	or	O
10	perianal	O
11	area	O
12	,	O
13	a	O
14	search	O
15	for	O
16	internal	O
17	malignancy	O
18	is	O
19	still	O
20	warranted	O
21	.	O

1	Although	O
2	the	O
3	gene	O
4	is	O
5	substantially	O
6	smaller	O
7	than	O
8	the	O
9	human	O
10	genes	O
11	for	O
12	other	O
13	mitochondrial	O
14	enzymes	O
15	,	O
16	its	O
17	intron	O
18	/	O
19	exon	O
20	organization	O
21	is	O
22	very	O
23	similar	O
24	,	O
25	especially	O
26	to	O
27	that	O
28	of	O
29	P450scc	B
30	.	O

1	In	O
2	addition	O
3	,	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	increase	O
9	in	O
10	postdexamethasone	O
11	cortical	O
12	concentrations	O
13	with	O
14	age	O
15	(	O
16	p	O
17	less	O
18	than	O
19	0	O
20	.	O
21	01	O
22	;	O
23	r	O
24	=	O
25	0	O
26	.	O
27	31	O
28	).	O

1	In	O
2	some	O
3	cases	O
4	,	O
5	the	O
6	aberrant	O
7	methylation	O
8	of	O
9	CpGs	B
10	within	O
11	5	O
12	'	O
13	regulatory	O
14	regions	O
15	has	O
16	led	O
17	to	O
18	suppression	O
19	of	O
20	gene	O
21	activity	O
22	.	O

1	Novel	O
2	8	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	(	O
8	Drosophila	O
9	DNA	O
10	replication	O
11	-	O
12	related	O
13	element	O
14	)	O
15	and	O
16	specific	O
17	binding	O
18	factor	O
19	involved	O
20	in	O
21	the	O
22	expression	O
23	of	O
24	Drosophila	O
25	genes	O
26	for	O
27	DNA	B
28	polymerase	I
29	alpha	I
30	and	O
31	proliferating	O
32	cell	O
33	nuclear	O
34	antigen	O
35	.	O

1	The	O
2	isolated	O
3	plasmin	O
4	fragments	O
5	of	O
6	VEGF	B
7	were	O
8	compared	O
9	with	O
10	respect	O
11	to	O
12	heparin	O
13	binding	O
14	,	O
15	interaction	O
16	with	O
17	soluble	B
18	VEGF	I
19	receptors	I
20	,	O
21	and	O
22	ability	O
23	to	O
24	promote	O
25	endothelial	O
26	cell	O
27	mitogenesis	O
28	.	O

1	Capnography	O
2	curves	O
3	of	O
4	40	O
5	HVS	O
6	patients	O
7	,	O
8	40	O
9	non	O
10	-	O
11	HVS	O
12	patients	O
13	with	O
14	psycho	O
15	-	O
16	somatic	O
17	complaints	O
18	and	O
19	26	O
20	healthy	O
21	controls	O
22	were	O
23	analyzed	O
24	.	O

1	The	O
2	injection	O
3	of	O
4	XDRP1	B
5	protein	I
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O

1	Pacing	O
2	the	O
3	Roux	O
4	limb	O
5	abolished	O
6	the	O
7	ectopic	O
8	pacemakers	O
9	,	O
10	restored	O
11	the	O
12	slow	O
13	emptying	O
14	of	O
15	liquids	O
16	to	O
17	the	O
18	more	O
19	rapid	O
20	rate	O
21	found	O
22	in	O
23	the	O
24	Billroth	O
25	dogs	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	:	O
31	paced	O
32	Roux	O
33	,	O
34	72	O
35	+/-	O
36	15	O
37	minutes	O
38	;	O
39	Billroth	O
40	,	O
41	43	O
42	+/-	O
43	9	O
44	minutes	O
45	;	O
46	p	O
47	greater	O
48	than	O
49	0	O
50	.	O
51	05	O
52	)	O
53	and	O
54	did	O
55	not	O
56	change	O
57	emptying	O
58	of	O
59	solids	O
60	.	O

1	Although	O
2	the	O
3	consumption	O
4	of	O
5	myoglobin	B
6	-	O
7	bound	O
8	O2	O
9	(	O
10	MbO2	O
11	)	O
12	stores	O
13	in	O
14	seal	O
15	muscles	O
16	has	O
17	been	O
18	demonstrated	O
19	in	O
20	seal	O
21	muscles	O
22	during	O
23	laboratory	O
24	simulations	O
25	of	O
26	diving	O
27	,	O
28	this	O
29	may	O
30	not	O
31	be	O
32	a	O
33	feature	O
34	of	O
35	normal	O
36	field	O
37	diving	O
38	in	O
39	which	O
40	measurements	O
41	of	O
42	heart	O
43	rate	O
44	and	O
45	lactate	O
46	production	O
47	show	O
48	marked	O
49	differences	O
50	from	O
51	the	O
52	profound	O
53	diving	O
54	response	O
55	induced	O
56	by	O
57	forced	O
58	immersion	O
59	.	O

1	A	O
2	specific	O
3	distal	O
4	promoter	O
5	controls	O
6	gamma	B
7	-	I
8	glutamyl	I
9	transpeptidase	I
10	gene	I
11	expression	O
12	in	O
13	undifferentiated	O
14	rat	O
15	transformed	O
16	liver	O
17	cells	O
18	.	O

1	Substitution	O
2	of	O
3	either	O
4	Val33	O
5	(	O
6	by	O
7	Gly	O
8	)	O
9	or	O
10	Gly28	B
11	(	O
12	by	O
13	Ser	O
14	),	O
15	two	O
16	of	O
17	the	O
18	most	O
19	conserved	O
20	residues	O
21	in	O
22	all	O
23	protein	O
24	kinases	O
25	,	O
26	resulted	O
27	in	O
28	enzyme	O
29	with	O
30	marginally	O
31	detectable	O
32	activity	O
33	.	O

1	The	O
2	average	O
3	values	O
4	were	O
5	199	O
6	and	O
7	424	O
8	revertants	O
9	/	O
10	g	O
11	for	O
12	the	O
13	hamburgers	O
14	and	O
15	hot	O
16	dogs	O
17	,	O
18	respectively	O
19	.	O

1	Both	O
2	filters	O
3	equally	O
4	contributed	O
5	to	O
6	elevation	O
7	of	O
8	iliac	O
9	venous	O
10	pressure	O
11	(	O
12	median	O
13	,	O
14	9	O
15	.	O
16	3	O
17	and	O
18	7	O
19	.	O
20	2	O
21	mm	O
22	Hg	O
23	[	O
24	n	O
25	=	O
26	9	O
27	]	O
28	with	O
29	the	O
30	spring	O
31	filter	O
32	and	O
33	RF02	O
34	filter	O
35	,	O
36	respectively	O
37	).	O

1	Some	O
2	of	O
3	the	O
4	PCR	O
5	products	O
6	contained	O
7	mutations	O
8	in	O
9	ATG1	O
10	and	O
11	/	O
12	or	O
13	ATG2	O
14	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	signaling	O
5	to	O
6	stress	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	(	O
12	SAPK	B
13	)/	O
14	Jun	B
15	NH2	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	)	O
22	and	O
23	p38	B
24	.	O

1	Heterogeneous	O
2	electron	O
3	transfer	O
4	of	O
5	cytochrome	B
6	c	I
7	facilitated	O
8	by	O
9	polypyrrole	O
10	and	O
11	methylene	O
12	blue	O
13	polypyrrole	O
14	film	O
15	modified	O
16	electrodes	O
17	.	O

1	In	O
2	one	O
3	of	O
4	these	O
5	tumors	O
6	the	O
7	observed	O
8	rearrangement	O
9	was	O
10	not	O
11	due	O
12	to	O
13	the	O
14	insertion	O
15	of	O
16	an	O
17	intact	O
18	MoMuLV	O
19	provirus	O
20	.	O

1	There	O
2	has	O
3	been	O
4	similar	O
5	improvement	O
6	in	O
7	treating	O
8	ampullary	O
9	and	O
10	periampullary	O
11	cancer	O
12	,	O
13	gallbladder	O
14	cancer	O
15	,	O
16	or	O
17	extrahepatic	O
18	bile	O
19	duct	O
20	cancer	O
21	.	O

1	A	O
2	putative	O
3	inhibitor	O
4	(	O
5	s	O
6	)	O
7	appears	O
8	to	O
9	co	O
10	-	O
11	elute	O
12	in	O
13	the	O
14	inactive	O
15	fraction	O
16	that	O
17	blocked	O
18	the	O
19	L	O
20	(	O
21	alpha	O
22	)	O
23	activity	O
24	.	O

1	The	O
2	calcium	O
3	requirement	O
4	for	O
5	hypothermic	O
6	storage	O
7	of	O
8	the	O
9	cardiac	O
10	explant	O
11	.	O

1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	O
6	and	O
7	Z	B
8	activate	O
9	the	O
10	cellular	O
11	stress	O
12	mitogen	B
13	-	I
14	activated	I
15	protein	I
16	(	I
17	MAP	I
18	)	I
19	kinases	I
20	,	O
21	p38	B
22	and	O
23	JNK	B
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	O
35	transcription	O
36	factor	O
37	ATF2	B
38	.	O

1	From	O
2	the	O
3	15	B
4	-	I
5	kb	I
6	clone	I
7	a	I
8	4	I
9	-	I
10	kb	I
11	EcoRI	I
12	fragment	I
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	B
32	gene	I
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	The	O
2	human	O
3	T	O
4	cell	O
5	lymphotropic	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	O
25	-	O
26	domain	O
27	/	O
28	leucine	O
29	-	O
30	zipper	O
31	(	O
32	bZip	O
33	)	O
34	protein	O
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	O
48	Tax	O
49	-	O
50	responsive	O
51	element	O
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O

1	Based	O
2	on	O
3	a	O
4	type	O
5	I	O
6	error	O
7	of	O
8	0	O
9	.	O
10	05	O
11	,	O
12	our	O
13	study	O
14	had	O
15	a	O
16	power	O
17	greater	O
18	than	O
19	or	O
20	equal	O
21	to	O
22	75	O
23	%	O
24	to	O
25	detect	O
26	group	O
27	differences	O
28	in	O
29	treatment	O
30	effect	O
31	of	O
32	greater	O
33	than	O
34	or	O
35	equal	O
36	to	O
37	15	O
38	%	O
39	to	O
40	20	O
41	%.	O

1	Effect	O
2	of	O
3	phenformin	O
4	on	O
5	gluconeogenesis	O
6	in	O
7	perfused	O
8	rat	O
9	liver	O
10	.	O

1	Deletion	O
2	analysis	O
3	of	O
4	the	O
5	ICL1	B
6	promoter	I
7	led	O
8	to	O
9	the	O
10	identification	O
11	of	O
12	an	O
13	upstream	O
14	activating	O
15	sequence	O
16	element	O
17	,	O
18	UASICL1	B
19	(	O
20	5	O
21	'	O
22	CATTCATCCG	O
23	3	O
24	'),	O
25	necessary	O
26	and	O
27	sufficient	O
28	for	O
29	conferring	O
30	carbon	O
31	source	O
32	-	O
33	dependent	O
34	regulation	O
35	on	O
36	a	O
37	heterologous	O
38	reporter	O
39	gene	O
40	.	O

1	Recently	O
2	,	O
3	the	O
4	3	O
5	.	O
6	6	O
7	-	O
8	kb	O
9	full	B
10	-	I
11	length	I
12	alpha	I
13	-	I
14	GalNAc	I
15	cDNA	I
16	sequence	I
17	was	O
18	isolated	O
19	and	O
20	found	O
21	to	O
22	have	O
23	remarkable	O
24	nucleotide	O
25	and	O
26	predicted	O
27	amino	O
28	acid	O
29	homology	O
30	(	O
31	55	O
32	.	O
33	8	O
34	and	O
35	46	O
36	.	O
37	9	O
38	%,	O
39	respectively	O
40	)	O
41	with	O
42	the	O
43	human	B
44	alpha	I
45	-	I
46	galactosidase	I
47	A	I
48	(	O
49	alpha	B
50	-	I
51	Gal	I
52	A	I
53	)	O
54	cDNA	O
55	.	O

1	Kodak	B
2	XV	I
3	-	I
4	2	I
5	film	I
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	In	O
2	consequence	O
3	,	O
4	the	O
5	gpI	O
6	derived	O
7	from	O
8	cells	O
9	infected	O
10	with	O
11	mO74	B
12	showed	O
13	antigenic	O
14	characteristics	O
15	similar	O
16	to	O
17	those	O
18	of	O
19	gpI	O
20	from	O
21	VZV	O
22	-	O
23	infected	O
24	cells	O
25	as	O
26	determined	O
27	from	O
28	the	O
29	immunoprecipitation	O
30	pattern	O
31	,	O
32	although	O
33	the	O
34	molecular	O
35	weight	O
36	of	O
37	each	O
38	polypeptide	O
39	was	O
40	different	O
41	,	O
42	and	O
43	antibody	O
44	produced	O
45	in	O
46	rabbits	O
47	infected	O
48	with	O
49	recombinant	O
50	virus	O
51	had	O
52	a	O
53	high	O
54	neutralizing	O
55	activity	O
56	,	O
57	when	O
58	the	O
59	reaction	O
60	was	O
61	performed	O
62	with	O
63	complement	O
64	.	O

1	Mammalian	O
2	sperm	O
3	motility	O
4	is	O
5	regulated	O
6	by	O
7	a	O
8	cascade	O
9	of	O
10	cAMP	O
11	-	O
12	dependent	O
13	protein	O
14	phosphorylation	O
15	events	O
16	mediated	O
17	by	O
18	protein	B
19	kinase	I
20	A	I
21	.	O

1	The	O
2	altered	O
3	amino	O
4	acid	O
5	residues	O
6	of	O
7	the	O
8	seven	O
9	mutant	O
10	9ORF1	O
11	polypeptides	O
12	clustered	O
13	within	O
14	three	O
15	separate	O
16	regions	O
17	referred	O
18	to	O
19	as	O
20	region	O
21	I	O
22	(	O
23	residues	O
24	34	O
25	to	O
26	41	O
27	),	O
28	region	O
29	II	O
30	(	O
31	residues	O
32	89	O
33	to	O
34	91	O
35	),	O
36	and	O
37	C	B
38	-	I
39	terminal	I
40	region	I
41	III	I
42	(	O
43	residues	O
44	122	O
45	to	O
46	125	O
47	).	O

1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	I
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O

1	One	O
2	of	O
3	these	O
4	genes	O
5	,	O
6	REC114	B
7	,	O
8	is	O
9	described	O
10	here	O
11	,	O
12	and	O
13	the	O
14	data	O
15	confirm	O
16	that	O
17	REC114	B
18	is	O
19	a	O
20	meiosis	O
21	-	O
22	specific	O
23	recombination	O
24	gene	O
25	with	O
26	no	O
27	detectable	O
28	function	O
29	in	O
30	mitosis	O
31	.	O

1	Expression	O
2	of	O
3	the	O
4	second	O
5	gene	O
6	(	O
7	XT3	O
8	)	O
9	was	O
10	found	O
11	to	O
12	be	O
13	conserved	O
14	in	O
15	human	O
16	kidney	O
17	,	O
18	and	O
19	partial	O
20	sequence	O
21	was	O
22	obtained	O
23	from	O
24	a	O
25	human	O
26	cDNA	O
27	library	O
28	.	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	An	O
2	immunoperoxidase	O
3	reaction	O
4	,	O
5	PAP	B
6	method	O
7	,	O
8	with	O
9	the	O
10	antiserum	O
11	of	O
12	Factor	B
13	VIII	I
14	as	O
15	the	O
16	primary	O
17	antibody	O
18	,	O
19	was	O
20	carried	O
21	out	O
22	in	O
23	the	O
24	endometrial	O
25	biopsies	O
26	to	O
27	detect	O
28	the	O
29	Factor	B
30	VIII	I
31	activity	O
32	in	O
33	the	O
34	endometrial	O
35	endothelium	O
36	before	O
37	and	O
38	after	O
39	insertion	O
40	of	O
41	LNG	O
42	-	O
43	IUD	O
44	-	O
45	20	O
46	.	O

1	Panlobular	O
2	emphysema	O

1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	B
6	level	O
7	nor	O
8	stimulated	O
9	FSH	B
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	IVF	O
18	success	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	O
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	mIU	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	B
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	mIU	O
49	/	O
50	ml	O
51	conceived	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O

1	P	B
2	-	I
3	CIP1	I
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	B
16	alpha	I
17	-	I
18	amidating	I
19	monooxygenase	I
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	The	O
2	results	O
3	presented	O
4	suggest	O
5	that	O
6	TIQ	O
7	reduces	O
8	the	O
9	turnover	O
10	rate	O
11	of	O
12	the	O
13	nigrostriatal	O
14	dopamine	O
15	neurons	O
16	after	O
17	repeated	O
18	administration	O
19	for	O
20	a	O
21	long	O
22	period	O
23	in	O
24	mice	O
25	.	O

1	Cortical	O
2	dysplasias	O
3	,	O
4	genetics	O
5	,	O
6	and	O
7	epileptogenesis	O
8	.	O

1	This	O
2	locus	O
3	maps	O
4	approximately	O
5	160	O
6	kbp	O
7	from	O
8	the	O
9	genes	O
10	encoding	O
11	cytadherence	O
12	-	O
13	associated	O
14	proteins	O
15	HMW1	O
16	and	O
17	HMW3	O
18	,	O
19	and	O
20	yet	O
21	insertions	O
22	therein	O
23	result	O
24	in	O
25	loss	O
26	of	O
27	these	O
28	proteins	O
29	and	O
30	a	O
31	hemadsorption	O
32	-	O
33	negative	O
34	(	O
35	HA	O
36	-)	O
37	phenotype	O
38	,	O
39	prompting	O
40	the	O
41	designation	O
42	cytadherence	O
43	-	O
44	regulatory	O
45	locus	O
46	(	O
47	crl	O
48	).	O

1	On	O
2	the	O
3	character	O
4	of	O
5	changes	O
6	in	O
7	the	O
8	enzyme	O
9	activity	O
10	in	O
11	the	O
12	brain	O
13	tissue	O
14	during	O
15	reflex	O
16	epilepsy	O

1	Various	O
2	treatment	O
3	modalities	O
4	are	O
5	reviewed	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	psychology	O
12	as	O
13	well	O
14	as	O
15	the	O
16	physiology	O
17	of	O
18	severe	O
19	intractable	O
20	pain	O
21	.	O

1	The	O
2	30	O
3	-	O
4	day	O
5	mortality	O
6	in	O
7	the	O
8	CPB	O
9	group	O
10	and	O
11	the	O
12	non	O
13	-	O
14	CPB	O
15	group	O
16	were	O
17	20	O
18	%	O
19	and	O
20	4	O
21	.	O
22	6	O
23	%,	O
24	respectively	O
25	which	O
26	was	O
27	not	O
28	statistically	O
29	significant	O
30	(	O
31	p	O
32	=	O
33	0	O
34	.	O
35	06	O
36	).	O

1	Signaling	O
2	from	O
3	the	O
4	small	B
5	GTP	I
6	-	I
7	binding	I
8	proteins	I
9	Rac1	I
10	and	O
11	Cdc42	B
12	to	O
13	the	O
14	c	B
15	-	I
16	Jun	I
17	N	I
18	-	I
19	terminal	I
20	kinase	I
21	/	O
22	stress	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	pathway	O
28	.	O

1	By	O
2	an	O
3	induced	O
4	-	O
5	fit	O
6	mechanism	O
7	,	O
8	contacts	O
9	with	O
10	the	O
11	anticodon	O
12	can	O
13	activate	O
14	formation	O
15	of	O
16	a	O
17	robust	O
18	transition	O
19	state	O
20	at	O
21	a	O
22	site	O
23	over	O
24	70	O
25	A	O
26	away	O
27	.	O

1	To	O
2	assess	O
3	the	O
4	functional	O
5	importance	O
6	of	O
7	these	O
8	NBS	O
9	in	O
10	the	O
11	overall	O
12	drug	O
13	resistance	O
14	phenotype	O
15	conferred	O
16	by	O
17	mdr1	B
18	,	O
19	we	O
20	introduced	O
21	amino	O
22	acid	O
23	substitutions	O
24	in	O
25	the	O
26	core	O
27	consensus	O
28	sequence	O
29	for	O
30	nucleotide	O
31	binding	O
32	,	O
33	GXGKST	O
34	.	O

1	Natural	O
2	and	O
3	induced	O
4	malarias	O
5	in	O
6	western	O
7	hemisphere	O
8	monkeys	O
9	.	O

1	Extreme	O
2	potency	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	Bone	O
2	marrow	O
3	abnormalities	O
4	in	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O
9	are	O
10	reviewed	O
11	and	O
12	the	O
13	current	O
14	understanding	O
15	of	O
16	the	O
17	pathological	O
18	mechanisms	O
19	leading	O
20	to	O
21	aplastic	O
22	anemia	O
23	is	O
24	discussed	O
25	.	O

1	In	O
2	the	O
3	former	O
4	cells	O
5	,	O
6	ets	B
7	-	I
8	2	I
9	was	O
10	a	O
11	CSF	B
12	-	I
13	1	I
14	immediate	I
15	-	I
16	early	I
17	response	I
18	gene	I
19	,	O
20	and	O
21	phosphorylated	O
22	ets	B
23	-	I
24	2	I
25	was	O
26	detected	O
27	after	O
28	2	O
29	to	O
30	4	O
31	h	O
32	,	O
33	coincident	O
34	with	O
35	expression	O
36	of	O
37	ets	B
38	-	I
39	2	I
40	protein	I
41	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	telomeres	O
7	of	O
8	the	O
9	two	O
10	nuclei	O
11	have	O
12	different	O
13	functions	O
14	.	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	appropriately	O
7	spaced	O
8	upstream	O
9	from	O
10	the	O
11	transcription	O
12	initiation	O
13	site	O
14	.	O

1	We	O
2	inserted	O
3	genes	O
4	or	O
5	gene	O
6	segments	O
7	,	O
8	that	O
9	code	O
10	for	O
11	the	O
12	bacterial	B
13	chloramphenicol	I
14	acetyltransferase	I
15	,	O
16	the	O
17	bacterial	O
18	gene	O
19	conferring	O
20	resistance	O
21	against	O
22	hygromycin	O
23	,	O
24	and	O
25	the	O
26	ORF	O
27	E7	O
28	of	O
29	the	O
30	human	O
31	papillomavirus	O
32	type	O
33	18	O
34	into	O
35	these	O
36	vectors	O
37	.	O

1	However	O
2	,	O
3	such	O
4	a	O
5	mechanism	O
6	was	O
7	not	O
8	detected	O
9	in	O
10	preliminary	O
11	observations	O
12	on	O
13	M	O
14	.	O
15	synoviae	O
16	.	O

1	We	O
2	examined	O
3	the	O
4	binding	O
5	of	O
6	purified	O
7	T3	B
8	receptor	I
9	alpha	I
10	(	O
11	T3R	B
12	alpha	I
13	),	O
14	overexpressed	O
15	in	O
16	Escherichia	O
17	coli	O
18	,	O
19	to	O
20	wild	O
21	-	O
22	type	O
23	and	O
24	up	O
25	and	O
26	down	O
27	mutations	O
28	of	O
29	the	O
30	rGH	B
31	T3RE	I
32	to	O
33	evaluate	O
34	whether	O
35	transcriptional	O
36	potency	O
37	correlates	O
38	with	O
39	changes	O
40	in	O
41	T3R	B
42	binding	O
43	.	O

1	Position	O
2	-	O
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	B
8	nerve	I
9	growth	I
10	factor	I
11	-	I
12	luciferase	I
13	reporter	I
14	gene	I
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O

1	Through	O
2	Southern	O
3	blot	O
4	analyses	O
5	of	O
6	DNA	O
7	from	O
8	backcross	O
9	and	O
10	cogenic	O
11	mice	O
12	,	O
13	recombinant	O
14	inbred	O
15	strains	O
16	,	O
17	and	O
18	somatic	O
19	cell	O
20	hybrids	O
21	,	O
22	the	O
23	genetic	O
24	loci	O
25	that	O
26	produce	O
27	the	O
28	cyclin	B
29	B1	I
30	-	I
31	related	I
32	sequences	I
33	(	O
34	designated	O
35	loci	O
36	Cycb1	B
37	-	I
38	rs1	I
39	to	O
40	Cycb1	B
41	-	I
42	rs9	I
43	)	O
44	were	O
45	mapped	O
46	on	O
47	mouse	O
48	chromosomes	O
49	5	O
50	,	O
51	1	O
52	,	O
53	17	O
54	,	O
55	4	O
56	,	O
57	14	O
58	,	O
59	13	O
60	,	O
61	7	O
62	,	O
63	X	O
64	,	O
65	and	O
66	8	O
67	,	O
68	respectively	O
69	.	O

1	Transcription	O
2	start	O
3	sites	O
4	of	O
5	the	O
6	plastid	B
7	ACCase	I
8	genes	I
9	were	O
10	estimated	O
11	from	O
12	the	O
13	longest	O
14	cDNA	O
15	clones	O
16	obtained	O
17	by	O
18	5	O
19	'-	O
20	RACE	O
21	(	O
22	rapid	O
23	amplification	O
24	of	O
25	cDNA	O
26	ends	O
27	).	O

1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O

1	GLUT5	B
2	mRNA	I
3	is	O
4	expressed	O
5	at	O
6	highest	O
7	levels	O
8	in	O
9	small	O
10	intestine	O
11	and	O
12	at	O
13	much	O
14	lower	O
15	levels	O
16	in	O
17	kidney	O
18	,	O
19	skeletal	O
20	muscle	O
21	,	O
22	and	O
23	adipose	O
24	tissue	O
25	.	O

1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	B
14	pfTrm1p	I
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	O
27	(	O
28	Asp	O
29	)	O
30	and	O
31	tRNA	O
32	(	O
33	Phe	O
34	)	O
35	from	O
36	yeast	O
37	.	O

1	This	O
2	study	O
3	demonstrates	O
4	that	O
5	alteration	O
6	of	O
7	CDKN2	B
8	is	O
9	one	O
10	of	O
11	the	O
12	most	O
13	frequent	O
14	genetic	O
15	abnormalities	O
16	in	O
17	prostate	O
18	cancer	O
19	and	O
20	may	O
21	contribute	O
22	to	O
23	prostate	O
24	carcinogenesis	O
25	.	O

1	The	O
2	pulpal	O
3	tissues	O
4	of	O
5	the	O
6	permanent	O
7	mandibular	O
8	molars	O
9	were	O
10	amputated	O
11	and	O
12	then	O
13	dressed	O
14	with	O
15	calcium	O
16	hydrate	O
17	.	O

1	G	B
2	-	I
3	CSF	I
4	(	O
5	480	O
6	micrograms	O
7	subcutaneously	O
8	(	O
9	s	O
10	.	O
11	c	O
12	.))	O
13	were	O
14	used	O
15	in	O
16	55	O
17	and	O
18	GM	B
19	-	I
20	CSF	I
21	(	O
22	400	O
23	micrograms	O
24	s	O
25	.	O
26	c	O
27	.)	O
28	in	O
29	28	O
30	chemotherapeutic	O
31	cycles	O
32	.	O

1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	O

1	Enhancement	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	Increased	O
2	dietary	O
3	energy	O
4	decreased	O
5	PAB	B
6	and	O
7	the	O
8	use	O
9	of	O
10	added	O
11	dietary	O
12	CO	O
13	rather	O
14	than	O
15	PF	O
16	decreased	O
17	PSHL	O
18	in	O
19	broiler	O
20	breeders	O
21	between	O
22	26	O
23	and	O
24	47	O
25	wk	O
26	of	O
27	age	O
28	.	O

1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O

1	Anterior	O
2	body	O
3	pattern	O
4	in	O
5	Drosophila	O
6	is	O
7	specified	O
8	by	O
9	the	O
10	graded	O
11	distribution	O
12	of	O
13	the	O
14	bicoid	O
15	protein	O
16	(	O
17	bcd	O
18	),	O
19	which	O
20	activates	O
21	subordinate	O
22	genes	O
23	in	O
24	distinct	O
25	anterior	O
26	domains	O
27	.	O

1	Results	O
2	confirmed	O
3	that	O
4	stress	O
5	produced	O
6	CA3	O
7	dendritic	O
8	atrophy	O
9	and	O
10	tianeptine	O
11	prevented	O
12	it	O
13	.	O

1	OKA	O
2	and	O
3	calyculin	B
4	A	I
5	do	O
6	not	O
7	decrease	O
8	OCFRE	O
9	DNA	O
10	-	O
11	protein	O
12	interactions	O
13	,	O
14	suggesting	O
15	that	O
16	important	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	are	O
22	phosphatase	O
23	regulated	O
24	.	O

1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	B
30	factor	I
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	O
40	rep3	B
41	gene	I
42	.	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	B
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	A	O
2	canonical	O
3	TATA	O
4	box	O
5	was	O
6	not	O
7	detected	O
8	.	O

1	Transactivation	O
2	of	O
3	the	O
4	HIV	B
5	-	I
6	1	I
7	LTR	I
8	by	O
9	T3R	B
10	alpha	I
11	and	O
12	several	O
13	receptor	O
14	mutants	O
15	revealed	O
16	that	O
17	the	O
18	50	O
19	-	O
20	amino	O
21	-	O
22	acid	O
23	N	O
24	-	O
25	terminal	O
26	A	O
27	/	O
28	B	O
29	region	O
30	of	O
31	T3R	B
32	alpha	I
33	,	O
34	known	O
35	to	O
36	interact	O
37	with	O
38	the	O
39	basal	O
40	transcription	O
41	factor	O
42	TFIIB	B
43	,	O
44	is	O
45	critical	O
46	for	O
47	activation	O
48	of	O
49	both	O
50	Tat	B
51	-	O
52	dependent	O
53	and	O
54	Tat	B
55	-	O
56	independent	O
57	responsive	O
58	sequences	O
59	of	O
60	the	O
61	LTR	O
62	.	O

1	Transcripts	O
2	for	O
3	both	O
4	ODV	O
5	-	O
6	E18	O
7	and	O
8	ODV	O
9	-	O
10	EC27	O
11	initiate	O
12	from	O
13	conserved	O
14	TAAG	O
15	motifs	O
16	,	O
17	and	O
18	transcripts	O
19	are	O
20	detected	O
21	from	O
22	16	O
23	through	O
24	72	O
25	hr	O
26	p	O
27	.	O
28	i	O
29	.	O

1	Immunohistochemical	O
2	staining	O
3	with	O
4	MIB	B
5	-	I
6	1	I
7	and	O
8	p53	B
9	antibodies	I
10	showed	O
11	low	O
12	(<	O
13	1	O
14	%)	O
15	and	O
16	negative	O
17	reaction	O
18	.	O

1	The	O
2	osmotic	O
3	diuretic	O
4	mannitol	O
5	was	O
6	administered	O
7	to	O
8	21	O
9	patients	O
10	.	O

1	The	O
2	purified	O
3	recombinant	B
4	protein	I
5	was	O
6	assayed	O
7	for	O
8	its	O
9	enzyme	O
10	activity	O
11	by	O
12	monitoring	O
13	transfer	O
14	of	O
15	[	O
16	3H	O
17	]	O
18	methyl	O
19	groups	O
20	from	O
21	the	O
22	substrate	O
23	DNA	O
24	to	O
25	the	O
26	MGMT	B
27	protein	I
28	;	O
29	the	O
30	activity	O
31	was	O
32	found	O
33	to	O
34	be	O
35	stable	O
36	at	O
37	90	O
38	degrees	O
39	C	O
40	for	O
41	at	O
42	least	O
43	30	O
44	min	O
45	.	O

1	Identification	O
2	of	O
3	Ets	B
4	-	O
5	and	O
6	notch	B
7	-	I
8	related	I
9	subunits	I
10	in	O
11	GA	B
12	binding	I
13	protein	I
14	.	O

1	This	O
2	family	O
3	of	O
4	proteins	O
5	binds	O
6	GC	O
7	-	O
8	rich	O
9	motifs	O
10	widely	O
11	distributed	O
12	in	O
13	gene	O
14	promoters	O
15	,	O
16	resulting	O
17	in	O
18	distinct	O
19	activation	O
20	or	O
21	repression	O
22	of	O
23	transcriptional	O
24	activities	O
25	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	on	O
5	coronary	O
6	circulation	O
7	:	O
8	effect	O
9	on	O
10	ECG	O
11	tracing	O

1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	O
7	protein	O
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	O
14	are	O
15	shown	O
16	to	O
17	react	O
18	positively	O
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	O
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O

1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	B
7	and	O
8	KlaB	B
9	polypeptides	I
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	B
19	polypeptide	I
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O

1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O

1	The	O
2	method	O
3	described	O
4	may	O
5	prove	O
6	useful	O
7	in	O
8	studying	O
9	the	O
10	physiology	O
11	of	O
12	the	O
13	nasal	O
14	cycle	O
15	.	O

1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O

1	Ex	O
2	vivo	O
3	MAO	O
4	inhibition	O
5	data	O
6	indicated	O
7	DPGPEA	O
8	to	O
9	be	O
10	an	O
11	inhibitor	O
12	of	O
13	MAO	B
14	-	I
15	B	I
16	,	O
17	although	O
18	the	O
19	effect	O
20	was	O
21	much	O
22	weaker	O
23	than	O
24	seen	O
25	with	O
26	tranylcypromine	O
27	or	O
28	pargyline	O
29	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	DNA	B
6	polymerase	I
7	delta	I
8	of	O
9	Saccharomyces	O
10	cerevisiae	O
11	,	O
12	an	O
13	enzyme	O
14	that	O
15	is	O
16	essential	O
17	for	O
18	viability	O
19	and	O
20	chromosomal	O
21	replication	O
22	,	O
23	is	O
24	also	O
25	required	O
26	for	O
27	base	O
28	excision	O
29	repair	O
30	of	O
31	exogenous	O
32	DNA	O
33	methylation	O
34	damage	O
35	.	O

1	The	O
2	RanQ69L	O
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	O
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	O
29	/	O
30	Nup214	B
31	.	O

1	Asthmatic	O
2	patients	O
3	showed	O
4	greater	O
5	responses	O
6	of	O
7	both	O
8	parameters	O
9	to	O
10	adrenaline	O
11	than	O
12	controls	O
13	indicating	O
14	that	O
15	long	O
16	-	O
17	term	O
18	corticosteroid	O
19	treatment	O
20	enhances	O
21	the	O
22	acute	O
23	responses	O
24	of	O
25	plasminogen	B
26	activator	I
27	and	I
28	clotting	I
29	factor	I
30	VIII	I
31	to	O
32	adrenaline	O
33	infusion	O
34	.	O

1	Refined	O
2	Cox	O
3	models	O
4	using	O
5	a	O
6	CD4	B
7	count	O
8	of	O
9	150	O
10	/	O
11	microL	O
12	rather	O
13	than	O
14	200	O
15	/	O
16	microL	O
17	to	O
18	distinguish	O
19	I0	O
20	and	O
21	I1	B
22	yielded	O
23	a	O
24	simplified	O
25	model	O
26	with	O
27	better	O
28	fit	O
29	to	O
30	the	O
31	observed	O
32	data	O
33	.	O

1	The	O
2	proliferation	O
3	potential	O
4	protein	O
5	-	O
6	related	O
7	(	O
8	P2P	B
9	-	I
10	R	I
11	)	O
12	gene	O
13	with	O
14	domains	O
15	encoding	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoprotein	O
19	association	O
20	and	O
21	Rb1	B
22	binding	O
23	shows	O
24	repressed	O
25	expression	O
26	during	O
27	terminal	O
28	differentiation	O
29	.	O

1	Leukocyte	O
2	enzyme	O
3	activity	O
4	and	O
5	blood	O
6	lymphocyte	O
7	blast	O
8	transformation	O
9	in	O
10	chronic	O
11	bronchitis	O

1	Three	O
2	mutants	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	widely	O
8	used	O
9	strain	O
10	,	O
11	PAO1	B
12	.	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	O
11	of	O
12	anastomotic	O
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	O
19	Billroth	O
20	'	O
21	s	O
22	type	O
23	II	O
24	reconstruction	O
25	varied	O
26	from	O
27	a	O
28	few	O
29	days	O
30	to	O
31	19	O
32	years	O
33	,	O
34	with	O
35	an	O
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O

1	To	O
2	circumvent	O
3	this	O
4	problem	O
5	,	O
6	a	O
7	simple	O
8	two	O
9	-	O
10	step	O
11	strategy	O
12	was	O
13	devised	O
14	by	O
15	which	O
16	essential	O
17	cis	O
18	-	O
19	acting	O
20	sites	O
21	like	O
22	the	O
23	a	O
24	sequence	O
25	can	O
26	be	O
27	readily	O
28	deleted	O
29	from	O
30	their	O
31	natural	O
32	loci	O
33	in	O
34	large	O
35	viral	O
36	DNA	O
37	genomes	O
38	.	O

1	For	O
2	higher	O
3	expression	O
4	of	O
5	lipA	B
6	in	O
7	S	O
8	.	O
9	lividans	O
10	,	O
11	the	O
12	gene	O
13	was	O
14	cloned	O
15	next	O
16	to	O
17	the	O
18	strong	O
19	aphII	B
20	promoter	I
21	.	O

1	ISIS	O
2	5	O
3	possibilities	O
4	.	O

1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O

1	Detailed	O
2	analysis	O
3	of	O
4	alpha1	B
5	,	O
6	3GT	O
7	transcripts	O
8	revealed	O
9	two	O
10	major	O
11	alternative	O
12	splicing	O
13	patterns	O
14	in	O
15	the	O
16	5	O
17	'-	O
18	untranslated	O
19	region	O
20	(	O
21	5	O
22	'-	O
23	UTR	O
24	)	O
25	and	O
26	evidence	O
27	for	O
28	minor	O
29	splicing	O
30	activity	O
31	that	O
32	occurs	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	specific	O
38	manner	O
39	.	O

1	Mechanisms	O
2	of	O
3	tachyphylaxis	O
4	in	O
5	regional	O
6	anesthesia	O
7	of	O
8	long	O
9	duration	O

1	Furthermore	O
2	,	O
3	experiments	O
4	with	O
5	32D	O
6	temperature	O
7	-	O
8	sensitive	O
9	p53	B
10	cells	O
11	indicate	O
12	that	O
13	aberrant	O
14	tal	O
15	-	O
16	1	O
17	expression	O
18	at	O
19	the	O
20	permissive	O
21	temperature	O
22	does	O
23	not	O
24	exert	O
25	a	O
26	proliferative	O
27	effect	O
28	but	O
29	causes	O
30	p53	B
31	-	O
32	mediated	O
33	apoptosis	O
34	,	O
35	i	O
36	.	O
37	e	O
38	.,	O
39	the	O
40	tal	O
41	-	O
42	1	O
43	proliferative	O
44	effect	O
45	depends	O
46	on	O
47	the	O
48	integrity	O
49	of	O
50	the	O
51	cell	O
52	cycle	O
53	checkpoints	O
54	of	O
55	the	O
56	host	O
57	cell	O
58	,	O
59	as	O
60	observed	O
61	for	O
62	c	B
63	-	I
64	myc	I
65	and	O
66	other	O
67	oncogenes	O
68	.	O
69	tal	O
70	-	O
71	1	O
72	mutant	O
73	experiments	O
74	indicate	O
75	that	O
76	ectopic	O
77	tal	O
78	-	O
79	1	O
80	effects	O
81	are	O
82	mediated	O
83	by	O
84	both	O
85	the	O
86	DNA	O
87	-	O
88	binding	O
89	and	O
90	the	O
91	heterodimerization	O
92	domains	O
93	,	O
94	while	O
95	the	O
96	N	O
97	-	O
98	terminally	O
99	truncated	O
100	tal	B
101	-	I
102	1	I
103	variant	I
104	(	O
105	M3	O
106	)	O
107	expressed	O
108	in	O
109	T	O
110	-	O
111	ALL	O
112	malignant	O
113	cells	O
114	mimics	O
115	the	O
116	effects	O
117	of	O
118	the	O
119	wild	O
120	-	O
121	type	O
122	protein	O
123	.	O

1	Analysis	O
2	of	O
3	a	O
4	Mac1p	B
5	mutant	I
6	,	O
7	refractile	O
8	for	O
9	copper	O
10	-	O
11	dependent	O
12	repression	O
13	of	O
14	the	O
15	Cu	O
16	(	O
17	I	O
18	)	O
19	transport	O
20	genes	O
21	,	O
22	showed	O
23	an	O
24	aberrant	O
25	pattern	O
26	of	O
27	CUP1	B
28	expression	O
29	and	O
30	copper	O
31	sensitivity	O
32	.	O

1	Intrathecal	O
2	acetyl	B
3	cholinesterase	I
4	inhibitors	O
5	produce	O
6	analgesia	O
7	that	O
8	is	O
9	synergistic	O
10	with	O
11	morphine	O
12	and	O
13	clonidine	O
14	in	O
15	rats	O
16	.	O

1	Replicating	O
2	simian	O
3	virus	O
4	40	O
5	(	O
6	SV40	O
7	)	O
8	chromosomes	O
9	were	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	to	O
15	other	O
16	eukaryotic	O
17	chromosomes	O
18	in	O
19	that	O
20	the	O
21	rate	O
22	and	O
23	extent	O
24	of	O
25	micrococcal	B
26	nuclease	I
27	(	I
28	MNase	I
29	)	O
30	digestion	O
31	were	O
32	greater	O
33	with	O
34	replicating	O
35	than	O
36	with	O
37	nonreplicating	O
38	mature	O
39	SV40	O
40	chromatin	O
41	.	O

1	With	O
2	regard	O
3	to	O
4	nonhematologic	O
5	toxicities	O
6	,	O
7	diarrhea	O
8	,	O
9	infection	O
10	and	O
11	elevated	O
12	serum	B
13	alkaline	I
14	phosphatase	I
15	of	O
16	grade	O
17	3	O
18	or	O
19	over	O
20	were	O
21	observed	O
22	in	O
23	2	O
24	%	O
25	of	O
26	cycles	O
27	,	O
28	but	O
29	were	O
30	tolerable	O
31	and	O
32	reversible	O
33	.	O

1	In	O
2	the	O
3	p51	O
4	subunit	O
5	,	O
6	the	O
7	Cys181	O
8	side	O
9	-	O
10	chain	O
11	is	O
12	oriented	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	Tyr181	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O

1	267	O
2	,	O
3	4870	O
4	-	O
5	4877	O
6	))	O
7	indicates	O
8	an	O
9	overall	O
10	identity	O
11	of	O
12	58	O
13	and	O
14	56	O
15	%,	O
16	respectively	O
17	,	O
18	with	O
19	a	O
20	91	O
21	and	O
22	92	O
23	%	O
24	identity	O
25	in	O
26	the	O
27	highly	O
28	conserved	O
29	transmembrane	O
30	and	O
31	cytoplasmic	O
32	domains	O
33	.	O

1	Internal	O
2	biliary	O
3	drainage	O
4	,	O
5	unlike	O
6	external	O
7	drainage	O
8	,	O
9	does	O
10	not	O
11	suppress	O
12	the	O
13	regeneration	O
14	of	O
15	cholestatic	O
16	rat	O
17	liver	O
18	after	O
19	partial	O
20	hepatectomy	O
21	.	O

1	We	O
2	show	O
3	that	O
4	stimulation	O
5	of	O
6	resting	O
7	splenic	O
8	B	O
9	cells	O
10	with	O
11	CD40L	B
12	-	O
13	expressing	O
14	Sf9	O
15	cells	O
16	induces	O
17	germ	B
18	-	I
19	line	I
20	gamma	I
21	1	I
22	and	I
23	epsilon	I
24	transcripts	I
25	independently	O
26	of	O
27	cytokines	O
28	.	O

1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O

1	RESULTS	O
2	:	O
3	The	O
4	cardiac	O
5	index	O
6	significantly	O
7	changed	O
8	with	O
9	varying	O
10	PaCO2	O
11	levels	O
12	(	O
13	hypocapnia	O
14	,	O
15	-	O
16	9	O
17	%;	O
18	hypercapnia	O
19	,	O
20	13	O
21	%).	O

1	The	O
2	first	O
3	open	O
4	reading	O
5	frame	O
6	of	O
7	the	O
8	blueberry	O
9	scorch	O
10	carlavirus	O
11	(	O
12	BBScV	O
13	)	O
14	genome	O
15	encodes	O
16	a	O
17	putative	O
18	replication	O
19	-	O
20	associated	O
21	protein	O
22	of	O
23	223	O
24	kDa	O
25	(	O
26	p223	O
27	).	O

1	Institution	O
2	of	O
3	both	O
4	intravenous	O
5	and	O
6	intracisternal	O
7	administration	O
8	of	O
9	amphotericin	O
10	B	O
11	and	O
12	possibly	O
13	concomitant	O
14	intravenous	O
15	administration	O
16	of	O
17	dexamethasone	O
18	may	O
19	be	O
20	warranted	O
21	in	O
22	situations	O
23	in	O
24	which	O
25	the	O
26	association	O
27	of	O
28	C	O
29	.	O
30	immitis	O
31	with	O
32	CNS	O
33	vasculitis	O
34	or	O
35	encephalitis	O
36	appears	O
37	likely	O
38	before	O
39	serologic	O
40	or	O
41	cultural	O
42	confirmation	O
43	of	O
44	C	O
45	.	O
46	immitis	O
47	infection	O
48	involving	O
49	the	O
50	CNS	O
51	is	O
52	available	O
53	.	O

1	The	O
2	peroxisome	B
3	proliferator	I
4	-	I
5	activated	I
6	receptors	I
7	(	O
8	PPARs	B
9	)	O
10	are	O
11	members	O
12	of	O
13	the	O
14	nuclear	B
15	hormone	I
16	receptor	I
17	superfamily	I
18	.	O

1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O

1	B	B
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	O
8	induced	O
9	apoptosis	O
10	in	O
11	the	O
12	WEHI	O
13	-	O
14	231	O
15	B	O
16	lymphoma	O
17	cell	O
18	line	O
19	can	O
20	be	O
21	prevented	O
22	by	O
23	engaging	O
24	CD40	B
25	.	O

1	Basal	O
2	plasma	O
3	AVP	B
4	levels	O
5	and	O
6	AVP	B
7	release	O
8	after	O
9	postural	O
10	change	O
11	were	O
12	assessed	O
13	,	O
14	and	O
15	plasma	O
16	NPY	O
17	levels	O
18	were	O
19	measured	O
20	in	O
21	the	O
22	same	O
23	samples	O
24	.	O

1	Fifty	O
2	-	O
3	four	O
4	patients	O
5	were	O
6	divided	O
7	into	O
8	groups	O
9	according	O
10	to	O
11	their	O
12	clinical	O
13	presentation	O
14	;	O
15	seven	O
16	asymptomatic	O
17	volunteers	O
18	,	O
19	20	O
20	patients	O
21	with	O
22	duodenal	O
23	-	O
24	gastric	O
25	reflux	O
26	gastropathy	O
27	(	O
28	DRG	O
29	),	O
30	16	O
31	patients	O
32	with	O
33	recurrent	O
34	ulcers	O
35	of	O
36	the	O
37	duodenal	O
38	bulb	O
39	(	O
40	RUD	O
41	),	O
42	and	O
43	11	O
44	patients	O
45	with	O
46	Moynihan	O
47	'	O
48	s	O
49	disease	O
50	.	O

1	Only	O
2	two	O
3	patients	O
4	(	O
5	0	O
6	.	O
7	3	O
8	%)	O
9	had	O
10	a	O
11	CA	B
12	125	I
13	response	O
14	at	O
15	the	O
16	time	O
17	of	O
18	clinical	O
19	progression	O
20	.	O

1	The	O
2	potency	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	Nim	O
8	(	O
9	0	O
10	.	O
11	5	O
12	mg	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	i	O
18	.	O
19	p	O
20	.)	O
21	was	O
22	similar	O
23	to	O
24	that	O
25	of	O
26	NBP	B
27	(	O
28	10	O
29	mg	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	i	O
35	.	O
36	p	O
37	.).	O

1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	I
10	beta	I
11	1	I
12	is	O
13	the	O
14	major	O
15	laminin	B
16	receptor	I
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O

1	Among	O
2	mammalian	O
3	HSFs	O
4	,	O
5	HSF1	B
6	has	O
7	been	O
8	shown	O
9	to	O
10	be	O
11	important	O
12	for	O
13	regulation	O
14	of	O
15	the	O
16	heat	O
17	-	O
18	induced	O
19	stress	O
20	gene	O
21	expression	O
22	,	O
23	whereas	O
24	the	O
25	function	O
26	of	O
27	HSF2	B
28	in	O
29	stress	O
30	response	O
31	is	O
32	unclear	O
33	.	O

1	Importance	O
2	of	O
3	determining	O
4	the	O
5	blood	O
6	sulfhydryl	O
7	groups	O
8	in	O
9	fractures	O
10	of	O
11	the	O
12	long	O
13	tubular	O
14	bones	O
15	complicated	O
16	by	O
17	infection	O

1	The	O
2	strong	O
3	conservation	O
4	of	O
5	the	O
6	inverted	O
7	terminal	O
8	repeat	O
9	sequence	O
10	may	O
11	reflect	O
12	a	O
13	common	O
14	integration	O
15	mechanism	O
16	for	O
17	VL30	O
18	elements	O
19	and	O
20	MuLV	O
21	proviruses	O
22	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	RNK	B
6	-	I
7	Met	I
8	-	I
9	1	I
10	is	O
11	a	O
12	serine	O
13	protease	O
14	with	O
15	unique	O
16	activity	O
17	that	O
18	is	O
19	expressed	O
20	in	O
21	the	O
22	granules	O
23	of	O
24	large	O
25	granular	O
26	lymphocytes	O
27	.	O

1	Am	O
2	.	O

1	The	O
2	rhabdomyosarcoma	O
3	R1H	O
4	growing	O
5	on	O
6	the	O
7	right	O
8	flank	O
9	of	O
10	male	O
11	WAG	O
12	/	O
13	Rij	O
14	rats	O
15	was	O
16	clamped	O
17	for	O
18	2	O
19	or	O
20	4	O
21	h	O
22	at	O
23	20	O
24	degrees	O
25	C	O
26	or	O
27	37	O
28	degrees	O
29	C	O
30	.	O

1	These	O
2	results	O
3	are	O
4	very	O
5	useful	O
6	for	O
7	deciding	O
8	on	O
9	the	O
10	doses	O
11	of	O
12	hormones	O
13	and	O
14	the	O
15	expected	O
16	serum	O
17	estradiol	O
18	level	O
19	in	O
20	HRT	O
21	for	O
22	Japanese	O
23	women	O
24	.	O

1	Liver	O
2	transplantation	O
3	in	O
4	one	O
5	patient	O
6	resolved	O
7	metabolic	O
8	complications	O
9	but	O
10	did	O
11	not	O
12	improve	O
13	PMN	O
14	count	O
15	or	O
16	the	O
17	infectious	O
18	status	O
19	,	O
20	while	O
21	neutropenia	O
22	was	O
23	corrected	O
24	by	O
25	G	B
26	-	I
27	CSF	I
28	.	O

1	A	O
2	striking	O
3	feature	O
4	of	O
5	the	O
6	recombinant	B
7	H19	I
8	allele	I
9	is	O
10	the	O
11	occurrence	O
12	of	O
13	a	O
14	parental	O
15	imprint	O
16	set	O
17	on	O
18	the	O
19	neo	B
20	replacement	I
21	cassette	I
22	.	O

1	17	O
2	volunteer	O
3	deaf	O
4	Ss	O
5	were	O
6	compared	O
7	with	O
8	18	O
9	volunteer	O
10	hearing	O
11	Ss	O
12	on	O
13	the	O
14	Stanford	O
15	Hypnotic	O
16	Clinical	O
17	Scale	O
18	(	O
19	SHCS	O
20	)	O
21	of	O
22	Morgan	O
23	and	O
24	J	O
25	.	O

1	In	O
2	most	O
3	cases	O
4	,	O
5	DR4	O
6	-	O
7	homozygous	O
8	,	O
9	DRB1	B
10	-	O
11	heterozygous	O
12	individuals	O
13	could	O
14	be	O
15	genotyped	O
16	with	O
17	the	O
18	panel	O
19	of	O
20	probes	O
21	.	O

1	The	O
2	Psc2	B
3	cDNA	I
4	contained	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	homologous	O
10	to	O
11	CP2	B
12	family	I
13	proteins	I
14	.	O

1	The	O
2	cycle	O
3	length	O
4	of	O
5	induced	O
6	VT	O
7	(	O
8	n	O
9	=	O
10	10	O
11	VTs	O
12	)	O
13	was	O
14	380	O
15	+/-	O
16	41	O
17	msec	O
18	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	The	O
2	so	O
3	-	O
4	called	O
5	"	O
6	SH3	B
7	"	O
8	segment	O
9	of	O
10	the	O
11	linker	O
12	domain	O
13	,	O
14	in	O
15	contrast	O
16	,	O
17	shows	O
18	species	O
19	-	O
20	specific	O
21	sequence	O
22	identity	O
23	in	O
24	all	O
25	but	O
26	one	O
27	amino	O
28	acid	O
29	residues	O
30	in	O
31	both	O
32	factors	O
33	,	O
34	in	O
35	cattle	O
36	,	O
37	human	O
38	,	O
39	and	O
40	mouse	O
41	.	O

1	The	O
2	patient	O
3	with	O
4	a	O
5	prolonged	O
6	fever	O
7	caused	O
8	by	O
9	dissecting	O
10	aneurysm	O
11	of	O
12	the	O
13	aorta	O
14	in	O
15	whom	O
16	pleuropneumonia	O
17	masked	O
18	the	O
19	real	O
20	diseases	O
21	has	O
22	been	O
23	presented	O
24	.	O

1	Regions	O
2	of	O
3	the	O
4	translated	O
5	open	O
6	reading	O
7	frames	O
8	of	O
9	cobA	B
10	and	O
11	the	O
12	third	O
13	intron	O
14	of	O
15	the	O
16	cob	B
17	gene	I
18	in	O
19	yeast	O
20	show	O
21	high	O
22	amino	O
23	acid	O
24	homology	O
25	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	IFN	B
6	-	I
7	gamma	I
8	stimulated	O
9	the	O
10	rapid	O
11	accumulation	O
12	of	O
13	interferon	B
14	regulated	I
15	factor	I
16	(	I
17	IRF	I
18	)-	I
19	1	I
20	mRNA	I
21	,	O
22	followed	O
23	by	O
24	a	O
25	delayed	O
26	and	O
27	dose	O
28	-	O
29	dependent	O
30	inhibition	O
31	of	O
32	alpha1	B
33	(	I
34	I	I
35	)	I
36	procollagen	I
37	mRNA	I
38	expression	O
39	in	O
40	skin	O
41	fibroblasts	O
42	from	O
43	several	O
44	different	O
45	donors	O
46	.	O

1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O

1	Based	O
2	on	O
3	213	O
4	determinations	O
5	,	O
6	the	O
7	control	O
8	mean	O
9	serum	O
10	CPK	B
11	activity	O
12	was	O
13	262	O
14	+/-	O
15	113	O
16	I	O
17	.	O
18	U	O
19	./	O
20	liter	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	a	O
6	)	O
7	the	O
8	likelihood	O
9	of	O
10	detecting	O
11	carcinoma	O
12	or	O
13	atypical	O
14	hyperplasia	O
15	exclusively	O
16	in	O
17	the	O
18	adipose	O
19	tissue	O
20	component	O
21	of	O
22	grossly	O
23	benign	O
24	breast	O
25	biopsies	O
26	is	O
27	extremely	O
28	low	O
29	,	O
30	and	O
31	(	O
32	b	O
33	)	O
34	a	O
35	possible	O
36	cost	O
37	-	O
38	effective	O
39	method	O
40	of	O
41	sampling	O
42	grossly	O
43	benign	O
44	breast	O
45	biopsies	O
46	consists	O
47	of	O
48	initially	O
49	submitting	O
50	a	O
51	maximum	O
52	of	O
53	10	O
54	blocks	O
55	of	O
56	fibrous	O
57	parenchyma	O
58	for	O
59	each	O
60	case	O
61	,	O
62	then	O
63	examining	O
64	the	O
65	remaining	O
66	tissue	O
67	histologically	O
68	only	O
69	if	O
70	carcinoma	O
71	or	O
72	atypical	O
73	hyperplasia	O
74	is	O
75	found	O
76	among	O
77	these	O
78	blocks	O
79	.	O

1	Experience	O
2	with	O
3	the	O
4	tensor	O
5	fasciae	O
6	latae	O
7	free	O
8	flap	O
9	.	O

1	Indium	O
2	-	O
3	111	O
4	leukocyte	O
5	imaging	O
6	in	O
7	patients	O
8	with	O
9	rheumatoid	O
10	arthritis	O
11	.	O

1	Determination	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	imaging	O
7	properties	O
8	of	O
9	a	O
10	light	O
11	microscope	O
12	system	O
13	.	O

1	Data	O
2	on	O
3	the	O
4	line	O
5	spread	O
6	function	O
7	(	O
8	LSF	O
9	)	O
10	were	O
11	obtained	O
12	from	O
13	the	O
14	image	O
15	of	O
16	a	O
17	0	O
18	.	O
19	2	O
20	mm	O
21	wide	O
22	slit	O
23	between	O
24	tungsten	O
25	blocks	O
26	that	O
27	were	O
28	positioned	O
29	at	O
30	the	O
31	isocentre	O
32	in	O
33	front	O
34	of	O
35	a	O
36	polystyrene	O
37	phantom	O
38	.	O

1	S	O
2	.,	O
3	K	O
4	.	O

1	We	O
2	generated	O
3	transformed	O
4	B	O
5	lymphoblast	O
6	cell	O
7	lines	O
8	from	O
9	controls	O
10	,	O
11	from	O
12	four	O
13	patients	O
14	with	O
15	p47	B
16	-	O
17	phox	B
18	-	O
19	deficient	O
20	chronic	O
21	granulomatous	O
22	disease	O
23	,	O
24	and	O
25	from	O
26	three	O
27	parents	O
28	.	O

1	Thus	O
2	,	O
3	depending	O
4	on	O
5	their	O
6	location	O
7	,	O
8	psoralen	O
9	cross	O
10	-	O
11	links	O
12	affected	O
13	different	O
14	steps	O
15	in	O
16	the	O
17	initiation	O
18	process	O
19	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	5	B
6	'	I
7	UTR	I
8	characteristic	O
9	of	O
10	testis	B
11	-	I
12	specific	I
13	c	I
14	-	I
15	mos	I
16	mRNA	I
17	strongly	O
18	represses	O
19	translation	O
20	relative	O
21	to	O
22	the	O
23	translation	O
24	of	O
25	transcripts	O
26	that	O
27	contain	O
28	a	O
29	5	B
30	'	I
31	UTR	I
32	derived	I
33	from	I
34	beta	I
35	-	I
36	globin	I
37	mRNA	I
38	,	O
39	and	O
40	this	O
41	is	O
42	mainly	O
43	due	O
44	to	O
45	the	O
46	four	O
47	uORFs	O
48	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	wild	O
6	-	O
7	type	O
8	protein	O
9	,	O
10	expression	O
11	of	O
12	p45	B
13	NF	I
14	-	I
15	E2	I
16	lacking	O
17	this	O
18	activation	O
19	domain	O
20	in	O
21	an	O
22	NF	B
23	-	I
24	E2	I
25	null	O
26	cell	O
27	line	O
28	fails	O
29	to	O
30	support	O
31	enhancer	O
32	-	O
33	dependent	O
34	transcription	O
35	in	O
36	transient	O
37	assays	O
38	.	O

1	Acute	O
2	experiments	O
3	on	O
4	nembutal	O
5	-	O
6	anesthetized	O
7	cats	O
8	(	O
9	50	O
10	mg	O
11	/	O
12	kg	O
13	)	O
14	were	O
15	employed	O
16	to	O
17	investigate	O
18	the	O
19	effect	O
20	of	O
21	1	O
22	T	O
23	pulsating	O
24	magnetic	O
25	field	O
26	(	O
27	PMF	O
28	)	O
29	on	O
30	neuromuscular	O
31	system	O
32	of	O
33	the	O
34	leg	O
35	.	O

1	CONCLUSION	O
2	:	O
3	NBP	B
4	pre	O
5	-	O
6	treatment	O
7	or	O
8	post	O
9	-	O
10	treatment	O
11	markedly	O
12	enhanced	O
13	the	O
14	rCBF	O
15	to	O
16	striatum	O
17	in	O
18	RMCAO	O
19	rats	O
20	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	ORF	O
7	of	O
8	hAMPK	B
9	encodes	O
10	552	O
11	amino	O
12	acids	O
13	(	O
14	aa	O
15	)	O
16	(	O
17	62	O
18	.	O
19	250	O
20	kDa	O
21	)	O
22	and	O
23	is	O
24	highly	O
25	conserved	O
26	with	O
27	rAMPK	O
28	with	O
29	identities	O
30	of	O
31	97	O
32	.	O
33	3	O
34	and	O
35	90	O
36	%	O
37	at	O
38	the	O
39	aa	O
40	and	O
41	nt	O
42	levels	O
43	,	O
44	respectively	O
45	.	O

1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O

1	These	O
2	striations	O
3	were	O
4	caused	O
5	by	O
6	contact	O
7	between	O
8	the	O
9	sharp	O
10	edge	O
11	of	O
12	the	O
13	upper	O
14	canine	O
15	and	O
16	the	O
17	P3	O
18	during	O
19	honing	O
20	(	O
21	canine	O
22	/	O
23	premolar	O
24	complex	O
25	).	O

1	The	O
2	failures	O
3	frequently	O
4	were	O
5	related	O
6	to	O
7	patient	O
8	intolerance	O
9	or	O
10	poor	O
11	mechanical	O
12	fit	O
13	and	O
14	occurred	O
15	in	O
16	the	O
17	first	O
18	few	O
19	days	O
20	or	O
21	first	O
22	few	O
23	months	O
24	after	O
25	insertion	O
26	.	O

1	5	O
2	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	and	O
6	DNase	B
7	I	I
8	footprinting	O
9	experiments	O
10	using	O
11	purified	O
12	42	O
13	kDa	O
14	repressor	O
15	isoform	O
16	confirmed	O
17	that	O
18	CIRs	O
19	5	O
20	and	O
21	6	O
22	were	O
23	indeed	O
24	the	O
25	targets	O
26	for	O
27	binding	O
28	of	O
29	this	O
30	protein	O
31	.	O

1	Modification	O
2	of	O
3	dopamine	B
4	D2	I
5	receptor	I
6	activity	O
7	by	O
8	pergolide	O
9	in	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	:	O
15	an	O
16	in	O
17	vivo	O
18	study	O
19	by	O
20	PET	O
21	.	O

1	In	O
2	several	O
3	studies	O
4	the	O
5	RDFS	O
6	has	O
7	shown	O
8	evidence	O
9	of	O
10	reliability	O
11	and	O
12	validity	O
13	.	O

1	N	O
2	-	O
3	Substituted	O
4	trimethylsilylcarbamates	O
5	were	O
6	tested	O
7	as	O
8	derivatizing	O
9	reagents	O
10	for	O
11	gas	O
12	chromatographic	O
13	analysis	O
14	.	O

1	The	O
2	experimental	O
3	end	O
4	points	O
5	were	O
6	the	O
7	time	O
8	required	O
9	for	O
10	treated	O
11	tumors	O
12	to	O
13	reach	O
14	3	O
15	times	O
16	their	O
17	treatment	O
18	size	O
19	,	O
20	the	O
21	survival	O
22	of	O
23	stem	O
24	cells	O
25	in	O
26	the	O
27	duodenal	O
28	crypts	O
29	,	O
30	and	O
31	the	O
32	breathing	O
33	rate	O
34	measured	O
35	early	O
36	(	O
37	19	O
38	-	O
39	23	O
40	weeks	O
41	)	O
42	and	O
43	late	O
44	(	O
45	41	O
46	-	O
47	46	O
48	weeks	O
49	)	O
50	after	O
51	treatment	O
52	.	O

1	Synchronous	O
2	extracts	O
3	showed	O
4	no	O
5	significant	O
6	migration	O
7	inhibition	O
8	in	O
9	allogeneic	O
10	assays	O
11	.	O

1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	Dr1	B
8	-	I
9	like	I
10	protein	I
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	argues	O
17	for	O
18	the	O
19	ubiquity	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	genera	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	Dr1	O
38	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	AP	B
6	-	I
7	A	I
8	may	O
9	be	O
10	potentially	O
11	useful	O
12	in	O
13	the	O
14	management	O
15	of	O
16	heart	O
17	failure	O
18	.	O

1	In	O
2	Group	O
3	IV	O
4	dogs	O
5	that	O
6	received	O
7	alpha	B
8	-	I
9	MSH	I
10	only	O
11	during	O
12	reperfusion	O
13	,	O
14	BAEPs	O
15	were	O
16	increased	O
17	approximately	O
18	10	O
19	to	O
20	14	O
21	%	O
22	more	O
23	than	O
24	in	O
25	Group	O
26	II	O
27	during	O
28	the	O
29	late	O
30	reperfusion	O
31	period	O
32	.	O

1	In	O
2	Xenopus	O
3	laevis	O
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	B
10	factor	I
11	1	I
12	-	I
13	alpha	I
14	variant	I
15	EF	I
16	-	I
17	1	I
18	alpha	I
19	O	I
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O

1	A	O
2	13	O
3	base	O
4	-	O
5	pair	O
6	oligonucleotide	O
7	spanning	O
8	nucleotides	O
9	+	O
10	80	O
11	to	O
12	+	O
13	92	O
14	of	O
15	the	O
16	5	B
17	S	I
18	RNA	I
19	gene	I
20	retained	O
21	specific	O
22	and	O
23	high	O
24	-	O
25	affinity	O
26	binding	O
27	,	O
28	although	O
29	the	O
30	latter	O
31	was	O
32	reduced	O
33	sixfold	O
34	relative	O
35	to	O
36	longer	O
37	DNA	O
38	fragments	O
39	.	O

1	Survey	O
2	on	O
3	antibody	O
4	against	O
5	egg	O
6	drop	O
7	syndrome	O
8	-	O
9	1976	O
10	virus	O
11	among	O
12	chicken	O
13	flocks	O
14	in	O
15	Japan	O
16	.	O

1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O

1	Timing	O
2	of	O
3	symptoms	O
4	and	O
5	oocyst	O
6	excretion	O
7	in	O
8	human	O
9	cryptosporidiosis	O
10	.	O

1	The	O
2	psychologic	O
3	factors	O
4	associated	O
5	wth	O
6	serious	O
7	illness	O
8	,	O
9	terminal	O
10	prognoses	O
11	,	O
12	and	O
13	dying	O
14	complicate	O
15	the	O
16	scenario	O
17	even	O
18	more	O
19	as	O
20	compared	O
21	with	O
22	that	O
23	of	O
24	nonmalignant	O
25	pain	O
26	.	O

1	Human	B
2	SRF	I
3	-	I
4	related	I
5	proteins	I
6	:	O
7	DNA	O
8	-	O
9	binding	O
10	properties	O
11	and	O
12	potential	O
13	regulatory	O
14	targets	O
15	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	distinct	O
6	cytoplasmic	O
7	domains	O
8	of	O
9	these	O
10	cytokine	O
11	receptors	O
12	elicit	O
13	convergent	O
14	signaling	O
15	pathways	O
16	and	O
17	provide	O
18	evidence	O
19	that	O
20	beta	B
21	c	I
22	and	O
23	IL	B
24	-	I
25	2R	I
26	beta	I
27	function	O
28	as	O
29	a	O
30	complete	O
31	signal	O
32	transducer	O
33	.	O

1	Teratogenic	O
2	effects	O
3	of	O
4	actinomycin	O
5	D	O
6	in	O
7	rats	O

1	Viral	O
2	genomic	O
3	RNA	O
4	for	O
5	these	O
6	reactions	O
7	was	O
8	obtained	O
9	directly	O
10	from	O
11	fecal	O
12	specimens	O
13	of	O
14	infected	O
15	infant	O
16	rats	O
17	.	O

1	Electrocardiographic	O
2	QRS	O
3	complexes	O
4	and	O
5	vectorcardiographic	O
6	QRS	O
7	loop	O

1	SCA	O
2	was	O
3	resistant	O
4	to	O
5	inhibitors	O
6	of	O
7	serine	O
8	,	O
9	aspartyl	O
10	,	O
11	and	O
12	metalloproteases	O
13	,	O
14	but	O
15	it	O
16	was	O
17	sensitive	O
18	to	O
19	N	O
20	-	O
21	ethylmaleimide	O
22	.	O

1	Serum	O
2	levels	O
3	of	O
4	albumin	B
5	,	O
6	globulin	B
7	,	O
8	and	O
9	coagulation	O
10	protein	O
11	activity	O
12	were	O
13	measured	O
14	preshock	O
15	,	O
16	postshock	O
17	,	O
18	and	O
19	daily	O
20	for	O
21	3	O
22	days	O
23	;	O
24	skin	O
25	lymph	O
26	levels	O
27	were	O
28	measured	O
29	on	O
30	Day	O
31	3	O
32	.	O

1	Accurate	O
2	evaluation	O
3	of	O
4	the	O
5	treatment	O
6	results	O
7	in	O
8	unresectable	O
9	lung	O
10	cancer	O
11	patients	O
12	must	O
13	take	O
14	the	O
15	strong	O
16	prognostic	O
17	factors	O
18	into	O
19	account	O
20	.	O

1	D	O
2	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Cdc42p	B
6	is	O
7	in	O
8	fact	O
9	required	O
10	for	O
11	pheromone	O
12	response	O
13	and	O
14	that	O
15	interaction	O
16	with	O
17	the	O
18	PAK	B
19	Ste20p	I
20	is	O
21	critical	O
22	for	O
23	that	O
24	role	O
25	.	O

1	The	O
2	subjects	O
3	of	O
4	the	O
5	study	O
6	were	O
7	10	O
8	normal	O
9	subjects	O
10	and	O
11	64	O
12	patients	O
13	with	O
14	gastroduodenal	O
15	disease	O
16	.	O

1	The	O
2	GTPase	B
3	activity	O
4	of	O
5	CDC42Ce	O
6	is	O
7	moderately	O
8	stimulated	O
9	by	O
10	human	B
11	n	I
12	-	I
13	chimaerin	I
14	,	O
15	a	O
16	GTPase	B
17	-	I
18	activating	I
19	protein	I
20	for	O
21	the	O
22	related	O
23	p21	B
24	rac1	I
25	.	O

1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O

1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O

1	This	O
2	relatively	O
3	simple	O
4	and	O
5	easily	O
6	performed	O
7	technique	O
8	of	O
9	measuring	O
10	deep	O
11	muscle	O
12	temperature	O
13	appears	O
14	to	O
15	be	O
16	a	O
17	useful	O
18	adjunct	O
19	in	O
20	choosing	O
21	the	O
22	amputation	O
23	level	O
24	.	O

1	Consistent	O
2	with	O
3	effects	O
4	on	O
5	STAT	B
6	activation	O
7	,	O
8	altered	O
9	SHP	B
10	-	I
11	1	I
12	expression	O
13	also	O
14	affected	O
15	EGF	B
16	-	O
17	induced	O
18	activation	O
19	of	O
20	the	O
21	mitogen	B
22	-	I
23	activated	I
24	protein	I
25	kinase	I
26	pathway	O
27	;	O
28	expression	O
29	of	O
30	SHP	B
31	-	I
32	1	I
33	-(	O
34	Cys	O
35	-->	O
36	Ser	O
37	)	O
38	inhibited	O
39	activity	O
40	of	O
41	MEK	B
42	by	O
43	approximately	O
44	25	O
45	%,	O
46	whereas	O
47	expression	O
48	of	O
49	SHP	B
50	-	I
51	1	I
52	resulted	O
53	in	O
54	a	O
55	approximately	O
56	25	O
57	%	O
58	increase	O
59	.	O

1	Age	O
2	at	O
3	POI	O
4	and	O
5	asymptote	O
6	were	O
7	achieved	O
8	later	O
9	for	O
10	Line	O
11	RBC2	O
12	than	O
13	for	O
14	Line	O
15	F	O
16	.	O

1	This	O
2	study	O
3	describes	O
4	a	O
5	new	O
6	MADS	B
7	box	I
8	gene	I
9	,	O
10	nmhC5	O
11	,	O
12	which	O
13	along	O
14	with	O
15	nmh7	O
16	(	O
17	J	O
18	.	O

1	E1A	B
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	B
20	promoter	I
21	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	O
7	CBF2	B
8	for	O
9	binding	O
10	to	O
11	the	O
12	LMP	B
13	-	I
14	1	I
15	,	O
16	LMP	B
17	-	I
18	2	I
19	,	O
20	and	O
21	CD23	B
22	promoters	I
23	were	O
24	also	O
25	measured	O
26	.	O

1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O

1	Twenty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	80	O
7	,	O
8	6	O
9	%)	O
10	with	O
11	mixed	O
12	neoplasms	O
13	were	O
14	operated	O
15	on	O
16	by	O
17	total	O
18	conservative	O
19	parotidectomy	O
20	(	O
21	T	O
22	.	O
23	C	O
24	.	O
25	P	O
26	.),	O
27	3	O
28	(	O
29	9	O
30	,	O
31	7	O
32	%)	O
33	by	O
34	S	O
35	.	O
36	P	O
37	.	O
38	and	O
39	3	O
40	(	O
41	9	O
42	,	O
43	7	O
44	%)	O
45	by	O
46	En	B
47	.	O

1	Experimental	O
2	cardiotoxicity	O
3	of	O
4	adriamycin	O

1	Specimens	O
2	were	O
3	assayed	O
4	for	O
5	alpha	B
6	-	I
7	fetoprotein	I
8	,	O
9	unconjugated	O
10	estriol	O
11	,	O
12	free	O
13	alpha	O
14	hCG	B
15	,	O
16	and	O
17	total	O
18	hCG	B
19	.	O

1	Thus	O
2	,	O
3	the	O
4	pol	B
5	alpha	I
6	-	I
7	primase	I
8	complex	O
9	appears	O
10	to	O
11	act	O
12	processively	O
13	for	O
14	only	O
15	a	O
16	short	O
17	distance	O
18	.	O

1	Rifabutin	B
2	has	O
3	substantial	O
4	efficacy	O
5	when	O
6	combined	O
7	with	O
8	other	O
9	agents	O
10	.	O

1	We	O
2	present	O
3	this	O
4	case	O
5	because	O
6	of	O
7	the	O
8	rarity	O
9	of	O
10	left	O
11	ventricular	O
12	involvement	O
13	associated	O
14	with	O
15	ARVD	O
16	.	O

1	Serum	O
2	IgG	B
3	was	O
4	initially	O
5	elevated	O
6	in	O
7	6	O
8	patients	O
9	.	O

1	Coliphage	O
2	186	O
3	B	O
4	is	O
5	a	O
6	72	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	belonging	O
12	to	O
13	the	O
14	Ogr	B
15	family	I
16	of	O
17	analogous	O
18	transcription	O
19	factors	O
20	present	O
21	in	O
22	P2	O
23	-	O
24	like	O
25	phage	O
26	,	O
27	which	O
28	contain	O
29	a	O
30	Cys	O
31	-	O
32	X2	O
33	-	O
34	Cys	O
35	-	O
36	X22	B
37	-	I
38	Cys	I
39	-	I
40	X4	I
41	-	I
42	Cys	I
43	presumptive	I
44	zinc	I
45	-	I
46	finger	I
47	motif	I
48	.	O

1	III	O
2	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	B
5	homologue	I
6	(	I
7	BarX	I
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	Ninety	O
2	-	O
3	four	O
4	percent	O
5	of	O
6	the	O
7	EPs	O
8	were	O
9	tubal	O
10	,	O
11	and	O
12	90	O
13	%	O
14	of	O
15	the	O
16	tubes	O
17	exhibited	O
18	some	O
19	pathologic	O
20	changes	O
21	,	O
22	including	O
23	chronic	O
24	salpingitis	O
25	(	O
26	49	O
27	.	O
28	5	O
29	%)	O
30	and	O
31	follicular	O
32	salpingitis	O
33	(	O
34	10	O
35	%),	O
36	among	O
37	others	O
38	.	O

1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O

1	Local	O
2	graft	O
3	irradiation	O
4	as	O
5	an	O
6	adjunct	O
7	to	O
8	pharmacologic	O
9	immunosuppression	O
10	.	O

1	DATA	O
2	SYNTHESIS	O
3	:	O
4	Intracoronary	O
5	ultrasound	O
6	has	O
7	been	O
8	shown	O
9	to	O
10	improve	O
11	upon	O
12	demonstrated	O
13	weaknesses	O
14	of	O
15	coronary	O
16	angiography	O
17	.	O

1	With	O
2	stepwise	O
3	reductions	O
4	in	O
5	flow	O
6	,	O
7	the	O
8	peak	O
9	(	O
10	S	O
11	)	O
12	and	O
13	trough	O
14	(	O
15	D	O
16	)	O
17	points	O
18	of	O
19	the	O
20	maximum	O
21	shifted	O
22	-	O
23	frequency	O
24	envelope	O
25	fell	O
26	in	O
27	parallel	O
28	in	O
29	a	O
30	linear	O
31	fashion	O
32	until	O
33	D	O
34	reached	O
35	zero	O
36	.	O

1	In	O
2	subjects	O
3	(	O
4	n	O
5	=	O
6	5	O
7	)	O
8	with	O
9	quadriplegia	O
10	and	O
11	reduced	O
12	sympathetic	O
13	tone	O
14	secondary	O
15	to	O
16	cervical	O
17	cord	O
18	trauma	O
19	,	O
20	TcpO2	O
21	at	O
22	42	O
23	degrees	O
24	C	O
25	and	O
26	vasodilation	O
27	index	O
28	were	O
29	increased	O
30	(	O
31	45	O
32	.	O
33	0	O
34	mmHg	O
35	and	O
36	0	O
37	.	O
38	61	O
39	);	O
40	TcpO2	O
41	at	O
42	45	O
43	degrees	O
44	C	O
45	did	O
46	not	O
47	change	O
48	.	O

1	Commercially	O
2	available	O
3	formulations	O
4	of	O
5	2	O
6	.	O
7	5	O
8	%	O
9	and	O
10	5	O
11	%	O
12	lambdacyhalothrin	O
13	can	O
14	be	O
15	diluted	O
16	either	O
17	with	O
18	water	O
19	for	O
20	ULV	O
21	cold	O
22	aerosol	O
23	space	O
24	-	O
25	spraying	O
26	or	O
27	with	O
28	diesel	O
29	/	O
30	kerosene	O
31	for	O
32	thermal	O
33	fogging	O
34	at	O
35	recommended	O
36	application	O
37	rates	O
38	of	O
39	0	O
40	.	O
41	5	O
42	-	O
43	1	O
44	g	O
45	ai	O
46	/	O
47	ha	B
48	for	O
49	mosquito	O
50	control	O
51	and	O
52	2	O
53	g	O
54	ai	O
55	/	O
56	ha	B
57	for	O
58	housefly	O
59	control	O
60	.	O

1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	O
9	Rho	B
10	-	I
11	like	I
12	GTPases	I
13	,	O
14	we	O
15	show	O
16	that	O
17	the	O
18	expression	O
19	of	O
20	beta1A	B
21	,	O
22	beta1D	O
23	,	O
24	or	O
25	IL2R	O
26	-	O
27	beta1A	O
28	in	O
29	GE11	O
30	or	O
31	GD25	O
32	cells	O
33	triggers	O
34	activation	O
35	of	O
36	both	O
37	RhoA	B
38	and	O
39	Rac1	B
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	B
45	.	O

1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	B
11	-	I
12	2	I
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O

1	The	O
2	marker	O
3	orders	O
4	from	O
5	the	O
6	genetic	O
7	and	O
8	RH	O
9	maps	O
10	were	O
11	consistent	O
12	.	O

1	Thomas	O
2	'	O
3	Hospital	O
4	solution	O
5	(	O
6	with	O
7	95	O
8	%	O
9	O2	O
10	:	O
11	5	O
12	%	O
13	CO2	O
14	)	O
15	can	O
16	meet	O
17	the	O
18	metabolic	O
19	demand	O
20	of	O
21	the	O
22	ischaemic	O
23	myocardium	O
24	and	O
25	thus	O
26	increase	O
27	the	O
28	safe	O
29	duration	O
30	of	O
31	cardiac	O
32	arrest	O
33	.	O

1	Genes	O
2	for	O
3	ocs	B
4	element	I
5	binding	I
6	factors	I
7	(	O
8	OBFs	O
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	O
16	basic	B
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	I
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	technique	O
6	of	O
7	low	O
8	-	O
9	frequency	O
10	kindling	O
11	is	O
12	a	O
13	useful	O
14	experimental	O
15	model	O
16	in	O
17	assessing	O
18	the	O
19	effects	O
20	of	O
21	antipsychotic	O
22	or	O
23	antiepileptic	O
24	drugs	O
25	on	O
26	the	O
27	excitability	O
28	of	O
29	the	O
30	limbic	O
31	regions	O
32	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	accepted	O
6	that	O
7	the	O
8	p53	B
9	C	I
10	-	O
11	terminus	O
12	plays	O
13	a	O
14	central	O
15	role	O
16	in	O
17	controlling	O
18	the	O
19	activity	O
20	of	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	molecule	O
26	.	O

1	J	O
2	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	binding	O
9	of	O
10	the	O
11	GA	B
12	-	I
13	binding	I
14	protein	I
15	(	O
16	GABP	B
17	)	O
18	to	O
19	ets	B
20	sequence	I
21	motifs	I
22	within	O
23	each	O
24	repeated	O
25	unit	O
26	is	O
27	required	O
28	for	O
29	transcriptional	O
30	activation	O
31	of	O
32	the	O
33	COXIV	O
34	promoter	O
35	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	effect	O
6	in	O
7	augmenting	O
8	the	O
9	neutrophil	O
10	response	O
11	to	O
12	eccentric	O
13	exercise	O
14	,	O
15	vitamin	O
16	E	O
17	causes	O
18	a	O
19	greater	O
20	increase	O
21	in	O
22	circulating	O
23	creatine	B
24	kinase	I
25	activity	O
26	,	O
27	perhaps	O
28	indicating	O
29	increased	O
30	skeletal	O
31	muscle	O
32	repair	O
33	.	O

1	Lung	O
2	prostacyclin	O
3	production	O
4	may	O
5	be	O
6	related	O
7	to	O
8	flow	O
9	.	O

1	This	O
2	dynamic	O
3	response	O
4	strongly	O
5	suggests	O
6	that	O
7	the	O
8	p53	B
9	and	O
10	Rb	B
11	tumor	I
12	suppressor	I
13	pathways	O
14	are	O
15	intact	O
16	in	O
17	HeLa	O
18	cells	O
19	and	O
20	that	O
21	repression	O
22	of	O
23	HPV	B
24	E6	I
25	and	O
26	E7	B
27	mobilizes	O
28	these	O
29	pathways	O
30	in	O
31	an	O
32	orderly	O
33	fashion	O
34	to	O
35	deliver	O
36	growth	O
37	inhibitory	O
38	signals	O
39	to	O
40	the	O
41	cells	O
42	.	O

1	The	O
2	effect	O
3	of	O
4	feeding	O
5	patterns	O
6	on	O
7	fat	O
8	deposition	O
9	in	O
10	mice	O
11	.	O

1	A	O
2	developmentally	O
3	regulated	O
4	4	O
5	.	O
6	6	O
7	kb	O
8	mRNA	O
9	is	O
10	recognized	O
11	on	O
12	Northern	O
13	blots	O
14	of	O
15	oocyte	O
16	RNA	O
17	using	O
18	the	O
19	X	O
20	.	O
21	laevis	O
22	cDNA	O
23	.	O

1	Spatial	O
2	accuracy	O
3	of	O
4	primary	O
5	and	O
6	secondary	O
7	memory	O
8	-	O
9	guided	O
10	saccades	O
11	in	O
12	schizophrenic	O
13	patients	O
14	.	O

1	Expression	O
2	in	O
3	established	O
4	LCLs	O
5	,	O
6	occurring	O
7	irrespective	O
8	of	O
9	virus	O
10	producer	O
11	status	O
12	,	O
13	was	O
14	not	O
15	a	O
16	consequence	O
17	of	O
18	continued	O
19	in	O
20	vitro	O
21	passage	O
22	;	O
23	thus	O
24	,	O
25	appropriately	O
26	spliced	O
27	BamHI	B
28	-	I
29	A	I
30	transcripts	I
31	could	O
32	be	O
33	amplified	O
34	from	O
35	normal	O
36	B	O
37	cells	O
38	within	O
39	1	O
40	day	O
41	of	O
42	their	O
43	experimental	O
44	infection	O
45	in	O
46	vitro	O
47	,	O
48	along	O
49	with	O
50	BamHI	B
51	-	I
52	C	I
53	/	I
54	W	I
55	promoter	I
56	-	O
57	initiated	O
58	but	O
59	not	O
60	BamHI	B
61	-	I
62	F	I
63	promoter	I
64	-	O
65	initiated	O
66	mRNAs	O
67	.	O

1	The	O
2	proteins	O
3	are	O
4	more	O
5	than	O
6	90	O
7	%	O
8	identical	O
9	to	O
10	each	O
11	other	O
12	within	O
13	the	O
14	protein	B
15	kinase	I
16	domain	I
17	but	O
18	only	O
19	51	O
20	-	O
21	59	O
22	%	O
23	identical	O
24	to	O
25	other	O
26	casein	B
27	kinase	I
28	I	I
29	isoforms	I
30	within	O
31	this	O
32	region	O
33	.	O

1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	B
21	-	I
22	7	I
23	MX	I
24	,	O
25	while	O
26	S1	B
27	-	I
28	M1	I
29	-	I
30	80	I
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O

1	The	O
2	recently	O
3	developed	O
4	gamma	B
5	-	I
6	interferon	I
7	(	O
8	IFN	B
9	-	I
10	gamma	I
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O

1	This	O
2	E	O
3	box	O
4	sequence	O
5	(	O
6	CACGTG	O
7	)	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	binding	O
13	element	O
14	for	O
15	USF	B
16	(	O
17	upstream	B
18	stimulatory	I
19	factor	I
20	),	O
21	a	O
22	member	O
23	of	O
24	the	O
25	helix	O
26	-	O
27	loop	O
28	-	O
29	helix	O
30	family	O
31	of	O
32	transcription	O
33	factors	O
34	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	has	O
5	confirmed	O
6	that	O
7	this	O
8	mutation	O
9	affects	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	region	O
15	of	O
16	the	O
17	alpha	O
18	subunit	O
19	,	O
20	changing	O
21	a	O
22	leucine	O
23	residue	O
24	at	O
25	position	O
26	290	O
27	to	O
28	a	O
29	histidine	O
30	(	O
31	rpoAL290H	O
32	).	O

1	Antibodies	O
2	raised	O
3	against	O
4	GST	B
5	mSH2	I
6	-	I
7	B	I
8	identified	O
9	a	O
10	cellular	O
11	protein	O
12	of	O
13	92	O
14	kDa	O
15	that	O
16	was	O
17	not	O
18	found	O
19	to	O
20	be	O
21	phosphorylated	O
22	on	O
23	Tyr	O
24	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	stereotypy	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	striatal	O
16	dopaminergic	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	striatal	O
32	cholinergic	O
33	-	O
34	dopaminergic	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	shifted	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	manifestation	O
53	.	O

1	Retransformation	O
2	of	O
3	uvsH77	B
4	mutants	I
5	with	O
6	the	O
7	rescued	O
8	cosmids	O
9	from	O
10	the	O
11	MMS	O
12	-	O
13	resistant	O
14	transformants	O
15	resulted	O
16	in	O
17	restoration	O
18	of	O
19	both	O
20	UV	O
21	and	O
22	MMS	O
23	resistance	O
24	to	O
25	wild	O
26	-	O
27	type	O
28	levels	O
29	.	O

1	The	O
2	5	O
3	'	O
4	external	O
5	transcribed	O
6	spacer	O
7	(	O
8	ETS	B
9	)	O
10	region	O
11	of	O
12	the	O
13	pre	O
14	-	O
15	rRNA	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	contains	O
20	a	O
21	sequence	O
22	with	O
23	10	O
24	bp	O
25	of	O
26	perfect	O
27	complementarity	O
28	to	O
29	the	O
30	U3	O
31	snoRNA	O
32	.	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	Negatively	O
2	supercoiled	O
3	plasmid	O
4	pUC19	O
5	did	O
6	not	O
7	compete	O
8	,	O
9	whereas	O
10	an	O
11	otherwise	O
12	identical	O
13	plasmid	O
14	pUC19	O
15	(	O
16	CG	O
17	),	O
18	which	O
19	contained	O
20	a	O
21	(	O
22	dG	O
23	-	O
24	dC	O
25	)	O
26	7	O
27	segment	O
28	in	O
29	the	O
30	Z	O
31	-	O
32	form	O
33	was	O
34	an	O
35	excellent	O
36	competitor	O
37	.	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	O
9	medical	O
10	applications	O
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	O
16	NMR	O
17	,	O
18	with	O
19	help	O
20	of	O
21	some	O
22	examples	O
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	RESULTS	O
2	:	O
3	Among	O
4	women	O
5	,	O
6	the	O
7	age	O
8	-	O
9	related	O
10	decline	O
11	in	O
12	BMD	O
13	at	O
14	all	O
15	non	O
16	-	O
17	spine	O
18	skeletal	O
19	sites	O
20	was	O
21	significantly	O
22	different	O
23	from	O
24	zero	O
25	,	O
26	with	O
27	the	O
28	largest	O
29	decline	O
30	seen	O
31	at	O
32	the	O
33	femoral	O
34	neck	O
35	(-.	O
36	0038	O
37	g	O
38	/	O
39	cm2	O
40	/	O
41	y	O
42	,	O
43	p	O
44	<	O
45	.	O
46	001	O
47	)	O
48	and	O
49	the	O
50	smallest	O
51	at	O
52	the	O
53	trochanter	O
54	of	O
55	the	O
56	hip	O
57	(-.	O
58	0023	O
59	g	O
60	/	O
61	cm2	O
62	/	O
63	y	O
64	,	O
65	p	O
66	=	O
67	.	O
68	03	O
69	).	O

1	Also	O
2	,	O
3	the	O
4	amplitude	O
5	of	O
6	the	O
7	oscillatory	O
8	potentials	O
9	(	O
10	O1	O
11	+	O
12	O2	O
13	+	O
14	O3	O
15	+	O
16	O4	O
17	)	O
18	was	O
19	significantly	O
20	reduced	O
21	in	O
22	the	O
23	early	O
24	postoperative	O
25	period	O
26	.	O

1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	His	B
2	carnitine	I
3	palmitoyltransferase	I
4	(	I
5	CPT	I
6	)	I
7	I	I
8	and	I
9	II	I
10	activities	O
11	were	O
12	0	O
13	.	O
14	06	O
15	and	O
16	0	O
17	.	O
18	12	O
19	nmol	O
20	/	O
21	min	O
22	/	O
23	mg	O
24	protein	O
25	,	O
26	as	O
27	compared	O
28	with	O
29	a	O
30	mean	O
31	value	O
32	of	O
33	0	O
34	.	O
35	22	O
36	+/-	O
37	0	O
38	.	O
39	14	O
40	and	O
41	0	O
42	.	O
43	27	O
44	+/-	O
45	0	O
46	.	O
47	07	O
48	nmol	O
49	/	O
50	min	O
51	/	O
52	mg	O
53	protein	O
54	,	O
55	respectively	O
56	,	O
57	in	O
58	control	O
59	subjects	O
60	.	O

1	Muscular	O
2	pathology	O

1	I	O
2	.	O

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	The	O
2	CHARGE	O
3	association	O
4	is	O
5	a	O
6	collection	O
7	of	O
8	multisystem	O
9	congenital	O
10	anomalies	O
11	including	O
12	choanal	O
13	atresia	O
14	.	O

1	VP5	B
2	,	O
3	which	O
4	encodes	O
5	the	O
6	major	O
7	capsid	B
8	protein	I
9	,	O
10	each	O
11	fused	O
12	to	O
13	the	O
14	chloramphenicol	B
15	acetyltransferase	I
16	gene	I
17	.	O

1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	O
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	B
16	alpha1	I
17	-	I
18	2	I
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	B
40	and	O
41	Gpi7p	B
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	B
47	-	I
48	4	I
49	-	I
50	and	I
51	alpha1	I
52	-	I
53	6	I
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O

1	We	O
2	have	O
3	identified	O
4	in	O
5	the	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	of	O
11	the	O
12	Drosophila	O
13	copia	O
14	retrotransposon	O
15	,	O
16	3	O
17	'	O
18	to	O
19	the	O
20	left	B
21	LTR	I
22	,	O
23	a	O
24	sequence	O
25	for	O
26	transcriptional	O
27	regulation	O
28	by	O
29	homeoproteins	O
30	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O

1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	I
11	TAF	I
12	complexes	I
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	B
19	class	I
20	I	I
21	-	I
22	specific	I
23	transcription	I
24	initiation	I
25	factor	I
26	TIF	I
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O

1	Competitive	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	O
6	chain	O
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	B
14	-	I
15	1alpha	I
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O

1	Near	O
2	term	O
3	,	O
4	under	O
5	experimental	O
6	conditions	O
7	,	O
8	maternal	O
9	and	O
10	fetal	O
11	blood	O
12	gases	O
13	,	O
14	pH	O
15	,	O
16	uterine	O
17	and	O
18	umbilical	O
19	blood	O
20	flows	O
21	were	O
22	measured	O
23	or	O
24	calculated	O
25	.	O

1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O

1	Also	O
2	,	O
3	the	O
4	human	B
5	glycoprotein	I
6	alpha	I
7	-	I
8	subunit	I
9	promoter	I
10	was	O
11	induced	O
12	10	O
13	-	O
14	fold	O
15	by	O
16	FSK	B
17	in	O
18	GH4	O
19	rat	O
20	pituitary	O
21	cells	O
22	.(	O
23	ABSTRACT	O
24	TRUNCATED	O
25	AT	O
26	400	O
27	WORDS	O
28	)	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	B
5	-	I
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	These	O
2	sequences	O
3	were	O
4	then	O
5	used	O
6	to	O
7	clone	O
8	the	O
9	full	O
10	-	O
11	length	O
12	genes	O
13	from	O
14	a	O
15	yeast	O
16	genomic	O
17	library	O
18	.	O

1	There	O
2	are	O
3	no	O
4	introns	O
5	within	O
6	the	O
7	gene	O
8	,	O
9	which	O
10	contains	O
11	a	O
12	9360	O
13	-	O
14	bp	O
15	open	O
16	reading	O
17	frame	O
18	and	O
19	encodes	O
20	a	O
21	377	O
22	-	O
23	kDa	O
24	protein	O
25	.	O

1	ERV1	O
2	is	O
3	involved	O
4	in	O
5	the	O
6	cell	O
7	-	O
8	division	O
9	cycle	O
10	and	O
11	the	O
12	maintenance	O
13	of	O
14	mitochondrial	O
15	genomes	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	relative	O
6	strengths	O
7	of	O
8	the	O
9	promoters	O
10	were	O
11	similar	O
12	in	O
13	different	O
14	contexts	O
15	.	O

1	Acetoin	O
2	-	O
3	dependent	O
4	expression	O
5	of	O
6	the	O
7	acoABCD	B
8	operon	I
9	could	O
10	be	O
11	restored	O
12	in	O
13	the	O
14	E	O
15	.	O
16	coli	O
17	acoK	O
18	mutants	O
19	by	O
20	supplying	O
21	a	O
22	plasmid	O
23	carrying	O
24	an	O
25	intact	O
26	acoK	O
27	,	O
28	suggesting	O
29	a	O
30	transactivating	O
31	function	O
32	of	O
33	the	O
34	gene	O
35	product	O
36	.	O

1	Recognition	O
2	of	O
3	emphysema	O
4	was	O
5	poor	O
6	when	O
7	radiographs	O
8	of	O
9	inadequate	O
10	quality	O
11	were	O
12	included	O
13	(	O
14	anteroposterior	O
15	films	O
16	or	O
17	films	O
18	from	O
19	patients	O
20	with	O
21	acute	O
22	or	O
23	chronic	O
24	lung	O
25	disease	O
26	).	O

1	A	O
2	unified	O
3	approach	O
4	to	O
5	the	O
6	standardization	O
7	of	O
8	allergens	O
9	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	B
27	/	O
28	gp46	B
29	complex	I
30	.	O

1	This	O
2	test	O
3	should	O
4	provide	O
5	another	O
6	practical	O
7	means	O
8	to	O
9	study	O
10	leprosy	O
11	.	O

1	Cerebral	O
2	flow	O
3	and	O
4	resistance	O
5	showed	O
6	minor	O
7	reductions	O
8	with	O
9	HD	O
10	.	O

1	Potential	O
2	indicators	O
3	were	O
4	assessed	O
5	for	O
6	the	O
7	two	O
8	classifications	O
9	of	O
10	protein	O
11	-	O
12	energy	O
13	malnutrition	O
14	in	O
15	the	O
16	guidelines	O
17	for	O
18	integrated	O
19	management	O
20	of	O
21	childhood	O
22	illness	O
23	:	O
24	severe	O
25	malnutrition	O
26	,	O
27	which	O
28	requires	O
29	immediate	O
30	referral	O
31	to	O
32	hospital	O
33	,	O
34	and	O
35	very	O
36	low	O
37	weight	O
38	,	O
39	which	O
40	calls	O
41	for	O
42	feeding	O
43	assessment	O
44	,	O
45	nutritional	O
46	counselling	O
47	and	O
48	follow	O
49	-	O
50	up	O
51	.	O

1	These	O
2	results	O
3	illuminate	O
4	a	O
5	hitherto	O
6	unanticipated	O
7	function	O
8	of	O
9	U6	B
10	RNA	O
11	:	O
12	the	O
13	modulation	O
14	of	O
15	a	O
16	phosphorylation	O
17	-	O
18	dephosphorylation	O
19	cycle	O
20	of	O
21	C1	B
22	hnRNP	I
23	protein	I
24	that	O
25	influences	O
26	the	O
27	binding	O
28	affinity	O
29	of	O
30	this	O
31	protein	O
32	for	O
33	pre	O
34	-	O
35	mRNA	O
36	.	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	O
16	p53	B
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	ATF	B
6	-	I
7	2	I
8	plays	O
9	a	O
10	central	O
11	role	O
12	in	O
13	TGF	B
14	-	I
15	beta	I
16	signaling	O
17	by	O
18	acting	O
19	as	O
20	a	O
21	common	O
22	nuclear	O
23	target	O
24	of	O
25	both	O
26	Smad	B
27	and	O
28	TAK1	B
29	pathways	O
30	.	O

1	Clinical	O
2	course	O
3	and	O
4	nursing	O
5	care	O
6	of	O
7	patients	O
8	with	O
9	decubitus	O
10	ulcer	O
11	--	O
12	use	O
13	of	O
14	pillows	O
15	stuffed	O
16	with	O
17	buckwheat	O
18	chaff	O

1	High	O
2	levels	O
3	of	O
4	serum	B
5	calcitonin	I
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O

1	The	O
2	euglobulin	O
3	clot	O
4	lysis	O
5	time	O
6	was	O
7	slightly	O
8	longer	O
9	in	O
10	the	O
11	smokers	O
12	than	O
13	in	O
14	the	O
15	non	O
16	-	O
17	smokers	O
18	in	O
19	all	O
20	three	O
21	experimental	O
22	situations	O
23	,	O
24	but	O
25	the	O
26	differences	O
27	were	O
28	not	O
29	significant	O
30	.	O

1	We	O
2	suggest	O
3	that	O
4	sensitivity	O
5	to	O
6	photoperiod	O
7	in	O
8	pallid	O
9	bats	O
10	,	O
11	as	O
12	in	O
13	several	O
14	other	O
15	mammals	O
16	,	O
17	is	O
18	mediated	O
19	by	O
20	the	O
21	pineal	O
22	gland	O
23	.	O

1	An	O
2	immunologically	O
3	related	O
4	protein	O
5	was	O
6	detected	O
7	in	O
8	ribosome	O
9	and	O
10	membrane	O
11	fractions	O
12	of	O
13	mitochondria	O
14	from	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	The	O
2	hIGF	B
3	-	I
4	I	I
5	gene	I
6	has	O
7	two	O
8	promoters	O
9	,	O
10	P1	O
11	and	O
12	P2	O
13	.	O

1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	B
12	nucleotide	I
13	exchange	I
14	factors	I
15	or	O
16	GTPase	B
17	-	I
18	activating	I
19	proteins	I
20	in	O
21	the	O
22	c	B
23	-	I
24	cbl	I
25	gene	I
26	.	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	B
12	interaction	O
13	.	O

1	Late	O
2	mRNA	O
3	selected	O
4	by	O
5	a	O
6	cDNA	O
7	homologous	O
8	to	O
9	the	O
10	HindIII	B
11	-	I
12	P	I
13	/	I
14	EcoRI	I
15	-	I
16	B	I
17	region	I
18	of	O
19	the	O
20	AcNPV	O
21	map	O
22	directed	O
23	the	O
24	synthesis	O
25	of	O
26	31K	O
27	and	O
28	30K	B
29	proteins	I
30	which	O
31	comigrated	O
32	with	O
33	the	O
34	31K	O
35	and	O
36	30K	O
37	proteins	O
38	translated	O
39	from	O
40	RNA	O
41	selected	O
42	by	O
43	the	O
44	HindIII	B
45	-	I
46	A	I
47	/	I
48	EcoRI	I
49	-	I
50	C	I
51	/	O
52	SstI	B
53	-	I
54	G	I
55	cDNA	I
56	.	O

1	Cat	B
2	proteins	I
3	are	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	when	O
8	co	O
9	-	O
10	expressed	O
11	in	O
12	cells	O
13	with	O
14	the	O
15	focal	B
16	adhesion	I
17	kinase	I
18	Fak	I
19	and	O
20	Src	B
21	.	O

1	The	O
2	mustard	O
3	chloroplast	O
4	gene	O
5	rps16	O
6	is	O
7	split	O
8	by	O
9	an	O
10	887	O
11	bp	O
12	group	O
13	II	O
14	(	O
15	or	O
16	III	O
17	)	O
18	intron	O
19	.	O

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	B
11	oxidase	I
12	inhibitors	O
13	.	O

1	However	O
2	,	O
3	besides	O
4	the	O
5	kinase	O
6	catalytic	O
7	domain	O
8	and	O
9	double	O
10	leucine	O
11	/	O
12	isoleucine	O
13	zippers	O
14	,	O
15	there	O
16	was	O
17	no	O
18	significant	O
19	homology	O
20	with	O
21	known	O
22	proteins	O
23	.	O

1	A	O
2	one	O
3	-	O
4	way	O
5	analysis	O
6	of	O
7	variance	O
8	,	O
9	performed	O
10	separately	O
11	for	O
12	men	O
13	and	O
14	women	O
15	for	O
16	differences	O
17	among	O
18	the	O
19	three	O
20	phobic	O
21	groups	O
22	on	O
23	field	O
24	dependence	O
25	,	O
26	showed	O
27	significance	O
28	(	O
29	rho	O
30	less	O
31	than	O
32	.	O
33	05	O
34	)	O
35	for	O
36	the	O
37	females	O
38	,	O
39	with	O
40	the	O
41	famale	O
42	agoraphobic	O
43	being	O
44	more	O
45	field	O
46	dependent	O
47	than	O
48	the	O
49	female	O
50	simple	O
51	phobic	O
52	groups	O
53	,	O
54	but	O
55	not	O
56	for	O
57	the	O
58	males	O
59	.	O

1	A	O
2	novel	O
3	cDNA	O
4	clone	O
5	termed	O
6	R2	B
7	was	O
8	isolated	O
9	by	O
10	subtractive	O
11	hybridization	O
12	of	O
13	a	O
14	cDNA	O
15	library	O
16	of	O
17	phytohemagglutinin	B
18	(	O
19	PHA	B
20	)/	O
21	phorbol	O
22	myristate	O
23	acetate	O
24	-	O
25	stimulated	O
26	Jurkat	O
27	cells	O
28	and	O
29	by	O
30	rescreening	O
31	a	O
32	cDNA	O
33	library	O
34	of	O
35	PHA	B
36	-	O
37	stimulated	O
38	peripheral	O
39	blood	O
40	lymphocytes	O
41	.	O

1	Nucleotide	O
2	sequences	O
3	between	O
4	the	O
5	env	B
6	gene	I
7	and	O
8	the	O
9	LTR	O
10	of	O
11	SFV	O
12	-	O
13	1	O
14	were	O
15	determined	O
16	.	O

1	Specific	O
2	hyperimmune	O
3	globulins	O
4	to	O
5	pathogens	O
6	such	O
7	as	O
8	Haemophilus	O
9	influenzae	O
10	and	O
11	Streptococcus	O
12	pneumoniae	O
13	have	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	The	O
2	Nmd3	B
3	protein	I
4	sequence	I
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O

1	However	O
2	,	O
3	tyrA	B
4	can	O
5	be	O
6	expressed	O
7	efficiently	O
8	from	O
9	an	O
10	internal	O
11	promoter	O
12	which	O
13	appears	O
14	to	O
15	lie	O
16	within	O
17	the	O
18	3	O
19	'	O
20	portion	O
21	of	O
22	aroF	O
23	.	O

1	Statistics	O
2	of	O
3	the	O
4	past	O
5	5	O
6	years	O

1	In	O
2	contrast	O
3	,	O
4	overproduction	O
5	of	O
6	Der3p	B
7	is	O
8	lethal	O
9	in	O
10	a	O
11	sec61	B
12	-	I
13	2	I
14	strain	O
15	at	O
16	the	O
17	permissive	O
18	temperature	O
19	of	O
20	25	O
21	degrees	O
22	C	O
23	.	O

1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	O
10	gene	O
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O

1	Overexpression	O
2	of	O
3	EFG1	B
4	in	O
5	C	O
6	.	O
7	albicans	O
8	leads	O
9	to	O
10	enhanced	O
11	filamentous	O
12	growth	O
13	in	O
14	the	O
15	form	O
16	of	O
17	extended	O
18	pseudohyphae	O
19	in	O
20	liquid	O
21	and	O
22	on	O
23	solid	O
24	media	O
25	.	O

1	In	O
2	a	O
3	gel	O
4	retardation	O
5	assay	O
6	using	O
7	HepG2	O
8	nuclear	O
9	extracts	O
10	,	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	sequence	O
16	from	O
17	-	O
18	74	O
19	to	O
20	-	O
21	46	O
22	showed	O
23	a	O
24	shifted	O
25	band	O
26	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	Lipoprotein	B
2	lipase	I
3	(	O
4	LPL	B
5	),	O
6	a	O
7	key	O
8	enzyme	O
9	in	O
10	normal	O
11	lipoprotein	O
12	metabolism	O
13	,	O
14	has	O
15	a	O
16	complex	O
17	pattern	O
18	of	O
19	regulation	O
20	and	O
21	tissue	O
22	-	O
23	specific	O
24	expression	O
25	.	O

1	However	O
2	,	O
3	an	O
4	intrinsic	O
5	DNA	O
6	-	O
7	binding	O
8	subunit	O
9	for	O
10	HiNF	B
11	-	I
12	D	I
13	was	O
14	not	O
15	identified	O
16	.	O

1	Genitography	O
2	in	O
3	intersexual	O
4	states	O
5	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	O
17	yeast	O
18	cdc28	B
19	mutation	O
20	.	O

1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	B
7	-	I
8	1	I
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	O
15	Oct	B
16	-	I
17	1	I
18	-	O
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	brk	B
6	consists	O
7	of	O
8	8	O
9	exons	O
10	,	O
11	whose	O
12	boundaries	O
13	are	O
14	distinct	O
15	from	O
16	other	O
17	non	O
18	-	O
19	receptor	O
20	PTK	B
21	family	I
22	members	I
23	,	O
24	again	O
25	indicating	O
26	a	O
27	structural	O
28	and	O
29	functional	O
30	divergence	O
31	.	O

1	Repression	O
2	is	O
3	alleviated	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	B
10	)	O
11	or	O
12	three	O
13	(	O
14	for	O
15	E2	B
16	-	I
17	C	I
18	)	O
19	promoter	O
20	-	O
21	proximal	O
22	copies	O
23	of	O
24	E2	B
25	-	I
26	RS	I
27	are	O
28	mutated	O
29	.	O

1	The	O
2	FinO	B
3	protein	I
4	of	O
5	IncF	O
6	plasmids	O
7	binds	O
8	FinP	O
9	antisense	O
10	RNA	O
11	and	O
12	its	O
13	target	O
14	,	O
15	traJ	B
16	mRNA	I
17	,	O
18	and	O
19	promotes	O
20	duplex	O
21	formation	O
22	.	O

1	Evidence	O
2	from	O
3	the	O
4	structure	O
5	of	O
6	a	O
7	number	O
8	of	O
9	cDNA	O
10	clones	O
11	,	O
12	as	O
13	well	O
14	as	O
15	S1	B
16	nuclease	I
17	and	O
18	primer	O
19	extension	O
20	studies	O
21	supports	O
22	the	O
23	hypothesis	O
24	that	O
25	the	O
26	PTHrP	B
27	gene	I
28	contains	O
29	at	O
30	least	O
31	two	O
32	mRNA	O
33	transcription	O
34	start	O
35	points	O
36	that	O
37	define	O
38	two	O
39	putative	O
40	regulatory	O
41	domains	O
42	.	O

1	Chronic	O
2	dose	O
3	effects	O
4	of	O
5	methyl	O
6	parathion	O
7	on	O
8	nuthatches	O
9	:	O
10	cholinesterase	B
11	and	O
12	ptilochronology	O
13	.	O

1	Therefore	O
2	,	O
3	ICSBP	B
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	B
14	-	I
15	inducible	I
16	genes	I
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	TATA	O
7	-	O
8	less	O
9	promoter	O
10	for	O
11	the	O
12	human	B
13	beta	I
14	3	I
15	integrin	I
16	gene	I
17	.	O

1	Several	O
2	artifacts	O
3	occurred	O
4	that	O
5	interfered	O
6	with	O
7	visualization	O
8	of	O
9	the	O
10	diaphragm	O
11	.	O

1	We	O
2	linked	O
3	a	O
4	4	O
5	.	O
6	1	O
7	-	O
8	kilobase	O
9	pair	O
10	HindIII	O
11	DNA	O
12	fragment	O
13	from	O
14	the	O
15	region	O
16	upstream	O
17	of	O
18	the	O
19	human	B
20	AP	I
21	endonuclease	I
22	gene	I
23	(	O
24	APE	O
25	)	O
26	to	O
27	the	O
28	chloramphenicol	B
29	acetyltransferase	I
30	(	O
31	CAT	B
32	)	O
33	gene	O
34	.	O

1	Optically	O
2	detected	O
3	librons	O
4	and	O
5	phonons	O
6	in	O
7	crystalline	O
8	C60	O
9	.	O

1	Further	O
2	experiments	O
3	will	O
4	be	O
5	required	O
6	to	O
7	highlight	O
8	the	O
9	in	O
10	vivo	O
11	role	O
12	of	O
13	ELE1	B
14	in	O
15	nuclear	O
16	receptor	O
17	functioning	O
18	.	O

1	The	O
2	systolic	O
3	pressure	O
4	gradient	O
5	(	O
6	SPG	O
7	)	O
8	between	O
9	the	O
10	left	O
11	ventricle	O
12	(	O
13	LV	O
14	)	O
15	and	O
16	left	O
17	atrium	O
18	(	O
19	LA	O
20	)	O
21	was	O
22	obtained	O
23	from	O
24	high	O
25	-	O
26	fidelity	O
27	pressure	O
28	transducers	O
29	.	O

1	Modeling	O
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	B
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	B
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	B
26	,	O
27	and	O
28	H11	O
29	.	O

1	Thus	O
2	,	O
3	the	O
4	synergistic	O
5	effects	O
6	of	O
7	HNF	B
8	-	I
9	1beta	I
10	and	O
11	the	O
12	GR	B
13	on	O
14	dexamethasone	O
15	-	O
16	stimulated	O
17	promoter	O
18	activity	O
19	require	O
20	that	O
21	they	O
22	are	O
23	bound	O
24	to	O
25	the	O
26	HNF	B
27	-	I
28	1	I
29	site	I
30	and	O
31	the	O
32	GRE	O
33	,	O
34	respectively	O
35	,	O
36	and	O
37	may	O
38	involve	O
39	protein	O
40	-	O
41	protein	O
42	interactions	O
43	between	O
44	the	O
45	transcription	O
46	factors	O
47	,	O
48	or	O
49	between	O
50	them	O
51	and	O
52	the	O
53	basal	O
54	transcription	O
55	machinery	O
56	or	O
57	a	O
58	steroid	B
59	receptor	I
60	coactivator	I
61	.	O

1	Either	O
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O

1	Cowpox	O
2	virus	O
3	contains	O
4	two	O
5	copies	O
6	of	O
7	an	O
8	early	O
9	gene	O
10	encoding	O
11	a	O
12	soluble	O
13	secreted	O
14	form	O
15	of	O
16	the	O
17	type	B
18	II	I
19	TNF	I
20	receptor	I
21	.	O

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	Therefore	O
2	the	O
3	procedure	O
4	of	O
5	Lich	O
6	-	O
7	Gregoir	O
8	is	O
9	not	O
10	to	O
11	be	O
12	recommended	O
13	in	O
14	adults	O
15	.	O

1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O

1	The	O
2	accuracies	O
3	of	O
4	presence	O
5	or	O
6	absence	O
7	of	O
8	neuroblastoma	O
9	were	O
10	compared	O
11	between	O
12	131I	O
13	-	O
14	MIBG	O
15	imaging	O
16	and	O
17	several	O
18	tumor	O
19	markers	O
20	.	O

1	More	O
2	recently	O
3	,	O
4	however	O
5	,	O
6	a	O
7	number	O
8	of	O
9	developments	O
10	such	O
11	as	O
12	the	O
13	successful	O
14	use	O
15	of	O
16	the	O
17	inhaled	O
18	steroid	O
19	budesonide	O
20	and	O
21	oral	O
22	dexamethasone	O
23	have	O
24	reinforced	O
25	the	O
26	argument	O
27	for	O
28	using	O
29	steroids	O
30	.	O

1	The	O
2	differential	O
3	investigation	O
4	of	O
5	lipoproteins	O
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	B
13	-	I
14	density	I
15	lipoprotein	I
16	(	O
17	HDL	B
18	)	O
19	fractions	O
20	are	O
21	absolutely	O
22	or	O
23	relatively	O
24	decreased	O
25	with	O
26	respect	O
27	to	O
28	low	B
29	-	I
30	density	I
31	lipoproteins	I
32	(	O
33	LDL	B
34	)	O
35	in	O
36	cerebral	O
37	infarcts	O
38	and	O
39	in	O
40	transient	O
41	ischaemic	O
42	attacks	O
43	.	O

1	The	O
2	12S	B
3	E1A	I
4	product	I
5	does	O
6	not	O
7	activate	O
8	a	O
9	TRE	O
10	sequence	O
11	,	O
12	but	O
13	cotransfection	O
14	with	O
15	c	B
16	-	I
17	jun	I
18	circumvents	O
19	this	O
20	lack	O
21	of	O
22	stimulation	O
23	.	O

1	Chemical	O
2	constituents	O
3	of	O
4	the	O
5	gentianaceae	O
6	V	O
7	:	O
8	tetraoxygenated	O
9	xanthones	O
10	of	O
11	Swertia	O
12	chirata	O
13	Buch	O
14	.-	O
15	Ham	O
16	.	O

1	Although	O
2	the	O
3	mechanism	O
4	of	O
5	action	O
6	of	O
7	ICRF	B
8	-	I
9	159	I
10	and	O
11	187	O
12	has	O
13	not	O
14	been	O
15	clearly	O
16	defined	O
17	,	O
18	it	O
19	is	O
20	evident	O
21	from	O
22	both	O
23	preclinical	O
24	and	O
25	early	O
26	clinical	O
27	studies	O
28	that	O
29	these	O
30	compounds	O
31	are	O
32	of	O
33	interest	O
34	.	O

1	Increasing	O
2	the	O
3	cut	B
4	-	O
5	off	O
6	point	O
7	to	O
8	3	O
9	positive	O
10	responses	O
11	decreased	O
12	the	O
13	sensitivity	O
14	to	O
15	81	O
16	%	O
17	and	O
18	increased	O
19	the	O
20	specificity	O
21	to	O
22	94	O
23	%.	O

1	The	O
2	efficacy	O
3	of	O
4	these	O
5	immunosuppressive	O
6	drugs	O
7	is	O
8	clinical	O
9	proven	O
10	.	O

1	Nuclear	B
2	hormone	I
3	receptors	I
4	(	O
5	NRs	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O

1	Erythrocyte	O
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O

1	These	O
2	studies	O
3	support	O
4	the	O
5	view	O
6	that	O
7	HMG	B
8	I	I
9	(	O
10	Y	O
11	)	O
12	is	O
13	an	O
14	important	O
15	cofactor	O
16	for	O
17	HLA	B
18	-	I
19	DRA	I
20	gene	I
21	activation	O
22	by	O
23	Oct	B
24	-	I
25	2A	I
26	and	O
27	provide	O
28	insights	O
29	into	O
30	its	O
31	mechanism	O
32	of	O
33	action	O
34	.	O

1	NIK	B
2	-	I
3	244	I
4	suppressed	O
5	coronary	O
6	ligation	O
7	-	O
8	and	O
9	digitalis	O
10	-	O
11	induced	O
12	arrhythmias	O
13	,	O
14	and	O
15	the	O
16	minimum	O
17	effective	O
18	plasma	O
19	concentrations	O
20	for	O
21	arrhythmias	O
22	induced	O
23	by	O
24	24	O
25	-	O
26	h	O
27	and	O
28	48	O
29	-	O
30	h	O
31	coronary	O
32	ligation	O
33	and	O
34	digitalis	O
35	were	O
36	0	O
37	.	O
38	41	O
39	+/-	O
40	0	O
41	.	O
42	10	O
43	(	O
44	by	O
45	1	O
46	mg	O
47	/	O
48	kg	O
49	i	O
50	.	O
51	v	O
52	.),	O
53	0	O
54	.	O
55	70	O
56	+/-	O
57	0	O
58	.	O
59	13	O
60	(	O
61	by	O
62	1	O
63	mg	O
64	/	O
65	kg	O
66	i	O
67	.	O
68	v	O
69	.),	O
70	and	O
71	0	O
72	.	O
73	21	O
74	+/-	O
75	0	O
76	.	O
77	08	O
78	(	O
79	by	O
80	0	O
81	.	O
82	5	O
83	mg	O
84	/	O
85	kg	O
86	i	O
87	.	O
88	v	O
89	.)	O
90	microgram	O
91	/	O
92	ml	O
93	,	O
94	respectively	O
95	(	O
96	mean	O
97	+/-	O
98	SD	O
99	of	O
100	the	O
101	mean	O
102	,	O
103	n	O
104	=	O
105	6	O
106	).	O

1	RU486	B
2	and	O
3	ONO	O
4	802	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O

1	Finally	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	alpha	I
10	can	O
11	also	O
12	active	O
13	the	O
14	GM	B
15	-	I
16	CSF	I
17	receptor	I
18	alpha	I
19	promoter	I
20	in	O
21	nonmyeloid	O
22	cells	O
23	.	O

1	The	O
2	importance	O
3	of	O
4	selective	O
5	renal	O
6	vein	O
7	phlebography	O
8	in	O
9	the	O
10	evaluation	O
11	of	O
12	unexplained	O
13	hematuria	O
14	and	O
15	filing	O
16	defects	O
17	in	O
18	the	O
19	excretory	O
20	urogram	O
21	is	O
22	illustrated	O
23	.	O

1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	B
9	/	O
10	mTOR	B
11	protein	I
12	and	O
13	a	O
14	FRAP	B
15	/	O
16	mTOR	B
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	O
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	B
28	-	I
29	BP1	I
30	.	O

1	In	O
2	the	O
3	second	O
4	experiment	O
5	,	O
6	a	O
7	stable	O
8	nickel	O
9	isotope	O
10	,	O
11	61Ni	O
12	,	O
13	was	O
14	given	O
15	in	O
16	drinking	O
17	water	O
18	to	O
19	20	O
20	nickel	O
21	-	O
22	sensitized	O
23	women	O
24	and	O
25	20	O
26	age	O
27	-	O
28	matched	O
29	controls	O
30	,	O
31	both	O
32	groups	O
33	having	O
34	vesicular	O
35	hand	O
36	eczema	O
37	of	O
38	the	O
39	pompholyx	O
40	type	O
41	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	support	O
6	a	O
7	model	O
8	in	O
9	which	O
10	Tax	B
11	anchors	I
12	CBP	I
13	to	O
14	the	O
15	HTLV	O
16	-	O
17	1	O
18	promoter	O
19	,	O
20	with	O
21	strong	O
22	transcriptional	O
23	activation	O
24	resulting	O
25	from	O
26	the	O
27	CBP	B
28	-	O
29	associated	O
30	activities	O
31	of	O
32	nucleosome	O
33	remodeling	O
34	and	O
35	recruitment	O
36	of	O
37	the	O
38	general	O
39	transcription	O
40	machinery	O
41	.	O

1	In	O
2	rats	O
3	bearing	O
4	Walker	O
5	-	O
6	256	O
7	-	O
8	carcinosarcoma	O
9	4	O
10	-	O
11	EPI	O
12	was	O
13	effective	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	Microvessels	O
2	were	O
3	counted	O
4	in	O
5	a	O
6	x200	O
7	field	O
8	(	O
9	0	O
10	.	O
11	754	O
12	mm2	O
13	)	O
14	in	O
15	the	O
16	area	O
17	of	O
18	maximal	O
19	angiogenesis	O
20	.	O

1	We	O
2	examined	O
3	Akt	B
4	activation	O
5	in	O
6	Lyn	B
7	-,	O
8	Syk	B
9	-	O
10	and	O
11	Btk	B
12	-	O
13	deficient	O
14	DT40	O
15	cells	O
16	and	O
17	B	O
18	cells	O
19	from	O
20	Lyn	B
21	(-/-)	O
22	mice	O
23	.	O

1	Prior	O
2	to	O
3	meals	O
4	2	O
5	to	O
6	3	O
7	times	O
8	daily	O
9	,	O
10	1	O
11	-	O
12	2	O
13	tablespoons	O
14	of	O
15	Alzoon	O
16	are	O
17	recommended	O
18	.	O

1	Consistent	O
2	with	O
3	the	O
4	in	O
5	vivo	O
6	result	O
7	,	O
8	the	O
9	pseudorevertant	O
10	endonucleases	O
11	in	O
12	the	O
13	crude	O
14	cell	O
15	extract	O
16	display	O
17	site	O
18	-	O
19	specific	O
20	partial	O
21	DNA	O
22	cleavage	O
23	activity	O
24	.	O

1	The	O
2	transcript	O
3	was	O
4	initially	O
5	identified	O
6	as	O
7	a	O
8	partial	O
9	cDNA	O
10	sequence	O
11	in	O
12	the	O
13	course	O
14	of	O
15	constructing	O
16	a	O
17	transcript	O
18	map	O
19	of	O
20	the	O
21	region	O
22	between	O
23	markers	O
24	D11S1765	B
25	and	O
26	uteroglobin	B
27	known	O
28	to	O
29	encompass	O
30	the	O
31	gene	O
32	causing	O
33	Best	O
34	disease	O
35	.	O

1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	O
7	1	O
8	insulin	B
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	O
14	IGF	B
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	O
19	cytoplasmic	O
20	TyrRS	O
21	activity	O
22	was	O
23	produced	O
24	.	O

1	65	O
2	,	O
3	3829	O
4	-	O
5	3838	O
6	,	O
7	1991	O
8	),	O
9	a	O
10	truncated	O
11	form	O
12	of	O
13	the	O
14	IE	B
15	polypeptide	I
16	lacking	I
17	IE	I
18	amino	I
19	acid	I
20	residues	I
21	1	I
22	-	I
23	322	I
24	(	O
25	and	O
26	,	O
27	therefore	O
28	lacks	O
29	the	O
30	deduced	O
31	transcriptional	O
32	activation	O
33	domain	O
34	),	O
35	fails	O
36	to	O
37	transactivate	O
38	the	O
39	EHV	B
40	-	I
41	1	I
42	tk	I
43	promoter	I
44	,	O
45	but	O
46	retains	O
47	the	O
48	ability	O
49	to	O
50	down	O
51	-	O
52	regulate	O
53	the	O
54	EHV	B
55	-	I
56	1	I
57	IE	I
58	promoter	I
59	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	B
14	fluid	I
15	gamma	I
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	Furthermore	O
2	,	O
3	the	O
4	use	O
5	of	O
6	zero	O
7	-	O
8	loss	O
9	filtering	O
10	in	O
11	combination	O
12	with	O
13	exit	O
14	wavefront	O
15	reconstruction	O
16	is	O
17	considerably	O
18	more	O
19	effective	O
20	at	O
21	removing	O
22	the	O
23	effects	O
24	of	O
25	multiple	O
26	elastic	O
27	and	O
28	inelastic	O
29	scattering	O
30	and	O
31	microscope	O
32	objective	O
33	lens	O
34	aberrations	O
35	than	O
36	either	O
37	technique	O
38	by	O
39	itself	O
40	.	O

1	CKII	O
2	as	O
3	a	O
4	CD44	B
5	-	I
6	associated	I
7	serine	I
8	kinase	I
9	therefore	O
10	may	O
11	serve	O
12	as	O
13	an	O
14	important	O
15	molecule	O
16	in	O
17	a	O
18	signaling	O
19	cascade	O
20	that	O
21	produces	O
22	a	O
23	variety	O
24	of	O
25	cellular	O
26	responses	O
27	in	O
28	MDA231	O
29	breast	O
30	cancer	O
31	cells	O
32	.	O

1	A	O
2	.	O

1	Number	O
2	and	O
3	size	O
4	of	O
5	the	O
6	myelin	O
7	structures	O
8	in	O
9	the	O
10	pneumocytes	O
11	typ	O
12	II	O
13	increased	O
14	simultaneously	O
15	.	O

1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O

1	The	O
2	unexpected	O
3	presence	O
4	of	O
5	the	O
6	tRNA	O
7	(	O
8	trp	B
9	)(	I
10	CCA	I
11	)-	I
12	gene	I
13	transcript	I
14	in	O
15	mitochondria	O
16	is	O
17	also	O
18	reported	O
19	.	O

1	Catecholamines	O
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O

1	Physiology	O
2	and	O
3	Physiopathology	O

1	Our	O
2	results	O
3	,	O
4	however	O
5	,	O
6	were	O
7	obtained	O
8	for	O
9	Z	B
10	itself	O
11	and	O
12	not	O
13	for	O
14	[	O
15	Z	O
16	].	O

1	CONCLUSION	O
2	:	O
3	Sonographic	O
4	angiography	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	nodules	O
15	in	O
16	patients	O
17	with	O
18	CRF	B
19	.	O

1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O

1	The	O
2	mature	O
3	AP	B
4	-	I
5	2	I
6	mRNA	I
7	is	O
8	spliced	O
9	from	O
10	7	O
11	exons	O
12	distributed	O
13	over	O
14	a	O
15	region	O
16	of	O
17	18	O
18	kb	O
19	genomic	O
20	DNA	O
21	.	O

1	A	O
2	full	O
3	-	O
4	length	O
5	cDNA	O
6	clone	O
7	isolated	O
8	from	O
9	a	O
10	rat	O
11	lung	O
12	library	O
13	was	O
14	predicted	O
15	to	O
16	encode	O
17	a	O
18	55	O
19	-	O
20	kDa	O
21	protein	O
22	containing	O
23	at	O
24	its	O
25	amino	O
26	terminus	O
27	a	O
28	targeting	O
29	domain	O
30	that	O
31	binds	O
32	to	O
33	the	O
34	ANP	B
35	-	I
36	receptor	I
37	kinase	I
38	-	I
39	like	I
40	domain	I
41	and	O
42	containing	O
43	at	O
44	its	O
45	carboxyl	O
46	terminus	O
47	a	O
48	putative	O
49	protein	B
50	-	I
51	serine	I
52	phosphatase	I
53	domain	I
54	.	O

1	This	O
2	TC	B
3	-	I
4	II	I
5	enhanson	I
6	,	O
7	which	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	kappa	B
13	B	I
14	motif	I
15	from	O
16	the	O
17	kappa	B
18	chain	I
19	enhancer	I
20	,	O
21	was	O
22	active	O
23	in	O
24	both	O
25	lymphoid	O
26	and	O
27	non	O
28	-	O
29	lymphoid	O
30	cells	O
31	,	O
32	which	O
33	contrasts	O
34	with	O
35	the	O
36	previously	O
37	reported	O
38	lymphoid	O
39	cell	O
40	specificity	O
41	of	O
42	the	O
43	kappa	B
44	B	I
45	motif	I
46	.	O

1	The	O
2	implications	O
3	for	O
4	estimates	O
5	of	O
6	cortical	O
7	magnification	O
8	and	O
9	possible	O
10	differences	O
11	in	O
12	the	O
13	specializations	O
14	of	O
15	foveal	O
16	and	O
17	peripheral	O
18	vision	O
19	are	O
20	discussed	O
21	.	O

1	As	O
2	an	O
3	initial	O
4	step	O
5	towards	O
6	the	O
7	characterization	O
8	of	O
9	replicative	O
10	DNA	O
11	polymerases	O
12	of	O
13	trypanosomes	O
14	,	O
15	we	O
16	have	O
17	cloned	O
18	,	O
19	sequenced	O
20	and	O
21	examined	O
22	the	O
23	expression	O
24	of	O
25	the	O
26	Trypanosoma	O
27	(	O
28	Trypanozoon	O
29	)	O
30	brucei	O
31	brucei	O
32	gene	O
33	that	O
34	encodes	O
35	the	O
36	DNA	B
37	polymerase	I
38	alpha	I
39	catalytic	I
40	core	I
41	(	O
42	pol	B
43	alpha	I
44	).	O

1	On	O
2	long	O
3	-	O
4	term	O
5	follow	O
6	-	O
7	up	O
8	,	O
9	there	O
10	was	O
11	no	O
12	significant	O
13	difference	O
14	in	O
15	the	O
16	incidence	O
17	of	O
18	hospitalizations	O
19	(	O
20	1	O
21	per	O
22	2	O
23	.	O
24	1	O
25	vs	O
26	.	O

1	The	O
2	synergistic	O
3	effect	O
4	due	O
5	to	O
6	the	O
7	5	O
8	'-	O
9	3	O
10	'	O
11	cooperation	O
12	was	O
13	at	O
14	least	O
15	fourfold	O
16	greater	O
17	than	O
18	the	O
19	sum	O
20	of	O
21	the	O
22	contributions	O
23	of	O
24	the	O
25	individual	O
26	UTRs	O
27	.	O

1	Its	O
2	transcription	O
3	product	O
4	,	O
5	a	O
6	1	O
7	.	O
8	3	O
9	kb	O
10	mRNA	O
11	,	O
12	is	O
13	polyadenylated	O
14	at	O
15	a	O
16	site	O
17	containing	O
18	consensus	O
19	eukaryotic	O
20	polyadenylation	O
21	signals	O
22	and	O
23	mapping	O
24	87	O
25	bp	O
26	downstream	O
27	of	O
28	the	O
29	translation	O
30	termination	O
31	codon	O
32	for	O
33	CG30	B
34	.	O

1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	Marek	B
7	'	I
8	s	I
9	disease	I
10	virus	I
11	serotype	I
12	2	I
13	glycoprotein	I
14	M	I
15	gene	I
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	B
20	M	I
21	genes	I
22	of	O
23	Herpesviridae	O
24	family	O
25	.	O

1	The	O
2	mutant	O
3	allele	O
4	of	O
5	the	O
6	alpha	B
7	1	I
8	-	I
9	tubulin	I
10	gene	I
11	was	O
12	designated	O
13	tua1	B
14	-	I
15	1	I
16	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	O
6	factor	B
7	VIII	I
8	:	O
9	coagulant	O
10	(	O
11	F	O
12	.	O
13	VIII	O
14	:	O
15	C	O
16	)	O
17	and	O
18	C1	B
19	-	I
20	esterase	I
21	inhibitor	O
22	(	O
23	C1	B
24	-	I
25	INH	I
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	O
37	factors	O
38	VII	O
39	(	O
40	F	O
41	.	O
42	VII	O
43	),	O
44	IX	B
45	(	I
46	F	I
47	.	I
48	IX	I
49	),	O
50	and	O
51	X	O
52	(	O
53	F	O
54	.	O
55	X	O
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O

1	Activation	O
2	of	O
3	ERK1	B
4	/	I
5	2	I
6	is	O
7	correlated	O
8	with	O
9	induction	O
10	of	O
11	the	O
12	immediate	B
13	-	I
14	early	I
15	response	I
16	genes	I
17	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	minimal	O
6	promoter	O
7	was	O
8	found	O
9	to	O
10	be	O
11	controlled	O
12	by	O
13	a	O
14	combination	O
15	of	O
16	the	O
17	activities	O
18	of	O
19	the	O
20	transcription	O
21	factors	O
22	Sp1	B
23	,	O
24	Sp3	B
25	,	O
26	and	O
27	NF	B
28	-	I
29	Y	I
30	.	O

1	The	O
2	inhibitory	O
3	response	O
4	to	O
5	taps	O
6	is	O
7	essentially	O
8	a	O
9	protective	O
10	reflex	O
11	which	O
12	probably	O
13	serves	O
14	to	O
15	reduce	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	jaw	O
21	-	O
22	closing	O
23	muscles	O
24	when	O
25	one	O
26	bites	O
27	unexpectedly	O
28	on	O
29	hard	O
30	objects	O
31	.	O

1	The	O
2	indications	O
3	for	O
4	its	O
5	use	O
6	include	O
7	every	O
8	primary	O
9	and	O
10	secondary	O
11	rhinoplasty	O
12	candidate	O
13	unless	O
14	tip	O
15	grafts	O
16	are	O
17	going	O
18	to	O
19	be	O
20	under	O
21	tension	O
22	or	O
23	if	O
24	the	O
25	deformity	O
26	is	O
27	minor	O
28	.	O

1	Both	O
2	HERV	B
3	-	I
4	K	I
5	type	I
6	1	I
7	and	O
8	2	O
9	clones	O
10	were	O
11	isolated	O
12	.	O

1	Cranio	O
2	-	O
3	caudal	O
4	differences	O
5	in	O
6	granulation	O
7	tissue	O
8	formation	O
9	:	O
10	an	O
11	experimental	O
12	study	O
13	in	O
14	the	O
15	rat	O
16	.	O

1	We	O
2	now	O
3	describe	O
4	the	O
5	identification	O
6	of	O
7	DEK	B
8	as	O
9	this	O
10	43	O
11	-	O
12	kDa	O
13	pets	O
14	factor	O
15	.	O

1	Unlike	O
2	ARF	B
3	,	O
4	the	O
5	ARP	B
6	immunoreactivity	O
7	was	O
8	detected	O
9	in	O
10	plasma	O
11	membranes	O
12	but	O
13	not	O
14	in	O
15	cytosol	O
16	of	O
17	fractionated	O
18	3T3	O
19	-	O
20	L1	O
21	cells	O
22	.	O

1	One	O
2	of	O
3	its	O
4	lysine	O
5	residues	O
6	is	O
7	modified	O
8	by	O
9	spermidine	O
10	to	O
11	form	O
12	hypusine	O
13	,	O
14	a	O
15	posttranslational	O
16	modification	O
17	unique	O
18	to	O
19	eIF	B
20	-	I
21	5A	I
22	.	O

1	The	O
2	negative	O
3	calcium	O
4	balance	O
5	with	O
6	hyperparathyroidemia	O
7	occurred	O
8	after	O
9	continuous	O
10	oral	O
11	administration	O
12	of	O
13	Cd	O
14	and	O
15	developed	O
16	via	O
17	increased	O
18	urinary	O
19	excretion	O
20	of	O
21	calcium	O
22	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	Drosophila	O
6	melanogaster	O
7	(	O
8	Dm	O
9	)	O
10	cDNA	O
11	encoding	O
12	a	O
13	polypeptide	O
14	that	O
15	has	O
16	extensive	O
17	sequence	O
18	similarity	O
19	to	O
20	the	O
21	mammalian	B
22	MAPKAPK	I
23	-	I
24	2	I
25	.	O

1	Ultimate	O
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	B
19	6	I
20	V	I
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O

1	In	O
2	calves	O
3	receiving	O
4	milk	O
5	-	O
6	substitute	O
7	diets	O
8	containing	O
9	80	O
10	-	O
11	260	O
12	g	O
13	DM	O
14	/	O
15	kg	O
16	,	O
17	milk	O
18	intakes	O
19	were	O
20	reduced	O
21	by	O
22	up	O
23	to	O
24	30	O
25	%	O
26	on	O
27	the	O
28	1st	O
29	day	O
30	that	O
31	calves	O
32	were	O
33	fed	O
34	once	O
35	daily	O
36	instead	O
37	of	O
38	twice	O
39	daily	O
40	.	O

1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	B
6	),	O
7	and	O
8	Efs	O
9	/	O
10	Sin	O
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	Viral	O
2	infections	O
3	have	O
4	long	O
5	been	O
6	suspected	O
7	to	O
8	be	O
9	causative	O
10	agents	O
11	in	O
12	a	O
13	number	O
14	of	O
15	inner	O
16	ear	O
17	dysfunctions	O
18	.	O

1	Spectrophotometric	O
2	microanalysis	O
3	of	O
4	ethylenediaminotetracetic	O
5	acid	O
6	in	O
7	pharmaceutical	O
8	preparations	O

1	Xenopus	O
2	homolog	O
3	of	O
4	the	O
5	mos	B
6	protooncogene	I
7	transforms	O
8	mammalian	O
9	fibroblasts	O
10	and	O
11	induces	O
12	maturation	O
13	of	O
14	Xenopus	O
15	oocytes	O
16	.	O

1	Just	O
2	before	O
3	inserting	O
4	on	O
5	the	O
6	anterior	O
7	margin	O
8	and	O
9	apex	O
10	of	O
11	the	O
12	iliac	O
13	crest	O
14	it	O
15	widens	O
16	,	O
17	assuming	O
18	the	O
19	aspect	O
20	of	O
21	a	O
22	small	O
23	cone	O
24	.	O

1	One	O
2	millimolar	O
3	ouabain	O
4	completely	O
5	inhibited	O
6	net	O
7	HCO3	O
8	-	O
9	secretion	O
10	.	O

1	A	O
2	new	O
3	hemagglutination	O
4	test	O
5	for	O
6	the	O
7	on	O
8	-	O
9	slide	O
10	assay	O
11	of	O
12	rheumatoid	B
13	factor	I

1	2	O
2	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	O
11	lumbar	O
12	disc	O
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	B
20	-	I
21	1	I
22	alpha	I
23	are	O
24	produced	O
25	,	O
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	Liver	O
2	microsomes	O
3	of	O
4	the	O
5	shag	B
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	epoxide	O
14	hydrase	O
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	hydroxylating	O
24	capacity	O
25	of	O
26	liver	O
27	microsomes	O
28	from	O
29	the	O
30	rat	O
31	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	B
8	could	O
9	activate	O
10	p96h2bk	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	O
16	Ras	B
17	.	O

1	Oleate	O
2	induced	O
3	steady	O
4	-	O
5	state	O
6	levels	O
7	of	O
8	M	B
9	-	I
10	CPT	I
11	I	I
12	mRNA	I
13	4	I
14	.	O
15	5	O
16	-	O
17	fold	O
18	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	O
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	B
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	O
35	were	O
36	constructed	O
37	.	O

1	Recent	O
2	studies	O
3	have	O
4	revealed	O
5	unconventional	O
6	myosin	B
7	V	I
8	to	O
9	be	O
10	an	O
11	important	O
12	actin	B
13	-	O
14	based	O
15	molecular	O
16	motor	O
17	involved	O
18	in	O
19	vesicular	O
20	movement	O
21	.	O

1	This	O
2	study	O
3	determined	O
4	the	O
5	arthritogenic	O
6	potential	O
7	of	O
8	silicone	O
9	gel	O
10	by	O
11	either	O
12	mixing	O
13	it	O
14	with	O
15	bovine	B
16	collagen	I
17	II	I
18	(	O
19	BII	O
20	)	O
21	or	O
22	by	O
23	injecting	O
24	silicone	O
25	gel	O
26	alone	O
27	in	O
28	DA	O
29	rats	O
30	.	O

1	In	O
2	14	O
3	patients	O
4	whose	O
5	PaCO2	O
6	was	O
7	greater	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	39	O
13	torr	O
14	(	O
15	range	O
16	39	O
17	to	O
18	58	O
19	torr	O
20	)	O
21	and	O
22	clinical	O
23	asthma	O
24	score	O
25	was	O
26	6	O
27	or	O
28	greater	O
29	,	O
30	PaCO2	O
31	decreased	O
32	a	O
33	mean	O
34	of	O
35	11	O
36	.	O
37	7	O
38	torr	O
39	during	O
40	a	O
41	mean	O
42	of	O
43	8	O
44	.	O
45	1	O
46	hours	O
47	.	O

1	According	O
2	to	O
3	the	O
4	results	O
5	of	O
6	assays	O
7	obtained	O
8	with	O
9	the	O
10	use	O
11	of	O
12	assay	O
13	systems	O
14	ORTHO	O
15	ELISA	O
16	and	O
17	ABBOTT	B
18	HCV	I
19	EIA	I
20	(	O
21	USA	O
22	),	O
23	the	O
24	detection	O
25	rate	O
26	of	O
27	anti	B
28	-	I
29	HCV	I
30	-	I
31	C100	I
32	-	I
33	3	I
34	among	O
35	primary	O
36	blood	O
37	donors	O
38	in	O
39	Moscow	O
40	was	O
41	1	O
42	.	O
43	37	O
44	%	O
45	and	O
46	was	O
47	not	O
48	different	O
49	from	O
50	that	O
51	among	O
52	HBsAg	B
53	carriers	O
54	(	O
55	1	O
56	.	O
57	8	O
58	%)	O
59	and	O
60	among	O
61	donors	O
62	with	O
63	anti	B
64	-	I
65	HCV	I
66	-	I
67	C100	I
68	-	I
69	3	I
70	in	O
71	the	O
72	blood	O
73	(	O
74	1	O
75	.	O
76	6	O
77	%)	O
78	(	O
79	p	O
80	<	O
81	0	O
82	.	O
83	01	O
84	).	O

1	Deep	O
2	tans	O
3	were	O
4	induced	O
5	over	O
6	the	O
7	backs	O
8	of	O
9	volunteers	O
10	with	O
11	repeated	O
12	exposure	O
13	to	O
14	longwave	O
15	ultraviolet	O
16	radiation	O
17	(	O
18	UV	O
19	-	O
20	A	O
21	).	O

1	The	O
2	selective	O
3	5	B
4	-	I
5	HT3	I
6	receptor	I
7	antagonists	O
8	ramosetron	O
9	(	O
10	YM060	O
11	),	O
12	YM114	B
13	(	O
14	KAE	O
15	-	O
16	393	O
17	),	O
18	granisetron	O
19	and	O
20	ondansetron	O
21	,	O
22	and	O
23	the	O
24	substituted	O
25	benzamides	O
26	(	O
27	5	O
28	-	O
29	HT4	B
30	receptor	I
31	agonist	I
32	/	I
33	5	I
34	-	I
35	HT3	I
36	receptor	I
37	antagonists	O
38	)	O
39	cisapride	O
40	mosapride	O
41	and	O
42	SC	O
43	-	O
44	53116	O
45	dose	O
46	-	O
47	dependently	O
48	enhanced	O
49	gastric	O
50	emptying	O
51	in	O
52	normal	O
53	rats	O
54	.	O

1	The	O
2	eluting	O
3	solvent	O
4	was	O
5	methanol	O
6	-	O
7	chloroform	O
8	(	O
9	10	O
10	+	O
11	90	O
12	)	O
13	at	O
14	a	O
15	flow	O
16	rate	O
17	of	O
18	2	O
19	.	O
20	0	O
21	ml	O
22	/	O
23	min	O
24	.	O

1	Carcinoembryonic	B
2	antigen	I
3	(	O
4	CEA	B
5	)	O
6	procedures	O
7	and	O
8	clinical	O
9	evaluation	O
10	.	O

1	One	O
2	hundred	O
3	units	O
4	/	O
5	kg	O
6	of	O
7	recombinant	B
8	human	I
9	erythropoietin	I
10	(	O
11	rhEPO	B
12	)	O
13	was	O
14	given	O
15	subcutaneously	O
16	3	O
17	times	O
18	a	O
19	week	O
20	for	O
21	3	O
22	weeks	O
23	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	E1A243	B
6	,	O
7	YY1	B
8	represses	O
9	CRE	O
10	-	O
11	dependent	O
12	transcription	O
13	of	O
14	c	B
15	-	I
16	fos	I
17	by	O
18	physically	O
19	interacting	O
20	with	O
21	ATF	B
22	/	O
23	CREB	B
24	proteins	I
25	bound	O
26	to	O
27	the	O
28	-	O
29	67	O
30	CRE	O
31	.	O

1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O

1	In	O
2	HCMV	O
3	(	O
4	Towne	O
5	)-	O
6	infected	O
7	HF	O
8	cells	O
9	at	O
10	24	O
11	to	O
12	48	O
13	h	O
14	,	O
15	IE2	B
16	also	O
17	accumulated	O
18	in	O
19	newly	O
20	formed	O
21	viral	O
22	DNA	O
23	replication	O
24	compartments	O
25	containing	O
26	the	O
27	polymerase	B
28	processivity	I
29	factor	I
30	(	O
31	UL44	O
32	),	O
33	the	O
34	single	O
35	-	O
36	stranded	O
37	DNA	O
38	binding	O
39	protein	O
40	(	O
41	SSB	O
42	;	O
43	UL57	O
44	),	O
45	the	O
46	UL112	B
47	-	I
48	113	I
49	accessory	I
50	protein	I
51	,	O
52	and	O
53	newly	O
54	incorporated	O
55	bromodeoxyuridine	O
56	(	O
57	BrdU	O
58	).	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	(	I
5	hnRNP	I
6	)	I
7	core	I
8	protein	I
9	A1	I
10	is	O
11	a	O
12	major	O
13	component	O
14	of	O
15	mammalian	B
16	hnRNP	I
17	40	I
18	S	I
19	particles	O
20	.	O

1	Harel	O
2	,	O
3	E	O
4	.	O
5	M	O
6	.	O

1	By	O
2	in	O
3	vitro	O
4	immunoprecipitations	O
5	and	O
6	gel	O
7	shift	O
8	assays	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	classes	O
14	of	O
15	high	O
16	affinity	O
17	Engrailed	O
18	-	O
19	binding	O
20	sites	O
21	upstream	O
22	of	O
23	each	O
24	of	O
25	the	O
26	two	O
27	polyhomeotic	O
28	transcription	O
29	units	O
30	.	O

1	Two	O
2	independent	O
3	promoters	O
4	as	O
5	well	O
6	as	O
7	5	O
8	'	O
9	untranslated	O
10	regions	O
11	regulate	O
12	Dd	B
13	ras	I
14	expression	O
15	in	O
16	Dictyostelium	O
17	.	O

1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O

1	This	O
2	conformer	O
3	features	O
4	a	O
5	Type	O
6	I	O
7	beta	O
8	-	O
9	turn	O
10	and	O
11	has	O
12	extensive	O
13	hydrophobic	O
14	contacts	O
15	with	O
16	the	O
17	FKBP12	B
18	binding	O
19	surface	O
20	.	O

1	New	O
2	technologies	O
3	in	O
4	diagnosis	O
5	and	O
6	classification	O
7	of	O
8	malignancy	O
9	.	O

1	A	O
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	B
7	-	I
8	36	I
9	survey	I
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Lrp	B
6	binds	O
7	a	O
8	central	O
9	palindromic	O
10	site	O
11	,	O
12	interacting	O
13	predominantly	O
14	with	O
15	the	O
16	major	O
17	groove	O
18	of	O
19	its	O
20	DNA	O
21	target	O
22	,	O
23	and	O
24	that	O
25	additional	O
26	dimers	O
27	bind	O
28	to	O
29	flanking	O
30	sites	O
31	to	O
32	form	O
33	a	O
34	nucleoprotein	O
35	activation	O
36	complex	O
37	.	O

1	RNA	B
2	polymerase	I
3	bound	O
4	to	O
5	the	O
6	+	O
7	10A	O
8	promoter	O
9	partially	O
10	protects	O
11	a	O
12	20	O
13	base	O
14	-	O
15	pair	O
16	sequence	O
17	from	O
18	DNase	B
19	I	I
20	digestion	O
21	upstream	O
22	of	O
23	the	O
24	start	O
25	site	O
26	.	O

1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	plus	O
14	c	B
15	-	I
16	Fos	I
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	B
22	-	O
23	CAT	B
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	B
29	-	I
30	1	I
31	,	O
32	GATA	B
33	-	I
34	2	I
35	or	O
36	GATA	B
37	-	I
38	3	I
39	did	O
40	not	O
41	.	O

1	Introduction	O
2	of	O
3	v	B
4	-	I
5	fms	I
6	into	O
7	a	O
8	CSF	B
9	-	I
10	1	I
11	dependent	I
12	murine	I
13	macrophage	I
14	cell	O
15	line	O
16	induced	O
17	factor	O
18	independence	O
19	and	O
20	tumorigenicity	O
21	by	O
22	a	O
23	nonautocrine	O
24	mechanism	O
25	.	O

1	Bailey	O
2	Instruments	O
3	and	O
4	Owen	O
5	Mumford	O
6	filaments	O
7	were	O
8	the	O
9	most	O
10	accurate	O
11	with	O
12	100	O
13	%	O
14	buckling	O
15	within	O
16	+/-	O
17	1	O
18	.	O
19	0	O
20	g	O
21	of	O
22	10	O
23	g	O
24	.	O

1	Symposium	O
2	on	O
3	presenile	O
4	spongy	O
5	encephalopathies	O
6	.	O

1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O

1	Generally	O
2	ILC	O
3	and	O
4	ILVF	O
5	values	O
6	decreased	O
7	with	O
8	increasing	O
9	exposure	O
10	time	O
11	with	O
12	rate	O
13	constants	O
14	ranging	O
15	from	O
16	0	O
17	.	O
18	03	O
19	to	O
20	0	O
21	.	O
22	33	O
23	day	O
24	-	O
25	1	O
26	(	O
27	wet	O
28	and	O
29	lipid	O
30	weight	O
31	)	O
32	for	O
33	ILC	O
34	and	O
35	0	O
36	.	O
37	03	O
38	to	O
39	0	O
40	.	O
41	31	O
42	day	O
43	-	O
44	1	O
45	for	O
46	ILVF	O
47	.	O

1	The	O
2	mechanistic	O
3	implications	O
4	of	O
5	aromatic	O
6	non	O
7	-	O
8	responsiveness	O
9	of	O
10	autonomously	O
11	expressed	O
12	A	O
13	-	O
14	domain	O
15	,	O
16	despite	O
17	its	O
18	demonstrated	O
19	ability	O
20	to	O
21	bind	O
22	phenol	O
23	,	O
24	are	O
25	discussed	O
26	.	O

1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	B
16	c	I
17	-	I
18	myb	I
19	intron	I
20	1	I
21	transcription	O
22	pause	O
23	region	O
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	I
63	factors	I
64	(	O
65	IRFs	O
66	)	O
67	nuclear	O
68	proteins	O
69	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	M	B
2	-	I
3	Ras	I
4	interacted	O
5	poorly	O
6	in	O
7	a	O
8	yeast	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	with	O
14	multiple	O
15	Ras	B
16	effectors	O
17	,	O
18	including	O
19	c	B
20	-	I
21	Raf	I
22	-	I
23	1	I
24	,	I
25	A	I
26	-	I
27	Raf	I
28	,	O
29	B	B
30	-	I
31	Raf	I
32	,	O
33	phosphoinositol	B
34	-	I
35	3	I
36	kinase	I
37	delta	I
38	,	O
39	RalGDS	O
40	,	O
41	and	O
42	Rin1	B
43	.	O

1	We	O
2	compared	O
3	the	O
4	volume	O
5	of	O
6	the	O
7	pulmonary	O
8	extravascular	O
9	,	O
10	extracellular	O
11	water	O
12	space	O
13	using	O
14	sodium	O
15	and	O
16	sucrose	O
17	indicators	O
18	in	O
19	8	O
20	normal	O
21	and	O
22	11	O
23	edematous	O
24	rabbit	O
25	lungs	O
26	by	O
27	steady	O
28	-	O
29	state	O
30	techniques	O
31	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	UBP41	B
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	recycling	O
14	of	O
15	ubiquitin	B
16	by	O
17	hydrolysis	O
18	of	O
19	branched	O
20	poly	O
21	-	O
22	ubiquitin	O
23	chains	O
24	generated	O
25	by	O
26	the	O
27	action	O
28	of	O
29	26	O
30	S	O
31	proteasome	O
32	on	O
33	poly	O
34	-	O
35	ubiquitinated	O
36	protein	O
37	substrates	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	production	O
45	of	O
46	free	O
47	ubiquitin	B
48	from	O
49	linear	O
50	poly	O
51	-	O
52	ubiquitin	B
53	chains	I
54	and	O
55	of	O
56	certain	O
57	ribosomal	O
58	proteins	O
59	from	O
60	ubiquitin	B
61	fusion	O
62	proteins	O
63	.	O

1	Rip1p	B
2	is	O
3	inessential	O
4	,	O
5	associated	O
6	with	O
7	nuclear	O
8	pore	O
9	complexes	O
10	,	O
11	and	O
12	structurally	O
13	related	O
14	to	O
15	the	O
16	FG	B
17	-	I
18	nucleoporin	I
19	family	I
20	of	I
21	pore	I
22	proteins	I
23	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	Two	O
2	episodes	O
3	of	O
4	peritonitis	O
5	occurred	O
6	while	O
7	the	O
8	patient	O
9	received	O
10	CAPD	O
11	(	O
12	1	O
13	episode	O
14	/	O
15	3	O
16	.	O
17	5	O
18	patient	O
19	-	O
20	months	O
21	).	O

1	The	O
2	5	O
3	'-	O
4	nontranslated	O
5	sequences	O
6	and	O
7	parts	O
8	of	O
9	the	O
10	coding	O
11	sequences	O
12	of	O
13	various	O
14	yeast	O
15	genes	O
16	have	O
17	been	O
18	cloned	O
19	into	O
20	representative	O
21	lacZ	B
22	fusion	O
23	vectors	O
24	.	O

1	188	O
2	patients	O
3	received	O
4	cimetidine	O
5	400	O
6	mg	O
7	q	O
8	.	O
9	i	O
10	.	O
11	d	O
12	.	O
13	intravenously	O
14	and	O
15	1	O
16	,	O
17	000	O
18	mg	O
19	daily	O
20	orally	O
21	in	O
22	divided	O
23	doses	O
24	.	O

1	We	O
2	sought	O
3	to	O
4	determine	O
5	whether	O
6	such	O
7	differences	O
8	in	O
9	polyadenylation	O
10	affect	O
11	the	O
12	steady	O
13	-	O
14	state	O
15	levels	O
16	of	O
17	DHFR	B
18	and	O
19	mRNAs	O
20	expressed	O
21	from	O
22	either	O
23	allele	O
24	and	O
25	,	O
26	in	O
27	a	O
28	more	O
29	general	O
30	sense	O
31	,	O
32	to	O
33	ask	O
34	whether	O
35	differences	O
36	in	O
37	3	O
38	'	O
39	end	O
40	RNA	O
41	processing	O
42	in	O
43	a	O
44	gene	O
45	containing	O
46	multiple	O
47	poly	O
48	(	O
49	A	O
50	)	O
51	sites	O
52	affects	O
53	the	O
54	final	O
55	level	O
56	of	O
57	gene	O
58	expression	O
59	.	O

1	Further	O
2	support	O
3	for	O
4	a	O
5	direct	O
6	interaction	O
7	of	O
8	Tub4p	B
9	,	O
10	Spc98p	B
11	and	O
12	Spc97p	B
13	comes	O
14	from	O
15	the	O
16	toxicity	O
17	of	O
18	strong	O
19	SPC97	O
20	overexpression	O
21	which	O
22	is	O
23	suppressed	O
24	by	O
25	co	O
26	-	O
27	overexpression	O
28	of	O
29	TUB4	B
30	or	O
31	SPC98	O
32	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	B
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O

1	Unfortunately	O
2	,	O
3	these	O
4	preservatives	O
5	may	O
6	also	O
7	interfere	O
8	with	O
9	microbiological	O
10	assays	O
11	used	O
12	to	O
13	determine	O
14	product	O
15	sterility	O
16	or	O
17	bioburden	O
18	levels	O
19	.	O

1	The	O
2	4	O
3	degrees	O
4	stimuli	O
5	were	O
6	found	O
7	to	O
8	elicit	O
9	scalp	O
10	distributions	O
11	for	O
12	the	O
13	pattern	O
14	reversal	O
15	P100	O
16	and	O
17	the	O
18	pattern	O
19	onset	O
20	C1	O
21	consistent	O
22	with	O
23	striate	O
24	and	O
25	extrastriate	O
26	visual	O
27	cortical	O
28	origins	O
29	respectively	O
30	.	O

1	The	O
2	proposed	O
3	mechanism	O
4	of	O
5	effect	O
6	states	O
7	that	O
8	mono	O
9	(	O
10	2	O
11	-	O
12	ethylhexyl	O
13	)	O
14	phthalate	O
15	(	O
16	MEHP	O
17	),	O
18	the	O
19	primary	O
20	hydrolysis	O
21	product	O
22	of	O
23	DEHP	O
24	,	O
25	mimics	O
26	the	O
27	inducing	O
28	prostaglandins	O
29	(	O
30	PG	O
31	)	O
32	PGD	O
33	(	O
34	2	O
35	),	O
36	9alpha	B
37	,	O
38	11betaPGF2	O
39	,	O
40	and	O
41	PGF2alpha	B
42	,	O
43	and	O
44	thromboxanes	O
45	in	O
46	the	O
47	lungs	O
48	,	O
49	thereby	O
50	increasing	O
51	the	O
52	risk	O
53	of	O
54	inducing	O
55	inflammation	O
56	in	O
57	the	O
58	airways	O
59	,	O
60	which	O
61	is	O
62	a	O
63	characteristic	O
64	of	O
65	asthma	O
66	.	O

1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	O
22	),	O
23	whereas	O
24	bFcgamma2R	O
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O

1	The	O
2	mean	O
3	serum	O
4	creatinine	O
5	levels	O
6	were	O
7	similar	O
8	at	O
9	one	O
10	year	O
11	(	O
12	SPK	B
13	1	I
14	.	O
15	8	O
16	,	O
17	KTA	O
18	1	O
19	.	O
20	9	O
21	mg	O
22	/	O
23	d	O
24	).(	O
25	ABSTRACT	O
26	TRUNCATED	O
27	AT	O
28	250	O
29	WORDS	O
30	)	O

1	RNA	O
2	transcripts	O
3	that	O
4	hybridize	O
5	to	O
6	the	O
7	introduced	O
8	foreign	O
9	gene	O
10	have	O
11	been	O
12	identified	O
13	.	O

1	In	O
2	Rat	O
3	-	O
4	1a	O
5	cells	O
6	the	O
7	expression	O
8	of	O
9	human	B
10	c	I
11	-	I
12	jun	I
13	mRNA	I
14	was	O
15	associated	O
16	with	O
17	the	O
18	ability	O
19	to	O
20	clone	O
21	in	O
22	soft	O
23	agarose	O
24	and	O
25	form	O
26	tumors	O
27	in	O
28	nude	O
29	mice	O
30	.	O

1	The	O
2	respiratory	O
3	rate	O
4	was	O
5	13	O
6	+/-	O
7	1	O
8	breaths	O
9	/	O
10	min	O
11	with	O
12	52	O
13	+/-	O
14	4	O
15	%	O
16	of	O
17	the	O
18	respiratory	O
19	cycle	O
20	spent	O
21	in	O
22	inspiration	O
23	;	O
24	end	O
25	-	O
26	tidal	O
27	CO2	O
28	pressure	O
29	increased	O
30	by	O
31	3	O
32	.	O
33	3	O
34	+/-	O
35	1	O
36	.	O
37	0	O
38	Torr	O
39	during	O
40	runs	O
41	at	O
42	SIP	O
43	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	epidermal	B
6	growth	I
7	factor	I
8	or	O
9	platelet	B
10	-	I
11	derived	I
12	growth	I
13	factor	I
14	stimulation	O
15	of	O
16	intact	O
17	human	O
18	or	O
19	murine	O
20	cells	O
21	leads	O
22	to	O
23	phosphorylation	O
24	of	O
25	Nck	B
26	protein	I
27	on	O
28	tyrosine	O
29	,	O
30	serine	O
31	,	O
32	and	O
33	threonine	O
34	residues	O
35	.	O

1	This	O
2	promoter	O
3	segment	O
4	could	O
5	drive	O
6	expression	O
7	of	O
8	a	O
9	luciferase	B
10	reporter	I
11	gene	I
12	,	O
13	could	O
14	confer	O
15	correct	O
16	transcriptional	O
17	initiation	O
18	to	O
19	the	O
20	reporter	O
21	and	O
22	could	O
23	confer	O
24	the	O
25	EGF	B
26	-	O
27	responsiveness	O
28	previously	O
29	observed	O
30	in	O
31	the	O
32	native	O
33	gene	O
34	.	O

1	Interestingly	O
2	,	O
3	virions	O
4	also	O
5	contained	O
6	smaller	O
7	proteins	O
8	that	O
9	reacted	O
10	with	O
11	antibodies	O
12	specific	O
13	for	O
14	the	O
15	accessory	O
16	proteins	O
17	as	O
18	well	O
19	as	O
20	SN	O
21	and	O
22	CAT	B
23	fusion	O
24	partners	O
25	.	O

1	Subsequently	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	epithelialization	O
11	and	O
12	caused	O
13	protracted	O
14	inflammation	O
15	.	O

1	Fas	O
2	has	O
3	been	O
4	shown	O
5	to	O
6	require	O
7	ICE	B
8	(	O
9	interleukin	B
10	-	I
11	1	I
12	beta	I
13	-	I
14	converting	I
15	enzyme	I
16	)	I
17	family	I
18	proteases	I
19	to	O
20	induce	O
21	apoptosis	O
22	from	O
23	studies	O
24	utilizing	O
25	the	O
26	cowpox	B
27	ICE	I
28	inhibitor	I
29	protein	I
30	CrmA	I
31	,	O
32	the	O
33	synthetic	O
34	tetrapeptide	O
35	ICE	B
36	inhibitor	O
37	YVAD	O
38	-	O
39	CMK	O
40	,	O
41	and	O
42	the	O
43	tripeptide	B
44	pan	I
45	-	I
46	ICE	I
47	inhibitor	O
48	Z	O
49	-	O
50	VAD	O
51	-	O
52	FMK	O
53	.	O

1	Thus	O
2	,	O
3	the	O
4	active	O
5	-	O
6	site	O
7	mutation	O
8	prevents	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	processing	O
14	of	O
15	the	O
16	N	O
17	-	O
18	glycosylated	O
19	73	O
20	-	O
21	kDa	O
22	precursor	O
23	of	O
24	PrB	B
25	to	O
26	the	O
27	41	O
28	.	O
29	5	O
30	kDa	O
31	pro	O
32	-	O
33	PrB	O
34	in	O
35	the	O
36	endoplasmic	O
37	reticulum	O
38	.	O

1	We	O
2	found	O
3	that	O
4	T3	O
5	(	O
6	10	O
7	(-	O
8	8	O
9	)	O
10	M	O
11	)	O
12	selectively	O
13	stimulates	O
14	transcription	O
15	from	O
16	rGH	O
17	-	O
18	TRE	O
19	-	O
20	and	O
21	TREpal	O
22	-,	O
23	but	O
24	not	O
25	ME	B
26	-	O
27	TRE	O
28	-	O
29	and	O
30	F2	O
31	-	O
32	TRE	O
33	-,	O
34	containing	O
35	templates	O
36	in	O
37	which	O
38	these	O
39	TREs	O
40	are	O
41	linked	O
42	in	O
43	front	O
44	of	O
45	the	O
46	rGH	B
47	minimal	I
48	promoter	I
49	containing	O
50	only	O
51	the	O
52	TATA	B
53	box	I
54	binding	I
55	protein	I
56	,	O
57	but	O
58	not	O
59	any	O
60	other	O
61	proximal	O
62	binding	O
63	protein	O
64	,	O
65	sequence	O
66	.	O

1	During	O
2	a	O
3	28	O
4	-	O
5	week	O
6	promotion	O
7	bioassay	O
8	,	O
9	groups	O
10	of	O
11	30	O
12	male	O
13	CD	O
14	-	O
15	1	O
16	mice	O
17	were	O
18	treated	O
19	once	O
20	with	O
21	50	O
22	microliter	O
23	of	O
24	either	O
25	DMBA	O
26	(	O
27	1	O
28	.	O
29	0	O
30	mg	O
31	/	O
32	ml	O
33	)	O
34	or	O
35	acetone	O
36	,	O
37	rested	O
38	for	O
39	2	O
40	weeks	O
41	,	O
42	and	O
43	then	O
44	treated	O
45	twice	O
46	per	O
47	week	O
48	with	O
49	test	O
50	material	O
51	for	O
52	the	O
53	remaining	O
54	25	O
55	weeks	O
56	.	O

1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	B
6	ETS1	I
7	gene	I
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	identified	O
8	as	O
9	CACGTGACCCG	O
10	,	O
11	is	O
12	located	O
13	34	O
14	bp	O
15	upstream	O
16	from	O
17	the	O
18	transcription	O
19	initiation	O
20	site	O
21	,	O
22	and	O
23	contains	O
24	the	O
25	core	O
26	sequence	O
27	of	O
28	the	O
29	upstream	O
30	promoter	O
31	sequence	O
32	of	O
33	Ad2MLP	O
34	.	O

1	The	O
2	DNA	O
3	sequence	O
4	immediately	O
5	upstream	O
6	from	O
7	the	O
8	-	O
9	10	O
10	hexamer	O
11	contained	O
12	the	O
13	TGn	O
14	motif	O
15	described	O
16	as	O
17	an	O
18	extended	O
19	-	O
20	10	O
21	region	O
22	in	O
23	prokaryotic	O
24	promoters	O
25	.	O

1	Effects	O
2	of	O
3	posteroventral	O
4	pallidotomy	O
5	on	O
6	Parkinson	O
7	'	O
8	s	O
9	disease	O
10	.	O

1	Sleep	O
2	was	O
3	determined	O
4	again	O
5	for	O
6	an	O
7	additional	O
8	3	O
9	days	O
10	and	O
11	6	O
12	hours	O
13	.	O

1	Studies	O
2	on	O
3	the	O
4	method	O
5	of	O
6	size	O
7	reduction	O
8	of	O
9	medicinal	O
10	compounds	O
11	.	O

1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O

1	The	O
2	concentrations	O
3	of	O
4	apo	B
5	A	I
6	-	I
7	I	I
8	and	O
9	apo	B
10	A	I
11	-	I
12	II	I
13	of	O
14	abstainers	O
15	decreased	O
16	significantly	O
17	compared	O
18	with	O
19	the	O
20	corresponding	O
21	changes	O
22	in	O
23	controls	O
24	.	O

1	LPO	B
2	and	O
3	SOD	B
4	levels	O
5	were	O
6	measured	O
7	at	O
8	five	O
9	points	O
10	before	O
11	and	O
12	during	O
13	the	O
14	operation	O
15	.	O

1	After	O
2	MOPP	O
3	therapy	O
4	,	O
5	complete	O
6	remission	O
7	of	O
8	Hodgkin	O
9	'	O
10	s	O
11	disease	O
12	was	O
13	accompanied	O
14	by	O
15	normalization	O
16	of	O
17	the	O
18	glucocerebrosidase	O
19	level	O
20	and	O
21	disappearance	O
22	of	O
23	Gaucher	O
24	'	O
25	s	O
26	cells	O
27	.	O

1	Virol	O
2	.	O

1	Workplace	O
2	violence	O
3	--	O
4	nurses	O
5	at	O
6	risk	O
7	.	O

1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O

1	It	O
2	could	O
3	be	O
4	detected	O
5	exclusively	O
6	in	O
7	the	O
8	culture	O
9	medium	O
10	of	O
11	cDNA	O
12	-	O
13	transfected	O
14	COS	O
15	cells	O
16	.	O

1	Relatively	O
2	large	O
3	DNA	O
4	rearrangements	O
5	spanning	O
6	the	O
7	region	O
8	with	O
9	tandem	O
10	direct	O
11	repeats	O
12	encoding	O
13	the	O
14	carboxy	B
15	-	I
16	terminal	I
17	histone	I
18	H1	I
19	-	I
20	like	I
21	structure	I
22	of	O
23	AlgP	O
24	were	O
25	detected	O
26	in	O
27	several	O
28	strains	O
29	upon	O
30	conversion	O
31	from	O
32	the	O
33	mucoid	O
34	to	O
35	the	O
36	nonmucoid	O
37	phenotype	O
38	.	O

1	Differential	O
2	sensitivity	O
3	of	O
4	the	O
5	MMPI	O
6	-	O
7	2	O
8	depression	O
9	scales	O
10	and	O
11	subscales	O
12	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	show	O
8	that	O
9	SRm160	B
10	/	O
11	300	O
12	is	O
13	required	O
14	for	O
15	a	O
16	purine	O
17	-	O
18	rich	O
19	ESE	O
20	to	O
21	promote	O
22	the	O
23	splicing	O
24	of	O
25	a	O
26	pre	O
27	-	O
28	mRNA	O
29	derived	O
30	from	O
31	the	O
32	Drosophila	B
33	doublesex	I
34	gene	I
35	.	O

1	In	O
2	a	O
3	similar	O
4	fashion	O
5	to	O
6	adipose	O
7	stromal	O
8	cells	O
9	,	O
10	serum	O
11	potentiated	O
12	the	O
13	response	O
14	to	O
15	dexamethasone	O
16	but	O
17	had	O
18	no	O
19	effect	O
20	on	O
21	phorbol	O
22	ester	O
23	-	O
24	stimulated	O
25	activity	O
26	.	O

1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O

1	Subhuman	O
2	primates	O
3	appear	O
4	to	O
5	be	O
6	more	O
7	sensitive	O
8	to	O
9	reproductive	O
10	and	O
11	other	O
12	adverse	O
13	effects	O
14	of	O
15	PCBs	O
16	than	O
17	humans	O
18	.	O

1	Gel	O
2	retardation	O
3	assays	O
4	detected	O
5	ZiaR	O
6	-	O
7	dependent	O
8	complexes	O
9	forming	O
10	with	O
11	the	O
12	zia	O
13	operator	O
14	-	O
15	promoter	O
16	and	O
17	ZiaR	B
18	-	O
19	DNA	O
20	binding	O
21	was	O
22	enhanced	O
23	by	O
24	treatment	O
25	with	O
26	a	O
27	metal	O
28	-	O
29	chelator	O
30	in	O
31	vitro	O
32	.	O

1	We	O
2	investigated	O
3	the	O
4	smoking	O
5	habits	O
6	of	O
7	relapsers	O
8	1	O
9	year	O
10	after	O
11	quitting	O
12	in	O
13	a	O
14	smoking	O
15	cessation	O
16	trial	O
17	using	O
18	nicotine	O
19	or	O
20	placebo	O
21	patches	O
22	.	O

1	The	O
2	DNA	O
3	sequences	O
4	upstream	O
5	of	O
6	these	O
7	termini	O
8	exhibit	O
9	homology	O
10	to	O
11	plant	O
12	mitochondrial	O
13	-	O
14	processing	O
15	sites	O
16	,	O
17	therefore	O
18	the	O
19	proximal	O
20	5	O
21	'	O
22	ends	O
23	are	O
24	most	O
25	probably	O
26	generated	O
27	by	O
28	RNA	O
29	processing	O
30	.	O

1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	This	O
2	motif	O
3	is	O
4	similar	O
5	to	O
6	but	O
7	distinct	O
8	from	O
9	the	O
10	LIM	B
11	domain	I
12	and	O
13	the	O
14	RING	O
15	finger	O
16	family	O
17	,	O
18	and	O
19	is	O
20	reminiscent	O
21	of	O
22	known	O
23	metal	O
24	-	O
25	binding	O
26	regions	O
27	.	O

1	After	O
2	a	O
3	survey	O
4	of	O
5	the	O
6	anatomical	O
7	and	O
8	physiological	O
9	basis	O
10	of	O
11	operative	O
12	treatment	O
13	of	O
14	behaviour	O
15	disorders	O
16	by	O
17	stereotactic	O
18	lesions	O
19	in	O
20	the	O
21	amygdala	O
22	and	O
23	the	O
24	posterior	O
25	medial	O
26	hypothalamus	O
27	the	O
28	author	O
29	describes	O
30	his	O
31	own	O
32	experiences	O
33	with	O
34	603	O
35	operations	O
36	for	O
37	control	O
38	of	O
39	conservatively	O
40	untreatable	O
41	aggressiveness	O
42	.	O

1	The	O
2	HPLC	O
3	method	O
4	involves	O
5	an	O
6	octadecylsilane	O
7	column	O
8	at	O
9	55	O
10	degrees	O
11	C	O
12	,	O
13	a	O
14	mixture	O
15	of	O
16	water	O
17	-	O
18	acetonitrile	O
19	-	O
20	orthophosphoric	O
21	acid	O
22	(	O
23	779	O
24	:	O
25	220	O
26	:	O
27	1	O
28	,	O
29	v	B
30	/	I
31	v	I
32	)	I
33	as	O
34	mobile	O
35	phase	O
36	and	O
37	detection	O
38	at	O
39	226	O
40	nm	O
41	.	O

1	Active	O
2	lambda	O
3	and	O
4	kappa	B
5	antibody	I
6	gene	I
7	rearrangement	O
8	in	O
9	Abelson	O
10	murine	O
11	leukemia	O
12	virus	O
13	-	O
14	transformed	O
15	pre	O
16	-	O
17	B	O
18	cell	O
19	lines	O
20	.	O

1	The	O
2	other	O
3	is	O
4	located	O
5	at	O
6	-	O
7	1335	O
8	,	O
9	outside	O
10	this	O
11	highly	O
12	conserved	O
13	region	O
14	.	O

1	Alena	O
2	is	O
3	a	O
4	nurse	O
5	in	O
6	Prague	O
7	--	O
8	she	O
9	dreams	O
10	of	O
11	higher	O
12	wages	O
13	and	O
14	a	O
15	trip	O
16	across	O
17	the	O
18	ocean	O

1	Identification	O
2	of	O
3	an	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	in	O
9	the	O
10	Marek	O
11	'	O
12	s	O
13	disease	O
14	virus	O
15	long	O
16	internal	O
17	repeat	O
18	region	O
19	which	O
20	encodes	O
21	a	O
22	unique	O
23	14	O
24	-	O
25	kilodalton	O
26	polypeptide	O
27	.	O

1	In	O
2	patients	O
3	in	O
4	group	O
5	A	O
6	("	O
7	normal	O
8	"	O
9	CI	O
10	),	O
11	the	O
12	CI	O
13	,	O
14	heart	O
15	rate	O
16	and	O
17	the	O
18	mean	O
19	circumferential	O
20	fiber	O
21	shortening	O
22	velocity	O
23	(	O
24	mVCF	O
25	)	O
26	were	O
27	normal	O
28	,	O
29	but	O
30	the	O
31	TPR	O
32	was	O
33	increased	O
34	significantly	O
35	.	O

1	Cholangiography	O
2	was	O
3	performed	O
4	in	O
5	all	O
6	cases	O
7	and	O
8	classified	O
9	by	O
10	a	O
11	scoring	O
12	system	O
13	specifically	O
14	developed	O
15	for	O
16	pediatric	O
17	patients	O
18	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	O
28	1	O
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O

1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	In	O
2	two	O
3	further	O
4	cases	O
5	(	O
6	one	O
7	type	O
8	I	O
9	and	O
10	one	O
11	type	O
12	III	O
13	SMA	O
14	),	O
15	de	O
16	novo	O
17	deletions	O
18	of	O
19	only	O
20	one	O
21	copy	O
22	of	O
23	Ag1	B
24	-	I
25	CA	I
26	and	I
27	C212	I
28	were	O
29	found	O
30	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	DNA	B
9	polymerase	I
10	gene	I
11	of	O
12	Bombyx	O
13	mori	O
14	nuclear	O
15	polyhedrosis	O
16	virus	O
17	.	O

1	IFN	B
2	-	I
3	gamma	I
4	was	O
5	elevated	O
6	during	O
7	active	O
8	TB	O
9	when	O
10	compared	O
11	with	O
12	healthy	O
13	controls	O
14	,	O
15	declining	O
16	during	O
17	and	O
18	after	O
19	treatment	O
20	.	O

1	E	O
2	.,	O
3	Scott	O
4	,	O
5	J	O
6	.	O

1	Midge	O
2	control	O
3	in	O
4	flood	O
5	channels	O
6	.	O

1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O

1	Inducible	O
2	VT	O
3	was	O
4	suppressed	O
5	entirely	O
6	in	O
7	one	O
8	patient	O
9	.	O

1	Serine	O
2	528	O
3	is	O
4	phosphorylated	O
5	in	O
6	vivo	O
7	in	O
8	several	O
9	cell	O
10	lines	O
11	,	O
12	and	O
13	substitution	O
14	of	O
15	serine	O
16	528	O
17	to	O
18	alanine	O
19	(	O
20	S528A	O
21	)	O
22	resulted	O
23	in	O
24	an	O
25	increased	O
26	ability	O
27	of	O
28	Myb	B
29	to	O
30	transactivate	O
31	a	O
32	synthetic	O
33	promoter	O
34	containing	O
35	five	O
36	copies	O
37	of	O
38	the	O
39	mim	B
40	-	I
41	1A	I
42	Myb	I
43	-	I
44	responsive	I
45	element	I
46	and	O
47	a	O
48	minimal	O
49	herpes	O
50	tk	B
51	promoter	I
52	.	O

1	Statistics	O
2	for	O
3	nurse	O
4	managers	O
5	--	O
6	3	O
7	.	O

1	Also	O
2	,	O
3	samples	O
4	of	O
5	serum	O
6	were	O
7	absorbed	O
8	with	O
9	the	O
10	various	O
11	solid	O
12	-	O
13	phase	O
14	allergens	O
15	and	O
16	the	O
17	reactivity	O
18	of	O
19	the	O
20	remaining	O
21	IgE	B
22	antibodies	I
23	was	O
24	determined	O
25	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	One	O
6	hundred	O
7	eighty	O
8	-	O
9	four	O
10	chemotherapy	O
11	-	O
12	naive	O
13	patients	O
14	receiving	O
15	high	O
16	-	O
17	dose	O
18	cisplatin	O
19	(	O
20	81	O
21	to	O
22	120	O
23	mg	O
24	/	O
25	m2	O
26	)	O
27	were	O
28	randomized	O
29	to	O
30	receive	O
31	one	O
32	of	O
33	four	O
34	granisetron	O
35	doses	O
36	(	O
37	5	O
38	,	O
39	10	O
40	,	O
41	20	O
42	,	O
43	or	O
44	40	O
45	micrograms	O
46	/	O
47	kg	O
48	)	O
49	administered	O
50	before	O
51	chemotherapy	O
52	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	EGF	B
8	/	O
9	Ras	B
10	/	O
11	Raf	B
12	induces	O
13	transcription	O
14	via	O
15	combined	O
16	activation	O
17	of	O
18	ATF3	B
19	/	O
20	c	B
21	-	I
22	Jun	I
23	and	O
24	a	O
25	52	O
26	-	O
27	kDa	O
28	nuclear	O
29	factor	O
30	,	O
31	whereas	O
32	JunD	B
33	acts	O
34	as	O
35	a	O
36	repressor	O
37	of	O
38	this	O
39	response	O
40	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	),	O
10	a	O
11	proinflammatory	O
12	cytokine	O
13	,	O
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	testosterone	O
19	production	O
20	in	O
21	mouse	O
22	Leydig	O
23	cells	O
24	.	O

1	A	O
2	215	O
3	-	O
4	base	O
5	-	O
6	pair	O
7	(	O
8	bp	O
9	)	O
10	region	O
11	of	O
12	the	O
13	mouse	B
14	MOPC	I
15	41	I
16	kappa	I
17	light	I
18	-	I
19	chain	I
20	immunoglobulin	I
21	gene	I
22	enhancer	I
23	has	O
24	been	O
25	analyzed	O
26	for	O
27	specific	O
28	binding	O
29	of	O
30	lymphoid	O
31	and	O
32	nonlymphoid	O
33	nuclear	O
34	factors	O
35	.	O

1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	greatly	O
6	increased	O
7	human	B
8	chorionic	I
9	gonadotropin	I
10	(	O
11	hCG	B
12	)	O
13	levels	O
14	and	O
15	suppressed	O
16	TSH	B
17	levels	O
18	suggest	O
19	that	O
20	hCG	B
21	has	O
22	thyrotropic	O
23	activity	O
24	.	O

1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	B
7	but	O
8	sparing	O
9	the	O
10	PHC	B
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	B
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O

1	Treatment	O
2	with	O
3	heparin	O
4	,	O
5	plasminogen	B
6	activators	I
7	and	O
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O

1	Subsequent	O
2	experiments	O
3	showed	O
4	that	O
5	motoric	O
6	tasks	O
7	rather	O
8	than	O
9	cognitive	O
10	aspects	O
11	of	O
12	the	O
13	COWA	O
14	task	O
15	were	O
16	critical	O
17	in	O
18	potentiating	O
19	finger	O
20	-	O
21	tapping	O
22	performance	O
23	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	describe	O
7	the	O
8	characterization	O
9	of	O
10	two	O
11	early	B
12	class	I
13	II	I
14	flagellar	I
15	genes	I
16	contained	O
17	in	O
18	the	O
19	orfX	B
20	-	I
21	fliP	I
22	locus	I
23	.	O

1	In	O
2	turn	O
3	,	O
4	assembly	O
5	of	O
6	this	O
7	complex	O
8	mediates	O
9	the	O
10	enzymatic	O
11	activation	O
12	of	O
13	the	O
14	p21	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	1	I
20	and	O
21	facilitates	O
22	actin	B
23	polymerization	O
24	.	O

1	This	O
2	region	O
3	is	O
4	required	O
5	for	O
6	activation	O
7	of	O
8	DNA	O
9	binding	O
10	of	O
11	MyoD	B
12	and	O
13	E12	B
14	homodimers	I
15	and	O
16	E12	B
17	/	O
18	MyoD	B
19	heterodimers	O
20	.	O

1	These	O
2	factors	O
3	belong	O
4	to	O
5	a	O
6	set	O
7	of	O
8	genetically	O
9	distinct	O
10	molecules	O
11	,	O
12	including	O
13	AP	B
14	-	I
15	4	I
16	and	O
17	MLTF	B
18	,	O
19	that	O
20	bind	O
21	to	O
22	the	O
23	CACCTGTC	O
24	motif	O
25	or	O
26	related	O
27	sequences	O
28	.	O

1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	afterbirth	O
7	samples	O
8	from	O
9	physiological	O
10	full	O
11	-	O
12	term	O
13	pregnancies	O
14	.	O

1	Higher	O
2	CYP3A23	O
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	Normal	B
2	alpha1	I
3	(	I
4	I	I
5	)	I
6	collagen	I
7	mRNA	I
8	showed	O
9	no	O
10	significant	O
11	reduction	O
12	when	O
13	AR	B
14	or	O
15	IR	B
16	was	O
17	expressed	O
18	from	O
19	the	O
20	pHbetaAPr	B
21	-	I
22	1	I
23	-	I
24	neo	I
25	vector	I
26	and	O
27	a	O
28	small	O
29	(	O
30	10	O
31	-	O
32	20	O
33	%)	O
34	but	O
35	significant	O
36	reduction	O
37	when	O
38	either	O
39	ribozyme	O
40	was	O
41	expressed	O
42	from	O
43	the	O
44	pCI	O
45	.	O
46	neo	O
47	vector	O
48	.	O

1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O

1	Further	O
2	,	O
3	Ser	O
4	/	O
5	Thr	O
6	phosphorylation	O
7	of	O
8	downstream	O
9	molecules	O
10	Akt	B
11	and	O
12	p70	B
13	S6	I
14	kinase	I
15	was	O
16	inhibited	O
17	.	O

1	Histamine	O
2	reactivity	O
3	had	O
4	returned	O
5	to	O
6	normal	O
7	in	O
8	half	O
9	the	O
10	workers	O
11	who	O
12	had	O
13	left	O
14	their	O
15	original	O
16	factories	O
17	,	O
18	but	O
19	in	O
20	only	O
21	one	O
22	worker	O
23	who	O
24	had	O
25	moved	O
26	within	O
27	her	O
28	original	O
29	factory	O
30	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	murine	O
9	p44	B
10	MAP	I
11	kinase	I
12	(	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	1	I
19	)	I
20	gene	I
21	,	O
22	the	O
23	determination	O
24	of	O
25	its	O
26	intron	O
27	/	O
28	exon	O
29	boundaries	O
30	,	O
31	and	O
32	the	O
33	characterization	O
34	of	O
35	its	O
36	promoter	O
37	.	O

1	RESULTS	O
2	:	O
3	Basal	O
4	plasma	O
5	IGF	B
6	-	I
7	I	I
8	levels	O
9	as	O
10	well	O
11	as	O
12	body	O
13	mass	O
14	index	O
15	(	O
16	BMI	O
17	)	O
18	were	O
19	lower	O
20	in	O
21	amenorrheic	O
22	patients	O
23	than	O
24	in	O
25	healthy	O
26	controls	O
27	.	O

1	Galphaq	O
2	,	O
3	Galpha12	B
4	,	O
5	and	O
6	Galpha13	O
7	,	O
8	but	O
9	not	O
10	Galphai	O
11	,	O
12	activate	O
13	SRF	B
14	through	O
15	RhoA	B
16	.	O

1	To	O
2	test	O
3	the	O
4	role	O
5	of	O
6	ML	O
7	in	O
8	human	O
9	reproductive	O
10	axis	O
11	,	O
12	128	O
13	healthy	O
14	children	O
15	,	O
16	68	O
17	boys	O
18	and	O
19	60	O
20	girls	O
21	,	O
22	were	O
23	studied	O
24	.	O

1	Roizman	O
2	,	O
3	J	O
4	.	O

1	Domain	O
2	II	O
3	is	O
4	highly	O
5	homologous	O
6	to	O
7	the	O
8	LDL	B
9	receptor	I
10	and	O
11	contains	O
12	four	O
13	repeats	O
14	with	O
15	perfect	O
16	conservation	O
17	of	O
18	all	O
19	6	O
20	consecutive	O
21	cysteines	O
22	.	O

1	Therefore	O
2	the	O
3	prevalences	O
4	of	O
5	total	O
6	diabetes	O
7	and	O
8	GDM	O
9	were	O
10	1	O
11	.	O
12	19	O
13	%	O
14	and	O
15	0	O
16	.	O
17	56	O
18	%,	O
19	respectively	O
20	.	O

1	2	O
2	.	O
3	numerous	O
4	narrow	O
5	shunt	O
6	vessels	O
7	departing	O
8	continuously	O
9	from	O
10	the	O
11	primary	O
12	arteries	O
13	to	O
14	feed	O
15	a	O
16	secondary	O
17	arterial	O
18	system	O
19	which	O
20	parallels	O
21	the	O
22	primary	O
23	one	O
24	.	O

1	Like	O
2	other	O
3	members	O
4	of	O
5	this	O
6	family	O
7	,	O
8	the	O
9	AP	B
10	-	I
11	4	I
12	HLH	I
13	motif	I
14	and	O
15	the	O
16	adjacent	O
17	basic	O
18	domain	O
19	are	O
20	necessary	O
21	and	O
22	sufficient	O
23	to	O
24	confer	O
25	site	O
26	-	O
27	specific	O
28	DNA	O
29	binding	O
30	.	O

1	Oligonucleotide	O
2	competitors	O
3	were	O
4	used	O
5	to	O
6	evaluate	O
7	the	O
8	accessibility	O
9	of	O
10	the	O
11	TATA	O
12	-	O
13	binding	O
14	site	O
15	in	O
16	TIF	B
17	-	I
18	IB	I
19	,	O
20	TFIID	B
21	,	O
22	and	O
23	TFIIIB	O
24	.	O

1	Osteosarcoma	O
2	caused	O
3	by	O
4	3	O
5	,	O
6	4	O
7	-	O
8	benzopyrene	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	Streptococcal	O
2	preparation	O
3	(	O
4	OK	O
5	-	O
6	432	O
7	),	O
8	a	O
9	new	O
10	type	O
11	of	O
12	anti	O
13	-	O
14	cancer	O
15	agent	O
16	,	O
17	was	O
18	given	O
19	to	O
20	the	O
21	patients	O
22	with	O
23	advanced	O
24	cancer	O
25	in	O
26	combination	O
27	with	O
28	Mitomycin	O
29	-	O
30	C	O
31	,	O
32	5	O
33	-	O
34	FU	O
35	and	O
36	Cytosine	O
37	arabinoside	O
38	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	B
5	/	O
6	RXRalpha	B
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	O
12	-	O
13	PPRE	O
14	luciferase	B
15	reporter	O
16	construct	O
17	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	O
16	isozymes	O
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	Following	O
2	chondroitinase	O
3	AC	O
4	and	O
5	ABC	O
6	digestion	O
7	,	O
8	staining	O
9	reactions	O
10	suggested	O
11	that	O
12	the	O
13	highest	O
14	levels	O
15	of	O
16	dermatan	O
17	sulfate	O
18	were	O
19	in	O
20	the	O
21	diabetes	O
22	resistant	O
23	group	O
24	(	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	compared	O
32	to	O
33	diabetic	O
34	,	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	001	O
41	compared	O
42	to	O
43	diabetes	O
44	prone	O
45	)	O
46	and	O
47	the	O
48	highest	O
49	levels	O
50	of	O
51	chondroitin	O
52	sulfates	O
53	were	O
54	in	O
55	the	O
56	diabetes	O
57	prone	O
58	group	O
59	(	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	001	O
66	).	O

1	Subsequent	O
2	cloning	O
3	and	O
4	nucleotide	O
5	sequence	O
6	analysis	O
7	of	O
8	the	O
9	S	O
10	.	O
11	pombe	O
12	adenylate	B
13	kinase	I
14	gene	I
15	,	O
16	adk1	B
17	,	O
18	revealed	O
19	a	O
20	coding	O
21	region	O
22	of	O
23	660	O
24	nucleotides	O
25	.	O

1	Glucagon	B
2	also	O
3	induced	O
4	LUC	O
5	activity	O
6	very	O
7	strongly	O
8	when	O
9	the	O
10	CRE1	B
11	and	O
12	CRE2	B
13	sites	I
14	were	O
15	combined	O
16	;	O
17	induction	O
18	of	O
19	the	O
20	(	O
21	CRE1	B
22	)	O
23	3	O
24	(	O
25	CRE2	O
26	)	O
27	2SV40	O
28	-	O
29	LUC	O
30	constructs	O
31	was	O
32	positively	O
33	modulated	O
34	by	O
35	the	O
36	pO2	O
37	.	O

1	We	O
2	studied	O
3	the	O
4	GR	B
5	in	O
6	DMS	O
7	-	O
8	79	O
9	cells	O
10	derived	O
11	from	O
12	a	O
13	human	O
14	ACTH	B
15	-	O
16	secreting	O
17	small	O
18	cell	O
19	lung	O
20	cancer	O
21	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterised	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	protozoan	O
15	parasite	O
16	Leishmania	O
17	major	O
18	.	O

1	If	B
2	hnRNP	I
3	K	I
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	,	O
9	then	O
10	interactions	O
11	with	O
12	the	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcription	O
17	apparatus	O
18	are	O
19	predicted	O
20	.	O

1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	O
6	and	O
7	serum	B
8	LH	I
9	and	O
10	FSH	B
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	collagen	B
7	binding	O
8	has	O
9	not	O
10	been	O
11	shown	O
12	.	O

1	The	O
2	Harleco	O
3	apparatus	O
4	is	O
5	a	O
6	simple	O
7	,	O
8	useful	O
9	,	O
10	cost	O
11	-	O
12	effective	O
13	adjunct	O
14	to	O
15	the	O
16	diagnosis	O
17	and	O
18	treatment	O
19	of	O
20	this	O
21	life	O
22	-	O
23	threatening	O
24	condition	O
25	.	O

1	Both	O
2	4	O
3	,	O
4	8	O
5	-	O
6	DiMeIQx	O
7	and	O
8	A	O
9	alpha	O
10	C	O
11	were	O
12	found	O
13	at	O
14	<	O
15	1	O
16	p	O
17	.	O
18	p	O
19	.	O
20	b	O
21	.	O

1	High	O
2	-	O
3	affinity	O
4	binding	O
5	sites	O
6	for	O
7	both	O
8	GR	B
9	and	O
10	AP	B
11	-	I
12	1	I
13	nucleoproteins	I
14	were	O
15	identified	O
16	at	O
17	adjacent	O
18	elements	O
19	within	O
20	the	O
21	nGRE	O
22	.	O

1	VDR	B
2	/	O
3	RXR	B
4	bound	O
5	well	O
6	to	O
7	the	O
8	VDREs	O
9	and	O
10	to	O
11	DR4	O
12	and	O
13	DR5	O
14	using	O
15	the	O
16	electrophoretic	O
17	mobility	O
18	shift	O
19	assay	O
20	.	O

1	C	O
2	.	O

1	The	O
2	new	O
3	FIGO	O
4	definition	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	O
9	IA	O
10	:	O
11	a	O
12	critique	O
13	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	E	O
2	50	O
3	,	O
4	843	O
5	(	O
6	1994	O
7	)].	O

1	The	O
2	neglect	O
3	of	O
4	Richards	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	strictly	O
18	scientific	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	psychological	O
33	theory	O
34	.	O

1	Similarly	O
2	,	O
3	a	O
4	human	O
5	but	O
6	not	O
7	a	O
8	bovine	B
9	alpha	I
10	transgene	I
11	was	O
12	expressed	O
13	in	O
14	placenta	O
15	in	O
16	transgenic	O
17	mice	O
18	.	O

1	Several	O
2	cytokines	O
3	exhibit	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	temporal	O
9	regulation	O
10	as	O
11	well	O
12	as	O
13	somnogenic	O
14	potency	O
15	(	O
16	e	O
17	.	O
18	g	O
19	.,	O
20	interleukin	B
21	-	I
22	1	I
23	[	I
24	IL	I
25	-	I
26	1	I
27	],	I
28	tumor	I
29	necrosis	I
30	factor	I
31	-	I
32	alpha	I
33	[	O
34	TNF	B
35	-	I
36	alpha	I
37	]).	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	NQO2	O
8	and	O
9	NQO1	B
10	gene	I
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	NQO2	B
17	gene	I
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	NQO	B
26	gene	I
27	family	I
28	in	O
29	human	O
30	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	COX12	O
7	,	O
8	the	O
9	nuclear	O
10	gene	O
11	for	O
12	subunit	O
13	VIb	O
14	of	O
15	Saccharomyces	B
16	cerevisiae	I
17	cytochrome	I
18	c	I
19	oxidase	I
20	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	contribution	O
6	of	O
7	specific	O
8	TATA	B
9	-	I
10	binding	I
11	protein	I
12	(	I
13	TBP	I
14	)-	O
15	TATA	O
16	interactions	O
17	to	O
18	the	O
19	promoter	O
20	activity	O
21	of	O
22	a	O
23	constitutively	O
24	expressed	O
25	silkworm	O
26	tRNA	O
27	(	O
28	C	O
29	)(	O
30	Ala	O
31	)	O
32	gene	O
33	and	O
34	have	O
35	also	O
36	asked	O
37	whether	O
38	the	O
39	lack	O
40	of	O
41	similar	O
42	interactions	O
43	accounts	O
44	for	O
45	the	O
46	low	O
47	promoter	O
48	activity	O
49	of	O
50	a	O
51	silk	O
52	gland	O
53	-	O
54	specific	O
55	tRNA	O
56	(	O
57	SG	O
58	)(	O
59	Ala	O
60	)	O
61	gene	O
62	.	O

1	Post	O
2	-	O
3	translational	O
4	modifications	O
5	such	O
6	as	O
7	glycosylation	O
8	and	O
9	phosphorylation	O
10	could	O
11	be	O
12	excluded	O
13	as	O
14	potential	O
15	explanations	O
16	for	O
17	the	O
18	protein	O
19	heterogeneity	O
20	.	O

1	Constantly	O
2	rectilinear	O
3	pressure	O
4	curves	O
5	without	O
6	uterine	O
7	activities	O
8	are	O
9	interpreted	O
10	as	O
11	characteristic	O
12	tocographic	O
13	criteria	O
14	of	O
15	an	O
16	advanced	O
17	ectopic	O
18	gravidity	O
19	.	O

1	Finding	O
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O

1	The	O
2	dying	O
3	tTG	O
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	C	B
2	/	I
3	EBP	I
4	beta	I
5	V	I
6	>	I
7	A	I
8	selectively	O
9	binds	O
10	only	O
11	the	O
12	subset	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	sites	I
18	that	O
19	are	O
20	also	O
21	DBP	B
22	sites	I
23	,	O
24	both	O
25	as	O
26	oligonucleotides	O
27	and	O
28	within	O
29	the	O
30	natural	O
31	contexts	O
32	of	O
33	the	O
34	albumin	B
35	and	O
36	cholesterol	B
37	hydroxylase	I
38	promoters	I
39	.	O

1	Methods	O
2	of	O
3	clinical	O
4	and	O
5	experimental	O
6	algesimetry	O
7	are	O
8	described	O
9	that	O
10	have	O
11	been	O
12	used	O
13	to	O
14	evaluate	O
15	effects	O
16	of	O
17	peripherally	O
18	and	O
19	centrally	O
20	acting	O
21	analgesics	O
22	.	O

1	Enhancer	O
2	activity	O
3	requires	O
4	both	O
5	the	O
6	AP	B
7	-	I
8	1	I
9	site	I
10	and	O
11	these	O
12	adjacent	O
13	sequences	O
14	.	O

1	These	O
2	results	O
3	demonstrate	O
4	the	O
5	existence	O
6	of	O
7	different	O
8	PI	B
9	3	I
10	-	I
11	kinase	I
12	isoforms	I
13	and	O
14	define	O
15	a	O
16	family	O
17	of	O
18	genes	O
19	encoding	O
20	distinct	O
21	PI	B
22	3	I
23	-	I
24	kinase	I
25	catalytic	O
26	subunits	O
27	that	O
28	can	O
29	associate	O
30	with	O
31	p85	B
32	.	O

1	Avian	O
2	reproductive	O
3	system	O
4	:	O
5	daily	O
6	variations	O
7	in	O
8	responses	O
9	to	O
10	hormones	O
11	.	O

1	The	O
2	encoded	O
3	protein	O
4	has	O
5	a	O
6	leader	O
7	sequence	O
8	of	O
9	27	O
10	amino	O
11	acids	O
12	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	I
30	p27	I
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	O
40	and	O
41	cyclin	B
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O

1	Parathyroid	B
2	hormone	I
3	regulation	O
4	of	O
5	bone	B
6	sialoprotein	I
7	(	O
8	BSP	O
9	)	O
10	gene	O
11	transcription	O
12	is	O
13	mediated	O
14	through	O
15	a	O
16	pituitary	B
17	-	I
18	specific	I
19	transcription	I
20	factor	I
21	-	I
22	1	I
23	(	O
24	Pit	B
25	-	I
26	1	I
27	)	O
28	motif	O
29	in	O
30	the	O
31	rat	B
32	BSP	I
33	gene	I
34	promoter	I
35	.	O

1	The	O
2	interaction	O
3	of	O
4	zf4	B
5	-	I
6	6	I
7	with	O
8	full	B
9	-	I
10	length	I
11	5	I
12	S	I
13	RNA	I
14	was	O
15	far	O
16	more	O
17	sensitive	O
18	to	O
19	non	O
20	-	O
21	specific	O
22	competitor	O
23	concentration	O
24	than	O
25	was	O
26	the	O
27	zf4	B
28	-	I
29	7	I
30	:	I
31	5	I
32	S	I
33	RNA	I
34	interaction	O
35	,	O
36	suggesting	O
37	that	O
38	finger	O
39	seven	O
40	contributes	O
41	to	O
42	both	O
43	affinity	O
44	and	O
45	specificity	O
46	in	O
47	this	O
48	protein	O
49	:	O
50	RNA	O
51	interaction	O
52	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	TATA	O
8	element	O
9	is	O
10	critical	O
11	for	O
12	basal	O
13	and	O
14	Tat	B
15	-	I
16	induced	I
17	HIV	I
18	-	I
19	1	I
20	gene	I
21	expression	O
22	.	O

1	E2	O
2	point	O
3	mutants	O
4	unable	O
5	to	O
6	inhibit	O
7	cell	O
8	growth	O
9	did	O
10	not	O
11	repress	O
12	cdc25A	O
13	and	O
14	cdc25B	B
15	expression	O
16	,	O
17	nor	O
18	did	O
19	the	O
20	cell	O
21	cycle	O
22	inhibitors	O
23	hydroxyurea	O
24	and	O
25	mimosine	O
26	.	O

1	Mutations	O
2	in	O
3	the	O
4	small	O
5	subunit	O
6	of	O
7	ribulosebisphosphate	O
8	carboxylase	O
9	affect	O
10	subunit	O
11	binding	O
12	and	O
13	catalysis	O
14	.	O

1	In	O
2	contrast	O
3	,	O
4	in	O
5	LL	O
6	patients	O
7	during	O
8	ENL	O
9	the	O
10	ConA	B
11	-	O
12	induced	O
13	suppressor	O
14	response	O
15	was	O
16	markedly	O
17	reduced	O
18	.	O

1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	O
16	,	O
17	HC	B
18	-	O
19	Pro	O
20	,	O
21	P1	O
22	,	O
23	P3	O
24	,	O
25	and	O
26	CP	O
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O

1	Endo16	B
2	transcripts	I
3	are	O
4	confined	O
5	to	O
6	the	O
7	definitive	O
8	vegetal	O
9	plate	O
10	in	O
11	blastula	O
12	stage	O
13	embryos	O
14	;	O
15	at	O
16	gastrula	O
17	stage	O
18	this	O
19	gene	O
20	is	O
21	expressed	O
22	throughout	O
23	the	O
24	archenteron	O
25	,	O
26	but	O
27	later	O
28	only	O
29	in	O
30	the	O
31	midgut	O
32	.	O

1	Exploratory	O
2	-	O
3	motor	O
4	task	O
5	to	O
6	evaluate	O
7	right	O
8	frontal	O
9	lobe	O
10	damage	O
11	.	O

1	Sequential	O
2	MR	O
3	examinations	O
4	of	O
5	the	O
6	nasal	O
7	cavity	O
8	and	O
9	paranasal	O
10	sinuses	O
11	were	O
12	performed	O
13	within	O
14	a	O
15	6	O
16	-	O
17	8	O
18	h	O
19	period	O
20	in	O
21	five	O
22	normal	O
23	volunteers	O
24	.	O

1	A	O
2	tobacco	O
3	homologue	O
4	(	O
5	trolC	O
6	)	O
7	of	O
8	the	O
9	rolC	B
10	gene	I
11	of	O
12	the	O
13	Agrobacterium	O
14	rhizogenes	O
15	Ri	O
16	-	O
17	plasmid	O
18	was	O
19	cloned	O
20	and	O
21	sequenced	O
22	from	O
23	Nicotiana	O
24	tabacum	O
25	L	O
26	.	O
27	cv	O
28	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	B
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	A	O
2	human	O
3	SPT3	O
4	-	O
5	TAFII31	O
6	-	O
7	GCN5	B
8	-	I
9	L	I
10	acetylase	I
11	complex	I
12	distinct	I
13	from	I
14	transcription	I
15	factor	I
16	IID	I
17	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	B
22	-	I
23	dependent	I
24	kinases	I
25	(	O
26	CDKs	B
27	).	O

1	An	O
2	experimental	O
3	long	O
4	-	O
5	term	O
6	study	O
7	.	O

1	With	O
2	only	O
3	purified	O
4	T	B
5	antigen	I
6	in	O
7	the	O
8	presence	O
9	of	O
10	topoisomerase	B
11	I	I
12	to	O
13	unwind	O
14	purified	O
15	DNA	O
16	,	O
17	ori	B
18	-	I
19	auxiliary	I
20	sequences	I
21	strongly	O
22	facilitated	O
23	T	B
24	-	I
25	antigen	I
26	-	O
27	dependent	O
28	DNA	O
29	conformational	O
30	changes	O
31	consistent	O
32	with	O
33	melting	O
34	the	O
35	first	O
36	50	O
37	base	O
38	pairs	O
39	.	O

1	Coronary	O
2	vasoconstriction	O
3	caused	O
4	by	O
5	endothelin	B
6	-	I
7	1	I
8	is	O
9	enhanced	O
10	by	O
11	ischemia	O
12	-	O
13	reperfusion	O
14	and	O
15	by	O
16	norepinephrine	O
17	present	O
18	in	O
19	concentrations	O
20	typically	O
21	observed	O
22	after	O
23	neonatal	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	O
13	tissue	O
14	inhibitor	O
15	of	O
16	metalloproteinases	B
17	-	I
18	1	I
19	(	O
20	TIMP	B
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	Patients	O
2	with	O
3	more	O
4	than	O
5	250	O
6	PVC	O
7	/	O
8	24	O
9	hours	O
10	were	O
11	selected	O
12	for	O
13	distribution	O
14	of	O
15	PVC	O
16	and	O
17	CI	O
18	evaluation	O
19	.	O

1	Bacteria	O
2	can	O
3	also	O
4	cause	O
5	a	O
6	labyrinthitis	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	Treponemas	O
18	Pallidum	O
19	,	O
20	a	O
21	spirochaete	O
22	which	O
23	causes	O
24	syphilis	O
25	and	O
26	Borrelia	O
27	Burgdorferi	O
28	,	O
29	a	O
30	spirochaete	O
31	that	O
32	causes	O
33	Lyme	O
34	Disease	O
35	,	O
36	must	O
37	be	O
38	mentioned	O
39	.	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	O
16	-	O
17	specific	O
18	GTPase	B
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	I
25	alpha	I
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	O
32	-	O
33	specific	O
34	GTPase	B
35	-	I
36	activating	I
37	protein	I
38	for	O
39	p21rac	O
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	,	O
6	basal	O
7	GH	B
8	and	O
9	somatomedin	B
10	-	I
11	C	I
12	levels	O
13	decreased	O
14	from	O
15	a	O
16	mean	O
17	(+/-	O
18	standard	O
19	error	O
20	of	O
21	the	O
22	mean	O
23	)	O
24	of	O
25	52	O
26	.	O
27	3	O
28	+/-	O
29	12	O
30	.	O
31	7	O
32	to	O
33	11	O
34	.	O
35	1	O
36	+/-	O
37	6	O
38	.	O
39	3	O
40	ng	O
41	/	O
42	ml	O
43	and	O
44	from	O
45	7	O
46	.	O
47	6	O
48	+/-	O
49	0	O
50	.	O
51	7	O
52	to	O
53	2	O
54	.	O
55	5	O
56	+/-	O
57	0	O
58	.	O
59	5	O
60	U	O
61	/	O
62	ml	O
63	,	O
64	respectively	O
65	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	these	O
7	clones	O
8	encode	O
9	two	O
10	distinct	O
11	forms	O
12	of	O
13	translocase	B
14	.	O

1	Both	O
2	verapamil	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	additive	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	prolonging	O
13	AV	O
14	nodal	O
15	conduction	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	verapamil	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	AV	O
32	nodal	O
33	block	O
34	.	O

1	CIITA	B
2	mRNA	I
3	is	O
4	normally	O
5	inducible	O
6	by	O
7	IFN	B
8	-	I
9	gamma	I
10	in	O
11	class	O
12	II	O
13	non	O
14	-	O
15	inducible	O
16	,	O
17	RB	B
18	-	O
19	defective	O
20	lines	O
21	,	O
22	and	O
23	in	O
24	one	O
25	line	O
26	,	O
27	re	O
28	-	O
29	expression	O
30	of	O
31	RB	B
32	has	O
33	no	O
34	effect	O
35	on	O
36	CIITA	B
37	mRNA	I
38	induction	O
39	levels	O
40	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	the	O
6	minimal	O
7	control	O
8	element	O
9	(	O
10	AX	B
11	470	I
12	)	O
13	specifying	O
14	the	O
15	anterior	O
16	boundary	O
17	of	O
18	Hox	B
19	expression	O
20	was	O
21	designated	O
22	as	O
23	Hoxa	B
24	-	I
25	7	I
26	enhancer	I
27	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	O
11	to	O
12	mSos1	B
13	(	O
14	MyrSos1	B
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	B
28	C	I
29	terminus	I
30	(	O
31	MyrSos1	B
32	-	I
33	deltaC	I
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	3	O
2	-(	O
3	N	O
4	-	O
5	Alkyl	O
6	-	O
7	N	O
8	-	O
9	2	O
10	-	O
11	chloroethylaminomethyl	O
12	)-	O
13	5	O
14	-	O
15	or	O
16	7	O
17	-	O
18	halogenobenzo	O
19	[	O
20	b	O
21	]	O
22	thiophen	O
23	hydrochlorides	O
24	.	O

1	Furthermore	O
2	,	O
3	although	O
4	the	O
5	regional	O
6	distribution	O
7	of	O
8	lean	O
9	tissue	O
10	mass	O
11	in	O
12	the	O
13	trunk	O
14	and	O
15	legs	O
16	remained	O
17	fairly	O
18	constant	O
19	at	O
20	different	O
21	pubertal	O
22	stages	O
23	,	O
24	the	O
25	regional	O
26	distribution	O
27	of	O
28	fat	O
29	was	O
30	altered	O
31	significantly	O
32	,	O
33	becoming	O
34	more	O
35	central	O
36	and	O
37	less	O
38	peripheral	O
39	.	O

1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O

1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O

1	French	O
2	bean	O
3	contains	O
4	a	O
5	small	O
6	family	O
7	of	O
8	genes	O
9	encoding	O
10	PAL	B
11	and	O
12	two	O
13	of	O
14	these	O
15	genes	O
16	,	O
17	PAL2	B
18	and	O
19	PAL3	B
20	,	O
21	have	O
22	been	O
23	shown	O
24	to	O
25	be	O
26	differentially	O
27	expressed	O
28	at	O
29	the	O
30	mRNA	O
31	level	O
32	in	O
33	bean	O
34	tissues	O
35	.	O

1	Analysis	O
2	of	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	A	O
2	range	O
3	of	O
4	normal	O
5	ventricular	O
6	measurements	O
7	for	O
8	the	O
9	EMI	O
10	scan	O
11	is	O
12	suggested	O
13	.	O

1	Near	O
2	a	O
3	third	O
4	(	O
5	31	O
6	.	O
7	6	O
8	%)	O
9	of	O
10	Insulin	B
11	Dependent	O
12	and	O
13	a	O
14	third	O
15	(	O
16	33	O
17	.	O
18	41	O
19	%)	O
20	for	O
21	Non	B
22	Insulin	I
23	Dependent	O
24	were	O
25	of	O
26	D	O
27	,	O
28	F	O
29	,	O
30	H	O
31	White	O
32	'	O
33	s	O
34	Class	O
35	.	O

1	Polyglactin	B
2	910	I
3	suture	O
4	absorption	O
5	and	O
6	the	O
7	role	O
8	of	O
9	cellular	O
10	enzymes	O
11	.	O

1	Changes	O
2	in	O
3	prognosis	O
4	of	O
5	twin	B
6	births	O
7	over	O
8	20	O
9	years	O
10	.	O

1	However	O
2	,	O
3	there	O
4	is	O
5	still	O
6	a	O
7	subset	O
8	of	O
9	tumors	O
10	that	O
11	displayed	O
12	no	O
13	changes	O
14	in	O
15	these	O
16	genes	O
17	.	O

1	Standardized	O
2	gastric	O
3	wall	O
4	specimens	O
5	from	O
6	the	O
7	area	O
8	of	O
9	grossly	O
10	healed	O
11	ulcers	O
12	were	O
13	obtained	O
14	,	O
15	processed	O
16	,	O
17	and	O
18	evaluated	O
19	by	O
20	light	O
21	microscopy	O
22	and	O
23	by	O
24	transmission	O
25	electron	O
26	microscopy	O
27	.	O

1	The	O
2	experimental	O
3	design	O
4	represents	O
5	a	O
6	2	O
7	x	O
8	3	O
9	factorial	O
10	arrangement	O
11	of	O
12	treatments	O
13	with	O
14	three	O
15	dietary	O
16	levels	O
17	of	O
18	incorporation	O
19	of	O
20	RSB	O
21	(	O
22	0	O
23	,	O
24	50	O
25	,	O
26	and	O
27	100	O
28	%),	O
29	and	O
30	chickens	O
31	either	O
32	infected	O
33	or	O
34	uninfected	O
35	.	O

1	Conversely	O
2	,	O
3	treatment	O
4	of	O
5	human	B
6	protein	I
7	-	I
8	tyrosine	I
9	phosphatase	I
10	alpha	I
11	-	O
12	overexpressing	O
13	cells	O
14	with	O
15	phenylarsine	O
16	oxide	O
17	led	O
18	to	O
19	a	O
20	loss	O
21	of	O
22	the	O
23	constitutive	O
24	NF	B
25	-	I
26	kappa	I
27	B	I
28	activity	O
29	.	O

1	Distal	O
2	tubular	O
3	acidification	O
4	and	O
5	the	O
6	threshold	O
7	for	O
8	proximal	O
9	tubular	O
10	bicarbonate	O
11	reabsorption	O
12	were	O
13	normal	O
14	,	O
15	as	O
16	was	O
17	urine	O
18	concentrating	O
19	capacity	O
20	.	O

1	As	O
2	with	O
3	the	O
4	heterologous	O
5	DNA	O
6	binding	O
7	domain	O
8	,	O
9	MZF	B
10	-	I
11	1	I
12	represses	O
13	reporter	O
14	gene	O
15	expression	O
16	in	O
17	nonhematopoietic	O
18	cell	O
19	lines	O
20	and	O
21	activates	O
22	expression	O
23	in	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	.	O

1	We	O
2	report	O
3	a	O
4	prevalence	O
5	study	O
6	of	O
7	the	O
8	best	O
9	visual	O
10	acuity	O
11	in	O
12	the	O
13	affected	O
14	eye	O
15	of	O
16	100	O
17	selected	O
18	patients	O
19	with	O
20	herpetic	O
21	keratitis	O
22	seen	O
23	during	O
24	a	O
25	two	O
26	-	O
27	year	O
28	period	O
29	.	O

1	Another	O
2	common	O
3	mutation	O
4	involved	O
5	amino	O
6	acids	O
7	that	O
8	are	O
9	thought	O
10	to	O
11	make	O
12	specific	O
13	contacts	O
14	with	O
15	DNA	O
16	.	O

1	Asymptomatic	O
2	bacteriospermia	O
3	and	O
4	fertility	O

1	Clb	B
2	/	O
3	Cdc28	B
4	kinases	O
5	promote	O
6	nuclear	O
7	export	O
8	of	O
9	the	O
10	replication	O
11	initiator	O
12	proteins	O
13	Mcm2	O
14	-	O
15	7	O
16	.	O

1	Reaction	O
2	times	O
3	to	O
4	tachistoscopically	O
5	presented	O
6	stimuli	O
7	in	O
8	diabetics	O

1	Like	O
2	the	O
3	p190	B
4	-	I
5	B	I
6	exon	O
7	,	O
8	the	O
9	first	O
10	exon	O
11	of	O
12	p190	B
13	-	I
14	A	I
15	is	O
16	extremely	O
17	large	O
18	(	O
19	3	O
20	.	O
21	7	O
22	kb	O
23	in	O
24	length	O
25	),	O
26	encoding	O
27	both	O
28	the	O
29	GTPase	B
30	and	O
31	middle	B
32	domains	I
33	(	O
34	residues	O
35	1	O
36	-	O
37	1228	O
38	),	O
39	but	O
40	not	O
41	the	O
42	remaining	O
43	GAP	B
44	domain	I
45	,	O
46	suggesting	O
47	a	O
48	high	O
49	conservation	O
50	of	O
51	genomic	O
52	structure	O
53	between	O
54	two	O
55	p190	B
56	genes	I
57	.	O

1	Dangers	O
2	in	O
3	use	O
4	of	O
5	live	O
6	-	O
7	virus	O
8	vaccines	O
9	.	O

1	Chem	O
2	.	O

1	7	O
2	.	O

1	RACK1	B
2	,	O
3	a	O
4	receptor	O
5	for	O
6	activated	O
7	C	B
8	kinase	I
9	and	O
10	a	O
11	homolog	O
12	of	O
13	the	O
14	beta	O
15	subunit	O
16	of	O
17	G	B
18	proteins	I
19	,	O
20	inhibits	O
21	activity	O
22	of	O
23	src	B
24	tyrosine	I
25	kinases	I
26	and	O
27	growth	O
28	of	O
29	NIH	O
30	3T3	O
31	cells	O
32	.	O

1	That	O
2	sequence	O
3	strongly	O
4	promoted	O
5	the	O
6	transcription	O
7	of	O
8	the	O
9	promotorless	O
10	chloramphenicol	B
11	acetyltranferase	I
12	(	O
13	CAT	B
14	)	O
15	gene	O
16	in	O
17	cells	O
18	of	O
19	pancreatic	O
20	origin	O
21	(	O
22	AR	B
23	-	I
24	42J	I
25	)	O
26	but	O
27	not	O
28	in	O
29	cells	O
30	of	O
31	non	O
32	-	O
33	pancreatic	O
34	origin	O
35	(	O
36	Rat	B
37	2	I
38	and	O
39	IEC	B
40	6	I
41	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O

1	Volunteers	O
2	were	O
3	irradiated	O
4	on	O
5	their	O
6	backs	O
7	with	O
8	suberythemal	O
9	UV	O
10	daily	O
11	for	O
12	5	O
13	d	O
14	after	O
15	application	O
16	of	O
17	the	O
18	sunscreens	O
19	and	O
20	their	O
21	base	O
22	lotion	O
23	to	O
24	different	O
25	sites	O
26	.	O

1	Both	O
2	receptors	O
3	utilize	O
4	protein	B
5	tyrosine	I
6	kinases	I
7	(	O
8	PTKs	B
9	)	O
10	for	O
11	the	O
12	phosphorylation	O
13	of	O
14	various	O
15	signaling	O
16	molecules	O
17	,	O
18	a	O
19	process	O
20	that	O
21	is	O
22	critical	O
23	for	O
24	the	O
25	function	O
26	of	O
27	both	O
28	receptors	O
29	.	O

1	Effects	O
2	of	O
3	diltiazem	O
4	on	O
5	netilmicin	O
6	-	O
7	induced	O
8	nephrotoxicity	O
9	in	O
10	rabbits	O
11	.	O

1	We	O
2	propose	O
3	that	O
4	two	O
5	pathways	O
6	regulate	O
7	Stat5	B
8	serine	O
9	phosphorylation	O
10	,	O
11	one	O
12	that	O
13	is	O
14	prolactin	B
15	-	O
16	activated	O
17	and	O
18	PD98059	O
19	-	O
20	resistant	O
21	and	O
22	one	O
23	that	O
24	is	O
25	constitutively	O
26	active	O
27	and	O
28	PD98059	O
29	-	O
30	sensitive	O
31	and	O
32	preferentially	O
33	targets	O
34	Stat5a	O
35	.	O

1	Cyclin	B
2	D1	I
3	promoter	I
4	activity	O
5	was	O
6	stimulated	O
7	by	O
8	overexpression	O
9	of	O
10	mitogen	B
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	(	O
16	p41MAPK	B
17	)	O
18	or	O
19	c	B
20	-	I
21	Ets	I
22	-	I
23	2	I
24	through	O
25	the	O
26	proximal	O
27	22	O
28	base	O
29	pairs	O
30	.	O

1	This	O
2	work	O
3	unravels	O
4	a	O
5	new	O
6	model	O
7	for	O
8	the	O
9	ets	B
10	-	I
11	1	I
12	/	O
13	ets	B
14	-	I
15	2	I
16	gene	I
17	'	O
18	s	O
19	evolution	O
20	,	O
21	based	O
22	for	O
23	the	O
24	first	O
25	time	O
26	on	O
27	both	O
28	structural	O
29	and	O
30	functional	O
31	evidences	O
32	.	O

1	Among	O
2	82	O
3	superficial	O
4	lesions	O
5	34	O
6	were	O
7	classified	O
8	as	O
9	showing	O
10	CR	O
11	and	O
12	another	O
13	23	O
14	as	O
15	showing	O
16	PR	O
17	,	O
18	with	O
19	a	O
20	response	O
21	rate	O
22	of	O
23	69	O
24	.	O
25	5	O
26	%.	O

1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	B
36	(	O
37	Right	O
38	E	O
39	-	O
40	box	O
41	)	O
42	site	O
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O

1	The	O
2	YccA	B
3	protein	I
4	was	O
5	found	O
6	to	O
7	be	O
8	degraded	O
9	in	O
10	an	O
11	FtsH	B
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	vivo	O
17	and	O
18	in	O
19	vitro	O
20	,	O
21	whereas	O
22	the	O
23	YccA11	B
24	mutant	I
25	protein	I
26	,	O
27	lacking	O
28	eight	O
29	amino	O
30	acid	O
31	residues	O
32	within	O
33	the	O
34	amino	O
35	-	O
36	terminal	O
37	cytoplasmic	O
38	domain	O
39	,	O
40	was	O
41	refractory	O
42	to	O
43	the	O
44	degradation	O
45	.	O

1	Derivatives	O
2	of	O
3	boswellic	O
4	acids	O
5	.	O

1	Enterococcus	O
2	faecium	O
3	strains	O
4	with	O
5	vanA	O
6	-	O
7	mediated	O
8	glycopeptide	O
9	resistance	O
10	were	O
11	isolated	O
12	by	O
13	enrichment	O
14	culture	O
15	from	O
16	the	O
17	intestines	O
18	and	O
19	feces	O
20	of	O
21	several	O
22	animal	O
23	species	O
24	,	O
25	mainly	O
26	horses	O
27	and	O
28	dogs	O
29	(	O
30	8	O
31	%	O
32	positive	O
33	),	O
34	chickens	O
35	(	O
36	7	O
37	%	O
38	positive	O
39	),	O
40	and	O
41	pigs	O
42	(	O
43	6	O
44	%	O
45	positive	O
46	).	O

1	A	O
2	reduction	O
3	in	O
4	blood	O
5	pressure	O
6	was	O
7	only	O
8	observed	O
9	at	O
10	the	O
11	end	O
12	of	O
13	the	O
14	study	O
15	,	O
16	from	O
17	142	O
18	+/-	O
19	17	O
20	/	O
21	86	O
22	.	O
23	6	O
24	+/-	O
25	9	O
26	.	O
27	1	O
28	to	O
29	139	O
30	+/-	O
31	13	O
32	/	O
33	82	O
34	.	O
35	9	O
36	+/-	O
37	8	O
38	.	O
39	9	O
40	mmHg	O
41	(	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	for	O
49	DBP	B
50	).	O

1	Accordingly	O
2	,	O
3	no	O
4	Ha	B
5	-	I
6	ras	I
7	codon	I
8	12	I
9	mutations	I
10	are	O
11	found	O
12	in	O
13	the	O
14	EtNU	O
15	-	O
16	induced	O
17	mammary	O
18	tumors	O
19	.	O

1	Despite	O
2	the	O
3	activation	O
4	of	O
5	these	O
6	intracellular	O
7	signaling	O
8	molecules	O
9	,	O
10	PDGF	B
11	beta	I
12	receptor	I
13	activation	O
14	elicited	O
15	no	O
16	detectable	O
17	effect	O
18	on	O
19	cell	O
20	proliferation	O
21	or	O
22	differentiation	O
23	.	O

1	In	O
2	a	O
3	group	O
4	of	O
5	13	O
6	patients	O
7	with	O
8	obliterative	O
9	arteriopathies	O
10	of	O
11	the	O
12	lower	O
13	limbs	O
14	the	O
15	plasma	O
16	levels	O
17	of	O
18	thrombomodulin	B
19	(	O
20	TM	O
21	),	O
22	betathromboglobulin	B
23	(	O
24	beta	O
25	-	O
26	TG	O
27	),	O
28	D	O
29	-	O
30	dimer	O
31	(	O
32	DD	O
33	)	O
34	and	O
35	plasminogen	B
36	activator	I
37	-	I
38	inhibitor	I
39	(	O
40	pAI	B
41	-	I
42	1	I
43	)	O
44	were	O
45	measured	O
46	,	O
47	and	O
48	compared	O
49	to	O
50	the	O
51	values	O
52	obtained	O
53	from	O
54	10	O
55	healthy	O
56	volunteers	O
57	.	O

1	Primary	O
2	infection	O
3	is	O
4	usually	O
5	managed	O
6	conservatively	O
7	.	O

1	Major	O
2	clinical	O
3	symptoms	O
4	of	O
5	the	O
6	disease	O
7	were	O
8	defined	O
9	in	O
10	this	O
11	group	O
12	of	O
13	patients	O
14	.	O

1	Transfer	O
2	also	O
3	correlated	O
4	inversely	O
5	with	O
6	gastric	O
7	juice	O
8	pH	O
9	(	O
10	r	O
11	=	O
12	-	O
13	0	O
14	.	O
15	619	O
16	,	O
17	P	O
18	<	O
19	0	O
20	.	O
21	02	O
22	).	O

1	Human	B
2	PDK1	I
3	is	O
4	homologous	O
5	to	O
6	the	O
7	Drosophila	B
8	protein	I
9	kinase	I
10	DSTPK61	I
11	,	O
12	which	O
13	has	O
14	been	O
15	implicated	O
16	in	O
17	the	O
18	regulation	O
19	of	O
20	sex	O
21	differentiation	O
22	,	O
23	oogenesis	O
24	and	O
25	spermatogenesis	O
26	.	O

1	Therefore	O
2	,	O
3	mechanisms	O
4	that	O
5	control	O
6	activation	O
7	of	O
8	the	O
9	MAP	B
10	kinase	I
11	cascade	O
12	temporally	O
13	and	O
14	spatially	O
15	may	O
16	be	O
17	important	O
18	for	O
19	specification	O
20	of	O
21	cellular	O
22	responses	O
23	.	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	O
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	O
17	-	O
18	1	O
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	O
34	involved	O
35	in	O
36	the	O
37	HIV	O
38	-	O
39	1	O
40	Env	O
41	-	O
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	Feeding	O
2	behavior	O
3	,	O
4	circannual	O
5	body	O
6	weight	O
7	and	O
8	hibernation	O
9	rhythms	O
10	in	O
11	European	O
12	hamsters	O
13	lesioned	O
14	in	O
15	the	O
16	noradrenergic	O
17	ascending	O
18	bundles	O

1	Drug	O
2	inhibition	O
3	of	O
4	whole	O
5	blood	O
6	aspirin	B
7	esterase	I
8	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	almost	O
6	6	O
7	kb	O
8	of	O
9	DNA	O
10	sequence	O
11	is	O
12	presented	O
13	,	O
14	including	O
15	1251	O
16	bp	O
17	5	O
18	'	O
19	to	O
20	the	O
21	gene	O
22	,	O
23	over	O
24	4	O
25	kb	O
26	of	O
27	exon	O
28	and	O
29	exon	O
30	-	O
31	intron	O
32	junctions	O
33	,	O
34	and	O
35	583	O
36	bp	O
37	3	O
38	'	O
39	to	O
40	the	O
41	gene	O
42	.	O

1	Four	O
2	CsA	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	persistently	O
8	elevated	O
9	UAER	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	microalbuminuria	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	UAER	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O

1	Hex	B
2	is	O
3	expressed	O
4	in	O
5	the	O
6	developing	O
7	liver	O
8	coincident	O
9	with	O
10	the	O
11	forkhead	B
12	/	O
13	winged	B
14	helix	I
15	transcription	I
16	factor	I
17	,	O
18	Hepatocyte	B
19	Nuclear	I
20	Factor	I
21	3beta	I
22	(	O
23	HNF3beta	B
24	).	O

1	A	O
2	group	O
3	of	O
4	66	O
5	DSM	O
6	-	O
7	IV	O
8	paranoid	O
9	schizophrenic	O
10	in	O
11	-	O
12	patients	O
13	were	O
14	assessed	O
15	three	O
16	times	O
17	using	O
18	the	O
19	SAPS	O
20	,	O
21	SANS	O
22	,	O
23	BPRS	O
24	and	O
25	PAS	B
26	.	O

1	Epididymal	O
2	growth	O
3	was	O
4	retarded	O
5	in	O
6	animals	O
7	maintained	O
8	solely	O
9	on	O
10	chickpea	O
11	haulm	O
12	and	O
13	improved	O
14	with	O
15	supplementation	O
16	.	O

1	The	O
2	reduced	O
3	rate	O
4	of	O
5	F	O
6	absorption	O
7	and	O
8	slower	O
9	rise	O
10	in	O
11	plasma	O
12	F	O
13	concentration	O
14	accompanying	O
15	delayed	O
16	gastric	O
17	emptying	O
18	indicate	O
19	that	O
20	passage	O
21	of	O
22	F	O
23	into	O
24	the	O
25	small	O
26	intestine	O
27	is	O
28	the	O
29	major	O
30	factor	O
31	in	O
32	rapid	O
33	F	O
34	absorption	O
35	.	O

1	Blood	O
2	pressure	O
3	in	O
4	children	O
5	.	O

1	SUP46	O
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	B
11	protein	I
12	S13	I
13	.	O

1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	B
9	EGF	I
10	receptor	I
11	DER	I
12	/	O
13	Egfr	B
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	O
23	for	O
24	Vein	O
25	.	O

1	A	O
2	study	O
3	in	O
4	vivo	O
5	of	O
6	adrenergic	O
7	receptors	O
8	in	O
9	the	O
10	rectum	O
11	and	O
12	in	O
13	the	O
14	internal	O
15	and	O
16	sphincter	O
17	of	O
18	the	O
19	cat	O
20	.	O

1	Truncations	O
2	composed	O
3	of	O
4	78	O
5	and	O
6	64	O
7	amino	O
8	acids	O
9	were	O
10	translocated	O
11	across	O
12	the	O
13	endoplasmic	O
14	reticulum	O
15	membrane	O
16	,	O
17	and	O
18	translocation	O
19	was	O
20	found	O
21	to	O
22	be	O
23	strictly	O
24	co	O
25	-	O
26	translational	O
27	and	O
28	SRP	B
29	-	O
30	dependent	O
31	.	O

1	Mutations	O
2	within	O
3	the	O
4	C	O
5	terminus	O
6	of	O
7	c	B
8	-	I
9	fos	I
10	at	O
11	serine	O
12	residues	O
13	that	O
14	are	O
15	phosphorylation	O
16	targets	O
17	for	O
18	growth	O
19	factors	O
20	and	O
21	MAP	B
22	kinase	I
23	completely	O
24	abrogate	O
25	transactivation	O
26	and	O
27	block	O
28	potentiation	O
29	by	O
30	MAP	B
31	kinase	I
32	.	O

1	Gab2	B
2	,	O
3	a	O
4	new	O
5	pleckstrin	B
6	homology	I
7	domain	I
8	-	I
9	containing	I
10	adapter	I
11	protein	I
12	,	O
13	acts	O
14	to	O
15	uncouple	O
16	signaling	O
17	from	O
18	ERK	B
19	kinase	I
20	to	O
21	Elk	B
22	-	I
23	1	I
24	.	O

1	Cys	O
2	-	O
3	757	O
4	within	O
5	the	O
6	(	O
7	Fe4S4	O
8	)-	O
9	siroheme	O
10	-	O
11	binding	O
12	domain	O
13	was	O
14	essential	O
15	for	O
16	native	O
17	enzyme	O
18	activity	O
19	.	O

1	During	O
2	organogenesis	O
3	,	O
4	HFH	B
5	-	I
6	8	I
7	expression	O
8	is	O
9	found	O
10	in	O
11	the	O
12	splanchnic	O
13	mesoderm	O
14	in	O
15	close	O
16	apposition	O
17	of	O
18	the	O
19	gut	O
20	endoderm	O
21	,	O
22	suggesting	O
23	a	O
24	role	O
25	in	O
26	mesenchymal	O
27	-	O
28	epithelial	O
29	induction	O
30	of	O
31	lung	O
32	and	O
33	gut	O
34	morphogenesis	O
35	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	traI	B
8	structural	I
9	gene	I
10	and	O
11	application	O
12	of	O
13	purified	B
14	mutant	I
15	TraI	I
16	proteins	I
17	for	O
18	in	O
19	vitro	O
20	assays	O
21	served	O
22	to	O
23	evaluate	O
24	the	O
25	functional	O
26	importance	O
27	of	O
28	conserved	O
29	amino	O
30	acid	O
31	residues	O
32	.	O

1	Viruses	O
2	were	O
3	isolated	O
4	from	O
5	9	O
6	lungs	O
7	:	O
8	7	O
9	with	O
10	PI	O
11	-	O
12	3V	O
13	,	O
14	1	O
15	with	O
16	NCP	B
17	BVDV	I
18	type	I
19	1	I
20	,	O
21	and	O
22	1	O
23	with	O
24	both	O
25	BVHV	O
26	-	O
27	1	O
28	and	O
29	BVDV	O
30	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	conservation	O
6	of	O
7	nucleotides	O
8	154	O
9	to	O
10	156	O
11	is	O
12	likely	O
13	to	O
14	be	O
15	a	O
16	consequence	O
17	of	O
18	their	O
19	role	O
20	as	O
21	a	O
22	sequence	O
23	-	O
24	specific	O
25	recognition	O
26	element	O
27	for	O
28	the	O
29	SRP54	B
30	protein	I
31	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	B
6	inhibits	I
7	tyrosine	I
8	phosphatases	I
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	B
16	.	O

1	SPP41	B
2	was	O
3	cloned	O
4	and	O
5	sequenced	O
6	and	O
7	found	O
8	to	O
9	be	O
10	essential	O
11	.	O
12	spp43	O
13	is	O
14	allelic	O
15	to	O
16	the	O
17	previously	O
18	identified	O
19	suppressor	O
20	srn1	O
21	,	O
22	which	O
23	encodes	O
24	a	O
25	negative	O
26	regulator	O
27	of	O
28	gene	O
29	expression	O
30	.	O

1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O

1	In	O
2	a	O
3	recent	O
4	measles	O
5	epidemic	O
6	in	O
7	El	O
8	Paso	O
9	,	O
10	TX	O
11	,	O
12	120	O
13	,	O
14	000	O
15	records	O
16	were	O
17	screened	O
18	using	O
19	these	O
20	criteria	O
21	,	O
22	and	O
23	as	O
24	a	O
25	result	O
26	13	O
27	,	O
28	000	O
29	students	O
30	were	O
31	vaccinated	O
32	.	O

1	Vivid	O
2	visual	O
3	hallucinations	O
4	without	O
5	other	O
6	psychopathology	O
7	have	O
8	been	O
9	reported	O
10	for	O
11	several	O
12	hundred	O
13	years	O
14	.	O

1	Deletions	O
2	were	O
3	examined	O
4	in	O
5	the	O
6	LYS2	B
7	gene	I
8	,	O
9	using	O
10	a	O
11	set	O
12	of	O
13	31	O
14	-	O
15	to	O
16	156	O
17	-	O
18	bp	O
19	inserts	O
20	that	O
21	included	O
22	inserts	O
23	with	O
24	no	O
25	apparent	O
26	potential	O
27	for	O
28	secondary	O
29	structure	O
30	as	O
31	well	O
32	as	O
33	two	O
34	quasipalindromes	O
35	.	O

1	We	O
2	determined	O
3	how	O
4	DNA	O
5	repair	O
6	is	O
7	affected	O
8	by	O
9	TFA1	B
10	conditional	O
11	mutations	O
12	.	O

1	IV	O
2	.	O

1	Moreover	O
2	,	O
3	following	O
4	a	O
5	single	O
6	intravenous	O
7	injection	O
8	of	O
9	the	O
10	bicistronic	O
11	vector	O
12	complexed	O
13	to	O
14	cationic	O
15	liposomes	O
16	into	O
17	recipient	O
18	mice	O
19	,	O
20	delivery	O
21	of	O
22	MDR1	B
23	and	O
24	GC	O
25	cDNAs	O
26	was	O
27	achieved	O
28	in	O
29	all	O
30	the	O
31	organs	O
32	we	O
33	tested	O
34	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	results	O
5	suggest	O
6	that	O
7	vibration	O
8	-	O
9	induced	O
10	neural	O
11	involvement	O
12	can	O
13	be	O
14	considered	O
15	neither	O
16	pure	O
17	digital	O
18	neuropathy	O
19	,	O
20	nor	O
21	definite	O
22	CTS	O
23	,	O
24	as	O
25	previously	O
26	described	O
27	.	O

1	The	O
2	PSS	O
3	gene	O
4	was	O
5	subcloned	O
6	into	O
7	a	O
8	1	O
9	.	O
10	1	O
11	-	O
12	kb	O
13	fragment	O
14	of	O
15	the	O
16	yeast	O
17	DNA	O
18	on	O
19	the	O
20	YEp13	O
21	vector	O
22	.	O

1	An	O
2	11	O
3	-	O
4	month	O
5	-	O
6	old	O
7	girl	O
8	suffering	O
9	from	O
10	Dandy	O
11	-	O
12	Walker	O
13	malformation	O
14	(	O
15	DWM	O
16	)	O
17	associated	O
18	with	O
19	tetralogy	O
20	of	O
21	Fallot	O
22	(	O
23	TOF	O
24	)	O
25	is	O
26	presented	O
27	.	O

1	Interestingly	O
2	,	O
3	we	O
4	find	O
5	that	O
6	the	O
7	interaction	O
8	between	O
9	Tat	B
10	and	O
11	hCycT1	B
12	requires	O
13	zinc	O
14	as	O
15	well	O
16	as	O
17	essential	O
18	cysteine	O
19	residues	O
20	in	O
21	both	O
22	proteins	O
23	.	O

1	Ritanserin	B
2	is	O
3	a	O
4	new	O
5	substance	O
6	with	O
7	highly	O
8	selective	O
9	blocking	O
10	activity	O
11	on	O
12	S2	O
13	receptors	O
14	for	O
15	5	O
16	-	O
17	HT	O
18	in	O
19	the	O
20	central	O
21	nervous	O
22	system	O
23	.	O

1	The	O
2	levels	O
3	of	O
4	NPY	O
5	-	O
6	ir	O
7	in	O
8	the	O
9	rat	O
10	vas	O
11	deferens	O
12	were	O
13	not	O
14	affected	O
15	by	O
16	either	O
17	surgical	O
18	or	O
19	pharmacological	O
20	treatment	O
21	.	O

1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	thrombotic	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	stenting	O
13	might	O
14	be	O
15	minimized	O
16	by	O
17	employing	O
18	gold	O
19	stents	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	steel	O
28	in	O
29	supporting	O
30	a	O
31	functional	O
32	neo	B
33	-	O
34	endothelium	O
35	.	O

1	Influence	O
2	of	O
3	diet	O
4	on	O
5	urinary	O
6	VMA	O
7	excretion	O
8	.	O

1	A	O
2	conserved	O
3	role	O
4	for	O
5	L1	O
6	as	O
7	a	O
8	transmembrane	O
9	link	O
10	between	O
11	neuronal	O
12	adhesion	O
13	and	O
14	membrane	O
15	cytoskeleton	O
16	assembly	O
17	.	O

1	XYL1	B
2	was	O
3	isolated	O
4	as	O
5	a	O
6	highly	O
7	expressed	O
8	fusion	O
9	clone	O
10	from	O
11	a	O
12	'	O
13	lacZ	B
14	translational	O
15	fusion	O
16	library	O
17	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	promoter	O
7	and	O
8	enhancer	O
9	regions	O
10	identified	O
11	here	O
12	are	O
13	essential	O
14	for	O
15	maintaining	O
16	the	O
17	efficient	O
18	promoter	O
19	activity	O
20	of	O
21	the	O
22	human	O
23	activin	O
24	betaA	O
25	subunit	O
26	gene	O
27	.	O

1	3	O
2	.	O

1	Gaucher	O
2	'	O
3	s	O
4	disease	O
5	is	O
6	a	O
7	rare	O
8	metabolic	O
9	disorder	O
10	characterized	O
11	by	O
12	the	O
13	lack	O
14	of	O
15	beta	B
16	-	I
17	glucocerebrosidase	I
18	enzyme	I
19	.	O

1	Transfection	O
2	of	O
3	non	O
4	-	O
5	deleted	O
6	expression	O
7	vector	O
8	into	O
9	NIH3T3	O
10	cells	O
11	results	O
12	in	O
13	acquisition	O
14	of	O
15	focus	O
16	-	O
17	forming	O
18	activity	O
19	while	O
20	a	O
21	deleted	O
22	form	O
23	of	O
24	expression	O
25	vector	O
26	fails	O
27	to	O
28	show	O
29	this	O
30	activity	O
31	even	O
32	in	O
33	the	O
34	presence	O
35	of	O
36	basic	B
37	FGF	I
38	.	O

1	We	O
2	also	O
3	provide	O
4	evidence	O
5	that	O
6	gar2	O
7	is	O
8	phosphorylated	O
9	in	O
10	vitro	O
11	by	O
12	a	O
13	p13	O
14	(	O
15	suc1	O
16	)-	O
17	Sepharose	O
18	-	O
19	bound	O
20	kinase	O
21	from	O
22	Schizosaccharomyces	O
23	pombe	O
24	extracts	O
25	that	O
26	displays	O
27	cell	O
28	cycle	O
29	-	O
30	regulated	O
31	activity	O
32	similar	O
33	to	O
34	that	O
35	of	O
36	the	O
37	p34	B
38	(	O
39	cdc2	B
40	(	O
41	kinase	O
42	.	O

1	SPECT	O
2	examination	O
3	of	O
4	the	O
5	TMJ	O
6	using	O
7	99m	O
8	Tc	O
9	-	O
10	MDP	O
11	was	O
12	performed	O
13	in	O
14	43	O
15	patients	O
16	with	O
17	arthrographically	O
18	proven	O
19	anterior	O
20	dislocation	O
21	of	O
22	the	O
23	disc	O
24	and	O
25	in	O
26	30	O
27	normals	O
28	.	O

1	The	O
2	cell	O
3	cycle	O
4	and	O
5	transcriptional	O
6	defects	O
7	caused	O
8	by	O
9	taf17	B
10	(	O
11	slm7	B
12	-	I
13	1	I
14	)	O
15	are	O
16	consistent	O
17	with	O
18	the	O
19	role	O
20	of	O
21	TAF	B
22	(	I
23	II	I
24	)	O
25	s	O
26	as	O
27	modulators	O
28	of	O
29	transcriptional	O
30	activation	O
31	and	O
32	may	O
33	reflect	O
34	a	O
35	role	O
36	for	O
37	TAF17	B
38	in	O
39	regulating	O
40	activation	O
41	by	O
42	SBF	O
43	and	O
44	MBF	O
45	.	O

1	Angiotensin	B
2	converting	I
3	enzyme	I
4	inhibitors	O
5	enhance	O
6	the	O
7	antihypertensive	O
8	efficacy	O
9	of	O
10	diuretics	O
11	and	O
12	blunt	O
13	or	O
14	prevent	O
15	adverse	O
16	metabolic	O
17	effects	O
18	.	O

1	After	O
2	14	O
3	d	O
4	of	O
5	overfeeding	O
6	,	O
7	hepatic	O
8	PL	O
9	profiles	O
10	were	O
11	identical	O
12	in	O
13	the	O
14	two	O
15	breeds	O
16	and	O
17	similar	O
18	to	O
19	that	O
20	in	O
21	control	O
22	livers	O
23	;	O
24	choline	O
25	-	O
26	containing	O
27	PL	O
28	accounted	O
29	for	O
30	95	O
31	%	O
32	of	O
33	total	O
34	PL	O
35	.	O

1	DNA	O
2	strand	O
3	exchange	O
4	catalyzed	O
5	by	O
6	Rad51	B
7	protein	I
8	is	O
9	also	O
10	greatly	O
11	stimulated	O
12	by	O
13	RPA	B
14	.	O

1	Some	O
2	8	O
3	.	O
4	8	O
5	kb	O
6	of	O
7	the	O
8	Lactobacillus	O
9	sake	O
10	plasmid	O
11	pCIM1	O
12	was	O
13	sequenced	O
14	,	O
15	revealing	O
16	eight	O
17	tightly	O
18	clustered	O
19	open	O
20	reading	O
21	frames	O
22	(	O
23	ORFs	O
24	)	O
25	downstream	O
26	from	O
27	lasA	O
28	,	O
29	which	O
30	encodes	O
31	pre	O
32	-	O
33	lactocin	O
34	S	O
35	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	O
8	-	O
9	risk	O
10	population	O
11	may	O
12	experience	O
13	life	O
14	-	O
15	threatening	O
16	late	O
17	effects	O
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	O
45	dysfunction	O
46	.	O

1	However	O
2	,	O
3	a	O
4	surprisingly	O
5	high	O
6	degree	O
7	of	O
8	conservation	O
9	of	O
10	intron	O
11	sequences	O
12	was	O
13	observed	O
14	between	O
15	both	O
16	species	O
17	.	O

1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O

1	A	O
2	careful	O
3	,	O
4	radiolabelled	O
5	tissue	O
6	-	O
7	distribution	O
8	study	O
9	is	O
10	warranted	O
11	to	O
12	elucidate	O
13	the	O
14	complicated	O
15	metabolic	O
16	fate	O
17	of	O
18	perhexiline	O
19	.	O

1	In	O
2	the	O
3	pRb	B
4	(-)	O
5	SAOS	O
6	-	O
7	2	O
8	cell	O
9	line	O
10	transiently	O
11	transfected	O
12	with	O
13	a	O
14	reporter	O
15	plasmid	O
16	containing	O
17	six	O
18	tal	B
19	-	I
20	1	I
21	binding	I
22	site	I
23	,	O
24	pRb	B
25	enhances	O
26	the	O
27	transcriptional	O
28	activity	O
29	of	O
30	tal	O
31	-	O
32	1	O
33	-	O
34	E12	B
35	-	I
36	Lmo2	I
37	and	O
38	tal	O
39	-	O
40	1	O
41	-	O
42	E12	B
43	-	I
44	Lmo2	I
45	-	I
46	Ldb1	I
47	complexes	I
48	but	O
49	not	O
50	that	O
51	of	O
52	a	O
53	tal	O
54	-	O
55	1	O
56	-	O
57	E12	B
58	heterodimer	O
59	.	O

1	Oligosynaptic	O
2	EPSP	O
3	components	O
4	were	O
5	consistently	O
6	modulated	O
7	only	O
8	in	O
9	the	O
10	superficial	O
11	peroneal	O
12	responses	O
13	in	O
14	flexor	O
15	motoneurons	O
16	,	O
17	which	O
18	exhibited	O
19	enhanced	O
20	amplitude	O
21	during	O
22	the	O
23	flexion	O
24	phase	O
25	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O

1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	O
41	acid	O
42	decarboxylase	O
43	.	O

1	To	O
2	determine	O
3	which	O
4	region	O
5	of	O
6	SulA	B
7	is	O
8	essential	O
9	for	O
10	the	O
11	inhibition	O
12	of	O
13	cell	O
14	division	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	series	O
20	of	O
21	N	O
22	-	O
23	terminal	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	deletions	O
29	of	O
30	SulA	B
31	and	O
32	a	O
33	series	O
34	of	O
35	alanine	O
36	substitution	O
37	mutants	O
38	.	O

1	Myocardial	O
2	SPET	O
3	imaging	O
4	with	O
5	99Tcm	B
6	-	I
7	tetrofosmin	I
8	in	O
9	clinical	O
10	practice	O
11	:	O
12	comparison	O
13	of	O
14	a	O
15	1	O
16	day	O
17	and	O
18	a	O
19	2	O
20	day	O
21	imaging	O
22	protocol	O
23	.	O

1	Plasma	O
2	vitamin	O
3	E	O
4	,	O
5	total	O
6	lipids	O
7	and	O
8	myeloperoxidase	B
9	levels	O
10	during	O
11	spinal	O
12	surgery	O
13	.	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	proteasome	O
6	inhibition	O
7	leads	O
8	to	O
9	upregulation	O
10	of	O
11	specific	O
12	members	O
13	of	O
14	transcription	O
15	factor	O
16	families	O
17	controlling	O
18	cellular	O
19	stress	O
20	response	O
21	and	O
22	proliferation	O
23	.	O

1	Scalp	O
2	flaps	O
3	can	O
4	be	O
5	expanded	O
6	just	O
7	to	O
8	the	O
9	point	O
10	of	O
11	becoming	O
12	noticeable	O
13	over	O
14	4	O
15	to	O
16	6	O
17	weeks	O
18	followed	O
19	by	O
20	scalp	O
21	flap	O
22	transposition	O
23	and	O
24	easy	O
25	closure	O
26	of	O
27	the	O
28	donor	O
29	site	O
30	.	O

1	Supplementary	O
2	Phase	O
3	Contraste	O
4	RSE	O
5	("	O
6	Rapid	O
7	Sequential	O
8	Excitation	O
9	")	O
10	sequences	O
11	were	O
12	carried	O
13	out	O
14	in	O
15	29	O
16	patients	O
17	.	O

1	A	O
2	transcription	O
3	factor	O
4	exclusion	O
5	assay	O
6	was	O
7	used	O
8	to	O
9	show	O
10	that	O
11	the	O
12	PCF1	B
13	mutation	O
14	affects	O
15	two	O
16	distinct	O
17	stages	O
18	in	O
19	transcription	O
20	:	O
21	one	O
22	prior	O
23	to	O
24	and	O
25	one	O
26	after	O
27	stable	O
28	complex	O
29	formation	O
30	;	O
31	and	O
32	that	O
33	these	O
34	effects	O
35	are	O
36	mediated	O
37	by	O
38	a	O
39	component	O
40	of	O
41	the	O
42	stable	O
43	complex	O
44	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	the	O
7	deduced	O
8	amino	O
9	acid	O
10	sequence	O
11	of	O
12	the	O
13	3T3	B
14	-	I
15	L1	I
16	adipocyte	I
17	insulin	I
18	receptor	I
19	of	O
20	the	O
21	mouse	O
22	was	O
23	determined	O
24	.	O

1	In	O
2	the	O
3	current	O
4	model	O
5	,	O
6	Wingless	O
7	/	O
8	Wnt	B
9	signal	O
10	stabilizes	O
11	Armadillo	O
12	/	O
13	beta	B
14	-	I
15	catenin	I
16	,	O
17	which	O
18	then	O
19	accumulates	O
20	in	O
21	nuclei	O
22	and	O
23	binds	O
24	TCF	B
25	/	O
26	LEF	B
27	family	I
28	proteins	I
29	,	O
30	forming	O
31	bipartite	O
32	transcription	O
33	factors	O
34	which	O
35	activate	O
36	transcription	O
37	of	O
38	Wingless	O
39	/	O
40	Wnt	B
41	responsive	I
42	genes	I
43	.	O

1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	O
20	photosynthesis	O
21	genes	O
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O

1	Possible	O
2	relationship	O
3	between	O
4	hyperinsulinemia	O
5	and	O
6	glomerular	O
7	hypertrophy	O
8	in	O
9	nephrosclerosis	O
10	.	O

1	Yeast	B
2	U1	I
3	snRNP	I
4	therefore	O
5	contains	O
6	16	O
7	different	O
8	proteins	O
9	,	O
10	including	O
11	seven	O
12	snRNP	O
13	core	O
14	proteins	O
15	,	O
16	three	O
17	homologues	O
18	of	O
19	the	O
20	metazoan	B
21	U1	I
22	snRNP	I
23	-	I
24	specific	I
25	proteins	I
26	,	O
27	and	O
28	six	O
29	yeast	O
30	-	O
31	specific	O
32	U1	B
33	snRNP	I
34	proteins	I
35	.	O

1	Moreover	O
2	,	O
3	xTAK1KN	O
4	could	O
5	block	O
6	the	O
7	expression	O
8	of	O
9	ventral	O
10	mesoderm	O
11	marker	O
12	genes	O
13	induced	O
14	by	O
15	Smad1	B
16	or	O
17	5	O
18	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O

1	Selective	O
2	activation	O
3	of	O
4	adrenaline	O
5	secretion	O
6	by	O
7	the	O
8	rat	O
9	adrenal	O
10	in	O
11	neuroglycopenia	O
12	detected	O
13	via	O
14	microdialysis	O

1	We	O
2	have	O
3	identified	O
4	three	O
5	binding	O
6	sites	O
7	for	O
8	protein	O
9	complexes	O
10	:	O
11	a	O
12	palindrome	O
13	,	O
14	a	O
15	direct	O
16	repeat	O
17	,	O
18	and	O
19	a	O
20	C	O
21	+	O
22	T	O
23	sequence	O
24	that	O
25	corresponds	O
26	to	O
27	seven	O
28	GAGA	O
29	motifs	O
30	on	O
31	the	O
32	transcribed	O
33	strand	O
34	.	O

1	Abdominal	O
2	tumors	O
3	in	O
4	childhood	O
5	.	O

1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	distant	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	hydrogen	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O

1	Previous	O
2	investigators	O
3	have	O
4	suggested	O
5	that	O
6	subretinal	O
7	blood	O
8	damages	O
9	the	O
10	retina	O
11	in	O
12	part	O
13	because	O
14	of	O
15	its	O
16	solid	O
17	fibrin	B
18	meshwork	I
19	.	O

1	Group	O
2	I	O
3	consisted	O
4	of	O
5	six	O
6	noncholestatic	O
7	patients	O
8	;	O
9	group	O
10	II	O
11	consisted	O
12	of	O
13	nine	O
14	mildly	O
15	cholestatic	O
16	patients	O
17	with	O
18	mild	O
19	hepatic	O
20	impairment	O
21	(	O
22	conjugated	O
23	bilirubin	O
24	,	O
25	47	O
26	mumol	O
27	liter	O
28	-	O
29	1	O
30	;	O
31	alkaline	B
32	phosphatase	I
33	,	O
34	280	O
35	IU	O
36	liter	O
37	-	O
38	1	O
39	;	O
40	gamma	B
41	-	I
42	glutamyltranspeptidase	I
43	,	O
44	190	O
45	IU	O
46	liter	O
47	-	O
48	1	O
49	);	O
50	group	O
51	III	O
52	consisted	O
53	of	O
54	six	O
55	benign	O
56	intrahepatic	O
57	cholestatic	O
58	patients	O
59	with	O
60	high	O
61	isolated	O
62	conjugated	O
63	hyperbilirubinemia	O
64	(	O
65	98	O
66	.	O
67	1	O
68	mumol	O
69	liter	O
70	-	O
71	1	O
72	).	O

1	Handgrip	O
2	dynamometry	O
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O

1	We	O
2	established	O
3	that	O
4	the	O
5	2	B
6	.	I
7	6	I
8	kb	I
9	mRNA	I
10	V	I
11	-	I
12	1	I
13	and	O
14	the	O
15	2	O
16	.	O
17	3	O
18	kb	O
19	GGT	B
20	mRNA	I
21	V	I
22	-	I
23	2	I
24	derive	O
25	,	O
26	by	O
27	alternate	O
28	splicing	O
29	,	O
30	from	O
31	a	O
32	primary	O
33	transcript	O
34	initiated	O
35	on	O
36	a	O
37	distal	O
38	promoter	O
39	on	O
40	the	O
41	rat	B
42	GGT	I
43	gene	I
44	.	O

1	Two	O
2	hundred	O
3	sixty	O
4	-	O
5	four	O
6	patients	O
7	scheduled	O
8	for	O
9	DCBM	O
10	were	O
11	randomized	O
12	to	O
13	receive	O
14	intravenously	O
15	geG	O
16	0	O
17	.	O
18	25	O
19	mg	O
20	(	O
21	geG	O
22	-	O
23	25	O
24	),	O
25	or	O
26	geG	O
27	0	O
28	.	O
29	5	O
30	mg	O
31	(	O
32	geG	O
33	-	O
34	50	O
35	),	O
36	or	O
37	HBB	O
38	20	O
39	mg	O
40	as	O
41	hypotonic	O
42	agent	O
43	.	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	B
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	B
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	B
18	SH3	I
19	domains	I
20	.	O

1	The	O
2	incidence	O
3	of	O
4	tumours	O
5	in	O
6	young	O
7	chickens	O
8	.	O

1	Insertion	O
2	of	O
3	short	O
4	oligonucleotides	O
5	encoding	O
6	the	O
7	basic	O
8	amino	O
9	acid	O
10	motifs	O
11	726	O
12	-	O
13	GRKRKSP	O
14	-	O
15	732	O
16	from	O
17	IE175	B
18	and	O
19	500	O
20	-	O
21	VRPRKRR	O
22	-	O
23	506	O
24	from	O
25	IE110	B
26	into	O
27	deleted	O
28	cytoplasmic	O
29	forms	O
30	of	O
31	the	O
32	two	O
33	proteins	O
34	restored	O
35	the	O
36	karyophilic	O
37	phenotype	O
38	and	O
39	confirmed	O
40	that	O
41	these	O
42	motifs	O
43	are	O
44	both	O
45	necessary	O
46	and	O
47	sufficient	O
48	for	O
49	proper	O
50	nuclear	O
51	localization	O
52	.	O

1	The	O
2	analysis	O
3	of	O
4	two	O
5	distinct	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	pathways	O
12	shows	O
13	that	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	-	I
20	Jun	I
21	N	I
22	-	I
23	terminal	I
24	kinase	I
25	activation	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	phosphorylation	O
31	of	O
32	ATF	B
33	-	I
34	2	I
35	,	O
36	c	B
37	-	I
38	Jun	I
39	,	O
40	and	O
41	JunD	B
42	,	O
43	is	O
44	required	O
45	not	O
46	only	O
47	for	O
48	the	O
49	IL	B
50	-	I
51	1	I
52	-	O
53	but	O
54	also	O
55	for	O
56	the	O
57	TPA	O
58	-	O
59	dependent	O
60	induction	O
61	,	O
62	while	O
63	the	O
64	extracellular	B
65	signal	I
66	-	I
67	related	I
68	kinase	I
69	1	I
70	(	O
71	ERK	B
72	-	I
73	1	I
74	)	O
75	and	O
76	ERK	B
77	-	I
78	2	I
79	activation	O
80	is	O
81	involved	O
82	in	O
83	the	O
84	TPA	O
85	-	O
86	but	O
87	not	O
88	in	O
89	the	O
90	IL	B
91	-	I
92	1	I
93	-	O
94	dependent	O
95	stimulation	O
96	of	O
97	the	O
98	uPA	B
99	enhancer	I
100	.	O

1	Stimulation	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	killed	O
7	Bordetella	O
8	pertussis	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	beneficial	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O

1	The	O
2	mean	O
3	power	O
4	(	O
5	in	O
6	mu	B
7	W	I
8	)	O
9	required	O
10	to	O
11	produce	O
12	the	O
13	observed	O
14	flow	O
15	rate	O
16	was	O
17	estimated	O
18	at	O
19	each	O
20	outflow	O
21	pressure	O
22	as	O
23	the	O
24	product	O
25	of	O
26	the	O
27	flow	O
28	rate	O
29	and	O
30	the	O
31	pressure	O
32	across	O
33	the	O
34	lymphatic	O
35	vessel	O
36	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	have	O
7	analyzed	O
8	the	O
9	structure	O
10	of	O
11	human	O
12	gene	O
13	for	O
14	Gx	B
15	alpha	I
16	,	O
17	which	O
18	spans	O
19	more	O
20	than	O
21	60	O
22	kilobases	O
23	.	O

1	However	O
2	,	O
3	further	O
4	analyses	O
5	of	O
6	the	O
7	data	O
8	indicate	O
9	that	O
10	increasing	O
11	VO2	O
12	AT	O
13	(	O
14	r	O
15	=	O
16	-	O
17	0	O
18	.	O
19	63	O
20	,	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	rather	O
29	than	O
30	VO2max	O
31	(	O
32	r	O
33	=	O
34	-	O
35	0	O
36	.	O
37	15	O
38	)	O
39	could	O
40	result	O
41	in	O
42	improving	O
43	the	O
44	10	O
45	,	O
46	000	O
47	m	O
48	race	O
49	performance	O
50	to	O
51	a	O
52	larger	O
53	extent	O
54	,	O
55	and	O
56	that	O
57	the	O
58	absolute	O
59	amount	O
60	of	O
61	change	O
62	(	O
63	delta	O
64	)	O
65	in	O
66	the	O
67	10	O
68	,	O
69	000	O
70	m	O
71	run	O
72	time	O
73	is	O
74	best	O
75	accounted	O
76	for	O
77	by	O
78	a	O
79	combination	O
80	of	O
81	delta	O
82	VO2	O
83	AT	O
84	and	O
85	delta	O
86	5	O
87	,	O
88	000	O
89	m	O
90	run	O
91	time	O
92	.	O

1	The	O
2	need	O
3	in	O
4	the	O
5	small	O
6	hospital	O
7	.	O

1	Fifty	O
2	min	O
3	after	O
4	release	O
5	from	O
6	stress	O
7	,	O
8	increases	O
9	in	O
10	plasma	O
11	corticosterone	O
12	levels	O
13	induced	O
14	by	O
15	stress	O
16	recovered	O
17	in	O
18	the	O
19	biting	O
20	group	O
21	but	O
22	remained	O
23	high	O
24	in	O
25	the	O
26	non	O
27	-	O
28	biting	O
29	group	O
30	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	B
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	B
11	promoter	I
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	B
23	1	I
24	(	I
25	I	I
26	)	I
27	collagen	I
28	promoter	I
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	O
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	B
50	gene	I
51	expression	O
52	in	O
53	bone	O
54	.	O

1	However	O
2	,	O
3	the	O
4	published	O
5	reports	O
6	consist	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	and	O
14	limited	O
15	data	O
16	.	O

1	Forty	O
2	-	O
3	eight	O
4	sequences	O
5	,	O
6	30	O
7	not	O
8	previously	O
9	identified	O
10	as	O
11	IR	B
12	-	O
13	responsive	O
14	,	O
15	were	O
16	significantly	O
17	regulated	O
18	by	O
19	IR	B
20	.	O

1	Alpha	B
2	-	I
3	1	I
4	antitrypsin	I
5	and	O
6	Indian	O
7	childhood	O
8	cirrhosis	O
9	.	O

1	One	O
2	complex	O
3	appears	O
4	to	O
5	be	O
6	ubiquitous	O
7	but	O
8	enriched	O
9	in	O
10	lymphoid	O
11	cells	O
12	and	O
13	represents	O
14	the	O
15	binding	O
16	of	O
17	a	O
18	potentially	O
19	novel	O
20	factor	O
21	with	O
22	an	O
23	apparent	O
24	molecular	O
25	mass	O
26	of	O
27	approximately	O
28	50	O
29	kDa	O
30	.	O

1	The	O
2	application	O
3	of	O
4	ultrafiltration	O
5	to	O
6	sample	O
7	preparation	O
8	in	O
9	the	O
10	detection	O
11	and	O
12	quantification	O
13	of	O
14	ethylene	O
15	glycol	O
16	in	O
17	plasma	O
18	by	O
19	gas	O
20	chromatography	O
21	is	O
22	described	O
23	.	O

1	In	O
2	a	O
3	highly	O
4	select	O
5	group	O
6	of	O
7	stable	O
8	hypertensive	O
9	patients	O
10	,	O
11	we	O
12	have	O
13	assessed	O
14	the	O
15	strength	O
16	of	O
17	association	O
18	between	O
19	various	O
20	blood	O
21	pressure	O
22	measurements	O
23	(	O
24	24	O
25	h	O
26	average	O
27	automated	O
28	ambulatory	O
29	blood	O
30	pressure	O
31	,	O
32	4	O
33	h	O
34	automated	O
35	ambulatory	O
36	morning	O
37	average	O
38	blood	O
39	pressure	O
40	,	O
41	multiple	O
42	office	O
43	visit	O
44	average	O
45	blood	O
46	pressure	O
47	,	O
48	and	O
49	a	O
50	single	O
51	office	O
52	visit	O
53	average	O
54	blood	O
55	pressure	O
56	)	O
57	and	O
58	various	O
59	echocardiographic	O
60	indices	O
61	of	O
62	hypertensive	O
63	cardiac	O
64	target	O
65	organ	O
66	damage	O
67	(	O
68	left	O
69	atrial	O
70	diameter	O
71	,	O
72	left	O
73	ventricular	O
74	end	O
75	diastolic	O
76	diameter	O
77	,	O
78	posterior	O
79	wall	O
80	thickness	O
81	,	O
82	combined	O
83	wall	O
84	thickness	O
85	,	O
86	relative	O
87	wall	O
88	thickness	O
89	,	O
90	left	O
91	ventricular	O
92	mass	O
93	and	O
94	mass	O
95	index	O
96	,	O
97	and	O
98	combined	O
99	wall	O
100	thickness	O
101	/	O
102	left	O
103	ventricular	O
104	diastolic	O
105	diameter	O
106	ratio	O
107	).	O

1	In	O
2	addition	O
3	to	O
4	DNA	O
5	-	O
6	protein	O
7	interactions	O
8	,	O
9	protein	O
10	-	O
11	protein	O
12	interactions	O
13	with	O
14	partner	O
15	proteins	O
16	often	O
17	play	O
18	major	O
19	roles	O
20	in	O
21	targeting	O
22	ETS	B
23	-	I
24	domain	I
25	proteins	I
26	to	O
27	specific	O
28	promoters	O
29	.	O

1	Weight	O
2	loss	O
3	reduces	O
4	arterial	O
5	pressure	O
6	by	O
7	a	O
8	decrease	O
9	in	O
10	intravascular	O
11	volume	O
12	and	O
13	cardiac	O
14	output	O
15	associated	O
16	with	O
17	a	O
18	fall	O
19	in	O
20	sympathetic	O
21	activity	O
22	.	O

1	Most	O
2	,	O
3	however	O
4	,	O
5	would	O
6	tell	O
7	the	O
8	spouse	O
9	the	O
10	full	O
11	truth	O
12	about	O
13	both	O
14	diagnosis	O
15	and	O
16	prognosis	O
17	.	O

1	SPECT	O
2	is	O
3	an	O
4	important	O
5	aid	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	AIDS	O
11	dementia	O
12	complex	O
13	and	O
14	contributes	O
15	to	O
16	the	O
17	understanding	O
18	of	O
19	the	O
20	pathophysiological	O
21	mechanisms	O
22	of	O
23	this	O
24	disorder	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	MIB	O
5	on	O
6	the	O
7	dose	O
8	-	O
9	response	O
10	curve	O
11	of	O
12	externally	O
13	applied	O
14	noradrenaline	O
15	was	O
16	also	O
17	studied	O
18	.	O

1	Poly	O
2	(	O
3	dT	O
4	)	O
5	and	O
6	denatured	O
7	calf	O
8	thymus	O
9	DNA	O
10	were	O
11	more	O
12	effective	O
13	than	O
14	were	O
15	other	O
16	polynucleotides	O
17	tested	O
18	in	O
19	promoting	O
20	accumulation	O
21	of	O
22	19	O
23	HDP	O
24	*;	O
25	(	O
26	dT	O
27	)	O
28	8	O
29	was	O
30	as	O
31	effective	O
32	as	O
33	were	O
34	longer	O
35	molecules	O
36	of	O
37	(	O
38	dT	O
39	)	O
40	n	O
41	,	O
42	but	O
43	(	O
44	dT	O
45	)	O
46	4	O
47	and	O
48	(	O
49	dT	O
50	)	O
51	6	O
52	were	O
53	much	O
54	less	O
55	effective	O
56	,	O
57	indicating	O
58	that	O
59	the	O
60	binding	O
61	site	O
62	involved	O
63	in	O
64	19	O
65	HDP	O
66	*	O
67	accumulation	O
68	covered	O
69	between	O
70	6	O
71	and	O
72	8	O
73	residues	O
74	of	O
75	(	O
76	dT	O
77	)	O
78	n	O
79	.	O

1	VII	O
2	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	these	O
6	results	O
7	may	O
8	raise	O
9	the	O
10	interesting	O
11	possibility	O
12	of	O
13	providing	O
14	a	O
15	means	O
16	of	O
17	identifying	O
18	greater	O
19	or	O
20	lesser	O
21	susceptibility	O
22	to	O
23	the	O
24	coronary	O
25	effects	O
26	of	O
27	Type	O
28	A	O
29	behavior	O
30	.	O

1	The	O
2	major	O
3	inserted	O
4	DNA	O
5	has	O
6	no	O
7	significant	O
8	homology	O
9	to	O
10	published	O
11	human	B
12	nucleic	I
13	acid	I
14	sequences	I
15	.	O

1	The	O
2	frequency	O
3	of	O
4	PPNG	O
5	strains	O
6	increased	O
7	from	O
8	1	O
9	.	O
10	7	O
11	%	O
12	in	O
13	1981	O
14	to	O
15	6	O
16	.	O
17	7	O
18	%	O
19	in	O
20	1985	O
21	.	O

1	In	O
2	the	O
3	ePTFE	O
4	specimens	O
5	,	O
6	tissue	O
7	coverage	O
8	had	O
9	increased	O
10	.	O

1	The	O
2	binding	O
3	specificity	O
4	of	O
5	this	O
6	protein	O
7	was	O
8	compared	O
9	to	O
10	that	O
11	of	O
12	human	B
13	E2F	I
14	using	O
15	a	O
16	number	O
17	of	O
18	mutant	B
19	E2F	I
20	sites	I
21	as	O
22	competitors	O
23	.	O

1	Curing	O
2	shrinkage	O
3	and	O
4	volumetric	O
5	changes	O
6	of	O
7	resin	O
8	-	O
9	modified	O
10	glass	O
11	ionomer	O
12	restorative	O
13	materials	O
14	.	O

1	Although	O
2	not	O
3	consistently	O
4	identified	O
5	in	O
6	all	O
7	samples	O
8	,	O
9	secondary	O
10	Academic	O
11	,	O
12	Personal	O
13	Responsibility	O
14	,	O
15	and	O
16	Community	O
17	/	O
18	Vocational	O
19	dimensions	O
20	were	O
21	also	O
22	identified	O
23	.	O

1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	B
19	chalcone	I
20	synthase	I
21	promoter	I
22	.	O

1	Seven	O
2	clones	O
3	encoding	O
4	interferon	B
5	response	I
6	element	I
7	binding	I
8	factors	I
9	have	O
10	been	O
11	isolated	O
12	from	O
13	a	O
14	mouse	O
15	fibroblast	O
16	lambda	O
17	gt11	O
18	cDNA	O
19	library	O
20	by	O
21	using	O
22	a	O
23	32P	O
24	end	O
25	-	O
26	labeled	O
27	tandem	O
28	trimer	O
29	of	O
30	the	O
31	mouse	B
32	(	I
33	2	I
34	'-	I
35	5	I
36	')	I
37	oligoadenylate	I
38	synthetase	I
39	gene	I
40	interferon	I
41	response	I
42	element	I
43	as	O
44	a	O
45	probe	O
46	.	O

1	This	O
2	growth	O
3	arrest	O
4	is	O
5	partly	O
6	suppressed	O
7	on	O
8	minimal	O
9	medium	O
10	or	O
11	under	O
12	conditions	O
13	in	O
14	which	O
15	the	O
16	cells	O
17	are	O
18	less	O
19	dependent	O
20	on	O
21	mitochondrial	O
22	metabolism	O
23	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	A	O
2	technique	O
3	for	O
4	thermal	O
5	imaging	O
6	of	O
7	the	O
8	animal	O
9	and	O
10	human	O
11	brain	O
12	cortex	O
13	using	O
14	an	O
15	infrared	O
16	optical	O
17	system	O
18	is	O
19	described	O
20	.	O

1	Furthermore	O
2	,	O
3	the	O
4	amount	O
5	of	O
6	tRNA	O
7	(	O
8	3Lys	O
9	)	O
10	that	O
11	was	O
12	placed	O
13	onto	O
14	viral	O
15	RNA	O
16	in	O
17	mutated	O
18	viruses	O
19	was	O
20	significantly	O
21	less	O
22	than	O
23	that	O
24	placed	O
25	in	O
26	the	O
27	wild	O
28	-	O
29	type	O
30	virus	O
31	.	O

1	Thus	O
2	,	O
3	NART	O
4	-	O
5	R	O
6	performance	O
7	may	O
8	not	O
9	be	O
10	a	O
11	valid	O
12	estimate	O
13	of	O
14	baseline	O
15	IQ	O
16	for	O
17	patients	O
18	with	O
19	neurologic	O
20	disorders	O
21	with	O
22	suspected	O
23	language	O
24	impairment	O
25	.	O

1	Estrogen	O
2	replacement	O
3	,	O
4	either	O
5	as	O
6	17	O
7	beta	O
8	-	O
9	estradiol	O
10	or	O
11	beta	O
12	-	O
13	estradiol	O
14	-	O
15	3	O
16	-	O
17	benzoate	O
18	via	O
19	subcutaneous	O
20	Silastic	O
21	capsules	O
22	,	O
23	was	O
24	associated	O
25	with	O
26	elevated	O
27	rates	O
28	of	O
29	heat	O
30	production	O
31	and	O
32	dry	O
33	heat	O
34	loss	O
35	relative	O
36	to	O
37	untreated	O
38	ovariectomized	O
39	controls	O
40	.	O

1	C3	B
2	toxin	I
3	completely	O
4	inhibited	O
5	RhoA	B
6	function	O
7	,	O
8	partially	O
9	inhibited	O
10	SRE	O
11	:	O
12	Luc	B
13	activity	O
14	,	O
15	but	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	LPA	O
21	-	O
22	stimulated	O
23	c	B
24	-	I
25	Fos	I
26	expression	O
27	.	O

1	Surveillance	O
2	for	O
3	preeclampsia	O
4	was	O
5	conducted	O
6	by	O
7	personnel	O
8	unaware	O
9	of	O
10	treatment	O
11	-	O
12	group	O
13	assignments	O
14	,	O
15	using	O
16	standardized	O
17	measurements	O
18	of	O
19	blood	O
20	pressure	O
21	and	O
22	urinary	O
23	protein	O
24	excretion	O
25	at	O
26	uniformly	O
27	scheduled	O
28	prenatal	O
29	visits	O
30	,	O
31	protocols	O
32	for	O
33	monitoring	O
34	these	O
35	measurements	O
36	during	O
37	the	O
38	hospitalization	O
39	for	O
40	delivery	O
41	,	O
42	and	O
43	reviews	O
44	of	O
45	medical	O
46	records	O
47	of	O
48	unscheduled	O
49	outpatient	O
50	visits	O
51	and	O
52	all	O
53	hospitalizations	O
54	.	O

1	A	O
2	genetic	O
3	complementation	O
4	system	O
5	was	O
6	developed	O
7	in	O
8	which	O
9	tobacco	O
10	etch	O
11	virus	O
12	(	O
13	TEV	B
14	)	I
15	polymerase	I
16	(	O
17	NIb	O
18	)-	O
19	expressing	O
20	transgenic	O
21	plants	O
22	or	O
23	protoplasts	O
24	were	O
25	inoculated	O
26	with	O
27	NIb	O
28	-	O
29	defective	O
30	TEV	O
31	mutants	O
32	.	O

1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	B
38	delta	I
39	mutation	O
40	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	of	O
10	the	O
11	CD69	O
12	gene	O
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	a	O
18	potential	O
19	TATA	O
20	element	O
21	30	O
22	base	O
23	pairs	O
24	upstream	O
25	of	O
26	the	O
27	major	O
28	transcription	O
29	initiation	O
30	site	O
31	and	O
32	several	O
33	putative	O
34	binding	O
35	sequences	O
36	for	O
37	inducible	O
38	transcription	O
39	factors	O
40	(	O
41	NF	B
42	-	I
43	kappa	I
44	B	I
45	,	O
46	Egr	B
47	-	I
48	1	I
49	,	O
50	AP	B
51	-	I
52	1	I
53	),	O
54	which	O
55	might	O
56	mediate	O
57	the	O
58	inducible	O
59	expression	O
60	of	O
61	this	O
62	gene	O
63	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	heterotrimeric	B
7	G	I
8	proteins	I
9	that	O
10	transduce	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	O
22	-	O
23	terminal	O
24	alpha	O
25	-	O
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	repeating	O
32	units	O
33	called	O
34	WD	O
35	(	O
36	Trp	B
37	-	I
38	Asp	I
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	140	O
46	different	O
47	proteins	O
48	.	O

1	(	O
2	3	O
3	).	O

1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O

1	Fas	O
2	-	O
3	resistant	O
4	DT	O
5	-	O
6	40	O
7	lymphoma	O
8	B	O
9	-	O
10	cells	O
11	rendered	O
12	BTK	B
13	-	O
14	deficient	O
15	through	O
16	targeted	O
17	disruption	O
18	of	O
19	the	O
20	btk	B
21	gene	I
22	by	O
23	homologous	O
24	recombination	O
25	knockout	O
26	underwent	O
27	apoptosis	O
28	after	O
29	Fas	O
30	ligation	O
31	,	O
32	but	O
33	wild	O
34	-	O
35	type	O
36	DT	O
37	-	O
38	40	O
39	cells	O
40	or	O
41	BTK	B
42	-	O
43	deficient	O
44	DT	O
45	-	O
46	40	O
47	cells	O
48	reconstituted	O
49	with	O
50	wild	B
51	-	I
52	type	I
53	human	I
54	btk	I
55	gene	I
56	did	O
57	not	O
58	.	O

1	The	O
2	high	O
3	density	O
4	of	O
5	tegumental	O
6	spines	O
7	on	O
8	posterior	O
9	half	O
10	of	O
11	the	O
12	body	O
13	and	O
14	the	O
15	distribution	O
16	of	O
17	type	O
18	II	O
19	papillae	O
20	on	O
21	dorsal	O
22	surface	O
23	are	O
24	considered	O
25	to	O
26	be	O
27	characteristic	O
28	of	O
29	C	O
30	.	O
31	armatus	O
32	.	O

1	Age	O
2	and	O
3	sex	O
4	structure	O
5	of	O
6	the	O
7	natural	O
8	population	O
9	of	O
10	Ornithodoros	B
11	tatarovski	I
12	Ol	I
13	.	O

1	The	O
2	FAS	B
3	promoter	I
4	was	O
5	up	O
6	-	O
7	regulated	O
8	by	O
9	insulin	B
10	through	O
11	the	O
12	proximal	O
13	insulin	B
14	response	I
15	sequence	I
16	containing	O
17	an	O
18	E	O
19	-	O
20	box	O
21	motif	O
22	at	O
23	the	O
24	-	O
25	65	O
26	-	O
27	base	O
28	pair	O
29	position	O
30	.	O

1	Grossly	O
2	,	O
3	the	O
4	experimental	O
5	vulvitis	O
6	was	O
7	identical	O
8	to	O
9	the	O
10	field	O
11	condition	O
12	,	O
13	and	O
14	bacteria	O
15	indistinguishable	O
16	from	O
17	the	O
18	inoculated	O
19	strains	O
20	were	O
21	reisolated	O
22	.	O

1	She	O
2	improved	O
3	with	O
4	a	O
5	combination	O
6	of	O
7	benzodiazepines	O
8	and	O
9	the	O
10	acetylcholinesterase	B
11	inhibitor	O
12	physostigmine	O
13	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	were	O
6	performed	O
7	using	O
8	the	O
9	LPS	O
10	-	O
11	and	O
12	IL	B
13	-	I
14	1	I
15	-	I
16	responsive	I
17	element	I
18	(	O
19	LILRE	O
20	)	O
21	oligonucleotide	O
22	,	O
23	a	O
24	gamma	O
25	interferon	B
26	activation	I
27	site	I
28	-	I
29	like	I
30	site	I
31	that	O
32	is	O
33	present	O
34	in	O
35	the	O
36	human	B
37	IL	I
38	-	I
39	1beta	I
40	promoter	I
41	.	O

1	Deletion	O
2	and	O
3	mutational	O
4	analyses	O
5	revealed	O
6	two	O
7	positive	O
8	cis	O
9	-	O
10	regulatory	O
11	elements	O
12	in	O
13	this	O
14	region	O
15	that	O
16	are	O
17	essential	O
18	for	O
19	CSX1	B
20	expression	O
21	in	O
22	cardiomyocytes	O
23	.	O

1	Sequence	O
2	conservation	O
3	is	O
4	greatest	O
5	for	O
6	residues	O
7	located	O
8	near	O
9	the	O
10	active	O
11	centers	O
12	of	O
13	the	O
14	exo	O
15	and	O
16	pol	B
17	domains	I
18	of	O
19	the	O
20	E	B
21	.	I
22	coli	I
23	DNA	I
24	polymerase	I
25	I	I
26	structure	I
27	.	O

1	To	O
2	elucidate	O
3	whether	O
4	potential	O
5	endocrine	O
6	changes	O
7	resulted	O
8	from	O
9	acute	O
10	hypoxaemia	O
11	alone	O
12	,	O
13	the	O
14	underlying	O
15	disease	O
16	,	O
17	or	O
18	unspecific	O
19	influences	O
20	connected	O
21	with	O
22	the	O
23	ICU	O
24	setting	O
25	,	O
26	all	O
27	measurements	O
28	were	O
29	compared	O
30	to	O
31	those	O
32	of	O
33	a	O
34	completely	O
35	healthy	O
36	reference	O
37	group	O
38	(	O
39	REF	O
40	)	O
41	with	O
42	comparable	O
43	acute	O
44	experimental	O
45	hypoxaemia	O
46	.	O

1	The	O
2	detection	O
3	of	O
4	ORF	O
5	-	O
6	1	O
7	sequences	O
8	in	O
9	human	O
10	tumors	O
11	,	O
12	while	O
13	not	O
14	proof	O
15	per	O
16	se	O
17	,	O
18	is	O
19	a	O
20	prerequisite	O
21	for	O
22	establishing	O
23	its	O
24	role	O
25	in	O
26	tumor	O
27	development	O
28	.	O

1	In	O
2	PB	O
3	mice	O
4	,	O
5	there	O
6	was	O
7	only	O
8	a	O
9	small	O
10	deficit	O
11	in	O
12	the	O
13	number	O
14	of	O
15	the	O
16	hippocampal	O
17	pyramidal	O
18	neurons	O
19	compared	O
20	to	O
21	controls	O
22	(	O
23	15	O
24	%,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	01	O
31	),	O
32	and	O
33	no	O
34	deficit	O
35	in	O
36	the	O
37	granule	O
38	cells	O
39	.	O

1	Supplementation	O
2	was	O
3	stopped	O
4	when	O
5	pl	O
6	-	O
7	ALB	O
8	reached	O
9	2	O
10	.	O
11	0	O
12	g	O
13	/	O
14	dL	O
15	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	properties	O
6	of	O
7	the	O
8	protein	O
9	encoded	O
10	by	O
11	neu	B
12	,	O
13	we	O
14	created	O
15	a	O
16	fusion	O
17	gene	O
18	that	O
19	joins	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	of	O
24	neu	B
25	to	O
26	the	O
27	extracellular	O
28	portion	O
29	of	O
30	an	O
31	immunoglobulin	B
32	heavy	I
33	chain	I
34	.	O

1	Crohn	O
2	'	O
3	s	O
4	disease	O
5	in	O
6	prolonged	O
7	remission	O
8	:	O
9	should	O
10	one	O
11	augment	O
12	protein	O
13	-	O
14	calorie	O
15	intake	O
16	as	O
17	compared	O
18	to	O
19	healthy	O
20	subjects	O
21	?]	O
22	The	O
23	aim	O
24	of	O
25	our	O
26	two	O
27	year	O
28	prospective	O
29	study	O
30	was	O
31	to	O
32	evaluate	O
33	whether	O
34	adult	O
35	Crohn	O
36	'	O
37	s	O
38	disease	O
39	patients	O
40	in	O
41	prolonged	O
42	remission	O
43	(	O
44	CDAI	O
45	<	O
46	150	O
47	),	O
48	in	O
49	order	O
50	to	O
51	maintain	O
52	their	O
53	body	O
54	weight	O
55	as	O
56	close	O
57	as	O
58	possible	O
59	to	O
60	the	O
61	ideal	O
62	one	O
63	,	O
64	need	O
65	a	O
66	protein	O
67	-	O
68	calorie	O
69	intake	O
70	higher	O
71	than	O
72	the	O
73	predicted	O
74	one	O
75	and	O
76	that	O
77	of	O
78	healthy	O
79	controls	O
80	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O

1	Intra	O
2	-	O
3	articular	O
4	dislocation	O
5	of	O
6	the	O
7	patella	O
8	.	O

1	The	O
2	p97	O
3	-	O
4	depleted	O
5	nuclei	O
6	remained	O
7	largely	O
8	competent	O
9	for	O
10	nuclear	O
11	protein	O
12	import	O
13	.	O

1	A	O
2	genomic	O
3	clone	O
4	,	O
5	pTt21	B
6	,	O
7	containing	O
8	DNA	O
9	apparently	O
10	transcribed	O
11	specifically	O
12	in	O
13	Trypanosoma	O
14	cruzi	O
15	trypomastigotes	O
16	,	O
17	was	O
18	obtained	O
19	by	O
20	differentially	O
21	screening	O
22	a	O
23	genomic	O
24	library	O
25	with	O
26	trypomastigote	O
27	and	O
28	epimastigote	O
29	cDNA	O
30	.	O

1	The	O
2	cDNA	O
3	was	O
4	expressed	O
5	in	O
6	Saccharomyces	O
7	cerevisiae	O
8	under	O
9	the	O
10	control	O
11	of	O
12	the	O
13	yeast	B
14	triose	I
15	phosphate	I
16	isomerase	I
17	promoter	I
18	.	O

1	The	O
2	sequencing	O
3	of	O
4	Stellate	O
5	copies	O
6	located	O
7	along	O
8	the	O
9	discontinuous	O
10	cluster	O
11	revealed	O
12	a	O
13	complex	O
14	pattern	O
15	of	O
16	diversification	O
17	.	O

1	By	O
2	stepwise	O
3	linear	O
4	multiple	O
5	regression	O
6	analysis	O
7	,	O
8	ionized	O
9	magnesium	O
10	was	O
11	significantly	O
12	related	O
13	to	O
14	cyclosporin	O
15	trough	O
16	level	O
17	and	O
18	total	O
19	cholesterol	O
20	but	O
21	not	O
22	to	O
23	serum	O
24	creatinine	O
25	,	O
26	time	O
27	after	O
28	transplant	O
29	or	O
30	the	O
31	dose	O
32	of	O
33	cyclosporin	O
34	.	O

1	Reye	O
2	'	O
3	s	O
4	syndrome	O
5	:	O
6	reports	O
7	of	O
8	7	O
9	cases	O
10	in	O
11	the	O
12	period	O
13	1982	O
14	-	O
15	1987	O

1	Tumours	O
2	of	O
3	the	O
4	cavum	O
5	oris	O
6	and	O
7	oropharynx	O
8	of	O
9	T1	O
10	-	O
11	stage	O
12	are	O
13	possible	O
14	only	O
15	in	O
16	1	O
17	of	O
18	3	O
19	cases	O
20	.	O

1	In	O
2	Xenopus	O
3	,	O
4	BMPs	O
5	act	O
6	as	O
7	epidermal	O
8	inducers	O
9	and	O
10	also	O
11	as	O
12	negative	O
13	regulators	O
14	of	O
15	neurogenesis	O
16	.	O

1	The	O
2	MCAD	B
3	nuclear	I
4	receptor	I
5	response	I
6	element	I
7	1	I
8	(	O
9	NRRE	B
10	-	I
11	1	I
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	B
18	alpha	I
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O

1	The	O
2	induction	O
3	by	O
4	pseudorabies	O
5	virus	O
6	of	O
7	an	O
8	IL	B
9	-	I
10	6	I
11	construct	O
12	containing	O
13	the	O
14	IL	B
15	-	I
16	6	I
17	TATA	I
18	box	I
19	and	O
20	the	O
21	RNA	O
22	start	O
23	site	O
24	("	O
25	initiator	O
26	"	O
27	or	O
28	Inr	O
29	element	O
30	)	O
31	but	O
32	not	O
33	the	O
34	MRE	O
35	region	O
36	was	O
37	also	O
38	repressed	O
39	by	O
40	Dex	O
41	in	O
42	the	O
43	presence	O
44	of	O
45	wild	O
46	-	O
47	type	O
48	GR	O
49	.	O

1	We	O
2	demonstrate	O
3	that	O
4	the	O
5	protein	O
6	is	O
7	a	O
8	murine	O
9	homologue	O
10	of	O
11	SAF	B
12	-	I
13	A	I
14	which	O
15	has	O
16	been	O
17	shown	O
18	to	O
19	bind	O
20	selectively	O
21	to	O
22	MARs	B
23	and	O
24	is	O
25	responsible	O
26	for	O
27	the	O
28	satMa	O
29	-	O
30	binding	O
31	activity	O
32	in	O
33	the	O
34	chromatographic	O
35	fractions	O
36	.	O

1	Role	O
2	of	O
3	the	O
4	transcription	O
5	start	O
6	site	O
7	core	O
8	region	O
9	and	O
10	transcription	O
11	factor	O
12	YY1	B
13	in	I
14	Rous	I
15	sarcoma	I
16	virus	I
17	long	I
18	terminal	I
19	repeat	I
20	promoter	I
21	activity	O
22	.	O

1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	these	O
6	genes	O
7	differ	O
8	at	O
9	only	O
10	nine	O
11	positions	O
12	,	O
13	resulting	O
14	in	O
15	three	O
16	amino	O
17	acid	O
18	differences	O
19	.	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	The	O
2	reduced	O
3	NO	O
4	production	O
5	in	O
6	these	O
7	cells	O
8	was	O
9	associated	O
10	with	O
11	low	O
12	levels	O
13	of	O
14	mRNA	O
15	of	O
16	inducible	O
17	NO	B
18	synthetase	I
19	.	O

1	The	O
2	52	O
3	-	O
4	protein	O
5	subunit	O
6	of	O
7	T4	B
8	DNA	I
9	topoisomerase	I
10	is	O
11	homologous	O
12	to	O
13	the	O
14	gyrA	B
15	-	I
16	protein	I
17	of	I
18	gyrase	I
19	.	O

1	We	O
2	produced	O
3	transgenic	O
4	plants	O
5	expressing	O
6	the	O
7	antisense	O
8	Arabidopsis	O
9	HD	O
10	(	O
11	AtHD1	B
12	)	O
13	gene	O
14	.	O

1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	O
10	RNA	O
11	,	O
12	Lyp2	B
13	.	O

1	Childhood	O
2	misbehavior	O
3	and	O
4	the	O
5	risk	O
6	of	O
7	injecting	O
8	drug	O
9	use	O
10	.	O

1	Since	O
2	1967	O
3	at	O
4	the	O
5	times	O
6	of	O
7	their	O
8	biennial	O
9	ABCC	O
10	/	O
11	RERF	B
12	radiological	O
13	examinations	O
14	,	O
15	all	O
16	Adult	O
17	Health	O
18	Study	O
19	(	O
20	AHS	O
21	)	O
22	subjects	O
23	have	O
24	been	O
25	interviewed	O
26	to	O
27	determine	O
28	the	O
29	exposures	O
30	to	O
31	medical	O
32	x	O
33	-	O
34	rays	O
35	they	O
36	experienced	O
37	in	O
38	institutions	O
39	other	O
40	than	O
41	RERF	O
42	in	O
43	order	O
44	to	O
45	estimate	O
46	the	O
47	numbers	O
48	of	O
49	examinations	O
50	and	O
51	corresponding	O
52	doses	O
53	which	O
54	they	O
55	received	O
56	.	O

1	8	O
2	%	O
3	(	O
4	95	O
5	%	O
6	CI	O
7	,	O
8	21	O
9	.	O
10	3	O
11	-	O
12	44	O
13	.	O
14	3	O
15	%).	O

1	Snail	O
2	mortality	O
3	did	O
4	not	O
5	differ	O
6	among	O
7	the	O
8	various	O
9	treatment	O
10	conditions	O
11	.	O

1	The	O
2	selenium	O
3	level	O
4	and	O
5	glutathione	B
6	peroxidase	I
7	activity	O
8	in	O
9	the	O
10	blood	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	stomach	O
16	mucosa	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	high	O
23	-	O
24	selenium	O
25	diet	O
26	group	O
27	than	O
28	in	O
29	the	O
30	low	O
31	-	O
32	selenium	O
33	diet	O
34	group	O
35	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	B
7	proteins	I
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	O
15	NHP6A	O
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	Activity	O
2	of	O
3	palgD	O
4	in	O
5	the	O
6	cysB	B
7	mutant	I
8	,	O
9	in	O
10	CHA	B
11	and	O
12	in	O
13	the	O
14	non	O
15	-	O
16	mucoid	O
17	strain	O
18	PAO	O
19	was	O
20	assessed	O
21	by	O
22	the	O
23	use	O
24	of	O
25	a	O
26	transcriptional	O
27	algD	O
28	-	O
29	xylE	B
30	fusion	I
31	.	O

1	Self	O
2	-	O
3	emasculation	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	psychiatric	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O

1	Immunity	O
2	acquired	O
3	by	O
4	mice	O
5	during	O
6	I	O
7	.	O
8	scapularis	O
9	nymphal	O
10	activity	O
11	in	O
12	early	O
13	summer	O
14	may	O
15	exclude	O
16	a	O
17	large	O
18	proportion	O
19	of	O
20	the	O
21	mouse	O
22	population	O
23	from	O
24	maintaining	O
25	E	O
26	.	O
27	phagocytophila	O
28	during	O
29	the	O
30	period	O
31	of	O
32	larval	O
33	activity	O
34	later	O
35	in	O
36	the	O
37	season	O
38	.	O

1	An	O
2	endometrial	O
3	luteal	O
4	phase	O
5	deficiency	O
6	was	O
7	detected	O
8	in	O
9	15	O
10	(	O
11	30	O
12	%)	O
13	of	O
14	aborting	O
15	patients	O
16	.	O

1	Raman	O
2	investigation	O
3	of	O
4	YBa2	B
5	-	O
6	xLaxCu3O7	O
7	ceramics	O
8	.	O

1	Thus	O
2	,	O
3	the	O
4	human	B
5	D1A	I
6	gene	I
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	RU486	B
6	-	I
7	PR	I
8	-	I
9	B	I
10	interacts	O
11	physically	O
12	with	O
13	NCoR	B
14	in	O
15	vitro	O
16	.	O

1	This	O
2	coat	B
3	protein	I
4	consists	O
5	of	O
6	Sar1p	B
7	,	O
8	the	O
9	Sec23p	B
10	protein	I
11	complex	I
12	containing	O
13	Sec23p	B
14	and	O
15	Sec24p	B
16	,	O
17	and	O
18	the	O
19	Sec13p	B
20	protein	I
21	complex	I
22	containing	O
23	Sec13p	B
24	and	O
25	a	O
26	novel	O
27	150	O
28	-	O
29	kDa	O
30	protein	O
31	,	O
32	p150	O
33	.	O

1	Consequently	O
2	functional	O
3	mRNAs	O
4	can	O
5	be	O
6	produced	O
7	by	O
8	endogenous	B
9	RNA	I
10	polymerase	I
11	I	I
12	.	O

1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	O
25	temperature	O
26	-	O
27	sensitive	O
28	liposomes	O
29	circulating	O
30	in	O
31	the	O
32	retinal	O
33	vasculature	O
34	.	O

1	The	O
2	0	O
3	.	O
4	22	O
5	-	O
6	kb	O
7	NheI	O
8	/	O
9	BglII	B
10	promoter	I
11	exhibited	O
12	PMA	O
13	inducibility	O
14	in	O
15	myeloid	O
16	cells	O
17	and	O
18	contained	O
19	a	O
20	PMA	O
21	-	O
22	responsive	O
23	element	O
24	recognized	O
25	by	O
26	Sp1	B
27	and	O
28	EGR	B
29	-	I
30	1	I
31	transcription	I
32	factors	I
33	.	O

1	The	O
2	role	O
3	of	O
4	transport	O
5	by	O
6	sea	O
7	ice	O
8	from	O
9	the	O
10	Kara	O
11	Sea	O
12	into	O
13	the	O
14	Arctic	O
15	Ocean	O
16	was	O
17	assessed	O
18	by	O
19	a	O
20	small	O
21	subgroup	O
22	at	O
23	GEOMAR	O
24	.	O

1	Risks	O
2	of	O
3	chronicity	O
4	following	O
5	acute	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	:	O
11	a	O
12	review	O
13	.	O

1	GETS	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	many	O
8	tissues	O
9	,	O
10	but	O
11	is	O
12	enriched	O
13	in	O
14	retina	O
15	and	O
16	brain	O
17	.	O

1	Three	O
2	missense	O
3	mutants	O
4	in	O
5	subunit	O
6	a	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	F1F0	I
12	-	I
13	ATPase	I
14	were	O
15	isolated	O
16	and	O
17	characterized	O
18	after	O
19	hydroxylamine	O
20	mutagenesis	O
21	of	O
22	a	O
23	plasmid	O
24	carrying	O
25	the	O
26	uncB	O
27	(	O
28	subunit	O
29	a	O
30	)	O
31	gene	O
32	.	O

1	Since	O
2	GAGs	B
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O

1	Vitrectomy	O
2	was	O
3	still	O
4	a	O
5	significant	O
6	risk	O
7	factor	O
8	when	O
9	macular	O
10	holes	O
11	were	O
12	excluded	O
13	.	O

1	These	O
2	results	O
3	were	O
4	corroborated	O
5	in	O
6	a	O
7	subsequent	O
8	study	O
9	in	O
10	which	O
11	30	O
12	hypogonadal	O
13	men	O
14	were	O
15	supplemented	O
16	with	O
17	SLT	O
18	5	O
19	mg	O
20	three	O
21	times	O
22	daily	O
23	for	O
24	6	O
25	months	O
26	.	O

